var images_info;if (!images_info) images_info =[]; images_info["81"]={"81000":{"type":"graphic_table","displayName":"Combination chemotherapy desmoids","title":"Nondoxorubicin-containing chemotherapy combinations used in the treatment of desmoid tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nondoxorubicin-containing chemotherapy combinations used in the treatment of desmoid tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">No of patients</td> <td class=\"subtitle1\">Duration of therapy</td> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Range of duration of response in months*</td> <td class=\"subtitle1\">Author; year</td> </tr> <tr class=\"divider_bottom\"> <td>MTX+VB<sup>&#182;</sup></td> <td>30</td> <td>38 weekly cycles over 390 days</td> <td> <p>0 CR</p> <p>12 PR</p> 18 MR/SD</td> <td>5-127</td> <td>Azzarelli A; 2001</td> </tr> <tr class=\"divider_bottom\"> <td>MTX+VB<sup>&#182;</sup></td> <td>26</td> <td>2.5 to 12 (median 10) months</td> <td> <p>1 CR</p> <p>4 PR, 3 MR</p> 10 SD, 8 PD</td> <td>2.1-71</td> <td>Skapec S; 2007</td> </tr> <tr class=\"divider_bottom\"> <td>MTX+VB</td> <td>10</td> <td>2 to 35 months</td> <td> <p>3 CR</p> <p>2 PR</p> 5 SD</td> <td>2-51 (median 31)</td> <td>Skapec S; 1998</td> </tr> <tr class=\"divider_bottom\"> <td>MTX+VB</td> <td>8</td> <td>1 to 12 months</td> <td> <p>2 CR</p> <p>5 PR</p> 1 MR</td> <td>2-30 (median 6)</td> <td>Weiss A; 1989</td> </tr> <tr class=\"divider_bottom\"> <td>MTX+VB</td> <td>5</td> <td>12 months</td> <td> <p>2 CR</p> <p>1 PR</p> <p>1 MR</p> 1 SD</td> <td>7-76<sup>&#916;</sup></td> <td>Reich S; 1999</td> </tr> <tr class=\"divider_bottom\"> <td>MTX-VB</td> <td>29</td> <td>NR</td> <td>21 PR or SD</td> <td>NR</td> <td>Dileo P; 2008</td> </tr> <tr class=\"divider_bottom\"> <td>MTX+VB</td> <td>18</td> <td>3 weeks to one year</td> <td> <p>2 PR</p> <p>11 SD</p> 4 PD</td> <td>1-192 </td> <td>Constantinidou A; 2010</td> </tr> <tr class=\"divider_bottom\"> <td>MTX+VB</td> <td>27</td> <td>Median 18 weeks </td> <td> <p>4 PR</p> 14 SD</td> <td>1-145<sup>&#167;</sup></td> <td>Garbay D; 2012</td> </tr> <tr class=\"divider_bottom\"> <td>VCR+DACT+Cy</td> <td>6</td> <td>3 weeks to 13 months</td> <td> <p>4 CR<sup>&#9674;</sup></p> <p>1 PR</p> 1 PD</td> <td>28.4-140</td> <td>Raney B; 1987</td> </tr> <tr> <td>MTX-VN</td> <td>17</td> <td>NR</td> <td> <p>3 CR</p> <p>7 PR</p> <p>2 MR</p> 3 SD</td> <td>0.1-0.9 years</td> <td>Weiss A; 1999</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MTX: methotrexate; VB: vinblastine; VCR: vincristine; VN: vinorelbine; DACT: actinomycin D; Cy: cyclophosphamide; CR: complete response; PR: partial response; SD: stable disease; OR: objective response; MR: minor response; NR: not reported.<br />* Measured from onset of therapy.<br />¶ Prospective Phase II trial.<br />Δ Duration of response was counted from the end of therapy. Treatment duration was listed as 12 months but the authors did not provide individual data on treatment duration.<br /><FONT class=lozenge>◊</FONT> Two patients who attained a CR also received radiation therapy (5600 cGy) after 15 to 18 cycles.<br />§ Range of duration of progression-free survival for 49 patients treated with a nonanthracycline-containing chemotherapy regimen, 27 of whom&nbsp;received MTX-VB.</div><div id=\"graphicVersion\">Graphic 81000 Version 9.0</div></div></div>"},"81002":{"type":"graphic_algorithm","displayName":"US 2011 trauma field triage algorithm","title":"US 2011 trauma field triage algorithm","html":"<div class=\"graphic\"><div style=\"width: 653px\" class=\"figure\"><div class=\"ttl\">US 2011 trauma field triage algorithm</div><div class=\"cntnt\"><img style=\"width:633px; height:863px;\" src=\"images/EM/81002_Revised_trauma_triage_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EMS: emergency medical services.<br> * The upper limit of respiratory rate in infants is &gt;29 breaths per minute to maintain a higher level of overtriage for infants.<br> Δ Trauma centers are designated Level I-IV. A Level I center has the greatest amount of resources and personnel for care of the injured patient and provides regional leadership in education, research, and prevention programs. A Level II facility offers similar resources to a Level I facility, possibly differing only in continuous availability of certain subspecialties or sufficient prevention, education, and research activities for Level I designation; Level II facilities are not required to be resident or fellow education centers. A Level III center is capable of assessment, resuscitation, and emergency surgery, with severely injured patients being transferred to a Level I or II facility. A Level IV trauma center is capable of providing 24-hour physician coverage, resuscitation, and stabilization to injured patients before transfer to a facility that provides a higher level of trauma care.<br> <span class=lozenge>◊</span> Any injury noted in Step two or mechanism identified in Step three triggers a &quot;yes&quot; response.<br> § Age &lt;15 years.<br> ¥ Intrusion refers to interior compartment intrusion, as opposed to deformation which refers to exterior damage.<br> &#135; Includes pedestrians or bicyclists thrown or run over by a motor vehicle or those with estimated impact &gt;20 mph with a motor vehicle.<br> &#134; Local or regional protocols should be used to determine the most appropriate level of trauma center within the defined trauma system; need not be the highest-level trauma center.<br> ** Age &gt;55 years.<br> ΔΔ Patients with both burns and concomitant trauma for whom the burn injury poses the greatest risk for morbidity and mortality should be transferred to a burn center. If the nonburn trauma presents a greater immediate risk, the patient may be stabilized in a trauma center and then transferred to a burn center.<br> <span class=\"double_lozenge\">◊◊</span> Patients who do not meet any of the triage criteria in Steps one through four should be transported to the most appropriate medical facility as outlined in local EMS protocols.</div><div class=\"graphic_reference\">Reproduced from: Sasser SM, Hunt RC, Faul M, et al. Guidelines for field triage of injured patients: Recommendations of the National Expert Panel on Field Triage, 2011. MMWR 2012; 61:1.</div><div id=\"graphicVersion\">Graphic 81002 Version 3.0</div></div></div>"},"81003":{"type":"graphic_picture","displayName":"LCDD in small intestine","title":"Light chain deposition disease in the small intestine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light chain deposition disease in the small intestine</div><div class=\"cntnt\"><img style=\"width:384px; height:252px;\" src=\"images/NEPH/81003_LCDD_in_small_intestine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunoperoxidase stain of a small intestinal biopsy from a patient with light chain deposition disease and malabsorption shows the presence kappa light chains; a stain for lambda light chains was negative.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 81003 Version 1.0</div></div></div>"},"81004":{"type":"graphic_waveform","displayName":"H reflex","title":"H reflex","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">H reflex</div><div class=\"cntnt\"><img style=\"width:515px; height:464px;\" src=\"images/NEURO/81004_H_reflex.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The H reflex with tibial nerve stimulation in the popliteal fossa, recording from the soleus muscle. The H reflex is visible only with submaximal stimulation. With a slow increase in stimulus strength, the H reflex appears as the stimulus changes from subthreshold to submaximal. The amplitude of the H reflex is greatest just below the threshold for the appearance of the compound muscle action potential (CMAP or M response). With increasing stimulus strength, the H reflex amplitude declines as M response amplitude increases. The H reflex disappears with maximal and supramaximal stimulation.</div><div id=\"graphicVersion\">Graphic 81004 Version 2.0</div></div></div>"},"81005":{"type":"graphic_diagnosticimage","displayName":"MR normal placenta","title":"Magnetic resonance image of normal placental attachment (no accreta)","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of normal placental attachment (no accreta)</div><div class=\"cntnt\"><img style=\"width:482px; height:290px;\" src=\"images/OBGYN/81005_MR_normal_placenta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note homogeneity of the placental mass, no &quot;bulging&quot; of the placenta toward the bladder, and the well delineated uterine wall.</div><div class=\"graphic_reference\">Courtesy of Robert Resnik, MD.</div><div id=\"graphicVersion\">Graphic 81005 Version 2.0</div></div></div>"},"81006":{"type":"graphic_diagnosticimage","displayName":"Ultrasound tibialis anterior with foot inversion","title":"Ultrasound of the tibialis anterior with foot inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the tibialis anterior with foot inversion</div><div class=\"cntnt\"><img style=\"width:442px; height:317px;\" src=\"images/NEURO/81006_US_tibialis_ant_foot_inv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are axial images of the tibialis anterior with the foot in neutral position (left, A) and with the foot inverted (right, B). Note that the interosseus membrane (arrows) bulges out with foot inversion due to thickening of the tibialis posterior muscle that lies just deep to it. Needle electromyography or therapeutic botulinum toxin injections can be guided by ultrasound through the anterior tibialis to locate this muscle.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 81006 Version 3.0</div></div></div>"},"81008":{"type":"graphic_figure","displayName":"CRP troponin mortality","title":"C-reactive protein and troponin T are predictive of mortality","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">C-reactive protein and troponin T are predictive of mortality</div><div class=\"cntnt\"><img style=\"width:533px; height:305px;\" src=\"images/CARD/81008_CRP_troponin_mortality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the TIMI 11A study of 630 patients with unstable angina or a non-Q wave myocardial infarction, an early positive troponin T level (cTnT) and C-reactive protein (CRP) level &#8805;1.55 mg/dL were both associated with an increased mortality at 14 days; the mortality was highest when both levels were elevated.</div><div class=\"graphic_reference\">Data from: Morrow DA, Rifai N, Antman EM, et al. J Am Coll Cardiol 1998; 31:1460.</div><div id=\"graphicVersion\">Graphic 81008 Version 2.0</div></div></div>"},"81011":{"type":"graphic_picture","displayName":"Porokeratosis of Mibelli","title":"Porokeratosis of Mibelli","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Porokeratosis of Mibelli</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/81011_Porokeratosis_Mibelli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large plaque with a slightly atrophic center and a prominent peripheral keratotic ridge is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81011 Version 4.0</div></div></div>"},"81013":{"type":"graphic_figure","displayName":"Branchial cleft cysts","title":"Branchial cleft cysts","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Branchial cleft cysts</div><div class=\"cntnt\"><img style=\"width:540px; height:527px;\" src=\"images/PC/81013_Branchial_cleft_cysts.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81013 Version 2.0</div></div></div>"},"81014":{"type":"graphic_picture","displayName":"Vasculitic ulcers in Behçet's syndrome","title":"Vasculitic ulcers in Behçet's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vasculitic ulcers in Behçet's syndrome</div><div class=\"cntnt\"><img style=\"width:413px; height:288px;\" src=\"images/RHEUM/81014_Vasculitic_ulcers_in_Behcet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Painful vasculitic ulcers of scrotum, penis, and fingers in a patient with Behçet's syndrome.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 81014 Version 3.0</div></div></div>"},"81015":{"type":"graphic_diagnosticimage","displayName":"Carpal tunnel view of the wrist","title":"Carpal tunnel view of the wrist","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Carpal tunnel view of the wrist</div><div class=\"cntnt\"><img style=\"width:500px; height:325px;\" src=\"images/EM/81015_Carpal_tunnel_RG_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph above shows a carpal tunnel view of the wrist. The palmar ridge of the trapezium can be seen in profile at the base of the first metacarpal (arrow). This view also shows the hook of the hamate in profile (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 81015 Version 6.0</div></div></div>"},"81016":{"type":"graphic_figure","displayName":"Finasteride in BPH","title":"Finasteride reduces surgery and acute urinary retention in BPH","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Finasteride reduces surgery and acute urinary retention in BPH</div><div class=\"cntnt\"><img style=\"width:501px; height:246px;\" src=\"images/ENDO/81016_Finasteride_in_BPH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of finasteride (5 mg/day) versus placebo on the probability of surgery and acute urinary retention in 3016 men with moderate to severe benign prostatic hyperplasia. Both endpoints were significantly (p&lt;0.001) reduced in the men treated with finasteride.</div><div class=\"graphic_reference\">Data from McConnell JD, Bruskewitz R, Walsh P, et al, N Engl J Med 1998; 338:557.</div><div id=\"graphicVersion\">Graphic 81016 Version 3.0</div></div></div>"},"81017":{"type":"graphic_figure","displayName":"Kustner incision","title":"Küstner incision","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">K&#252;stner incision</div><div class=\"cntnt\"><img style=\"width:469px; height:354px;\" src=\"images/SURG/81017_Kustner_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse incision to sheath, subcutaneous tissue separated from linea alba. Midline incision in linea alba.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 81017 Version 3.0</div></div></div>"},"81018":{"type":"graphic_picture","displayName":"Lichen simplex chronicus2","title":"Vulvar lichen simplex chronicus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar lichen simplex chronicus</div><div class=\"cntnt\"><img style=\"width:351px; height:432px;\" src=\"images/OBGYN/81018_Lichen_simplex_chronicus2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 81018 Version 3.0</div></div></div>"},"81019":{"type":"graphic_figure","displayName":"Trigger points myofascial pain","title":"Trigger points in myofascial pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trigger points in myofascial pain syndrome</div><div class=\"cntnt\"><img style=\"width:313px; height:463px;\" src=\"images/RHEUM/81019_Trigger_points_myofascial_p.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with myofascial pain syndrome have tenderness within the affected muscle and soft tissue. Trigger points arising in the erector spinae muscles, the gluteal fascia, and the presacral fascia are common.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 81019 Version 2.0</div></div></div>"},"81022":{"type":"graphic_figure","displayName":"Stage I palliative repair for HLHS","title":"Stage I palliative repair for HLHS","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Stage I palliative repair for HLHS</div><div class=\"cntnt\"><img style=\"width:597px; height:271px;\" src=\"images/PEDS/81022_Stage1palliatrepairHLHS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stage I palliation of hypoplastic left heart syndrome.<br />(Panel A) Stage I palliation (Norwood procedure) using a modified Blalock-Thomas-Taussig (BT) shunt for provision of pulmonary blood flow. The shunt originates from the innominate artery and inserts into the central pulmonary artery.<br />(Panel B) Stage I palliation using a right ventricle (RV)-to-pulmonary artery (PA) conduit (Sano modification) for provision of pulmonary blood flow. A larger 5 or 6 mm graft is placed between the right ventricle and the central pulmonary artery.<br />(Panel C) Stage I palliation using a hybrid approach. Pulmonary blood flow is restricted with branch pulmonary artery bands, and the ductal patency is maintained by placement of a stent. A stent is placed to create a nonrestrictive atrial septal defect.</div><div class=\"graphic_reference\">Reproduced with permission from: Tweddell J, Hoffman G, Ghanayem N, et al. Hypoplastic left heart syndrome. In: Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 7<SUP>th</SUP> ed, Allen H, Driscoll D, Shaddy R, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81022 Version 9.0</div></div></div>"},"81027":{"type":"graphic_picture","displayName":"Enanthem in Coxsackie infection","title":"Enanthem in coxsackievirus infection","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Enanthem in coxsackievirus infection</div><div class=\"cntnt\"><img style=\"width:504px; height:388px;\" src=\"images/ID/81027_Enanthem_coxsackie_infec_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scattered petechiae appear centrally, and there is a vesicle posteriorly at the junction of the hard and soft palates. Coxsackievirus produces lesions toward the posterior of the oropharynx, whereas herpes simplex virus appears anteriorly.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81027 Version 2.0</div></div></div>"},"81028":{"type":"graphic_table","displayName":"Canada guide pulmonary disease kidney transplantation","title":"Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation, continued</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pulmonary disease</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendations</td> </tr> <tr> <td class=\"sublist2_start\">1. Patients with the following respiratory conditions and severity are not candidates for kidney transplantation:</td> </tr> <tr> <td class=\"sublist2\">Requirement for home oxygen therapy (Grade C)</td> </tr> <tr> <td class=\"sublist2\">Uncontrolled asthma (Grade C)</td> </tr> <tr> <td class=\"sublist2\">Severe cor pulmonale</td> </tr> <tr> <td class=\"sublist2\">Severe COPD-pulmonary fibrosis or restrictive disease with any of the following parameters (Grade C):</td> </tr> <tr> <td class=\"sublist3\">Best forced expiratory volume in&nbsp;one second (FEV<sub>1</sub>) &#60;25% predicted value</td> </tr> <tr> <td class=\"sublist3\">PO<sub>2</sub> room air &#60;60 mmHg with exercise desaturation, SaO<sub>2</sub> &#60;90%</td> </tr> <tr> <td class=\"sublist3\">More than four&nbsp;lower respiratory infections in the last 12 months</td> </tr> <tr> <td class=\"sublist3\">Moderate disease with evidence of progression</td> </tr> <tr> <td class=\"indent1\">2. Patients with moderate COPD-pulmonary fibrosis or restrictive disease with any of the following parameters have a relative contraindication for kidney transplantation (Grade C):</td> </tr> <tr> <td class=\"sublist2\">Best FEV<sub>1</sub> 25 to 50% of predicted value</td> </tr> <tr> <td class=\"sublist2\">PO<sub>2</sub> room air &#60;60 to 70 mmHg</td> </tr> <tr> <td class=\"sublist2\">Restrictive disease with exercise desaturation, SaO<sub>2</sub> 90%</td> </tr> <tr> <td class=\"indent1\">3. Patients should be strongly encouraged to stop smoking before kidney transplantation. Patients who continue to smoke may be eligible for kidney transplantation with full informed consent regarding their increased risk (Grade C).</td> </tr> <tr> <td class=\"indent1\">4. Children with bronchopulmonary dysplasia, pulmonary hypoplasia, or other significant chronic lung disease should be evaluated for transplantation in consultation with a pediatric respirologist (Grade C).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The strength of evidence supporting each recommendation was graded using the system developed by the Canadian Task Force on Preventive Health Care as follows:<br />Grade A - There is good evidence to support<br />Grade B - There is fair evidence to support<br />Grade C - The existing evidence is conflicting, but other factors may influence decision-making<br />Grade D - There is fair evidence to recommend against<br />Grade E - There is good evidence to recommend against</div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation: Consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:S1. Copyright © 2005 CMA Media Inc.</div><div id=\"graphicVersion\">Graphic 81028 Version 3.0</div></div></div>"},"81029":{"type":"graphic_picture","displayName":"Ant scleritis inflammation","title":"Acute necrotizing anterior scleritis with inflammation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute necrotizing anterior scleritis with inflammation</div><div class=\"cntnt\"><img style=\"width:322px; height:215px;\" src=\"images/RHEUM/81029_Ant_scleritis_inflammation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute necrotizing scleritis with inflammation in a patient with rheumatoid arthritis. Anterior bulging of the inflamed sclera is seen in association with scleral thinning due to necrosis.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 81029 Version 2.0</div></div></div>"},"81030":{"type":"graphic_diagnosticimage","displayName":"Syringomyelia with Chiari I malformation","title":"Syringomyelia associated with a Chiari I malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Syringomyelia associated with a Chiari I malformation</div><div class=\"cntnt\"><img style=\"width:334px; height:576px;\" src=\"images/NEURO/81030_Chiari_Syringomyelia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal T1-weighted MRI reveals syringomyelia (arrows) involving the lower cervical spinal cord in a patient with a Chiari I malformation.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 81030 Version 5.0</div></div></div>"},"81032":{"type":"graphic_table","displayName":"Biochemical findings rickets","title":"Biochemical findings in rickets","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biochemical findings in rickets</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Calcium</td> <td class=\"subtitle1\">Phosphorus</td> <td class=\"subtitle1\">Alkaline phosphatase</td> <td class=\"subtitle1\">PTH</td> <td class=\"subtitle1\">25 OHD</td> <td class=\"subtitle1\">1,25 (OH)<sub>2</sub>D</td> <td class=\"subtitle1\">Urine calcium</td> </tr> <tr> <td rowspan=\"4\"><strong>Calcipenic rickets</strong></td> <td>Vitamin D deficient rickets</td> <td class=\"centered\">&#8595; or N</td> <td class=\"centered\">&#8595; or N</td> <td class=\"centered\">&#8593; or &#8593;&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593; or N*</td> <td class=\"centered\">&#8595; or N</td> </tr> <tr> <td>1-alpha-hydroxylase deficiency<sup>&#182;</sup></td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595; or N</td> <td class=\"centered\">&#8593;&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>25-hydroxylase deficiency&nbsp;<br /> (variable severity)</td> <td class=\"centered\">&#8595; or N&nbsp;</td> <td class=\"centered\">&#8595; &nbsp;</td> <td class=\"centered\">&#8593;&#8593;&nbsp;</td> <td class=\"centered\">&#8593;&nbsp;</td> <td class=\"centered\">&#8595;&nbsp;</td> <td class=\"centered\">N&nbsp;</td> <td class=\"centered\">&#8595;&nbsp;</td> </tr> <tr> <td>Hereditary resistance to vitamin D<sup>&#916;</sup></td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595; or N</td> <td class=\"centered\">&#8593;&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N</td> <td class=\"centered\">&#8593;&#8593;</td> <td class=\"centered\">&#8595;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Phosphopenic rickets</strong></td> <td>X-linked hypophosphatemia</td> <td class=\"centered\">N</td> <td class=\"centered\">&#8595;&#8595;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N or slightly &#8593;</td> <td class=\"centered\">N</td> <td class=\"centered\">N or &#8595;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>Hereditary hypophosphatemic rickets with hypercalciuria</td> <td class=\"centered\">N</td> <td class=\"centered\">&#8595; or &#8595;&#8595;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N or &#8595;</td> <td class=\"centered\">N</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td>Nutritional phosphate deprivation</td> <td class=\"centered\">&#8593; or N</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593; or &#8593;&#8593;</td> <td class=\"centered\">&#8595; or N</td> <td class=\"centered\">N</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593; or N</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Calcipenic rickets refers to disorders in which intestinal absorption of calcium is too low to match the calcium demands imposed by bone growth. The term \"hypocalcemic\" rickets is also used, but can be misleading because calcipenic rickets is not always associated with low serum levels of calcium. Among the forms of phosphopenic rickets, nutritional phosphate deprivation can be distinguished by the finding of low&nbsp;urine phosphate (elevated renal tubular reabsorption of phosphate [TRP]), whereas those due to renal phosphate losses usually manifest increased urine phosphate clearance (low TRP). </div><div class=\"graphic_footnotes\">↑: increased; ↓: decreased; N: normal; PTH: parathyroid hormone; 25(OH)D: 25-hydroxyvitamin D; 1,25(OH)<SUB>2</SUB>D: 1,25-dihydroxyvitamin D.<br />* In vitamin D deficient rickets, 1,25(OH)<SUB>2</SUB>D usually is increased or normal. Occasionally, it may be deceased.<br />¶ 1-alpha-hydroxylase deficiency was previously known as vitamin D-dependent rickets type 1 or pseudo-vitamin D deficiency rickets. <br />Δ Hereditary resistance to vitamin D was previously known as vitamin D-dependent rickets type 2. </div><div class=\"graphic_reference\">Modified with permission from: McMillan JA, DeAngelis CD, Feigin RD, Warshaw JB. Oski's Pediatrics: Principles and Practice, 3rd ed. Lippincott Williams and Wilkins, Philadelphia 1999. p.1619. Copyright &copy; 1999 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 81032 Version 15.0</div></div></div>"},"81033":{"type":"graphic_table","displayName":"Infectious causes generalized lymphadenopathy children","title":"Infectious causes of generalized lymphadenopathy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of generalized lymphadenopathy in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Infectious</td> <td class=\"subtitle1\">Selected clinical features that may be present</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Viral</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> <td>Tonsillopharyngitis, splenomegaly (&#62;50 percent), fever, malaise, fatigue, periorbital edema</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> <td>Fever, malaise, fatigue, occasional hepatosplenomegaly</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> <td>Grouped vesicles; gingivostomatitis</td> </tr> <tr> <td class=\"indent1\">Varicella zoster virus</td> <td>Generalized vesicular rash appearing in crops</td> </tr> <tr> <td class=\"indent1\">Adenovirus</td> <td>Respiratory tract symptoms, pharyngitis, conjunctivitis</td> </tr> <tr> <td class=\"indent1\">Rubella</td> <td>Fever and rash; may be asymptomatic</td> </tr> <tr> <td class=\"indent1\">Hepatitis B virus</td> <td>High-risk sexual behavior, exposure to blood products</td> </tr> <tr> <td class=\"indent1\">Rubeola (measles)</td> <td>Maculopapular rash with cranial to caudal progression, cough, coryza, conjunctivitis, Koplik spots</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus</td> <td>Recurrent bacterial infection, opportunistic infection, fever, diarrhea, encephalopathy, failure to thrive, hepatosplenomegaly</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fungal</td> </tr> <tr> <td class=\"indent1\">Coccidioidomycosis (valley fever)</td> <td>Pneumonia; travel to or residence in endemic area (eg, southwestern United States)</td> </tr> <tr> <td class=\"indent1\">Blastomycosis</td> <td>Pneumonia; travel to or residence in an endemic area (eg, southeastern and south central United States, Africa)</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis</td> <td>Pneumonia; travel to or residence in an endemic area (eg, Ohio, Mississippi, and Missouri River valleys)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Bacterial</td> </tr> <tr> <td class=\"indent1\">Group A streptococcal disease</td> <td>Rash followed by desquamation</td> </tr> <tr> <td class=\"indent1\">Brucellosis</td> <td>Fever, sweats, malaise, fatigue, weight loss, ingestion of unpasteurized milk; exposure to cattle, sheep, or goats</td> </tr> <tr> <td class=\"indent1\">Tularemia</td> <td>Fever, chills, headache; ingestion of undercooked meats, exposure to rabbits, rodents, biting flies, or mosquitoes</td> </tr> <tr> <td class=\"indent1\">Leptospirosis</td> <td>Fever, rigors, myalgia, headache, conjunctival injection, rash, hepatosplenomegaly</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Spirochetal</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> <td>Rash, fever, malaise, anorexia, and weight loss; hepatomegaly</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> <td>Erythema migrans, fever, headache, myalgia, malaise, arthralgia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Parasitic</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis</td> <td>Most infections in immunocompetent hosts are asymptomatic; myalgia, fatigue, fever, splenomegaly, and maculopapular rash may be present; exposure to cats</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis</td> <td>Cutaneous lesions, organomegaly, fever, cachexia; exposure to sandflies</td> </tr> <tr> <td class=\"indent1\">Malaria</td> <td>Fever, travel to or residence in an endemic area</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Malley R. Lymphadenopathy. In: Textbook of Pediatric Emergency Medicine, 5<SUP>th</SUP> ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.421.</div><div id=\"graphicVersion\">Graphic 81033 Version 7.0</div></div></div>"},"81034":{"type":"graphic_table","displayName":"Histologic features NSIP","title":"Histologic features of nonspecific interstitial pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic features of nonspecific interstitial pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key histologic features</td> </tr> <tr> <td class=\"subtitle2_single\">Cellular pattern*</td> </tr> <tr> <td class=\"indent1\">Mild to moderate interstitial chronic inflammation</td> </tr> <tr> <td class=\"indent1\">Type II pneumocyte hyperplasia in areas of inflammation</td> </tr> <tr> <td class=\"subtitle2_single\">Fibrosing pattern*</td> </tr> <tr> <td class=\"indent1\">Dense or loose interstitial fibrosis lacking the temporal heterogeneity pattern and/or patchy features of UIP</td> </tr> <tr> <td class=\"indent1\">Lung architecture may appear lost on examination of H&#38;E-stained section, but is relatively preserved with elastin stains</td> </tr> <tr> <td class=\"indent1\">Interstitial chronic inflammation - mild or moderate</td> </tr> <tr> <td class=\"subtitle1_single\">Pertinent negative findings</td> </tr> <tr> <td class=\"subtitle2_single\">Cellular pattern</td> </tr> <tr> <td class=\"indent1\">Dense interstitial fibrosis: absent</td> </tr> <tr> <td class=\"indent1\">Organizing pneumonia: absent or not prominent</td> </tr> <tr> <td class=\"indent1\">Diffuse severe alveolar septal inflammation: absent</td> </tr> <tr> <td class=\"subtitle2_single\">Fibrosing pattern</td> </tr> <tr> <td class=\"indent1\">Temporal heterogeneity pattern: fibroblastic foci with dense fibrosis are inconspicuous or absent - this is especially important in cases with patchy involvement and subpleural or paraseptal distribution</td> </tr> <tr> <td class=\"subtitle2_single\">Both patterns</td> </tr> <tr> <td class=\"indent1\">Acute lung injury pattern, especially hyaline membranes: absent</td> </tr> <tr> <td class=\"indent1\">Eosinophils: inconspicuous or absent</td> </tr> <tr> <td class=\"indent1\">Granulomas: inconspicuous or absent</td> </tr> <tr> <td class=\"indent1\">Viral inclusions and organisms on special stains: not present</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* There is a spectrum from cellular to fibrosing patterns, with some cases showing a combination of cellular and fibrosing features.<BR>UIP: usual interstitial pneumonia; H&amp;E: hematoxylin and eosin.</div><div id=\"graphicVersion\">Graphic 81034 Version 3.0</div></div></div>"},"81035":{"type":"graphic_diagnosticimage","displayName":"Overlapping fracture","title":"Complete fracture","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Complete fracture</div><div class=\"cntnt\"><img style=\"width:520px; height:320px;\" src=\"images/EM/81035_Overlapping_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overlapping complete fracture of radius and ulna (100 percent displaced) in a 7-year-old child.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 81035 Version 2.0</div></div></div>"},"81036":{"type":"graphic_figure","displayName":"Mullerian anomalies","title":"Mullerian uterine anomalies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mullerian uterine anomalies</div><div class=\"cntnt\"><img style=\"width:448px; height:637px;\" src=\"images/OBGYN/81036_Mullerian_anomalies.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, mullerian anomalies and intrauterine adhesions. Fertil Steril 1988; 49:944. Copyright &#169;1988 American Society for Reproductive Medicine.</div><div id=\"graphicVersion\">Graphic 81036 Version 1.0</div></div></div>"},"81037":{"type":"graphic_table","displayName":"Clinical situations associated with vitamin deficiency","title":"Clinical situations in which vitamin deficiency syndromes occur","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical situations in which vitamin deficiency syndromes occur</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Poor intake</td> <td>Poverty, older adults, alcoholics, restrictive diets (eg, vegan)</td> </tr> <tr> <td>Malabsorption</td> <td>Celiac disease, Crohn disease, short bowel, gastric bypass, older adults</td> </tr> <tr> <td>Abnormal losses</td> <td>Hemodialysis, chronic diarrhea</td> </tr> <tr> <td>Abnormal metabolism</td> <td>Genetic polymorphisms, alcoholism (increases folate metabolism)</td> </tr> <tr> <td>Inadequate synthesis</td> <td>Vitamin D (Northern climates, homebound, little exposed skin)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81037 Version 4.0</div></div></div>"},"81038":{"type":"graphic_diagnosticimage","displayName":"FDG PET CT lung","title":"FDG-PET/CT of a malignant lung mass","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FDG-PET/CT of a malignant lung mass</div><div class=\"cntnt\"><img style=\"width:504px; height:389px;\" src=\"images/PULM/81038_FDG_PET_CT_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image demonstrates a malignant lung mass as seen on an integrated 18-fluoro-2-deoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) scan. The increased activity of the mass is the result of the uptake and accumulation of FDG by the metabolically active tumor cells.</div><div id=\"graphicVersion\">Graphic 81038 Version 4.0</div></div></div>"},"81039":{"type":"graphic_picture","displayName":"Dissecting cellulitis scars","title":"Dissecting cellulitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dissecting cellulitis of the scalp</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/81039_Dissecting_cellulitis_scars.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive scarring in a patient with dissecting cellulitis of the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81039 Version 3.0</div></div></div>"},"81040":{"type":"graphic_picture","displayName":"Primary sclerosing cholangitis","title":"Primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:351px; height:239px;\" src=\"images/GAST/81040_Primary_sclerosing_cholangi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a liver biopsy in primary sclerosing cholangitis showing mononuclear cell infiltration and charactertistic concentric fibrosis around a small bile duct.</div><div class=\"graphic_reference\">Courtesy of Edward L Krawitt, MD.</div><div id=\"graphicVersion\">Graphic 81040 Version 1.0</div></div></div>"},"81042":{"type":"graphic_picture","displayName":"Molluscum penis 1","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:432px; height:267px;\" src=\"images/DERM/81042_Molluscum_penis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic dome-shaped, shiny, waxy papules are present on the penis.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81042 Version 2.0</div></div></div>"},"81043":{"type":"graphic_table","displayName":"Infections causing liver granulomas","title":"Infections causing granulomatous hepatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infections causing granulomatous hepatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bacterial</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td>MAC</td> </tr> <tr> <td>Brucellosis</td> </tr> <tr> <td>Lepromatous leprosy</td> </tr> <tr> <td>BCG infection</td> </tr> <tr> <td>Listeriosis</td> </tr> <tr> <td>Melioidosis</td> </tr> <tr> <td>Tularemia</td> </tr> <tr> <td>Yersiniosis</td> </tr> <tr> <td>Psittacosis</td> </tr> <tr> <td>Whipple disease</td> </tr> <tr> <td>Catch scratch fever</td> </tr> <tr> <td class=\"subtitle1_single\">Viral</td> </tr> <tr> <td>CMV</td> </tr> <tr> <td>EBV</td> </tr> <tr> <td>Hepatitis A, B and C</td> </tr> <tr> <td class=\"subtitle1_single\">Fungal</td> </tr> <tr> <td>Histoplasmosis</td> </tr> <tr> <td>Coccidioidomycosis</td> </tr> <tr> <td>Cryptococcus</td> </tr> <tr> <td>Nocardiosis</td> </tr> <tr> <td>Candidiasis</td> </tr> <tr> <td class=\"subtitle1_single\">Parasitic</td> </tr> <tr> <td>Toxoplasmosis</td> </tr> <tr> <td>Schistosomiasis</td> </tr> <tr> <td>Visceral larva migrans</td> </tr> <tr> <td>Visceral leishmaniasis</td> </tr> <tr> <td class=\"subtitle1_single\">Rickettsial</td> </tr> <tr> <td>Coxiella burnetii (Q fever)</td> </tr> <tr> <td>Bontonneuse fever</td> </tr> <tr> <td class=\"subtitle1_single\">Spirochetal</td> </tr> <tr> <td>Secondary syphilis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81043 Version 4.0</div></div></div>"},"81045":{"type":"graphic_table","displayName":"Clinical features of opioid withdrawal","title":"Clinical features of opioid withdrawal","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of opioid withdrawal</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Vital Signs</td> </tr> <tr> <td>Blood pressure increased or unchanged; decreased if hypovolemic</td> </tr> <tr> <td>Heart rate increased or unchanged</td> </tr> <tr> <td>Respiratory rate increased or unchanged</td> </tr> <tr> <td>Temperature unchanged</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td>Nausea, vomiting</td> </tr> <tr> <td>Diarrhea, increased bowel sounds</td> </tr> <tr> <td class=\"subtitle1_single\">Neurological</td> </tr> <tr> <td>Mental status usually normal, irritable</td> </tr> <tr> <td>Restlessness</td> </tr> <tr> <td>Seizures (neonates only)</td> </tr> <tr> <td>Tremor</td> </tr> <tr> <td>Yawning</td> </tr> <tr> <td class=\"subtitle1_single\">Ophthalmologic</td> </tr> <tr> <td>Lacrimation</td> </tr> <tr> <td>Mydriasis</td> </tr> <tr> <td class=\"subtitle1_single\">Skin</td> </tr> <tr> <td>Piloerection</td> </tr> <tr> <td>Diaphoresis</td> </tr> <tr> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81045 Version 4.0</div></div></div>"},"81047":{"type":"graphic_diagnosticimage","displayName":"Saethre Chotzen radiograph","title":"Anteroposterior radiograph in a patient with Saethre-Chotzen syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anteroposterior radiograph in a patient with Saethre-Chotzen syndrome</div><div class=\"cntnt\"><img style=\"width:360px; height:484px;\" src=\"images/PEDS/81047_Saethre_Chotzen_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior plagiocephaly demonstrated in a patient with Saethre-Chotzen syndrome. Note the closure of the metopic suture (arrow) although both coronal sutures (arrowheads) remain present.</div><div class=\"graphic_reference\">Courtesy of Raoul CM Hennekam, MD, PhD.</div><div id=\"graphicVersion\">Graphic 81047 Version 3.0</div></div></div>"},"81049":{"type":"graphic_picture","displayName":"Leukoplakia - buccal","title":"Leukoplakia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukoplakia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81049_Leukoplakia_buccal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A white plaque is present on the buccal mucosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81049 Version 3.0</div></div></div>"},"81050":{"type":"graphic_figure","displayName":"Mastectomy incisions for inner quadrant tumors","title":"Mastectomy incisions for tumors of the inner quadrants of the breast","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mastectomy incisions for tumors of the inner quadrants of the breast</div><div class=\"cntnt\"><img style=\"width:504px; height:614px;\" src=\"images/SURG/81050_Mastectomyincisinnerquad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Design of the obliquely placed modiﬁed Stewart incision for cancer of the inner quadrant of the breast. The medial extent of the incision often must incorporate skin to the midsternum to allow a 1 to 2 cm margin in all directions from the edge of the tumor. Lateral extent of the incision ends at the anterior margin of the latissimus.</div><div class=\"graphic_reference\">Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81050 Version 8.0</div></div></div>"},"81055":{"type":"graphic_diagnosticimage","displayName":"Brain MRI 16-year-old vanishing white matter disease","title":"Brain MRI of a 16-year-old girl with vanishing white matter disease","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a 16-year-old girl with vanishing white matter disease</div><div class=\"cntnt\"><img style=\"width:588px; height:187px;\" src=\"images/NEURO/81055_MRI_girl_age_16_VWM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MR images of Patient 3. Shown are the transverse T2-weighted (A, B), proton density (C), and coronal FLAIR (D) images. The abnormal cerebral hemispheric white matter has a homogeneously high signal on T2-weighted images, but partly high and partly low signals on proton density and FLAIR images. The signal intensity is lowest in the white matter closest to the lateral ventricles (C, D). Note the radiating stripelike pattern in the low-signal intensity areas (C, D). Within the posterior limb of the internal capsule, a double line of signal abnormality is seen (B; arrows). Within the brainstem, the central tegmental tracts (A; small arrows) and transverse pontine fibers (A; large arrows) are involved.</div><div class=\"graphic_footnotes\">MR: magnetic resonance; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">Reproduced with permission from: Van der Knaap MS, Kamphorst W, Barth PG. Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology 1998; 51:540. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81055 Version 13.0</div></div></div>"},"81056":{"type":"graphic_diagnosticimage","displayName":"Drill use for bx femoral cortex","title":"Use of a drill to facilitate bone biopsy of a lymphoma involving the cortex of the femur","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Use of a drill to facilitate bone biopsy of a lymphoma involving the cortex of the femur</div><div class=\"cntnt\"><img style=\"width:552px; height:320px;\" src=\"images/ONC/81056_Drill_use_for_bx_femoral_co.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A drill was used to create a hole in the femoral cortex (panel A). A soft tissue biopsy device (TEMNO) was then introduced through the drill hole to obtain a biopsy of this lymphoma (panel B).</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 81056 Version 3.0</div></div></div>"},"81058":{"type":"graphic_picture","displayName":"JXG multiple lesions","title":"Juvenile xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81058_Multiple_JXG_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple scalp lesions in a young child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81058 Version 3.0</div></div></div>"},"81059":{"type":"graphic_figure","displayName":"Pressure sore sites PI","title":"Pressure sore sites","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Pressure sore sites</div><div class=\"cntnt\"><img style=\"width:570px; height:431px;\" src=\"images/PI/81059_Pressure_ulcer_sites_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These drawings show the most common places that people get pressure sores.</div><div class=\"graphic_reference\">Reproduced with permission from: Taylor CR, Lillis C, LeMone P, Lynn P. Fundamentals of Nursing: The Art And Science Of Nursing Care, Sixth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81059 Version 3.0</div></div></div>"},"81060":{"type":"graphic_picture","displayName":"Uncomplicated local reaction to Hymenoptera sting","title":"Uncomplicated local reaction to Hymenoptera sting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uncomplicated local reaction to Hymenoptera sting</div><div class=\"cntnt\"><img style=\"width:396px; height:344px;\" src=\"images/ALLRG/81060_Stinglocalrxnuncomplic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Uncomplicated local reactions from the sting of Hymenoptera insects usually consist of erythema and an area of painful swelling 1 to 2 cm in diameter surrounding the puncture site from the stinger. These reactions typically subside within a few hours.</div><div class=\"graphic_reference\">Courtesy of Theodore Freeman, MD.</div><div id=\"graphicVersion\">Graphic 81060 Version 4.0</div></div></div>"},"81062":{"type":"graphic_table","displayName":"Primary AED therapy for status epilepticus","title":"Primary AED therapy for status epilepticus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary AED therapy for status epilepticus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Initial IV dose</td> <td class=\"subtitle1\">Rate of infusion</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Lorazepam</strong></td> <td>0.1 mg/kg (maximum dose 4 mg)</td> <td class=\"divider_bottom\" rowspan=\"2\">2 mg/min</td> <td>Sedation, hypotension</td> </tr> <tr class=\"divider_bottom\"> <td>May repeat in 5-10 min</td> <td>Respiratory depression</td> </tr> <tr> <td rowspan=\"2\"><strong>Fosphenytoin</strong></td> <td rowspan=\"2\">20 mg PE/kg IV</td> <td>3 mg PE/kg/min</td> <td>Hypotension, arrhythmias</td> </tr> <tr> <td>Maximum rate 150 mg PE/min</td> <td>Cardiac monitoring required</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AED: antiepileptic drug; PE: phenytoin equivalents.</div><div id=\"graphicVersion\">Graphic 81062 Version 4.0</div></div></div>"},"81063":{"type":"graphic_picture","displayName":"Proximal subungual onychomycosis","title":"Proximal subungual onychomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal subungual onychomycosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81063_Prox_sub_onychomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proximal, white discoloration of the nail plate is noted. The nail fold is uninvolved.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81063 Version 4.0</div></div></div>"},"81064":{"type":"graphic_picture","displayName":"Complete gastric intestinal metaplasia","title":"Complete gastric intestinal metaplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete gastric intestinal metaplasia</div><div class=\"cntnt\"><img style=\"width:396px; height:296px;\" src=\"images/ONC/81064_Complete_metaplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In complete intestinal metaplasia, the glands and foveolar epithelium are replaced by small intestine type mucosa with&nbsp;goblet cells, eosinophilic enterocytes&nbsp;and a&nbsp;\"brush border.\"</div><div id=\"graphicVersion\">Graphic 81064 Version 2.0</div></div></div>"},"81067":{"type":"graphic_picture","displayName":"Hemophagocytic syndrome","title":"Infection-associated hemophagocytic syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infection-associated hemophagocytic syndrome</div><div class=\"cntnt\"><img style=\"width:420px; height:285px;\" src=\"images/HEME/81067_Hemophagocytic_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow from a child with hemophagocytic syndrome, secondary to Epstein-Barr virus infection. Reactive histiocytes show phagocytosis of nucleated red blood cells (red arrows) and platelets (black arrows). Wright-Giemsa stain.</div><div class=\"graphic_reference\">From: Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 81067 Version 3.0</div></div></div>"},"81068":{"type":"graphic_figure","displayName":"Beta agonist effect in EIB","title":"Inhaled beta-agonists protect against exercise-induced bronchoconstriction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inhaled beta-agonists protect against exercise-induced bronchoconstriction</div><div class=\"cntnt\"><img style=\"width:397px; height:337px;\" src=\"images/PULM/81068_Beta_agonists_for_EIB.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The degree of exercise-induced bronchoconstriction (as measured by a fall in peak expiratory flow) with placebo, inhaled salbutamol (albuterol), or the long-acting inhaled beta-2 agonist formoterol. Formoterol produced more prolonged protection than salbutamol.</div><div class=\"graphic_reference\">Data from Henriksen JM, Agertoft L, Pedersen S, J Allergy Clin Immunol 1992; 89:1176.</div><div id=\"graphicVersion\">Graphic 81068 Version 2.0</div></div></div>"},"81069":{"type":"graphic_table","displayName":"Hemodyn pulm thromboend I","title":"Hemodynamics after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamics after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody> <tr> <td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">Preoperative</td> <td class=\"subtitle1\">Postoperative</td> </tr> <tr>\n<td>PA mean pressure (mmHg)</td> <td>46 &plusmn;\n12</td> <td>28 &plusmn; 9*</td> </tr>\n<tr> <td>PA systolic pressure (mmHg)</td> <td>76\n&plusmn; 21</td> <td>47 &plusmn; 16*</td> </tr>\n<tr> <td>Cardiac output (L/min)</td> <td>3.7\n&plusmn; 1.1</td> <td>5.7 &plusmn; 1.2*</td> </tr>\n<tr> <td>PVR (dynes x sec x cm<sup>-5</sup>)</td>\n<td>901\n&plusmn; 467</td> <td>261 &plusmn; 163*</td> </tr>\n</tbody></table></div><div class=\"graphic_lgnd\">Immediate pulmonary hemodynamic results in 128 or 150 patients in whom postoperative values were obtained 48 to 72 hours after admission to the intensive care unit, off all vasoactive drugs. There were highly significant (* p&lt;0.001) reductions in pulmonary artery (PA) mean pressure and systolic pressure and pulmonary vascular resistance (PVR) and an increase in cardiac output.</div><div id=\"graphicVersion\">Graphic 81069 Version 1.0</div></div></div>"},"81070":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM Brain CT","title":"Patient with an arteriovenous malformation in right lower lobe who developed a stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with an arteriovenous malformation in right lower lobe who developed a stroke</div><div class=\"cntnt\"><img style=\"width:288px; height:358px;\" src=\"images/PULM/81070_Pulm_AVM_Brain_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the brain shows a right-sided ischemic stroke in the middle cerebral artery territory.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 81070 Version 4.0</div></div></div>"},"81072":{"type":"graphic_table","displayName":"PFT interpretation in children","title":"Guide for pulmonary function interpretation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guide for pulmonary function interpretation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Parameter</td> <td class=\"subtitle1\" colspan=\"3\">Pattern</td> </tr> <tr> <td class=\"subtitle2\">Restrictive</td> <td class=\"subtitle2\">Obstructive</td> <td class=\"subtitle2\">Combined</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Lung volumes</td> </tr> <tr> <td class=\"indent1\">Total lung capacity (TLC)</td> <td>&#8595;</td> <td>Normal or &#8593;</td> <td>&#8595;</td> </tr> <tr> <td class=\"indent1\">Vital capacity</td> <td>&#8595;</td> <td>Normal or &#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"indent1\">Residual volume (RV)</td> <td>Normal or &#8595;</td> <td>Normal or &#8593;</td> <td>Normal or &#8593;</td> </tr> <tr> <td class=\"indent1\">RV/TLC ratio</td> <td>Normal or &#8593;</td> <td>&#8593;</td> <td>&#8593;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Maximal expiratory flow rates</td> </tr> <tr> <td class=\"indent1\">FEV1</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"indent1\">FEV1:FVC</td> <td>Normal</td> <td>&#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"indent1\">FEF 25% to 75%</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"indent1\">Peak expiratory flow</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> </tr> <tr> <td class=\"indent1\">Flow-volume curve</td> <td>&#8595; Volume</td> <td>&#8595; Flows</td> <td>&#8595; Flows and volume</td> </tr> <tr> <td class=\"indent1\">Bronchodilator response</td> <td>None</td> <td>&#8593; Flows</td> <td>Normal or &#8593; flows</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gas exchange</td> </tr> <tr> <td class=\"indent1\">DLCO</td> <td>Normal or &#8595;</td> <td>Normal or &#8593;</td> <td>Normal, &#8593;, or &#8595;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Maximal expiratory flow rates can be obtained by spirometry, whereas the other measures of lung function require full pulmonary function testing.</div><div class=\"graphic_footnotes\">FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; FEF 25% to 75%: forced expiratory flow rate between 25 percent and 75 percent of the exhaled vital capacity; DLCO: carbon monoxide-diffusing capacity.</div><div class=\"graphic_reference\">Adapted with permission from: Fraire JA, Keens TG. Pulmonary function tests in children: Guidelines for interpretation. J Respir Dis Pediatricians 2003; 5:211. Copyright &copy; 2003 Cliggott Publishing Group.</div><div id=\"graphicVersion\">Graphic 81072 Version 4.0</div></div></div>"},"81073":{"type":"graphic_table","displayName":"Probabilities for thrombolysis","title":"Baseline probabilities for thrombolytic decision tree (example for decision analysis)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Baseline probabilities for thrombolytic decision tree (example for decision analysis)</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td colspan=\"2\"><em><strong>For illustration purposes only</strong></em></td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td class=\"subtitle1\">Parameter</td>\r\n                    <td class=\"subtitle1\">Percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Probability that the patient is having a myocardial infarction (MI)</td>\r\n                    <td class=\"sublist_other_start\">83</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">If the patient is having an MI, probability of death</td>\r\n                    <td class=\"sublist_other\">29</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">If the patient is not having an MI, probability of death</td>\r\n                    <td class=\"sublist_other\">2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Probability of a patient having a severe or fatal complication of thrombolytic therapy</td>\r\n                    <td>0.40</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>In a patient having an MI, relative reduction in mortality from treatment with thrombolytic therapy</td>\r\n                    <td>13</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Data from: Krumholz HM, Pasternak RC, Weinstein MC, et al, N Engl J Med 1992; 327:7.</div><div id=\"graphicVersion\">Graphic 81073 Version 6.0</div></div></div>"},"81074":{"type":"graphic_figure","displayName":"Gastric prolapse","title":"Gastric prolapse due to slippage of gastric band","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric prolapse due to slippage of gastric band</div><div class=\"cntnt\"><img style=\"width:400px; height:418px;\" src=\"images/SURG/81074_Gastric_prolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Band slippage can result in prolapse of part of the stomach through the band, with varying degrees of gastric obstruction.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 81074 Version 3.0</div></div></div>"},"81075":{"type":"graphic_figure","displayName":"Incision rectovaginal fistula","title":"Repair of a small rectovaginal fistula through a transvaginal approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a small rectovaginal fistula through a transvaginal approach</div><div class=\"cntnt\"><img style=\"width:365px; height:433px;\" src=\"images/OBGYN/81075_Incision_rectovaginal_fistu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An elliptical incision is made about the fistula tract.</div><div id=\"graphicVersion\">Graphic 81075 Version 1.0</div></div></div>"},"81076":{"type":"graphic_table","displayName":"Cultivable flora oral cavity","title":"Predominant cultivable flora from various sites of the oral cavity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predominant cultivable flora from various sites of the oral cavity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Group </td> <td class=\"subtitle1\" rowspan=\"2\">Predominant genus or family </td> <td class=\"subtitle1\" colspan=\"4\">Total viable count (mean percent) </td> </tr> <tr> <td class=\"subtitle2\">Tongue </td> <td class=\"subtitle2\">Saliva </td> <td class=\"subtitle2\">Gingival crevice </td> <td class=\"subtitle2\">Dental plaque </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Anaerobes (1011 CFU/g)* </td> </tr> <tr> <td class=\"indent1\">Gram + cocci </td> <td><em>Peptostreptococcus</em></td> <td>4.2</td> <td>13.0</td> <td>7.4</td> <td>13.0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Gram - cocci, Gram + rods </td> <td><em>Veillonella</em></td> <td>16.0</td> <td>15.9</td> <td>10.7</td> <td>6.0</td> </tr> <tr> <td><em>Actinomyces</em>, <em>Eubacterium</em>, <em>Lactobacillus</em>, <em>Leptotrichia</em></td> <td>7.4</td> <td>4.8</td> <td>20.2</td> <td>18.0</td> </tr> <tr> <td class=\"indent1\">Gram - rods </td> <td><em>Fusobacterium</em>, <em>Bacteroides</em>, <em>Prevotella</em>, <em>Porphyromonas</em></td> <td>8.2</td> <td>4.8</td> <td>16.1</td> <td>10.0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Aerobes (1010 CFU/g)* </td> </tr> <tr> <td class=\"indent1\">Gram + cocci </td> <td><em>Streptococcus</em></td> <td>44.8</td> <td>46.2</td> <td>28.8</td> <td>28.0</td> </tr> <tr> <td class=\"indent1\">Gram - cocci </td> <td><em>Moraxella</em></td> <td>3.4</td> <td>1.2</td> <td>0.4</td> <td>0.4</td> </tr> <tr> <td class=\"indent1\">Gram + rods </td> <td><em>Lactobacillus</em>, <em>Corynebacterium</em></td> <td>13.0</td> <td>11.8</td> <td>15.3</td> <td>24.0</td> </tr> <tr> <td class=\"indent1\">Gram - rods </td> <td><em>Enterobacteriaceae</em></td> <td>3.2</td> <td>2.3</td> <td>1.2</td> <td>Not done</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Total viable colony-forming units per g net weight.</div><div class=\"graphic_reference\">Modified from Chow, AW, Roser, SM, Brady, FA, Ann Intern Med 1978; 88:392.</div><div id=\"graphicVersion\">Graphic 81076 Version 2.0</div></div></div>"},"81079":{"type":"graphic_table","displayName":"Active and maintenance therapy of gastroduodenal ulcers","title":"Recommendations for PPI doses in active and maintenance therapy of gastroduodenal ulcers*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for PPI doses in active and maintenance therapy of gastroduodenal ulcers*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose (adult)</td> </tr> <tr> <td>Dexlansoprazole</td> <td>30 to 60 mg</td> </tr> <tr> <td>Esomeprazole</td> <td>20 to 40 mg</td> </tr> <tr> <td>Lansoprazole</td> <td>15 to 30 mg</td> </tr> <tr> <td>Omeprazole</td> <td>20 to 40 mg</td> </tr> <tr> <td>Pantoprazole</td> <td>20 to 40 mg</td> </tr> <tr> <td>Rabeprazole</td> <td>20 mg</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">All administered by mouth daily before breakfast</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPI: proton pump inhibitor.<br> * As a general rule, active duodenal ulcers should be treated for four weeks and gastric ulcers for eight weeks.</div><div class=\"graphic_reference\">Adapted from: Wolfe MM, Sachs G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118:S9.</div><div id=\"graphicVersion\">Graphic 81079 Version 3.0</div></div></div>"},"81080":{"type":"graphic_table","displayName":"ACC AHA HRS AV block","title":"ACC/AHA/HRS guideline summary: Indications for permanent pacing in acquired atrioventricular (AV) block in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/HRS guideline summary: Indications for permanent pacing in acquired atrioventricular (AV) block in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement that permanent pacing is indicated in adults with acquired AV block in the following settings: </td> </tr> <tr> <td class=\"sublist2_start\">&#8226; Third-degree and advanced second-degree AV block at any anatomic level: </td> </tr> <tr> <td class=\"sublist2\">1. Associated with bradycardia with symptoms (including heart failure) or ventricular arrhythmias presumed to be due to AV block. (Level of Evidence: C) </td> </tr> <tr> <td class=\"sublist2\">2. Associated with arrhythmias and other medical conditions that require drug therapy that results in symptomatic bradycardia. (Level of Evidence: C) </td> </tr> <tr> <td class=\"sublist2\">3. In awake, symptom-free patients in sinus rhythm, with documented periods of asystole &#8805;3.0 seconds or any escape rate &#60;40 bpm, or with an escape rhythm that is below the AV node. (Level of Evidence: C) </td> </tr> <tr> <td class=\"sublist2\">4. In awake, symptom-free patients with AF and bradycardia with 1 or more pauses of at least 5 seconds or longer. (Level of Evidence: C) </td> </tr> <tr> <td class=\"sublist2\">5. After catheter ablation of the AV junction. (Level of Evidence: C) </td> </tr> <tr> <td class=\"sublist2\">6. Associated with postoperative AV block that is not expected to resolve after cardiac surgery. (Level of Evidence: C) </td> </tr> <tr> <td class=\"sublist2\">7. Associated with neuromuscular diseases with AV block, such as myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb dystrophy (limb-girdle muscular dystrophy), and peroneal muscular atrophy, with or without symptoms. (Level of Evidence: B) </td> </tr> <tr> <td class=\"indent1\">&#8226; Second-degree AV block with associated symptomatic bradycardia regardless of type or site of block. (Level of Evidence: B) </td> </tr> <tr> <td class=\"indent1\">&#8226; Asymptomatic persistent third-degree AV block at any anatomic site with average awake ventricular rates of 40 bpm or faster if cardiomegaly or LV dysfunction is present or if the site of block is below the AV node. (Level of Evidence: B) </td> </tr> <tr> <td class=\"indent1\">&#8226; Second- or third-degree AV block during exercise in the absence of myocardial ischemia. (Level of Evidence: C) </td> </tr> <tr> <td class=\"subtitle1_single\">Class IIa - The weight of evidence or opinion is in favor of the usefulness of permanent pacing in adults with acquired AV block in the following settings: </td> </tr> <tr> <td class=\"indent1\">&#8226; Persistent third-degree AV block with an escape rate &#62;40 bpm in asymptomatic adult patients without cardiomegaly. (Level of Evidence: C) </td> </tr> <tr> <td class=\"indent1\">&#8226; Asymptomatic second-degree AV block at intra- or infra-His levels found at electrophysiological study. (Level of Evidence: B) </td> </tr> <tr> <td class=\"indent1\">&#8226; First- or second-degree AV block with symptoms similar to those of pacemaker syndrome or hemodynamic compromise. (Level of Evidence: B) </td> </tr> <tr> <td class=\"indent1\">&#8226; Asymptomatic type II second-degree AV block with a narrow QRS. When type II second-degree AV block occurs with a wide QRS, including isolated right bundle branch block, pacing becomes a Class I recommendation. (Level of Evidence: B) </td> </tr> <tr> <td class=\"subtitle1_single\">Class IIb - The weight of evidence or opinion is less well established for the usefulness of permanent pacing in adults with acquired AV block in the following settings: </td> </tr> <tr> <td class=\"indent1\">&#8226; Neuromuscular diseases such as myotonic muscular dystrophy, Erb dystrophy (limb-girdle muscular dystrophy), and peroneal muscular atrophy with any degree of AV block (including first-degree AV block), with or without symptoms, because there may be unpredictable progression of AV conduction disease. (Level of Evidence: B) </td> </tr> <tr> <td class=\"indent1\">&#8226; AV block in the setting of drug use and/or drug toxicity when the block is expected to recur even after the drug is withdrawn. (Level of Evidence: B) </td> </tr> <tr> <td class=\"subtitle1_single\">Class III - There is evidence and/or general agreement that permanent pacing in adults with acquired AV block is not useful in the following settings: </td> </tr> <tr> <td class=\"indent1\">&#8226; Asymptomatic first-degree AV block. (Level of Evidence: B) </td> </tr> <tr> <td class=\"indent1\">&#8226; Asymptomatic type I second-degree AV block at the supra-His (AV node) level or that which is not known to be intra- or infra-Hisian. (Level of Evidence: C) </td> </tr> <tr> <td class=\"indent1\">&#8226; AV block that is expected to resolve and is unlikely to recur (eg, drug toxicity, Lyme disease, or transient increases in vagal tone or during hypoxia in sleep apnea syndrome in the absence of symptoms). (Level of Evidence: B) </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular; LV: left ventricular; AF: atrial fibrillation.</div><div class=\"graphic_reference\">Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.</div><div id=\"graphicVersion\">Graphic 81080 Version 5.0</div></div></div>"},"81081":{"type":"graphic_picture","displayName":"Selective media GI pathogens","title":"Isolation of enteric pathogens from stool using selective media","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Isolation of enteric pathogens from stool using selective media</div><div class=\"cntnt\"><img style=\"width:471px; height:172px;\" src=\"images/ID/81081_Selective_media_GI_pathogen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Selective media used in the isolation of enteric pathogens from stool. On each plate, Shigella is indicated by the arrowhead and Escherichia coli by the arrow; all three media differentiate lactose fermenting from nonlactose fermenting organisms by pH sensitive dyes. Panel A: MacConkey agar; panel B: Hektoen enteric agar; and panel C: Xylose lysine deoxycholate agar.</div><div class=\"graphic_reference\">Courtesy of Michael S Glickman, MD.</div><div id=\"graphicVersion\">Graphic 81081 Version 2.0</div></div></div>"},"81082":{"type":"graphic_diagnosticimage","displayName":"Salter I fracture","title":"Salter I fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Salter I fracture</div><div class=\"cntnt\"><img style=\"width:445px; height:348px;\" src=\"images/EM/81082_Salter_I_fracture_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior-posterior (A) and oblique (B) views of the right ankle. Salter Harris type I fracture of the distal fibula. Notice the lateral malleolar soft tissue swelling (arrowheads) with the widening of the fibular physis (arrow) and a slight medial displacement of the epiphysis (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of David Mathison, MD and Dewesh Agrawal, MD.</div><div id=\"graphicVersion\">Graphic 81082 Version 4.0</div></div></div>"},"81084":{"type":"graphic_table","displayName":"Processed EEG brain monitors","title":"Processed EEG brain monitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Processed EEG brain monitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"3\" width=\"26%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Monitor*</td> <td class=\"subtitle1\">Manufacturer<sup>&#182;</sup></td> <td class=\"subtitle1\">Parameters</td> <td class=\"subtitle1\">Monitoring range</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Unprocessed <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">electroencephalogram&nbsp;(</span>EEG)</td> <td class=\"divider_bottom\" rowspan=\"6\">Non-proprietary</td> <td class=\"divider_bottom\" rowspan=\"6\">Alpha, beta, gamma, delta, theta waves, sleep spindles; K complexes, spectral edge frequency, burst suppression; isoelectricity.</td> <td> <p>No specific index</p> Permutation entropy can be derived</td> <td> <p>Advantages: Rapid response time, cheap, non-proprietary.</p> Disadvantages: No index or value, requires attention, requires training.</td> </tr> <tr> <td>High frequency, low amplitude (gamma and beta dominance)</td> <td>Wakefulness common.</td> </tr> <tr> <td>Alpha oscillations</td> <td>Drowsiness/sedation common.</td> </tr> <tr> <td>Spindles, K complexes, some delta waves</td> <td>Explicit recall rare.</td> </tr> <tr> <td>Slow delta waves, spectral edge &#60;12</td> <td>Surgical anesthesia common.</td> </tr> <tr class=\"divider_bottom\"> <td>Burst suppression and isoelectricity</td> <td>Deep anesthesia common.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Bispectral index (BIS)</td> <td class=\"divider_bottom\" rowspan=\"6\">Covidien Medical</td> <td class=\"divider_bottom\" rowspan=\"6\">Bispectral index (proprietary algorithm) based upon beta power, bispectral coherence (synchfastslow), and burst suppression ratio.</td> <td>0 to 100</td> <td> <p>Raw EEG and parameters such as spectral edge frequency can and should be displayed.</p> <p>Advantages: Index value can be used to guide anesthesia. May improve outcomes.</p> Disadvantages: Slow response time, costly, proprietary.</td> </tr> <tr> <td>80 to 100</td> <td>Wakefulness common.</td> </tr> <tr> <td>60 to 80</td> <td>Drowsiness/sedation common.</td> </tr> <tr> <td>50 to 60</td> <td>Explicit recall rare.</td> </tr> <tr> <td>30 to 50</td> <td>Surgical anesthesia common.</td> </tr> <tr class=\"divider_bottom\"> <td>0 to 30</td> <td>Deep anesthesia common.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Entropy</td> <td class=\"divider_bottom\" rowspan=\"6\">GE Healthcare</td> <td class=\"divider_bottom\" rowspan=\"6\">State entropy (SE) and response entropy (RE) indices; burst suppression ratio; entropy of EEG signal decreases with sleep and anesthesia.</td> <td> <p>SE: (0 to 100)</p> RE: (0 to 91)</td> <td>SE of EEG signal calculated up to 32 Hz. RE includes additional frequencies up to 47 Hz. SE is always &#8804;RE. Raw EEG can and should be displayed.</td> </tr> <tr> <td>80 to 100</td> <td>Wakefulness common.</td> </tr> <tr> <td>Sudden drop in entropy</td> <td>May be associated with loss of responsiveness.</td> </tr> <tr> <td>40 to 60</td> <td> <p>Explicit recall rare.</p> Surgical anesthesia common.</td> </tr> <tr> <td>Sudden rise in RE</td> <td>May indicate pain or muscle activity.</td> </tr> <tr class=\"divider_bottom\"> <td>Lower entropy numbers and burst suppression</td> <td>Deep anesthesia common.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"> <p>A-line</p> <p>AEP Monitor/2</p> (Adds EEG parameters)</td> <td class=\"divider_bottom\" rowspan=\"6\">Danmeter a/s</td> <td class=\"divider_bottom\" rowspan=\"6\">Middle latency auditory evoked potentials (MLAEPs); ARX Auditory Index (AAI); middle latency (20 to 80 msec); Composite AAI Index (Proprietary - combines EEG and MLAEP information).</td> <td>0 to 100</td> <td>Full range.</td> </tr> <tr> <td>60 to 100</td> <td>Wakefulness common.</td> </tr> <tr> <td>40 to 60</td> <td>Drowsiness/sedation common.</td> </tr> <tr> <td>25 to 40</td> <td>Light anesthesia common.</td> </tr> <tr> <td>15 to 25</td> <td>Surgical anesthesia common.</td> </tr> <tr class=\"divider_bottom\"> <td>0 to 15</td> <td>Deep anesthesia common.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\"> <p>Cerebral State</p> <p>Hand-held device</p> Wireless connection to anesthesia monitor</td> <td class=\"divider_bottom\" rowspan=\"7\">Danmeter a/s</td> <td class=\"divider_bottom\" rowspan=\"7\">Cerebral State Index (CSI) (Proprietary); burst suppression electromyography and signal quality are indicated; index derived mainly from alpha and beta EEG ratios, burst suppression.</td> <td>0 to 100</td> <td>Full range.</td> </tr> <tr> <td>90 to 100</td> <td>Wakefulness common.</td> </tr> <tr> <td>80 to 90</td> <td>Drowsiness common.</td> </tr> <tr> <td>60 to 80</td> <td>Light anesthesia common.</td> </tr> <tr> <td>40 to 60</td> <td>Surgical anesthesia common.</td> </tr> <tr> <td>10 to 40</td> <td>Deep anesthesia common.</td> </tr> <tr class=\"divider_bottom\"> <td>0 to 10</td> <td>Burst suppression or isoelectric EEG.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Narcotrend</td> <td class=\"divider_bottom\" rowspan=\"7\">MT MonitorTechnik GmbH &#38; Co. KG</td> <td class=\"divider_bottom\" rowspan=\"7\">Cerebrogram (Proprietary); Raw EEG waveform displayed; median and spectral edge frequencies; power in EEG frequency bands is shown.</td> <td>A to F</td> <td>Full range.</td> </tr> <tr> <td>A</td> <td>Wakefulness common.</td> </tr> <tr> <td>B</td> <td>Drowsiness common.</td> </tr> <tr> <td>C</td> <td>Light anesthesia common.</td> </tr> <tr> <td>D</td> <td>Surgical anesthesia common.</td> </tr> <tr> <td>E</td> <td>Deep anesthesia common.</td> </tr> <tr class=\"divider_bottom\"> <td>F</td> <td>Burst suppression or isoelectric EEG.</td> </tr> <tr class=\"divider_bottom\"> <td>NeuroSense monitor</td> <td>NeuroWave systems Inc.</td> <td>The index is calculated via analysis of the EEG signals in the gamma frequency band; uses bilateral frontal EEG channels for derivation of index.</td> <td>1 to 100</td> <td> <p>Conceptualized for use in closed-loop anesthesia.</p> Promoted as having a rapid response time. </td> </tr> <tr class=\"divider_bottom\"> <td>qCON 2000 monitor</td> <td>Quantum Medical</td> <td>The qCON index (proprietary) is a measure of hypnosis that is derived from spectral analysis and burst suppression rate. The qNOX reference scale (proprietary) is derived through EEG signals in patients moving in response to nailbed pressure, and is the component designed for noxiousness. The proprietary algorithm of this device, based on \"Adaptive Neuro Fuzzy Inference System\" (proprietary), assumes that the EEG signal contains dissociable information on hypnosis and nociception.</td> <td>0 to 99</td> <td> <p>Theoretically provides information on both hypnosis and nociception.</p> <p>Promoted as having a rapid response time.</p> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">SEDline</td> <td class=\"divider_bottom\" rowspan=\"6\">Hospira</td> <td class=\"divider_bottom\" rowspan=\"6\">Patient state index (PSI) (proprietary); raw EEG waveform displayed; density spectral array (DSA) shown; converts EEG acquired from four active, ground and reference electrodes into a proprietary index; anteriorization of EEG power; loss of coherence.</td> <td>0 to 100</td> <td>Full range.</td> </tr> <tr> <td>90 to 100</td> <td>Wakefulness common.</td> </tr> <tr> <td>50 to 90</td> <td>Drowsiness/sedation common.</td> </tr> <tr> <td>25 to 50</td> <td>Surgical anesthesia common.</td> </tr> <tr> <td>10 to 25</td> <td>Deep anesthesia common.</td> </tr> <tr class=\"divider_bottom\"> <td>0 to 10</td> <td>Burst suppression or isoelectric EEG.</td> </tr> <tr> <td rowspan=\"5\">SNAP II</td> <td rowspan=\"5\">Stryker</td> <td rowspan=\"5\">SNAP index (Proprietary); spectral analysis of low (0 to 18 Hz) and high (&#62;80 Hz) frequency EEG components; PDA portable device; raw EEG waveform displayed.</td> <td>0 to 100</td> <td>Full range.</td> </tr> <tr> <td>90 to 100</td> <td>Wakefulness common.</td> </tr> <tr> <td>65 to 90</td> <td>Drowsiness/sedation common.</td> </tr> <tr> <td>50 to 65</td> <td>Surgical anesthesia common.</td> </tr> <tr> <td>0 to 50</td> <td>Deep anesthesia common.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All brain monitors are not specific for the anesthetic state. Patient morbidity, drugs and even natural sleep can confound anesthetic depth monitoring.<br />&para; Specific manufacturer guidelines for use may vary.</div><div id=\"graphicVersion\">Graphic 81084 Version 7.0</div></div></div>"},"81085":{"type":"graphic_diagnosticimage","displayName":"Transverse fracture of the 5th metacarpal shaft","title":"Transverse fracture of the 5th metacarpal shaft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse fracture of the 5th metacarpal shaft</div><div class=\"cntnt\"><img style=\"width:330px; height:487px;\" src=\"images/EM/81085_5th_MC_transverse_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse fractures of the metacarpal shaft (white arrow) are usually stable.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 81085 Version 2.0</div></div></div>"},"81086":{"type":"graphic_picture","displayName":"Positive skin patch test","title":"Positive patch test reactions","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Positive patch test reactions</div><div class=\"cntnt\"><img style=\"width:483px; height:302px;\" src=\"images/ID/81086_Positive_skin_patch_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) At a 48-hour reading of abacavir patch test; image is of a patient participating in a large clinical study in which the four patch testing wells contained, in a blinded configuration, (i) abacavir commercial (Ziagen) formulation at 1 percent in white petrolatum, (ii) abacavir commercial (Ziagen) formulation at 10 percent in white petrolatum, (iii) petrolatum control and (iv) Ziagen excipient control; Panel B) close-up showing vesicular reaction.</div><div class=\"graphic_reference\">Reproduced with permission from: Shear NH, Milpied B, Bruynzeel DP, Phillips EJ. A review of drug patch testing and implications for HIV clinicians. AIDS 2008; 22:999. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81086 Version 8.0</div></div></div>"},"81090":{"type":"graphic_movie","displayName":"VSD closure device 2D","title":"VSD closure device 2D","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">VSD closure device 2D</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/81090_VSDclosuredevicemovie.mp4\" style=\"width:496px;height:400px\"></div><img style=\"width:545px; height:345px;\" src=\"images/CARD/81090_VSDclosuredeviceposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;is&nbsp;a movie&nbsp;clip from mid esophageal apical four chamber&nbsp;view obtained during intraoperative transesophageal echocardiography.&nbsp; Still on cardiopulmonary bypass, the VSD device has now been deployed and is stably seated on the muscular septum occluding the large defect. Note that the delivery cable has now been removed in the real time image.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; IVS: intraventricular septum; RV: right ventricle; LV: left ventricle; small arrows: Amplatzer VSD occluder device; large arrow: delivery cable.</div><div id=\"graphicVersion\">Graphic 81090 Version 4.0</div></div></div>"},"81091":{"type":"graphic_table","displayName":"Chemo response saliv gland tum","title":"Chemotherapy response in different histologies of salivary gland tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy response in different histologies of salivary gland tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Agent/regimen</td> <td class=\"subtitle1\" colspan=\"3\">Histology</td> </tr> <tr> <td class=\"subtitle2\">Adenoid cystic cancer</td> <td class=\"subtitle2\">Mucoepidermoid cancer</td> <td class=\"subtitle2\">Adenocarcinoma</td> </tr> <tr> <td class=\"subtitle3\">Number of responses/total number of patients, (percent)</td> <td class=\"subtitle3\">Number of responses/total number of patients, (percent)</td> <td class=\"subtitle3\">Number of responses/total number of patients, (percent)</td> </tr> <tr> <td>Cisplatin<sup>[1,2]</sup></td> <td>2/32 (6)</td> <td>1/5</td> <td>0/5</td> </tr> <tr> <td>Vinorelbine<sup>[3]</sup></td> <td>2/13 (15)</td> <td>-</td> <td>2/5</td> </tr> <tr> <td>Mitoxantrone<sup>[4,5]</sup></td> <td>5/50 (10)</td> <td>-</td> <td>-</td> </tr> <tr> <td>Epirubicin<sup>[6]</sup></td> <td>2/20 (10)</td> <td>-</td> <td>-</td> </tr> <tr> <td>Methotrexate<sup>[7]</sup></td> <td>-</td> <td>2/5 (40)</td> <td>-</td> </tr> <tr> <td>Paclitaxel<sup>[8]</sup></td> <td>0/14</td> <td>3/14 (21)</td> <td>5/17 (29)</td> </tr> <tr> <td>CAP or CAP/5-FU<sup>[7,9-14]</sup></td> <td>12/43 (28)</td> <td>5/6 (83)</td> <td>23/37 (62)</td> </tr> <tr> <td>Cis/anthracycline &#177; 5 FU<sup>[15-18]</sup></td> <td>6/19 (32)</td> <td>1/4</td> <td>8/14 (57)</td> </tr> <tr> <td>Cyclophos/doxorubicin<sup>[7,19]</sup></td> <td>2/6</td> <td>0/6</td> <td>1/1</td> </tr> <tr> <td>Cis/MTX/bleo<sup>[7,19]</sup></td> <td>0/3</td> <td>2/3 (66)</td> <td>-</td> </tr> <tr> <td>Cis/5-FU<sup>[20]</sup></td> <td>0/11</td> <td>-</td> <td>-</td> </tr> <tr> <td>Cis/vinorelbine<sup>[3]</sup></td> <td>4/9 (44)</td> <td>-</td> <td>1/5</td> </tr> <tr> <td>Cis/doxorubicin/bleo<sup>[2]</sup></td> <td>3/9 (33)</td> <td>-</td> <td>-</td> </tr> <tr> <td>Carbo/paclitaxel<sup>[21,22]</sup></td> <td>2/10 (20)</td> <td>-</td> <td>1/1</td> </tr> <tr> <td>Cis/gemcitabine<sup>[23]</sup></td> <td>2/10 (20)</td> <td>1/4 (25)</td> <td>3/8 (38)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAP: cyclophosphanide, doxorubicin, cisplatin; Cis: cisplatin; MTX: methotrexate; Bleo: bleomycin; Carbo: carboplatin; 5-FU: 5-fluorouracil.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Licitra, L; et al. Cancer 1991; 68:1874. </li> <li>de Haan, L; et al. Head Neck 1992; 14:273. </li> <li>Airoldi, M; et al. Cancer 2001; 91:541. </li> <li>Mattox, D; et al. Invest New Drugs 1990; 8:105. </li> <li>Verweij, J; et al. Ann Oncol 1996; 7:867. </li> <li>Vermorken, J; et al. Ann Oncol 1993; 4:785. </li> <li>Kaplan, M; et al. Otolaryngol Head Neck Surg 1986; 95:165. </li> <li>Gilbert, J; et al. Head Neck 2006; 28:197. </li> <li>Licitra, L; et al. Ann Oncol 1996; 7:640. </li> <li>Dreyfuss, A; et al. Cancer 1987; 60:2869. </li> <li>Creagan, E; et al. Cancer 1988; 62:2313. </li> <li>Belani, C; et al. Med Pediatr Oncol 1988; 16:197. </li> <li>Dimery, I; et al. J Clin Oncol 1990; 8:1056. </li> <li>Alberts, D; et al. Cancer 1981; 47:645. </li> <li>Airoldi, M; et al. Tumor 1989; 75:252. </li> <li>Venook, A; et al. J Clin Oncol 1987; 5:951. </li> <li>Tsukuda, M; et al. J Cancer Res Clin Oncol 1993; 119:756. </li> <li>White, J; et al. Clin Oncol 2004; 16:159. </li> <li>Posner, M; et al. Cancer 1982; 50:2261. </li> <li>Hill, M; et al. Oral Oncol 1997; 33:275. </li> <li>Ruzich, J; et al. Head Neck 2002; 24:406. </li> <li>Airoldi, M; et al. Anticancer Res 2000; 20:3781. </li> <li>Laurie, SA; et al. Cancer 2010; 116:362. </li> </ol></div><div id=\"graphicVersion\">Graphic 81091 Version 3.0</div></div></div>"},"81092":{"type":"graphic_diagnosticimage","displayName":"Electroanatomic map LV ischemia","title":"Endocardial electroanatomic map of myocardial ischemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endocardial electroanatomic map of myocardial ischemia</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/CARD/81092_Electroanatomic_map_LV_isch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are the right anterior oblique (A) and left anterior oblique (B) left ventricular (LV) local shortening (LS) map. Red represents regions with reduced LS (&lt;6 percent); yellow and green represents regions with mildly reduced LS (6 to 10 percent); blue and purple represent regions with LS &gt;10 percent. Panel C is the regional view of the same ventricle, presenting average LS values in 12 segments. Panel D is the right anterior oblique and panel E the left anterior oblique views of a unipolar voltage (UpV) of the same ventricle. Colors represent peak-to-peak amplitude of intracardiac electrogram, ranging from ≤5 mV (red) to ≥16 mV (purple). Panel F is the regional view representing average regional UpV values of the same 12 segments. Ischemia produces a reduction in LS and decreased UpV.</div><div class=\"graphic_reference\">Reprinted with permission from: Fuchs S, Hendel RC, Baim DS, et al. Am J Cardiol 2001; 87:874 with permission from Excerpta Medica Inc.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 81092 Version 3.0</div></div></div>"},"81094":{"type":"graphic_picture","displayName":"Intravascular lymphoma brain biopsy","title":"Intravascular lymphoma brain biopsy","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Intravascular lymphoma brain biopsy</div><div class=\"cntnt\"><img style=\"width:545px; height:409px;\" src=\"images/HEME/81094_Intravasc_lymph_brain_biop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain biopsy of a patient with intravascular lymphoma demonstrates CD20 positive neoplastic lymphoid cells lodged within in the capillaries and post-capillary venules.</div><div class=\"graphic_reference\">Kindly provided by Nika Aljinovic, MD and German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 81094 Version 1.0</div></div></div>"},"81095":{"type":"graphic_picture","displayName":"Pedunculated gastric neuroendocrine tumor","title":"Gastric well-differentiated neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric well-differentiated neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:427px; height:268px;\" src=\"images/GAST/81095_Pedunculatedgastriccarcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power view demonstrates a solitary, pedunculated gastric well-differentiated neuroendocrine tumor.</div><div class=\"graphic_reference\">From Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of Tumor Pathology (electronic fascicle), Third series, Fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 81095 Version 3.0</div></div></div>"},"81096":{"type":"graphic_figure","displayName":"Fistulas bladder vagina uterus","title":"Anatomic types of female urogenital fistulas","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Anatomic types of female urogenital fistulas</div><div class=\"cntnt\"><img style=\"width:544px; height:358px;\" src=\"images/OBGYN/81096_Fistulas_bladder_vagina_ute.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ol>&#xD;&#xA;    <li>Vesicocervical fistula;</li>&#xD;&#xA;    <li>Juxtacervical vesicovaginal fistula;</li>&#xD;&#xA;    <li>Midvaginal vesicovaginal fistula;</li>&#xD;&#xA;    <li>Suburethral vesicovaginal fistula;</li>&#xD;&#xA;    <li>Urethrovaginal fistula.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 81096 Version 4.0</div></div></div>"},"81098":{"type":"graphic_picture","displayName":"Bilateral scleritis","title":"Bilateral scleritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral scleritis</div><div class=\"cntnt\"><img style=\"width:432px; height:284px;\" src=\"images/RHEUM/81098_Bilateral_scleritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral anterior scleritis in a patient with Cogan's syndrome, manifested by ocular pain and erythema. (The patient also had vertigo and bilateral sensorineural hearing loss as a complication of her Cogan's syndrome.)</div><div id=\"graphicVersion\">Graphic 81098 Version 2.0</div></div></div>"},"81101":{"type":"graphic_diagnosticimage","displayName":"Lymphoma kidney","title":"Lymphoma affecting the kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoma affecting the kidney</div><div class=\"cntnt\"><img style=\"width:407px; height:251px;\" src=\"images/HEME/81101_Lymphoma_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography of the abdomen demonstrates bulky, irregular involvement of the right kidney (arrows), along with a moderate degree of enlargement of retroperitoneal nodes (arrowhead) in a patient with transformed follicular non-Hodgkin lymphoma.</div><div class=\"graphic_reference\">Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.</div><div id=\"graphicVersion\">Graphic 81101 Version 4.0</div></div></div>"},"81102":{"type":"graphic_table","displayName":"Bacterial tracheitis DDx","title":"Differential diagnosis of bacterial tracheitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of bacterial tracheitis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Condition\n   </td>\n   <td  class=\"subtitle1\">\n   Characteristic features\n   </td>\n   <td  class=\"subtitle1\">\n   Radiographic features\n   </td>\n   </tr>\n   <tr>\n   <td>Bacterial tracheitis</td>\n   <td>Fever; toxic appearance</td>\n   <td>Intraluminal membranes and tracheal wall irregularity</td>\n   </tr>\n   <tr>\n   <td>Epiglottitis</td>\n   <td>Fever, toxic appearance; anxiety out of proportion to degree of respiratory distress; \"tripod\" and/or \"sniffing\" posture; drooling</td>\n   <td>Swollen epiglottis (\"thumb sign\") on lateral neck radiograph</td>\n   </tr>\n   <tr>\n   <td>Laryngotracheitis (croup)</td>\n   <td>Typically occurs in children 6 to 36 months; \"barking\" cough, stridor; \"steeple sign\" on anteroposterior neck radiograph</td>\n   <td>\t<p>Tapering of upper airway (\"steeple sign\") on anteroposterior neck radiograph</p>\n\t<p>Subglottic narrowing and distended hypopharynx on lateral neck radiograph</p>\n</td>\n   </tr>\n   <tr>\n   <td>Peritonsillar abscess</td>\n   <td>Typically occurs in older children and adolescents; drooling; trismus; muffled voice; tonsillar swelling with deviation of the uvula</td>\n   <td>Radiographs usually not necessary for diagnosis</td>\n   </tr>\n   <tr>\n   <td>Retropharyngeal abscess</td>\n   <td>Typically occurs in children aged two to four years; neck pain, fever, pain with swallowing; drooling; unwillingness to move the neck; trismus; midline or unilateral swelling of posterior pharyngeal wall</td>\n   <td>Widening of the retropharyngeal space and reversal of the normal cervical spine curvature</td>\n   </tr>\n   <tr>\n   <td>Severe bacterial pneumonia</td>\n   <td>Signs of lower respiratory tract infection (eg, crackles, consolidation)</td>\n   <td>Pulmonary infiltrate with or without parapneumonic effusion</td>\n   </tr>\n   <tr>\n   <td>Foreign-body aspiration</td>\n   <td>History of sudden onset of choking (though this history is frequently absent); hoarseness or stridor with laryngeal or upper-esophageal foreign body</td>\n   <td>Visualization of radio-opaque foreign body; upper-esophageal foreign body may cause distortion or deviation of extrathoracic trachea</td>\n   </tr>\n   <tr>\n   <td>Diphtheria</td>\n   <td>Sore throat; malaise; low-grade fever; diphtheritic membrane (exceedingly rare in countries with high rates of diphtheria immunization)</td>\n   <td>Radiographs usually not necessary for diagnosis</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 81102 Version 1.0</div></div></div>"},"81104":{"type":"graphic_picture","displayName":"Beryllium skin nodules","title":"Beryllium skin nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Beryllium skin nodules</div><div class=\"cntnt\"><img style=\"width:432px; height:299px;\" src=\"images/PULM/81104_Beryllium_skin_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Lee S Newman, MD, MA.</div><div id=\"graphicVersion\">Graphic 81104 Version 1.0</div></div></div>"},"81106":{"type":"graphic_diagnosticimage","displayName":"Pleural lymphoma II CT","title":"Pleural lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural lymphoma</div><div class=\"cntnt\"><img style=\"width:360px; height:266px;\" src=\"images/PULM/81106_Pleural_lymphoma_II_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pleural lymphoma involving the left pleural space. CT scan shows a large left pleural effusion producing diaphragmatic inversion. Anterior left parietal pleural tumor nodules are visible.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 81106 Version 3.0</div></div></div>"},"81107":{"type":"graphic_figure","displayName":"Trigeminocervical nucleus","title":"Mechanism of pain referral from the cervical spine to the head","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Mechanism of pain referral from the cervical spine to the head</div><div class=\"cntnt\"><img style=\"width:477px; height:572px;\" src=\"images/NEURO/81107_Trigeminocervical_nucleusPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nociceptive afferents of the trigeminal and upper three cervical spinal nerves converge onto second-order neurons in the trigeminocervical nucleus in the upper cervical spinal cord. This convergence mediates the referral of pain signals from the neck to regions of the head innervated by cervical nerves or the trigeminal nerve.</div><div class=\"graphic_reference\">Reproduced from: Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009; 8:959. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 81107 Version 1.0</div></div></div>"},"81108":{"type":"graphic_algorithm","displayName":"Diagnosis esophageal dysphagia","title":"Approach to the patient with esophageal dysphagia","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with esophageal dysphagia</div><div class=\"cntnt\"><img style=\"width:586px; height:589px;\" src=\"images/GAST/81108_Diagnosis_esophageal_dyspha.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease.<br />* Performing a barium swallow prior to an upper endoscopy is controversial.</div><div id=\"graphicVersion\">Graphic 81108 Version 3.0</div></div></div>"},"81109":{"type":"graphic_figure","displayName":"CNS lymphoma PCR study","title":"Polymerase chain reaction of cells from the cerebrospinal fluid demonstrate lymphoma","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Polymerase chain reaction of cells from the cerebrospinal fluid demonstrate lymphoma</div><div class=\"cntnt\"><img style=\"width:471px; height:219px;\" src=\"images/HEME/81109_CNS_lymphoma_PCR_study.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This gel shows PCR results for three CSF samples (marked 1,2,3) from the same patient with lymphomatous meningitis. Also shown is a negative control (N), a sample from a patient with infection (polyclonal, P), and a positive control (C). The narrow bands seen for the patient's samples (arrows) and the positive control indicate a uniform population of cells with the same immunoglobulin heavy chain (IgH) rearrangement.</div><div id=\"graphicVersion\">Graphic 81109 Version 2.0</div></div></div>"},"81112":{"type":"graphic_picture","displayName":"Hepatic candidiasis histology","title":"Histology in hepatosplenic candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology in hepatosplenic candidiasis</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/ID/81112_Hepatic_candidiasis_histolo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy of chronic disseminated candidiasis showing granulomas on hematoxylin and eosin staining.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 81112 Version 1.0</div></div></div>"},"81113":{"type":"graphic_figure","displayName":"Diagram of a water treatment system for HD","title":"Schematic diagram of a water treatment system for hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of a water treatment system for hemodialysis</div><div class=\"cntnt\"><img style=\"width:511px; height:336px;\" src=\"images/NEPH/81113_Design_water_treatment_ed2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram of one possible water treatment system that begins with feed water entering the system at the left side. In our example (refer to UpToDate topic and tables on water purification systems in hemodialysis), DI has been included in addition to reverse osmosis because the required reduction in fluoride was close to the limit that can be achieved by reverse osmosis alone. Because a deionizer was included after the reverse osmosis unit, a bacteria- and endotoxin-retentive filter was added to protect the water storage and distribution system from bacterial contamination.</div><div class=\"graphic_footnotes\">DI: deionization.</div><div id=\"graphicVersion\">Graphic 81113 Version 7.0</div></div></div>"},"81115":{"type":"graphic_diagnosticimage","displayName":"Postoperative splenic shift CT","title":"Postpneumonectomy shift of the spleen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postpneumonectomy shift of the spleen</div><div class=\"cntnt\"><img style=\"width:360px; height:231px;\" src=\"images/PULM/81115_Postoperative_splenic_shift.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT scan demonstrates the postoperative change in location of the spleen (arrow) and illustrates the potential risk of splenic injury with blind chest tube or needle placement into the postpneumonectomy space.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Richard Irwin, MD.</div><div id=\"graphicVersion\">Graphic 81115 Version 4.0</div></div></div>"},"81116":{"type":"graphic_figure","displayName":"Component separation technique with mesh","title":"Component separation technique with mesh","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Component separation technique with mesh</div><div class=\"cntnt\"><img style=\"width:527px; height:184px;\" src=\"images/SURG/81116_CST-with-mesh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the repair of the abdominal wall defect using the component separation technique and mesh.</div><div id=\"graphicVersion\">Graphic 81116 Version 1.0</div></div></div>"},"81117":{"type":"graphic_diagnosticimage","displayName":"Buckle fracture radius ulna","title":"Distal radius and ulna torus (buckle) fractures in an 8-year-old child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal radius and ulna torus (buckle) fractures in an 8-year-old child</div><div class=\"cntnt\"><img style=\"width:446px; height:453px;\" src=\"images/EM/81117_Buckle_fx_radius_ulna.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cortical bone compression of the distal radius and ulna are evident in both radiographic views (white arrows) and appear as a bony discontinuity or bump.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 81117 Version 4.0</div></div></div>"},"81118":{"type":"graphic_figure","displayName":"Bipolar radiofrequency ablation","title":"Bipolar radiofrequency endometrial ablation ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bipolar radiofrequency endometrial ablation </div><div class=\"cntnt\"><img style=\"width:422px; height:242px;\" src=\"images/OBGYN/81118_NovaSure_ablation_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Novaure endometrial ablation system</div><div id=\"graphicVersion\">Graphic 81118 Version 3.0</div></div></div>"},"81119":{"type":"graphic_figure","displayName":"Efficacy of amiodarone and flecainide in AF","title":"Efficacy of amiodarone in rate control for atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of amiodarone in rate control for atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:425px; height:281px;\" src=\"images/CARD/81119_Amiodarone_v_flecainide_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of intravenous placebo, amiodarone, and flecainide on the ventricular response to atrial fibrillation in patients who failed to revert to sinus rhythm after the initiation of therapy. Amiodarone slowed the ventricular response, an effect that was not seen with flecainide or placebo. Although flecainide was less effective for rate control, it was associated with earlier reversion to sinus rhythm than amiodarone or placebo. Note that the time scale is nonlinear.</div><div class=\"graphic_reference\">Data from Donovan KD, Power BM, Hockings GE, et al. Am J Cardiol 1995; 75:693.</div><div id=\"graphicVersion\">Graphic 81119 Version 3.0</div></div></div>"},"81121":{"type":"graphic_picture","displayName":"Erythromelalgia","title":"Erythromelalgia involving the hands in essential thrombocythemia","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Erythromelalgia involving the hands in essential thrombocythemia</div><div class=\"cntnt\"><img style=\"width:505px; height:307px;\" src=\"images/HEME/81121_Erythromelalgia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the presence of erythromelalgia of the hands in a woman with essential thrombocythemia. This condition is associated with burning pain in the feet or hands accompanied by erythema, pallor, or cyanosis, in the presence of palpable pulses, and is common in both essential thrombocythemia and polycythemia vera.</div><div class=\"graphic_reference\">Photograph courtesy of Dr. Ayalew Tefferi, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 81121 Version 2.0</div></div></div>"},"81122":{"type":"graphic_table","displayName":"Fisher SAH CT grading scale","title":"Fisher grade of cerebral vasospasm risk in subarachnoid hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fisher grade of cerebral vasospasm risk in subarachnoid hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Group</td>\n\n      <td class=\"subtitle1\">Appearance of blood on head CT scan</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1</td>\n\n      <td>No blood detected</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2</td>\n\n      <td>Diffuse deposition or thin layer with all vertical layers (in interhemispheric fissure, insular cistern, ambient cistern) less than 1 mm thick</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>3</td>\n\n      <td>Localized clot and/or vertical layers 1 mm or more in thickness</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4</td>\n\n      <td>Intracerebral or intraventricular clot with diffuse or no subarachnoid blood</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Fisher, CM, Kistler, JP, Davis, JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by CT scanning. Neurosurgery 1980; 6:1.</div><div id=\"graphicVersion\">Graphic 81122 Version 1.0</div></div></div>"},"81123":{"type":"graphic_figure","displayName":"Causes of persistent diarrhea","title":"Causes of persistent diarrhea in children in developing countries","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Causes of persistent diarrhea in children in developing countries</div><div class=\"cntnt\"><img style=\"width:502px; height:518px;\" src=\"images/PEDS/81123_Caus_persist_diarrhea.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mary Penny, MD.</div><div id=\"graphicVersion\">Graphic 81123 Version 3.0</div></div></div>"},"81124":{"type":"graphic_figure","displayName":"Natural history of AS","title":"Natural history of aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Natural history of aortic stenosis</div><div class=\"cntnt\"><img style=\"width:494px; height:263px;\" src=\"images/CARD/81124_Natural_history_of_AS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the natural history of aortic stenosis and of the major impact of aortic valve replacement. Survival is excellent during the prolonged asymptomatic phase. After the development of symptoms, however, mortality exceeds 90 percent within a few years. Aortic valve replacement prevents this rapid downhill course.</div><div id=\"graphicVersion\">Graphic 81124 Version 1.0</div></div></div>"},"81126":{"type":"graphic_figure","displayName":"Superior pole vessels","title":"Superior pole vessels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior pole vessels</div><div class=\"cntnt\"><img style=\"width:446px; height:431px;\" src=\"images/SURG/81126_Superior_pole_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superior pole vessels demonstrated with right-angle clamp.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81126 Version 10.0</div></div></div>"},"81127":{"type":"graphic_picture","displayName":"Reduced epidermal nerve fiber density","title":"Reduced epidermal nerve fiber density","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Reduced epidermal nerve fiber density</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/NEURO/81127_Red_epiderm_nerve_fib_den.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a reduction in the epidermal nerve fiber density in this biopsy from a patient with diabetic neuropathy.</div><div class=\"graphic_reference\">Courtesy of&nbsp;A. Gordon Smith, MD</div><div id=\"graphicVersion\">Graphic 81127 Version 3.0</div></div></div>"},"81128":{"type":"graphic_movie","displayName":"Tai chi","title":"Balance exercises: Tai chi","html":"<div class=\"graphic normal\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Balance exercises: Tai chi</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/81128_Taichivideo.mp4\" style=\"width:464px;height:336px\"></div><img style=\"width:360px; height:246px;\" src=\"images/PC/81128_Taichiimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Balance is important to help you perform many of your daily activities and prevent falls. Research has shown that tai chi can significantly reduce the risk of falls among older people. In tai chi, which is sometimes called \"moving meditation,\" you work to improve your balance by moving your body slowly, gently, and precisely, while breathing deeply.<br />Other benefits from practicing tai chi include:<br /><UL>&#xD;&#xA;<LI>Improvements in bone and heart health </LI>&#xD;&#xA;<LI>Easing of pain and stiffness from osteoarthritis </LI>&#xD;&#xA;<LI>Better sleep </LI>&#xD;&#xA;<LI>Improvements in overall wellness </LI></UL>Watch this video from the National Center for Complementary and Alternative Medicine (NCCAM) at NIH to see a demonstration of tai chi.<br /><br />While practicing tai chi, try to put aside distracting thoughts and focus on being aware of your movements.</div><div class=\"graphic_reference\">Reproduced from: the National Center for Complementary and Alternative Medicine. Available at:&nbsp;<a href=\"http://nccam.nih.gov/health/taichi\" target=\"_blank\">http://nccam.nih.gov/health/taichi</a> (Accessed March 23, 2012).</div><div id=\"graphicVersion\">Graphic 81128 Version 2.0</div></div></div>"},"81129":{"type":"graphic_diagnosticimage","displayName":"Cobblestone in Crohn SBFT","title":"Cobblestone appearance in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cobblestone appearance in Crohn disease</div><div class=\"cntnt\"><img style=\"width:334px; height:392px;\" src=\"images/GAST/81129_Cobblestone_in_Crohns_SBFT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through study demonstrates diffuse thickening of the small bowel mucosa in a patient with Crohn disease. The cobblestone appearance is produced by barium being dispersed between the edematous inflamed mucosa.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 81129 Version 3.0</div></div></div>"},"81130":{"type":"graphic_diagnosticimage","displayName":"Dissection of the abdominal aorta on longitudinal ultrasound ","title":"Dissection of the abdominal aorta on longitudinal ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dissection of the abdominal aorta on longitudinal ultrasound</div><div class=\"cntnt\"><img style=\"width:272px; height:224px;\" src=\"images/CARD/81130_Abdominal_aorta_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long axis view shows a dissection of the abdominal aorta (AAo) and the presence of a spiral flap (f).</div><div id=\"graphicVersion\">Graphic 81130 Version 4.0</div></div></div>"},"81131":{"type":"graphic_diagnosticimage","displayName":"Plummer Vinson syndrome","title":"Barium swallow in a patient with Plummer Vinson syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barium swallow in a patient with Plummer Vinson syndrome</div><div class=\"cntnt\"><img style=\"width:234px; height:324px;\" src=\"images/GAST/81131_Plummer_Vinson_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This barium swallow study obtained in a 53-year-old female with dysphagia and anemia demonstrates an upper esophageal web (black arrow) immediately above a tight stricture of the esophagus (white arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 81131 Version 3.0</div></div></div>"},"81132":{"type":"graphic_movie","displayName":"External rotation technique for shoulder reduction","title":"External rotation technique for reducing anterior shoulder dislocation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External rotation technique for reducing anterior shoulder dislocation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/81132_Externalrotation.mp4\" style=\"width:448px;height:352px\"></div><img style=\"width:432px; height:324px;\" src=\"images/EM/81132_Extrotation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The external rotation technique can be used to reduce anterior glenohumeral (shoulder) dislocations.</div><div class=\"graphic_reference\">Reproduced from: Simon and Sherman, Emergency Orthopedics, 6th edition. DVD © Scott Sherman. All rights reserved.</div><div id=\"graphicVersion\">Graphic 81132 Version 3.0</div></div></div>"},"81133":{"type":"graphic_figure","displayName":"Phenethylamine structure","title":"Phenethylamine structure","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Phenethylamine structure</div><div class=\"cntnt\"><img style=\"width:463px; height:156px;\" src=\"images/EM/81133_Phenethylamine_structure.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81133 Version 1.0</div></div></div>"},"81136":{"type":"graphic_picture","displayName":"Chronic scleritis inflammation","title":"Chronic necrotizing anterior scleritis with inflammation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic necrotizing anterior scleritis with inflammation</div><div class=\"cntnt\"><img style=\"width:332px; height:215px;\" src=\"images/RHEUM/81136_Chronic_scleritis_inflammat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic necrotizing anterior scleritis with inflammation in a patient with granulomatosis with polyangiitis (Wegener's). Significant thinning of the sclera permits the visualization of the underlying choroid through the scleral wall.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 81136 Version 3.0</div></div></div>"},"81137":{"type":"graphic_table","displayName":"Normal reference ranges in pregnant women","title":"Normal reference ranges in pregnant women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal reference ranges in pregnant women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Nonpregnant woman*</td> <td class=\"subtitle1\">First trimester</td> <td class=\"subtitle1\">Second trimester</td> <td class=\"subtitle1\">Third trimester</td> <td class=\"subtitle1\">References</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Hematology</td> </tr> <tr> <td class=\"indent1\">Erythropoietin<sup>&#182;</sup> (units/L)</td> <td>4-27</td> <td>12-25</td> <td>8-67</td> <td>14-222</td> <td>1-3</td> </tr> <tr> <td class=\"indent1\">Ferritin<sup>&#182;</sup> (ng/mL)</td> <td>10-150<sup>&#916;</sup></td> <td>6-130</td> <td>2-230</td> <td>0-116</td> <td>1-8</td> </tr> <tr> <td class=\"indent1\">Folate, red blood cell (ng/mL)</td> <td>150-450</td> <td>137-589</td> <td>94-828</td> <td>109-663</td> <td>6, 9, 10</td> </tr> <tr> <td class=\"indent1\">Folate, serum (ng/mL)</td> <td>5.4-18.0</td> <td>2.6-15.0</td> <td>0.8-24.0</td> <td>1.4-20.7</td> <td>1, 6, 9-13</td> </tr> <tr> <td class=\"indent1\">Haptoglobin (mg/mL)</td> <td>25-250</td> <td>130 +/- 43</td> <td>115 +/- 50</td> <td>135 +/- 65</td> <td>93</td> </tr> <tr> <td class=\"indent1\">Hemoglobin<sup>&#182;</sup> (g/dL)</td> <td>12-15.8<sup>&#916;</sup></td> <td>11.6-13.9</td> <td>9.7-14.8</td> <td>9.5-15.0</td> <td>2, 3, 6, 7, 13</td> </tr> <tr> <td class=\"indent1\">Hematocrit<sup>&#182;</sup> (percent)</td> <td>35.4-44.4</td> <td>31.0-41.0</td> <td>30.0-39.0</td> <td>28.0-40.0</td> <td>1, 2, 5, 6, 13-15</td> </tr> <tr> <td class=\"indent1\">Iron, total binding capacity<sup>&#182;</sup> (mcg/dL)</td> <td>251-406</td> <td>278-403</td> <td>Not reported</td> <td>359-609</td> <td>7</td> </tr> <tr> <td class=\"indent1\">Iron, serum<sup>&#182;</sup> (mcg/dL)</td> <td>41-141</td> <td>72-143</td> <td>44-178</td> <td>30-193</td> <td>2, 7</td> </tr> <tr> <td class=\"indent1\">Mean corpuscular hemoglobin (pg/cell)</td> <td>27-32</td> <td>30-32</td> <td>30-33</td> <td>29-32</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Mean corpuscular volume (xm<sup>3</sup>)</td> <td>79-93</td> <td>81-96</td> <td>82-97</td> <td>81-99</td> <td>5, 6, 13, 14</td> </tr> <tr> <td class=\"indent1\">Platelet (x10<sup>9</sup>/L)</td> <td>165-415</td> <td>174-391</td> <td>155-409</td> <td>146-429</td> <td>5, 6, 14, 16, 17</td> </tr> <tr> <td class=\"indent1\">Mean platelet volume (mcm<sup>3</sup>)</td> <td>6.4-11.0</td> <td>7.7-10.3</td> <td>7.8-10.2</td> <td>8.2-10.4</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Red blood cell count (x10<sup>6</sup>/mm<sup>3</sup>)</td> <td>4.00-5.20<sup>&#916;</sup></td> <td>3.42-4.55</td> <td>2.81-4.49</td> <td>2.71-4.43</td> <td>5, 6, 13, 14</td> </tr> <tr> <td class=\"indent1\">Red cell distribution width (percent)</td> <td>&#60;14.5</td> <td>12.5-14.1</td> <td>13.4-13.6</td> <td>12.7-15.3</td> <td>5</td> </tr> <tr> <td class=\"sublist2_start\">White blood cell count (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"sublist_other_start\">3.5-9.1 </td> <td class=\"sublist_other_start\">5.7-13.6</td> <td class=\"sublist_other_start\">5.6-14.8</td> <td class=\"sublist_other_start\">5.9-16.9</td> <td class=\"sublist_other_start\">5, 6, 13, 14, 18</td> </tr> <tr> <td class=\"sublist2\">Neutrophils (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"sublist_other\">1.4-4.6</td> <td class=\"sublist_other\">3.6-10.1</td> <td class=\"sublist_other\">3.8-12.3</td> <td class=\"sublist_other\">3.9-13.1</td> <td class=\"sublist_other\">5, 14, 16, 18</td> </tr> <tr> <td class=\"sublist2\">Lymphocytes (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"sublist_other\">0.7-4.6</td> <td class=\"sublist_other\">1.1-3.6</td> <td class=\"sublist_other\">0.9-3.9</td> <td class=\"sublist_other\">1.0-3.6</td> <td class=\"sublist_other\">5, 14, 16, 18</td> </tr> <tr> <td class=\"sublist2\">Monocytes (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"sublist_other\">0.1-0.7</td> <td class=\"sublist_other\">0.1-1.1</td> <td class=\"sublist_other\">0.1-1.1</td> <td class=\"sublist_other\">0.1-1.4</td> <td class=\"sublist_other\">5, 14, 18</td> </tr> <tr> <td class=\"sublist2\">Eosinophils (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"sublist_other\">0-0.6</td> <td class=\"sublist_other\">0-0.6</td> <td class=\"sublist_other\">0-0.6</td> <td class=\"sublist_other\">0-0.6</td> <td class=\"sublist_other\">14, 18</td> </tr> <tr> <td class=\"sublist2\">Basophils (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"sublist_other\">0-0.2</td> <td class=\"sublist_other\">0-0.1</td> <td class=\"sublist_other\">0-0.1</td> <td class=\"sublist_other\">0-0.1</td> <td class=\"sublist_other\">14, 18</td> </tr> <tr> <td class=\"indent1\">Transferrin (mg/dL)</td> <td>200-400</td> <td>254-344</td> <td>220-441</td> <td>288-530</td> <td>4, 5</td> </tr> <tr> <td class=\"indent1\">Transferrin, saturation without iron (percent)</td> <td>22-46<sup>&#182;</sup></td> <td>Not reported</td> <td>10-44</td> <td>5-37</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Transferrin, saturation with iron (percent)</td> <td>22-46<sup>&#182;</sup></td> <td>Not reported</td> <td>18-92</td> <td>9-98</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Coagulation</td> </tr> <tr> <td class=\"indent1\">Antithrombin, functional (percent)</td> <td>70-130</td> <td>89-114</td> <td>78-126</td> <td>82-116</td> <td>17, 19, 20</td> </tr> <tr> <td class=\"indent1\">D-dimer (mcg/mL)</td> <td>0.22-0.74</td> <td>0.05-0.95</td> <td>0.32-1.29</td> <td>0.13-1.7</td> <td>17, 20-24, 87</td> </tr> <tr> <td class=\"indent1\">Factor V (percent)</td> <td>50-150</td> <td>75-95</td> <td>72-96</td> <td>60-88</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Factor VII (percent)</td> <td>50-150</td> <td>100-146</td> <td>95-153</td> <td>149-211</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Factor VIII (percent)</td> <td>50-150</td> <td>90-210</td> <td>97-312</td> <td>143-353</td> <td>17, 25</td> </tr> <tr> <td class=\"indent1\">Factor IX (percent)</td> <td>50-150</td> <td>103-172</td> <td>154-217</td> <td>164-235</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Factor XI (percent)</td> <td>50-150</td> <td>80-127</td> <td>82-144</td> <td>65-123</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Factor XII (percent)</td> <td>50-150</td> <td>78-124</td> <td>90-151</td> <td>129-194</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Fibrinogen (mg/dL)</td> <td>211-496</td> <td>244-510</td> <td>291-538</td> <td>301-696</td> <td>5, 17, 20, 21, 23, 24, 87</td> </tr> <tr> <td class=\"indent1\">Homocysteine (mmol/L)</td> <td>4.4-10.8</td> <td>3.34-11</td> <td>2.0-26.9</td> <td>3.2-21.4</td> <td>6, 9, 10-12</td> </tr> <tr> <td class=\"indent1\">International Normalized Ratio</td> <td>0.9-1.04<sup>&#9674;</sup></td> <td>0.86-1.08</td> <td>0.83-1.02</td> <td>0.80-1.09</td> <td>19, 24</td> </tr> <tr> <td class=\"indent1\">Partial thromboplastin time, activated (sec)</td> <td>26.3-39.4</td> <td>23.0-38.9</td> <td>22.9-38.1</td> <td>22.6-35.0</td> <td>5, 17, 19, 24</td> </tr> <tr> <td class=\"indent1\">Plasminogen activator inhibitor-1 (PAI-1) antigen (pg/mL)</td> <td>17.3 +/&ndash; 5.7</td> <td>17.7 +/&ndash; 1.9</td> <td>Not reported</td> <td>66.4 +/&ndash; 4.9</td> <td>87</td> </tr> <tr> <td class=\"indent1\">Plasminogen activator inhibitor-1 (PAI-1) activity (arbitrary units)</td> <td>9.3 +/&ndash; 1.9</td> <td>9.0 +/&ndash; 0.8</td> <td>Not reported</td> <td>31.4 +/&ndash; 3.0</td> <td>87</td> </tr> <tr> <td class=\"indent1\">Prothrombin time (sec)</td> <td>12.7-15.4</td> <td>9.7-13.5</td> <td>9.5-13.4</td> <td>9.6-12.9</td> <td>5, 17, 24</td> </tr> <tr> <td class=\"indent1\">Protein C, functional (percent)</td> <td>70-130</td> <td>78-121</td> <td>83-133</td> <td>67-135</td> <td>19, 25, 26</td> </tr> <tr> <td class=\"indent1\">Protein S, total (percent)</td> <td>70-140</td> <td>39-105</td> <td>27-101</td> <td>33-101</td> <td>17, 25, 26</td> </tr> <tr> <td class=\"indent1\">Protein S, free (percent)</td> <td>70-140</td> <td>34-133</td> <td>19-113</td> <td>20-65</td> <td>25, 26</td> </tr> <tr> <td class=\"indent1\">Protein S, functional activity (percent)</td> <td>65-140</td> <td>57-95</td> <td>42-68</td> <td>16-42</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Tissue plasminogen activator (ng/mL)</td> <td>1.6-13<sup>&#167;</sup></td> <td>1.8-6.0</td> <td>2.36-6.6</td> <td>3.34-9.20</td> <td>17, 19, 87</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tissue plasminogen activator inhibitor-1 (ng/mL)</td> <td>4-43</td> <td>16-33</td> <td>36-55</td> <td>67-92</td> <td>17</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">von Willebrand measurements</td> </tr> <tr> <td class=\"indent1\">von Willebrand factor antigen (percent)</td> <td>75-125</td> <td>62-318</td> <td>90-247</td> <td>84-422</td> <td>20, 27, 28</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ADAMTS-13, von Willebrand cleaving protease</td> <td>40-170<sup>&#165;</sup></td> <td>40-160</td> <td>22-135</td> <td>38-105</td> <td>20, 28</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Blood chemical constituents</td> </tr> <tr> <td class=\"indent1\">Alanine transaminase (units/L)</td> <td>7-41</td> <td>3-30</td> <td>2-33</td> <td>2-25</td> <td>4, 5, 8, 29</td> </tr> <tr> <td class=\"indent1\">Albumin (g/dL)</td> <td>4.1-5.3<sup>&#916;</sup></td> <td>3.1-5.1</td> <td>2.6-4.5</td> <td>2.3-4.2</td> <td>29-32</td> </tr> <tr> <td class=\"indent1\">Alkaline phosphatase (units/L)</td> <td>33-96</td> <td>17-88</td> <td>25-126</td> <td>38-229</td> <td>4, 5, 8, 29, 30</td> </tr> <tr> <td class=\"indent1\">Alpha-1 antitrypsin (mg/dL)</td> <td>100-200</td> <td>225-323</td> <td>273-391</td> <td>327-487</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Alpha-fetoprotein (ng/mL)</td> <td>&#8212;</td> <td>&#8212;</td> <td>Approximately 130-400</td> <td>Approximately 130-590</td> <td>95</td> </tr> <tr> <td class=\"indent1\">Ammonia (microM)</td> <td>31 +/- 3.2</td> <td>&#8212;</td> <td>&#8212;</td> <td>27.3 +/- 1.6</td> <td>94</td> </tr> <tr> <td class=\"indent1\">Amylase (units/L)</td> <td>20-96</td> <td>24-83</td> <td>16-73</td> <td>15-81</td> <td>4, 5, 33, 34</td> </tr> <tr> <td class=\"indent1\">Anion gap (mmol/L)</td> <td>7-16</td> <td>13-17</td> <td>12-16</td> <td>12-16</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Aspartate transaminase (units/L)</td> <td>12-38</td> <td>3-23</td> <td>3-33</td> <td>4-32</td> <td>4, 5, 8, 29</td> </tr> <tr> <td class=\"indent1\">Bicarbonate (mmol/L)</td> <td>22-30</td> <td>20-24</td> <td>20-24</td> <td>20-24</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Bilirubin, total (mg/dL)</td> <td>0.3-1.3</td> <td>0.1-0.4</td> <td>0.1-0.8</td> <td>0.1-1.1</td> <td>4, 29</td> </tr> <tr> <td class=\"indent1\">Bilirubin, unconjugated (mg/dL)</td> <td>0.2-0.9</td> <td>0.1-0.5</td> <td>0.1-0.4</td> <td>0.1-0.5</td> <td>5, 29</td> </tr> <tr> <td class=\"indent1\">Bilirubin, conjugated (mg/dL)</td> <td>0.1-0.4</td> <td>0-0.1</td> <td>0-0.1</td> <td>0-0.1</td> <td>29</td> </tr> <tr> <td class=\"indent1\">Bile acids (mmol/L)</td> <td>0.3-4.8<sup>&#135;</sup></td> <td>0-4.9</td> <td>0-9.1</td> <td>0-11.3</td> <td>29, 35</td> </tr> <tr> <td class=\"indent1\">CA-125 antigen (units/mL)</td> <td>7.2-27.0</td> <td>2/2-268</td> <td>12-25.1</td> <td>16.8-43.8</td> <td>88, 89, 90</td> </tr> <tr> <td class=\"indent1\">Calcium, ionized (mg/dL)</td> <td>4.5-5.3</td> <td>4.5-5.1</td> <td>4.4-5.0</td> <td>4.4-5.3</td> <td>5, 31, 36, 37</td> </tr> <tr> <td class=\"indent1\">Calcium, total (mg/dL)</td> <td>8.7-10.2</td> <td>8.8-10.6</td> <td>8.2-9.0</td> <td>8.2-9.7</td> <td>4, 5, 30, 32, 36-38</td> </tr> <tr> <td class=\"indent1\">Ceruloplasmin (mg/dL)</td> <td>25-63</td> <td>30-49</td> <td>40-53</td> <td>43-78</td> <td>5, 39</td> </tr> <tr> <td class=\"indent1\">Chloride (mEq/L)</td> <td>102-109</td> <td>101-105</td> <td>97-109</td> <td>97-109</td> <td>4, 5, 40</td> </tr> <tr> <td class=\"indent1\">Creatinine (mg/dL)</td> <td>0.5-0.9<sup>&#916;</sup></td> <td>0.4-0.7</td> <td>0.4-0.8</td> <td>0.4-0.9</td> <td>4, 5, 46</td> </tr> <tr> <td class=\"indent1\">Gamma-glutamyl transpeptidase (units/L)</td> <td>9-58</td> <td>2-23</td> <td>4-22</td> <td>3-26</td> <td>4, 5, 8, 29</td> </tr> <tr> <td class=\"indent1\">Lactate dehydrogenase (units/L)</td> <td>115-221</td> <td>78-433</td> <td>80-447</td> <td>82-524</td> <td>4, 5, 32, 8</td> </tr> <tr> <td class=\"indent1\">Lipase (units/L)</td> <td>3-43</td> <td>21-76</td> <td>26-100</td> <td>41-112</td> <td>33</td> </tr> <tr> <td class=\"indent1\">Magnesium (mg/dL)</td> <td>1.5-2.3</td> <td>1.6-2.2</td> <td>1.5-2.2</td> <td>1.1-2.2</td> <td>4, 5, 30-32, 36, 38</td> </tr> <tr> <td class=\"indent1\">Osmolality (mOsm/kg H20)</td> <td>275-295</td> <td>275-280</td> <td>276-289</td> <td>278-280</td> <td>38, 41</td> </tr> <tr> <td class=\"indent1\">Phosphate (mg/dL)</td> <td>2.5-4.3</td> <td>3.1-4.6</td> <td>2.5-4.6</td> <td>2.8-4.6</td> <td>4, 5, 30, 31, 42</td> </tr> <tr> <td class=\"indent1\">Potassium (mEq/L)</td> <td>3.5-5.0</td> <td>3.6-5.0</td> <td>3.3-5.0</td> <td>3.3-5.1</td> <td>4, 5, 15, 31, 32, 38, 40</td> </tr> <tr> <td class=\"indent1\">Prealbumin (mg/dL)</td> <td>17-34</td> <td>15-27</td> <td>20-27</td> <td>14-23</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Protein, total (g/dL)</td> <td>6.7-8.6</td> <td>6.2-7.6</td> <td>5.7-6.9</td> <td>5.6-6.7</td> <td>5, 31, 32</td> </tr> <tr> <td class=\"indent1\">Sodium (mEq/L)</td> <td>136-146</td> <td>133-148</td> <td>129-148</td> <td>130-148</td> <td>4, 5, 15, 31, 32, 38, 41</td> </tr> <tr> <td class=\"indent1\">Urea nitrogen (mg/dL)</td> <td>7-20</td> <td>7-12</td> <td>3-13</td> <td>3-11</td> <td>4, 5, 40</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Uric acid (mg/dL)</td> <td>2.5-5.6<sup>&#916;</sup></td> <td>2.0-4.2</td> <td>2.4-4.9</td> <td>3.1-6.3</td> <td>4, 5, 41</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Metabolic and endocrine tests</td> </tr> <tr> <td class=\"indent1\">Aldosterone (ng/dL)</td> <td>2-9</td> <td>6-104</td> <td>9-104</td> <td>15-101</td> <td>43, 44, 45</td> </tr> <tr> <td class=\"indent1\">Angiotensin converting enzyme (units/L)</td> <td>9-67</td> <td>1-38</td> <td>1-36</td> <td>1-39</td> <td>39, 46</td> </tr> <tr> <td class=\"indent1\">Alpha-fetoprotein (ng/mL)</td> <td>0-8.5</td> <td>Not reported</td> <td>50-425</td> <td>50-590</td> <td>84, 86</td> </tr> <tr> <td class=\"indent1\">Cortisol (mcg/dL)</td> <td>0-25</td> <td>7-19</td> <td>10-42</td> <td>12-50</td> <td>5, 45</td> </tr> <tr> <td class=\"indent1\">Hemoglobin A<sub>1C</sub> (percent)</td> <td>4-6</td> <td>4-6</td> <td>4-6</td> <td>4-7</td> <td>36, 47, 48</td> </tr> <tr> <td class=\"indent1\">Parathyroid hormone (pg/mL)</td> <td>8-51</td> <td>10-15</td> <td>18-25</td> <td>9-26</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Parathyroid hormone-related protein (pmol/L)</td> <td>&#60;1.3<sup>&#134;</sup></td> <td>0.7-0.9</td> <td>1.8-2.2</td> <td>2.5-2.8</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Renin, plasma activity (ng/mL/hour)</td> <td>0.3-9.0<sup>&#134;</sup></td> <td>Not reported</td> <td>7.5-54.0</td> <td>5.9-58.8</td> <td>40, 44</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <p>Thyroid-stimulating hormone (milli-int. units/mL)</p> [American Thyroid Association recommendation]**</td> <td rowspan=\"2\">0.34-4.25</td> <td>0.60-3.40</td> <td>0.37-3.60</td> <td>0.38-4.04</td> <td>4, 5, 49</td> </tr> <tr> <td>0.1-2.5</td> <td>0.2-3.0</td> <td>0.3-3.0</td> <td>85</td> </tr> <tr> <td class=\"indent1\">Thyroxine-binding globulin (mg/dL)</td> <td>1.3-3.0</td> <td>1.8-3.2</td> <td>2.8-4.0</td> <td>2.6-4.2</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Thyroxine, free (ng/dL)</td> <td>0.8-1.7</td> <td>0.8-1.2</td> <td>0.6-1.0</td> <td>0.5-0.8</td> <td>5, 49</td> </tr> <tr> <td class=\"indent1\">Thyroxine, total (mcg/dL)</td> <td>5.4-11.7</td> <td>6.5-10.1</td> <td>7.5-10.3</td> <td>6.3-9.7</td> <td>5, 32</td> </tr> <tr> <td class=\"indent1\">Triiodothyronine, free (pg/mL)</td> <td>2.4-4.2</td> <td>4.1-4.4</td> <td>4.0-4.2</td> <td>Not reported</td> <td>49</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Triiodothyronine, total (ng/dL)</td> <td>77-135</td> <td>97-149</td> <td>117-169</td> <td>123-162</td> <td>5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Vitamins and minerals</td> </tr> <tr> <td class=\"indent1\">Copper (mcg/dL)</td> <td>70-140</td> <td>112-199</td> <td>165-221</td> <td>130-240</td> <td>50, 51, 5</td> </tr> <tr> <td class=\"indent1\">Selenium (mcg/L)</td> <td>63-160</td> <td>116-146</td> <td>75-145</td> <td>71-133</td> <td>5, 50</td> </tr> <tr> <td class=\"indent1\">Vitamin A (retinol) (mcg/dL)</td> <td>20-100</td> <td>32-47</td> <td>35-44</td> <td>29-42</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Vitamin B12 (pg/mL)</td> <td>279-966</td> <td>118-438</td> <td>130-656</td> <td>99-526</td> <td>6, 10</td> </tr> <tr> <td class=\"indent1\">Vitamin C (ascorbic acid) (mg/dL)</td> <td>0.4-1.0</td> <td>Not reported</td> <td>Not reported</td> <td>0.9-1.3</td> <td>52</td> </tr> <tr> <td class=\"indent1\">Vitamin D, 1,25-dihydroxy (pg/mL)</td> <td>25-45</td> <td>20-65</td> <td>72-160</td> <td>60-119</td> <td>30, 36</td> </tr> <tr> <td class=\"indent1\">Vitamin D, 24,25-dihydroxy (ng/mL)</td> <td>0.5-5.0<sup>&#134;</sup></td> <td>1.2-1.8</td> <td>1.1-1.5</td> <td>0.7-0.9</td> <td>53</td> </tr> <tr> <td class=\"indent1\">Vitamin D, 25-hydroxy (ng/mL)</td> <td>14-80</td> <td>18-27</td> <td>10-22</td> <td>10-18</td> <td>30, 53</td> </tr> <tr> <td class=\"indent1\">Vitamin E (&#945;-tocopherol) (mcg/mL)</td> <td>5-18</td> <td>7-13</td> <td>10-16</td> <td>13-23</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zinc (mcg/dL)</td> <td>75-120</td> <td>57-88</td> <td>51-80</td> <td>50-77</td> <td>5, 13, 50</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Autoimmune and inflammatory mediators</td> </tr> <tr> <td class=\"indent1\">C3 complement (mg/dL)</td> <td>83-177</td> <td>62-98</td> <td>73-103</td> <td>77-111</td> <td>5</td> </tr> <tr> <td class=\"indent1\">C4 complement (mg/dL)</td> <td>16-47</td> <td>18-36</td> <td>18-34</td> <td>22-32</td> <td>5</td> </tr> <tr> <td class=\"indent1\">C-reactive protein (mg/L)</td> <td>0.2-3.0</td> <td>Not reported</td> <td>0.4-20.3</td> <td>0.4-8.1</td> <td>54</td> </tr> <tr> <td class=\"indent1\">Erythrocyte sedimentation rate (mm/hour)</td> <td>0-20<sup>&#916;</sup></td> <td>4-57</td> <td>7-47</td> <td>13-70</td> <td>55</td> </tr> <tr> <td class=\"indent1\">Immunoglobulin A (mg/dL)</td> <td>70-350</td> <td>95-243</td> <td>99-237</td> <td>112-250</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Immunoglobulin G (mg/dL)</td> <td>700-1700</td> <td>981-1267</td> <td>813-1131</td> <td>678-990</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Immunoglobulin M (mg/dL)</td> <td>50-300</td> <td>78-232</td> <td>74-218</td> <td>85-269</td> <td>5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Sex hormones</td> </tr> <tr> <td class=\"indent1\">Dehydroepiandrosterone sulfate (mmol/L)</td> <td>1.3-6.8<sup>&#134;</sup></td> <td>2.0-16.5</td> <td>0.9-7.8</td> <td>0.8-6.5</td> <td>56</td> </tr> <tr> <td class=\"indent1\">Estradiol (pg/mL)</td> <td>&#60;20-443<sup>&#916;</sup><sup>,&#182;</sup><sup>&#182;</sup></td> <td>188-2497</td> <td>1278-7192</td> <td>6137-3460</td> <td>56, 57</td> </tr> <tr> <td class=\"indent1\">Progesterone (ng/mL)</td> <td>&#60;1-20<sup>&#916;</sup></td> <td>8-48</td> <td>&nbsp;</td> <td>99-342</td> <td>56, 57</td> </tr> <tr> <td class=\"indent1\">Prolactin (ng/mL)</td> <td>0-20</td> <td>36-213</td> <td>110-330</td> <td>137-372</td> <td>30, 47, 57, 58</td> </tr> <tr> <td class=\"indent1\">Sex hormone binding globulin (nmol/L)</td> <td>18-114<sup>&#916;</sup></td> <td>39-131</td> <td>214-717</td> <td>216-724</td> <td>56, 59</td> </tr> <tr> <td class=\"indent1\">Testosterone (ng/dL)</td> <td>6-86<sup>&#916;</sup></td> <td>25.7-211.4</td> <td>34.3-242.9</td> <td>62.9-308.6</td> <td>56</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">17-hydroxyprogesterone (nmol/L)</td> <td>0.6-10.6<sup>&#916;</sup><sup>,&#134;</sup></td> <td>5.2-28.5</td> <td>5.2-28.5</td> <td>15.5-84</td> <td>56</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Lipids</td> </tr> <tr> <td class=\"sublist2_start\">Cholesterol, total (mg/dL)</td> <td class=\"sublist_other_start\">&#60;200</td> <td class=\"sublist_other_start\">141-210</td> <td class=\"sublist_other_start\">176-299</td> <td class=\"sublist_other_start\">219-349</td> <td class=\"sublist_other_start\">5, 60-62</td> </tr> <tr> <td class=\"sublist2\">High-density lipoprotein cholesterol (mg/dL)</td> <td class=\"sublist_other\">40-60</td> <td class=\"sublist_other\">40-78</td> <td class=\"sublist_other\">52-87</td> <td class=\"sublist_other\">48-87</td> <td class=\"sublist_other\">5, 60-63</td> </tr> <tr> <td class=\"sublist2\">Low-density lipoprotein cholesterol (mg/dL)</td> <td class=\"sublist_other\">&#60;100</td> <td class=\"sublist_other\">60-153</td> <td class=\"sublist_other\">77-184</td> <td class=\"sublist_other\">101-224</td> <td class=\"sublist_other\">5, 60-63</td> </tr> <tr> <td class=\"sublist2\">Very-low-density lipoprotein cholesterol (mg/dL)</td> <td class=\"sublist_other\">6-40<sup>&#134;</sup></td> <td class=\"sublist_other\">10-18</td> <td class=\"sublist_other\">13-23</td> <td class=\"sublist_other\">21-36</td> <td class=\"sublist_other\">62</td> </tr> <tr> <td class=\"indent1\">Triglycerides (mg/dL)</td> <td>&#60;150</td> <td>40-159</td> <td>75-382</td> <td>131-453</td> <td>4, 5, 60-63</td> </tr> <tr> <td class=\"indent1\">Apolipoprotein A-I (mg/dL)</td> <td>119-240</td> <td>111-150</td> <td>142-253</td> <td>145-262</td> <td>4, 47, 61</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Apolipoprotein B (mg/dL)</td> <td>52-163</td> <td>58-81</td> <td>66-188</td> <td>85-238</td> <td>4, 47, 61</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Cardiac function</td> </tr> <tr> <td class=\"indent1\">Cardiac output (L/min)</td> <td>4.8-6.8</td> <td>5.6-9.7</td> <td>5.5-9.9</td> <td>4.8-8.7</td> <td>64, 65, 66, 67, 68</td> </tr> <tr> <td class=\"indent1\">Cardiac index (L/min/m<sup>2</sup>)</td> <td>2.6-4.2</td> <td>3.2-4.6</td> <td>3.1-4.7</td> <td>2.5-4.4</td> <td>65, 68</td> </tr> <tr> <td class=\"indent1\">Stroke volume (mL)</td> <td>79-90</td> <td>77.5-107.6</td> <td>70.3-107.6</td> <td>54-99</td> <td>65, 68, 69</td> </tr> <tr> <td class=\"indent1\">Stroke index (mL/m<sup>2</sup>)</td> <td>&nbsp;</td> <td>46-62</td> <td>39-62</td> <td>30-42</td> <td>65</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Systemic vascular resistance (dyns/cm<sup>5</sup>)</td> <td>700-1600</td> <td>747-1485</td> <td>692-1201</td> <td>1034-1201</td> <td>65, 67, 70</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Echocardiography</td> </tr> <tr> <td class=\"indent1\">Intraventricular septal dimension (cm)</td> <td>0.7-0.9</td> <td>0.63-0.83</td> <td>0.65-0.85</td> <td>0.66-0.9</td> <td>68, 69, 70, 91, 92</td> </tr> <tr> <td class=\"indent1\">Posterior ventricular wall dimension (cm)</td> <td>0.75-0.9</td> <td>0.56-0.8</td> <td>0.59-0.9</td> <td>0.59-0.9</td> <td>68, 69, 70, 91, 92</td> </tr> <tr> <td class=\"indent1\">Left ventricular mass (g)</td> <td>116-143</td> <td>108-167</td> <td>115-150</td> <td>128-162</td> <td>68, 70, 91, 92</td> </tr> <tr> <td class=\"indent1\">Left ventricular mass index</td> <td>40-78</td> <td>53-79</td> <td>58-82</td> <td>60-88</td> <td>68, 70, 91, 92</td> </tr> <tr> <td class=\"indent1\">E/A ratio</td> <td>1.4-1.75</td> <td>1.6</td> <td>1.4</td> <td>1.3</td> <td>68, 70</td> </tr> <tr> <td class=\"indent1\">Left ventricular diastolic diameter (cm)</td> <td>4.3-4.8</td> <td>4.3-4.6</td> <td>4.4-4.9</td> <td>5.1</td> <td>69, 70</td> </tr> <tr> <td class=\"indent1\">Left ventricular systolic diameter (cm)</td> <td>2.8-3.1</td> <td>2.8-2.9</td> <td>2.8-3.4</td> <td>2.8-3.3</td> <td>69, 70</td> </tr> <tr> <td class=\"indent1\">Left vent, fractional shortening (percent)</td> <td>35-36</td> <td>35-37</td> <td>3.5</td> <td>35-36</td> <td>69, 70</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Left vent ejection fraction (percent)</td> <td>60-73</td> <td>61-75</td> <td>61-63</td> <td>60-73</td> <td>69, 70</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Cardiac function (blood tests)</td> </tr> <tr> <td class=\"indent1\">Atrial natriuretic peptide (pg/mL)</td> <td>Not reported</td> <td>Not reported</td> <td>28.1-70.1</td> <td>Not reported</td> <td>73</td> </tr> <tr> <td class=\"indent1\">B-type natriuretic peptide (pg/mL)</td> <td>&#60;167 (age- and gender-specific)</td> <td>18.4</td> <td>13.5-29.5</td> <td>15.5-46</td> <td>71, 72, 73</td> </tr> <tr> <td class=\"indent1\">Creatine kinase (units/L)</td> <td>39-238<sup>&#916;</sup></td> <td>27-83</td> <td>25-75</td> <td>13-101</td> <td>5, 74</td> </tr> <tr> <td class=\"indent1\">Creatine kinase-MB (units/L)</td> <td>&#60;6<sup>&#916;&#916;</sup></td> <td>&#8212;</td> <td>&#8212;</td> <td>1.8-2.4</td> <td>74</td> </tr> <tr> <td class=\"indent1\">N-terminal pro-brain natriuretic peptide (pg/mL)</td> <td>50 +/- 26</td> <td>60 +/- 45</td> <td>60 +/- 40</td> <td>43 +/- 34</td> <td>96</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Troponin I (ng/mL)</td> <td>0-0.08</td> <td>Not reported</td> <td>Not reported</td> <td>0-0.064 (intrapartum)</td> <td>75, 76</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Blood gas</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">pH</td> <td rowspan=\"2\">7.38-7.42 (arterial)</td> <td rowspan=\"2\">7.36-7.52 (venous)</td> <td rowspan=\"2\">7.40-7.52 (venous)</td> <td>7.41-7.53 (venous)</td> <td rowspan=\"2\">31, 77</td> </tr> <tr> <td>7.39-7.45 (arterial)</td> </tr> <tr> <td class=\"indent1\">PO<sub>2</sub> (mmHg)</td> <td>90-100</td> <td>93-100</td> <td>90-98</td> <td>92-107</td> <td>77, 78</td> </tr> <tr> <td class=\"indent1\">PCO<sub>2</sub> (mmHg)</td> <td>38-42</td> <td>Not reported</td> <td>Not reported</td> <td>25-33</td> <td>77</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bicarbonate (HCO<sub>3</sub><sup>&ndash;</sup>) (mEq/L)</td> <td>22-26</td> <td>Not reported</td> <td>Not reported</td> <td>16-22</td> <td>77</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Renal function tests</td> </tr> <tr> <td class=\"indent1\">Effective renal plasma flow (mL/min)</td> <td>492-696<sup>&#916;</sup><sup>,&#134;</sup></td> <td>696-985</td> <td>612-1170</td> <td>595-945</td> <td>79, 80</td> </tr> <tr> <td class=\"indent1\">Glomerular filtration rate (GFR) (mL/min)</td> <td>106-132<sup>&#916;</sup></td> <td>131-166</td> <td>135-170</td> <td>117-182</td> <td>79, 80, 81</td> </tr> <tr> <td class=\"indent1\">Filtration fraction (percent)</td> <td>16.9-24.7<sup>&#9674;</sup><sup>&#9674;</sup></td> <td>14.7-21.6</td> <td>14.3-21.9</td> <td>17.1-25.1</td> <td>79, 80, 81</td> </tr> <tr> <td class=\"indent1\">Osmolarity, urine (mOsm/kg)</td> <td>500-800</td> <td>326-975</td> <td>278-1066</td> <td>238-1034</td> <td>82</td> </tr> <tr> <td class=\"indent1\">24-h albumin excretion (mg/24 hours)</td> <td>&#60;30</td> <td>5-15</td> <td>4-18</td> <td>3-22</td> <td>82, 83</td> </tr> <tr> <td class=\"indent1\">24-h calcium excretion (mmol/24 hours)</td> <td>&#60;7.5<sup>&#134;</sup></td> <td>1.6-5.2</td> <td>0.3-6.9</td> <td>0.8-4.2</td> <td>15</td> </tr> <tr> <td class=\"indent1\">24-h creatinine clearance (mL/min)</td> <td>91-130</td> <td>69-140</td> <td>55-136</td> <td>50-166</td> <td>15, 80</td> </tr> <tr> <td class=\"indent1\">24-h creatinine excretion (mmol/24 hours)</td> <td>8.8-14<sup>&#134;</sup></td> <td>10.6-11.6</td> <td>10.3-11.5</td> <td>10.2-11.4</td> <td>82</td> </tr> <tr> <td class=\"indent1\">24-h potassium excretion (mmol/24 hours)</td> <td>25-100<sup>&#134;</sup></td> <td>17-33</td> <td>10-38</td> <td>11-35</td> <td>15</td> </tr> <tr> <td class=\"indent1\">24-h protein excretion (mg/24 hours)</td> <td>&#60;150</td> <td>19-141</td> <td>47-186</td> <td>46-185</td> <td>83</td> </tr> <tr> <td class=\"indent1\">24-h sodium excretion (mmol/24 hours)</td> <td>100-260<sup>&#134;</sup></td> <td>53-215</td> <td>34-213</td> <td>37-149</td> <td>15, 41</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Unless otherwise specified, all normal reference values are from the seventeenth edition of <EM>Harrison's Principles of Internal Medicine</EM><SUP>[84]</SUP>.<br />¶ Range includes references with and without iron supplementation.<br />Δ Normal reference range is specific range for females.<br /><FONT class=lozenge>◊</FONT> Reference values are from Cerneca et al: Coagulation and fibrinolysis changes in normal pregnancy increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis<SUP>[19]</SUP>.<br />§ References values are from Cerneca et al and Choi et al: Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy<SUP>[17,19]</SUP>.<br />¥ Reference values are from Mannuci et al: Changes in health and disease of the metalloprotease that cleaves von Willebrand factor<SUP>[28]</SUP>.<br />‡ Reference values are from Bacq Y et al: Liver function tests in normal pregnancy: a prospective study of 102 pregnant women and 102 matched controls<SUP>[29]</SUP>.<br />† Reference values are from the fifteenth edition of <EM>Harrison's Principles of Internal Medicine</EM><SUP>[85]</SUP>.<br />** The American Thyroid Association recommends these TSH ranges if individual laboratories do not determine their own trimester-specific reference ranges.<br />¶¶ Range is for premenopausal females and varies by menstrual cycle phase.<br />ΔΔ Reference values are from Leiserowitz GS et al: Creatine kinase and its MB isoenzyme in the third trimester and the peripartum period<SUP>[74]</SUP>.<br /><FONT class=double_lozenge>◊◊</FONT> Reference values are from Dunlop W: Serial changes in renal haemodynamics during normal human pregnancy<SUP>[79]</SUP>.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Beguin Y, Lipscei G, Thourmsin H, et al: Blunted erythropoietin production and decreased erythropoiesis in early pregnancy. Blood 78(1):89, 1991. </LI>&#xD;&#xA;<LI>Bianco I, Mastropietro F, D'Aseri C, et al: Serum levels of erythropoietin and soluble transferrin receptor during pregnancy in non-β-thalassemic and β-thalassemic women. Haematologica 85:902, 2000 [PMID: 10980626]. </LI>&#xD;&#xA;<LI>Milman N, Graudal N, Nielsen OJ: Serum erythropoietin during normal pregnancy: Relationship to hemoglobin and iron status markers and impact of iron supplementation in a longitudinal, placebo-controlled study on 118 women. Int J Hematol 66:159, 1997 [PMID: 9277046]. </LI>&#xD;&#xA;<LI>Larsson A, Palm M, Hansson L-O, et al: Reference values for clinical chemistry tests during normal pregnancy. BJOG 115:874, 2008 [PMID: 18485166]. </LI>&#xD;&#xA;<LI>Lockitch G: Handbook of Diagnostic Biochemistry and Hematology in Normal Pregnancy. Boca Raton, FL, CRC Press, 1993. </LI>&#xD;&#xA;<LI>Milman N, Bergholt T, Byg KE, et al: Reference intervals for haematological variables during normal pregnancy and postpartum in 434 healthy Danish women. Eur J Haematol 79:39, 2007 [PMID: 17598837]. </LI>&#xD;&#xA;<LI>Romslo I, Haram K, Sagen N, et al: Iron requirement in normal pregnancy as assessed by serum ferritin, serum transferring saturation and erythrocyte protoporphyrin determinations. Br J Obstet Gynaecol 90:101, 1983 [PMID: 6824608]. </LI>&#xD;&#xA;<LI>Van Buul EJA, Steegers EAP, Jongsma HW, et al: Haematological and biochemical profile of uncomplicated pregnancy in nulliparous women; a longitudinal study. Neth J Med 46:73, 1995. </LI>&#xD;&#xA;<LI>Milman N, Byg KE, Hvas AM, et al: Erythrocyte folate, plasma folate and plasma homocysteine during normal pregnancy and postpartum: A longitudinal study comprising 404 Danish women. Eur J Haematol 76:200, 2006 [PMID: 16412135]. </LI>&#xD;&#xA;<LI>Walker MC, Smith GN, Perkins SL, et al: Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 180:660, 1999 [PMID: 10076144]. </LI>&#xD;&#xA;<LI>López-Quesada E, Vilaseca MA, Lailla JM: Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia. Eur J Obstet Gynecol Reprod Biol 108:45, 2003 [PMID: 19899161]. </LI>&#xD;&#xA;<LI>Özerol E, Özerol I, Gökdeniz R, et al: Effect of smoking on serum concentrations of total homocysteine, folate, vitamin B12, and nitric oxide in pregnancy: A preliminary study. Fetal Diagn Ther 19:145, 2004. </LI>&#xD;&#xA;<LI>Qvist I, Abdulla M, Jägerstad M, et al: Iron, zinc and folate status during pregnancy and two months after delivery. Acta Obstet Gynecol Scand 65:15, 1986 [PMID: 3716775]. </LI>&#xD;&#xA;<LI>Balloch AJ, Cauchi MN: Reference ranges for haematology parameters in pregnancy derived from patient populations. Clin Lab Haemat 15:7, 1993 [PMID: 8472501]. </LI>&#xD;&#xA;<LI>Singh HJ, Mohammad NH, Nila A: Serum calcium and parathormone during normal pregnancy in Malay women. J Matern Fetal Med 8:95, 1999 [PMID: 10338062]. </LI>&#xD;&#xA;<LI>AzizKarim S, Khurshid M, Rizvi JH, et al: Platelets and leucocyte counts in pregnancy. J Pak Med Assoc 42:86, 1992. </LI>&#xD;&#xA;<LI>Choi JW, Pai SH: Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy. Ann Hematol 81:611, 2002 [PMID: 12454697]. </LI>&#xD;&#xA;<LI>Belo L, Santos-Silva A, Rocha S, et al: Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol 123:46, 2005 [PMID: 16260340]. </LI>&#xD;&#xA;<LI>Cerneca F, Ricci G, Simeone R, et al: Coagulation and fibrinolysis changes in normal pregnancy increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 73:31, 1997 [PMID: 9175686]. </LI>&#xD;&#xA;<LI>Lattuada A, Rossi E, Calzarossa C, et al: Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 88(9):1029, 2003. </LI>&#xD;&#xA;<LI>Francalanci I, Comeglio P, Liotta AA, et al: D-Dimer concentrations during normal pregnancy, as measured by ELISA. Thromb Res 78:399, 1995 [PMID: 7660356]. </LI>&#xD;&#xA;<LI>Kline JA, Williams GW, Hernandez-Nino J: D-Dimer concentrations in normal pregnancy: New diagnostic thresholds are needed. Clin Chem 51:825, 2005 [PMID: 15764641]. </LI>&#xD;&#xA;<LI>Morse M: Establishing a normal range for D-dimer levels through pregnancy to aid in the diagnosis of pulmonary embolism and deep vein thrombosis. J Thromb Haemost 2:1202, 2004 [PMID: 15219216]. </LI>&#xD;&#xA;<LI>Liu XH, Jiang YM, Shi H, et al: Prospective, sequential, longitudinal study of coagulation changes during pregnancy in Chinese women. Int J Gynaecol Obstet 105(3):240, 2009. </LI>&#xD;&#xA;<LI>Lefkowitz JB, Clarke SH, Barbour LA: Comparison of protein S functional and antigenic assays in normal pregnancy. Am J Obstet Gynecol 175:657, 1996 [PMID: 8828430]. </LI>&#xD;&#xA;<LI>Faught W, Garner P, Jones G, et al: Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol 172:147, 1995 [PMID: 7847526]. </LI>&#xD;&#xA;<LI>Wickström K, Edelstam G, Löwbeer CH, et al: Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 64:31, 2004 [PMID: 13035697]. </LI>&#xD;&#xA;<LI>Mannucci PM, Canciani MT, Forza I, et al: Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98(9):2730, 2001. </LI>&#xD;&#xA;<LI>Bacq Y, Zarka O, Bréchot JF, et al: Liver function tests in normal pregnancy: A prospective study of 102 pregnant women and 102 matched controls. Hepatology 23:1030, 1996 [PMID: 8621129]. </LI>&#xD;&#xA;<LI>Ardawi MSM, Nasrat HAN, BA'Aqueel HS: Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: A longitudinal study. Eur J Endocrinol 137:402, 1997 [PMID: 9368509]. </LI>&#xD;&#xA;<LI>Handwerker SM, Altura BT, Altura BM: Serum ionized magnesium and other electrolytes in the antenatal period of human pregnancy. J Am Coll Nutr 15:36, 1996 [PMID: 8632112]. </LI>&#xD;&#xA;<LI>Hytten FE, Lind T: Diagnostic Indices in Pregnancy. Summit, NJ, CIBA-GEIGY Corporation, 1975. </LI>&#xD;&#xA;<LI>Karsenti D, Bacq Y, Bréchot JF, et al: Serum amylase and lipase activities in normal pregnancy: A prospective case-control study. Am J Gastroenterol 96:697, 2001 [PMID: 11280536]. </LI>&#xD;&#xA;<LI>Strickland DM, Hauth JC, Widish J, et al: Amylase and isoamylase activities in serum of pregnant women. Obstet Gynecol 63:389, 1984 [PMID: 6199704]. </LI>&#xD;&#xA;<LI>Carter J: Serum bile acids in normal pregnancy. BJOG 98:540, 1991 [PMID: 1873244]. </LI>&#xD;&#xA;<LI>Mimouni F, Tsang RC, Hertzbert VS, et al: Parathyroid hormone and calcitriol changes in normal and insulin-dependent diabetic pregnancies. Obstet Gynecol 74:49, 1989 [PMID: 2733941]. </LI>&#xD;&#xA;<LI>Pitkin RM, Gebhardt MP: Serum calcium concentrations in human pregnancy. Am J Obstet Gynecol 127:775, 1977 [PMID: 848531]. </LI>&#xD;&#xA;<LI>Shakhmatova EI, Osipova NA, Natochin YV: Changes in osmolality and blood serum ion concentrations in pregnancy. Hum Physiol 26:92, 2000. </LI>&#xD;&#xA;<LI>Louro MO, Cocho JA, Tutor JC: Assessment of copper status in pregnancy by means of determining the specific oxidase activity of ceruloplasmin. Clin Chim Acta 312:123, 2001 [PMID: 11580917]. </LI>&#xD;&#xA;<LI>Dux S, Yaron A, Carmel A, et al: Renin, aldosterone, and serum-converting enzyme activity during normal and hypertensive pregnancy. Gynecol Obstet Invest 17:252, 1984 [PMID: 6329926]. </LI>&#xD;&#xA;<LI>Davison JB, Vallotton MB, Lindheimer MD: Plasma osmolality and urinary concentration and dilution during and after pregnancy: Evidence that lateral recumbency inhibits maximal urinary concentrating ability. BJOG 88:472, 1981 [PMID: 7236550]. </LI>&#xD;&#xA;<LI>Kato T, Seki K, Matsui H, et al: Monomeric calcitonin in pregnant women and in cord blood. Obstet Gynecol 92:241, 1998 [PMID: 9699759]. </LI>&#xD;&#xA;<LI>Elsheikh A, Creatsas G, Mastorakos G, et al: The renin-aldosterone system during normal and hypertensive pregnancy. Arch Gynecol Obstet 264:182, 2001 [PMID: 11205704]. </LI>&#xD;&#xA;<LI>Kim EH, Lim JH, Kim YH, et al: The relationship between aldosterone to renin ratio and RI value of the uterine artery in the preeclamptic patient vs. normal pregnancy. Yonsei Med J 49(1):138, 2008. </LI>&#xD;&#xA;<LI>Suri D, Moran J, Hibbard JU, et al: Assessment of adrenal reserve in pregnancy: Defining the normal response to the adrenocorticotropin stimulation test. J Clin Endocrinol Metab 91:3866, 2006 [PMID: 16895954]. </LI>&#xD;&#xA;<LI>Parente JV, Franco JG, Greene LJ, et al: Angiotensin-converting enzyme: Serum levels during normal pregnancy. Am J Obstet Gynecol 135:586, 1979 [PMID: 228554]. </LI>&#xD;&#xA;<LI>Montelongo A, Lasunción MA, Pallardo LF, et al: Longitudinal study of plasma lipoproteins and hormones during pregnancy in normal and diabetic women. Diabetes 41:1651, 1992 [PMID: 1446807]. </LI>&#xD;&#xA;<LI>Radder JK, Van Roosmalen J: HbAIC in healthy, pregnant women. Neth J Med 63:256, 2005 [PMID: 16093576]. </LI>&#xD;&#xA;<LI>Price A, Obel O, Cresswell J, et al: Comparison of thyroid function in pregnant and non-pregnant Asian and western Caucasian women. Clin Chim Acta 208:91, 2001. </LI>&#xD;&#xA;<LI>Álvarez SI, Castañón SG, Ruata MLC, et al: Updating of normal levels of copper, zinc and selenium in serum of pregnant women. J Trace Elem Med Biol 21(S1):49, 2007. </LI>&#xD;&#xA;<LI>Ilhan N, Ilhan N, Simsek M: The changes of trace elements, malondialdehyde levels and superoxide dismutase activities in pregnancy with or without preeclampsia. Clin Biochem 35:393, 2002 [PMID: 12270770]. </LI>&#xD;&#xA;<LI>Sharma SC, Sabra A, Molloy A, et al: Comparison of blood levels of histamine and total ascorbic acid in pre-eclampsia with normal pregnancy. Hum Nutr Clin Nutr 38C:3, 1984. </LI>&#xD;&#xA;<LI>Reiter EO, Braunstein GD, Vargas A, et al: Changes in 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D during pregnancy. Am J Obstet Gynecol 135:227, 1979 [PMID: 474676]. </LI>&#xD;&#xA;<LI>Hwang HS, Kwon JY, Kim MA, et al: Maternal serum highly sensitive C-reactive protein in normal pregnancy and pre-eclampsia. Int J Gynecol Obstet 98:105, 2007 [PMID: 17588579]. </LI>&#xD;&#xA;<LI>van den Broek NR, Letsky EA: Pregnancy and the erythrocyte sedimentation rate. Br J Obstet Gynaecol 108:1164, 2001. </LI>&#xD;&#xA;<LI>O'Leary P, Boyne P, Flett P, et al: Longitudinal assessment of changes in reproductive hormones during normal pregnancy. Clin Chem 35(5):667, 1991. </LI>&#xD;&#xA;<LI>Carranza-Lira S, Hernández F, Sánchez M, et al: Prolactin secretion in molar and normal pregnancy. Int J Gynaecol Obstet 60:137, 1998 [PMID: 9509951]. </LI>&#xD;&#xA;<LI>Larrea F, Méndez I, Parra A: Serum pattern of different molecular forms of prolactin during normal human pregnancy. Hum Reprod 8:1617, 1993 [PMID: 8300816]. </LI>&#xD;&#xA;<LI>Acromite MT, Mantzoros CS, Leach RE, et al: Androgens in preeclampsia. Am J Obstet Gynecol 180:60, 1999 [PMID: 9914579]. </LI>&#xD;&#xA;<LI>Belo L, Caslake M, Gaffney D, et al: Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis 162:425, 2002 [PMID: 11996963]. </LI>&#xD;&#xA;<LI>Desoye G, Schweditsch MO, Pfeiffer KP, et al: Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. J Clin Endocrinol Metab 64:704, 1987 [PMID: 3546352]. </LI>&#xD;&#xA;<LI>Jimenez DM, Pocovi M, Ramon-Cajal J, et al: Longitudinal study of plasma lipids and lipoprotein cholesterol in normal pregnancy and puerperium. Gynecol Obstet Invest 25:158, 1988 [PMID: 3391425]. </LI>&#xD;&#xA;<LI>Piechota W, Staszewski A: Reference ranges of lipids and apolipoproteins in pregnancy. Eur J Obstet Gynecol Reprod Biol 45:27, 1992 [PMID: 1618359]. </LI>&#xD;&#xA;<LI>Rang S, van Montfrans GA, Wolf H. Serial hemodynamic measurement in normal pregnancy, preeclampsia, and intrauterine growth restriction. Am J Obstet Gynecol. 198(5):519.e1-9, 2008 PMID: 18279824. </LI>&#xD;&#xA;<LI>Moertl MG, Ulrich D, Pickel K, et al: Changes in haemodynamic and autonomous nervous system parameters measured non-invasively throughout normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 144 Suppl 1:S179-83. 2009 PMID: 19285779.</LI>&#xD;&#xA;<LI>Pandey Ak, Das A, Srinivas C, et al: Maternal myocardial performances in various stages of pregnancy and post-partum. Research Jour of Cardiology 3(1):9-16, 2010. </LI>&#xD;&#xA;<LI>Lees M. Central circulatory responses in normotensive and hypertensive pregnancy. Postgrad Med J. 55(643): 311–314, 1979. PMCID: PMC2425449. </LI>&#xD;&#xA;<LI>Poppas A, Shroff SG, Korcarz CE, et al: Serial assessment of the cardiovascular system in normal pregnancy: Role of arterial compliance and pulsatile arterial load. Circulation 95:2407-2415, 1997. </LI>&#xD;&#xA;<LI>Katz R, Karliner JS, Resnik R: Effects of a natural volume overload state (pregnancy) on left ventricular performance in normal human subjects. Circulation 58: 434-441, 1978. </LI>&#xD;&#xA;<LI>Mesa A, Jessurun C, Hernandez A, et al: Left ventricular diastolic function in normal human pregnancy. Circulation 99:511-517, 1999. </LI>&#xD;&#xA;<LI>Resnik JL, Hong C, Resnik R, et al: Evaluation of B-type natriuetic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 193:450-458, 2005. </LI>&#xD;&#xA;<LI>Hamid RR, Larsson A, Pernow J, et al: Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens 27L2257-2264, 2009. </LI>&#xD;&#xA;<LI>Borghi CB, Esposti DD, Immordino V, et al: Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. Am J Obstet Gynecol 183:140, 2000 [PMID: 10920322]. </LI>&#xD;&#xA;<LI>Leiserowitz GS, Evans AT, Samuels SJ, et al: Creatine kinase and its MB isoenzyme in the third trimester and the peripartum period. J Reprod Med 37:910, 1992 [PMID: 1460608]. </LI>&#xD;&#xA;<LI>Koscica KL, Bebbington M, Bernstein PS: Are maternal serum troponin I levels affected by vaginal or cesarean delivery? Am J Perinatol 21(1):31, 2004. </LI>&#xD;&#xA;<LI>Shivvers SA, Wians FH, Keffer JH, et al: Maternal cardiac troponin I levels during labor and delivery. Am J Obstet Gynecol 180:122, 1999 [PMID: 9914590]. </LI>&#xD;&#xA;<LI>Fadel HE, Northrop G, Misenhimer HR, et al: Acid-base determinations in amniotic fluid and blood of normal late pregnancy. Obstet Gynecol 53:99, 1979 [PMID: 32503]. </LI>&#xD;&#xA;<LI>Spiropoulos K, Prodromaki E, Tsapanos V: Effect of body position on PaO2 and PaCO2 during pregnancy. Gynecol Obstet Invest 58:22, 2004 [PMID: 15028865]. </LI>&#xD;&#xA;<LI>Dunlop W: Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol 88:1, 1981 [PMID: 7459285]. </LI>&#xD;&#xA;<LI>Ezimokhai M, Davison JM, Philips PR, et al: Non-postural serial changes in renal function during the third trimester of normal human pregnancy. Br J Obstet Gynaecol 88:465, 1981 [PMID: 7236549]. </LI>&#xD;&#xA;<LI>Moran P, Baylis PH, Lindheimer, et al: Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 14:648, 2003 [PMID: 12595500]. </LI>&#xD;&#xA;<LI>Risberg A, Larsson A, Olsson K, et al: Relationship between urinary albumin and albumin/creatinine ratio during normal pregnancy and pre-eclampsia. Scand J Clin Lab Invest 64:17, 2004 [PMID: 15025425]. </LI>&#xD;&#xA;<LI>Higby K, Suiter CR, Phelps JY, et al: Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol 171:984, 1994 [PMID: 7943114]. </LI>&#xD;&#xA;<LI>Kratz A, Pesce MA, Basner RC, Einstein AJ. Appendix: Laboratory values of clinical importance. In: Longo DL, Fauci AS, Kasper DL, et al (Eds). Harrison's Principles of Internal Medicine, 18th ed, McGraw-Hill, New York 2012. Appendix 1, p A-1. </LI>&#xD;&#xA;<LI>Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081. </LI>&#xD;&#xA;<LI>Leek AE, Ruoss CF, Kitau MJ, Chard T. Magernal plasma alphafetoprotein levels in the second half of normal pregnancy: Relationship to fetal weight, and maternal age and parity. BJOG 1975; 82:669.</LI>&#xD;&#xA;<LI>Hale SA, Sobel B, Benvenuto A, et al. Coagulation and fibrinolytic system protein profiles in women with normal pregnancies and pregnancies complicated by hypertension. Pregnancy Hypertens 2012; 2:152.</LI>&#xD;&#xA;<LI>Spitzer M, Kaushal N, Benjamin F. Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 1998; 43:387.</LI>&#xD;&#xA;<LI>Aslam N, Ong C, Woelfer B, et al. Serum CA-125 at 11-14 weeks of gestation in women with morphologically normal ovaries. BJOG 2000; 107:689.</LI>&#xD;&#xA;<LI>Jacobs IJ, Fay TN, Stabile I, et al. The distribution of CA 125 in the reproductive tract of pregnant and non-pregnant women. Br J Obstet Gynaecol 1988; 95:1190.</LI>&#xD;&#xA;<LI>Savu O, Jurcuţ R, Giuşcă S, et al. Morphological and functional adaptation of the maternal heart during pregnancy. Circ Cardiovasc Imaging 2012; 5:289.</LI>&#xD;&#xA;<LI>Vitarelli A, Capotosto L. Role of echocardiography in the assessment and management of adult congenital heart disease in pregnancy. Int J Cardiovasc Imaging 2011; 27:843.</LI>&#xD;&#xA;<LI>Haram K, Augensen K, Elsayed S. Serum protein pattern in normal pregnancy with special reference to acute-phase reactants. BJOG 1983; 90:139.</LI>&#xD;&#xA;<LI>Jozwik M, Jozwik M, Pierzycki K, et al. Maternal and fetal blood ammonia concentrations in normal term human pregnancies. Biol Neonate 2005; 87:38.</LI>&#xD;&#xA;<LI>Leek AE, Ruoss CF, Kitau MG, et al. Maternal plasma alphafetoprotein levels in the second half of normal pregnancy: relationship to fetal weight and maternal age and parity. BJOG 1975; 82:669.</LI>&#xD;&#xA;<LI>Burlingame J, Hyeong JA, Tang WHW. Changes in cardiovascular biomarkers throughout pregnancy and the remote postpartum period. Am J Obstet Gynecol 2013; 208:S97.</LI></OL>Modified and reproduced with permission from: Abbassi-Ghanavati M, Greer LG. Reference Table of Normal Laboratory Values in Uncomplicated Pregnancies. In: Cunningham FG, Leveno KJ, Bloom S, Hauth JC, Rouse DJ, Spong CY. Williams Obstetrics, 23rd Edition. New York: McGraw-Hill, 2010. Copyright © 2010 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 81137 Version 42.0</div></div></div>"},"81138":{"type":"graphic_table","displayName":"Irritant contact dermatitis clinical classification","title":"Clinical classification of irritant contact dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical classification of irritant contact dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Type</td>\r\n                    <td class=\"subtitle1\">History</td>\r\n                    <td class=\"subtitle1\">Clinical manifestation</td>\r\n                    <td class=\"subtitle1\">Prognosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Acute ICD</td>\r\n                    <td>\r\n                    <p>Acute exposure, usually accidental, to potent irritants (strong acids or alkalis) </p>\r\n                    <p>May develop within minutes after exposure to powerful irritants</p>\r\n                    <p>Nearly all exposed individuals develop skin lesions</p>\r\n                    </td>\r\n                    <td>\r\n                    <p>Erythema, edema, vesicles, bullae, epidermal necrosis</p>\r\n                    <p>Symptoms: stinging, burning, and pain</p>\r\n                    <p>Decrescendo phenomenon: the healing process begins soon after the removal of the offending substance</p>\r\n                    </td>\r\n                    <td>Good</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td>Delayed acute ICD</td>\r\n                    <td>\r\n                    <p>Delayed onset (8-24 hrs after exposure)</p>\r\n                    <p>Some chemicals, such as dithranol (anthralin), podophyllin, epichlorhydrin, propane sulfone, ethylene oxide, and benzalkonium chloride</p>\r\n                    </td>\r\n                    <td>\r\n                    <p>Similar clinical manifestation to acute ICD</p>\r\n                    <p>Patch testing: highly recommended for differential diagnosis from ACD</p>\r\n                    </td>\r\n                    <td>Good</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td>Irritant reaction</td>\r\n                    <td>\r\n                    <p>High-risk groups: wet-work workers such as hairdressers, food preparation workers, bar workers, new mothers, or cleaning personnel</p>\r\n                    </td>\r\n                    <td>\r\n                    <p>Mild erythema, vesicles or erosions, dryness, chapping, and scaling</p>\r\n                    <p>Usually occur under occlusive areas</p>\r\n                    <p>May evolve to chronic cumulative ICD</p>\r\n                    </td>\r\n                    <td>Good</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td>Chronic cumulative ICD&nbsp;</td>\r\n                    <td>\r\n                    <p>Most common type of ICD</p>\r\n                    <p>Repeated&nbsp;exposure to weak irritants (soaps, detergents, surfactants, solvents,&nbsp;or oils) </p>\r\n                    <p>High-risk groups: hairdressers, healthcare personnel, cleaning workers, and metal workers</p>\r\n                    </td>\r\n                    <td>\r\n                    <p>Erythema and dryness that progress to hyperkeratosis, fissuring, and lichenification</p>\r\n                    <p>Patch testing: highly recommended for differential diagnosis from ACD</p>\r\n                    </td>\r\n                    <td>Variable</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td>Traumatic ICD</td>\r\n                    <td>Slower onset after laceration, burn, or acute ICD</td>\r\n                    <td>\r\n                    <p>Erythema, vesicles or papules, and scaling</p>\r\n                    <p>Prolonged healing time</p>\r\n                    </td>\r\n                    <td>Variable</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td>Acneiform or pustular ICD</td>\r\n                    <td>\r\n                    <p>Rare, slow onset</p>\r\n                    <p>Tar, oils, naphthalenes, asphalt, chlorinated agents, or grease</p>\r\n                    </td>\r\n                    <td>\r\n                    <p>&nbsp;</p>\r\n                    <p>Papular or pustular lesions</p>\r\n                    </td>\r\n                    <td>Good</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td>Non-erythematous (suberythematous) irritation</td>\r\n                    <td>\r\n                    <p>Slow onset</p>\r\n                    <p>Surfactants in soaps, detergents, or cosmetics (cocoamidopropyl betaine, coconut diethanolamide)</p>\r\n                    </td>\r\n                    <td>\r\n                    <p>Subjective discomfort such as stinging, itching, or burning, without visible clinical signs</p>\r\n                    <p>Histologic changes </p>\r\n                    </td>\r\n                    <td>Variable</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td>Sensory (subjective) irritation</td>\r\n                    <td>\r\n                    <p>Acute onset</p>\r\n                    <p>Mostly in middle-aged women</p>\r\n                    <p>Mainly cosmetic products containing&nbsp;lactic acid or sorbic acid</p>\r\n                    </td>\r\n                    <td>\r\n                    <p>Lack of clinical signs of inflammation</p>\r\n                    <p>Subjective feeling of stinging, itching, and burning</p>\r\n                    </td>\r\n                    <td>Excellent </td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td>Friction irritation</td>\r\n                    <td>\r\n                    <p>Slow onset</p>\r\n                    <p>Repeated microtrauma and friction from&nbsp;handling wood, plants, coarse paper, or&nbsp;rock wool&nbsp;</p>\r\n                    </td>\r\n                    <td>Lichenification, hyperkeratosis</td>\r\n                    <td>Variable</td>\r\n                </tr>\r\n                <tr class=\"divider_top\">\r\n                    <td>Asteatotic irritant dermatitis</td>\r\n                    <td>\r\n                    <p>Slow onset</p>\r\n                    <p>High risk group: elderly</p>\r\n                    <p>Mostly in winter</p>\r\n                    </td>\r\n                    <td>\r\n                    <p>Erythema, dry and cracked skin</p>\r\n                    <p>Intense itching</p>\r\n                    </td>\r\n                    <td>Variable</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Adapted from:<br> <ol> <li>Watkins SA, Maibach HI. The hardening phenomenon in irritant contact dermatitis: An interpretative update. Contact Dermatitis 2009; 60:123. </li> <li>Amado A, Taylor JS, Sood A. Irritant Contact Dermatitis. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill Medical 2008. p.395. </li> </ol></div><div id=\"graphicVersion\">Graphic 81138 Version 2.0</div></div></div>"},"81139":{"type":"graphic_table","displayName":"Risk factors for gallstones","title":"Major risk factors for the development of gallstones","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major risk factors for the development of gallstones</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Age</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Female sex</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Genetic</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Pima Indians and certain other Native Americans</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Chileans</td>\n    </tr>\n    <tr>\n\n      <td>Pregnancy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Obesity</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Rapid weight loss</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Very low calorie diet</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Surgical therapy of morbid obesity</td>\n    </tr>\n    <tr>\n\n      <td>Cirrhosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemolytic anemias</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypertriglyceridemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Medications</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Estrogen and oral contraceptives</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Clofibrate</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Ceftriaxone</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Octreotide</td>\n    </tr>\n    <tr>\n\n      <td>Terminal ileal resection</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Gallbladder stasis</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Diabetes mellitus</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Total parenteral nutrition</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Postvagotomy</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Octreotide or somatostatinoma</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Spinal cord injury</td>\n    </tr>\n    <tr>\n\n      <td>Reduced physical activity (at least in men)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81139 Version 1.0</div></div></div>"},"81141":{"type":"graphic_diagnosticimage","displayName":"3D ultrasound of normal fetal face","title":"Normal face and lip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal face and lip</div><div class=\"cntnt\"><img style=\"width:333px; height:346px;\" src=\"images/OBGYN/81141_U-S_fetal_face_normal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rendered three-dimensional image of a second trimester fetal face. The image demonstrates normal nose and lips.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 81141 Version 3.0</div></div></div>"},"81142":{"type":"graphic_figure","displayName":"SVC veins mediastinum","title":"Anatomy of the superior vena cava and veins of the mediastinum","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Anatomy of the superior vena cava and veins of the mediastinum</div><div class=\"cntnt\"><img style=\"width:539px; height:559px;\" src=\"images/ONC/81142_SVC_veins_mediastinum.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81142 Version 2.0</div></div></div>"},"81144":{"type":"graphic_table","displayName":"Classification organic acidemia","title":"Classification of organic acidemias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of organic acidemias</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Branched-chain organic acidemias</td> </tr> <tr> <td>Methylmalonic aciduria and related disorders</td> </tr> <tr> <td>Propionic acidemia</td> </tr> <tr> <td>Isovaleric aciduria</td> </tr> <tr> <td>3-methylcrotonylglycinuria</td> </tr> <tr> <td>3-methylglutaconic aciduria</td> </tr> <tr> <td>3-hydroxyisobutyric aciduria</td> </tr> <tr> <td class=\"subtitle1_single\">Multiple carboxylase deficiency</td> </tr> <tr> <td>Holocarboxylase synthetase deficiency</td> </tr> <tr> <td>Biotinidase deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Glutaric aciduria type I and related conditions</td> </tr> <tr> <td>Glutaric aciduria type I</td> </tr> <tr> <td>L-2-hydroxyglutaric aciduria</td> </tr> <tr> <td>Mevalonic aciduria</td> </tr> <tr> <td class=\"subtitle1_single\">Fatty acid oxidation defects</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of energy metabolism</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81144 Version 2.0</div></div></div>"},"81145":{"type":"graphic_table","displayName":"Genes involved DSD A","title":"Genes known to be involved in disorders of sex development (DSD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genes known to be involved in disorders of sex development (DSD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">OMIM No.</td> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Gonad</td> <td class=\"subtitle1\">Mullerian structures</td> <td class=\"subtitle1\">External genitalia</td> <td class=\"subtitle1\">Associated features/variant phenotypes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">46,XY DSD</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"9\">Disorders of gonadal (testicular) development: single-gene disorders</td> </tr> <tr> <td class=\"indent2\">WT1</td> <td>TF</td> <td>607102</td> <td>11p13</td> <td>AD</td> <td>Dysgenetic testis</td> <td>+/&ndash;</td> <td>Female or ambiguous</td> <td>Wilms' tumor, renal abnormalities, gonadal tumors (WAGR, Denys-Drash and Frasier syndromes)</td> </tr> <tr> <td class=\"indent2\">NR5A1 (SF1)</td> <td>Nuclear receptor TF</td> <td>184757</td> <td>9q33</td> <td>AD/AR</td> <td>Dysgenetic testis</td> <td>+/&ndash;</td> <td>Female or ambiguous</td> <td>More severe phenotypes include primary adrenal failure; milder phenotypes have isolated partial gonadal dysgenesis</td> </tr> <tr> <td class=\"indent2\">SRY</td> <td>TF</td> <td>480000</td> <td>Yp11.3</td> <td>Y</td> <td>Dysgenetic testis or ovotestis</td> <td>+/&ndash;</td> <td>Female or ambiguous</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">SOX9</td> <td>TF</td> <td>608160</td> <td>17q24-25</td> <td>AD</td> <td>Dysgenetic testis or ovotestis</td> <td>+/&ndash;</td> <td>Female or ambiguous</td> <td>Camptomelic dysplasia (17q24 rearrangements; milder phenotype than point mutations)</td> </tr> <tr> <td class=\"indent2\">DHH</td> <td>Signaling molecule</td> <td>605423</td> <td>12q13.1</td> <td>AR</td> <td>Dysgenetic testis</td> <td>+</td> <td>Female</td> <td>The severe phenotype of 1 patient included minifascicular neuropathy; other patients have isolated gonadal dysgenesis</td> </tr> <tr> <td class=\"indent2\">ATRX</td> <td>Helicase (? chromatin remodeling)</td> <td>300032</td> <td>Xq13.3</td> <td>X</td> <td>Dysgenetic testis</td> <td>&ndash;</td> <td>Female, ambiguous, or male</td> <td>&#945;-Thalassemia, mental retardation</td> </tr> <tr> <td class=\"indent2\">ARX</td> <td>TF</td> <td>300382</td> <td>Xp22.13</td> <td>X</td> <td>Dysgenetic testis</td> <td>&ndash;</td> <td>Ambiguous</td> <td>X-linked lissencephaly, epilepsy, temperature instability</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"9\">Disorders of gonadal (testicular) development: chromosomal changes involving key candidate genes</td> </tr> <tr> <td class=\"indent2\">DMRT1</td> <td>TF</td> <td>602424</td> <td>9p24.3</td> <td>Monosomic deletion</td> <td>Dysgenetic testis</td> <td>+/&ndash;</td> <td>Female or ambiguous</td> <td>Mental retardation</td> </tr> <tr> <td class=\"indent2\">NR0B1 (DAX1)</td> <td>Nuclear receptor TF</td> <td>300018</td> <td>Xp21.3</td> <td>dupXp21</td> <td>Dysgenetic testis or ovary</td> <td>+/&ndash;</td> <td>Female or ambiguous</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">WNT4</td> <td>Signaling molecule</td> <td>603490</td> <td>1p35</td> <td>dup1p35</td> <td>Dysgenetic testis</td> <td>+</td> <td>Ambiguous</td> <td>Mental retardation</td> </tr> <tr> <td class=\"indent2\">WWOX</td> <td>Steroid metabolism</td> <td>605131</td> <td>16q23</td> <td>del16q23</td> <td>Dysgenetic testis</td> <td>&ndash;</td> <td>Ambiguous</td> <td>46,XX mother of index case had normal female genitalia and late menarche</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"9\">Disorders in hormone synthesis or action</td> </tr> <tr> <td class=\"indent2\">LHGCR</td> <td>G-protein receptor</td> <td>152790</td> <td>2p21</td> <td>AR</td> <td>Testis</td> <td>&ndash;</td> <td>Female, ambiguous, or micropenis</td> <td>Leydig cell hypoplasia</td> </tr> <tr> <td class=\"indent2\">DHCR7</td> <td>Enzyme</td> <td>602858</td> <td>11q12-13</td> <td>AR</td> <td>Testis</td> <td>&ndash;</td> <td>Variable</td> <td>Smith-Lemli-Opitz syndrome: coarse facies, second-third toe syndactyly, failure to thrive, developmental delay, cardiac and visceral abnormalities</td> </tr> <tr> <td class=\"indent2\">StAR (steroidogenic acute regulatory protein)</td> <td>Mitochondrial membrane protein</td> <td>600617</td> <td>8p11.2</td> <td>AR</td> <td>Testis</td> <td>&ndash;</td> <td>Female</td> <td>Congenital lipoid adrenal hyperplasia (primary adrenal failure), pubertal failure</td> </tr> <tr> <td class=\"indent2\">CYP11A1</td> <td>Enzyme</td> <td>118485</td> <td>15q23-24</td> <td>AR</td> <td>Testis</td> <td>&ndash;</td> <td>Female or ambiguous</td> <td>CAH (primary adrenal failure), pubertal failure</td> </tr> <tr> <td class=\"indent2\">HSD3B2</td> <td>Enzyme</td> <td>201810</td> <td>1p13.1</td> <td>AR</td> <td>Testis</td> <td>&ndash;</td> <td>Ambiguous</td> <td>CAH, primary adrenal failure, partial androgenization caused by dehydroepiandrosterone sulfate</td> </tr> <tr> <td class=\"indent2\">CYP17</td> <td>Enzyme</td> <td>202110</td> <td>10q24.3</td> <td>AR</td> <td>Testis</td> <td>&ndash;</td> <td>Female, ambiguous, or micropenis</td> <td>CAH, hypertension caused by corticosterone and 11-deoxycorticosterone (except in isolated 17,20-lyase deficiency)</td> </tr> <tr> <td class=\"indent2\">POR (P450 oxidoreductase)</td> <td>CYP enzyme electron donor</td> <td>124015</td> <td>7q11.2</td> <td>AR</td> <td>Testis</td> <td>&ndash;</td> <td>Male or ambiguous</td> <td>Mixed features of 21-hydroxylase deficiency, 17 &#945;-hydroxylase/17,20-lyase deficiency, and aromatase deficiency; sometimes associated with Antley Bixler craniosynostosis</td> </tr> <tr> <td class=\"indent2\">HSD17B3</td> <td>Enzyme</td> <td>605573</td> <td>9q22</td> <td>AR</td> <td>Testis</td> <td>&ndash;</td> <td>Female or ambiguous</td> <td>Partial androgenization at puberty, androstenedione/testosterone ratio</td> </tr> <tr> <td class=\"indent2\">SRD5A2</td> <td>Enzyme</td> <td>607306</td> <td>2p23</td> <td>AR</td> <td>Testis</td> <td>&ndash;</td> <td>Ambiguous or micropenis</td> <td>Partial androgenization at puberty, testosterone/dihydrotestosterone ratio</td> </tr> <tr> <td class=\"indent2\">Anti-Mullerian hormone</td> <td>Signaling molecule</td> <td>600957</td> <td>19p13.3-13.2</td> <td>AR</td> <td>Testis</td> <td>+</td> <td>Normal male</td> <td rowspan=\"2\">Persistent Mullerian duct syndrome; male external genitalia, bilateral cryptorchidism </td> </tr> <tr> <td class=\"indent2\">Anti-Mullerian hormone receptor</td> <td>Serine-threonine kinase transmembrane receptor</td> <td>600956</td> <td>12q13</td> <td>AR</td> <td>Testis</td> <td>+</td> <td>Normal male</td> </tr> <tr> <td class=\"indent2\">Androgen receptor</td> <td>Nuclear receptor TF</td> <td>313700</td> <td>Xq11-12</td> <td>X</td> <td>Testis</td> <td>&ndash;</td> <td>Female, ambiguous, micropenis, or normal male</td> <td>Phenotypic spectrum from CAIS (female external genitalia) and PAIS (ambiguous) to normal male genitalia/infertility</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Chromosomal rearrangements likely to include key genes are included.</div><div class=\"graphic_footnotes\">OMIM: Online Mendelian Inheritance in Man; TF: transcription factor; AD: autosomal dominant (often do novo mutation); AR: autosomal recessive; Y: Y-chromosomal; X: X-chromosomal.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 118, Pages e488-e500, Copyright © 2006 by the AAP.</div><div id=\"graphicVersion\">Graphic 81145 Version 17.0</div></div></div>"},"81147":{"type":"graphic_diagnosticimage","displayName":"Pancoast tumor PET","title":"Pancoast tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancoast tumor</div><div class=\"cntnt\"><img style=\"width:229px; height:444px;\" src=\"images/PULM/81147_Pancoast_tumor_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PET image showing intense metabolic activity in the apical mass but no adenopathy.</div><div class=\"graphic_footnotes\">PET: positron emission tomography.</div><div id=\"graphicVersion\">Graphic 81147 Version 3.0</div></div></div>"},"81148":{"type":"graphic_table","displayName":"Drugs cutaneous vasculitis","title":"Drugs alleged to cause cutaneous small vessel vasculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs alleged to cause&nbsp;cutaneous small vessel&nbsp;vasculitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Anti-infective agents </td> </tr> <tr> <td>Penicillin</td> </tr> <tr> <td>Doxycycline</td> </tr> <tr> <td>Clindamycin</td> </tr> <tr> <td>Rifampicin</td> </tr> <tr> <td>Gentamicin</td> </tr> <tr> <td>Ciprofloxacin</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td>Chloramphenicol</td> </tr> <tr> <td>Ampicillin</td> </tr> <tr> <td>Griseofulvin</td> </tr> <tr> <td>Acyclovir</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>Ofloxacin</td> </tr> <tr> <td>Zidovudine</td> </tr> <tr> <td class=\"subtitle1_single\">Cancer chemotherapeutic and adjuvants </td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Tamoxifen</td> </tr> <tr> <td>Levamisole</td> </tr> <tr> <td>Hexamethylene bisacetamide</td> </tr> <tr> <td>Busulfan</td> </tr> <tr> <td class=\"subtitle1_single\">Nonsteroidal antiinflammatory drugs </td> </tr> <tr> <td>Acetylsalicylic acid</td> </tr> <tr> <td>Diclofenac</td> </tr> <tr> <td>Ibuprofen</td> </tr> <tr> <td>Indomethacin</td> </tr> <tr> <td>Flurbiprofen</td> </tr> <tr> <td>Naproxen</td> </tr> <tr> <td>Tenoxicam</td> </tr> <tr> <td>Fenbufen</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Psychoactive drugs </td> </tr> <tr> <td>Amitriptyline</td> </tr> <tr> <td>Maprotiline</td> </tr> <tr> <td>Trazodone</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular and diuretic drugs, thiazides </td> </tr> <tr> <td>Procainamide</td> </tr> <tr> <td>Quinidine</td> </tr> <tr> <td>Atenolol</td> </tr> <tr> <td>Acebutolol</td> </tr> <tr> <td>Diltiazem</td> </tr> <tr> <td>Captopril</td> </tr> <tr> <td>Hydrochlorothiazide</td> </tr> <tr> <td>Furosemide</td> </tr> <tr> <td>Amiodarone</td> </tr> <tr> <td>Hydralazine</td> </tr> <tr> <td>Spironolactone</td> </tr> <tr> <td>Guanethidine</td> </tr> <tr> <td>Methyldopa</td> </tr> <tr> <td class=\"subtitle1_single\">Anticoagulants and thrombolytic agents </td> </tr> <tr> <td>Heparin</td> </tr> <tr> <td>Warfarin</td> </tr> <tr> <td>Anisoylated streptokinase activator complex</td> </tr> <tr> <td>Streptokinase</td> </tr> <tr> <td class=\"subtitle1_single\">Beta-andrenergic receptor agonists </td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Ritodrine</span></td> </tr> <tr> <td>Terbutaline</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Intravenous formulations </td> </tr> <tr> <td>Radiocontrast media containing iodine</td> </tr> <tr> <td>Iron-dextran preparations</td> </tr> <tr> <td class=\"subtitle1_single\">Anticonvulsants </td> </tr> <tr> <td>Sodium valproate</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous substances </td> </tr> <tr> <td>Acetaminophen (paracetamol)</td> </tr> <tr> <td>Allopurinol</td> </tr> <tr> <td>Azathioprine</td> </tr> <tr> <td>Cimetidine</td> </tr> <tr> <td>Colchicine</td> </tr> <tr> <td>Drug abuse</td> </tr> <tr> <td>D-penicillamine</td> </tr> <tr> <td>Food additives</td> </tr> <tr> <td>G-CSF</td> </tr> <tr> <td>GM-CSF</td> </tr> <tr> <td>Gold</td> </tr> <tr> <td>Interferon-alfa</td> </tr> <tr> <td>Metformin</td> </tr> <tr> <td>Methylthiouracil</td> </tr> <tr> <td>Potassium iodine</td> </tr> <tr> <td>Propylthiouracil</td> </tr> <tr> <td>Quinine</td> </tr> <tr> <td>Retinoids</td> </tr> <tr> <td>Vaccination with BCG</td> </tr> <tr> <td>Vitamin B6</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; BCG: Bacille Calmette-Guérin.</div><div id=\"graphicVersion\">Graphic 81148 Version 5.0</div></div></div>"},"81150":{"type":"graphic_table","displayName":"Diagnosis of possible MSA","title":"Criteria for the diagnosis of possible multiple system atrophy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the diagnosis of possible multiple system atrophy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">A sporadic, progressive, adult (<strong>&#62;30 years of age</strong>)-onset disease characterized by:</td> </tr> <tr> <td class=\"indent1\">Parkinsonism (bradykinesia with rigidity, tremor, or postural instability) <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction) <strong>and</strong></td> </tr> <tr> <td class=\"indent1\">At least one feature suggesting autonomic dysfunction (otherwise unexplained urinary urgency, frequency or incomplete bladder emptying, erectile dysfunction in males, or significant orthostatic blood pressure decline that does not meet the level required in probable MSA) <strong>and</strong></td> </tr> <tr> <td class=\"indent1\">At least one of the additional features shown in Table 3</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670.</div><div id=\"graphicVersion\">Graphic 81150 Version 4.0</div></div></div>"},"81151":{"type":"graphic_table","displayName":"Fat soluble vitamins Daily Recommended Intake","title":"Dietary reference intakes for fat-soluble vitamins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary reference intakes for fat-soluble vitamins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nutrient</td> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">RDA*/AI<sup>&#182;</sup></td> <td class=\"subtitle1\">UL<sup>&#916;</sup></td> <td class=\"subtitle1\">Adverse effects of excess</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Vitamin A</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"21\">1 mcg retinol activity equivalent = 3.3 unit vitamin A</td> <td class=\"subtitle3\">&nbsp;</td> <td class=\"subtitle3\">Micrograms daily</td> <td class=\"subtitle3\">Micrograms daily</td> <td class=\"divider_bottom\" rowspan=\"21\">Ataxia, alopecia, hyperlipidemia, hepatotoxicity, bone and muscle pain; teratogenic</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Infants</td> </tr> <tr> <td class=\"sublist1\">0 to 6 months</td> <td class=\"sublist_other\">400<sup>&#182;</sup></td> <td class=\"sublist_other\">600</td> </tr> <tr> <td class=\"sublist1\">7 to 12 months</td> <td class=\"sublist_other\">500<sup>&#182;</sup></td> <td class=\"sublist_other\">600</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Children</td> </tr> <tr> <td class=\"sublist1\">1 to 3 years</td> <td class=\"sublist_other\">300</td> <td class=\"sublist_other\">600</td> </tr> <tr> <td class=\"sublist1\">4 to 8 years</td> <td class=\"sublist_other\">400</td> <td class=\"sublist_other\">900</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Males</td> </tr> <tr> <td class=\"sublist1\">9 to 13 years</td> <td class=\"sublist_other\">600</td> <td class=\"sublist_other\">1700</td> </tr> <tr> <td class=\"sublist1\">14 to 18 years</td> <td class=\"sublist_other\">900</td> <td class=\"sublist_other\">2800</td> </tr> <tr> <td class=\"sublist1\">&#8805;19 years</td> <td class=\"sublist_other\">900</td> <td class=\"sublist_other\">3000</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Females</td> </tr> <tr> <td class=\"sublist1\">9 to 13 years</td> <td class=\"sublist_other\">600</td> <td class=\"sublist_other\">1700</td> </tr> <tr> <td class=\"sublist1\">14 to 18 years</td> <td class=\"sublist_other\">700</td> <td class=\"sublist_other\">2800</td> </tr> <tr> <td class=\"sublist1\">&#8805;19 years</td> <td class=\"sublist_other\">700</td> <td class=\"sublist_other\">3000</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Pregnancy</td> </tr> <tr> <td class=\"sublist1\">&#60;18 years</td> <td class=\"sublist_other\">750</td> <td class=\"sublist_other\">2800</td> </tr> <tr> <td class=\"sublist1\">&#8805;19 years</td> <td class=\"sublist_other\">770</td> <td class=\"sublist_other\">3000</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Lactation</td> </tr> <tr> <td class=\"sublist1\">&#60;18 years</td> <td class=\"sublist_other\">1200</td> <td class=\"sublist_other\">2800</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">&#8805;19 years</td> <td class=\"sublist_other\">1300</td> <td class=\"sublist_other\">3000</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Vitamin D</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"12\"> <p>(calciferol)</p> 1 mcg calciferol = 40 int. unit</td> <td class=\"subtitle3\">&nbsp;</td> <td class=\"subtitle3\">Micrograms daily</td> <td class=\"subtitle3\">Micrograms daily</td> <td class=\"divider_bottom\" rowspan=\"12\">Hypercalcemia, hypercalciuria, polydipsia, polyuria, confusion, anorexia, vomiting, bone demineralization</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Infants</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"2\">0 to 12 months</td> <td class=\"sublist_other\" rowspan=\"2\">10 (400 int. unit)<sup>&#182;</sup></td> <td class=\"sublist_other\">0 to 6 months: 25 (1000 int. unit)</td> </tr> <tr> <td class=\"sublist_other\">6 to 12 months: 37.5 (1500 int. unit)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Children and adolescents</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"3\">1 to 18 years</td> <td class=\"sublist_other\" rowspan=\"3\">15 (600 int. unit)</td> <td class=\"sublist_other\">1 to 3 years: 62.5 (2500 int. unit)</td> </tr> <tr> <td class=\"sublist_other\">4 to 8 years: 75 (3000 int. unit)</td> </tr> <tr> <td class=\"sublist_other\">9 to 18 years: 100 (4000 int. unit)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Males and females (including pregnancy and lactation)</td> </tr> <tr> <td class=\"sublist1\">19 to 50 years</td> <td class=\"sublist_other\">15 (600 int. unit)</td> <td class=\"sublist_other\">100 (4000 int. unit)</td> </tr> <tr> <td class=\"sublist1\">50 to 70 years</td> <td class=\"sublist_other\">15</td> <td class=\"sublist_other\">100</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">&#62;70 years</td> <td class=\"sublist_other\">20 (800 int. unit)</td> <td class=\"sublist_other\">100</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Vitamin E</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"14\"> <p>(alpha-tocopherol)</p> 1 mg = 1.47 int. unit \"natural source\" vitamin E, or 2.2 int. unit synthetic vitamin E</td> <td class=\"subtitle3\">&nbsp;</td> <td class=\"subtitle3\">Milligrams daily</td> <td class=\"subtitle3\">Milligrams daily</td> <td class=\"divider_bottom\" rowspan=\"14\">Increased risk of bleeding; possibly increased risk of necrotizing enterocolitis in infants</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Infants</td> </tr> <tr> <td class=\"sublist1\">0 to 6 months</td> <td class=\"sublist_other\">4<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1\">7 to 12 months</td> <td class=\"sublist_other\">5<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Children</td> </tr> <tr> <td class=\"sublist1\">1 to 3 years</td> <td class=\"sublist_other\">6</td> <td class=\"sublist_other\">200</td> </tr> <tr> <td class=\"sublist1\">4 to 8 years</td> <td class=\"sublist_other\">7</td> <td class=\"sublist_other\">300</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Males and females (including pregnancy)</td> </tr> <tr> <td class=\"sublist1\">9 to 13 years</td> <td class=\"sublist_other\">11</td> <td class=\"sublist_other\">600</td> </tr> <tr> <td class=\"sublist1\">14 to 18 years</td> <td class=\"sublist_other\">15</td> <td class=\"sublist_other\">800</td> </tr> <tr> <td class=\"sublist1\">&#62;18 years</td> <td class=\"sublist_other\">15</td> <td class=\"sublist_other\">1000</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Lactation</td> </tr> <tr> <td class=\"sublist1\">&#8804;18 years</td> <td class=\"sublist_other\">19</td> <td class=\"sublist_other\">800</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">&#62;19 years</td> <td class=\"sublist_other\">19</td> <td class=\"sublist_other\">1000</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Vitamin K</td> </tr> <tr> <td rowspan=\"15\">&nbsp;</td> <td class=\"subtitle3\">&nbsp;</td> <td class=\"subtitle3\">Micrograms daily</td> <td class=\"subtitle3\">Micrograms daily</td> <td rowspan=\"15\">No adverse effects associated with vitamin K consumption from food or supplements have been reported; however, data are limited</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Infants</td> </tr> <tr> <td class=\"sublist1\">0 to 6 months</td> <td class=\"sublist_other\">2<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1\">7 to 12 months</td> <td class=\"sublist_other\">2.5<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Children</td> </tr> <tr> <td class=\"sublist1\">1 to 3 years</td> <td class=\"sublist_other\">30<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1\">4 to 8 years</td> <td class=\"sublist_other\">55<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Males</td> </tr> <tr> <td class=\"sublist1\">9 to 13 years</td> <td class=\"sublist_other\">60<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1\">14 to 18 years</td> <td class=\"sublist_other\">75<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1\">&#62;19 years</td> <td class=\"sublist_other\">120<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Females (including pregnancy and lactation)</td> </tr> <tr> <td class=\"sublist1\">9 to 13 years</td> <td class=\"sublist_other\">60<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1\">14 to 18 years</td> <td class=\"sublist_other\">75<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist1\">&#62;19 years</td> <td class=\"sublist_other\">90<sup>&#182;</sup></td> <td class=\"sublist_other\">ND</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Vitamin A doses given as retinol activity equivalents (RAE). 1 RAE = 1 mcg retinol, 12 mcg beta-carotene, 14 mcg alpha-carotene, or 24 mcg beta-cryptoxanthin.</div><div class=\"graphic_footnotes\"><FONT color=black>RDA: recommended dietary allowance;</FONT><FONT color=black> AI: adequate intake; </FONT>UL: upper tolerable level.<br />*&nbsp;Values in this column represent the recommended dietary allowance (RDA) unless otherwise indicated. The RDA is the level of dietary intake that is sufficient to meet the daily nutrient requirements of 97 percent of the individuals in a specific life stage group.<br />¶ These values represent&nbsp;an adequate intake (AI). The&nbsp;AI represents an approximation of the average nutrient intake that sustains a defined nutritional state, based on observed or experimentally determined values in a defined population.<br />Δ The UL is the maximum level of daily nutrient intake that is likely to pose no risk of adverse health effects in almost all individuals in the specified life-stage or gender group.</div><div class=\"graphic_reference\">Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Otten JJ, Hellwig JP, Meyers LD (Eds), The National Academies Press, Washington, DC 2006. pp.530-541. Modified with permission from the National Academies Press, Copyright &copy; 2006, National Academy of Sciences.<br />Sources: Dietary reference intakes for Thiamin, Riboflavin, Niacin, Vitamin B<sub>6</sub>, Folate, Vitamin B<sub>12</sub>, Panthothenic acid, Biotin, and Choline (1998); Dietary reference intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (2000); Dietary Reference Intake reports of the Food and Nutrition Board, Institute of Medicine (2010). These reports may be accessed via <a href=\"http://www.nap.edu/\" target=\"_blank\">www.nap.edu</a>.</div><div id=\"graphicVersion\">Graphic 81151 Version 23.0</div></div></div>"},"81152":{"type":"graphic_picture","displayName":"Spinal hypermobility","title":"Spinal hypermobility","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spinal hypermobility</div><div class=\"cntnt\"><img style=\"width:189px; height:289px;\" src=\"images/RHEUM/81152_Spinal_hypermobility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While keeping the knees locked straight, the person with joint laxity can bend and lay palms to floor.</div><div class=\"graphic_reference\">Courtesy of Robert Sheon, MD.</div><div id=\"graphicVersion\">Graphic 81152 Version 2.0</div></div></div>"},"81153":{"type":"graphic_figure","displayName":"Amphetamine structure","title":"Amphetamine structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amphetamine structure</div><div class=\"cntnt\"><img style=\"width:325px; height:168px;\" src=\"images/EM/81153_Amphetamine_structure.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81153 Version 1.0</div></div></div>"},"81154":{"type":"graphic_algorithm","displayName":"Evaluate and treat pheo","title":"Evaluation and treatment of catecholamine-producing tumors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation and treatment of catecholamine-producing tumors</div><div class=\"cntnt\"><img style=\"width:381px; height:757px;\" src=\"images/ENDO/81154_Evaluatetreatpheo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Nmet: normetanephrine; Met: metanephrine; MRI: magnetic resonance imaging; CT: computed tomography; 123I-MIBG: 123I-meta-iodobenzylguanidine; 68-Ga DOTATATE PET: gallium 68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-octreotate; FDG: fluorodeoxyglucose; PET: positron emission tomography.</div><div class=\"graphic_reference\">Modified and reprinted with permission from: Young WF Jr. Pheochromocytoma: 1926-1993. In: Trends in Endocrinology and Metabolism, vol 4, Elsevier Science, Inc 1993. p.122.</div><div id=\"graphicVersion\">Graphic 81154 Version 7.0</div></div></div>"},"81156":{"type":"graphic_table","displayName":"Evaluation hypotension by TEE","title":"Evaluation of hypotension by transesophageal echocardiography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of hypotension by transesophageal echocardiography</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Etiology</td>\n\n      <td class=\"subtitle1_single\">EDA</td>\n\n      <td class=\"subtitle1_single\">FAC</td>\n\n      <td class=\"subtitle1_single\">PVF</td>\n\n      <td class=\"subtitle1_single\">E/A</td>\n\n      <td class=\"subtitle1_single\">SWMA</td>\n\n      <td class=\"subtitle1_single\">Other</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypovolemia</td>\n\n      <td>&#8595;&#8595;</td>\n\n      <td>&#8593;&#8593;</td>\n\n      <td>S &#62; D</td>\n\n      <td>&#8595;</td>\n\n      <td>+/ -</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sepsis</td>\n\n      <td>&#8595;</td>\n\n      <td>Variably &#8593;</td>\n\n      <td>S &#62; D</td>\n\n      <td>&#8595;</td>\n\n      <td>-</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiogenic</td>\n\n      <td>&#8593;</td>\n\n      <td>&#8595;&#8595;</td>\n\n      <td>S &#60; D</td>\n\n      <td>&#8593;</td>\n\n      <td>+ /-</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>RV infarct</td>\n\n      <td>Variable</td>\n\n      <td>NL/&#8595;</td>\n\n      <td>S &#62; D</td>\n\n      <td>&#8595;</td>\n\n      <td>+</td>\n\n      <td>&#8595;RVEF &#8593;RV</td>\n\n    </tr>\n\n    <tr>\n\n      <td>MR</td>\n\n      <td>&#8593;</td>\n\n      <td>&#8593;</td>\n\n      <td>SFR</td>\n\n      <td>&#8593;</td>\n\n      <td>+ /-</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pul embolism</td>\n\n      <td>&#8595;</td>\n\n      <td>&#8593;</td>\n\n      <td>S &#62; D</td>\n\n      <td>&#8595;</td>\n\n      <td>-</td>\n\n      <td>&#8595;RVEF &#8593;RV</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tamponade</td>\n\n      <td>&#8595;</td>\n\n      <td>&#8593;</td>\n\n      <td>Resp var*</td>\n\n      <td> Resp var*</td>\n\n      <td>-</td>\n\n      <td>&#8595;RVEF, RV</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">EDA: left ventricular end-diastolic area; FAC: LV fractional area change; PVF: pulmonary venous flow; E/A: ratio of early to late mitral inflow; SWMA: LV segmental wall motion abnormalties; RVEF: right ventricular ejection fraction; RA: right atrium; S: systolic flow; D: diastolic flow; SFR: systolic flow reversal; MR: mitral regurgitation.<br> * Reciprocating respiratory changes in LA, LV dimensions.</div><div id=\"graphicVersion\">Graphic 81156 Version 1.0</div></div></div>"},"81157":{"type":"graphic_figure","displayName":"Normal vision","title":"Normal vision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal vision</div><div class=\"cntnt\"><img style=\"width:396px; height:360px;\" src=\"images/PC/81157_Normal_vision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The eye's optical system focuses light on to the retina primarily due to the shape of the cornea.</div><div id=\"graphicVersion\">Graphic 81157 Version 1.0</div></div></div>"},"81158":{"type":"graphic_picture","displayName":"Coronary artery after stent ACS","title":"Coronary artery after stent implantation in a patient with acute coronary syndrome","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Coronary artery after stent implantation in a patient with acute coronary syndrome</div><div class=\"cntnt\"><img style=\"width:514px; height:514px;\" src=\"images/CARD/81158_Coronary_artery_stent_ACS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The individual stent struts can be recognized as signal rich, bright yellow structures casting a dorsal shadow on the vessel wall. Stent struts in 5 o'clock position are not apposed against the vessel wall (arrows). There is tissue protruding between the stent struts in 11 o'clock position, and mural thrombus formation in 2 and 4 o'clock position visible (open arrows). (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.</div><div class=\"graphic_footnotes\">OCT: St. Jude/Lightlab Imaging C7XR.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 81158 Version 2.0</div></div></div>"},"81159":{"type":"graphic_picture","displayName":"UV lesions V","title":"Urticarial vasculitis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Urticarial vasculitis</div><div class=\"cntnt\"><img style=\"width:468px; height:310px;\" src=\"images/ALLRG/81159_UV_lesions_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urticarial patches with annular, semiannular, and occasionally concentric formation. Note scattered associated ecchymoses.</div><div id=\"graphicVersion\">Graphic 81159 Version 2.0</div></div></div>"},"81161":{"type":"graphic_figure","displayName":"Endothelin system","title":"Endothelin system in vascular tissue","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Endothelin system in vascular tissue</div><div class=\"cntnt\"><img style=\"width:471px; height:307px;\" src=\"images/PULM/81161_Endothelin_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ET: endothelin-1; BIG-ET-1: proendothelin-1; ECE: endothelin-converting enzyme; NO: nitric oxide; PGI2: prostacyclin.</div><div class=\"graphic_reference\">Reproduced with permission from: Dupuis, J. Endothelin- receptor antagonists in pulmonary hypertension. Lancet 2001; 358:1114. Copyright © 2001, The Lancet Ltd.</div><div id=\"graphicVersion\">Graphic 81161 Version 2.0</div></div></div>"},"81162":{"type":"graphic_figure","displayName":"Montgomery-Asberg Depression Rating Scale - page 3","title":"Montgomery-Asberg Depression Rating Scale, page 3","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Montgomery-Asberg Depression Rating Scale, page 3</div><div class=\"cntnt\"><img style=\"width:599px; height:589px;\" src=\"images/PSYCH/81162_Montgomery_pg3_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Montgomery, SA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382.</div><div id=\"graphicVersion\">Graphic 81162 Version 3.0</div></div></div>"},"81164":{"type":"graphic_figure","displayName":"Pathways of glycogen metabolism","title":"Metabolic pathways of glycogen metabolism and glycolysis","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Metabolic pathways of glycogen metabolism and glycolysis</div><div class=\"cntnt\"><img style=\"width:553px; height:600px;\" src=\"images/PEDS/81164_Pathway_glycogen_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure&nbsp;shows the sites of enzymatic defects resulting in clinical glycogenoses. The glycogen storage disease types are as follows: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Type 0: Glycogen synthase deficiency </LI>&#xD;&#xA;<LI>Type Ia: Glucose 6-phosphatase (G6Pase) deficiency or von Gierke disease </LI>&#xD;&#xA;<LI>Type II: Acid maltase deficiency or Pompe disease </LI>&#xD;&#xA;<LI>Type III: Glycogen debrancher deficiency </LI>&#xD;&#xA;<LI>Type IV: Glycogen branching deficiency or Andersen disease </LI>&#xD;&#xA;<LI>Type V: Muscle phosphorylase deficiency or McArdle disease </LI>&#xD;&#xA;<LI>Type VI: Liver phosphorylase deficiency or Hers disease </LI>&#xD;&#xA;<LI>Type VII: Phosphofructokinase (PFK) deficiency or Tarui disease </LI>&#xD;&#xA;<LI>Type IX: Phosphorylase b kinase (PBK) deficiency </LI>&#xD;&#xA;<LI>Type X: Phosphoglycerate mutase (PGAM2) deficiency </LI>&#xD;&#xA;<LI>Type XI: Lactate dehydrogenase (LDH) deficiency </LI>&#xD;&#xA;<LI>Type XII: Aldolase A deficiency </LI>&#xD;&#xA;<LI>Type XIII: Beta-enolase deficiency </LI>&#xD;&#xA;<LI>Type XIV: Phosphoglucomutase-1 (PGM1) deficiency </LI></UL>Other deficiency syndromes, enzymes, and intermediates include the following: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Fructose-1,6-bisphosphatase (F-1,6-BP) deficiency </LI>&#xD;&#xA;<LI>Glucokinase (GK) </LI>&#xD;&#xA;<LI>Glucose transporter 2 (GLUT2) deficiency or Fanconi-Bickel syndrome </LI>&#xD;&#xA;<LI>Phosphoglycerate kinase (PGK) deficiency </LI>&#xD;&#xA;<LI>Phosphophoenol pyruvate carboxykinase (PEPCK) deficiency </LI>&#xD;&#xA;<LI>Phosphorylase limit dextrin (PLD) </LI>&#xD;&#xA;<LI>Pyruvate carboxylase (PC) deficiency </LI>&#xD;&#xA;<LI>Pyruvate dehydrogenase (PDH) </LI>&#xD;&#xA;<LI>Pyruvate kinase (PK) deficiency </LI>&#xD;&#xA;<LI>Uridine diphosphoglucose (UDPG) </LI>&#xD;&#xA;<LI>Uridine diphosphoglucose pyrophosphorylase (UDPG-P) </LI></UL></div><div class=\"graphic_reference\">Adapted from: Griggs R, Mendell J, Miller R. Metabolic myopathies. In: Evaluation and Treatment of Myopathies, Griggs R, Mendell J, Miller R (Eds), FA Davis Co., Philadelphia 1995. p.247.</div><div id=\"graphicVersion\">Graphic 81164 Version 10.0</div></div></div>"},"81165":{"type":"graphic_diagnosticimage","displayName":"CT axial dilated sm bowel","title":"Small bowel obstruction CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction CT</div><div class=\"cntnt\"><img style=\"width:396px; height:299px;\" src=\"images/GAST/81165_CT_axial_dilated_sm_bowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel obstruction seen on CT scan showing dilated, fluid-filled loops of small bowel.</div><div class=\"graphic_reference\">Courtesy of Richard A Hodin, MD.</div><div id=\"graphicVersion\">Graphic 81165 Version 2.0</div></div></div>"},"81166":{"type":"graphic_table","displayName":"DDx SLL path","title":"Differential diagnosis of small lymphocytic lymphoma (SLL)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of small lymphocytic lymphoma (SLL)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Immunophenotype</td> <td class=\"subtitle1\">Genetic features/other</td> </tr> <tr class=\"divider_bottom\"> <td>Small lymphocytic lymphoma</td> <td>Lymph node infiltrate typically composed of small lymphocytes with condensed chromatin, round nuclei, and occasionally a small nucleolus. Larger lymphoid cells cluster in pseudofollicles, known as proliferation centers. These proliferation centers may form a nodular pattern of infiltration.</td> <td>Always express CD5. Usually express CD23. Expression of CD20 and surface immunoglobulin is dim. Do not overexpress cyclin D1 and do not express CD10.</td> <td>del13q, del 11q, del17p, trisomy 12</td> </tr> <tr class=\"divider_bottom\"> <td>Mantle cell lymphoma</td> <td>Monomorphous small to medium-sized B lymphocytes with irregular nuclei. No proliferation centers.</td> <td>CD5+ and CD23&ndash;; the vast majority overexpress cyclin D1.</td> <td>t(11;14)</td> </tr> <tr class=\"divider_bottom\"> <td>Hairy cell leukemia</td> <td>The typical hairy cell leukemia cell is mononuclear and one to two times the size of a small lymphocyte. Bone marrow biopsy demonstrates a \"fried egg\" appearance with an interstitial pattern of infiltration.</td> <td>Unlike SLL, most cases of HCL express CD11c, CD103, CD123, cyclin D1, and/or annexin A1.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Follicular lymphoma</td> <td>Nodular growth pattern of follicle center cells (centrocytes and centroblasts).</td> <td>Typically express CD10, HLA-DR, pan B cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA.</td> <td>t(14;18)</td> </tr> <tr class=\"divider_bottom\"> <td>Lymphoplasmacytic lymphoma</td> <td> <p>&#8805;10 percent infiltration by small lymphocytes, plasmacytoid lymphocytes, and plasma cells, with variable numbers of admixed immunoblasts.</p> <p>Characteristic (but not pathognomonic) hyperplasia of mast cells in marrow.</p> Lymph notes are usually diffusely effaced. Proliferation centers and marginal zone type differentiation are absent.</td> <td> <p>Express pan B cell antigens (CD19, CD20, CD22, CD79a). Most, but not all, cases fail to express CD5.</p> <p>Variable expression of CD11c, CD43, CD25. Most cases express IgM; fewer express IgG or IgA.</p> CD10 and cyclin D1 are not expressed.</td> <td> <p>Majority have a monoclonal IgM paraprotein.</p> No specific chromosomal abnormalities.</td> </tr> <tr class=\"divider_bottom\"> <td>B cell prolymphocytic lymphoma</td> <td>Prolymphocytes &#62;55 percent of the neoplastic cells. Bone marrow has interstitial pattern of infiltration. Lymph nodes may show vague nodularity, but proliferation centers are absent.</td> <td>Express bright surface IgM +/&ndash; IgD and bright CD20 as well as other B cell antigens (CD19, CD22, CD79a, FMC7).</td> <td> <p>t(11;14) must be excluded.</p> No associated paraproteinemia.</td> </tr> <tr> <td>Histologic transformation to diffuse large B cell lymphoma</td> <td>Large, transformed B cells with prominent nucleoli and basophilic cytoplasm demonstrating a diffuse growth pattern and a high (&#62;40 percent) proliferation fraction.</td> <td>Express pan B cell antigens (CD19, CD20, CD79a), CD45, and monoclonal surface membrane IgM. Some cases will demonstrate CD5.</td> <td>Genetic abnormalities varied.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81166 Version 4.0</div></div></div>"},"81169":{"type":"graphic_figure","displayName":"Radial head fracture mechanism","title":"Mechanism of radial head fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanism of radial head fracture</div><div class=\"cntnt\"><img style=\"width:313px; height:490px;\" src=\"images/EM/81169_Radial_head_fx_mechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fall onto an outstretched hand is a common mechanism for many fractures of the wrist and forearm, including the scaphoid, distal radius, and radial head. Such falls can also strain or rupture the interosseous membrane.</div><div class=\"graphic_reference\">Reproduced with permission from: Mezera K, Hotchkiss RN. Fractures and dislocation of the elbow. In: Rockwood and Green's Fractures in Adults, 5th ed, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81169 Version 9.0</div></div></div>"},"81170":{"type":"graphic_waveform","displayName":"Advanced case 2","title":"Advanced case 2","html":"<div class=\"graphic normal\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Advanced case 2</div><div class=\"cntnt\"><img style=\"width:465px; height:128px;\" src=\"images/CARD/81170_Advanced_case_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81170 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"81172":{"type":"graphic_diagnosticimage","displayName":"Alveolar cell carcinoma PA","title":"Bronchiololaveolar cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiololaveolar cell carcinoma</div><div class=\"cntnt\"><img style=\"width:361px; height:348px;\" src=\"images/PULM/81172_Alveolar_cell_carcinoma_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows bilateral large opacities: right upper lobe consolidation and patchy lingular opacification. Air bronchograms are clearly visible.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 81172 Version 3.0</div></div></div>"},"81173":{"type":"graphic_picture","displayName":"Poison oak","title":"Poison oak","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Poison oak</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/81173_Poisonoak.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81173 Version 4.0</div></div></div>"},"81175":{"type":"graphic_picture","displayName":"Herpes virus","title":"Herpes simplex virus electron micrograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex virus electron micrograph</div><div class=\"cntnt\"><img style=\"width:360px; height:295px;\" src=\"images/PEDS/81175_Herpes_virus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph (55,000X magnification) of human tissue containing herpes virus particles exhibiting characteristic enveloped capsids with icosahedral symmetry.</div><div class=\"graphic_reference\">Courtesy of John M Hicks, MD, PhD, DDS, Department of Pathology, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 81175 Version 1.0</div></div></div>"},"81176":{"type":"graphic_figure","displayName":"Pericardiocentesis sites","title":"Pericardiocentesis sites","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Pericardiocentesis sites</div><div class=\"cntnt\"><img style=\"width:500px; height:417px;\" src=\"images/EM/81176_Pericardiocent_site_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the picture above, possible needle entry sites for emergency pericardiocentesis are designated by red dots. Emergency pericardiocentesis is most commonly performed using the left intercostal, left parasternal, or apical approach.</div><div class=\"graphic_reference\">Picture courtesy of Robert Reardon, MD.</div><div id=\"graphicVersion\">Graphic 81176 Version 5.0</div></div></div>"},"81177":{"type":"graphic_picture","displayName":"Postadolescent acne on chin","title":"Postadolescent acne in an adult female","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Postadolescent acne in an adult female</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/81177_Postadolescent_acne_chin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory papules and pustules are present on the chin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81177 Version 4.0</div></div></div>"},"81179":{"type":"graphic_table","displayName":"Adult screening effective doses","title":"Adult screening effective doses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult screening effective doses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Average effective dose (mSv)</td> <td class=\"subtitle1\">Number of chest x-rays (PA/lateral) with equivalent radiation dose*</td> </tr> <tr> <td>Dual x-ray absorpitometry (DEXA)</td> <td>Conventional radiography</td> <td>0.001</td> <td>0.01</td> </tr> <tr> <td>Dual x-ray absorpitometry with CT</td> <td>Computed tomography</td> <td>0.04</td> <td>0.4</td> </tr> <tr> <td>Mammogram (2 views)</td> <td>Conventional radiography</td> <td>0.4</td> <td>4</td> </tr> <tr> <td>CT coronary calcium score</td> <td>Computed tomography</td> <td>3</td> <td>30</td> </tr> <tr> <td>CT colonography (virtual colonoscopy)</td> <td>Computed tomography</td> <td>10</td> <td>100</td> </tr> <tr> <td>Whole body screening CT</td> <td>Computed tomography</td> <td>12</td> <td>120</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* PA and lateral chest radiograph = .1 mSv.</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Mettler, FA, Huda, W, Yoshizumi, TT, Mahesh, M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248:254. </li> <li>Smith-Bindman, R, Lipson, J, Marcus, R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169:2078. </li> <li>Shrimpton, PC, Hillier, MC, Lewis, MA, Dunn, M. National survey of doses from CT in the UK: 2003. Br J Radiol 2006; 79:968. </li> <li>Diederich, S, Lenzen, H. Radiation exposure associated with imaging of the chest: comparison of different radiographic and computed tomography techniques. Cancer 2000; 89:2457. </li> <li>Brenner, DJ, Elliston, CD. Estimated radiation risks potentially associated with full-body CT screening. Radiology 2004; 232:735. </li> </ol></div><div id=\"graphicVersion\">Graphic 81179 Version 4.0</div></div></div>"},"81180":{"type":"graphic_figure","displayName":"Live births after clomiphene","title":"Live birth following clomiphene citrate","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Live birth following clomiphene citrate</div><div class=\"cntnt\"><img style=\"width:572px; height:371px;\" src=\"images/ENDO/81180_Live_births_after_clomiphen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A two-step nomogram predicting chances for live birth following clomiphene citrate on the basis of initial screening characteristics.</div><div class=\"graphic_footnotes\">BMI: body mass index; FAI: free androgen index; T: testosterone; SHBG: sex hormone-binding globulin.</div><div class=\"graphic_reference\">Reproduced with permission from: Imani, B, Eijkemans, MJ, te Velde, ER, et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002; 77:91. Copyright © 2002 American Society for Reproductive Medicine.</div><div id=\"graphicVersion\">Graphic 81180 Version 2.0</div></div></div>"},"81182":{"type":"graphic_table","displayName":"HBV consensus definitions","title":"Glossary of clinical terms used in HBV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glossary of clinical terms used in HBV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitions</td> </tr> <tr> <td class=\"subtitle2_single\">Chronic hepatitis B</td> </tr> <tr> <td class=\"indent1\">Chronic necroinflammatory disease of the liver caused by persistent infection with hepatitis B virus. Chronic hepatitis B can be subdivided into HBeAg-positive and HBeAg-negative chronic hepatitis B.</td> </tr> <tr> <td class=\"subtitle2_single\">Inactive HBsAg carrier state</td> </tr> <tr> <td class=\"indent1\">Persistent HBV infection of the liver without significant, ongoing necroinflammatory disease.</td> </tr> <tr> <td class=\"subtitle2_single\">Resolved hepatitis B</td> </tr> <tr> <td class=\"indent1\">Previous HBV infection without further virological, biochemical, or histological evidence of active virus infection or disease.</td> </tr> <tr> <td class=\"subtitle2_single\">Acute exacerbation or flare of hepatitis B</td> </tr> <tr> <td class=\"indent1\">Intermittent elevations of aminotransferase activity to more than 10 times the upper limit of normal and more than twice the baseline value.</td> </tr> <tr> <td class=\"subtitle2_single\">Reactivation of hepatitis B</td> </tr> <tr> <td class=\"indent1\">Reappearance of active necroinflammatory disease of the liver in a person known to have the inactive HBsAg carrier state or resolved hepatitis B.</td> </tr> <tr> <td class=\"subtitle2_single\">HBeAg clearance</td> </tr> <tr> <td class=\"indent1\">Loss of HBeAg in a person who was previously HBeAg positive.</td> </tr> <tr> <td class=\"subtitle2_single\">HBeAg seroconversion</td> </tr> <tr> <td class=\"indent1\">Loss of HBeAg and detection of anti-HBe.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; anti-HBe: hepatitis B e antibody.</div><div id=\"graphicVersion\">Graphic 81182 Version 2.0</div></div></div>"},"81184":{"type":"graphic_picture","displayName":"Adie's pupil","title":"Left Adie's pupil","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left Adie's pupil</div><div class=\"cntnt\"><img style=\"width:253px; height:505px;\" src=\"images/NEURO/81184_Adies_pupil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) The left pupil is dilated and poorly reactive to light. B) At near, the left pupil constricts slowly. C) After instillation of dilute pilocarpine (0.1 percent), the left pupil constricts while the right pupil does not constrict.</div><div id=\"graphicVersion\">Graphic 81184 Version 1.0</div></div></div>"},"81185":{"type":"graphic_table","displayName":"Recom Adj Sys Rx in Older women with br ca","title":"Recommendations for adjuvant systemic therapy in women older than 70 years of age with breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for adjuvant systemic therapy in women older than 70 years of age with breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk category</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Suggested therapy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Very low</td> <td class=\"sublist1_start\">If all of the following:</td> <td class=\"divider_bottom\" rowspan=\"2\">No treatment or endocrine* therapy.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Tumor size &#60;1 cm</p> <p>Histologic grade 1</p> <p>ER/PR-positive</p> <p>HER2-negative</p> No angiolymphatic invasion</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Low</td> <td class=\"sublist1_start\">If all of the following:</td> <td class=\"divider_bottom\" rowspan=\"2\">Endocrine therapy* is recommended if ER/PR-positive. Addition of chemotherapy could be considered if patient is healthy.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Tumor size &#8804;2 cm</p> <p>Node-negative</p> <p>Favorable histopathologic features (eg, grade 1)</p> <p>ER/PR-positive</p> <p>HER2-negative</p> <p>No angiolymphatic invasion</p> Low risk by gene expression analysis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Intermediate</td> <td class=\"sublist1_start\">If node negative and at least one of the following:</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Endocrine* therapy is recommended if ER/PR-positive. Addition of chemotherapy suggested if patient is non-frail<sup>&#182;</sup> and willing to accept risks.</p> If HER2-positive, addition of trastuzumab is suggested, if the patient is non-frail<sup>&#182;</sup>, lacks cardiac comorbidity, and/or is willing to accept the risks.</td> </tr> <tr> <td class=\"indent1\"> <p>Tumor size &#62;2 cm</p> <p>Unfavorable histopathologic features (eg, grade 2 to 3)</p> <p>ER/PR-negative</p> <p>HER2-positive</p> Presence of angiolymphatic invasion</td> </tr> <tr> <td> <p><strong>OR</strong></p> Tumor &#8805;2 cm and ER/PR-positive and high risk gene expression analysis (eg, Oncotype DX)</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>OR</strong></p> If one to three involved axillary nodes and ER/PR-positive and HER2-negative</td> </tr> <tr> <td rowspan=\"2\">High</td> <td>If one to three involved axillary nodes and ER/PR-negative, or HER2-positive</td> <td rowspan=\"2\"> <p>Chemotherapy recommended.</p> <p>If HER2-positive, add trastuzumab.</p> If ER/PR-positive, add endocrine* therapy.</td> </tr> <tr> <td class=\"sublist1_start\"> <p><strong>OR</strong></p> Four or more involved axillary nodes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ER/PR: estrogen and/or progesterone receptor.<br />* Adjuvant endocrine therapy includes use of an aromatase inhibitor (anastrozole, letrozole, or exemestane) or tamoxifen for at least five years.<br />&#182; Frailty is defined as a decreased reserve and diminished resistance to stressors. Criteria that define frailty include a five or greater pound weight loss in the past year, slow walking speed (six to seven seconds or more required to walk 15 feet), and/or decreased physical activity per week.</div><div id=\"graphicVersion\">Graphic 81185 Version 5.0</div></div></div>"},"81188":{"type":"graphic_diagnosticimage","displayName":"MRI of CIS presenting as optic neuritis","title":"Brain MRI of a clinically isolated syndrome suggestive of multiple sclerosis presenting as optic neuritis","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a clinically isolated syndrome suggestive of multiple sclerosis presenting as optic neuritis</div><div class=\"cntnt\"><img style=\"width:451px; height:493px;\" src=\"images/NEURO/81188_CIS_MRI_optic_neuritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI of a 30-year-old woman presenting with optic neuritis. Fat saturated T2-weighted coronal (A) image shows hyperintensity in the right optic nerve (arrow). Post-gadolinium fat-saturated T1-weighted coronal (B) image shows abnormal enhancement in the right optic nerve (arrow). Four years later, sagittal FLAIR (C) shows two plaques radiating outward from the corpus callosum (arrowheads), suggestive of multiple sclerosis.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery.</div><div id=\"graphicVersion\">Graphic 81188 Version 6.0</div></div></div>"},"81191":{"type":"graphic_table","displayName":"Studies of systemic therapy for brain metastases breast cancer","title":"Selected studies of systemic therapy for brain metastases from breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected studies of systemic therapy for brain metastases from breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study </td> <td class=\"subtitle1\">Regimen </td> <td class=\"subtitle1\">Patient population </td> <td class=\"subtitle1\">Total number of&nbsp;patients </td> <td class=\"subtitle1\">Number&nbsp;of&nbsp;patients with breast cancer and brain metastases </td> <td class=\"subtitle1\">Objective response rate (percent) </td> <td class=\"subtitle1\">TTP/PFS </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>Rosner et al<sup>[1]</sup></td> <td>Various (CFP, CFPMV, MVP, CA)</td> <td>Breast cancer</td> <td>100</td> <td>100</td> <td>50</td> <td>NR</td> <td>Case series</td> </tr> <tr> <td>Boogerd et al<sup>[2]</sup></td> <td>Oral CMF (n=20), or CAF (n=2)</td> <td>Breast cancer</td> <td>22</td> <td>22</td> <td>54</td> <td>NR</td> <td>Case series</td> </tr> <tr> <td>Friedman et al<sup>[3]</sup></td> <td>Temozolomide 150 mg/m<sup>2</sup> days 1-7, 15-21, every 28 days</td> <td>Solid tumors</td> <td>52</td> <td>15</td> <td>6</td> <td>NR</td> <td>No responses seen in breast cancer patients</td> </tr> <tr> <td>Siena et al<sup>[4]</sup></td> <td>Temozolomide 150 mg/m<sup>2</sup> days 1-7, 15-21, every 28 days</td> <td>Solid tumors</td> <td>62</td> <td>21</td> <td>19 (in subset of patients with breast cancer)</td> <td>1.9 months</td> <td>&nbsp;</td> </tr> <tr> <td>Trudeau et al<sup>[5]</sup></td> <td>Temozolomide 150 mg/m<sup>2</sup> days 1-7, 15-21, every 28 days</td> <td>Breast cancer</td> <td>19</td> <td>5</td> <td>0</td> <td>NR</td> <td>&nbsp;</td> </tr> <tr> <td>Rivera et al<sup>[6]</sup></td> <td>Escalating doses of capecitabine and temozolomide</td> <td>Breast cancer</td> <td>24</td> <td>24</td> <td>18</td> <td>3 months</td> <td>&nbsp;</td> </tr> <tr> <td>Franciosi et al<sup>[7]</sup></td> <td> <p>Cisplatin 100 mg/m<sup>2</sup> day 1</p> <p>Etoposide 100 mg/m<sup>2</sup> days 1, 3, and 5, every 21 days</p> </td> <td>Solid tumors</td> <td>107</td> <td>56</td> <td>38 (in subset of patients with breast cancer)</td> <td>4 months</td> <td>No prior radiation therapy allowed; 36 percent of&nbsp;patients had not had prior systemic treatment for breast cancer</td> </tr> <tr> <td>Christodoulou et al<sup>[8]</sup></td> <td> <p>Temozolomide 150 mg/m<sup>2</sup> days 1-5</p> <p>Cisplatin 75 mg/m<sup>2</sup> day 1, every 21 days</p> </td> <td>Solid tumors</td> <td>32</td> <td>15</td> <td>40 (in subset of patients with breast cancer)</td> <td>2.9 months</td> <td>&nbsp;</td> </tr> <tr> <td>Lin et al<sup>[9]</sup></td> <td>Lapatinib</td> <td>HER2+ breast cancer</td> <td>39</td> <td>39</td> <td>2.6</td> <td>3 months</td> <td>64 percent had two or more prior lines of systemic treatment (trastuzumab plus chemotherapy)&nbsp;</td> </tr> <tr> <td>Lin et al<sup>[10]</sup></td> <td>Lapatinib</td> <td>HER2+ breast cancer</td> <td>237</td> <td>237</td> <td>6</td> <td>2.4 months</td> <td>All patiens previously treated with radiation therapy; overall survival was 6 months</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TTP: time to tumor progression; PFS: progress-free survival; NR: not reported; CFP: cyclophosphamide, fluorouracil, and prednisone; CFPMV: cyclophosphamide, fluorouracil, and prednisone plus methotrexate and vincristine; MVP: methotrexate, vincristine, and prednisone; CA: cyclophosphamide and adriamycin; CMF: cyclophosphamide, methotrexate, and fluorouracil; CAF: cyclophosphamide, doxorubicin, and fluorouracil; HER2+: human epidermal growth factor receptor 2.</div><div class=\"graphic_reference\">1. Rosner D, Nemoto T,&#160;Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58:832.<br> 2. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992; 69:972.<br> 3. Friedman HS, Evans, B and Reardon, DA. Phase II trial of temozolomide for patients with progressive brain metastases (abstract #408). Proc Am Soc Clin Oncol 2003; 22:102.<br> 4. Siena S, Landonio G, Beaietta E. Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer (abstract #407). Proc Am Soc Clin Oncol 2003; 22:407.<br> 5. Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006; 17:952.<br> 6. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107:1348.<br> 7. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85:1599.<br> 8. Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005; 71:61.<br> 9. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26:1993.<br> 10. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15:1452.</div><div id=\"graphicVersion\">Graphic 81191 Version 2.0</div></div></div>"},"81192":{"type":"graphic_picture","displayName":"Posterior vitreous detachment","title":"Posterior vitreous detachment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior vitreous detachment</div><div class=\"cntnt\"><img style=\"width:344px; height:297px;\" src=\"images/PC/81192_Posterior_vitreous_detachme.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A horseshoe retinal tear with bridging retinal vein is evident. Vitreous is attached to the anterior flap of this tear. The bridging retinal vessel increases the risk of developing a vitreous hemorrhage.</div><div class=\"graphic_reference\">Reproduced with permission from: Ryan SJ, Langmore SE, Hinton D, Ogden TE. The Retina, 3rd ed, Volume 3: Surgical Retina, Mosby-Year Book, Inc., St. Louis 2001. Copyright &#169; 2001 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 81192 Version 2.0</div></div></div>"},"81194":{"type":"graphic_diagnosticimage","displayName":"Doppler ultrasound of the basilar artery","title":"Doppler ultrasound of the basilar artery in a newborn with hypoxic-ischemic brain injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler ultrasound of the basilar artery in a newborn with hypoxic-ischemic brain injury</div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/PEDS/81194_Hypoxic-ischemic_brain_inju.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Doppler ultrasound of the basilar artery (top center image) with systole/diastole profile (bottom display) in a term newborn with hypoxic-ischemic brain injury. The resistive index (RI) of 0.35 is characteristic of the reperfusion edema phase and is associated with a poor neurodevelopmental outcome.</div><div id=\"graphicVersion\">Graphic 81194 Version 3.0</div></div></div>"},"81196":{"type":"graphic_diagnosticimage","displayName":"Standard AP radiograph of foot","title":"Standard AP radiograph of foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard AP radiograph of foot</div><div class=\"cntnt\"><img style=\"width:242px; height:562px;\" src=\"images/EM/81196_Normal_foot_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The AP radiograph provides a better view of the proximal fifth metatarsal.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 81196 Version 3.0</div></div></div>"},"81197":{"type":"graphic_figure","displayName":"Causes of torsional nystagmus","title":"Causes of torsional nystagmus in 41 patients","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Causes of torsional nystagmus in 41 patients</div><div class=\"cntnt\"><img style=\"width:484px; height:278px;\" src=\"images/PC/81197_Causes_of_torsional_nystagm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">The numbers in parentheses associated with the pie graph represent the percent of patients with each cause.</div><div id=\"graphicVersion\">Graphic 81197 Version 1.0</div></div></div>"},"81198":{"type":"graphic_figure","displayName":"Achilles calcaneus enthesis","title":"Illustration of a typical enthesis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Illustration of a typical enthesis</div><div class=\"cntnt\"><img style=\"width:576px; height:289px;\" src=\"images/RHEUM/81198_Achilles_calcaneus_enthesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel is an artist's rendering of a sagital section through the area where the achilles tendon attaches to the calcaneus. The transition from tendon to enthesial fibrocartilage to calcified fibrocartilage and finally bone is indicated. Right panel: right ankle and foot.</div><div class=\"graphic_footnotes\">TEN: Achilles tendon; CAL: calcaneus; EF: enthesial fibrocartilage; SF: sesamoid fibrocartilage; PF: periosteal fibrocartilage; RB: retrocalcaneal bursa; UF: uncalcified fibrocartilage; CF: calcified fibrocartilage; T: Tidemark.</div><div class=\"graphic_reference\">Reproduced with permission from: Wagget, AD, Ralphs, JR, Kwan, AP, et al. Characterization of collagens and proteoglycans at the intersection of the human achilles tendon. Matrix Biol 1998; 16:457. Copyright © 1998 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 81198 Version 3.0</div></div></div>"},"81200":{"type":"graphic_figure","displayName":"RF energy delivery","title":"The \"Stretta\" procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The &quot;Stretta&quot; procedure</div><div class=\"cntnt\"><img style=\"width:365px; height:282px;\" src=\"images/GAST/81200_RF_energy_delivery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing the balloon inflation, deployment of needles, RF energy delivery, and irrigation of the mucosa.</div><div class=\"graphic_reference\">Courtesy of George Triadafilopoulos, MD.</div><div id=\"graphicVersion\">Graphic 81200 Version 2.0</div></div></div>"},"81201":{"type":"graphic_table","displayName":"Pancreatic sphnctr HTN stenting","title":"Pancreatic stenting after biliary sphincterotomy for sphincter of Oddi dysfunction in patients with pancreatic sphincter hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pancreatic stenting after biliary sphincterotomy for sphincter of Oddi dysfunction in patients with pancreatic sphincter hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Therapy</td> <td class=\"subtitle1\" colspan=\"4\">Pancreatitis, percent</td> </tr> <tr> <td class=\"subtitle2\">Total</td> <td class=\"subtitle2\">Mild</td> <td class=\"subtitle2\">Moderate</td> <td class=\"subtitle2\">Severe</td> </tr> <tr> <td>Stent (n = 41)</td> <td>2 </td> <td>0 </td> <td>2 </td> <td>0</td> </tr> <tr> <td>No stent (n = 39)</td> <td>26*</td> <td>13 </td> <td>13 </td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* p = 0.003 (N.B. incidence of pancreatitis was 7 percent in the stent group when including two patients who developed pancreatitis after stent removal).</div><div class=\"graphic_reference\">Data from: Tarnasky PR, et al. Gastroenterology 1998; 15:1518.</div><div id=\"graphicVersion\">Graphic 81201 Version 2.0</div></div></div>"},"81204":{"type":"graphic_figure","displayName":"Spinal nerves thoracic vertebra","title":"Spinal nerves section through thoracic vertebra","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Spinal nerves section through thoracic vertebra</div><div class=\"cntnt\"><img style=\"width:554px; height:416px;\" src=\"images/ONC/81204_Spinal_nerves_thoracic_vert.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81204 Version 3.0</div></div></div>"},"81205":{"type":"graphic_table","displayName":"Altered oral physiology","title":"Conditions and therapies that can affect the physiology of the oral cavity in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions and therapies that can affect the physiology of the oral cavity in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Physiologic modification of the oral cavity</td> <td class=\"subtitle1\">Dental management</td> </tr> <tr> <td>Asthma</td> <td>Medications implicated in increased caries rate</td> <td>Modification of sucrose-containing medication intake</td> </tr> <tr> <td>Platelet disorders</td> <td>Oral mucosal and gingival bleeding</td> <td>Maintenance of oral hygiene</td> </tr> <tr> <td>Hemophilia</td> <td>Oral and mucosal bleeding</td> <td>Maintenance of oral hygiene</td> </tr> <tr> <td>Cancer and its treatment</td> <td>Oral bleeding; oral infection; impaired healing</td> <td>Treat according to protocols that account for impaired hematopoietic system</td> </tr> <tr> <td>Seizure disorders</td> <td>Decreased salivary flow; gingival overgrowth (diphenylhydantoin)</td> <td>Maintenance of oral hygiene; surgical management of gingival conditions</td> </tr> <tr> <td>Organ transplantation</td> <td>Gingival overgrowth secondary to cyclosporine and calcium channel blockers</td> <td>Maintenance of oral hygiene; surgical management of gingival conditions</td> </tr> <tr> <td>Behavioral, emotional, and psychiatric disorders treated with CNS medications</td> <td>Decreased salivary flow</td> <td>Maintenance of oral hygiene; use of topical fluoride mouth rinses</td> </tr> <tr> <td>Chronic renal failure</td> <td>Uremic bone disease; impaired healing</td> <td>Maintenance of oral hygiene</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> <td>Increased caries from sucrose-containing medications</td> <td>Maintenance of oral hygiene; use of topical fluoride mouth rinses</td> </tr> <tr> <td>Bulimia</td> <td>Erosion of teeth</td> <td>Restoration of teeth; use of topical fluorides</td> </tr> <tr> <td>Gastrostomy</td> <td>Increased calculus formation</td> <td>Maintenance of oral hygiene; increased frequency of calculus removal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div class=\"graphic_reference\">Reproduced with permission from: Casamassimo PS. Pediatr Clin North Am 2000; 47:1149. Copyright © 2000 W.B. Saunders Co.</div><div id=\"graphicVersion\">Graphic 81205 Version 5.0</div></div></div>"},"81208":{"type":"graphic_picture","displayName":"DAPI transverse appendix","title":"DAPI stain of a transverse appendix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">DAPI stain of a transverse appendix</div><div class=\"cntnt\"><img style=\"width:300px; height:429px;\" src=\"images/GAST/81208_DAPI_transverse_appendix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">DAPI stain of a transverse appendix section taken at a magnification of x100. No leukocytes can be seen within the appendix confirming that the appendix is not inflamed. Bacteria are homogeneously distributed in the lumen of the appendix and clearly demarcated from the mucosa by a mucus layer.</div><div class=\"graphic_reference\">Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.</div><div id=\"graphicVersion\">Graphic 81208 Version 2.0</div></div></div>"},"81209":{"type":"graphic_table","displayName":"Meningitis treatment based on susceptibility","title":"Recommendations for specific antimicrobial therapy of bacterial meningitis based on isolated pathogen and susceptibility testing*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for specific antimicrobial therapy of bacterial meningitis based on isolated pathogen and susceptibility testing*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Microorganism, susceptibility</td> <td class=\"subtitle1\">Standard therapy</td> <td class=\"subtitle1\">Alternative therapies<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Penicillin MIC</td> </tr> <tr> <td class=\"sublist2\">&#8804;0.06 mcg/mL</td> <td class=\"sublist_other\">Penicillin G or ampicillin</td> <td class=\"sublist_other\">Third-generation cephalosporin<sup>&#916;</sup>, chloramphenicol</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">&#8805;0.12 mcg/mL</td> </tr> <tr> <td class=\"sublist3\">Third-generation cephalosporin<sup>&#916;</sup> MIC &#60;1 mcg/mL</td> <td class=\"sublist_other\">Third-generation cephalosporin<sup>&#916;</sup></td> <td class=\"sublist_other\">Cefepime, meropenem</td> </tr> <tr> <td class=\"sublist3\">Third-generation cephalosporin<sup>&#916;</sup> MIC &#8805;1 mcg/mL</td> <td class=\"sublist_other\">Vancomycin plus a third-generation cephalosporin<sup>&#916;</sup><sup>&#9674;</sup></td> <td class=\"sublist_other\">Fluoroquinolone<sup>&#167;</sup></td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><em>Neisseria meningitidis</em></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Penicillin MIC</td> </tr> <tr> <td class=\"sublist2\">&#60;0.1 mcg/mL</td> <td class=\"sublist_other\">Penicillin G or ampicillin</td> <td class=\"sublist_other\">Third-generation cephalosporin<sup>&#916;</sup>, chloramphenicol</td> </tr> <tr> <td class=\"sublist2\">0.1 to 1.0 mcg/mL</td> <td class=\"sublist_other\">Third-generation cephalosporin<sup>&#916;</sup></td> <td class=\"sublist_other\">Fluoroquinolone, meropenem, chloramphenicol</td> </tr> <tr> <td><em>Listeria monocytogenes</em></td> <td>Ampicillin<sup>&#165;</sup> or penicillin G<sup>&#165;</sup></td> <td>Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td><em>Streptococcus agalactiae </em>(group B <em>Streptococcus</em>)</td> <td>Ampicillin<sup>&#165;</sup> or penicillin G<sup>&#165;</sup></td> <td>Third-generation cephalosporin<sup>&#916;</sup></td> </tr> <tr> <td><em>Escherichia coli</em> and other Enterobacteriaceae<sup>&#135;</sup></td> <td>Third-generation cephalosporin<sup>&#916;</sup></td> <td>Aztreonam, fluoroquinolone, meropenem, trimethoprim-sulfamethoxazole, ampicillin</td> </tr> <tr> <td><em>Pseudomonas aeruginosa</em><sup>&#135;</sup></td> <td>Cefepime or ceftazidime</td> <td>Aztreonam, ciprofloxacin, meropenem</td> </tr> <tr> <td><em>Acinetobacter baumannii</em></td> <td>Meropenem</td> <td>Colistin (usually formulated as colistimethate sodium)<sup>&#134;</sup> or polymyxin B<sup>&#134;</sup></td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><em>Haemophilus influenzae</em></td> </tr> <tr> <td class=\"sublist1\">Beta-lactamase negative</td> <td class=\"sublist_other\">Ampicillin</td> <td class=\"sublist_other\">Third-generation cephalosporin<sup>&#916;</sup>, cefepime, fluoroquinolone, aztreonam, chloramphenicol</td> </tr> <tr> <td class=\"sublist1\">Beta-lactamase positive</td> <td class=\"sublist_other\">Third-generation cephalosporin<sup>&#916;</sup></td> <td class=\"sublist_other\">Cefepime, fluoroquinolone, aztreonam, chloramphenicol</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"sublist1\">Methicillin susceptible</td> <td class=\"sublist_other\">Nafcillin or oxacillin</td> <td class=\"sublist_other\">Vancomycin, meropenem, linezolid, daptomycin</td> </tr> <tr> <td class=\"sublist1\">Methicillin resistant</td> <td class=\"sublist_other\">Vancomycin**</td> <td class=\"sublist_other\">Trimethoprim-sulfamethoxazole, linezolid, daptomycin</td> </tr> <tr> <td><em>Staphylococcus epidermidis</em></td> <td>Vancomycin**</td> <td>Linezolid</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><em>Enterococcus</em> species</td> </tr> <tr> <td class=\"sublist1\">Ampicillin susceptible</td> <td class=\"sublist_other\">Ampicillin plus gentamicin</td> <td class=\"sublist_other\">...</td> </tr> <tr> <td class=\"sublist1\">Ampicillin resistant</td> <td class=\"sublist_other\">Vancomycin plus gentamicin</td> <td class=\"sublist_other\">...</td> </tr> <tr> <td class=\"sublist1\">Ampicillin and vancomycin resistant</td> <td class=\"sublist_other\">Linezolid</td> <td class=\"sublist_other\">...</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration.<br />* For recommended dosages, refer to the UpToDate&nbsp;table on the recommended intravenous doses of antimicrobial therapy for adults with bacterial meningitis.<br />¶ There may not be clinical data to support all recommendations for alternative antibiotics in patients with bacterial meningitis, but specific agents are recommended based on cerebrospinal fluid (CSF) penetration in experimental animal models and in vitro activity against the offending organism.<br />Δ Ceftriaxone or cefotaxime.<br /><FONT class=lozenge>◊</FONT> Consider addition of rifampin if the MIC of ceftriaxone is &gt;2 mcg/mL.<br />§ Moxifloxacin is recommended given its excellent CSF penetration and in vitro activity against <EM>Streptococcus pneumoniae</EM>, although there are no clinical data available. If used, many authorities would combine moxifloxacin with vancomycin or a third-generation cephalosporin (cefotaxime or ceftriaxone).<br />¥ Addition of an aminoglycoside should be considered.<br />‡ Choice of a specific antimicrobial regimen must be guided by in vitro susceptibility test results.<br />† Should be administered not only by the intravenous route but also by the intraventricular or intrathecal route.<br />** Consider addition of rifampin.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in the treatment of bacterial meningitis. Lancet 2012; 380:1693.</LI></OL>Modified with permission from: Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright © 2004 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 81209 Version 16.0</div></div></div>"},"81210":{"type":"graphic_table","displayName":"Hachinski ischemic score","title":"Hachinski ischemic score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hachinski ischemic score</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Value</td> </tr> <tr> <td>Abrupt onset</td> <td class=\"centered\">2</td> </tr> <tr> <td>Stepwise deterioration</td> <td class=\"centered\">1</td> </tr> <tr> <td>Fluctuating course</td> <td class=\"centered\">2</td> </tr> <tr> <td>Nocturnal confusion</td> <td class=\"centered\">1</td> </tr> <tr> <td>Preservation of personality</td> <td class=\"centered\">1</td> </tr> <tr> <td>Depression</td> <td class=\"centered\">1</td> </tr> <tr> <td>Somatic complaints</td> <td class=\"centered\">1</td> </tr> <tr> <td>Emotional incontinence</td> <td class=\"centered\">1</td> </tr> <tr> <td>Hypertension</td> <td class=\"centered\">1</td> </tr> <tr> <td>History of stroke</td> <td class=\"centered\">2</td> </tr> <tr> <td>Associated atherosclerosis</td> <td class=\"centered\">1</td> </tr> <tr> <td>Focal neurologic symptoms</td> <td class=\"centered\">2</td> </tr> <tr> <td>Focal neurologic signs</td> <td class=\"centered\">2</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A high score (&ge;7) suggests vascular dementia, while a low score (&le;4) suggests Alzheimer disease.</div><div id=\"graphicVersion\">Graphic 81210 Version 4.0</div></div></div>"},"81214":{"type":"graphic_figure","displayName":"Pelvic ring fracture classification","title":"Young and Burgess classification for pelvic ring fractures","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Young and Burgess classification for pelvic ring fractures</div><div class=\"cntnt\"><img style=\"width:526px; height:408px;\" src=\"images/EM/81214_Pelvic_ring_fx_scheme.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The red arrows illustrate the force direction. (A) Lateral compression injuries with subsequent bilateral involvement as forces increase; (B) Anteroposterior injuries with progression of injury; (C) Vertical shear injury.</div><div class=\"graphic_reference\">Reproduced with permission from: Burgess AR, Eastridge BJ, Young JW, et al. Pelvic ring disruptions: effective classification system and treatment protocols. J Trauma 1990; 30:848. Copyright © 1990 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81214 Version 12.0</div></div></div>"},"81216":{"type":"graphic_figure","displayName":"Hemoglobin oxygen dissociation curve","title":"Oxyhemoglobin dissociation curve","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Oxyhemoglobin dissociation curve</div><div class=\"cntnt\"><img style=\"width:492px; height:488px;\" src=\"images/HEME/81216_Hb_oxygen_dissociation_curv.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depicted here is the oxyhemoglobin dissociation curve for normal adult hemoglobin (hemoglobin A, solid line). Note that at a partial pressure of oxygen&nbsp;of 27 mmHg on the X axis,&nbsp;hemoglobin is 50 percent&nbsp;saturated with oxygen (the P50 is 27 mmHg), and&nbsp;at an arterial partial pressure&nbsp;of oxygen of 100 mmHg, hemoglobin is 100&nbsp;percent&nbsp;saturated. At the typical mixed venous oxygen tension of approximately 40 mmHg, the oxygen saturation of hemoglobin is approximately 75 percent. Shifting the curve to the right (red line) can reduce oxygen&nbsp;saturation to 50 to 60 percent&nbsp;for the partial oxygen pressure of 40 mmHg, meaning&nbsp;that less oxygen is bound to hemoglobin and more oxygen is delivered to the tissues. The opposite occurs with left shifts (blue line). A high proportion of fetal hemoglobin, which has high oxygen affinity, shifts this curve to the left in newborns. The effect of right- or left-shifting of the curve is most pronounced at low partial pressures of oxygen. <br /></div><div id=\"graphicVersion\">Graphic 81216 Version 8.0</div></div></div>"},"81217":{"type":"graphic_table","displayName":"Differential diagnosis of osmolal gap","title":"Differential diagnosis of an elevated plasma/serum osmolal gap","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of an elevated plasma/serum osmolal gap</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">With anion gap metabolic acidosis</td> </tr> <tr> <td class=\"subtitle2_single\">Major causes of a large osmolal gap</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Ethylene glycol ingestion </li> <li>Methanol ingestion </li> <li>Propylene glycol infusion </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Causes of a smaller osmolal gap</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Severe chronic kidney disease without regular dialysis </li> <li>Ketoacidosis (diabetic or alcoholic) </li> <li>Lactic acidosis </li> <li>Paraldehyde ingestion or injection </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Without anion gap metabolic acidosis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Ethanol </li> <li>Isopropanol </li> <li>Diethyl ether </li> <li>Infusion of mannitol, sorbitol, or glycine </li> <li>Pseudohyponatremia (severe hyperlipidemia or hyperproteinemia) </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81217 Version 2.0</div></div></div>"},"81218":{"type":"graphic_table","displayName":"Cataract classification","title":"Classification of cataracts in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of cataracts in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Anterior polar</td> <td>Anterior poles; usually bilateral</td> <td>Often hereditary</td> </tr> <tr> <td>Persistent fetal vasculature</td> <td>Posterior; unilateral</td> <td>Associated with microphthalmia and glaucoma</td> </tr> <tr> <td rowspan=\"2\">Posterior polar</td> <td>Unilateral posterior pole (Mittendorf dot)</td> <td>&nbsp;</td> </tr> <tr> <td>Bilateral posterior pole</td> <td>May be associated with defects in the posterior capsule</td> </tr> <tr> <td>Posterior lentiglobus/lenticonus</td> <td>Posterior capsule; mainly unilateral</td> <td>Usually sporadic</td> </tr> <tr> <td>Posterior subcapsular</td> <td>Immediately anterior to posterior capsule</td> <td>Associated with inflammatory conditions, glucocorticoids use, ionizing radiation</td> </tr> <tr> <td>Total (diffuse, complete)</td> <td>Involve entire crystalline lens</td> <td>Usually seen after trauma</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Zonular cataracts</td> </tr> <tr> <td class=\"sublist1\">Lamellar</td> <td class=\"sublist_other\">Layer of cortex peripheral to the Y sutures of the lens; usually bilateral</td> <td class=\"sublist_other\">May be hereditary (autosomal dominant) or acquired</td> </tr> <tr> <td class=\"sublist1\">Nuclear</td> <td class=\"sublist_other\">Embryonal or fetal nucleus; unilateral or blateral</td> <td class=\"sublist_other\">Microphthalmia and microcornia are usually present</td> </tr> <tr> <td class=\"sublist1\">Sutural</td> <td class=\"sublist_other\">Y sutures</td> <td class=\"sublist_other\">&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81218 Version 2.0</div></div></div>"},"81219":{"type":"graphic_figure","displayName":"Etiology peripheral neuropathy","title":"Etiology of peripheral neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Etiology of peripheral neuropathy</div><div class=\"cntnt\"><img style=\"width:423px; height:318px;\" src=\"images/PEDS/81219_Etiology_peripheral_neuropa.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A comparison of the different causes of peripheral neuropathy in adults and children is depicted above.</div><div id=\"graphicVersion\">Graphic 81219 Version 1.0</div></div></div>"},"81221":{"type":"graphic_picture","displayName":"Pilomatricoma 1","title":"Pilomatricoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pilomatricoma</div><div class=\"cntnt\"><img style=\"width:432px; height:363px;\" src=\"images/DERM/81221_Pilomatricoma_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A firm blue-gray papule is present on the cheek of this 12-year-old girl.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 81221 Version 6.0</div></div></div>"},"81223":{"type":"graphic_figure","displayName":"Insertion of ring pessary","title":"Insertion of the ring vaginal pessary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insertion of the ring vaginal pessary</div><div class=\"cntnt\"><img style=\"width:350px; height:320px;\" src=\"images/OBGYN/81223_Insertion_of_ring_pessary.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Milex Products, Inc., Chicago, IL.</div><div id=\"graphicVersion\">Graphic 81223 Version 2.0</div></div></div>"},"81226":{"type":"graphic_picture","displayName":"Paget disease of the breast histology","title":"Paget disease of the breast histology","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paget disease of the breast histology</div><div class=\"cntnt\"><img style=\"width:504px; height:350px;\" src=\"images/ONC/81226_Paget_disease_breast_Light2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrograph of a hematoxylin and eosin-stained section of Paget disease of the nipple. The tumor cells, which are dispersed singly and in clusters within the epidermis, are characterized by abundant pale cytoplasm and large nuclei with variably prominent nucleoli.</div><div class=\"graphic_reference\">Courtesy of Donald L Weaver, MD.</div><div id=\"graphicVersion\">Graphic 81226 Version 4.0</div></div></div>"},"81227":{"type":"graphic_table","displayName":"Parinaud syndrome","title":"Ophthalmic findings in the Parinaud syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ophthalmic findings in the Parinaud syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Vertical gaze abnormalities, especially upgaze</td> </tr> <tr> <td>Downward gaze preference or tonic downward deviation of the eyes (\"setting-sun sign\")</td> </tr> <tr> <td>Primary position upbeat or downbeat nystagmus</td> </tr> <tr> <td>Impaired convergence and divergence</td> </tr> <tr> <td>Excessive convergence tone</td> </tr> <tr> <td>Convergence-retraction nystagmus</td> </tr> <tr> <td>Skew deviation, often with the higher eye on the side of the lesion</td> </tr> <tr> <td>Alternating adduction hypertropia or alternating adduction hypotropia</td> </tr> <tr> <td>Bilateral upper eyelid retraction (Collier \"tucked-lid\" sign)</td> </tr> <tr> <td>Bilateral ptosis</td> </tr> <tr> <td>Pupillary abnormalities (large with light-near dissociation)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Lee AG, Brazis PW. Clinical Pathways in Neuro-ophthalmology: An Evidence-based Approach, Thieme, New York 1998.</div><div id=\"graphicVersion\">Graphic 81227 Version 4.0</div></div></div>"},"81230":{"type":"graphic_picture","displayName":"Hysteroscopic view3","title":"Hysteroscopic view of complex atypical hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic view of complex atypical hyperplasia</div><div class=\"cntnt\"><img style=\"width:383px; height:268px;\" src=\"images/OBGYN/81230_Hysteroscopic_view3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysteroscopic view of complex atypical hyperplasia along the right lateral wall of the uterus while the left side is without significant tissue.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 81230 Version 2.0</div></div></div>"},"81231":{"type":"graphic_table","displayName":"BFM regimen","title":"Children's Cancer Group treatment schema for Pediatric Acute Lymphoblastic Leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Children's Cancer Group treatment schema for Pediatric Acute Lymphoblastic Leukemia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Standard therapy (CCG-BFM)</td> </tr> <tr> <td class=\"subtitle2_left\">Treatment</td> <td class=\"subtitle2_left\">Dose</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Consolidation phase (5 weeks)</td> </tr> <tr> <td class=\"indent2\">Prednisone</td> <td>7.5 mg/m<sup>2</sup>, day 0; 3.75 mg/m<sup>2</sup>, days 1, 2</td> </tr> <tr> <td class=\"indent2\">Cyclophosphamide</td> <td>1000 mg/m<sup>2</sup> IV, days 0, 14</td> </tr> <tr> <td class=\"indent2\">Mercaptopurine</td> <td>60 mg/m<sup>2</sup> orally, days 0-27</td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> IV, days 14, 21, 42, 49</td> </tr> <tr> <td class=\"indent2\">Cytarabine</td> <td>75 mg/m<sup>2</sup> IV, days 1-4, 8-11, 15-18, 22-25</td> </tr> <tr> <td class=\"indent2\">Intrathecal methotrexate*</td> <td>12 mg, days 1, 8, 15, 22</td> </tr> <tr> <td class=\"indent2\">Radiotherapy<sup>&#182;</sup></td> <td>Cranial, 1800 cGy; cranial, 2400 cGy, and spinal, 600 cGy</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Interim maintenance phase (8 weeks)</td> </tr> <tr> <td class=\"indent2\">Mercaptopurine</td> <td>60 mg/m<sup>2</sup> orally, days 0-41</td> </tr> <tr> <td class=\"indent2\">Methotrexate</td> <td>15 mg/m<sup>2</sup> orally, days 0, 7, 14, 21, 28, 35</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Delayed intensification phase (7 weeks)</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"2\">Reinduction phase (4 weeks)</td> </tr> <tr> <td class=\"sublist3\">Dexamethasone</td> <td class=\"sublist_other\">10 mg/m<sup>2</sup> orally, days 0-20, then taper for 7 days</td> </tr> <tr> <td class=\"sublist3\">Vincristine</td> <td class=\"sublist_other\">1.5 mg/m<sup>2</sup> IV, days 0,14, 21</td> </tr> <tr> <td class=\"sublist3\">Doxorubicin</td> <td class=\"sublist_other\">25 mg/m<sup>2</sup> IV, days 0, 7, 14</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"2\">Reconsolidation phase (3 weeks)</td> </tr> <tr> <td class=\"sublist3\">Asparaginase</td> <td class=\"sublist_other\">6000 units/m<sup>2</sup> IM, days 3, 5, 7, 10, 12, 14</td> </tr> <tr> <td class=\"sublist3\">Vincristine</td> <td class=\"sublist_other\">1.5 mg/m<sup>2</sup> IV, days 42, 29</td> </tr> <tr> <td class=\"sublist3\">Cyclophosphamide</td> <td class=\"sublist_other\">1000 mg/m<sup>2</sup> IV, days 28</td> </tr> <tr> <td class=\"sublist3\">Thioguanine</td> <td class=\"sublist_other\">60 mg/m<sup>2</sup> orally, days 28-41</td> </tr> <tr> <td class=\"sublist3\">Cytarabine</td> <td class=\"sublist_other\">75 mg/m<sup>2</sup> SC or IV, days 29-32, 36-39</td> </tr> <tr> <td class=\"sublist3\">Intrathecal methotrexate*</td> <td class=\"sublist_other\">12 mg, days 29, 36</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Long-term maintenance phase (12 weeks)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> IV, days 0, 28, 56</td> </tr> <tr> <td class=\"indent2\">Prednisone</td> <td>40 mg/m<sup>2</sup> orally, days 0-4, 28-32, 56-60</td> </tr> <tr> <td class=\"indent2\">Mercaptopurine</td> <td>75 mg/m<sup>2</sup> orally, days 0-83</td> </tr> <tr> <td class=\"indent2\">Methotrexate</td> <td>20 mg/m<sup>2</sup> orally, days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77</td> </tr> <tr> <td class=\"indent2\">Intrathecal methotrexate*</td> <td>12 mg, day 0</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Augmented BFM therapy</td> </tr> <tr> <td class=\"subtitle2_left\">Treatment</td> <td class=\"subtitle2_left\">Dose</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Consolidation phase (9 weeks)</td> </tr> <tr> <td class=\"indent2\">Cyclophosphamide</td> <td>1000 mg/m<sup>2</sup> IV, days 0, 28</td> </tr> <tr> <td class=\"indent2\">Cytarabine</td> <td>75 mg/m<sup>2</sup> SC or IV, days 1-4, 8-11, 29-32, 36-39</td> </tr> <tr> <td class=\"indent2\">Mercaptopurine</td> <td>60 mg/m<sup>2</sup> orally, days 0-13, 28-41</td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> IV, days 14, 21, 42, 49</td> </tr> <tr> <td class=\"indent2\">Asparaginase</td> <td>6000 units/m<sup>2</sup> IM, days 14,16, 18, 21, 23, 25, 42, 44, 46, 49, 51, 53</td> </tr> <tr> <td class=\"indent2\">Intrathecal methotrexate*</td> <td>12 mg, days 1, 8, 15, 22</td> </tr> <tr> <td class=\"indent2\">Radiotherapy<sup>&#182;</sup></td> <td>Cranial, 1800 cGy; cranial, 2400 cGy, and spinal, 600 cGy; testicular, 2400 cGy</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Interim maintenance phase (8 weeks)</td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> IV, days 0, 10, 20, 30, 40</td> </tr> <tr> <td class=\"indent2\">Methotrexate</td> <td>100 mg/mg<sup>2</sup> IV, days 0, 10, 20, 30, 40 (escalate by 50 mg/m<sup>2</sup> per dose)</td> </tr> <tr> <td class=\"indent2\">Asparaginase</td> <td>15,000 units/m<sup>2</sup> IM, days 1, 11, 21, 31, 41</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Delayed intensification I phase (8 weeks)</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"2\">Reinduction phase (4 weeks)</td> </tr> <tr> <td class=\"sublist3\">Dexamethasone</td> <td class=\"sublist_other\">10 mg/m<sup>2</sup> orally, days 0-20, then taper for 7 days</td> </tr> <tr> <td class=\"sublist3\">Vincristine</td> <td class=\"sublist_other\">1.5 mg/m<sup>2</sup> IV, days 0, 14, 21</td> </tr> <tr> <td class=\"sublist3\">Doxorubicin</td> <td class=\"sublist_other\">25 mg/m<sup>2</sup> IV, days 0, 7, 14</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"2\">Reconsolidation phase (4 weeks)</td> </tr> <tr> <td class=\"sublist3\">Asparaginase</td> <td class=\"sublist_other\">6000 units/m<sup>2</sup> IM, days 3, 5, 7, 10, 12, 14</td> </tr> <tr> <td class=\"sublist3\">Vincristine</td> <td class=\"sublist_other\">1.5 mg/m<sup>2</sup> IV, days 42, 49</td> </tr> <tr> <td class=\"sublist3\">Cyclophosphamide</td> <td class=\"sublist_other\">1000 mg/m<sup>2</sup> IV, day 28</td> </tr> <tr> <td class=\"sublist3\">Thioguanine</td> <td class=\"sublist_other\">60 mg/m<sup>2</sup> orally, days 28-41</td> </tr> <tr> <td class=\"sublist3\">Cytarabine</td> <td class=\"sublist_other\">75 mg/m<sup>2&nbsp;</sup>per day&nbsp;SC or IV, days 29-32, 36-39</td> </tr> <tr> <td class=\"sublist3\">Intrathecal methotrexate*</td> <td class=\"sublist_other\">12 mg, days 29, 36</td> </tr> <tr> <td class=\"sublist3\">Asparaginase</td> <td class=\"sublist_other\">6000 units/m<sup>2</sup> IV, days 42, 44, 46, 49, 51, 53</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Interim maintenance II phase (8 weeks)</td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> IV, days 0, 10, 20, 30, 40</td> </tr> <tr> <td class=\"indent2\">Methotrexate</td> <td>100 mg/m<sup>2</sup> IV, days 0, 10, 20, 30, 40 (escalate by 50 mg/m<sup>2</sup> per dose)</td> </tr> <tr> <td class=\"indent2\">Asparaginase</td> <td>15,000 units/m<sup>2</sup> IM, days 1, 11, 21, 31, 41</td> </tr> <tr> <td class=\"indent2\">Intrathecal methotrexate*</td> <td>12 mg, days 0, 20, 40</td> </tr> <tr> <td class=\"subtitle3_left\">Delayed intensification II phase (8 wk)</td> <td>Same as for delayed intensification I phase</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Long-term maintenance phase (12 weeks)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> IV, days 0, 28, 56</td> </tr> <tr> <td class=\"indent2\">Prednisone</td> <td>60 mg/m<sup>2</sup> orally, days 0-14, 28-32, 56-60</td> </tr> <tr> <td class=\"indent2\">Mercaptopurine</td> <td>75 mg/m<sup>2</sup> orally, days 0-83</td> </tr> <tr> <td class=\"indent2\">Methotrexate</td> <td>20 mg/m<sup>2</sup> orally, days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77</td> </tr> <tr> <td class=\"indent2\">Intrathecal methotrexate*</td> <td>12 mg, day 0</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Induction was as follows: vincristine, 1.5 mg/m<sup>2</sup> per week for 4 weeks; daunomycin, 25 mg/m<sup>2</sup> per week for 4 weeks; prednisone, 60 mg/m<sup>2</sup> per day for 28 days; asparaginase, 6000 units/m<sup>2</sup> IM 3 times a week for 9 doses; intrathecal cytarabine on day 0; and intrathecal methotrexate on day 14.</div><div class=\"graphic_footnotes\">IM: intramuscular, SC: subcutaneous, IV: intravenous.<br />* Patients with CNS disease at diagnosis did not receive intrathecal methotrexate on days 15 and 22 of consolidation therapy.<br />¶ During the first 2 weeks of consolidation therapy, patients without CNS disease at diagnosis received 1800 cGy of cranial radiotherapy in 10 fractions; patients with CNS disease at diagnosis received 2400 cGy to the cranial midplane in 12 fractions and 600 cGy to the spinal cord in 3 fractions. In the augmented therapy group, patients with testicular enlargement at diagnosis received 2400 cGy bilateral testicular radiation in 8 fractions.<br />Δ The cycles of maintenance therapy were repeated until the total duration of therapy, beginning with the first interim maintenance period, reached 2 years for girls and 3 years for boys.</div><div class=\"graphic_reference\">This research was originally published in Blood. Stock, W, La, M, Sanford, B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112:1646. Copyright &copy;2008 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 81231 Version 4.0</div></div></div>"},"81233":{"type":"graphic_picture","displayName":"HS Crohns1","title":"Crohn's disease mimicking hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn's disease mimicking hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:287px; height:432px;\" src=\"images/OBGYN/81233_HS_Crohns1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&#160;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 81233 Version 2.0</div></div></div>"},"81234":{"type":"graphic_diagnosticimage","displayName":"Fetal limb body wall complex","title":"Fetal limb-body wall complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal limb-body wall complex</div><div class=\"cntnt\"><img style=\"width:380px; height:269px;\" src=\"images/OBGYN/81234_Limb_body_wall_complex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow points to herniated abdominal contents/umbilical cord extending beyond amniotic membrane. Arrowhead points to measurement of nuchal translucency.</div><div class=\"graphic_reference\">Courtesy of Wendy Shaffer, RDMS and Joshua A. Copel, MD, Yale University School of Medicine.</div><div id=\"graphicVersion\">Graphic 81234 Version 4.0</div></div></div>"},"81236":{"type":"graphic_diagnosticimage","displayName":"Early asbestosis CXR","title":"Early asbestosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early asbestosis</div><div class=\"cntnt\"><img style=\"width:373px; height:349px;\" src=\"images/PULM/81236_Early_asbestosis_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows irregular opacities in lower lung fields that may be categorized as 0/1 or approaching 1/0 according to the ILO classification. Note pleural changes.</div><div class=\"graphic_footnotes\">The International Labor Organization (ILO) classification defines chest radiographs that are suggestive but not presumptively diagnostic as 0/1 and those that are presumptively diagnostic but not unequivocal as 1/0.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org</div><div id=\"graphicVersion\">Graphic 81236 Version 2.0</div></div></div>"},"81237":{"type":"graphic_algorithm","displayName":"Otorrhea inflammation","title":"Otorrhea with external auditory canal inflammation","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Otorrhea with external auditory canal inflammation</div><div class=\"cntnt\"><img style=\"width:522px; height:438px;\" src=\"images/EM/81237_Otorrhea_inflammation.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TM: tympanic membrane.<br>* Reexamine the ear after foreign body removal to ensure no tympanic membrane perforation or concurrent ear disease.<br>&#8226; Concurrent tympanostomy tube drainage or acute otitis media may be present.<br>&#916; Often thin brown otorrhea with pruritis.</div><div id=\"graphicVersion\">Graphic 81237 Version 1.0</div></div></div>"},"81240":{"type":"graphic_diagnosticimage","displayName":"Abdominal endograft limb thrombosis","title":"Abdominal endograft limb thrombosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdominal endograft limb thrombosis</div><div class=\"cntnt\"><img style=\"width:251px; height:338px;\" src=\"images/CARD/81240_Endograft_thrombosis_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The contrast angiogram shows absence of filling of the left limb of bifurcated endograft due to thrombosis (red arrow).</div><div id=\"graphicVersion\">Graphic 81240 Version 3.0</div></div></div>"},"81241":{"type":"graphic_picture","displayName":"Exstrophy Bryants traction","title":"Postoperative use of  Bryant's traction in patient with bladder exstrophy","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Postoperative use of  Bryant's traction in patient with bladder exstrophy</div><div class=\"cntnt\"><img style=\"width:501px; height:372px;\" src=\"images/PEDS/81241_Exstrophy_Bryants_traction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Newborn stabilized in modified Bryant's traction following complete primary repair of bladder exstrophy.</div><div class=\"graphic_reference\">Courtesy of Joseph Borer, MD.</div><div id=\"graphicVersion\">Graphic 81241 Version 5.0</div></div></div>"},"81242":{"type":"graphic_table","displayName":"Herbal causes hyperkalemia","title":"Herbal remedies associated with increased risk of hyperkalemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Herbal remedies associated with increased risk of hyperkalemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Noni juice (derived from the fruit of the noni tree, Morinda citrifolia)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Alfalfa (Medicago sativa)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dandelion (Taraxacum officinale)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Horsetail (Equisetum arvense)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nettle (Urtica dioica)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chan su (herb marketed as a topical aphrodisiac)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Milkweed (Asclepias species)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lily of the valley (Convallaria majalis)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Siberian ginseng (Eleutherococcus senticosus)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hawthorn berry (Crataegus species)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585.</div><div id=\"graphicVersion\">Graphic 81242 Version 2.0</div></div></div>"},"81244":{"type":"graphic_diagnosticimage","displayName":"Corkscrew esophagus barium swallow","title":"Corkscrew esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corkscrew esophagus</div><div class=\"cntnt\"><img style=\"width:202px; height:314px;\" src=\"images/GAST/81244_Corkscrew_esophagus_Ba_swal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Esophagram performed in a 72-year-old man with intractable retrosternal pain and reflux shows marked spasm throughout the length of the esophagus, which produces a corkscrew-like appearance.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 81244 Version 5.0</div></div></div>"},"81245":{"type":"graphic_picture","displayName":"Gingival infiltration in KS","title":"Gingival infiltration in Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingival infiltration in Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:360px; height:243px;\" src=\"images/ID/81245_Gingival_infiltration_in_KS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gingiva appears purple with infiltration. Disfiguing nodular KS lesions are also present on the adjoining area of the hard palate.</div><div class=\"graphic_reference\">Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds), Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 81245 Version 5.0</div></div></div>"},"81248":{"type":"graphic_figure","displayName":"Peritoneum colon rectum","title":"Idealized representation of the peritoneal and mesenteric relationships at various levels of the colon and rectum","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Idealized representation of the peritoneal and mesenteric relationships at various levels of the colon and rectum</div><div class=\"cntnt\"><img style=\"width:542px; height:494px;\" src=\"images/ONC/81248_Peritoneum_colon_rectum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both the transverse and sigmoid colon are located intraperitoneally; at these levels, the visceral peritoneum forms a complete covering over the exterior of the bowel (the serosa), which is continuous with the mesentery (transverse and sigmoid mesocolon). In contrast, the ascending and descending colon lie within the lateral peritoneal cavity with their posterior and lateral surfaces in the retroperitoneum. At these levels, the visceral peritoneum is only present anteriorly and medially; there is no true mesentery, since the developing mesentery has fused to the posterior parietal peritoneum. The upper portion of the rectum lies above the peritoneal reflection. The anterior surface is covered by peritoneum (which forms the rectovesical pouch in men and the rectouterine pouch in women); there is no serosa over its posterior surface. The lower rectum lies beneath the peritoneum and has no serosal layer.</div><div id=\"graphicVersion\">Graphic 81248 Version 3.0</div></div></div>"},"81249":{"type":"graphic_figure","displayName":"Pruzansky classification of mandibular abnormalities","title":"Pruzansky classification of mandibular abnormalities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pruzansky classification of mandibular abnormalities</div><div class=\"cntnt\"><img style=\"width:369px; height:367px;\" src=\"images/PEDS/81249_Pruzansky_mandible_classifi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type I: Mild ramus hypoplasia with body minimally affected. Type II: Small condylar head and ramus, flat infratemporal surface, flat condyle, absent glenoid, and coronoid may be absent. Type III: Ramus thin lamina or absent. No TMJ.</div><div class=\"graphic_footnotes\">TMJ: Temporomandibular joint.</div><div id=\"graphicVersion\">Graphic 81249 Version 3.0</div></div></div>"},"81250":{"type":"graphic_algorithm","displayName":"Goals of therapy in ICU","title":"Goals of therapy in ICU","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Goals of therapy in ICU</div><div class=\"cntnt\"><img style=\"width:521px; height:411px;\" src=\"images/PULM/81250_Goals_of_therapy_in_ICU.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81250 Version 3.0</div></div></div>"},"81251":{"type":"graphic_picture","displayName":"Malleable penile prosthesis","title":"Malleable penile prosthesis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Malleable penile prosthesis</div><div class=\"cntnt\"><img style=\"width:504px; height:501px;\" src=\"images/ENDO/81251_Malleable_penile_prosthesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of American Medical Systems, Inc. Minnetonka, Minnesota (www.AmericanMedicalSystems.com).</div><div id=\"graphicVersion\">Graphic 81251 Version 6.0</div></div></div>"},"81252":{"type":"graphic_algorithm","displayName":"Approach allergic rxs vaccines","title":"Suggested approach to suspected anaphylaxis to a vaccine","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Suggested approach to suspected anaphylaxis to a vaccine</div><div class=\"cntnt\"><img style=\"width:566px; height:656px;\" src=\"images/ALLRG/81252_Appr_allergic_rxs_vac.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; IgG: immunoglobulin G.</div><div class=\"graphic_reference\">Original figure modified for this publication. Kelso JM, Li JT. Practice Parameters: Adverse reactions to vaccines. Ann Allergy Asthma Immunol 2009; 103(4 Suppl 2):1-14. Copyright &copy; 2009 American College of Allergy, Asthma and Immunology.</div><div id=\"graphicVersion\">Graphic 81252 Version 11.0</div></div></div>"},"81253":{"type":"graphic_diagnosticimage","displayName":"Pneumatosis intestinalis of the colon on plain film","title":"Pneumatosis intestinalis of the colon on plain film","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumatosis intestinalis of the colon on plain film</div><div class=\"cntnt\"><img style=\"width:225px; height:288px;\" src=\"images/GAST/81253_Pneumatosis_ischemic_bowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A plain film of the abdomen demonstrates air within the wall of the ascending colon (arrow). This can be seen in ischemic bowel but may also occur after colonoscopy or surgical anastomoses and in patients taking corticosteroids or with HIV infection.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 81253 Version 5.0</div></div></div>"},"81255":{"type":"graphic_picture","displayName":"Liver mets colon cancer Gross","title":"Metastatic colon cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic colon cancer</div><div class=\"cntnt\"><img style=\"width:358px; height:286px;\" src=\"images/GAST/81255_Liver_mets_colon_cancer_Gro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple liver metastases seen during laparotomy in a patient with colon cancer.</div><div class=\"graphic_reference\">Courtesy of Richard B Freeman, Jr, MD.</div><div id=\"graphicVersion\">Graphic 81255 Version 1.0</div></div></div>"},"81256":{"type":"graphic_figure","displayName":"Distribution of AFP with NTDs","title":"Distribution of maternal serum alpha-fetoprotein (AFP)","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Distribution of maternal serum alpha-fetoprotein (AFP)</div><div class=\"cntnt\"><img style=\"width:461px; height:350px;\" src=\"images/OBGYN/81256_Distribution_of_AFP_with_NT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AFP levels (corrected for maternal weight) in pregnancies with open spina bifida and pregnancies without NTDs (unaffected) at 16 weeks of gestation with gestational age estimated by dates (from first day of LMP) and by ultrasound imaging (fetal BPD).&nbsp;MoM&nbsp;for unaffected pregnancies of the same gestational age.</div><div class=\"graphic_footnotes\">LMP:&nbsp;last menstrual period; BPD: biparietal diameter; AFP: alpha-fetoprotein; MoM: multiples of the median; NTD: neural tube defect.</div><div class=\"graphic_reference\">Data from: Ward N, Kennard A. Prenatal screening for neutral tube defects and down syndrome. In: Principles and Practice of Medical Genetics, 3rd ed, Rimoin DC (Ed), Churchill Livington Inc, New York 1997. p. 548.</div><div id=\"graphicVersion\">Graphic 81256 Version 6.0</div></div></div>"},"81257":{"type":"graphic_table","displayName":"Interpretation of reflex test results in pts with R117T mutation","title":"Interpretation of reflex test results after identification of a R117T mutation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of reflex test results after identification of a R117T mutation</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>R117H + 5T on one chromosome plus &#916;F508 on the other chromosome</td>\r\n  \r\n   <td>Classic cystic fibrosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Other combinations and male fetus</td>\r\n  \r\n   <td>CBAVD only</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   R117H + &#916;F508 on opposite chromosomes\r\n  \r\n   </td>\r\n  \r\n   <td>CBAVD</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   R117H + 5T on opposite chromosomes\r\n  \r\n   </td>\r\n  \r\n   <td>CBAVD</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   R117H + 7T on opposite chromosomes\r\n  \r\n   </td>\r\n  \r\n   <td>CBAVD</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   5T/5T homozygosity (5T on each chromosome)\r\n  \r\n   </td>\r\n  \r\n   <td>CBAVD</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=43252&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Interpretation_reflex_test.htm</title></head></div><div class=\"graphic_footnotes\">CBAVD: congenital bilateral absence of the vas deferens.</div><div id=\"graphicVersion\">Graphic 81257 Version 2.0</div></div></div>"},"81259":{"type":"graphic_picture","displayName":"Corneal pannus","title":"Corneal pannus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal pannus</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/PC/81259_Pannus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An area of corneal pannus with superficial blood vessel growth onto the inferior cornea at the&nbsp;five o'clock position.</div><div id=\"graphicVersion\">Graphic 81259 Version 4.0</div></div></div>"},"81260":{"type":"graphic_picture","displayName":"Seborrheic keratosis 2","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:400px; height:362px;\" src=\"images/DERM/81260_Seborrheic_keratosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lesion has a warty, tortoise shell-like, &quot;stuck on&quot; appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81260 Version 2.0</div></div></div>"},"81261":{"type":"graphic_figure","displayName":"HEV serologic course","title":"Hepatitis E virus (HEV) infection typical serologic course","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Hepatitis E virus (HEV) infection typical serologic course</div><div class=\"cntnt\"><img style=\"width:534px; height:319px;\" src=\"images/GAST/81261_HEV_serologic_course.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; IgG: immunoglobulin G.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. <A style=\"FONT-STYLE: italic\" href=\"http://www.cdc.gov/hepatitis/index.htm\" target=_blank>www.cdc.gov/hepatitis/index.htm</A></div><div id=\"graphicVersion\">Graphic 81261 Version 2.0</div></div></div>"},"81264":{"type":"graphic_picture","displayName":"Pontine infarct from basilar artery disease","title":"Myelin stain of the pons at necropsy after stroke due to basilar artery occlusive disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Myelin stain of the pons at necropsy after stroke due to basilar artery occlusive disease</div><div class=\"cntnt\"><img style=\"width:504px; height:342px;\" src=\"images/NEURO/81264_BA_related_pontine_infarct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large infarct (shown in white) involves the bilateral basis pontis and extends into the ventral portion of the pontine tegmentum.</div><div class=\"graphic_reference\">Reproduced with permission from: Caplan LR. Posterior circulation disease. Clinical findings, diagnosis, and management. Blackwell Science, Boston 1996. Copyright &copy; 1996 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 81264 Version 5.0</div></div></div>"},"81266":{"type":"graphic_table","displayName":"Cancer tests for back pain","title":"Diagnostic tests for cancer as cause of low back pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic tests for cancer as cause of low back pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Erythrocyte sedimentation rate</td> </tr> <tr> <td class=\"sublist1\">&#8805;20 mm/hour</td> <td class=\"sublist_other\">0.78</td> <td class=\"sublist_other\">0.67</td> </tr> <tr> <td class=\"sublist1\">&#8805;50 mm/hour</td> <td class=\"sublist_other\">0.56</td> <td class=\"sublist_other\">0.97</td> </tr> <tr> <td class=\"sublist1\">&#8805;100 mm/hour</td> <td class=\"sublist_other\">0.22</td> <td class=\"sublist_other\">0.996</td> </tr> <tr> <td>Anemia (hematocrit &#60;40 percent for men or &#60;38 percent for women)</td> <td>0.54</td> <td>0.86</td> </tr> <tr> <td>Hematocrit &#60;30</td> <td>0.09</td> <td>0.994</td> </tr> <tr> <td>White blood cell count&nbsp;&#8805;12,000</td> <td>0.22</td> <td>0.94</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WBC: White blood cell count.</div><div class=\"graphic_reference\">Data from: Deyo, RA, Diehl, AK. Cancer as a cause of back pain: frequency, clinical presentation, and diagnostic strategies. J Gen Int Med 1988; 3:230.</div><div id=\"graphicVersion\">Graphic 81266 Version 4.0</div></div></div>"},"81267":{"type":"graphic_picture","displayName":"Plasma cell granuloma","title":"Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung</div><div class=\"cntnt\"><img style=\"width:324px; height:217px;\" src=\"images/PULM/81267_Plasma_cell_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross photograph showing a large&nbsp;inflammatory myofibroblastic tumor (plasma cell granuloma) resected from a 21 year old man. Plasma cell granulomas are typically smaller but have been reported up to 36 centimeters in greatest dimension. The gross appearance is typically that of a firm, well-circumscribed solitary pulmonary nodule with a homogeneous solid cut surface. Areas of calcification can occur, as in this example.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 81267 Version 2.0</div></div></div>"},"81268":{"type":"graphic_table","displayName":"Spectrum of IgG4 systemic disease","title":"Spectrum of IgG4 systemic disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spectrum of IgG4 systemic disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Pancreas</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Autoimmune pancreatitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Bile ducts</td>\r\n        </tr>\r\n        <tr>\r\n            <td>IgG4-associated cholangitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Salivary gland</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Chronic sclerosing sialadenitis (K&#252;ttner's tumor)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Mikulicz's disease (IgG4-related plasmacytic exocrinopathy)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Chest</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Patchy ground glass, nodular, and consolidative lung opacities</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Mediastinal fibrosis, adenopathy</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Retroperitoneum</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Chronic periaortitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Idiopathic retroperitoneal fibrosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Kidneys</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Tubulointerstitial nephritis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Orbits</td>\r\n        </tr>\r\n        <tr>\r\n            <td>IgG4-associated pseudolymphoma</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Inflammatory bowel disease </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ulcerative colitis</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 81268 Version 5.0</div></div></div>"},"81269":{"type":"graphic_picture","displayName":"Hemi-uterus2","title":"Noncommunicating right hemiuterus has been removed laparoscopically; left functional unicornuate system is intact","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Noncommunicating right hemiuterus has been removed laparoscopically; left functional unicornuate system is intact</div><div class=\"cntnt\"><img style=\"width:504px; height:351px;\" src=\"images/OBGYN/81269_Hemiuterus2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81269 Version 13.0</div></div></div>"},"81270":{"type":"graphic_picture","displayName":"Erythema migrans","title":"Erythema migrans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema migrans</div><div class=\"cntnt\"><img style=\"width:241px; height:360px;\" src=\"images/ID/81270_Erythema_migrans_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema migrans with central clearing and a necrotic center.</div><div class=\"graphic_reference\">Courtesy of Dori F Zaleznik, MD.</div><div id=\"graphicVersion\">Graphic 81270 Version 1.0</div></div></div>"},"81271":{"type":"graphic_diagnosticimage","displayName":"Acute pyelonephritis DMSA","title":"Acute pyelonephritis on radionuclide scan","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Acute pyelonephritis on radionuclide scan</div><div class=\"cntnt\"><img style=\"width:469px; height:254px;\" src=\"images/NEPH/81271_Acute_pyelonephritis_DMSA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal scintigraphy with 99Tc-DMSA in a patient with acute pyelonephritis showing large defects in the upper and lower poles of the right kidney (which is on the right side in this view). Note smaller defects in the lower and upper pole of the left kidney, indicating that pyelonephritis, although clinically right sided, was in fact bilateral.</div><div class=\"graphic_footnotes\">DMSA: dimercaptosuccinic acid.</div><div class=\"graphic_reference\">Courtesy of Alain Meyrier, MD.</div><div id=\"graphicVersion\">Graphic 81271 Version 4.0</div></div></div>"},"81272":{"type":"graphic_picture","displayName":"Gelhorn pessaries","title":"Gelhorn vaginal pessaries","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gelhorn vaginal pessaries</div><div class=\"cntnt\"><img style=\"width:432px; height:214px;\" src=\"images/OBGYN/81272_Gelhorn_pessaries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short stem Gelhorn pessary can be useful for women with a short vagina.</div><div class=\"graphic_reference\">Courtesy of Leah Moynihan, RNC, MSN.</div><div id=\"graphicVersion\">Graphic 81272 Version 2.0</div></div></div>"},"81273":{"type":"graphic_picture","displayName":"Branchio oto renal syndrome","title":"Branchio-oto-renal syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Branchio-oto-renal syndrome</div><div class=\"cntnt\"><img style=\"width:296px; height:504px;\" src=\"images/PEDS/81273_Branchio_oto_renal_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preauricular appendages and a second branchial fistula in branchio-oto-renal syndrome.</div><div class=\"graphic_reference\">Courtesy of Glenn C. Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 81273 Version 1.0</div></div></div>"},"81274":{"type":"graphic_picture","displayName":"Asbestosis Photomicrograph","title":"Asbestosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asbestosis</div><div class=\"cntnt\"><img style=\"width:281px; height:188px;\" src=\"images/PULM/81274_Asbestosis_Photomicrograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph illustrates a relatively acellular fibrosing interstitial pneumonia in a patient with asbestosis. Alveolar septa are thickened by dense collagen deposition (arrow) resembling that seen in usual intersititial pneumonia.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 81274 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/54820_Normal_lung_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 54820 Version 1.0</div></div></div>"},"81275":{"type":"graphic_picture","displayName":"Molluscum in AIDS 2","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:396px; height:350px;\" src=\"images/DERM/81275_Molluscum_in_AIDS_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the double and &quot;giant lesions&quot; on the face of a patient with acquired immunodeficiency syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81275 Version 2.0</div></div></div>"},"81276":{"type":"graphic_picture","displayName":"Bronchoscopic laser coagulation","title":"Bronchoscopic laser coagulation","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic laser coagulation</div><div class=\"cntnt\"><img style=\"width:514px; height:258px;\" src=\"images/SURG/81276_Bronchoscopic_laser_coag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) During rigid bronchoscopic resection, coagulation is obtained using a bare laser fiber and Nd:YAG laser energy at low power density, causing tissue blanching.<br> (B) Tissue vaporization and char tissue formation are visible when high power density is used.</div><div id=\"graphicVersion\">Graphic 81276 Version 2.0</div></div></div>"},"81277":{"type":"graphic_picture","displayName":"Pathology of SCLC","title":"Pathology of small cell lung carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pathology of small cell lung carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/81277_Pathology_SCLC_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this particular case there is prominent nuclear molding, where the cells deform on another as they touch one another.</div><div class=\"graphic_reference\">Courtesy of Henry D Tazelaar, MD.</div><div id=\"graphicVersion\">Graphic 81277 Version 1.0</div></div></div>"},"81280":{"type":"graphic_table","displayName":"Chemo dose mod molc agents","title":"Dose modification for molecularly targeted agents used for cancer therapy in patients with preexisting liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose modification for molecularly targeted agents used for cancer therapy in patients with preexisting liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Liver function</td> <td class=\"subtitle1\">Percent dose reduction administered initially*</td> </tr> <tr class=\"divider_bottom\"> <td>Axitinib</td> <td>&nbsp;</td> <td>Refer to UpToDate text</td> </tr> <tr class=\"divider_bottom\"> <td>Bosutinib</td> <td>&nbsp;</td> <td>Reduced starting doses (200 mg daily) for mild, moderate, or severe hepatic impairment</td> </tr> <tr class=\"divider_bottom\"> <td>Crizotinib</td> <td>Refer to UpToDate text</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Erlotinib</td> <td>Direct bilirubin 1 to 7 mg/dL or ALT &#8805;3 times the ULN</td> <td>Start at 75 rather than 150 mg daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Everolimus</td> <td>Child-Pugh A</td> <td>25% dose reduction for patients treated for breast cancer, renal cell cancer, or pancreatic neuroendocrine tumor; for patients with subgependymal giant cell tumor, refer to manufacturer's FDA-approved package insert</td> </tr> <tr> <td>Child-Pugh B</td> <td>50% reduction for patients treated for breast cancer, renal cell cancer, or pancreatic neuroendocrine tumor; for patients with subgependymal giant cell tumor, refer to manufacturer's FDA-approved package insert</td> </tr> <tr class=\"divider_bottom\"> <td>Child-Pugh C</td> <td>If potential benefits outweigh risks, maximum daily dose of 2.5 mg recommended</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Ibrutinib</td> <td>Child-Pugh A</td> <td>140 rather than 420 mg daily</td> </tr> <tr class=\"divider_bottom\"> <td>Child-Pugh B or C</td> <td>Avoid use</td> </tr> <tr class=\"divider_bottom\"> <td>Imatinib</td> <td>Total bilirubin &#62;3 to 10 times the ULN</td> <td>25% dose reduction<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Lapatinib</td> <td>Severe hepatic impairment (Child-Pugh Class C)</td> <td>1250 mg per day initial dose (in conjunction with capecitabine) reduced to 750 mg once daily; 1500 mg per day initial dose (in conjunction with letrozole) reduced to 1000 mg once daily</td> </tr> <tr class=\"divider_bottom\"> <td>Lenvatinib</td> <td>Severe hepatic impairment (Child-Pugh Class C)</td> <td>Reduce initial dose from 24 to 12 mg once daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Nilotinib</td> <td>Mild to moderate impairment (Child-Pugh Class A/B)</td> <td>600 rather than 800 mg daily</td> </tr> <tr class=\"divider_bottom\"> <td>Severe hepatic impairment (Child-Pugh Class C)</td> <td>400 mg daily</td> </tr> <tr class=\"divider_bottom\"> <td>Ribociclib</td> <td>Moderate to severe hepatic impairment (Child-Pugh Class B/C)</td> <td>Reduce starting dose from 600 to 400 mg daily</td> </tr> <tr class=\"divider_bottom\"> <td>Pazopanib</td> <td>Total bilirubin &#8805;1.5 times the ULN and/or ALT &#8805;2 times the ULN</td> <td>Reduce to 200 mg daily</td> </tr> <tr class=\"divider_bottom\"> <td>Ponatinib</td> <td>Moderate to severe hepatic impairment (Child-Pugh B/C)</td> <td>Avoid use</td> </tr> <tr class=\"divider_bottom\"> <td>Regorafenib</td> <td>Child-Pugh C disease</td> <td>Avoid use</td> </tr> <tr class=\"divider_bottom\"> <td>Ruxolitinib</td> <td>Any</td> <td>Reduce initial dose for hepatic impairment and platelets 100,000 to 150,000/mm<sup>3</sup>; avoid use for any hepatic impairment and platelet count &#60;100,000/mm<sup>3</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Sunitinib</td> <td>Refer to UpToDate text</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Temsirolimus</td> <td>Total bilirubin &#62;1 to 1.5 times the ULN or AST greater than the ULN</td> <td>Reduce dose to 15 mg per week</td> </tr> <tr> <td>Total bilirubin &#62;1.5 times the ULN</td> <td>Avoid use</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; ULN: upper limit of normal.<br />* Subsequent doses may be escalated as tolerated.<br />¶ Others<SUP>[1]</SUP> suggest the need to limit the total daily dose to 500 mg even in the setting of mild liver impairment (bilirubin &lt;1.5 times the ULN).</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ramanathan RK, Egorin MJ, Takimoto CH, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26:563.</LI></OL></div><div id=\"graphicVersion\">Graphic 81280 Version 13.0</div></div></div>"},"81281":{"type":"graphic_picture","displayName":"Ocular fundus in pt with RP","title":"Ocular fundus photograph from patient with retinitis pigmentosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ocular fundus photograph from patient with retinitis pigmentosa</div><div class=\"cntnt\"><img style=\"width:432px; height:329px;\" src=\"images/PC/81281_OcularfundusinptwithRP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the waxy pallor of the optic disc, attenuated arterioles (black arrows), mottled appearance of the retina, and bone-spicules (white arrow).</div><div id=\"graphicVersion\">Graphic 81281 Version 3.0</div></div></div>"},"81282":{"type":"graphic_waveform","displayName":"Old inferior MI tutorial","title":"Chronic inferior wall myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Chronic inferior wall myocardial infarction</div><div class=\"cntnt\"><img style=\"width:520px; height:130px;\" src=\"images/CARD/81282_Old_inferior_MI_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chronic inferior wall infarct is characterized by the presence of initial Q waves which are deep and broad in the inferior leads 2, 3, aVF.</div><div id=\"graphicVersion\">Graphic 81282 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"81284":{"type":"graphic_table","displayName":"Risk factors for Achilles tendinopathy","title":"Important risk factors for Achilles tendinopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important risk factors for Achilles tendinopathy</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Stop-and-go sports (eg, basketball, soccer)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Previous Achilles tendon problems</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sudden increase in duration or intensity of running</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Male gender</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Obesity</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Increasing&nbsp;age</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Poor running mechanics</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Over or under pronation</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Flat foot (pes planus)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">High foot arch (pes cavus)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Leg length discrepancy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Foot malalignment</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Fluoroquinolone&nbsp;or glucocorticoid use</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 81284 Version 2.0</div></div></div>"},"81285":{"type":"graphic_table","displayName":"Disorders associated with bacterial overgrowth","title":"Disorders associated with bacterial overgrowth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with bacterial overgrowth</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Small intestinal stasis</td> </tr> <tr> <td class=\"subtitle2_single\">Anatomic abnormalities</td> </tr> <tr> <td class=\"indent1\">Small intestinal diverticulosis</td> </tr> <tr> <td class=\"indent1\">Surgically created blind loops (end-to-side anastomosis)</td> </tr> <tr> <td class=\"indent1\">Strictures (Crohn disease, radiation, surgery)</td> </tr> <tr> <td class=\"subtitle2_single\">Abnormal small intestinal motility</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Scleroderma</td> </tr> <tr> <td class=\"indent1\">Idiopathic intestinal pseudo-obstruction</td> </tr> <tr> <td class=\"indent1\">Radiation enteritis</td> </tr> <tr> <td class=\"indent1\">Crohn disease</td> </tr> <tr> <td class=\"subtitle1_single\">Abnormal communication between the proximal and distal gastrointestinal tract</td> </tr> <tr> <td class=\"indent1\">Gastrocolic or jejunocolic fistula</td> </tr> <tr> <td class=\"indent1\">Resection of the ileocecal valve</td> </tr> <tr> <td class=\"subtitle1_single\">Associations usually with multifactorial causes</td> </tr> <tr> <td class=\"indent1\">Hypochlorhydria due to atrophic gastritis or medications. These are usually not clinically significant unless they coexist with concomitant motility disturbances of the small bowel.</td> </tr> <tr> <td class=\"indent1\">Immunodeficiency states (common variable immunodeficiency, AIDS, severe malnutrition)</td> </tr> <tr> <td class=\"indent1\">Chronic pancreatitis</td> </tr> <tr> <td class=\"indent1\">Cirrhosis</td> </tr> <tr> <td class=\"indent1\">Alcoholism</td> </tr> <tr> <td class=\"indent1\">End-stage renal disease</td> </tr> <tr> <td class=\"indent1\">Advanced age</td> </tr> <tr> <td class=\"indent1\">Total parenteral nutrition (TPN) in children</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81285 Version 5.0</div></div></div>"},"81286":{"type":"graphic_picture","displayName":"Bone marrow features of T-LGL leukemia","title":"Bone marrow features of T-cell large granular lymphocyte leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow features of T-cell large granular lymphocyte leukemia</div><div class=\"cntnt\"><img style=\"width:435px; height:340px;\" src=\"images/HEME/81286_Bone_marrow_T-LGL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin staining of marrow biopsy reveals a slightly hypercellular marrow with subtle increase in interstitial lymphocytes, as shown by arrow (left). Immunohistochemistry analyses (right) highlight the presence of intrasinusoidal cytotoxic T-cell infiltrates, staining positive for CD8 (arrow) and granzyme B (inset). Micrographs were viewed with a Leica Leitz DMRB microscope using a 100x/1.30 oil immersion objective. Images were captured with a Sony Exwave HAD camera and manipulated using Tribyn Version 1.3 software.</div><div class=\"graphic_reference\">This research was originally published in Blood. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117:2764. Copyright &#169; 2011 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 81286 Version 2.0</div></div></div>"},"81287":{"type":"graphic_picture","displayName":"Solar lentigines face","title":"Solar lentigines","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Solar lentigines</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/81287_Solar_lentigines_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81287 Version 3.0</div></div></div>"},"81289":{"type":"graphic_table","displayName":"Differential diagnosis of seizures","title":"Imitators of epilepsy: Nonepileptic paroxysmal disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Imitators of epilepsy: Nonepileptic paroxysmal disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neonates</td> </tr> <tr> <td class=\"indent1\">Apnea</td> </tr> <tr> <td class=\"indent1\">Jitteriness</td> </tr> <tr> <td class=\"indent1\">Benign neonatal sleep myoclonus</td> </tr> <tr> <td class=\"indent1\">Hyperekplexia</td> </tr> <tr> <td class=\"subtitle1_single\">Infants</td> </tr> <tr> <td class=\"indent1\">Breath-holding spells</td> </tr> <tr> <td class=\"indent1\">Benign myoclonus of infancy</td> </tr> <tr> <td class=\"indent1\">Shuddering attacks</td> </tr> <tr> <td class=\"indent1\">Sandifer syndrome</td> </tr> <tr> <td class=\"indent1\">Benign torticollis in infancy</td> </tr> <tr> <td class=\"indent1\">Abnormal eye movements (eg, spasmus nutans, opsoclonus-myoclonus)</td> </tr> <tr> <td class=\"indent1\">Rhythmic movement disorder (head banging)</td> </tr> <tr> <td class=\"subtitle1_single\">Children</td> </tr> <tr> <td class=\"indent1\">Breath-holding spells</td> </tr> <tr> <td class=\"indent1\">Vasovagal syncope</td> </tr> <tr> <td class=\"indent1\">Migraine</td> </tr> <tr> <td class=\"indent1\">Benign paroxysmal vertigo</td> </tr> <tr> <td class=\"indent1\">Staring spells</td> </tr> <tr> <td class=\"indent1\">Tic disorders and stereotypies</td> </tr> <tr> <td class=\"indent1\">Rhythmic movement disorder</td> </tr> <tr> <td class=\"indent1\">Parasomnias</td> </tr> <tr> <td class=\"subtitle1_single\">Adolescents and young adults</td> </tr> <tr> <td class=\"indent1\">Vasovagal syncope</td> </tr> <tr> <td class=\"indent1\">Narcolepsy</td> </tr> <tr> <td class=\"indent1\">Periodic limb movements of sleep</td> </tr> <tr> <td class=\"indent1\">Sleep starts</td> </tr> <tr> <td class=\"indent1\">Paroxysmal dyskinesia</td> </tr> <tr> <td class=\"indent1\">Tic disorders</td> </tr> <tr> <td class=\"indent1\">Hemifacial spasm</td> </tr> <tr> <td class=\"indent1\">Stiff person syndrome</td> </tr> <tr> <td class=\"indent1\">Migraine</td> </tr> <tr> <td class=\"indent1\">Psychogenic nonepileptic pseudoseizures</td> </tr> <tr> <td class=\"indent1\">Hallucinations</td> </tr> <tr> <td class=\"subtitle1_single\">Older adults</td> </tr> <tr> <td class=\"indent1\">Cardiogenic syncope</td> </tr> <tr> <td class=\"indent1\">Transient ischemic attack</td> </tr> <tr> <td class=\"indent1\">Drop attacks</td> </tr> <tr> <td class=\"indent1\">Transient global amnesia</td> </tr> <tr> <td class=\"indent1\">Delirium or toxic-metabolic encephalopathy</td> </tr> <tr> <td class=\"indent1\">Rapid eye movement sleep behavior&nbsp;disorder</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81289 Version 5.0</div></div></div>"},"81291":{"type":"graphic_picture","displayName":"Flexible cylindrical diffuser","title":"Flexible cylindrical diffuser","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexible cylindrical diffuser</div><div class=\"cntnt\"><img style=\"width:360px; height:231px;\" src=\"images/PULM/81291_Flexible_cylindrical_diffus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light exits through the rigid tip laterally in a cylindrical fashion.</div><div class=\"graphic_reference\">Courtesy of Armin Ernst, MD.</div><div id=\"graphicVersion\">Graphic 81291 Version 2.0</div></div></div>"},"81292":{"type":"graphic_diagnosticimage","displayName":"CT and MRI showing pericardial thickening","title":"Normal and abnormal pericardium seen on computed tomography (CT) and magnetic resonance imaging (MRI) studies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal and abnormal pericardium seen on computed tomography (CT) and magnetic resonance imaging (MRI) studies</div><div class=\"cntnt\"><img style=\"width:370px; height:298px;\" src=\"images/CARD/81292_Pericard_thick_CT_MRI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) CT scan showing normal pericardium.<br> (B) CT scan showing thickened pericardium.<br> (C) MRI scan showing normal pericardium (arrows).<br> (D) MRI scan showing thickened pericardium.</div><div class=\"graphic_reference\">Reproduced with permission from: Breen JF. Imaging of the pericardium. J Thorac Imaging 2001; 16:47. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81292 Version 14.0</div></div></div>"},"81293":{"type":"graphic_picture","displayName":"Wrist extensor stretch PI","title":"Wrist extensor stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wrist extensor stretch</div><div class=\"cntnt\"><img style=\"width:370px; height:517px;\" src=\"images/PI/81293_Wrist_extensor_stretch_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hold left arm straight out in front of the body, with the palm facing down. Using the right hand, grasp the left hand and gently bend hand downward until you feel a stretch in the left forearm. Hold for 10 seconds. Relax. Repeat 10 times, then switch hands and repeat 10 times with the right hand.</div><div id=\"graphicVersion\">Graphic 81293 Version 4.0</div></div></div>"},"81294":{"type":"graphic_figure","displayName":"Methamphetamine structure","title":"Methamphetamine structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Methamphetamine structure</div><div class=\"cntnt\"><img style=\"width:324px; height:174px;\" src=\"images/EM/81294_Methamphetamine_structure.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81294 Version 1.0</div></div></div>"},"81295":{"type":"graphic_picture","displayName":"Psoriasis palmar","title":"Palmar psoriasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Palmar psoriasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/81295_Psoriasis_palmar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A scaly, erythematous patch on the palm of a patient with plaque psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81295 Version 5.0</div></div></div>"},"81300":{"type":"graphic_figure","displayName":"Posteromedial view right elbow","title":"Posteromedial view of right elbow","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Posteromedial view of right elbow</div><div class=\"cntnt\"><img style=\"width:457px; height:511px;\" src=\"images/EM/81300_Posteromedial_view_right_el.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81300 Version 2.0</div></div></div>"},"81305":{"type":"graphic_figure","displayName":"Entry into anterior cul-de-sac","title":"Entry into the vesicovaginal space (anterior cul-de-sac) during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Entry into the vesicovaginal space (anterior cul-de-sac) during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:395px; height:330px;\" src=\"images/OBGYN/81305_Entry_into_anterior_culdesa.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81305 Version 3.0</div></div></div>"},"81306":{"type":"graphic_diagnosticimage","displayName":"PSC liver US","title":"Primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:298px; height:268px;\" src=\"images/GAST/81306_PSC_liver_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image in a patient with primary sclerosing cholangitis shows dilation of segmental ducts (large arrows) and debris within the lumen of intrahepatic ducts (small arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 81306 Version 2.0</div></div></div>"},"81308":{"type":"graphic_picture","displayName":"Hypomelanosis of Ito - trunk and arms","title":"Hypomelanosis of Ito","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypomelanosis of Ito</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81308_Hypomel_Ito_trunk_arms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hypopigmented patches that follow the lines of Blaschko are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81308 Version 3.0</div></div></div>"},"81309":{"type":"graphic_picture","displayName":"Contact dermatitis rubber","title":"Contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contact dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:257px;\" src=\"images/DERM/81309_Contactdermatitisrubber.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient reacted to the rubber in the elastic waistband of her underpants. Note sparing at the sites where the garment did not come into constant contact with the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81309 Version 2.0</div></div></div>"},"81310":{"type":"graphic_picture","displayName":"Papillary carcinoma","title":"Papillary carcinoma: Findings on surgical histology","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papillary carcinoma: Findings on surgical histology</div><div class=\"cntnt\"><img style=\"width:360px; height:230px;\" src=\"images/ENDO/81310_Papillary_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen showing the classic histologic appearance of papillary cancer with papillary structure and no follicles or colloid. Follicular development can be seen in some of these carcinomas (follicular variant of papillary cancer); in them, the diagnosis is made from the cytologic features of the cells.</div><div id=\"graphicVersion\">Graphic 81310 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Sporadic macrofollicular goiter with normal macrofollicles: Findings on surgical histology</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/ENDO/71842_Thyroid_goiter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen of a sporadic macrofollicular goiter with normal large thyroid follicules filled with colloid. These follicles are disrupted by needle biopsy so that the colloid will smear across the slide or occassionally aggregate into droplets.</div><div id=\"graphicVersion\">Graphic 71842 Version 3.0</div></div></div>"},"81311":{"type":"graphic_picture","displayName":"Dutcher body PAS stain","title":"Lymphoplasmacytic lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoplasmacytic lymphoma</div><div class=\"cntnt\"><img style=\"width:291px; height:287px;\" src=\"images/HEME/81311_Dutcher_body_PAS_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PAS stain (red color) highlights numerous cytoplasmic immunoglobulin inclusions and their extensions into the nucleus (yellow arrow, Dutcher bodies).</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 81311 Version 1.0</div></div></div>"},"81312":{"type":"graphic_diagnosticimage","displayName":"Extrahepatic PSC US","title":"Extrahepatic primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extrahepatic primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:296px; height:252px;\" src=\"images/GAST/81312_Extrahepatic_PSC_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image of the right upper quadrant in a patient with ulcerative colitis and primary sclerosing cholangitis shows marked thickening of the wall of the common bile duct (arrows) and narrowing of its lumen (dashed arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 81312 Version 3.0</div></div></div>"},"81315":{"type":"graphic_table","displayName":"SSRI and SNRI meds","title":"Antidepressant medications: Usual dosing in adults and half-life information","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antidepressant medications: Usual dosing in adults&nbsp;and half-life information</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic drug name</td> <td class=\"subtitle1\">Trade name (US)</td> <td class=\"subtitle1\">Usual starting dose (mg<span style=\"color: black;\">)*</span></td> <td class=\"subtitle1\"><span style=\"color: black;\">Low starting dose (mg)*</span></td> <td class=\"subtitle1\"><span style=\"color: black;\">Usual daily dose (mg)</span></td> <td class=\"subtitle1\"><span style=\"color: black;\">Available oral doses (mg)</span></td> <td class=\"subtitle1\"><span style=\"color: black;\">Mean half-life, hours (active metabolites)<sup>&#182;</sup></span></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\"><span style=\"color: black;\">Selective serotonin reuptake inhibitors (SSRIs)</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Citalopram</span></td> <td><span style=\"color: black;\">Celexa</span></td> <td><span style=\"color: black;\">20</span></td> <td><span style=\"color: black;\">10</span></td> <td><span style=\"color: black;\">20 to 40<sup>&#916;&#9674;</sup></span></td> <td><span style=\"color: black;\">10, 20, 40, L</span></td> <td><span style=\"color: black;\">35; prolonged in hepatic impairment and older adults</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Escitalopram</span></td> <td><span style=\"color: black;\">Lexapro</span></td> <td><span style=\"color: black;\">10</span></td> <td><span style=\"color: black;\">5 to 10</span></td> <td><span style=\"color: black;\">10 to 20</span></td> <td><span style=\"color: black;\">5, 10, 20, L</span></td> <td><span style=\"color: black;\">27 to 32; prolonged in hepatic impairment and older adults</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Fluoxetine</span></td> <td><span style=\"color: black;\">Prozac</span></td> <td><span style=\"color: black;\">20</span></td> <td><span style=\"color: black;\">5</span></td> <td><span style=\"color: black;\">20 to 60<sup>&#916;</sup></span></td> <td><span style=\"color: black;\">10, 20, 40, 60,&nbsp;L</span></td> <td rowspan=\"2\"><span style=\"color: black;\">120&nbsp;(223); prolonged in&nbsp;severe hepatic impairment</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Fluoxetine weekly</span></td> <td><span style=\"color: black;\">Prozac Weekly</span></td> <td><span style=\"color: black;\">90</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> <td><span style=\"color: black;\">NA</span></td> <td><span style=\"color: black;\">90</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Fluvoxamine</span></td> <td><span style=\"color: black;\">Luvox</span></td> <td><span style=\"color: black;\">50</span></td> <td><span style=\"color: black;\">25</span></td> <td><span style=\"color: black;\">50 to 300<sup>&#916;</sup></span></td> <td> <p><span style=\"color: black;\">25, 50, 100</span></p> <p><span style=\"color: black;\">100, 150 (controlled release)</span></p> </td> <td><span style=\"color: black;\">15; prolonged in older adults</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Paroxetine</span></td> <td><span style=\"color: black;\">Paxil</span></td> <td><span style=\"color: black;\">20</span></td> <td><span style=\"color: black;\">5 to 10</span></td> <td><span style=\"color: black;\">20 to 60<sup>&#916;</sup></span></td> <td><span style=\"color: black;\">10, 20, 30, 40, L</span></td> <td><span style=\"color: black;\">21</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Paroxetine CR</span></td> <td> <p><span style=\"color: black;\">Paxil CR</span></p> </td> <td><span style=\"color: black;\">25</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> <td><span style=\"color: black;\">25 to 62.5</span></td> <td><span style=\"color: black;\">12.5, 25, 37.5</span></td> <td> <p><span style=\"color: black;\">15 to 20</span></p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><span style=\"color: black;\">Sertraline</span></td> <td><span style=\"color: black;\">Zoloft</span></td> <td><span style=\"color: black;\">50</span></td> <td><span style=\"color: black;\">12.5 to 25</span></td> <td><span style=\"color: black;\">50 to 200<sup>&#916;</sup></span></td> <td><span style=\"color: black;\">25, 50, 100, L</span></td> <td><span style=\"color: black;\">26 (66</span>)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Serotonin-norepine<span style=\"color: black;\">phrine reuptake inhibitors (SNRIs)</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Desvenlavaxine&nbsp;&nbsp;</span></td> <td><span style=\"color: black;\">Khedezla, Pristiq</span></td> <td><span style=\"color: black;\">50</span></td> <td><span style=\"color: black;\">25</span></td> <td><span style=\"color: black;\">50 to 100</span></td> <td><span style=\"color: black;\">25, 50, 100</span></td> <td><span style=\"color: black;\">11; prolonged in severe renal and hepatic impairment</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Duloxetine</span></td> <td><span style=\"color: black;\">Cymbalta, Irenka</span></td> <td><span style=\"color: black;\">30</span></td> <td><span style=\"color: black;\">20</span></td> <td><span style=\"color: black;\">60 to 90</span></td> <td><span style=\"color: black;\">20, 30, 40, 60</span></td> <td><span style=\"color: black;\">12; prolonged in older female patients</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Venlafaxine</span></td> <td><span style=\"color: black;\">Effexor</span></td> <td><span style=\"color: black;\">37.5</span></td> <td><span style=\"color: black;\">25</span></td> <td><span style=\"color: black;\">75 to 225</span></td> <td><span style=\"color: black;\">25, 37.5, 50, 75, 100</span></td> <td rowspan=\"2\"><span style=\"color: black;\">5 (11); prolonged in severe renal and hepatic impairment</span><br /> </td> </tr> <tr> <td class=\"indent1\">Venlafaxine XR</td> <td>Effexor XR</td> <td>37.5</td> <td>&nbsp;</td> <td>75 to 225</td> <td><span style=\"color: black;\">37.5, 75, 150, 225</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">L: liquid; NA: not applicable; CR: controlled release; XR: extended release.<br />* Lower starting doses are recommended for elderly patients and patients with panic disorder, significant anxiety, or hepatic disease.<br />¶ Mean half-lives of active metabolites are given in parentheses.<br />Δ Dose varies with diagnosis. <SPAN style=\"COLOR: black\">Refer to text for specific guidelines.<br /><FONT class=lozenge>◊</FONT> Maximum recommended dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels. Refer to topic&nbsp;review of pharmacology of SSRI antidepressants&nbsp;for more information. Specific interactions of citalopram&nbsp;and other medications&nbsp;may be determined using the drug interactions tool (Lexi-Interact) included in UpToDate.</SPAN> </div><div class=\"graphic_reference\">Data from: <FONT color=black>Martinez M, Marangell LB, Martinez JM. Psychopharmacology. In: American Psychiatric Publishing Textbook of Psychiatry, 5th ed, Hales RE, Yudofsky SC, Gabbard, GO (Eds), American Psychiatric Publishing, Inc, 2008 and Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</FONT></div><div id=\"graphicVersion\">Graphic 81315 Version 7.0</div></div></div>"},"81316":{"type":"graphic_diagnosticimage","displayName":"AP foot x-ray with metatarsal shaft fracture","title":"AP foot x-ray with metatarsal shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AP foot x-ray with metatarsal shaft fracture</div><div class=\"cntnt\"><img style=\"width:225px; height:432px;\" src=\"images/EM/81316_AP_metatarsal_shaft_fractur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The metatarsals 1 through 5 are labeled. There is a fracture in the third metatarsal shaft (arrow).</div><div class=\"graphic_footnotes\">AP: anterior-posterior.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.</div><div id=\"graphicVersion\">Graphic 81316 Version 4.0</div></div></div>"},"81317":{"type":"graphic_figure","displayName":"IGF1 and insulin receptor","title":"Schematic diagram of the structure of the IGF-I, insulin and hybrid receptors","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of the structure of the IGF-I, insulin and hybrid receptors</div><div class=\"cntnt\"><img style=\"width:553px; height:347px;\" src=\"images/ENDO/81317_IGF1_and_insulin_receptor.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IGF: insulin-like growth factor.</div><div class=\"graphic_reference\">Courtesy of David R Clemmons, MD.</div><div id=\"graphicVersion\">Graphic 81317 Version 2.0</div></div></div>"},"81323":{"type":"graphic_table","displayName":"Causes of neonatal pneumonia","title":"Common organisms associated with neonatal pneumonia according to route of acquisition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common organisms associated with neonatal pneumonia according to route of acquisition</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Transplacental</td></tr>\n\t\t\t\t\t\t\t<tr><td>Rubella</td></tr>\n\t\t\t\t\t\t\t<tr><td>Cytomegalovirus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Herpes simplex virus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Adenovirus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Mumps virus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Toxoplasma gondii</td></tr>\n\t\t\t\t\t\t\t<tr><td>Mycobacterium tuberculosis</td></tr>\n\t\t\t\t\t\t\t<tr><td>Treponema pallidum</td></tr>\n\t\t\t\t\t\t\t<tr><td>Listeria monocytogenes</td></tr>\n\t\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">At delivery</td></tr>\n\t\t\t\t\t\t\t<tr><td>Group B streptococci</td></tr>\n\t\t\t\t\t\t\t<tr><td>Escherichia coli</td></tr>\n\t\t\t\t\t\t\t<tr><td>Staphylococcus aureus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Klebsiella sp</td></tr>\n\t\t\t\t\t\t\t<tr><td>Other streptococci</td></tr>\n\t\t\t\t\t\t\t<tr><td>Haemophilus influenzae (nontypable)</td></tr>\n\t\t\t\t\t\t\t<tr><td>Candida sp</td></tr>\n\t\t\t\t\t\t\t<tr><td>Chlamydia tachomatis</td></tr>\n\t\t\t\t\t\t\t<tr><td>Ureaplasma urealyticum</td></tr>\n\t\t\t\t\t\t</tbody>\n\t\t\t\t\t</table>\n\t\t\t\t</td>\n\t\t\t\t<td class=\"container\">\n\t\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t\t<tbody>\n\t\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Amniotic fluid</td></tr>\n\t\t\t\t\t\t\t<tr><td>Cytomegalovirus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Herpes simplex virus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Enteroviruses</td></tr>\n\t\t\t\t\t\t\t<tr><td>Genital mycoplasma</td></tr>\n\t\t\t\t\t\t\t<tr><td>Listeria monocytogenes</td></tr>\n\t\t\t\t\t\t\t<tr><td>Chlamydia trachomatis</td></tr>\n\t\t\t\t\t\t\t<tr><td>Mycobacterium tuberculosis</td></tr>\n\t\t\t\t\t\t\t<tr><td>Group B streptococci</td></tr>\n\t\t\t\t\t\t\t<tr><td>Escherichia coli</td></tr>\n\t\t\t\t\t\t\t<tr><td>Haemophilus influenzae (nontypable)</td></tr>\n\t\t\t\t\t\t\t<tr><td>Ureaplasma urealyticum</td></tr>\n\t\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Nosocomial</td></tr>\n\t\t\t\t\t\t\t<tr><td>Staphylococcus aureus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Staphylococcus epidermidis</td></tr>\n\t\t\t\t\t\t\t<tr><td>Group B streptococci</td></tr>\n\t\t\t\t\t\t\t<tr><td>Klebsiella sp</td></tr>\n\t\t\t\t\t\t\t<tr><td>Enterobacter</td></tr>\n\t\t\t\t\t\t\t<tr><td>Pseudomonas</td></tr>\n\t\t\t\t\t\t\t<tr><td>Bacillus cereus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Citrobacter diversus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Influenza virus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Respiratory synctial virus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Enteroviruses</td></tr>\n\t\t\t\t\t\t\t<tr><td>Herpes virus</td></tr>\n\t\t\t\t\t\t\t<tr><td>Candida sp</td></tr>\n\t\t\t\t\t\t\t<tr><td>Aspergillus sp</td></tr>\n\t\t\t\t\t\t</tbody>\n\t\t\t\t\t</table>\n\t\t\t\t</td>\n\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81323 Version 1.0</div></div></div>"},"81325":{"type":"graphic_diagnosticimage","displayName":"Dilated sm bowel NG tube","title":"Small bowel obstruction plain x-ray (supine)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction plain x-ray (supine)</div><div class=\"cntnt\"><img style=\"width:396px; height:381px;\" src=\"images/GAST/81325_Dilated_sm_bowel_NG_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain, supine abdominal x-ray showing dilated small bowel. Note a nasogastric tube has passed beyond the pylorus into the duodenum.</div><div class=\"graphic_reference\">Courtesy of Richard A Hodin, MD.</div><div id=\"graphicVersion\">Graphic 81325 Version 2.0</div></div></div>"},"81327":{"type":"graphic_picture","displayName":"Kaposi sarcoma on TBBx","title":"Pulmonary Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:419px; height:272px;\" src=\"images/PULM/81327_Kaposis_sarcoma_on_TBBx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transbronchial biopsy specimen shows proliferation of spindle cells with associated hemorrhagic features that is characteristic of Kaposi sarcoma.</div><div class=\"graphic_reference\">From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 81327 Version 2.0</div></div></div>"},"81334":{"type":"graphic_table","displayName":"Antifibrotic Rx for scleroderma","title":"Antifibrotic therapies for systemic sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antifibrotic therapies for systemic sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Treatment</td>\r\n                    <td class=\"subtitle1\">Mechanism of action</td>\r\n                    <td class=\"subtitle1\">Comments</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>D-penicillamine</td>\r\n                    <td>Inhibits the formation of stable collagen cross-links by forming hydroxy-lysine aldehyde and lysine groups on collagen precursors.</td>\r\n                    <td>Widely used in UK, doses above 750 mg daily probably needed for any benefit. Open studies have shown beneficial effects on lung, skin and kidney disease in SSc. Placebo controlled trial currently underway in USA.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Interferon alpha</td>\r\n                    <td>Inhibits collagen production by dermal SSc fibroblasts in vitro, at transcriptional level. May also eliminate high collagen producing fibroblast subpopulations.</td>\r\n                    <td>Efficacy has been confirmed in open studies and a placebo controlled trial is currently underway in UK. Benefits must be balanced by the considerable morbidity of IFN administration.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Interferon gamma</td>\r\n                    <td>Similar to interferon alpha.</td>\r\n                    <td>Initial support for use from open studies and in vitro properties, but subsequent evaluation has been less favorable.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Colchicine</td>\r\n                    <td>Inhibition of collagen production by disrupting microtubule formation in fibroblast cytoskeleton. Possible enhancement of collagenase activity.</td>\r\n                    <td>Little used in most centers.</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 81334 Version 3.0</div></div></div>"},"81335":{"type":"graphic_figure","displayName":"Dip and plateau in constrictive pericarditis","title":"Dip and plateau in constrictive pericarditis","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Dip and plateau in constrictive pericarditis</div><div class=\"cntnt\"><img style=\"width:584px; height:392px;\" src=\"images/CARD/81335_Dip_plateau_constr_pericard.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemodynamic record of a patient with surgically proven constrictive pericarditis.<br> (A) Slow-paper-speed recording of high-gain left ventricular (LV) pressure and simultaneous right heart pullback from pulmonary capillary wedge (PCW) to pulmonary artery (PA), right ventricle (RV), and right atrium (RA).<br> (B) Fast-paper-speed recording of LV and simultaneous RV and RA pressure tracings. Note the increased and equal atrial and diastolic pressures, the prominent X and Y descents on the RA tracing, and the dip and plateau on the RV and LV tracings during longer diastoles.</div><div class=\"graphic_reference\">From: Hoit BD. Pericardial disease and pericardial heart disease. In: O'Rourke RA, ed. Stein's Internal Medicine, 5th Edition. St. Louis: Mosby-Year Book, 1998. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 81335 Version 1.0</div></div></div>"},"81336":{"type":"graphic_picture","displayName":"Demarcation membrane system EM","title":"Megakaryocyte demarcation membrane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Megakaryocyte demarcation membrane</div><div class=\"cntnt\"><img style=\"width:413px; height:246px;\" src=\"images/HEME/81336_Demarcation_membrane_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transmission electron micrograph of a mature megakaryocyte shows prominent proliferation of a surface-connected demarcation membrane system (thin arrow) which has sequestered the cytoplasm into platelet-sized subunits (thick arrow). This membrane will later serve to provide the surface membrane for many platelets.</div><div class=\"graphic_reference\">Reproduced with permission from: White, JG. Delivery of Platelets from Megakaryocytes. In: Molecular Biology and Differentiation of Megakaryocytes, Breton-Gorius, J, Levin, J, Nurden, AT, Williams, N (Eds) Copyright &#169; 1990 John Wiley &amp;Sons, Inc.</div><div id=\"graphicVersion\">Graphic 81336 Version 1.0</div></div></div>"},"81337":{"type":"graphic_picture","displayName":"Ultrathin pancreatoscope","title":"Ultrathin pancreatoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrathin pancreatoscope</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/GAST/81337_Ultrathin_pancreatoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrathin pancreatoscopes with an external diameter of 5 mm have been developed.</div><div class=\"graphic_reference\">Courtesy of Jurgen F Riemann, MD, PhD.</div><div id=\"graphicVersion\">Graphic 81337 Version 1.0</div></div></div>"},"81338":{"type":"graphic_table","displayName":"Motor features of Parkinson disease","title":"Motor features of Parkinson disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motor features of Parkinson disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cardinal manifestations</td> </tr> <tr> <td>Tremor</td> </tr> <tr> <td>Bradykinesia</td> </tr> <tr> <td>Rigidity</td> </tr> <tr> <td>Postural instability</td> </tr> <tr> <td class=\"subtitle1_single\">Other motor features</td> </tr> <tr> <td class=\"subtitle2_single\">Craniofacial</td> </tr> <tr> <td class=\"indent1\">Hypomimia (masked facial expression)</td> </tr> <tr> <td class=\"indent1\">Decreased eye blinking</td> </tr> <tr> <td class=\"indent1\">Speech disturbances (hypokinetic dysarthria, hypophonia)</td> </tr> <tr> <td class=\"indent1\">Dysphagia</td> </tr> <tr> <td class=\"indent1\">Sialorrhea</td> </tr> <tr> <td class=\"subtitle2_single\">Visual</td> </tr> <tr> <td class=\"indent1\">Blurred vision</td> </tr> <tr> <td class=\"indent1\">Impaired contrast sensitivity</td> </tr> <tr> <td class=\"indent1\">Hypometric saccades</td> </tr> <tr> <td class=\"indent1\">Impaired vestibuloocular reflex</td> </tr> <tr> <td class=\"indent1\">Impaired upward gaze and convergence</td> </tr> <tr> <td class=\"indent1\">Lid apraxia</td> </tr> <tr> <td class=\"subtitle2_single\">Musculoskeletal</td> </tr> <tr> <td class=\"indent1\">Micrographia</td> </tr> <tr> <td class=\"indent1\">Dystonia</td> </tr> <tr> <td class=\"indent1\">Myoclonus</td> </tr> <tr> <td class=\"indent1\">Stooped posture</td> </tr> <tr> <td class=\"indent1\">Camptocormia (severe anterior flexion of the thoracolumbar spine)</td> </tr> <tr> <td class=\"indent1\">Pisa syndrome (subacute axial dystonia with lateral flexion of the trunk, head, and neck) </td> </tr> <tr> <td class=\"indent1\">Kyphosis</td> </tr> <tr> <td class=\"indent1\">Scoliosis</td> </tr> <tr> <td class=\"indent1\">Difficulty turning in bed</td> </tr> <tr> <td class=\"subtitle2_single\">Gait</td> </tr> <tr> <td class=\"indent1\">Shuffling, short-stepped gait</td> </tr> <tr> <td class=\"indent1\">Freezing</td> </tr> <tr> <td class=\"indent1\">Festination</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81338 Version 5.0</div></div></div>"},"81339":{"type":"graphic_waveform","displayName":"ECG tetralogy of Fallot","title":"Electrocardiagram from an infant with tetralogy of Fallot","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Electrocardiagram from an infant with tetralogy of Fallot</div><div class=\"cntnt\"><img style=\"width:453px; height:263px;\" src=\"images/CARD/81339_ECG_tetralogy_Fallot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ECG in tetralogy of Fallot shows prominent P waves in V1 (*) suggesting right atrial enlargement. There are also prominent right ventricular forces (tall R waves in V1), an upright T wave in V1, and a marked rightward axis suggesting right ventricular hypertrophy.</div><div class=\"graphic_reference\">Courtesy of Thomas Doyle, MD.</div><div id=\"graphicVersion\">Graphic 81339 Version 2.0</div></div></div>"},"81342":{"type":"graphic_table","displayName":"Pressure versus transit","title":"Esophageal motility abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Esophageal motility abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Abnormal pressure and transit </td>\n\n</tr>\n<tr>\n<td>Achalasia</td>\n\n</tr>\n<tr>\n<td>Scleroderma</td>\n\n</tr>\n<tr>\n<td>Ineffective esophageal motility </td>\n\n</tr>\n<tr>\n<td>Distal esophageal spasm</td>\n\n</tr><tr><td class=\"subtitle1_single\">Abnormal pressure only</td></tr><tr><td>Nutcracker esophagus</td></tr><tr><td>Hypertensive LES</td></tr><tr><td>Hypotensive LES</td></tr><tr><td>Poorly relaxing LES</td></tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">6.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=20563&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Pressure_versus_transit.htm</title></head></div><div class=\"graphic_footnotes\">LES: lower esophageal sphincter.</div><div id=\"graphicVersion\">Graphic 81342 Version 2.0</div></div></div>"},"81343":{"type":"graphic_figure","displayName":"Blood vessels of the anterior abdominal wall","title":"Blood vessels of the anterior abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Blood vessels of the anterior abdominal wall</div><div class=\"cntnt\"><img style=\"width:540px; height:707px;\" src=\"images/SURG/81343_Abdominal-wall-vasculature.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The superior and inferior epigastric arteries provide a rich arcade, arising from the internal thoracic artery superiorly and the external iliac artery inferiorly. The musculophrenic artery, deep circumflex iliac artery, and subcostal arteries supply the lateral abdominal wall. The superficial epigastric veins and the superficial iliac veins can arise from the great saphenous vein.</div><div id=\"graphicVersion\">Graphic 81343 Version 5.0</div></div></div>"},"81345":{"type":"graphic_table","displayName":"Body CT in stage III melanoma","title":"Body computerized tomography for staging asymptomatic patients with stage III melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Body computerized tomography for staging asymptomatic patients with stage III melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Institution</td>\n\n      <td class=\"subtitle1\">N</td>\n\n      <td class=\"subtitle1\">True positive, percent</td>\n\n      <td class=\"subtitle1\">False positive, percent</td>\n\n      <td class=\"subtitle1\">New primaries, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>MDACC</td>\n\n      <td>89</td>\n\n      <td>6.7</td>\n\n      <td>22.4</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>MSKCC</td>\n\n      <td>136</td>\n\n      <td>4.4</td>\n\n      <td>8.4</td>\n\n      <td>1.4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>University of Michigan</td>\n\n      <td>127</td>\n\n      <td>16</td>\n\n      <td>12</td>\n\n      <td>0.7</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">MDACC: The University of Texas M.D. Anderson Cancer Center; MSKCC: Memorial Sloan-Kettering Cancer Center.<br> Results of computerized tomography of the chest, abdomen and pelvis in asymptomatic patients with documented local-regional metastases who have a normal chest x-ray and serum LDH concentration.</div><div class=\"graphic_reference\">Courtesy of Antonio Buzaid, MD.</div><div id=\"graphicVersion\">Graphic 81345 Version 1.0</div></div></div>"},"81347":{"type":"graphic_figure","displayName":"Vocal cord injury intubation","title":"Vocal cord injury with endotracheal tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vocal cord injury with endotracheal tube</div><div class=\"cntnt\"><img style=\"width:360px; height:185px;\" src=\"images/PULM/81347_Vocal_cord_injury_intubatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left: a schematic view of the larynx with an endotracheal tube positioned between the vocal cords. Right: at laryngoscopy following extubation or tracheostomy, ulcers along the posterior aspects of both vocal cords are commonly seen as shown in this schematic. The site of these ulcers corresponds to the area where the translaryngeal endotracheal tube pressed against the vocal cords.</div><div class=\"graphic_reference\">Redrawn from Colice, GL, Stukel, TA, Dain, B, Chest 1989; 89:877.</div><div id=\"graphicVersion\">Graphic 81347 Version 1.0</div></div></div>"},"81349":{"type":"graphic_table","displayName":"Comparison of parasomnias","title":"A comparison of parasomnias that occur on arousal from NREM sleep","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A comparison of parasomnias that occur on arousal from NREM sleep</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Confusional arousal</td> <td class=\"subtitle1\">Sleep terror</td> <td class=\"subtitle1\">Sleep walking</td> </tr> <tr> <td>Age of onset</td> <td>2 to 10 years</td> <td>2 to 10 years</td> <td>5 to 10 years</td> </tr> <tr> <td>Frequency</td> <td>3 to 4/week to 1 to 2/month</td> <td>3 to 4/week to 1 to 2/month</td> <td>3 to 4/week to 1 to 2/month</td> </tr> <tr> <td>Peak time of occurrence</td> <td>First third of night sleep</td> <td>First third of night sleep</td> <td>First third of night sleep</td> </tr> <tr> <td>Behavior during event</td> <td>Whimpering, some articulation, sitting up in bed, inconsolable</td> <td>Screaming, agitation, flushed face, sweating, inconsolable</td> <td>Walking about the room or house, may be quiet or agitated, unresponsive to verbal commands</td> </tr> <tr> <td>Electroencephalogram findings during event</td> <td>Slow wave sleep, with rhythmic theta or delta activity</td> <td>Slow wave sleep, with rhythmic theta or delta activity</td> <td>Slow wave sleep, with rhythmic theta or delta activity</td> </tr> <tr> <td>Duration</td> <td>10 to 30 minutes</td> <td>10 to 20 minutes</td> <td>10 to 20 minutes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NREM: non-rapid eye movement.</div><div class=\"graphic_reference\">Reproduced with permission from: Kotagal S. Parasomnias of childhood. Curr Opin Pediatr 2008; 20:659. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81349 Version 6.0</div></div></div>"},"81352":{"type":"graphic_picture","displayName":"Congenital syphilis rash on soles","title":"Congenital syphilis: Rash on soles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Rash on soles</div><div class=\"cntnt\"><img style=\"width:432px; height:233px;\" src=\"images/PEDS/81352_Cong_syphilis_rash_soles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmented lesions on the soles of an infant with congenital syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81352 Version 2.0</div></div></div>"},"81354":{"type":"graphic_table","displayName":"Maternal age aneuploidy risk","title":"Crude maternal age-specific rates for trisomy 21, Down syndrome, and all chromosome abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Crude maternal age-specific rates for trisomy 21, Down syndrome, and all chromosome abnormalities</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">\r\n  \r\n   Maternal age, years\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"2\" class=\"subtitle1\">\r\n  \r\n   Data from live births\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"2\" class=\"subtitle1\">\r\n  \r\n   Data from 2nd trimester amniocentesis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Trisomy 21\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   All chromosome abnormalities\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Trisomy 21\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   All chromosome abnormalities\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>33</td>\r\n  \r\n   <td>1/625</td>\r\n  \r\n   <td>1/345</td>\r\n  \r\n   <td>1/416</td>\r\n  \r\n   <td>1/208</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>34</td>\r\n  \r\n   <td>1/500</td>\r\n  \r\n   <td>1/277</td>\r\n  \r\n   <td>1/333</td>\r\n  \r\n   <td>1/151</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>35</td>\r\n  \r\n   <td>1/385</td>\r\n  \r\n   <td>1/204</td>\r\n  \r\n   <td>1/250</td>\r\n  \r\n   <td>1/132</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>36</td>\r\n  \r\n   <td>1/303</td>\r\n  \r\n   <td>1/167</td>\r\n  \r\n   <td>1/192</td>\r\n  \r\n   <td>1/105</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>37</td>\r\n  \r\n   <td>1/227</td>\r\n  \r\n   <td>1/130</td>\r\n  \r\n   <td>1/149</td>\r\n  \r\n   <td>1/83</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>38</td>\r\n  \r\n   <td>1/175</td>\r\n  \r\n   <td>1/103</td>\r\n  \r\n   <td>1/115</td>\r\n  \r\n   <td>1/65</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>39</td>\r\n  \r\n   <td>1/137</td>\r\n  \r\n   <td>1/81</td>\r\n  \r\n   <td>1/89</td>\r\n  \r\n   <td>1/53</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>40</td>\r\n  \r\n   <td>1/106</td>\r\n  \r\n   <td>1/63</td>\r\n  \r\n   <td>1/69</td>\r\n  \r\n   <td>1/40</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>41</td>\r\n  \r\n   <td>1/81</td>\r\n  \r\n   <td>1/50</td>\r\n  \r\n   <td>1/53</td>\r\n  \r\n   <td>1/31</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>42</td>\r\n  \r\n   <td>1/64</td>\r\n  \r\n   <td>1/39</td>\r\n  \r\n   <td>1/41</td>\r\n  \r\n   <td>1/25</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>43</td>\r\n  \r\n   <td>1/50</td>\r\n  \r\n   <td>1/30</td>\r\n  \r\n   <td>1/31</td>\r\n  \r\n   <td>1/19</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>44</td>\r\n  \r\n   <td>1/38</td>\r\n  \r\n   <td>1/24</td>\r\n  \r\n   <td>1/25</td>\r\n  \r\n   <td>1/15</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>45</td>\r\n  \r\n   <td>1/30</td>\r\n  \r\n   <td>1/19</td>\r\n  \r\n   <td>1/19</td>\r\n  \r\n   <td>1/12</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Data from: Schreinemachers, DM, Cross, PK, Hook, EB. Rates of trisomies 21, 18, 13 and other chromosome abnormalities in about 20,000 prenatal studies compared with estimated rates in live births. Hum Genet 1982; 61:318.</div><div id=\"graphicVersion\">Graphic 81354 Version 1.0</div></div></div>"},"81356":{"type":"graphic_algorithm","displayName":"Undifferentiated pediatric shock algorithm","title":"Approach to the classification of undifferentiated shock in children","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Approach to the classification of undifferentiated shock in children</div><div class=\"cntnt\"><img style=\"width:511px; height:604px;\" src=\"images/EM/81356_Algo_undiff_shock_child.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81356 Version 2.0</div></div></div>"},"81359":{"type":"graphic_figure","displayName":"Multivisceral transplant","title":"Multivisceral transplantation","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Multivisceral transplantation</div><div class=\"cntnt\"><img style=\"width:534px; height:529px;\" src=\"images/GAST/81359_Multivisceral_transplant.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified with permission from: Khan FA, Tzakis AG. Intestinal and multivisceral transplantation. In: Transplantation, Ginnis LC, Cosmi AB, and Morris PJ (Eds), Blackwell, Malden 1999. p.422.</div><div id=\"graphicVersion\">Graphic 81359 Version 2.0</div></div></div>"},"81361":{"type":"graphic_figure","displayName":"AF in EAVNC","title":"AF in EAVNC","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AF in EAVNC</div><div class=\"cntnt\"><img style=\"width:396px; height:444px;\" src=\"images/CARD/81361_AF_in_EAVNC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12 lead ECG during sinus rhythm (panel A) in a patient with enhanced atrioventricular nodal conduction (EAVNC). The ECG shows a normal PR interval and QRS complex without evidence of preexcitation. During atrial fibrillation (AF) (panel B), there is a rapid ventricular response of up to 270 beats/min, a result of EAVNC and a short AV nodal refractory period.</div><div id=\"graphicVersion\">Graphic 81361 Version 1.0</div></div></div>"},"81363":{"type":"graphic_table","displayName":"Avoidance measures for animal dander","title":"Avoidance measures for animal dander","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Avoidance measures for animal dander</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Removing animals from the house</td> </tr> <tr> <td class=\"indent1\">Keep animals outside (eg, in garage or kennel); restricting animals to certain rooms has not been shown to be effective.</td> </tr> <tr> <td class=\"indent1\">Once animal has been removed, the premises should be cleaned thoroughly.</td> </tr> <tr> <td class=\"subtitle1_single\">Controlling allergen with an animal in the house</td> </tr> <tr> <td class=\"indent1\">Difficult because the animal contains 10 to 50 mg of major allergen, while the quantities of airborne allergen are only 5 to 20 ng/m<sup>3</sup>. Using an air filter can only reduce airborne allergen.</td> </tr> <tr> <td class=\"indent1\">Reduce reservoirs: Remove carpets, reduce upholstered furniture to a minimum, replace drapes with blinds, and/or vacuum weekly using a vacuum with good filtration (ie, double thickness bags and/or HEPA filtration).</td> </tr> <tr> <td class=\"indent1\">Room air filters: HEPA or electrostatic (maintenance data are better defined for HEPA).</td> </tr> <tr> <td class=\"indent1\">Washing cats does not reduce allergen levels significantly. Washing dogs twice a week may help.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HEPA: high-efficiency particulate air.</div><div id=\"graphicVersion\">Graphic 81363 Version 4.0</div></div></div>"},"81364":{"type":"graphic_diagnosticimage","displayName":"Triquetrum fracture oblique plain radiograph","title":"Triquetrum fracture on plain radiograph oblique view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Triquetrum fracture on&nbsp;plain radiograph oblique view</div><div class=\"cntnt\"><img style=\"width:288px; height:384px;\" src=\"images/EM/81364_Triquetral_fracture_oblique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this oblique radiograph of the wrist, the shadow of the pisiform does not overlap the triquetrum fracture (arrow). Note the small fragment near the ulnar styloid. In this view the remainder of the wrist bones appear normal.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 81364 Version 6.0</div></div></div>"},"81367":{"type":"graphic_figure","displayName":"Hindgut formation","title":"Hindgut formation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hindgut formation</div><div class=\"cntnt\"><img style=\"width:309px; height:625px;\" src=\"images/PEDS/81367_Hindgut_formation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wedge of mesoderm divides the hindgut. Recall that the allantois diverticulum is trapped in the connecting stalk (A). A migrating urorectal septum of mesoderm pinches the base of the diverticulum off of the hindgut (B and C). This results in two portals to the outside world, one of which is still connected to the gut tube (anal) and one of which is a blind pouch (urogenital).</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler TW. Langman's Medical Embryology, 10th Edition. Baltimore: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81367 Version 1.0</div></div></div>"},"81368":{"type":"graphic_picture","displayName":"Acute retinal necrosis","title":"Acute retinal necrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute retinal necrosis</div><div class=\"cntnt\"><img style=\"width:280px; height:230px;\" src=\"images/RHEUM/81368_Acute_retinal_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Funduscopic photograph of a patient with acute retinal necrosis showing a characteristic patchy white yellow area.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 81368 Version 1.0</div></div></div>"},"81369":{"type":"graphic_figure","displayName":"Division of the left gastric vessels","title":"Division of the left gastric vessels","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Division of the left gastric vessels</div><div class=\"cntnt\"><img style=\"width:536px; height:346px;\" src=\"images/SURG/81369_Division_LT_gastrics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dissection is carried cephalad along the lesser curve of the stomach by dividing the gastrohepatic ligament towards the diaphragm. The left gastric vessels are identified and divided.</div><div id=\"graphicVersion\">Graphic 81369 Version 2.0</div></div></div>"},"81370":{"type":"graphic_table","displayName":"AIM 75_10","title":"Doxorubicin (Adriamycin), ifosfamide, and mesna (AIM 75/10) for advanced soft tissue sarcoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doxorubicin (Adriamycin), ifosfamide, and mesna (AIM 75/10) for advanced soft tissue sarcoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days until disease progression or maximum of six cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Doxorubicin</td> <td>25 mg/m<sup>2</sup> per day IV</td> <td>Dilute with 1000 mL normal saline (NS) and administer as a continuous IV infusion over 24 hours daily.</td> <td>Days 1 through 3</td> </tr> <tr> <td>IV mesna*</td> <td>0.5 g/m<sup>2</sup> IV bolus prior to each day's dose of ifosfamide, then 1.5 g/m<sup>2</sup> IV concurrently with ifosfamide (mix in same bag)</td> <td>Dilute 0.5 g/m<sup>2</sup> bolus dose in NS (total concentration of mesna should not exceed 20 mg/mL) and administer over 15 minutes prior to each daily dose of ifosfamide. Dilute mesna 1.5 g/m<sup>2</sup> dose in same 1000 mL NS bag as ifosfamide dose and deliver over four hours.</td> <td>Days 1 through 4</td> </tr> <tr> <td>Ifosfamide</td> <td>2.5 g/m<sup>2</sup> per day IV</td> <td>After mesna bolus (500 mg/m<sup>2</sup>), dilute with 1000 mL NS and administer concurrently with mesna (1.5 g/m<sup>2</sup>) in the same bag over four hours daily.</td> <td>Days 1 through 4</td> </tr> <tr> <td>Oral mesna</td> <td>1 g/m<sup>2</sup></td> <td>Orally at two and six hours after completion of each day's ifosfamide infusion (round to nearest tablet size).</td> <td>Days 1 through 4</td> </tr> <tr class=\"divider_bottom\"> <td>Pegfilgrastim</td> <td>6 mg subcutaneously</td> <td>Single injection.</td> <td>Day 6, at least 24 hours after completing chemotherapy</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Adequate hydration (at least two liters of oral or IV fluids per day) should be maintained with ifosfamide to reduce the risk of bladder toxicity.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% risk of emesis).<sup>&#182;</sup> </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> <li>Concomitant administration of aprepitant may increase the risk of ifosfamide neurotoxicity;<sup>[3-5]</sup> its use is avoided at some institutions. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is a vesicant; avoid extravasation. Administer infusional regimens through a central venous line. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The risk of febrile neutropenia with this regimen was &#62;20%,<sup>[1]</sup> even with primary prophylaxis with granulocyte colony stimulating factor in all patients. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, patients were excluded if they had a baseline total bilirubin of greater than 30 micromol/L (1.8 mg/dL) or a serum creatinine of greater than 120 micromol/L (1.4 mg/dL) or creatinine clearance (by Cockroft and Gault method) less than 65 mL/min.<sup>[1]</sup> A lower initial ifosfamide dose may be needed for patients with preexisting renal or liver impairment. A lower starting dose of doxorubicin may be needed for patients with preexisting liver impairment.<sup>[6]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is associated with cardiomyopathy, the incidence of which is related to the cumulative dose. Assess baseline LVEF prior to administration. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines.<sup>[6]</sup> </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Ifosfamide is associated with cumulative nephrotoxicity, mostly at a total dose above 60 g/m<sup>2</sup>. Clinical manifestations may include hypophosphatemia, renal potassium wasting, metabolic acidosis with a normal ion gap, and rarely, polyuria due to nephrogenic diabetes insipidus. Assess creatinine and electrolytes, including potassium and phosphate, daily during treatment and prior to each subsequent treatment cycle. </li> <li>Refer to UpToDate topic on \"Ifosfamide nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Mesna does not prevent hemorrhagic cystitis in all patients.<sup>[7]</sup> Monitor a morning specimen of urine for hematuria daily, on days 1 through 4. </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity (confusion, coma, rarely seizures, weakness, neuropathy, ataxia, cranial nerve dysfunction) daily on days 1 through 5. Central nervous system side effects may be especially problematic for those over age 60. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor cumulative doxorubicin dose. Reassess LVEF periodically during therapy as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, patients had to have an absolute neutrophil count greater than 2000 cells/microL and platelet count greater than 100,000/microL prior to initiating therapy.<sup>[1]</sup> The original protocol specified a one week delay for subsequent cycles for incomplete hematologic recovery.<sup>[8]</sup> A 20% dose reduction was performed for repeated neutropenic septic episodes despite growth factor support per protocol.<sup>[8]</sup> If the ifosfamide dose is adjusted, the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Formal guidelines are not provided for dose reduction in the event of neurotoxicity in the United States Prescribing Information. The original protocol recommended discontinuation of treatment for &#8805;grade 3 toxicity.<sup>[8]</sup> The United States Prescribing Information recommends discontinuation of treatment for encephalopathy.<sup>[2]</sup> Some centers advocate IV alkalinization to reduce the incidence of encephalopathy, but this is not a standard practice. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Renal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, treatment was discontinued if serum creatinine was &#62;2.5 upper limit of normal or creatinine clearance (by Cockroft and Gault method) was &#60;60 mL/min.<sup>[8]</sup> If ifosfamide dose is adjusted, the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Bladder toxicity</strong></td> <td colspan=\"3\"> <ul> <li>If microscopic hematuria (greater than 10 RBC per high power field) is present, withhold ifosfamide until complete resolution.<sup>[2]</sup> Although formal guidelines are not available, reduced ifosfamide dose may be needed for patients with grade 3 or worse cystitis that has not responded to increases in IV fluids or mesna. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, treatment was discontinued if LVEF dropped below 45% or if there was a drop of &#62;20% from baseline (confirmed three to five days later).<sup>[8]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; RBC: red blood cells.<br />* If the patient vomits within two hours of taking a dose of oral mesna, he or she should repeat the dose or receive an IV dose of mesna (at one-half of the dose, ie, 0.5 g/m<SUP>2</SUP>).<SUP>[7,9]</SUP><br />¶ The original protocol included only IV dexamethasone 8 mg and a 5HT3 receptor antagonist as antiemetics, and reported 78% nausea and 56% vomiting.<SUP>[1]</SUP></div><div class=\"graphic_reference\">References:&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;<ol>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;<li>Judson I, et al. Lancet Oncol 2014; 15:415.</li>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;<li>Ifosfamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed May 12, 2014).</li>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;<li>Durand JP, et al. Ann Oncol 2007; 18:808.</li>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;<li>Jarkowski A. Am J Health-Syst Pharm 2008; 65:2229.</li>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;<li>Howell JE, et al. J Oncol Pharm Practice 2008; 14:157.</li>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;<li>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed May 12, 2014).</li>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;<li>MESNA injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed May 12, 2014).</li>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;<li>Judson I, et al. Lancet Oncol 2014; 15:415. (Protocol available online at http://www.eortc.be/services/download/Protocols/62012.pdf, accessed May 19, 2014).</li>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;<li>Mesna tablets. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.gov, accessed May 13, 2014).10.</li>&#xD;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;</ol></div><div id=\"graphicVersion\">Graphic 81370 Version 17.0</div></div></div>"},"81371":{"type":"graphic_figure","displayName":"Hospitalization for neutropenia","title":"Hospitalization for neutropenia","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Hospitalization for neutropenia</div><div class=\"cntnt\"><img style=\"width:473px; height:381px;\" src=\"images/HEME/81371_Hospitalization_for_neutrop.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Estimated hospitalization rates (per 10,000 days at risk) and 95 percent confidence intervals (vertical bars) for bacterial infection per absolute neutrophil count (ANC) stratum in 2047 HIV-infected patients. The values are based upon the earliest lowest ANC stratum for each patient. Hospitalization rates increased progressively when the ANC fell below 750/&#181;L.</div><div class=\"graphic_reference\">Data from Jacobson, MA, Liu, RC, Davies, D, Cohen, PT, Arch Intern Med 1997; 157:1825.</div><div id=\"graphicVersion\">Graphic 81371 Version 1.0</div></div></div>"},"81373":{"type":"graphic_figure","displayName":"Immunohistol kidney Alport","title":"Immunohistological analysis of the renal distribution of type IV collagen chains","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Immunohistological analysis of the renal distribution of type IV collagen chains</div><div class=\"cntnt\"><img style=\"width:588px; height:295px;\" src=\"images/PEDS/81373_Immunohistol_kidney_Alport.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The analysis was carried out in (<STRONG>A-D</STRONG>) control, X-linked (<STRONG>E,F</STRONG>) male and (<STRONG>G,H</STRONG>) female Alport syndrome patients, and (<STRONG>I-L</STRONG>) patients with autosomal recessive Alport syndrome, using antibodies to α1(IV) (<STRONG>A,E,I</STRONG>), α3(IV) (<STRONG>B,F,J</STRONG>), or α5(IV) (<STRONG>C,G,K,L</STRONG>) chains. Double labeling was made with anti-α2(IV) in red, and anti-α5(IV) in green (<STRONG>D,H</STRONG>). In control kidney, the α1(IV) chain is present in the mesangial matrix, Bowman's capsule, and the extraglomerular basement membranes (<STRONG>A</STRONG>). The α3(IV) and α5(IV) chains are distributed within the GBM (<STRONG>B</STRONG> and <STRONG>C</STRONG>, respectively). The Bowman's capsule is strongly α5(IV)-positive (<STRONG>C</STRONG>). In X-linked Alport syndrome, no α3(IV) expression was detected in a male patient (id for α4-α5) (<STRONG>F</STRONG>), whereas the distribution is segmental in a female patient (<STRONG>G</STRONG>). In autosomal recessive Alport syndrome, no α3(IV)-α5(IV) labeling is detected in the GBM (<STRONG>J</STRONG>) whereas α5(IV) is expressed in Bowman's capsule (<STRONG>K</STRONG>) and the basement membranes of the collecting ducts (<STRONG>L</STRONG>). In both types of Alport syndrome, α1(IV) is diffusely expressed in the GBM (<STRONG>E,I</STRONG>).</div><div class=\"graphic_footnotes\">GBM: glomerular basement membrane.</div><div class=\"graphic_reference\">Reprinted with permission from: Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 2008; 1:24. Copyright ©2008 Macmillan Publishers Ltd.</div><div id=\"graphicVersion\">Graphic 81373 Version 2.0</div></div></div>"},"81374":{"type":"graphic_table","displayName":"Antidepressant side effects PI","title":"Chance of side effects with certain antidepressant medicines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chance of side effects with certain antidepressant medicines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">US brand name</td> <td class=\"subtitle1\">Dry mouth<br /> Blurred vision<br /> Trouble urinating<br /> Constipation<br /> Dizziness</td> <td class=\"subtitle1\">Drowsiness</td> <td class=\"subtitle1\">Trouble sleeping<br /> Jitteriness</td> <td class=\"subtitle1\">Nausea<br /> Vomiting<br /> Diarrhea</td> <td class=\"subtitle1\">Weight gain</td> <td class=\"subtitle1\">Sexual problems</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Selective serotonin reuptake inhibitors (SSRIs)*</td> </tr> <tr> <td class=\"indent1\">Citalopram</td> <td>Celexa</td> <td>None</td> <td>None</td> <td>Very low</td> <td>Very low</td> <td>Very low</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Escitalopram</td> <td>Lexapro</td> <td>None</td> <td>None</td> <td>Very low</td> <td>Very low</td> <td>Very low</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td>Prozac, Sarafem</td> <td>None</td> <td>None</td> <td>Low</td> <td>Very low</td> <td>Very low</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Fluvoxamine</td> <td>Luvox (only sold as generic in US)</td> <td>None</td> <td>Very low</td> <td>Very low</td> <td>Very low</td> <td>Very low</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Paroxetine</td> <td>Paxil, Pexeva, others</td> <td>Very low</td> <td>Very low</td> <td>Very low</td> <td>Very low</td> <td>Low</td> <td>High</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sertraline</td> <td>Zoloft</td> <td>None</td> <td>None</td> <td>Low</td> <td>Low<sup>&#182;</sup></td> <td>Very low</td> <td>Moderate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Atypical agents</td> </tr> <tr> <td class=\"indent1\">Bupropion</td> <td>Wellbutrin, Aplenzin, others</td> <td>None</td> <td>None</td> <td> <p>Quick-release: Low</p> Sustained release: Very low</td> <td>Very low</td> <td>None</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mirtazapine</td> <td>Remeron</td> <td>Very low</td> <td>High</td> <td>None</td> <td>None</td> <td>High</td> <td>Very low</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Serotonin-norepinephrine reuptake inhibitors (SNRIs)*</td> </tr> <tr> <td class=\"indent1\">Desvenlafaxine</td> <td>Pristiq, Khedezla</td> <td>None</td> <td>Very low</td> <td>Low</td> <td>Very low (after week 1)</td> <td>None</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Duloxetine</td> <td>Cymbalta</td> <td>None</td> <td>None</td> <td>Low</td> <td>Low</td> <td>None</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Levomilnacipran</td> <td>Fetzima</td> <td>Very low</td> <td>None</td> <td>Very low</td> <td>Low</td> <td>None</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Milnacipran</td> <td>Savella</td> <td>None</td> <td>Very low</td> <td>None</td> <td>Low</td> <td>None</td> <td>Low</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Venlafaxine</td> <td>Effexor</td> <td>None</td> <td>Very low</td> <td>Low</td> <td> <p>Quick-release: Low</p> Extended release: Very low</td> <td>None</td> <td>Moderate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Serotonin modulators</td> </tr> <tr> <td class=\"indent1\">Trazodone</td> <td>Desyrel (only sold as generic in US)</td> <td>None</td> <td>High</td> <td>None</td> <td> <p>Sleep-aid dose: Very low</p> Antidepressant dose: Moderate</td> <td> <p>Sleep-aid dose: None</p> Antidepressant dose: Very low</td> <td>Very low<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Vilazodone</td> <td>Viibryd</td> <td>None</td> <td>None</td> <td>Low</td> <td>High</td> <td>None</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Nefazodone<sup>&#9674;</sup></td> <td>Serzone (only sold as generic in US)</td> <td>Very low</td> <td>Low</td> <td>None</td> <td>Low</td> <td>None</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>* All SSRIs and SNRIs can cause nausea and stomach upset at first or when increasing dose. This usually goes away after about a week. Also, some SNRIs such as venlafaxine can increase your blood pressure. Talk to your doctor if you have high blood pressure.<br />¶ Sertraline is more likely than other SSRIs to cause diarrhea.<br />Δ Trazodone can cause an erection that lasts too long. This is a medical emergency.<br /><FONT class=lozenge>◊</FONT> Caution: Nefazodone can cause liver failure. Not available in Europe, Canada, and several other countries.</FONT></div><div class=\"graphic_reference\">Created with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved. </LI>&#xD;&#xA;<LI>Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric disease. Clin Pharm Ther 2011; 89:142-7. </LI></OL></div><div id=\"graphicVersion\">Graphic 81374 Version 19.0</div></div></div>"},"81375":{"type":"graphic_diagnosticimage","displayName":"Older stress fracture (Torg type II) of the fifth metatarsal","title":"Older stress fracture (Torg type II) of the fifth metatarsal","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Older stress fracture (Torg type II) of the fifth metatarsal</div><div class=\"cntnt\"><img style=\"width:468px; height:442px;\" src=\"images/EM/81375_Older_stress_fx_fifth_metat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This close up view from a plain radiograph shows an older stress fracture (Torg type II) of the fifth metatarsal diaphysis. Note the widened fracture line (arrow), extension of the fracture to the opposite cortex, intramedullary sclerosis, and significant periosteal new bone (causing lateral bulge of cortex). This stress fracture clearly lies distal to the intrametatarsal joint. There is great risk of nonunion with such diaphyseal stress fractures.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 81375 Version 7.0</div></div></div>"},"81378":{"type":"graphic_figure","displayName":"Pathogenesis cluster headache ","title":"Pathogenesis of cluster headache","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of cluster headache</div><div class=\"cntnt\"><img style=\"width:507px; height:563px;\" src=\"images/NEURO/81378_Cluster_HA_pathogenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic model showing most of the putative actors in CH pathogenesis. Pain afferents from the trigeminovascular system synapse on the trigeminocervical complex (TNC), and then project to the thalamus and lead to activation in cortical areas known to be involved in pain transmission. Either a direct influence of the hypothalamus or a reflex activation of the parasympathetic outflow from the superior salivatory nucleus (SSN) predominately through the pterygopalatine (sphenopalatine) ganglion, leads to the parasympathetic symptoms ipsilateral to the pain. A third-order sympathetic nerve lesion, thought to be caused by vascular changes in the cavernous sinus loggia with subsequent irritation of the local plexus of nerve fibers, results in a partial Horner's syndrome. The key site in the CNS for triggering the pain and controlling the cycling aspects is in the posterior hypothalamic grey matter region, modulated by phase-shifting in the suprachiasmatic nuclei.   </div><div class=\"graphic_footnotes\">Abbreviations: Ggl = ganglion, HT = hypothalamus, ICA = internal carotid artery, NV = trigeminal nerve, PPT = pterygopalatine, SCG = superior cervical ganglion, SN = suprachiasmatic nucleus, SSN = superior salivatory nucleus, TNC = trigeminal nucleus caudalis</div><div class=\"graphic_reference\">Modified from: May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet 2005; 366:847.</div><div id=\"graphicVersion\">Graphic 81378 Version 3.0</div></div></div>"},"81379":{"type":"graphic_table","displayName":"Male birth weight by gestational age","title":"Smoothed percentiles of birth weight (g) for male infants based on gestational age: United States (2009 to 2010)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Smoothed percentiles of birth weight (g) for male infants based on gestational age: United States (2009 to 2010)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"11\" width=\"9%\"></colgroup> <tbody> <tr class=\"centered\"> <td class=\"subtitle1\" rowspan=\"2\">Gestational age (week)</td> <td class=\"subtitle1\" colspan=\"7\">Percentile</td> <td class=\"subtitle1\" rowspan=\"2\"><em>n</em></td> <td class=\"subtitle1\" rowspan=\"2\">Mean</td> <td class=\"subtitle1\" rowspan=\"2\">SD</td> </tr> <tr> <td class=\"subtitle2\">3<sup>rd</sup></td> <td class=\"subtitle2\">5<sup>th</sup></td> <td class=\"subtitle2\">10<sup>th</sup></td> <td class=\"subtitle2\">50<sup>th</sup></td> <td class=\"subtitle2\">90<sup>th</sup></td> <td class=\"subtitle2\">95<sup>th</sup></td> <td class=\"subtitle2\">97<sup>th</sup></td> </tr> <tr class=\"centered\"> <td>22</td> <td>308</td> <td>330</td> <td>375</td> <td>499</td> <td>621</td> <td>658</td> <td>686</td> <td>1999</td> <td>495</td> <td>95</td> </tr> <tr class=\"centered\"> <td>23</td> <td>349</td> <td>381</td> <td>436</td> <td>586</td> <td>717</td> <td>761</td> <td>790</td> <td>2420</td> <td>583</td> <td>110</td> </tr> <tr class=\"centered\"> <td>24</td> <td>395</td> <td>434</td> <td>497</td> <td>675</td> <td>819</td> <td>868</td> <td>902</td> <td>3189</td> <td>669</td> <td>130</td> </tr> <tr class=\"centered\"> <td>25</td> <td>444</td> <td>488</td> <td>561</td> <td>771</td> <td>941</td> <td>996</td> <td>1037</td> <td>3620</td> <td>765</td> <td>159</td> </tr> <tr class=\"centered\"> <td>26</td> <td>495</td> <td>546</td> <td>629</td> <td>883</td> <td>1087</td> <td>1154</td> <td>1204</td> <td>4007</td> <td>869</td> <td>193</td> </tr> <tr class=\"centered\"> <td>27</td> <td>553</td> <td>614</td> <td>706</td> <td>1010</td> <td>1246</td> <td>1329</td> <td>1390</td> <td>4485</td> <td>1000</td> <td>216</td> </tr> <tr class=\"centered\"> <td>28</td> <td>628</td> <td>699</td> <td>802</td> <td>1149</td> <td>1422</td> <td>1520</td> <td>1590</td> <td>5128</td> <td>1138</td> <td>252</td> </tr> <tr class=\"centered\"> <td>29</td> <td>731</td> <td>809</td> <td>924</td> <td>1302</td> <td>1625</td> <td>1737</td> <td>1817</td> <td>5902</td> <td>1290</td> <td>281</td> </tr> <tr class=\"centered\"> <td>30</td> <td>860</td> <td>944</td> <td>1068</td> <td>1475</td> <td>1850</td> <td>1978</td> <td>2067</td> <td>7696</td> <td>1472</td> <td>304</td> </tr> <tr class=\"centered\"> <td>31</td> <td>1008</td> <td>1097</td> <td>1231</td> <td>1670</td> <td>2094</td> <td>2239</td> <td>2335</td> <td>10,218</td> <td>1663</td> <td>340</td> </tr> <tr class=\"centered\"> <td>32</td> <td>1176</td> <td>1271</td> <td>1415</td> <td>1888</td> <td>2357</td> <td>2517</td> <td>2620</td> <td>14,790</td> <td>1882</td> <td>372</td> </tr> <tr class=\"centered\"> <td>33</td> <td>1371</td> <td>1473</td> <td>1627</td> <td>2127</td> <td>2639</td> <td>2808</td> <td>2920</td> <td>22,509</td> <td>2126</td> <td>400</td> </tr> <tr class=\"centered\"> <td>34</td> <td>1590</td> <td>1697</td> <td>1859</td> <td>2381</td> <td>2933</td> <td>3107</td> <td>3224</td> <td>40,764</td> <td>2382</td> <td>423</td> </tr> <tr class=\"centered\"> <td>35</td> <td>1827</td> <td>1938</td> <td>2105</td> <td>2641</td> <td>3216</td> <td>3390</td> <td>3512</td> <td>73,875</td> <td>2653</td> <td>441</td> </tr> <tr class=\"centered\"> <td>36</td> <td>2076</td> <td>2187</td> <td>2355</td> <td>2895</td> <td>3481</td> <td>3654</td> <td>3782</td> <td>158,574</td> <td>2905</td> <td>442</td> </tr> <tr class=\"centered\"> <td>37</td> <td>2315</td> <td>2424</td> <td>2588</td> <td>3126</td> <td>3717</td> <td>3888</td> <td>4021</td> <td>379,037</td> <td>3149</td> <td>467</td> </tr> <tr class=\"centered\"> <td>38</td> <td>2522</td> <td>2626</td> <td>2782</td> <td>3313</td> <td>3901</td> <td>4071</td> <td>4205</td> <td>813,577</td> <td>3337</td> <td>446</td> </tr> <tr class=\"centered\"> <td>39</td> <td>2678</td> <td>2775</td> <td>2926</td> <td>3451</td> <td>4033</td> <td>4203</td> <td>4334</td> <td>1,242,244</td> <td>3465</td> <td>435</td> </tr> <tr class=\"centered\"> <td>40</td> <td>2774</td> <td>2869</td> <td>3017</td> <td>3545</td> <td>4124</td> <td>4297</td> <td>4421</td> <td>820,839</td> <td>3547</td> <td>433</td> </tr> <tr class=\"centered\"> <td>41</td> <td>2821</td> <td>2916</td> <td>3065</td> <td>3605</td> <td>4186</td> <td>4364</td> <td>4483</td> <td>316,857</td> <td>3624</td> <td>440</td> </tr> <tr class=\"centered\"> <td>42</td> <td>2828</td> <td>2929</td> <td>3082</td> <td>3635</td> <td>4227</td> <td>4412</td> <td>4528</td> <td>60,195</td> <td>3648</td> <td>450</td> </tr> <tr class=\"centered\"> <td>43</td> <td>2796</td> <td>2911</td> <td>3067</td> <td>3645</td> <td>4253</td> <td>4448</td> <td>4561</td> <td>9316</td> <td>3697</td> <td>469</td> </tr> <tr class=\"centered\"> <td>44</td> <td>2739</td> <td>2872</td> <td>3027</td> <td>3646</td> <td>4271</td> <td>4480</td> <td>4591</td> <td>812</td> <td>3623</td> <td>534</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Means, SDs, and smoothed percentiles for birth weight (g) for gestational age within the corrected dataset: US male singleton live births (2009 to 2010). The corrected dataset uses both last menstrual period (LMP) and clinical/obstetric-based estimates of gestational age, and reflects the application of the Basso and Wilcox algorithm<sup>[1]</sup> to correct likely errors in gestational age and excludes implausible birth weights for gestational age.</div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Basso O, Wilcox A. Mortality risk among preterm babies: immaturity versus underlying pathology. Epidemiology 2010; 21:521.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from Pediatrics, Vol. 133, Pages 844-53, Copyright &copy; 2014 by the AAP.</div><div id=\"graphicVersion\">Graphic 81379 Version 7.0</div></div></div>"},"81381":{"type":"graphic_picture","displayName":"Cutaneous involvement ILCL","title":"Skin biopsy intravascular large cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Skin biopsy intravascular large cell lymphoma</div><div class=\"cntnt\"><img style=\"width:514px; height:196px;\" src=\"images/HEME/81381_Cutaneous_ILCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A few vessels located deeply in the subcutaneous fat show intravascular proliferations.<br> (B) Large cells with large heterochromatic nuclei are seen in the lumen of a blood vessel. A reactive infiltrate of lymphocytes and plasma cells is present around the adjacent fat lobules. This infiltrate may be mistaken for a panniculitis.</div><div id=\"graphicVersion\">Graphic 81381 Version 2.0</div></div></div>"},"81382":{"type":"graphic_diagnosticimage","displayName":"Hemoperitoneum abdomen pelvis","title":"Female pelvic and abdominal hemoperitoneum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female pelvic and abdominal hemoperitoneum</div><div class=\"cntnt\"><img style=\"width:354px; height:583px;\" src=\"images/OBGYN/81382_Hemoperitoneum_abd_pelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Sagittal transvaginal view of pelvis shows no intrauterine pregnancy. There is a large amount of complex fluid (F) and clot (C) surrounding the uterus (calipers). The ovaries were difficult to identify due to extent of hemorrhage and patient discomfort. B) Scanning of the upper abdomen showed fluid extending into Morrison's Pouch. This patient was unstable and went to the OR. The hemoperitoneum was attributed to a ruptured hemorrhagic corpus luteum.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 81382 Version 4.0</div></div></div>"},"81383":{"type":"graphic_picture","displayName":"Gram stain CSF 3 with answer","title":"Haemophilus influenzae in cerebrospinal fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Haemophilus influenzae in cerebrospinal fluid</div><div class=\"cntnt\"><img style=\"width:371px; height:240px;\" src=\"images/ID/81383_Gram_stain_CSF_3_with_answe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and small, pleomorphic, gram-negative coccobacilli. <em>Haemophilus influenzae</em> grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 81383 Version 4.0</div></div></div>"},"81384":{"type":"graphic_table","displayName":"Survival DPAM versus muc cancer","title":"Comparative survival of appendiceal cancer according to histology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparative survival of appendiceal cancer according to histology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Subset</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Median survival, months</td> <td class=\"subtitle1\">Five-year survival, percent</td> <td class=\"subtitle1\">10-year survival, percent</td> </tr> <tr> <td>Disseminated peritoneal adenomucinosis (DPAM)</td> <td>65</td> <td>112.4</td> <td>75</td> <td>68</td> </tr> <tr> <td>Mucinous carcinomatosis</td> <td>43</td> <td>35</td> <td>26</td> <td>9</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DPAM: disseminated peritoneal adenomucinosis.</div><div class=\"graphic_reference\">Data from: Ronnett BM, Yan H, Kurman RJ, et al. Patients with Pseudomyxoma Peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001; 92:85.</div><div id=\"graphicVersion\">Graphic 81384 Version 2.0</div></div></div>"},"81385":{"type":"graphic_figure","displayName":"Trandolapril lowers mortality after MI","title":"Long-term mortality after myocardial infarction is reduced by trandolapril","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long-term mortality after myocardial infarction is reduced by trandolapril</div><div class=\"cntnt\"><img style=\"width:424px; height:456px;\" src=\"images/CARD/81385_Outcome_trandolapril_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 1749 patients in the TRACE study followed for a minimum of six years, treatment with trandolapril improved life expectancy by 15.3 months (6.2 versus 4.6 years for placebo). The number of lives saved per 1000 people treated are shown for each year.</div><div class=\"graphic_reference\">Data from Torp-Pederson C, Kober L, for the TRACE Study Group. Lancet 1999; 354:9.</div><div id=\"graphicVersion\">Graphic 81385 Version 3.0</div></div></div>"},"81386":{"type":"graphic_picture","displayName":"JXG single face nodule","title":"Juvenile xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:226px; height:159px;\" src=\"images/DERM/81386_JXG_single_face_nod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single nodule of juvenile xanthogranuloma in the nasolabial fold of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Kate P&#252;ttgen.</div><div id=\"graphicVersion\">Graphic 81386 Version 1.0</div></div></div>"},"81388":{"type":"graphic_diagnosticimage","displayName":"Functional PET imaging for metastatic GI neuroendocrine tumor","title":"Functional PET imaging techniques for metastatic gastrointestinal tract neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Functional PET imaging techniques for metastatic gastrointestinal tract neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:414px; height:584px;\" src=\"images/ONC/81388_Carcinoid_imag_techniques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Fused 18F-dihydroxy-phenyl-alanine (18F-DOPA) positron emission tomography (PET)/computed tomography scan<br />(B) Somatostatin receptor scintigraphy<br />(C) 18F-DOPA PET<br />(D) 11C-5-hydroxy-tryptophan (11C-5-HTP) PET of an 80-year-old male patient with metastatic neuroendocrine tumor of the gastrointestinal tract</div><div class=\"graphic_reference\">From: Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26:1489. Reprinted with permission. Copyright © 2008 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 81388 Version 6.0</div></div></div>"},"81389":{"type":"graphic_table","displayName":"Bridging anticoagulation","title":"Recommendations for preoperative and postoperative anticoagulation in patients on a vitamin K antagonist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for preoperative and postoperative anticoagulation in patients on a vitamin K antagonist</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Before surgery</td> <td class=\"subtitle1\">After surgery</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Venous thromboembolism</td> </tr> <tr> <td class=\"indent1\">Within first month</td> <td class=\"indent1\">IV heparin or SQ LMWH</td> <td class=\"indent1\">IV heparin or SQ LMWH</td> </tr> <tr> <td class=\"indent1\">Second/third month</td> <td class=\"indent1\">No change*</td> <td class=\"indent1\">IV heparin or SQ LMWH</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;3 months</td> <td class=\"indent1\">No change*</td> <td class=\"indent1\">SQ heparin or LWMH</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Arterial thromboembolism</td> </tr> <tr> <td class=\"indent1\">Recent, within one month</td> <td class=\"indent1\">IV heparin or SQ LMWH</td> <td class=\"indent1\">IV heparin or SQ LMWH</td> </tr> <tr> <td class=\"indent1\">Prophylaxis (eg, non-valvular AF, mechanical heart valve)</td> <td class=\"indent1\">No change*</td> <td class=\"indent1\">Resume oral anticoagulation<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Warfarin should be withheld to allow the INR to fall spontaneously to 1.5 to 2 before surgery is performed.</div><div class=\"graphic_footnotes\">IV: intravenous; SQ: subcutaneous; LMWH: low molecular weight heparin; AF: atrial fibrillation; INR: international normalized ratio.<br />* If the patient is hospitalized, SQ heparin or LMWH should be administered, but hospitalization is not recommended solely for this purpose.<br />¶ Can use SQ heparin or SQ LMWH if the surgery carries a high risk of postoperative thromboembolism.</div><div id=\"graphicVersion\">Graphic 81389 Version 4.0</div></div></div>"},"81390":{"type":"graphic_figure","displayName":"Pathogenesis end stage HCM","title":"Hypothetical model for the pathogenesis of the end-stage phase of hypertrophic cardiomyopathy with left ventricular wall thinning and cavity enlargement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypothetical model for the pathogenesis of the end-stage phase of hypertrophic cardiomyopathy with left ventricular wall thinning and cavity enlargement</div><div class=\"cntnt\"><img style=\"width:296px; height:458px;\" src=\"images/CARD/81390_PathogenesisendstageHCM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LV: left ventricular.</div><div class=\"graphic_footnotes\">* Indicates the following possibilities: 1) enhanced myocardial oxygen requirements and reduced myocardial capillary density relative to marked left ventricular hypertrophy (LVH); and 2) increased diastolic wall tension and coronary vascular resistance resulting from abnormal LV relaxation and impaired filling.</div><div class=\"graphic_reference\">Redrawn from Maron BJ, Spirito P, Am J Cardiol 1998; 81:1339.</div><div id=\"graphicVersion\">Graphic 81390 Version 2.0</div></div></div>"},"81391":{"type":"graphic_diagnosticimage","displayName":"Pulsed wave Doppler LV outflow","title":"Pulsed wave Doppler echocardiography flow signals from the left ventricular outflow tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulsed wave Doppler echocardiography flow signals from the left ventricular outflow tract</div><div class=\"cntnt\"><img style=\"width:371px; height:277px;\" src=\"images/CARD/81391_Pulsed_wave_Doppler_LV_outf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pulsed wave Doppler signal is obtained from the anteriorly angulated apical four chamber echocardiographic view. The arrow indicates the dashed line positioned by the sonographer to outline the signal. The area under the curve described by the tracing is integrated and expressed as the velocity time integral (VTI). In this example, the value of 16 cm represents an abnormally low value (normal&nbsp;&gt;18 cm).</div><div id=\"graphicVersion\">Graphic 81391 Version 4.0</div></div></div>"},"81393":{"type":"graphic_picture","displayName":"Pitted keratolysis","title":"Pitted keratolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pitted keratolysis</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/DERM/81393_Pitted_keratolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 20-year-old female with plantar hyperhidrosis exhibited asymptomatic&nbsp;cribriform pits on her soles. The feet were malodorous.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 81393 Version 7.0</div></div></div>"},"81394":{"type":"graphic_diagnosticimage","displayName":"Stage III lateral condyle fracture","title":"Stage III lateral condyle elbow fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stage III lateral condyle elbow fracture</div><div class=\"cntnt\"><img style=\"width:207px; height:432px;\" src=\"images/EM/81394_StageIIILCfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral condylar fracture with fragment displacement and rotation in a two-year-old girl (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Bachman D, Santora S. Orthopedic trauma. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81394 Version 14.0</div></div></div>"},"81395":{"type":"graphic_picture","displayName":"Duodenal amyloid HandE","title":"Amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amyloidosis</div><div class=\"cntnt\"><img style=\"width:363px; height:252px;\" src=\"images/GAST/81395_Duodenal_amyloid_HandE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic biopsy of nodular duodenal epithelium stained with hematoxylin and eosin. Note the pink amorphous deposit in the lamina propria (arrow).</div><div class=\"graphic_reference\">Courtesy of Michael Camilleri, MD.</div><div id=\"graphicVersion\">Graphic 81395 Version 1.0</div></div></div>"},"81397":{"type":"graphic_picture","displayName":"Poison ivy 1","title":"Poison ivy leaves and flowers","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Poison ivy leaves and flowers</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/81397_Poisonivy1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Green or green-reddish leaves grow in groups of three and have smooth, fine-toothed, or lobed margins, and small, yellow-green flowers form cream-colored fruit.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81397 Version 6.0</div></div></div>"},"81398":{"type":"graphic_picture","displayName":"Atopic dermatitis papular PI","title":"Atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:325px; height:432px;\" src=\"images/PI/81398_Atopic_derm_papular_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous erythematous papules are present on the hands of this patient with atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81398 Version 5.0</div></div></div>"},"81401":{"type":"graphic_table","displayName":"Autoimmune diseases in RPC","title":"Frequency of coexisting autoimmune diseases in 645 patients with relapsing polychondritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of coexisting autoimmune diseases in 645 patients with relapsing polychondritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Number</td> </tr> <tr> <td>Systemic vasculitis</td> <td>73*</td> </tr> <tr> <td>Rheumatoid disease</td> <td>31</td> </tr> <tr> <td>Lupus erythematous</td> <td>18</td> </tr> <tr> <td>Sj&#246;gren's syndrome</td> <td>15</td> </tr> <tr> <td>Beh&#231;et's disease</td> <td>8</td> </tr> <tr> <td>Ankylosing spondylitis</td> <td>7</td> </tr> <tr> <td>Reactive arthritis</td> <td>6</td> </tr> <tr> <td>Psoriatic arthritis</td> <td>4</td> </tr> <tr> <td>Systemic sclerosis</td> <td>2</td> </tr> <tr> <td>Polymyalgia rheumatica</td> <td>2</td> </tr> <tr> <td>Retroperitoneal fibrosis</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Encompasses both primary and secondary forms of vasculitis.</div><div id=\"graphicVersion\">Graphic 81401 Version 2.0</div></div></div>"},"81402":{"type":"graphic_table","displayName":"Frequency of maternal blood lead follow-up testing","title":"Frequency of maternal blood lead follow-up testing during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of maternal blood lead follow-up testing during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Venous blood lead level (BLL; mcg/dL)</td> <td class=\"subtitle1\">Perform follow-up test(s)</td> </tr> <tr> <td>&#60;5</td> <td>None (no follow-up testing is indicated).</td> </tr> <tr> <td>5 to 14</td> <td>Within&nbsp;one month. Obtain a maternal BLL* or cord BLL at delivery.</td> </tr> <tr> <td>15 to 24</td> <td>Within one month and then every&nbsp;two to&nbsp;three&nbsp;months. Obtain a maternal BLL* or cord BLL at delivery. More frequent testing may be indicated based on risk factor history.</td> </tr> <tr> <td>25 to 44</td> <td>Within&nbsp;one&nbsp;to four&nbsp;weeks and then every month. Obtain a maternal BLL* or cord BLL at delivery.</td> </tr> <tr> <td>&#8805;45</td> <td>Within 24 hours and then at frequent intervals depending on clinical interventions and trend in BLLs. Consultation with a clinician experienced in the management of pregnant women with BLLs in this range is strongly advised. Obtain a maternal BLL* or cord BLL at delivery.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BLL: blood lead level.<br />* If possible, obtain a maternal BLL prior to delivery since BLLs tend to rise over the course of pregnancy.</div><div class=\"graphic_reference\">Reproduced from: Ettinger AS, Wengrovitz AG. Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women. Centers for Disease Control and Prevention. November 2010.</div><div id=\"graphicVersion\">Graphic 81402 Version 5.0</div></div></div>"},"81404":{"type":"graphic_table","displayName":"Clinical practice recs for multiple comorbidities","title":"Recommendations based on clinical practice guidelines for a hypothetical 79-year-old woman with hypertension, diabetes mellitus, osteoarthritis, osteoporosis, and COPD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations based on clinical practice guidelines for a hypothetical 79-year-old woman with hypertension, diabetes mellitus, osteoarthritis, osteoporosis, and COPD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patient tasks</td> </tr> <tr> <td>Joint protection</td> </tr> <tr> <td>Energy conservation</td> </tr> <tr> <td>Exercise<br /> <ul> <li>Non-weightbearing if severe foot disease present or weightbearing for osteoporosis </li> <li>Aerobic exercise for 30 minutes on most days </li> <li>Muscle strengthening </li> <li>Range of motion </li> </ul> </td> </tr> <tr> <td>Avoid environmental exposures that might exacerbate chronic obstructive pulmonary disease (COPD)</td> </tr> <tr> <td>Wear appropriate footwear</td> </tr> <tr> <td>Limit intake of alcohol</td> </tr> <tr> <td>Maintain normal body weight (body mass index of between 18.5 and 24.9)</td> </tr> <tr> <td class=\"subtitle1_single\">Clinician tasks </td> </tr> <tr> <td>Administer vaccine<br /> <ul> <li>Pneumonia </li> <li>Influenza annually </li> </ul> </td> </tr> <tr> <td>Check blood pressure at all clinician visits and sometimes at home*</td> </tr> <tr> <td>Evaluate self-monitoring of blood glucose</td> </tr> <tr> <td>Foot examination at all clinician visits if neuropathy present; otherwise, check feet for protective sensation, structure, biomechanics, vascular status, and skin integrity annually </td> </tr> <tr> <td>Laboratory tests<br /> <ul> <li>Microalbuminuria annually if not already present </li> <li>Creatinine level and electrolytes at least&nbsp;one to&nbsp;two times per year </li> <li>Cholesterol levels annually </li> <li>Liver function biannually </li> <li>Glycosylated hemoglobin level biannually to quarterly, depending on level of control </li> </ul> </td> </tr> <tr> <td>Referrals<br /> <ul> <li>Physical therapy </li> <li>Ophthalmologic examination </li> <li>Pulmonary rehabilitation </li> <li>Dual-energy x-ray absorptiometry scan every other year </li> </ul> </td> </tr> <tr> <td>Patient education<br /> <ul> <li>High-risk foot conditions, foot care, and foot wear </li> <li>Osteoarthritis </li> <li>COPD medication and delivery system training </li> <li>Diabetes mellitus </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Ambulatory blood pressure monitoring is helpful if &quot;white coat hypertension&quot; is suspected and no target organ damage, apparent drug resistance, hypotensive symptoms with antihypertensive medication, or episodic hypertension.</div><div class=\"graphic_reference\">Reproduced with permission from: Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. JAMA 2005; 294:716. Copyright © 2005 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 81404 Version 10.0</div></div></div>"},"81405":{"type":"graphic_table","displayName":"Echinococcal cyst features","title":"Cyst characteristics of the four echinococcal species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cyst characteristics of the four echinococcal species</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Species </td> <td class=\"subtitle1\">Larval form in humans </td> <td class=\"subtitle1\">Cyst components </td> <td class=\"subtitle1\">Cyst growth </td> </tr> <tr> <td><em>E. granulosus</em></td> <td>Cystic, unilocular, expansile</td> <td>Metacestode has an internal germinative layer (endocyst) surrounded by a parasite-derived acellular laminated layer (exocyst), which in turn is surrounded by a host-derived adventitial layer (pericyst).</td> <td>Cells bud internally within the cystic cavity, then vacuolate and become \"brood\" capsules. Protoscolices develop within the brood capsules.</td> </tr> <tr> <td><em>E. multilocularis</em></td> <td>Multilocular, infiltrative</td> <td>Very thin laminated layer only and no pericyst, which enables tissue invasion.</td> <td>Germinative layer of the metacestode proliferates within cyst and exogenously to infiltrate host tissue. Cells from the germinative layer can detach and metastasize to other organs.</td> </tr> <tr> <td><em>E. vogeli </em>and <em>E. oligarthus</em></td> <td>Polycystic, expansile</td> <td>Large cysts with multiple vesicles are separated by septa lined by germinative epithelium. Externally, the cyst is surrounded by fibrous tissue.</td> <td>Brood capsules bud internally from the germinative epithelium. An expansile and infiltrative polycystic metacestode mass develops.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81405 Version 2.0</div></div></div>"},"81406":{"type":"graphic_figure","displayName":"Persistence of middle ear effusion after acute otitis media","title":"Persistence of middle ear effusion after acute otitis media","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Persistence of middle ear effusion after acute otitis media</div><div class=\"cntnt\"><img style=\"width:380px; height:288px;\" src=\"images/ID/81406_PersistenceofOMEafterAO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percent of children with middle ear effusion persisting for up to 12 weeks after an episode of acute otitis media.</div><div class=\"graphic_footnotes\">OME: otitis media with effusion.</div><div class=\"graphic_reference\">Adapted from:&nbsp;Bluestone CD,&nbsp;Klein JO,&nbsp;Otitis Media in Infants and Children,&nbsp;WB Saunders, Philadelphia 2001.</div><div id=\"graphicVersion\">Graphic 81406 Version 3.0</div></div></div>"},"81407":{"type":"graphic_figure","displayName":"Edinburgh depression scale 2","title":"Appendix A: Edinburgh Postnatal Depression Scale (EPDS) (continued)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Appendix A: Edinburgh Postnatal Depression Scale (EPDS) (continued)</div><div class=\"cntnt\"><img style=\"width:396px; height:537px;\" src=\"images/OBGYN/81407_Edinburghdepressionscal1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A score of 12 or more identifies most women with postpartum depression. Women who report depressive symptoms without suicidal ideation or major functional impairment (or score between 5 and 9 on the EPDS) should be re-evaluated within one month.</div><div class=\"graphic_reference\">Reproduced with permission from: Cox JL, Holden JM, Sagovsky R. Department of Psychiatry, University of Edinburgh.</div><div id=\"graphicVersion\">Graphic 81407 Version 3.0</div></div></div>"},"81414":{"type":"graphic_figure","displayName":"SEER surv adeno colon","title":"Observed survival rates for 28,491 cases with adenocarcinoma of the colon","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Observed survival rates for 28,491 cases with adenocarcinoma of the colon</div><div class=\"cntnt\"><img style=\"width:538px; height:516px;\" src=\"images/ONC/81414_SEERsurvadenocolonedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the SEER 1973-2005 Public Use File diagnosed in years 1998-2000. Stage I includes 7417; Stage IIA, 9956; Stage IIB, 997; Stage IIC, 725; Stage IIIA, 868; Stage IIIB, 1492; Stage IIIC, 2000; and Stage IV, 5036.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 81414 Version 13.0</div></div></div>"},"81415":{"type":"graphic_table","displayName":"Meds for Meniere disease","title":"Medications used to treat Meniere disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications used to treat Meniere disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Diuretics</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Hydrochlorthiazide</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Hydrochlorthiazide and triamterene (Maxzide, Dyazide)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Acetazolamide (Diamox)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Methazolamide (Neptazane)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Antiemetics</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Meclizine</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Dimenhydrinate (Dramamine)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Prochlorperazine (Compazine)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Promethazine (Phenergan)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Anxiolytics (suppress the central vestibular response)</td>\n\n\n    </tr>\n\n    \n    <tr>\n\n      <td>Diazepam (Valium)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Lorazepam (Ativan)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Alprazolam (Xanax)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Thorazine</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Chlorpromazine</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Immunomodulators (for acute severe exacerbations and patients with autoimmune antibodies)</td>\n\n\n    </tr>\n\n    \n    <tr>\n\n      <td>Prednisone</td>\n\n\n    </tr>\n\n    <tr>\n\t\n      <td>Dexamethasone</td>\n\n    </tr>\n\n    <tr>\n\t\n      <td>Methotrexate</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Antihistamines (in patients with concomittant allergy or food allergy)</td>\n\n\n    </tr>\n\n<tr>\n\t\n\t<td>Diphenhydramine (Benadryl)</td>\n\t\n</tr>\n\n    \n    <tr>\n\n      <td>Loratadine (Claritin)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Fexofenadrine (Allegra)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Ceftirizine (Zyrtec)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Hydroxyzine (Vistaril)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Ototoxic antibiotics</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Gentamicin</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Streptomycin</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Others</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Betahistine</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Scopolamine</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81415 Version 3.0</div></div></div>"},"81417":{"type":"graphic_figure","displayName":"Lymphatic filariasis map","title":"Countries where lymphatic filariasis is endemic and status of mass drug administration (MDA) in those countries, 2014","html":"<div class=\"graphic\"><div style=\"width: 948px\" class=\"figure\"><div class=\"ttl\">Countries where lymphatic filariasis is endemic and status of mass drug administration (MDA) in those countries, 2014</div><div class=\"cntnt\"><img style=\"width:928px; height:648px;\" src=\"images/ID/81417_Lymphatic_filariass_map2014.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.</div><div class=\"graphic_reference\">Reprinted from Global programme to eliminate lymphatic filariasis: Progress report, 2014, World Health Organization, p. 489, Copyright © 2015. Available from: <A href=\"http://www.who.int/lymphatic_filariasis/resources/who_wer9038/en/\" target=_blank>http://www.who.int/lymphatic_filariasis/resources/who_wer9038/en/</A>. (Accessed on December 15, 2016).</div><div id=\"graphicVersion\">Graphic 81417 Version 2.0</div></div></div>"},"81420":{"type":"graphic_movie","displayName":"TEE bicaval view pacemaker wire vegetation","title":"Transesophageal echocardiogram (TEE) bicaval view showing a vegetation on pacemaker wire suggesting endocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram (TEE) bicaval view showing a vegetation on pacemaker wire suggesting endocarditis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/81420_teepwendconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:266px; height:201px;\" src=\"images/CARD/81420_teepwend.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiogram shows a large vegetation on a pacemaker electrode suggesting an infected wire.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 81420 Version 3.0</div></div></div>"},"81423":{"type":"graphic_table","displayName":"Genetic disorders CV anomalies","title":"Selected genetic disorders associated with cardiovascular malformations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected genetic disorders associated with cardiovascular malformations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Cardiovascular anomaly</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Genetic associations</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/192350\" target=\"_blank\"><span style=\"color: #0000ff;\">VATER/VACTERL association</span></a></td> <td>Wide ranging (including VSD, TOF, TGA and others)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chromosomal syndromes</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/190685\" target=\"_blank\">Down syndrome</a> (trisomy 21)</td> <td>AV canal defect, VSD, ASD, TOF, PDA, pulmonary hypertension</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://ghr.nlm.nih.gov/condition/trisomy-18\" target=\"_blank\">Edwards syndrome</a> (trisomy 18)</td> <td>ASD, VSD, PDA, PS, AS, COA, TOF, HLHS, pulmonary hypertension</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://ghr.nlm.nih.gov/condition/trisomy-13\" target=\"_blank\"><span style=\"color: #0000ff;\">Patau syndrome</span></a> (trisomy 13)</td> <td>ASD, VSD, TOF, PS, AS, COA, HLHS, DORV, pulmonary hypertension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://ghr.nlm.nih.gov/condition/turner-syndrome\" spellcheck=\"true\" target=\"_blank\">Turner syndrome</a></td> <td>Aortic valve abnormalities, COA, systemic and pulmonary venous abnormalities, VSD, HLHS, ASD, aortic dilation/rupture</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chromosomal deletion/microdeletion syndromes</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/188400\" target=\"_blank\">DiGeorge syndrome</a> (22q11 deletion syndrome)</td> <td>TOF, IAA and other aortic arch anomalies, truncus arteriosus, VSD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/194050\" target=\"_blank\">Williams syndrome</a></td> <td>Pulmonary and aortic valve defects, ASD, VSD, coronary ostial stenosis, branch pulmonary artery stenosis, arteriopathy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Single gene syndromes &ndash;&nbsp;Autosomal dominant inheritance pattern</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/118450\" target=\"_blank\">Alagille syndrome</a></td> <td>Peripheral pulmonary artery stenosis, ASD, VSD, TOF, COA</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/103580\" target=\"_blank\">Albright hereditary osteodystrophy</a></td> <td>Cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/115150\" spellcheck=\"true\">Cardiofaciocutaneous syndrome</a></td> <td>PS, ASD, VSD, HCM</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/214800\" target=\"_blank\"><span style=\"color: #0000ff;\">CHARGE syndrome</span></a></td> <td>VSD, ASD, TOF, DORV, PDA, PS, pulmonary vein anomalies</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/218040\" spellcheck=\"true\" target=\"_blank\">Costello syndrome</a></td> <td>HCM, PS, ASD, VSD, atrial arrhythmias</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/130050\" spellcheck=\"true\" target=\"_blank\">Ehlers-Danlos syndrome (vascular type</a>)&nbsp;</td> <td>Rupture of large vessels</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/142900\" spellcheck=\"true\" target=\"_blank\">Holt-Oram syndrome</a></td> <td>ASD, VSD, left-sided lesions, conotruncal defects, AV block</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/151100\" spellcheck=\"true\" target=\"_blank\">Leopard syndrome</a></td> <td>PS, prolonged PR interval, ASD, VSD, HCM</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/154700\" spellcheck=\"true\" target=\"_blank\">Marfan syndrome</a></td> <td>Aortic root dilation/aneurysmal dissection, AI, MVP</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/160900\" target=\"_blank\">Myotonic dystrophy</a></td> <td>Cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/162200\" target=\"_blank\">Neurofibromatosis</a></td> <td>COA, renal artery stenosis</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/187300\" spellcheck=\"true\" target=\"_blank\">Osler-Weber-Rendu disease</a></td> <td>Multiple telangiectasis, pulmonary AVM </td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/154500\" spellcheck=\"true\" target=\"_blank\">Treacher Collins syndrome</a></td> <td>ASD, VSD, PDA</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/191100\" target=\"_blank\">Tuberous sclerosis</a></td> <td>Myocardial rhabdomyoma, WPW</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/163950\" spellcheck=\"true\" target=\"_blank\">Noonan syndrome</a></td> <td>PS, ASD, AS, subaortic stenosis, HCM</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Single gene syndromes&nbsp;<span style=\"font-family: 'Times New Roman',serif;\">&ndash;</span> Autosomal recessive inheritance pattern</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/201000\" spellcheck=\"true\" target=\"_blank\">Carpenter syndrome</a></td> <td>PDA</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/219100\" target=\"_blank\">Cutis laxa</a></td> <td>Pulmonary hypertension</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/225500\" spellcheck=\"true\" target=\"_blank\">Ellis-van Creveld syndrome</a></td> <td>ASD, AVSD</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/229300\" target=\"_blank\">Friedreich ataxia</a></td> <td>Cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/607014\" spellcheck=\"true\" target=\"_blank\">MPS type IH (Hurler syndrome)</a></td> <td>AI, MR, premature CAD, cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/607016\" spellcheck=\"true\" target=\"_blank\">MPS type IS (Scheie syndrome)</a></td> <td>Aortic valve disease</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/252300\" target=\"_blank\">MPS type IV (Morquio syndrome)</a></td> <td>Aortic valve disease</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/253200\" target=\"_blank\">MPS type VI (Maroteaux-Lamy syndrome)</a></td> <td>Aortic valve disease</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/232300\" target=\"_blank\">Pompe disease</a> (GSD type 2)</td> <td>Cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/264800\" target=\"_blank\">Pseudoxanthoma elasticum</a></td> <td>Premature CAD, MVP</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/270400\" spellcheck=\"true\" target=\"_blank\">Smith-Lemli-Opitz syndrome</a></td> <td>VSD, PDA, HLHS</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://omim.org/entry/274000\" spellcheck=\"true\" target=\"_blank\">Thrombocytopenia absent radii syndrome</a> (TAR)</td> <td>ASD, TOF</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Single gene syndromes&nbsp;<span style=\"font-family: 'Times New Roman',serif;\">&ndash;</span> X-linked inheritance pattern</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/309900\" spellcheck=\"true\" target=\"_blank\">MPS II (Hunter syndrome)</a></td> <td>Valvular disease, premature CAD, cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/310200\" target=\"_blank\">Duchenne muscular dystrophy</a></td> <td>Cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/310300\" target=\"_blank\">Emery-Dreifuss muscular dystrophy</a></td> <td>Cardiomyopathy</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/306955\" spellcheck=\"true\" target=\"_blank\">X-linked heterotaxy</a></td> <td>Heterotaxy</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/308300\" target=\"_blank\"><span style=\"color: #0000ff;\">Incontinentia pigmenti</span></a></td> <td>PDA, hypertension</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Genetic mutations associated with nonsyndromic congenital heart disease</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/108900\" spellcheck=\"true\" target=\"_blank\"><span style=\"color: #0000ff;\"><em>NKX2-5</em> mutation</span></a></td> <td>ASD, VSD, TOF, HLHS</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/600576\" spellcheck=\"true\" target=\"_blank\"><em>GATA4</em> mutation</a></td> <td>ASD, VSD, TOF</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/605101\" spellcheck=\"true\"><span style=\"color: #0000ff;\"><em>TAB2</em> mutation</span></a></td> <td>Valvular disease, VSD, TOF</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AI: aortic insufficiency; AS: aortic stenosis;&nbsp;ASD: atrial septal defect; AV: atrioventricular; AVM: arteriovenous malformation; AVSD: atrioventricular septal defect; CAD: coronary artery disease;&nbsp;CHARGE:&nbsp;Coloboma, Heart defect, Atresia choanae, Retarded growth and development, Genital abnormality, and Ear abnormality; COA: coarctation of the aorta;&nbsp;DORV: double outlet right ventricle; GSD: glycogen storage disease; HCM: hypertrophic cardiomyopathy; HLHS: hypoplastic left heart syndrome; IAA: interrupted aortic arch; MPS: mucopolysaccharidosis; MR: mitral regurgitation; MVP: mitral valve prolapse; PDA: patent ductus arteriosus; PS: pulmonic stenosis;&nbsp;TGA: transposition of the great arteries; TOF: tetralogy of Fallot;&nbsp;WPW: Wolff-Parkinson-White syndrome;&nbsp;VATER/VACTERL: Vertebral anomalies, Anal atresia, Cardiac defects, Tracheoesophageal fistula and/or Esophageal atresia, Renal &amp; Radial anomalies and Limb defects; VSD: ventricular septal defect. <br /></div><div id=\"graphicVersion\">Graphic 81423 Version 9.0</div></div></div>"},"81427":{"type":"graphic_diagnosticimage","displayName":"Upper GI barium study small bowel diverticula in scleroderma","title":"Upper GI barium study small bowel diverticula in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper GI barium study small bowel diverticula in scleroderma</div><div class=\"cntnt\"><img style=\"width:343px; height:292px;\" src=\"images/RHEUM/81427_Colon_diverticulae_sclerode.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper GI barium study in a patient with scleroderma shows wide-mouthed diverticula (arrows) in the proximal jejunum.</div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 81427 Version 3.0</div></div></div>"},"81428":{"type":"graphic_figure","displayName":"Regulation of fibrinolysis","title":"Regulation of fibrinolysis by plasminogen activator inhibitor-1 (PAI-1), α2-antiplasmin, and thrombin-activatable fibrinolysis inhibitor (TAFI)","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Regulation of fibrinolysis by plasminogen activator inhibitor-1 (PAI-1), &alpha;2-antiplasmin, and thrombin-activatable fibrinolysis inhibitor (TAFI)</div><div class=\"cntnt\"><img style=\"width:486px; height:336px;\" src=\"images/HEME/81428_Fibrinolyticpathwayedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PAI-1 inhibits plasmin formation by inhibiting t-PA. α<SUB>2</SUB>-antiplasmin inhibits the activity of plasmin, thereby inhibiting fibrinolysis. TAFI circulates in plasma as a zymogen. It is activated by thrombin when thrombin is bound on to its endothelial cofactor TM, and therefore represents a link between blood coagulation and fibrinolysis. During fibrinolysis, plasmin cleaves intact fibrin at lysine residues, initially yielding large, insoluble fibrin fragments with lysine residues at their carboxyl termini. Plasminogen binds avidly to C-terminal lysine residues within the partially degraded fibrin clot and assumes a conformation that is susceptible to activation by t-PA, thereby promoting plasmin formation, continued fibrinolysis (\"rapid fibrinolysis\"), and generation of smaller, soluble fibrin fragments that are dispersed by flowing blood. Activated TAFI (TAFI<SUB>a</SUB>) is a carboxypeptidase that removes lysine residues from the C-termini of partially degraded fibrin fragments. By removing C-terminal lysine residues from large fibrin fragments in the partially degraded clot, TAFI inhibits recruitment of plasminogen to the clot, thereby slowing fibrinolysis (\"slow fibrinolysis\").</div><div class=\"graphic_footnotes\">PAI-1: plasminogen activator inhibitor-1; t-PA: tissue-type plasminogen activator; TAFI: thrombin-activatable fibrinolysis inhibitor; TAFI<SUB>a</SUB>: activated form of TAFI; TM: thrombomodulin.</div><div class=\"graphic_reference\">Diagram supplied by William P Fay, MD.</div><div id=\"graphicVersion\">Graphic 81428 Version 7.0</div></div></div>"},"81429":{"type":"graphic_table","displayName":"Rx staph NVE","title":"Treatment regimens for native valve endocarditis due to <EM>Staphylococcus</EM>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment&nbsp;regimens for native valve endocarditis due to <EM>Staphylococcus</EM></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\" rowspan=\"2\">European Society of Cardiology<span style=\"font-size: 13px;\">*</span> (ESC)</td> <td class=\"subtitle1\" rowspan=\"2\">British Society for Antimicrobial Chemotherapy (BSAC)</td> </tr> <tr> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Pediatric</td> </tr> <tr> <td class=\"subtitle3\">Methicillin-susceptible strains<sup>&#182;</sup></td> <td class=\"subtitle3\">Methicillin-susceptible strains</td> <td class=\"subtitle3\">Methicillin-susceptible strains<sup>&#916;</sup></td> <td class=\"subtitle3\">Methicillin sensitive</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Nafcillin or oxacillin 12 g per 24 hours IV in&nbsp;four or&nbsp;six divided doses for 6 weeks</p> <p><strong>or</strong></p> Cefazolin<sup>&#9674;</sup> 6 g per 24 hours IV in&nbsp;three divided doses for 6 weeks</td> <td> <p>Nafcillin or oxacillin 200 mg/kg per 24 hours IV (maximum dose: 12 g per 24 hours) in&nbsp;four or&nbsp;six divided doses for 4 to 6 weeks</p> <p><strong>or</strong></p> Cefazolin<sup>&#9674;</sup> 100 mg/kg per 24 hours IV (maximum dose: 12 g per 24 hours) in&nbsp;three divided doses for 4 to 6 weeks</td> <td>Oxacillin or cloxacillin or flucloxacillin 12 g per 24 hours IV in&nbsp;four&nbsp;or six&nbsp;divided doses for 4 to 6 weeks <p><strong>or</strong></p> <p>Cefazolin<sup>&#9674;</sup> 6 g per 24 hours IV in three divided&nbsp;doses for 6 weeks</p> <p><strong>or</strong></p> <p>Cefotaxime<sup>&#9674;<span style=\"font-size: 13px;\"> </span></sup>6 g per 24 hours in three divided doses</p> </td> <td>Flucloxacillin 2 g IV every 4 to 6 hours for 4 weeks</td> </tr> <tr> <td class=\"subtitle3\">Methicillin-resistant strains</td> <td class=\"subtitle3\">Methicillin-resistant strains<sup>&#167;</sup></td> <td class=\"subtitle3\">Methicillin-resistant strains<sup>&#916;</sup></td> <td class=\"subtitle3\">Methicillin resistant</td> </tr> <tr> <td> <p>Vancomycin<sup>&#165;</sup> 30 mg/kg per 24 hours IV in&nbsp;two divided doses for 6 weeks</p> <p><strong>or</strong></p> <p>Daptomycin &#8805;8 mg/kg<sup>&#135;</sup> per 24 hours IV once daily for 6 weeks</p> </td> <td> <p>Vancomycin<sup>&#165;</sup> 40 mg/kg per 24 hours IV (maximum dose: 2 g per 24 hours unless levels are inappropriately low)&nbsp;in&nbsp;two or&nbsp;three divided doses for 6 weeks</p> </td> <td>Vancomycin<sup>&#165;</sup> 30 to 60&nbsp;mg/kg per 24 hours IV in&nbsp;two&nbsp;or three divided doses for 4 to 6 weeks <p><strong>or</strong>&nbsp;</p> <p>Daptomycin<sup>&#134;</sup><span style=\"font-size: 13px;\"> </span>10 mg/kg per 24 hours IV once daily for 4 to 6 weeks</p> </td> <td> <p>Vancomycin<sup>&#165;</sup> 1 g IV every 12 hours for 4 weeks</p> <p><strong>plus</strong></p> <p>Rifampicin 300 to 600 mg orally every 12 hours for 4 weeks</p> <p><strong>OR</strong></p> <p>Daptomycin 6 mg/kg IV every 24 hours for 4 weeks</p> <p><strong>plus </strong></p> <p>Rifampicin 300 to 600 mg&nbsp;orally&nbsp;every 24 hours for 4 weeks</p> <p><strong>or</strong></p> <p>Gentamicin 1 mg/kg IV every 12 hours for 4 weeks</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class=\"graphic_footnotes\">IV: intravenously; IM: intramuscularly.<br />* Pediatric doses (should not exceed adult doses): oxacillin, cloxacillin, or flucloxacillin: 200 to 300 mg/kg per 24 hours IV in four or six divided doses; trimethoprim-sulfamethoxazole (cotrimoxazole)&nbsp;12 mg/kg trimethoprim component per 24 hours IV in two divided doses; clindamycin 40 mg/kg per 24 hours IV in three divided doses; vancomycin 40 mg/kg per 24 hours IV in two or three divided doses; daptomycin 10 mg/kg per 24 hours IV once daily.<br />¶&nbsp;Regimens for complicated right-sided and all left-sided infective endocarditis.<br />Δ Another alternative regimen for <EM>S. aureus</EM> consists of trimethoprim-sulfamethoxazole (cotrimoxazole) 960 mg trimethoprim/4800 mg sulfamethoxazole per 24 hours IV in four or six divided doses for 1 week followed by 5 weeks of oral trimethoprim-sulfamethoxazole plus clindamycin 1800 mg per 24 hours IV in three divided doses for 1 week.<br />◊&nbsp;For use in patients with nonsevere penicillin allergy. Avoid cefazolin in complicating brain abscess; nafcillin is preferred.<br />§ Consultation with a pediatric infectious disease specialist is recommended in cases of infection due to methicillin-resistant strains.<br />¥&nbsp;Vancomycin&nbsp;dose adjusted for trough concentration of 10 to&nbsp;20 mcg/mL; some favor trough concentrations 15 to 20 mcg/mL.<br />‡&nbsp;Daptomycin selection and dosing should be assisted by infectious diseases consultation.<br />†&nbsp;Daptomycin is superior to vancomycin for<EM> S. aureus</EM> bacteremia with vancomycin MIC &gt;1 mg/L. Some experts recommend adding cloxacillin 12 g per 24 hours IV in six divided doses or fosfomycin 8 g per 24 hours IV in four divided doses to daptomycin in order to increase activity and avoid development of daptomycin resistance.</div><div class=\"graphic_reference\">Data from:<br /><br /><OL>&#xD;&#xA;<LI>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</LI>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI>&#xD;&#xA;<LI>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</LI>&#xD;&#xA;<LI>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</LI></OL></div><div id=\"graphicVersion\">Graphic 81429 Version 13.0</div></div></div>"},"81430":{"type":"graphic_figure","displayName":"Class Sacro CTs AAP","title":"Classification of sacrococcygeal teratomas","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Classification of sacrococcygeal teratomas</div><div class=\"cntnt\"><img style=\"width:500px; height:610px;\" src=\"images/ONC/81430_Class_Sacro_CTs_AAP.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Altman RP, Randolph JG, Lilly JR. Sacrococcygeal teratoma. American Academy of Pediatrics Surgical Section Survey - 1973. J Pediatr Surg 1974;9:389-98.</div><div id=\"graphicVersion\">Graphic 81430 Version 1.0</div></div></div>"},"81431":{"type":"graphic_diagnosticimage","displayName":"CT guided bone bx cerv spine","title":"CT-guided bone biopsy of a vertebral body in the cervical spine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT-guided bone biopsy of a vertebral body in the cervical spine</div><div class=\"cntnt\"><img style=\"width:389px; height:263px;\" src=\"images/ONC/81431_CT_guided_bone_bx_cerv_spin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This myeloma was associated with complete destruction of the C7 vertebral body. The use of CT to guide the bone biopsy permits accurate placement of the biopsy needle, avoiding the carotic sheath and the spinal canal.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 81431 Version 3.0</div></div></div>"},"81432":{"type":"graphic_table","displayName":"Postoperative fever in HIV-infected patients","title":"Potential causes of postoperative fever in HIV-infected patients without localizing symptoms or signs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential causes of postoperative fever in HIV-infected patients without localizing symptoms or signs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td>Abacavir</td> </tr> <tr> <td>Cephalosporins</td> </tr> <tr> <td>Dapsone</td> </tr> <tr> <td>Penicillins</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole (TMP-SMX)</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td><em>Mycobacterium avium </em>complex</td> </tr> <tr> <td><em>Pneumocystis jirovecci </em>pneumonia</td> </tr> <tr> <td>Sinusitis</td> </tr> <tr> <td>Toxoplasmosis</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplasia</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr> <td>Hypoadrenalism</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81432 Version 3.0</div></div></div>"},"81435":{"type":"graphic_picture","displayName":"Radial growth arrest","title":"Radial growth arrest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radial growth arrest</div><div class=\"cntnt\"><img style=\"width:442px; height:279px;\" src=\"images/EM/81435_Radialgrowtharrest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Anteroposterior x-ray of radial growth arrest and ulnar overgrowth after physeal fracture. Patient complained of ulnar-sided wrist pain and clicking. B) Clinical photograph of ulnar overgrowth and radial deviation deformity.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81435 Version 11.0</div></div></div>"},"81436":{"type":"graphic_table","displayName":"Gemcitabine for nonmetastatic pancreatic and biliary cancer","title":"Gemcitabine for nonmetastatic pancreatic and biliary cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine for nonmetastatic pancreatic and biliary cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 4 weeks. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr class=\"divider_bottom\"> <td>Gemcitabine</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (concentration no greater than 40 mg/mL) and administer over 30 minutes.</td> <td>Weekly for three weeks followed by one week of rest</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors not indicated (risk of neutropenic fever &#60;1%).</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose may be needed for patients with liver impairment.</li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including serum creatinine) and liver function prior to each cycle and otherwise as indicated during treatment.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>This regimen should not be initiated unless the white blood cell count is &#62;3500 cells/microL and platelets are &#8805;100,000/microL.<sup>[1]</sup> During therapy, the dose of gemcitabine should be decreased by 25% if the absolute neutrophil count decreases to &#60;1000 cells/microL but &#8805;500 cells/microL, or the platelets decrease to &#60;100,000/microL and &#8805;50,000/microL.<sup>[2]</sup> The United States Prescribing Information recommends holding gemcitabine for an absolute neutrophil count &#60;500 cells/microL or platelets &#60;50,000/microL.<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[2]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.</li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Oettle H, et al. JAMA 2007; 297:267.</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 28, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 81436 Version 18.0</div></div></div>"},"81437":{"type":"graphic_figure","displayName":"Drain placement at surgery","title":"Drain placement at surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drain placement at surgery</div><div class=\"cntnt\"><img style=\"width:434px; height:297px;\" src=\"images/SURG/81437_Drain_placement_at_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 81437 Version 2.0</div></div></div>"},"81440":{"type":"graphic_table","displayName":"Fatal asthma subtypes","title":"Fatal asthma subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fatal asthma subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">&nbsp;</td>\n\t\t\t\t\t<td class=\"subtitle1\">Rapid onset</td>\n\t\t\t\t\t<td class=\"subtitle1\">Slow onset</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Frequency</td>\n\t\t\t\t\t<td>8-14 percent</td>\n\t\t\t\t\t<td>86-92 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"4\">Triggers</td>\n\t\t\t\t\t<td>Allergen exposure</td>\n\t\t\t\t\t<td rowspan=\"4\">Respiratory tract infection</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Fume or irritant inhalation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Exercise or emotional stress</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Aspirin (ASA) and NSAIDs</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"2\">Pathology</td>\n\t\t\t\t\t<td>Empty, dry airways</td>\n\t\t\t\t\t<td>Mucus filled, wet airways</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Neutrophil-predominant</td>\n\t\t\t\t\t<td>Eosinophil-predominant</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cause of obstruction</td>\n\t\t\t\t\t<td>Bronchoconstriction</td>\n\t\t\t\t\t<td>Mucus plugging &amp; edema</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Recovery</td>\n\t\t\t\t\t<td>Rapid</td>\n\t\t\t\t\t<td>Less rapid</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory agents.</div><div id=\"graphicVersion\">Graphic 81440 Version 1.0</div></div></div>"},"81442":{"type":"graphic_figure","displayName":"Emergency pericardiocentesis subxiphoid approach","title":"Emergency pericardiocentesis subxiphoid approach","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Emergency pericardiocentesis subxiphoid approach</div><div class=\"cntnt\"><img style=\"width:521px; height:499px;\" src=\"images/EM/81442_Emergency_pericardiocentesis_subxiphoid_approach.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81442 Version 2.0</div></div></div>"},"81443":{"type":"graphic_picture","displayName":"Herpes zoster vesicle","title":"Vesicles of herpes zoster","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vesicles of herpes zoster</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81443_Herpes_zoster_vesicle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple vesicles are present in this patient with herpes zoster.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81443 Version 5.0</div></div></div>"},"81444":{"type":"graphic_table","displayName":"Prednisone insulin","title":"Blood glucose concentrations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood glucose concentrations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time of day</td> <td class=\"subtitle1\">Before start of prednisone (mg/dL)</td> <td class=\"subtitle1\">After start of prednisone (mg/dL)</td> </tr> <tr> <td>Before breakfast</td> <td>77 to 119</td> <td>93 to 138</td> </tr> <tr> <td>Before lunch</td> <td>95 to 136</td> <td>191 to 349</td> </tr> <tr> <td>Before supper</td> <td>105 to 141</td> <td>197 to 269</td> </tr> <tr> <td>Bedtime</td> <td>116 to 156</td> <td>151 to 253</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Lloyd Axelrod, MD.</div><div id=\"graphicVersion\">Graphic 81444 Version 3.0</div></div></div>"},"81445":{"type":"graphic_picture","displayName":"SVC syndrome appearance","title":"Superior vena cava syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior vena cava syndrome</div><div class=\"cntnt\"><img style=\"width:358px; height:504px;\" src=\"images/ONC/81445_SVC_syndrome_appearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A prominent venous pattern on the chest, facial edema, and a plethoric appearance is present in this man with SVC obstruction from lung cancer.</div><div class=\"graphic_reference\">Reproduced with permission from: Midthun, DE, et al. Clinical presentation of lung cancer. Lung Cancer 1996; :421. Copyright © Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 81445 Version 2.0</div></div></div>"},"81446":{"type":"graphic_diagnosticimage","displayName":"Rachitic Rosary","title":"Rachitic rosary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rachitic rosary</div><div class=\"cntnt\"><img style=\"width:340px; height:328px;\" src=\"images/PEDS/81446_Rachitic_Rosary.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a patient with rickets, demonstrating a &quot;rachitic rosary&quot;. Observe the opaque, bulbous indentations of the lung adjacent to the enlarged costochondral junctions (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ, Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81446 Version 2.0</div></div></div>"},"81447":{"type":"graphic_diagnosticimage","displayName":"Centerline measurements or abdominal aorta","title":"Centerline measurements of abdominal aorta","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Centerline measurements of abdominal aorta</div><div class=\"cntnt\"><img style=\"width:584px; height:292px;\" src=\"images/SURG/81447_Centerline_measurements.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Centerline measurement of AAA allows the accurate measurement of the treatment length and the landing zone diameters, accounting for tortuosity. It also allows an accurate estimation of the aortic neck angulation between the renal arteries and the aneurysm sac.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm; AP: antero-posterior.</div><div id=\"graphicVersion\">Graphic 81447 Version 2.0</div></div></div>"},"81449":{"type":"graphic_table","displayName":"Likelihood vaginitis by symptom","title":"Likelihood of common vaginal infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Likelihood of common vaginal infections</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">Infection</td>\n\n\n      <td class=\"subtitle1\">Sign/symptom</td>\n\n\n      <td class=\"subtitle1\">Likelihood ratio*</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"5\">Candidiasis</td>\n\n\n      <td>Pruritus absent</td>\n\n\n      <td>0.18 to 0.79</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      \n\n      <td>Pruritus as chief complaint </td>\n\n      <td>3.3</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Inflammatory signs present</td>\n\n      <td>1.4 to 8.4</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Curdlike discharge with pruritus</td>\n\n      <td>150</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Yeast not seen on KOH wet prep</td>\n\n      <td>0.51 to 0.66</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"2\">Bacterial vaginosis</td>\n\n\n      <td>No complaint of odor</td>\n\n\n      <td>0.07</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      \n\n      <td>Complaint of malodorous discharge</td>\n\n      <td>1.6 to 3.2</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"3\">Trichomoniasis</td>\n\n\n      <td>Inflammatory signs present</td>\n\n\n      <td>6.4</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Trichomonads on saline wet mount</td>\n\n      <td>51 to 310 </td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Trichomonads absent on saline wet mount</td>\n\n      <td>0.34 to 0.51</td>\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_footnotes\">KOH: Potassium hydroxide.<br> * Confidence intervals are wide, but significant.</div><div class=\"graphic_reference\">Adapted from Anderson, MR, Klink, K, Cohrssen, A. JAMA 2004; 291:1368.</div><div id=\"graphicVersion\">Graphic 81449 Version 1.0</div></div></div>"},"81450":{"type":"graphic_picture","displayName":"Fingerprint pattern in mixed cryo EM","title":"Fingerprint pattern in mixed cryoglobulinemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fingerprint pattern in mixed cryoglobulinemia</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/81450_Cryoglobulinemia_EM_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power electron micrograph of a cryoprecipitate in the mesangium, showing the characteristic substructure which often has a \"fingerprint\" appearance (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 81450 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"81451":{"type":"graphic_table","displayName":"Routine PN preterm infant","title":"Composition of routine parenteral nutrition (PN) regimen for premature infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of routine parenteral nutrition (PN) regimen for premature infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Component</td> <td class=\"subtitle1\">Concentration/additive</td> <td class=\"subtitle1\">Intake</td> </tr> <tr> <td>Glucose</td> <td>12.5 percent</td> <td>Glucose = 16 g/kg/day</td> </tr> <tr> <td>Amino acids*</td> <td>2.6 percent</td> <td>Amino acids = 3.5 g/kg/day</td> </tr> <tr> <td>Cysteine-HCl</td> <td>30 mg/g amino acids</td> <td>&nbsp;</td> </tr> <tr> <td>NaCl</td> <td>2.6 mmol = 2.6 mEq</td> <td>Na = 3.4 mmol/kg/day</td> </tr> <tr> <td>KCl</td> <td>0 to 0.2 mmol (mEq)</td> <td>Total K = 3.1 to 3.8 mmol/kg/day</td> </tr> <tr> <td>K<sub>2</sub>PO<sub>4</sub>-KHPO<sub>4</sub><sup>&#182;</sup></td> <td>1.5 to 2.0 mmol P</td> <td>P = 2.0 to 2.6 mmol/kg/day</td> </tr> <tr> <td>Ca gluconate<sup>&#916;</sup></td> <td>1.5 to 2.0 mmol Ca</td> <td>Ca = 2.0 to 2.6 mmol/kg/day</td> </tr> <tr> <td>MgSO<sub>4</sub></td> <td>0.25 mmol = 0.5 mEq</td> <td>Mg = 0.3 mmol/kg/day</td> </tr> <tr> <td>Multivitamin-Pediatric<sup>&#9674;</sup></td> <td>40 percent of vial (2 mL/kg/day)</td> <td>&nbsp;</td> </tr> <tr> <td>Trace element supplement&nbsp;(MTE-4<sup>)&#167;</sup></td> <td>0.2 mL/kg/day</td> <td>See below for Zn, Cu, Mn, Cr</td> </tr> <tr> <td>Zinc</td> <td>200 mcg/kg/day <br /> (in addition to Zn from MTE-4)</td> <td>See total zinc below</td> </tr> <tr> <td>Selenium</td> <td>2 mcg/kg/day</td> <td>&nbsp;</td> </tr> <tr> <td>Heparin</td> <td>1 unit/mL</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Intralipid&#174; 20 percent<sup>&#165;</sup></td> <td>15 mL/kg/day</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Total fluid</strong></td> <td><strong>150 mL/kg/day</strong></td> <td><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Routine use in premature infants generally after five days of age who had received the early PN regimen.</div><div class=\"graphic_footnotes\">* TrophAmine&reg; (B. Braun).<br />&para; Monobasic-dibasic phosphate contains 1.4 mmol K/mmol P or 1.3 mmol Na/mmol P, depending upon the preparation used. Use the higher P concentration for PN duration &gt;2 weeks.<br />&Delta; Use the higher concentration for PN duration &gt;2 weeks. Add last in the preparation of PN.<br /><span class=\"lozenge\">&loz;</span> Multivitamin-Pediatric, Mayne Pharma (USA), Inc, Paramus, NJ.<br />&sect; MTE-4, American Regent, Inc, Shirley, NY, provides:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Zn = 200 mcg/kg/day.</li>&#xD;&#xA;    <li>Cu = 20 mcg/kg/day.</li>&#xD;&#xA;    <li>Mn = 1 mcg/kg/day.</li>&#xD;&#xA;    <li>Cr = 0.4 mcg/kg/day.</li>&#xD;&#xA;</ul>&#xD;&#xA;Total zinc = 200 + 200 = 400 mcg/kg/day.<br />Usually begin MTE after two weeks; only Zn (400 mcg/kg/day) is needed prior to that time.<br />&yen; Begin lipid at 1 g/kg/day and increase stepwise to 3 to 4 g/kg/day.</div><div class=\"graphic_reference\">Reproduced with permission from: Schanler RJ. The low birth weight infant: Perinatal nutrition. In: Nutrition in Pediatrics: Basic Science and Clinical Applications, Walker WA, Watkins JB (Eds), B.C. Decker Inc., Hamilton, Ontario, Canada 1996. Copyright &copy; 1996 PMPH-USA, Ltd.</div><div id=\"graphicVersion\">Graphic 81451 Version 11.0</div></div></div>"},"81452":{"type":"graphic_picture","displayName":"Poncho wrap ventilator","title":"Poncho wrap ventilator","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Poncho wrap ventilator</div><div class=\"cntnt\"><img style=\"width:360px; height:172px;\" src=\"images/PULM/81452_Poncho_wrap_ventilator.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poncho wrap ventilator is shown, displaying plastic &quot;cage&quot; that fits over the chest within the wrap. Negative pressure generator (Thompson maxivent) powers the ventilator.</div><div id=\"graphicVersion\">Graphic 81452 Version 2.0</div></div></div>"},"81453":{"type":"graphic_picture","displayName":"Skin biopsy discoid SLE","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:360px; height:241px;\" src=\"images/RHEUM/81453_Skin_biopsy_discoid_SLE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An attenuated epidermis is surmounted by an orthohyperkeratotic scale with follicular plugging. An active vasculopathic interface dermatitis is present.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 81453 Version 2.0</div></div></div>"},"81454":{"type":"graphic_figure","displayName":"HbA1c and cholesterol orlistat","title":"Metabolic benefits of orlistat","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Metabolic benefits of orlistat</div><div class=\"cntnt\"><img style=\"width:559px; height:279px;\" src=\"images/ENDO/81454_HgbA1c_and_cholesterol_orli.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean (±SE) changes in HbA1c values (left panel) and serum total cholesterol concentrations (right panel) after treatment with orlistat or placebo for one year in patients with type 2 diabetes. Among patients who lost weight (which was more prominent and common in the orlistat group), orlistat therapy was associated with significantly greater improvements in HbA1c and serum total cholesterol. To convert the changes in serum cholesterol values to mg/dL, divide by 0.026.</div><div class=\"graphic_footnotes\">HbA1c: glycated hemoglobin; SE: standard error.</div><div class=\"graphic_reference\">Data from: Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21:1288.</div><div id=\"graphicVersion\">Graphic 81454 Version 4.0</div></div></div>"},"81455":{"type":"graphic_figure","displayName":"Age at onset of ILD","title":"Age at onset of presentation in different interstitial lung diseases","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Age at onset of presentation in different interstitial lung diseases</div><div class=\"cntnt\"><img style=\"width:471px; height:283px;\" src=\"images/PULM/81455_Age_at_onset_of_ILD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Idiopathic pulmonary fibrosis (IPF) has an older age distribution than either pulmonary Langerhans cell histiocytosis (LCH) or sarcoidosis.</div><div class=\"graphic_reference\">Data from King, TE, Jr. Interstitial lung diseases: General approaches. In: Parsons, PE, Heffner, JE, (Eds), Pulmonary and Respiratory Therapy Secrets, Philadelphia, Handley &amp;Belfus, Inc. 1997, p. 234.</div><div id=\"graphicVersion\">Graphic 81455 Version 1.0</div></div></div>"},"81456":{"type":"graphic_figure","displayName":"Reprogramming adult cells to become pluripotent cells","title":"Reprogramming adult cells to become pluripotent cells","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Reprogramming adult cells to become pluripotent cells</div><div class=\"cntnt\"><img style=\"width:609px; height:325px;\" src=\"images/PC/81456_Reprog_to_pluripotent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The introduction of defined factors (as genes, mRNA, or a combination with small molecules) permits the gradual reversion of a mature, somatic cell, such as a skin fibroblast, to an induced pluripotent (iPS) cell. Sequential changes in the targeted cell are thought to proceed in an orderly manner as indicated.</div><div class=\"graphic_reference\">Reproduced with permission from: Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev 2010; 24:2239. Copyright &#169; 2010 Cold Spring Harbor Laboratory Press.</div><div id=\"graphicVersion\">Graphic 81456 Version 2.0</div></div></div>"},"81457":{"type":"graphic_picture","displayName":"Contact dermatitis berloque 1","title":"Berloque dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Berloque dermatitis</div><div class=\"cntnt\"><img style=\"width:346px; height:540px;\" src=\"images/DERM/81457_Contact_dermatitis_berloq_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This adolescent developed hyperpigmented streaks from a photosensitizer in his sunscreen. After several days of erythema, the red patches became dark brown.</div><div class=\"graphic_reference\">Copyright © Kosman Sadek Zikry, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 81457 Version 6.0</div></div></div>"},"81458":{"type":"graphic_picture","displayName":"Rejected sputum specimen","title":"Rejected sputum specimen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rejected sputum specimen</div><div class=\"cntnt\"><img style=\"width:389px; height:252px;\" src=\"images/ID/81458_Rejected_sputum_specimen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The microbiology laboratory automatically rejects specimens such as this one with more than 10 squamous epithelial cells per low power field.</div><div class=\"graphic_reference\">Courtesy of Melvin P Weinstein, MD.</div><div id=\"graphicVersion\">Graphic 81458 Version 1.0</div></div></div>"},"81459":{"type":"graphic_algorithm","displayName":"Algorithm for hemoptysis in children","title":"Algorithm for management of hemoptysis in children","html":"<div class=\"graphic\"><div style=\"width: 1157px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of hemoptysis in children</div><div class=\"cntnt\"><img style=\"width:1137px; height:449px;\" src=\"images/PEDS/81459_Algo_hemoptysis_children.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CF: cystic fibrosis; BAE: bronchial artery embolization; BiPAP: bilevel positive airway pressure; ICU: intensive care unit; PEEP: positive end-expiratory pressure; ECMO: extracorporeal membrane oxygenation; PAH: pulmonary artery hypertension; CT: computerized tomography; NSAIDS: non-steroidal anti-inflammatory drugs; ENT: ear, nose, and throat; URI: upper respiratory tract infection; CBC: complete blood count; PT: prothrombin time; partial thromboplastin time; INR: international normalized ratio; AST: aspartate aminotransferase; ALT: alanine transaminase.<br />* Consultations for a patient with massive hemoptysis include surgery, and possibly interventional radiology, gastroenterology, and/or otorhinolaryngology (ENT).<br />¶ Clinical features suggestive of bronchitis include URI symptoms and forceful cough preceding the hemoptysis, and no focal opacities on chest radiograph. A bacterial cause of bronchitis is more likely if the child has a protracted \"wet\" cough (eg, &gt;8 weeks duration).<br />Δ Clinical features suggestive of foreign body aspiration include young child, history of choking (days to weeks prior to hemoptysis), new respiratory symptoms (eg, wheezing). The chest radiograph may or may not be normal.<br /><FONT class=lozenge>◊</FONT> For patients with CF, treatment of at least mild hemoptysis (≥5 mL) should include antibiotics and stopping of NSAIDS<SUP>[1]</SUP>.<br />§ A workup for hemoptysis of unknown cause typically includes the following elements. The selection of radiographic and bronchoscopic procedures varies, depending on the severity of symptoms and suspected cause. &#xD;&#xA;<UL>&#xD;&#xA;<LI>Laboratory testing: CBC; electrolytes; bleeding dyscrasia workup (PT, PTT, INR, studies to exclude von Willebrand disease); liver function tests (AST, ALT, alkaline phosphatase, albumin); urine analysis (especially for hematuria); blood gas (if respiratory distress)</LI>&#xD;&#xA;<LI>Radiography: Chest radiograph; CT scan with contrast</LI>&#xD;&#xA;<LI>Interventional: Flexible bronchoscopy with bronchoalveolar lavage; or rigid bronchoscopy (preferred in patients with massive hemoptysis, for hemostatic procedures)</LI></UL><br />¥ For patients with CF and massive hemoptysis, a consensus panel suggests proceeding directly to bronchial artery embolization (BAE), rather than pre-BAE evaluation with bronchoscopy<SUP>[1]</SUP>. Proceeding directly to BAE also may be appropriate for patients without CF, if the bleeding source is known or localized by radiography<SUP>[2]</SUP>.<br />‡ Hemostasis interventions at bronchoscopy may include infusion of cold saline or epinephrine; laser treatment; or balloon tamponade.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182:298.</li>&#xD;&#xA;    <li>Sopko DR, Smith TP. Bronchial artery embolization for hemoptysis. Semin Intervent Radiol 2011; 28:48.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 81459 Version 4.0</div></div></div>"},"81460":{"type":"graphic_table","displayName":"Asthma patient needs survey","title":"Individual patient needs survey*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Individual patient needs survey*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    \n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td><td class=\"subtitle1\">Strongly Agree</td>\n\n      <td class=\"subtitle1\">Agree</td>\n\n      <td class=\"subtitle1\">Undecided</td>\n\n      <td class=\"subtitle1\">Disagree</td>\n\n      <td class=\"subtitle1\">Strongly Disagree</td>\n\n    </tr>\n\n    <tr>\n\n      <td>I know what asthma is and can recognize the signs and symptoms of asthma.</td><td>1</td>\n\n      <td>2</td>\n\n      <td>3</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>I understand how each of my asthma medications works to improve my condition.</td><td rowspan=\"1\" colspan=\"1\">1</td><td colspan=\"1\">2</td><td colspan=\"1\">3</td><td colspan=\"1\">4</td><td>5</td>\n\n\n\n\n\n    </tr>\n\n\n    \n\n    <tr>\n\n      <td>I know what my asthma \"triggers\" are and how I can avoid them or reduce exposure to them.</td><td>1</td>\n\n      <td>2</td>\n\n      <td>3</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n    </tr>\n\n    \n\n\n    \n\n    <tr>\n\n      <td>I am confident I can prevent asthma symptoms from occurring in most situations. &nbsp; &nbsp;</td><td>1</td>\n\n      <td>2</td>\n\n      <td>3</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n    </tr>\n\n    \n\n\n    \n\n    \n\n    \n\n\n    \n\n    <tr>\n\n      <td>I am confident I can manage asthma symptoms when they occur.</td><td>1</td>\n\n      <td>2</td>\n\n      <td>3</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n    </tr>\n\n    \n\n\n    \n\n    <tr>\n\n      <td>I know how to monitor my airways with a peak flow meter to detect potential asthma episodes before they occur.</td><td>1</td>\n\n      <td>2</td>\n\n      <td>3</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n    </tr>\n\n    \n\n\n    \n\n    <tr>\n\n      <td>Having asthma does not prevent me from doing activities that I would do if I did not have it.</td><td>1</td>\n\n      <td>2</td>\n\n      <td>3</td>\n\n      <td>4&nbsp;</td>\n\n      <td>5</td>\n\n    </tr>\n\n    \n\n\n    \n\n    <tr>\n\n      <td>People around me (family, friends, co-workers, school personnel) are familiar with my asthma self-management plan.</td><td>1</td>\n\n      <td>2</td>\n\n      <td>3</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* As used by the author and his staff.</div><div id=\"graphicVersion\">Graphic 81460 Version 1.0</div></div></div>"},"81461":{"type":"graphic_diagnosticimage","displayName":"Subperiosteal abscess MRI","title":"Magnetic resonance image distal femoral osteomyelitis and subperiosteal abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image distal femoral osteomyelitis and subperiosteal abscess</div><div class=\"cntnt\"><img style=\"width:388px; height:584px;\" src=\"images/PEDS/81461_Subperiosteal_abscess_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A) and coronal (B) magnetic resonance images (post gadolinium infusion) of a 7-year-old with distal femoral osteomyelitis and subperiosteal abscess. The abscess is posterior on the axial view (arrow) and medial to the distal femur on the coronal view (arrow). The pus is dark and surrounded by an enhancing rim.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 81461 Version 1.0</div></div></div>"},"81462":{"type":"graphic_table","displayName":"Salmonella serogroups","title":"Salmonella serogroups: Examples of important specific serotypes and their characteristic clinical infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Salmonella serogroups: Examples of important specific serotypes and their characteristic clinical infections</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Serogroup</td>\n\n      <td class=\"subtitle1\">Example (serotype)*</td>\n\n      <td class=\"subtitle1\">Characteristic syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>A</td>\n\n      <td>S. paratyphi A</td>\n\n      <td>Enteric fever</td>\n\n    </tr>\n\n    <tr>\n\n      <td>B</td>\n\n      <td>S. paratyphi B</td>\n\n      <td>Enteric fever or gastroenteritis</td>\n\n    </tr>\n\n    <tr>\n      <td>B</td>\n      <td>S. typhimurium</td>\n      <td>Gastroenteritis</td>\n    </tr>\n    <tr>\n      <td>B</td>\n      <td>S. heidelberg</td>\n      <td>Gastroenteritis, bacteremia</td>\n    </tr>\n    <tr>\n\n      <td>C</td>\n\n      <td>S. paratyphi C</td>\n\n      <td>Enteric fever</td>\n\n    </tr>\n\n    <tr>\n      <td>C </td>\n      <td>S. choleraesuis</td>\n      <td>Bacteremia</td>\n    </tr>\n    <tr>\n      <td>C</td>\n      <td>S. newport</td>\n      <td>Gastroenteritis</td>\n    </tr>\n    <tr>\n\n      <td>D</td>\n\n      <td>S. typhi</td>\n\n      <td>Enteric fever</td>\n\n    </tr>\n    <tr>\n      <td>D</td>\n      <td>S. enteritidis</td>\n      <td>Gastroenteritis</td>\n    </tr>\n    <tr>\n      <td>D</td>\n      <td>S. dublin</td>\n      <td>Bacteremia</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* All listed serotypes are formally members of the species Salmonella enterica, subspecies enterica. There are many additional serotypes of Salmonellae that are named after geographical locales: S. javiana, S. tennessee, S. cubana, etc. Chronic biliary carriage occurs almost exclusively with S. typhi or S. paratyphi.</div><div id=\"graphicVersion\">Graphic 81462 Version 2.0</div></div></div>"},"81464":{"type":"graphic_figure","displayName":"Normal values for hematocrit and hemoglobin in infants","title":"Normal values for hematocrit and hemoglobin during the first year of life in healthy term infants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal values for hematocrit and hemoglobin during the first year of life in healthy term infants</div><div class=\"cntnt\"><img style=\"width:450px; height:328px;\" src=\"images/PEDS/81464_Infant_Hgb_Hct.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: <BR>1. Jopling J, Henry E, Wiedmeier SE, et al. Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data from a multihospital health care system. Pediatrics 2009; 123:e333.<BR>2. Oski FA, Naiman JL. Hematologic problems in the newborn, 2nd ed, WB Saunders, Philadelphia 1972; p.13.<BR>3. Saarinen UM, Siimes MA. Developmental changes in red blood cell counts and indices of infants after exclusion of iron deficiency by laboratory criteria and continuous iron supplementation. J Pediatr 1978; 92:412.</div><div id=\"graphicVersion\">Graphic 81464 Version 2.0</div></div></div>"},"81466":{"type":"graphic_figure","displayName":"SEER OS incidence","title":"Osteosarcoma incidence by disease sequence based on the surveillance, epidemiology, and end results 9 database, 1973 to 2004","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Osteosarcoma incidence by disease sequence based on the surveillance, epidemiology, and end results 9 database, 1973 to 2004</div><div class=\"cntnt\"><img style=\"width:588px; height:401px;\" src=\"images/ONC/81466_SEER_OS_incidence.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">OS: osteosarcoma.</div><div class=\"graphic_reference\">From: Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115:1531. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/cncr.24121/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/cncr.24121/abstract</a>. Copyright &copy; 2009 American Cancer Society. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://www.onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">www.onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 81466 Version 4.0</div></div></div>"},"81467":{"type":"graphic_table","displayName":"Poisoned patient ICU criteria","title":"Criteria for ICU admission of poisoned patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for ICU admission of poisoned patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>CNS depression, including significant lethargy, coma </td> </tr> <tr> <td>Agitation requiring chemical or physical restraint</td> </tr> <tr> <td>Respiratory depression (PCO2 &#62;45 mmHg), hypoxia or respiratory failure (ARDS), and/or endotracheal intubation</td> </tr> <tr> <td>Hypotension (SBP &#8804;80 mmHg)</td> </tr> <tr> <td>Seizures that are prolonged or recurring</td> </tr> <tr> <td>Second or third degree AV block on ECG</td> </tr> <tr> <td>Nonsinus cardiac rhythm on ECG</td> </tr> <tr> <td>Significant acid-base disturbances (eg, metabolic acidosis with pH &#8804;7.2)</td> </tr> <tr> <td>Significant metabolic abnormalities requiring close monitoring or aggressive correction</td> </tr> <tr> <td>Extremes of temperature (eg, hyperthermia with T &#62;104&#176;F)</td> </tr> <tr> <td class=\"sublist1_start\">Poisoning with a \"toxic time bomb\"</td> </tr> <tr> <td class=\"sublist1\">Ingested drug packets, sustained-release preparations</td> </tr> <tr> <td class=\"sublist1\">Quantitative level of drug which predicts unfavorable outcome</td> </tr> <tr> <td>Need for invasive hemodynamic monitoring (eg, pulmonary artery catheter or arterial line) or cardiac pacing</td> </tr> <tr> <td>Need for whole bowel irrigation to enhance GI elimination of poison</td> </tr> <tr> <td>Need for emergency hemodialysis, hemoperfusion, hemofiltration</td> </tr> <tr> <td>Need for emergency antidote which requires close monitoring (eg, crotalid antivenin, Digibind, physostigmine, naloxone drip)</td> </tr> <tr> <td>Ischemic chest pain from toxin (eg, cocaine, carbon monoxide)</td> </tr> <tr> <td>TCA or other drug exposure with QRS &#62;120 msec or QTc &#62;500 msec</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81467 Version 5.0</div></div></div>"},"81468":{"type":"graphic_picture","displayName":"Classic Kaposi sarcoma - patches and plaques","title":"Classic Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81468_Classic_Kaposis_sarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple red-brown patches and plaques are present on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81468 Version 5.0</div></div></div>"},"81469":{"type":"graphic_picture","displayName":"Botulinum toxin injection sites for horizontal neck lines","title":"Examples of botulinum toxin injection sites for horizontal neck lines","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Examples of botulinum toxin injection sites for horizontal neck lines</div><div class=\"cntnt\"><img style=\"width:504px; height:338px;\" src=\"images/DERM/81469_Injection-sites-for-horizonatal-neck-lines.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81469 Version 2.0</div></div></div>"},"81472":{"type":"graphic_figure","displayName":"CCr v KtV by gender in PD","title":"Graphs showing weekly creatinine clearance and Kt/V among CAPD patients according to transporter type and gender","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Graphs showing weekly creatinine clearance and Kt/V among CAPD patients according to transporter type and gender</div><div class=\"cntnt\"><img style=\"width:593px; height:288px;\" src=\"images/NEPH/81472_Ccr_v_KtV_by_gender_in_PD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The weekly Kt/V (left) is compared with the CCr (right) in anuric males and females of varying transporter types (L, LA, HA, and H are low, low-average, high-average, and high transporter types, respectively) who are on 8 liters of therapy per day. Since weight has a greater impact on Kt/V than on CCr, the Kt/V is higher in females compared&nbsp;with males; by comparison, the weekly CCr does not vary significantly with gender.</div><div class=\"graphic_footnotes\">CAPD: continuous ambulatory peritoneal dialysis; CCr: creatinine clearance.</div><div class=\"graphic_reference\">Data from Vonesh EF, Moran J. Discrepancies between urea&nbsp;Kt/V&nbsp;versus normalized creatinine clearance.&nbsp;Perit Dial Int 1997; 17:13.</div><div id=\"graphicVersion\">Graphic 81472 Version 4.0</div></div></div>"},"81475":{"type":"graphic_picture","displayName":"Punctate keratitis","title":"Punctate keratitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Punctate keratitis</div><div class=\"cntnt\"><img style=\"width:335px; height:504px;\" src=\"images/ID/81475_Punctate_keratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onchocercal punctate keratitis with dead microfilariae in cornea surrounded by white cell infiltrate.</div><div class=\"graphic_reference\">Reproduced with permission from: Murdoch ME, Murdoch IE. Onchocerciasis. In: Principles of Medicine in Africa, 3rd Ed, Parry E, Godfrey R, Mabey D, Gill G (Eds), Cambridge University Press 2004. Copyright &copy; 2004 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 81475 Version 1.0</div></div></div>"},"81478":{"type":"graphic_picture","displayName":"Chromate allergy","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:396px; height:256px;\" src=\"images/PEDS/81478_Chromate_allergy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Allergic contact dermatitis of top of foot from leather shoe (chromate allergy).</div><div class=\"graphic_reference\">Courtesy of William L Weston, MD.</div><div id=\"graphicVersion\">Graphic 81478 Version 1.0</div></div></div>"},"81479":{"type":"graphic_figure","displayName":"Scheuermann kyphosis","title":"Scheuermann kyphosis","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Scheuermann kyphosis</div><div class=\"cntnt\"><img style=\"width:513px; height:377px;\" src=\"images/PEDS/81479_Scheuermann_kyphosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with Scheuermann kyphosis have a rigid kyphosis with a relatively sharp angulation when the child bends over, best viewed from the side of the patient.</div><div id=\"graphicVersion\">Graphic 81479 Version 1.0</div></div></div>"},"81480":{"type":"graphic_figure","displayName":"Zones of adrenal tissue","title":"Zones of adrenal tissue","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Zones of adrenal tissue</div><div class=\"cntnt\"><img style=\"width:522px; height:543px;\" src=\"images/SURG/81480_Zonesadrenaltissue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing of the left adrenal gland showing the microstructure of the gland on a transverse cut. Note the capsular circulation and the connections through the sinusoids to the medullary vein.</div><div class=\"graphic_reference\">Reproduced with permission from: Uflacker, R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81480 Version 2.0</div></div></div>"},"81481":{"type":"graphic_table","displayName":"WHO classification of tumors of bone","title":"World Health Organization (WHO) classification of tumors of bone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification of&nbsp;tumors of bone</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Chondrogenic tumors</td> </tr> <tr> <td class=\"indent1\">Osteosarcoma</td> </tr> <tr> <td class=\"indent1\">Chondromas: enchondroma, periosteal chondroma</td> </tr> <tr> <td class=\"indent1\">Chondromyxoid fibroma</td> </tr> <tr> <td class=\"indent1\">Osteochondromyxoma</td> </tr> <tr> <td class=\"indent1\">Subungual exostosis and bizarre parosteal osteochondromatous proliferation</td> </tr> <tr> <td class=\"indent1\">Synovial chondromatosis</td> </tr> <tr> <td class=\"indent1\">Chondrosarcoma (grades I-III) including primary and secondary variants and periosteal chondrosarcoma</td> </tr> <tr> <td class=\"indent1\">Dedifferentiated chondrosarcoma</td> </tr> <tr> <td class=\"indent1\">Mesenchymal chondrosarcoma</td> </tr> <tr> <td class=\"indent1\">Clear cell chondrosarcoma</td> </tr> <tr> <td class=\"subtitle1_single\">Osteogenic tumors</td> </tr> <tr> <td class=\"indent1\">Osteoma</td> </tr> <tr> <td class=\"indent1\">Osteoid osteoma</td> </tr> <tr> <td class=\"indent1\">Osteoblastoma</td> </tr> <tr> <td class=\"indent1\">Low-grade central osteosarcoma</td> </tr> <tr> <td class=\"indent1\">Conventional osteosarcoma</td> </tr> <tr> <td class=\"indent1\">Telangiectatic osteosarcoma</td> </tr> <tr> <td class=\"indent1\">Small cell osteosarcoma</td> </tr> <tr> <td class=\"indent1\">Parosteal osteosarcoma</td> </tr> <tr> <td class=\"indent1\">Periosteal osteosarcoma</td> </tr> <tr> <td class=\"indent1\">High-grade surface osteosarcoma</td> </tr> <tr> <td class=\"subtitle1_single\">Fibrogenic tumors</td> </tr> <tr> <td class=\"indent1\">Desmoplastic fibroma of bone</td> </tr> <tr> <td class=\"indent1\">Fibrosarcoma of bone</td> </tr> <tr> <td class=\"subtitle1_single\">Fibrohistiocytic tumors</td> </tr> <tr> <td class=\"indent1\">Non-ossifying fibroma and benign fibrous histiocytoma of bone</td> </tr> <tr> <td class=\"subtitle1_single\">Ewing sarcoma</td> </tr> <tr> <td class=\"subtitle1_single\">Hematopoietic neoplasms</td> </tr> <tr> <td class=\"indent1\">Plasma cell myeloma</td> </tr> <tr> <td class=\"indent1\">Solitary plasmacytoma of bone</td> </tr> <tr> <td class=\"indent1\">Primary non-Hodgkin lymphoma of bone</td> </tr> <tr> <td class=\"subtitle1_single\">Osteoclastic giant cell-rich tumors</td> </tr> <tr> <td class=\"indent1\">Giant cell lesion of the small bones</td> </tr> <tr> <td class=\"indent1\">Giant cell tumor of bone</td> </tr> <tr> <td class=\"subtitle1_single\">Notochordal tumors</td> </tr> <tr> <td class=\"indent1\">Benign notochordal cell tumor</td> </tr> <tr> <td class=\"indent1\">Chordoma</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular tumors</td> </tr> <tr> <td class=\"indent1\">Hemangioma</td> </tr> <tr> <td class=\"indent1\">Epithelioid hemangioma</td> </tr> <tr> <td class=\"indent1\">Epithelioid hemangioendothelioma</td> </tr> <tr> <td class=\"indent1\">Angiosarcoma</td> </tr> <tr> <td class=\"subtitle1_single\">Myogenic, lipogenic, and epithelial tumors</td> </tr> <tr> <td class=\"indent1\">Leiomyosarcoma</td> </tr> <tr> <td class=\"indent1\">Lipoma</td> </tr> <tr> <td class=\"indent1\">Liposarcoma</td> </tr> <tr> <td class=\"indent1\">Adamantinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors of undefined neoplastic nature</td> </tr> <tr> <td class=\"indent1\">Aneurysmal bone cyst</td> </tr> <tr> <td class=\"indent1\">Simple bone cyst</td> </tr> <tr> <td class=\"indent1\">Fibrous dysplasia</td> </tr> <tr> <td class=\"indent1\">Osteofibrous dysplasia</td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"indent1\">Erdheim-Chester disease</td> </tr> <tr> <td class=\"indent1\">Chondromesenchymal hamartoma</td> </tr> <tr> <td class=\"indent1\">Rosai-Dorfman disease</td> </tr> <tr> <td class=\"subtitle1_single\">Undifferentiated high-grade pleomorphic sarcoma</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: WHO Classification of Tumours of Soft Tissue and Bone. Fletcher CMD, Bridge JA, Hogendoorn PCW, Merten F (Eds). World Health Organization Classification of Tumours. 4th edition. International Agency for Research on Cancer, Lyon, 2013.</div><div id=\"graphicVersion\">Graphic 81481 Version 5.0</div></div></div>"},"81482":{"type":"graphic_picture","displayName":"Auricular inflammation RPC","title":"Auricular inflammation in relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Auricular inflammation in relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:228px; height:352px;\" src=\"images/RHEUM/81482_Auricular_inflammation_RPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute auricular inflammation in a patient with relapsing polychondritis.</div><div class=\"graphic_reference\">Courtesy of Jerome H Herman, MD.</div><div id=\"graphicVersion\">Graphic 81482 Version 2.0</div></div></div>"},"81483":{"type":"graphic_picture","displayName":"Bullous impetigo infant","title":"Bullous impetigo in an infant","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous impetigo in an infant</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/81483_Bullous_impetigo_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81483 Version 3.0</div></div></div>"},"81484":{"type":"graphic_table","displayName":"ECG criteria for LBBB","title":"ECG in LBBB","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ECG in LBBB</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">QRS duration</td>\n\n      <td>&#8805;0.12\nsec</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Intrinsicoid deflection</td>\n\n      <td>&#62;0.05 sec in lead V6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"1\" rowspan=\"2\">Common pattern<br />\n      </td>\n\n      <td class=\"sublist1_start\">Loss of q wave and wide slurred R in I, aVL, and V6 rS\nor QS in V1 ST depression and T wave inversion in leftward leads; ST\nelevation and upright T waves in right precordial leads</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td class=\"sublist1\">These\nchanges reflect relentlessly leftward vectorial forces. V1 morphology\ndepends on initial leftward or rarely rightward forces. ST and T\nvectors are usually 180&ordm; discordant to the QRS vector.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"1\" rowspan=\"4\">Variant pattern<br />\n      </td>\n\n      <td>Terminal S wave in V6 but not usually in I.</td>\n\n    </tr>\n\n    <tr>\n      <td>Mean\nelectrical axis superior and to the left (about -55&ordm;).</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1_start\">ST\ndepression and T wave inversion in leftward leads; ST elevation and\nupright T waves in right precordial leads</td>\n    </tr>\n    <tr>\n\n\n      <td class=\"sublist1\">These\nchanges reflect superior and posterior displacement of loop with a\nterminal, often rightward, conduction delay. ST and T vectors are\ndiscordant to the QRS vector.</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Major electrocardiographic criteria for left bundle branch block.</div><div id=\"graphicVersion\">Graphic 81484 Version 1.0</div></div></div>"},"81485":{"type":"graphic_diagnosticimage","displayName":"Stenosis after gastric sleeve","title":"Stenosis after gastric sleeve","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Stenosis after gastric sleeve</div><div class=\"cntnt\"><img style=\"width:460px; height:504px;\" src=\"images/SURG/81485_Stenosis_gastric_sleeve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This film shows a proximal sleeve dilatation due to distal sleeve stenosis. The patient was subsequently converted to a Roux-en-Y gastric bypass.</div><div class=\"graphic_reference\">Courtesy of Raul J Rosenthal, MD, FACS, FASMBS.</div><div id=\"graphicVersion\">Graphic 81485 Version 3.0</div></div></div>"},"81488":{"type":"graphic_diagnosticimage","displayName":"Skeletal lead lines","title":"Skeletal lead lines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skeletal lead lines</div><div class=\"cntnt\"><img style=\"width:323px; height:432px;\" src=\"images/PEDS/81488_Skeletal_lead_lines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-bone radiographs demonstrating lead lines (increased opacity of the proximal tibial and fibular metaphyses, arrows) in a child with chronic lead toxicity.</div><div class=\"graphic_reference\">Courtesy of Richard Hurwitz, MD and Dean A Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 81488 Version 3.0</div></div></div>"},"81489":{"type":"graphic_picture","displayName":"Umbilical hernia in a patient with Beckwith-Wiedemann syndrome","title":"Umbilical hernia in a patient with Beckwith-Wiedemann syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical hernia in a patient with Beckwith-Wiedemann syndrome</div><div class=\"cntnt\"><img style=\"width:344px; height:313px;\" src=\"images/ALLRG/81489_Umbilical_hernia_BW_syndr.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81489 Version 1.0</div></div></div>"},"81493":{"type":"graphic_table","displayName":"Toxicity complement altern meds","title":"Toxicity of commonly used complementary and alternative medications ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxicity of commonly used complementary and alternative medications </div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">CAM</td>\n\n      <td class=\"subtitle1\">Indication</td>\n\n      <td class=\"subtitle1\">Toxicity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>St. John's wort</td>\n\n      <td>Depression</td>\n\n      <td>Nausea, hypersensitivity reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ephedra alkaloids</td>\n\n      <td>Weight reduction</td>\n\n      <td>Hypertension, tachycardia, stroke, seizures</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Kava</td>\n\n      <td>Anxiety</td>\n\n      <td>Yellow discoloration of skin/nails, hepatic dysfunction, stupor, visual disturbances, dizziness</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Echinacea</td>\n\n      <td>Respiratory infections</td>\n\n      <td>Hypersensitivity reactions (including anaphylaxis)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Saw palmetto</td>\n\n      <td>Benign prostatic hypertrophy</td>\n\n      <td>Diarrhea, constipation, headache, hypertension, nausea,\nurinary retention</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ginseng</td>\n\n      <td>Sedative</td>\n\n      <td>Diarrhea, headache, hypertension, insomnia, nausea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ginkgo</td>\n\n      <td>Dementia</td>\n\n      <td>Emesis, headache</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Green tea</td>\n\n      <td>Prostate cancer </td>\n\n      <td>Emesis, insomnia, diarrhea, confusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hydrazine sulfate </td>\n\n      <td>Appetite stimulant</td>\n\n      <td>Hepatorenal failure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Shark cartilage</td>\n\n      <td> Cancer</td>\n\n      <td>Emesis, constipation, hepatitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Laetrile</td>\n\n      <td>Cancer</td>\n\n      <td>Emesis, headache, dizziness, obtundation, dermatitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Antineoplastons</td>\n\n      <td>Gliomas</td>\n\n      <td>Somnolence, confusion</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">CAM: complementary and alternative medicine.</div><div class=\"graphic_reference\">Reproduced with permission from: Markman M. Safety issues in using complementary and alternative medicine. J Clin Oncol 2002; 20:39. Copyright &#169; 2002 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 81493 Version 3.0</div></div></div>"},"81494":{"type":"graphic_table","displayName":"Causes primary adrenal insufficienciency","title":"Causes of primary adrenal insufficiency in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of primary adrenal insufficiency in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Steroidogenesis disorders</td> </tr> <tr> <td class=\"sublist2_start\">Congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"sublist2\">21-hydroxylase deficiency (<em>CYP21A2 </em>mutations)</td> </tr> <tr> <td class=\"sublist2\">11-beta-hydroxylase deficiency (<em>CYP11B1 </em>mutations) </td> </tr> <tr> <td class=\"sublist2\">17-alpha-hydroxylase deficiency (<em>CYP17A1 </em>mutations)</td> </tr> <tr> <td class=\"sublist2\">3-beta-hydroxysteroid dehydrogenase deficiency (<em>HSD3B2</em> mutations)</td> </tr> <tr> <td class=\"sublist2\">Congenital lipoid adrenal hyperplasia (<em>CYP11A</em> mutations or StAR protein deficiency)</td> </tr> <tr> <td class=\"sublist2\">P450 oxidoreductase&nbsp;deficiency (apparent combined CYP21A2 and CYP17A1 deficiency)</td> </tr> <tr> <td class=\"sublist2_start\">Defects in aldosterone production</td> </tr> <tr> <td class=\"sublist2\">Aldosterone synthase deficiency (<em>CYP11B2 </em>mutations)</td> </tr> <tr> <td class=\"sublist2_start\">Defects in cholesterol biochemistry</td> </tr> <tr> <td class=\"sublist2\">Lysosomal acid lipase deficiency (Wolman disease)</td> </tr> <tr> <td class=\"sublist2\">Smith-Lemli-Opitz syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Adrenal damage or dysfunction</td> </tr> <tr> <td class=\"indent1\">Bilateral adrenal hemorrhage of the newborn</td> </tr> <tr> <td class=\"indent1\">Adrenal hemorrhage of acute infection</td> </tr> <tr> <td class=\"sublist2_start\">Autoimmunity</td> </tr> <tr> <td class=\"sublist2\">Polyglandular autoimmune syndromes</td> </tr> <tr> <td class=\"sublist2_start\">Infection</td> </tr> <tr> <td class=\"sublist2\">Tuberculosis</td> </tr> <tr> <td class=\"sublist2\">Fungal infection</td> </tr> <tr> <td class=\"sublist2\">Human immunodeficiency virus</td> </tr> <tr> <td class=\"sublist2\">Cytomegalovirus (CMV)</td> </tr> <tr> <td class=\"indent1\">Mitochondrial diseases due to mitochondrial DNA&nbsp;mutations (eg, some cases of Kearns Sayre, Pearson or MELAS syndromes)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Critical illness-related corticosteroid insufficiency (CIRCI)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Transient adrenal insufficiency in premature infants&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"sublist2_start\">Aminoglutethimide</td> </tr> <tr> <td class=\"indent1\">Ketoconazole</td> </tr> <tr> <td class=\"indent1\">Etomidate</td> </tr> <tr> <td class=\"indent1\">Mitotane&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Peroxisomal defects</td> </tr> <tr> <td class=\"indent1\">Adrenoleukodystrophy/adrenomyeloneuropathy (ALD/AMN)&nbsp; (X-linked)</td> </tr> <tr> <td class=\"indent1\">Neonatal adrenoleukodystrophy&nbsp;(autosomal recessive)</td> </tr> <tr> <td class=\"indent1\">Refsum disease (autosomal recessive)</td> </tr> <tr> <td class=\"indent1\">Zellweger syndrome (autosomal recessive)</td> </tr> <tr> <td class=\"subtitle1_single\">Abnormal adrenal development</td> </tr> <tr> <td class=\"indent1\">X-linked adrenal hypoplasia congenita (AHC), due to <em>DAX-1</em> mutations</td> </tr> <tr> <td class=\"indent1\">Adrenal hypoplasia due to steroidogenic factor-1 (<em>SF-1</em>) mutations</td> </tr> <tr> <td class=\"indent1\">IMAGe syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Inherited&nbsp;adrenal unresponsiveness to ACTH*<span style=\"color: #0000ff;\"></span></td> </tr> <tr> <td class=\"indent1\">Familial glucocorticoid deficiency (<em>MC2R</em> or <em>MRAP</em> mutations)</td> </tr> <tr> <td class=\"indent1\">Triple A syndrome (<em>AAAS </em>mutations)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IMAGe syndrome: Intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenital, and genital anomalies; DAX-1: dose-sensitive sex-reversal adrenal hypoplasia-congenita critical region on the X chromosome gene 1 (also known as NR0B1); AAAS: achalasia-addisonianism-alacrimia syndrome gene; MELAS syndrome: mitochondrial encephalopathy, lactic acidosis and stroke-like episodes.<br /><FONT color=black>*&nbsp;Familial glucocorticoid deficiency and triple A syndrome, patients usually have isolated glucocorticoid deficiency and not mineralocorticoid deficiency, so the clinical presentation&nbsp;may be&nbsp;similar to central adrenal insufficiency rather than primary adrenal insufficiency. However, hyperpigmentation may be present. </FONT></div><div class=\"graphic_reference\">Courtesy of Patricia Donohoue, MD.</div><div id=\"graphicVersion\">Graphic 81494 Version 17.0</div></div></div>"},"81495":{"type":"graphic_figure","displayName":"Classification of ROP","title":"International Classification of Retinopathy of Prematurity","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">International Classification of Retinopathy of Prematurity</div><div class=\"cntnt\"><img style=\"width:724px; height:1067px;\" src=\"images/PEDS/81495_Classification_of_ROP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classification of ROP based upon the International Classification of Retinopathy of Prematurity. The diagram depicts the left eye and is used to document the location and extent of ROP.</div><div class=\"graphic_footnotes\">ROP: retinopathy of prematurity.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123:991. </li>&#xD;&#xA;    <li>Katz X, Kychenthal A, Dorta P. Zone I retinopathy of prematurity. J AAPOS 2000; 4:373. </li>&#xD;&#xA;    <li>Wallace DK, Kylstra JA, Chesnutt DA. Prognostic significance of vascular dilation and tortuosity insufficient for plus disease in retinopathy of prematurity. J AAPOS 2000; 4:224. </li>&#xD;&#xA;    <li>Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. The Early Treatment for Retinopathy Of Prematurity Study: structural findings at age 2 years. Br J Ophthalmol 2006; 90:1378.</li>&#xD;&#xA;</ol>&#xD;&#xA;Figure adapted from: An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol 1984; 102:1130.</div><div id=\"graphicVersion\">Graphic 81495 Version 5.0</div></div></div>"},"81496":{"type":"graphic_diagnosticimage","displayName":"Axial CT of second branchial cleft cyst","title":"Axial computed tomography of second branchial cleft cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial computed tomography of second branchial cleft cyst</div><div class=\"cntnt\"><img style=\"width:351px; height:415px;\" src=\"images/ALLRG/81496_Ax_CT_sec_bran_cleft_cyst.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81496 Version 3.0</div></div></div>"},"81497":{"type":"graphic_table","displayName":"Physical anomalies associated with dyskeratosis congenita","title":"Physical anomalies associated with dyskeratosis congenita","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical anomalies associated with dyskeratosis congenita</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Anomaly</td> <td class=\"subtitle1\">Frequency (percent)</td> </tr> <tr> <td><strong>Any physical anomaly</strong></td> <td><strong>75</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Nails*</strong></td> <td rowspan=\"3\"><strong>70</strong></td> </tr> <tr> <td class=\"sublist1\">Dystrophic</td> </tr> <tr> <td class=\"sublist1\">Small thin nail plates with ridges</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Skin*</strong></td> <td rowspan=\"2\"><strong>67</strong></td> </tr> <tr> <td class=\"sublist1\">Reticular pigmentation</td> </tr> <tr class=\"divider_top\"> <td><strong>Oral leukoplakia*</strong></td> <td><strong>47</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Eyes</strong></td> <td rowspan=\"9\"><strong>29</strong></td> </tr> <tr> <td class=\"sublist1\">Lacrimal duct stenosis (causes tearing)</td> </tr> <tr> <td class=\"sublist1\">Epiphora</td> </tr> <tr> <td class=\"sublist1\">Blepharitis</td> </tr> <tr> <td class=\"sublist1\">Proliferative and exudative retinopathy (Revesz syndrome; can cause retinal detachment)</td> </tr> <tr> <td class=\"sublist1\">Strabismus</td> </tr> <tr> <td class=\"sublist1\">Cataracts</td> </tr> <tr> <td class=\"sublist1\">Absent eyelashes</td> </tr> <tr> <td class=\"sublist1\">Corneal ulcers</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Hair</strong></td> <td rowspan=\"3\"><strong>19</strong></td> </tr> <tr> <td class=\"sublist1\">Alopecia or sparse hair and eyebrows</td> </tr> <tr> <td class=\"sublist1\">Early graying and loss</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Teeth</strong></td> <td rowspan=\"4\"><strong>13</strong></td> </tr> <tr> <td class=\"sublist1\">Abnormally shaped or missing teeth</td> </tr> <tr> <td class=\"sublist1\">Periodontitis</td> </tr> <tr> <td class=\"sublist1\">Prone to caries</td> </tr> <tr class=\"divider_top\"> <td><strong>Developmental delay</strong></td> <td><strong>13</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Gastrointestinal anomalies</strong></td> <td rowspan=\"3\"><strong>12</strong></td> </tr> <tr> <td class=\"sublist1\">Esophageal stenosis (8 percent)</td> </tr> <tr> <td class=\"sublist1\">Hepatic fibrosis</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Skeletal</strong></td> <td rowspan=\"4\"><strong>12</strong></td> </tr> <tr> <td class=\"sublist1\">Short stature</td> </tr> <tr> <td class=\"sublist1\">Osteopenia</td> </tr> <tr> <td class=\"sublist1\">Avascular necrosis of the hip</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Head</strong></td> <td rowspan=\"4\"><strong>9</strong></td> </tr> <tr> <td class=\"sublist1\">Microcephaly</td> </tr> <tr> <td class=\"sublist1\">Cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome)</td> </tr> <tr> <td class=\"sublist1\">Dandy-Walker malformation</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Cardiopulmonary</strong></td> <td rowspan=\"3\"><strong>7</strong></td> </tr> <tr> <td class=\"sublist1\">Pulmonary fibrosis</td> </tr> <tr> <td class=\"sublist1\">Atrial or ventricular septal defect</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><strong>Genitourinary</strong></td> <td rowspan=\"5\"><strong>7</strong></td> </tr> <tr> <td class=\"sublist1\">Phimosis</td> </tr> <tr> <td class=\"sublist1\">Meatal stenosis</td> </tr> <tr> <td class=\"sublist1\">Hypospadias</td> </tr> <tr> <td class=\"sublist1\">Penile leukoplakia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Classic &quot;diagnostic triad&quot; for dyskeratosis congenita (all three features are present in about 45 percent of patients with this disorder).</div><div class=\"graphic_reference\">Data from: Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010; 24(3):101.</div><div id=\"graphicVersion\">Graphic 81497 Version 3.0</div></div></div>"},"81498":{"type":"graphic_figure","displayName":"Insertion of cube pessary","title":"Cube vaginal pessary in position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cube vaginal pessary in position</div><div class=\"cntnt\"><img style=\"width:370px; height:301px;\" src=\"images/OBGYN/81498_Insertion_of_cube_pessary.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Milex Products, Inc., Chicago, IL.</div><div id=\"graphicVersion\">Graphic 81498 Version 2.0</div></div></div>"},"81500":{"type":"graphic_figure","displayName":"Wrist arthrocentesis","title":"Wrist arthrocentesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wrist arthrocentesis</div><div class=\"cntnt\"><img style=\"width:426px; height:348px;\" src=\"images/RHEUM/81500_Wrist_arthrocentesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The needle is inserted at a point just distal to the radius and just ulnar to the anatomic snuff box (arrow). It is then directed perpendicularly. If bone is hit, the needle should be pulled back and slightly redirected toward the thumb.</div><div class=\"graphic_reference\">Reproduced from Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley WN, Harris ED Jr, Ruddy S (Eds), WB Saunders, Philadelphia 1993. p.545.</div><div id=\"graphicVersion\">Graphic 81500 Version 2.0</div></div></div>"},"81501":{"type":"graphic_diagnosticimage","displayName":"PIE in RDS","title":"Pulmonary interstitial emphysema in an infant with respiratory distress syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary interstitial emphysema in an infant with respiratory distress syndrome</div><div class=\"cntnt\"><img style=\"width:351px; height:291px;\" src=\"images/PEDS/81501_PIE_in_RDS.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gerardo Cabrera-Meza, MD.</div><div id=\"graphicVersion\">Graphic 81501 Version 2.0</div></div></div>"},"81502":{"type":"graphic_picture","displayName":"Nasopharyngeal swab","title":"Nasopharyngeal swab sampling for pertussis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Nasopharyngeal swab sampling for pertussis</div><div class=\"cntnt\"><img style=\"width:468px; height:358px;\" src=\"images/PC/81502_Nasopharyngeal_swab.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81502 Version 3.0</div></div></div>"},"81503":{"type":"graphic_figure","displayName":"FEV1 and survival AAT deficiency","title":"Survival in AAT according to FEV1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival in AAT according to FEV1</div><div class=\"cntnt\"><img style=\"width:391px; height:315px;\" src=\"images/PULM/81503_FEV1_and_survival_AAT_defic.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two year mortality rate in patients with alpha-1 antitrypsin deficiency according to FEV1. Mortality rises dramatically when the FEV1 falls below 35 percent predicted.</div><div class=\"graphic_footnotes\">FEV1: forced vital capacity in one second.</div><div class=\"graphic_reference\">Redrawn from Seersholm N, Dirksen A, Kok-Jensen A, Eur Respir J 1994; 7:1985.</div><div id=\"graphicVersion\">Graphic 81503 Version 2.0</div></div></div>"},"81505":{"type":"graphic_picture","displayName":"Active trachoma inflam","title":"Active trachoma: Inflammation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Active trachoma: Inflammation</div><div class=\"cntnt\"><img style=\"width:360px; height:437px;\" src=\"images/ID/81505_Active_trachoma_inflam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal eyelid. Deep tarsal vessels (arrow). <br />(B) World Health Organization grade TI (trachomatous inflammation, intense). To make a diagnosis of TI, papillary hypertrophy and inflammatory thickening of the upper tarsal conjunctiva must obscure more than half the deep tarsal vessels.</div><div id=\"graphicVersion\">Graphic 81505 Version 4.0</div></div></div>"},"81506":{"type":"graphic_table","displayName":"Protein intake CKD children","title":"Recommended dietary protein intake in children with chronic kidney disease*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended dietary protein intake in children with chronic kidney disease*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age</td> <td class=\"subtitle1\" colspan=\"5\">Dietary reference intake (DRI)</td> </tr> <tr> <td class=\"subtitle2\">DRI (g/kg/day)</td> <td class=\"subtitle2\">Recommended for CKD stage 3 (g/kg/day) (100 to 140 percent DRI)</td> <td class=\"subtitle2\">Recommended for CKD stages 4 or 5 (g/kg/day) (100 to 120 percent DRI)</td> <td class=\"subtitle2\">Recommended for HD (g/kg/day)<sup>&#182;</sup></td> <td class=\"subtitle2\">Recommended for PD (g/kg/day)<sup>&#916;</sup></td> </tr> <tr> <td>0 to 6 months</td> <td>1.5</td> <td>1.5 to 2.1</td> <td>1.5 to 1.8</td> <td>1.6</td> <td>1.8</td> </tr> <tr> <td>7 to 12 months</td> <td>1.2</td> <td>1.2 to 1.7</td> <td>1.2 to 1.5</td> <td>1.3</td> <td>1.5</td> </tr> <tr> <td>1 to 3 years</td> <td>1.05</td> <td>1.05 to 1.5</td> <td>1.05 to 1.25</td> <td>1.15</td> <td>1.3</td> </tr> <tr> <td>4 to 13 years</td> <td>0.95</td> <td>0.95 to 1.35</td> <td>0.95 to 1.15</td> <td>1.05</td> <td>1.1</td> </tr> <tr> <td>14 to 18 years</td> <td>0.85</td> <td>0.85 to 1.2</td> <td>0.85 to 1.05</td> <td>0.95</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; HD: hemodialysis; PD: peritoneal dialysis.<br />* Children with chronic kidney disease stages 3 to 5.<br />¶ DRI + 0.1 g/kg/day to compensate for dialytic losses.<br />Δ DRI + 0.15 to 0.3 g/kg/day depending on patient age to compensate for peritoneal losses.</div><div class=\"graphic_reference\">Reproduced with permission from: National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53:S11. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 81506 Version 8.0</div></div></div>"},"81507":{"type":"graphic_table","displayName":"Pelvic muscle exercises PI","title":"Pelvic muscle exercises","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pelvic muscle exercises</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>Identify the correct muscles to contract. Women can do this by placing a finger in the vagina and squeezing the muscles around their finger. Another way is for a woman to imagine that she is sitting on a marble. Imagine using the vaginal muscles to gently lift the marble off the chair. The muscles of the buttocks, abdomen, and thighs should not be used.</td> </tr> <tr class=\"divider_bottom\"> <td>Second, hold the pelvic muscle contraction approximately 8 to 10 seconds, and then relax the muscles; adequate relaxation is as important as contraction. In the beginning, it may not be possible to hold the contraction for more than one second. Perform 8 to 12 contractions followed by relaxation three times. Try to do this every day, but no less than three or four times a week. The exercise regimen should be continued for at least 15 to 20 weeks.</td> </tr> <tr class=\"divider_bottom\"> <td>Over time, try to hold the contraction harder and for a longer time. These exercises need to be continued indefinitely to have a lasting effect, similar to other forms of exercise.</td> </tr> <tr> <td>In patients whose muscles are weak, the exercises should initially be done while lying down. As the muscles become stronger, the exercises may be done while sitting or standing. The muscles should be contracted during activities that can cause urine leakage, such as during physical exercise, lifting, coughing, or sneezing.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81507 Version 5.0</div></div></div>"},"81508":{"type":"graphic_table","displayName":"Vaccine administration guidelines for adults","title":"Administering vaccines to adults: Dose, route, site, needle size, and preparation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Administering vaccines to adults: Dose, route, site, needle size, and preparation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Site</td> <td class=\"subtitle1\">Needle size</td> <td class=\"subtitle1\">Vaccine preparation</td> </tr> <tr> <td>Tetanus, Diphtheria (Td) with Pertussis (Tdap)</td> <td>0.5 mL</td> <td>IM</td> <td>Deltoid muscle</td> <td>22 to 25 g, 1 to 1&#189;\"*</td> <td rowspan=\"9\">Shake vial vigorously to obtain a uniform suspension prior to withdrawing each dose. Whenever solution and container permit, inspect vaccine visually for particulate matter and/or discoloration prior to administration. If problems are noted (eg, vaccine cannot be resuspended), the vaccine should not be administered.</td> </tr> <tr> <td>Hepatitis A (HepA)</td> <td>&#8804;18 yrs.:0.5 mL<br /> &#8804;19 yrs.:1.0 mL</td> <td>IM</td> <td>Deltoid muscle</td> <td>22 to 25 g, 1 to 1&#189;\"*</td> </tr> <tr> <td>Hepatitis B (HepB)</td> <td>&#8804;19 yrs.:0.5 mL<br /> &#8805;20 yrs.:1.0 mL</td> <td>IM</td> <td>Deltoid muscle</td> <td>22 to 25 g, 1 to 1&#189;\"*</td> </tr> <tr> <td>HepA+HepB (Twinrix)</td> <td>&#8805;18 yrs.:1.0 mL</td> <td>IM</td> <td>Deltoid muscle</td> <td>22 to 25 g, 1 to 1&#189;\"*</td> </tr> <tr> <td>Human papillomavirus (HPV)</td> <td>0.5 mL</td> <td>IM</td> <td>Deltoid muscle</td> <td>22 to 25 g, 1 to 1&#189;\"*</td> </tr> <tr> <td>Influenza, trivalent inactivated (TIV)</td> <td>0.5 mL</td> <td>IM</td> <td>Deltoid muscle</td> <td>22 to 25 g, 1 to 1&#189;\"*</td> </tr> <tr> <td rowspan=\"2\">Pneumococcal polysaccharide (PPSV)</td> <td rowspan=\"2\">0.5 mL</td> <td>IM</td> <td>Deltoid muscle</td> <td>22 to 25 g, 1 to 1&#189;\"*</td> </tr> <tr> <td>SC</td> <td>Fatty tissue over triceps</td> <td>23 to 25 g, ⅝\"</td> </tr> <tr> <td>Meningococcal, conjugated (MCV)</td> <td>0.5 mL</td> <td>IM</td> <td>Deltoid muscle</td> <td>22 to 25 g, 1 to 1&#189;\"*</td> </tr> <tr class=\"divider_top\"> <td>Meningococcal, polysaccharide (MPSV)</td> <td>0.5 mL</td> <td>SC</td> <td>Fatty tissue over triceps</td> <td>23 to 25 g, ⅝\"</td> <td rowspan=\"4\"> <p>Reconstitute just before using. Use only the diluent supplied with the vaccine. Inject the volume of the diluent shown on the diluent label into the vial of lyophilized vaccine and gently agitate to mix thoroughly. Withdraw the entire contents and administer immediately after reconstitution.</p> <p>Discard single dose MPSV, varicella, and zoster vaccines if not used within 30 minutes after reconstitution.</p> <p><strong>Note:</strong> Unused reconstituted MMR vaccine and multidose MPSV vaccine may be stored at 35&#176;46&#176;F (2&#176;8&#176;C) for a limited time. The reconstituted MPSV vaccine must be used within 35 days; the reconstituted MMR vaccine must be used within 8 hours. Do not freeze either reconstituted vaccine.</p> </td> </tr> <tr> <td>Measles, mumps, rubella (MMR)</td> <td>0.5 mL</td> <td>SC</td> <td>Fatty tissue over triceps</td> <td>23 to 25 g, ⅝\"</td> </tr> <tr> <td>Zoster (Zos)</td> <td>0.65 mL</td> <td>SC</td> <td>Fatty tissue over triceps</td> <td>23 to 25 g, ⅝\"</td> </tr> <tr> <td>Varicella (Var)</td> <td>0.5 mL</td> <td>SC</td> <td>Fatty tissue over triceps</td> <td>23 to 25 g, ⅝\"</td> </tr> <tr class=\"divider_top\"> <td>Influenza, live, attenuated (LAIV)</td> <td>0.2 mL (0.1 mL into each nostril)</td> <td>Intranasal spray</td> <td>Intranasal</td> <td>NA</td> <td>Consult package insert</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Please note:</STRONG> Always refer to the package insert included with each biologic for complete vaccine administration information. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations for the particular vaccine should be reviewed as well. Access the ACIP recommendations at <A href=\"http://www.immunize.org/acip\" target=_blank>www.immunize.org/acip</A>.</div><div class=\"graphic_footnotes\">IM: intramuscular; SC: subcutaneous; NA: not applicable.<br />* When giving intramuscular injections, a ⅝\" needle is sufficient in adults weighing &lt;130 lbs (&lt;60 kg); a 1\" needle is sufficient in adults weighing 130 to 152 lbs (60 to 70 kg); a 1 to 1½\" needle is recommended in women weighing 152 to 200 lbs (70 to 90 kg) and men weighing 152 to 260 lbs (70 to 118 kg); a 1½\" needle is recommended in women weighing &gt;200 lbs (&gt;90 kg) or men weighing &gt;260 lbs (&gt;118 kg). A ⅝\" (16 mm) needle may be used only if the skin is stretched tight, the subcutaneous tissue is not bunched, and injection is made at a 90-degree angle.</div><div class=\"graphic_reference\">Acquired from: <a href=\"http://www.immunize.org/catg.d/p3084.pdf\" target=\"_blank\">http://www.immunize.org/catg.d/p3084.pdf</a> on January 12, 2012. We thank the Immunization Action Coalition.</div><div id=\"graphicVersion\">Graphic 81508 Version 2.0</div></div></div>"},"81512":{"type":"graphic_figure","displayName":"Intercostal nerve block","title":"Intercostal nerve block","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Intercostal nerve block</div><div class=\"cntnt\"><img style=\"width:526px; height:690px;\" src=\"images/SURG/81512_Intercostal_nerve_block_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intercostal nerve block may be performed using an anatomic approach (at site B) by palpating the rib. Alternatively, ultrasound guidance may be used to inject&nbsp;local anesthetic more proximal in the course of the nerve (at site A), since palpation of the rib is less important. With either approach, the needle is inserted at the inferior border of the rib, and&nbsp;after negative aspiration, 3 to 5 mL of LA (0.2% ropivacaine or 0.25% bupivacaine with epinephrine 1:200,000)&nbsp;is injected.&nbsp;For details of intercostal nerve block, see topic text.</div><div id=\"graphicVersion\">Graphic 81512 Version 5.0</div></div></div>"},"81513":{"type":"graphic_diagnosticimage","displayName":"Aortogram of a bronchopulmonary sequestration","title":"Aortogram of a left lower lobe bronchopulmonary sequestration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortogram of a left lower lobe bronchopulmonary sequestration</div><div class=\"cntnt\"><img style=\"width:278px; height:366px;\" src=\"images/PEDS/81513_BPS_aortogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortogram demonstrating the systemic (aortic) origin of the arterial blood supply of a left lower lobe&nbsp;introlobar pulmonary&nbsp;sequestration (ILS). Note that the feeding vessels arise from the subdiaphragmatic aorta (arrow).</div><div class=\"graphic_reference\">Courtesy of Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 81513 Version 3.0</div></div></div>"},"81514":{"type":"graphic_figure","displayName":"CNS tumor child site","title":"Pediatric primary brain and CNS tumors: Distribution by site","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Pediatric primary brain and CNS tumors: Distribution by site</div><div class=\"cntnt\"><img style=\"width:582px; height:528px;\" src=\"images/PEDS/81514_CNS_tumor_child_site_edit2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution&nbsp;of primary brain and CNS tumors by site in children and adolescents (ages 0 to 19 years; n = 23,113), CBTRUS Statistical Report: NPCR and SEER, 2008 to 2012.</div><div class=\"graphic_footnotes\">CNS: central nervous system; CBTRUS: Central Brain Tumor Registry of the United States; NPCR: National Program of Cancer Registries; SEER: Surveillance, Epidemiology, and End Results Program.</div><div class=\"graphic_reference\">Reproduced with permission from: Quinn T. Ostrom, Haley Gittleman, Jordonna Fulop, Max Liu, Rachel Blanda, Courtney Kromer, Yingli Wolinsky, Carol Kruchko, and Jill S. Barnholtz-Sloan, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012, Neuro Oncol (2015) 17 (suppl 4): iv1-iv62 doi: 10.1093/neuonc/nov189.</div><div id=\"graphicVersion\">Graphic 81514 Version 6.0</div></div></div>"},"81516":{"type":"graphic_table","displayName":"Low-potassium foods Basic PI","title":"Some foods that are low in potassium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some foods that are low in potassium</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Fruits</td> <td class=\"subtitle1\">Vegetables</td> <td class=\"subtitle1\">Proteins</td> </tr> <tr> <td>Apple juice</td> <td>Alfalfa sprouts</td> <td>Almonds</td> </tr> <tr> <td>Apples and applesauce</td> <td>Asparagus</td> <td>Cashews </td> </tr> <tr> <td>Blackberries</td> <td>Cabbage (cooked)</td> <td>Chicken</td> </tr> <tr> <td>Blueberries</td> <td>Carrots (cooked)</td> <td>Eggs</td> </tr> <tr> <td>Cherries</td> <td>Cauliflower</td> <td>Flax seed</td> </tr> <tr> <td>Cranberries</td> <td>Celery</td> <td>Peanuts</td> </tr> <tr> <td>Grapefruit</td> <td>Corn</td> <td>Pumpkin seeds</td> </tr> <tr> <td>Grapes and grape juice</td> <td>Cucumber</td> <td>Shrimp</td> </tr> <tr> <td>Peaches</td> <td>Eggplant</td> <td>Sunflower seeds</td> </tr> <tr> <td>Pears</td> <td>Green beans</td> <td>Tuna</td> </tr> <tr> <td>Pineapple</td> <td>Green peas</td> <td>Turkey</td> </tr> <tr> <td>Plums</td> <td>Green peppers</td> <td>Walnuts</td> </tr> <tr> <td>Raspberries</td> <td>Kale</td> <td rowspan=\"11\">&nbsp;</td> </tr> <tr> <td>Strawberries</td> <td>Lettuce</td> </tr> <tr> <td>Watermelon</td> <td>Okra</td> </tr> <tr> <td rowspan=\"8\">&nbsp;</td> <td>Onions</td> </tr> <tr> <td>Radish</td> </tr> <tr> <td>Rhubarb</td> </tr> <tr> <td>Spinach</td> </tr> <tr> <td>Water chestnuts</td> </tr> <tr> <td>Wax beans</td> </tr> <tr> <td>Yellow squash</td> </tr> <tr> <td>Zucchini</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81516 Version 2.0</div></div></div>"},"81517":{"type":"graphic_figure","displayName":"Doppler signal echocardiogram","title":"Doppler signal from intracardiac blood flow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler signal from intracardiac blood flow</div><div class=\"cntnt\"><img style=\"width:439px; height:293px;\" src=\"images/CARD/81517_Doppler_signal_echocardiogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this display, time is on the x-axis and flow velocity on the y-axis. By convention, flow away from the transducer is displayed below the line and that toward the transducer above the line; this spectral information can be displayed in real time (Doppler figure). The Doppler signal portrays the entire period of flow, ie, acceleration (a), peak flow (pf), and deceleration (d).</div><div id=\"graphicVersion\">Graphic 81517 Version 2.0</div></div></div>"},"81518":{"type":"graphic_figure","displayName":"Fontanelles and suture lines","title":"Fetal head at term showing fontanelles, sutures, and biparietal diameter","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Fetal head at term showing fontanelles, sutures, and biparietal diameter</div><div class=\"cntnt\"><img style=\"width:502px; height:473px;\" src=\"images/OBGYN/81518_Fontanelles_and_suture_lines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior fontanelle is diamond shaped, at the intersection of four fetal skull bones, and usually the larger fontanelle, whereas the posterior fontanelle is triangular, at the intersection of three fetal skull bones, and usually the smaller fontanelle. </div><div id=\"graphicVersion\">Graphic 81518 Version 10.0</div></div></div>"},"81525":{"type":"graphic_table","displayName":"Etiologies of polyradiculopathy","title":"Etiologies of polyradiculopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of polyradiculopathy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Structural</td> </tr> <tr> <td class=\"sublist_other_start\">1. Spinal stenosis</td> </tr> <tr> <td class=\"indent2\">a. Congenital</td> </tr> <tr> <td class=\"indent3\">i. Achondroplasia</td> </tr> <tr> <td class=\"indent3\">ii. Hereditary (idiopathic)</td> </tr> <tr> <td class=\"indent2\">b. Acquired</td> </tr> <tr> <td class=\"indent3\">i. Ankylosing spondylitis</td> </tr> <tr> <td class=\"indent3\">ii. Degenerative</td> </tr> <tr> <td class=\"indent3\">iii. Iatrogenic</td> </tr> <tr> <td class=\"indent3\">iv. Paget disease</td> </tr> <tr> <td class=\"indent3\">v. Post-traumatic</td> </tr> <tr> <td class=\"sublist_other_start\">2. Tethered cord syndrome</td> </tr> <tr> <td class=\"sublist_other_start\">3. Primary tumors</td> </tr> <tr> <td class=\"indent2\">a. Dermoid</td> </tr> <tr> <td class=\"indent2\">b. Ependymoma</td> </tr> <tr> <td class=\"indent2\">c. Epidermoid</td> </tr> <tr> <td class=\"indent2\">d. Ganglioneuroma</td> </tr> <tr> <td class=\"indent2\">e. Hemangioblastoma</td> </tr> <tr> <td class=\"indent2\">f. Lipoma</td> </tr> <tr> <td class=\"indent2\">g. Lymphoma</td> </tr> <tr> <td class=\"indent2\">h. Neurofibroma</td> </tr> <tr> <td class=\"indent2\">i. Osteoma</td> </tr> <tr> <td class=\"indent2\">j. Paraganglioma</td> </tr> <tr> <td class=\"indent2\">k. Plasmacytoma</td> </tr> <tr> <td class=\"indent2\">l. Schwannoma</td> </tr> <tr> <td class=\"sublist_other_start\">4. Leptomeningeal metastasis</td> </tr> <tr> <td class=\"indent2\">a. Leukemia</td> </tr> <tr> <td class=\"indent2\">b. Lymphoma</td> </tr> <tr> <td class=\"indent2\">c. Solid tumors</td> </tr> <tr> <td class=\"sublist_other_start\">5. Dural ectasia</td> </tr> <tr> <td class=\"sublist_other_start\">6. Lumbosacral spinal cysts</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Nonstructural</td> </tr> <tr> <td class=\"sublist_other_start\">1. Diabetes</td> </tr> <tr> <td class=\"indent2\">a. Diabetic amyotrophy (diabetic lumbosacral radiculoplexus neuropathy)</td> </tr> <tr> <td class=\"indent2\">b. Thoracic radiculopathy</td> </tr> <tr> <td class=\"indent2\">c. Diabetic cervical radiculoplexus neuropathy</td> </tr> <tr> <td class=\"sublist_other_start\">2. Infectious non-HIV related</td> </tr> <tr> <td class=\"indent2\">a. Hepatitis C</td> </tr> <tr> <td class=\"indent2\">b. Human T-lymphotropic virus (HTLV-I)</td> </tr> <tr> <td class=\"indent2\">c. Lyme disease</td> </tr> <tr> <td class=\"indent2\">d. Mycobacteria</td> </tr> <tr> <td class=\"indent2\">e. Varicella-zoster virus</td> </tr> <tr> <td class=\"sublist_other_start\">3. HIV/AIDS-related</td> </tr> <tr> <td class=\"indent2\">a. Cryptococcal infection</td> </tr> <tr> <td class=\"indent2\">b. Cytomegalovirus infection</td> </tr> <tr> <td class=\"indent2\">c. Lymphomatous meningitis</td> </tr> <tr> <td class=\"indent2\">d. Mycobacterial infection</td> </tr> <tr> <td class=\"indent2\">e. Treponemal infection</td> </tr> <tr> <td class=\"sublist_other_start\">4. Arachnoiditis</td> </tr> <tr> <td class=\"indent2\">a. Idiopathic</td> </tr> <tr> <td class=\"indent2\">b. Intrathecal medications (eg, methotrexate)</td> </tr> <tr> <td class=\"indent2\">c. Neurocysticercosis</td> </tr> <tr> <td class=\"indent2\">d. Post myelography</td> </tr> <tr> <td class=\"indent2\">e. Post-traumatic</td> </tr> <tr> <td class=\"indent2\">f. Subarachnoid hemorrhage</td> </tr> <tr> <td class=\"sublist_other_start\">5. Sarcoidosis</td> </tr> <tr> <td class=\"sublist_other_start\">6. Radiation-induced</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Seward Rutkove, MD and Andrew Tarulli, MD.</div><div id=\"graphicVersion\">Graphic 81525 Version 3.0</div></div></div>"},"81526":{"type":"graphic_table","displayName":"Staging of HL in pregnancy","title":"Staging studies in pregnant women with Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging studies in pregnant women with Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">History and physical examination</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Blood tests</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Complete blood count with differential</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Erythrocyte sedimentation rate</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Serum creatinine concentration</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Liver enzymes, including LDH and alkaline phosphatase</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>HIV serology</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Evaluation for supradiaphragmatic disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Single posterior/anterior view chest x-ray with adequate abdominal shielding</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Magnetic resonance imaging (if abnormalities seen on chest x-ray)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Computerized tomography (if MRI not available)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Evaluation for intraabdominal disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Magnetic resonance imaging</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Ultrasound (if MRI not available)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Computerized tomography (if MRI and ultrasound not available)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Bone marrow biopsy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>A unilateral bone marrow biopsy should be performed for patients with B symptoms; clinical stage IIB to IV disease; and for patients with anemia, leukopenia, or thrombocytopenia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Not indicated</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Gallium scan</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>PET scan</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Bone scan</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 81526 Version 3.0</div></div></div>"},"81527":{"type":"graphic_picture","displayName":"Reimplantation avulsed teeth","title":"Reimplantation of avulsed teeth","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Reimplantation of avulsed teeth</div><div class=\"cntnt\"><img style=\"width:493px; height:108px;\" src=\"images/PEDS/81527_Reimplantation_avulsed_teet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tooth should be handled carefully by the crown to prevent damage to the periodontal ligament. Debris should be removed by gentle rinsing with saline or tap water; attempts should not be made to sterilize or scrub the tooth. The tooth should be manually reimplanted in the socket (C). The tooth is kept in place by the child through finger pressure or by biting on a gauze pad.</div><div class=\"graphic_reference\">Reproduced with permission from McTigue DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 4th ed, WB Saunders, Philadelphia 2005. Copyright &#169; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 81527 Version 2.0</div></div></div>"},"81528":{"type":"graphic_figure","displayName":"Probability of cancer in a solitary pulmonary nodule","title":"Estimating the probability of cancer (PCa) in a solitary pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Estimating the probability of cancer (PCa) in a solitary pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:528px; height:318px;\" src=\"images/PULM/81528_Probability_pulmonary_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Cummings, SR, Lillington, GA, Richard, RJ, Am Rev Respir Dis 1986; 134:449.</div><div id=\"graphicVersion\">Graphic 81528 Version 6.0</div></div></div>"},"81529":{"type":"graphic_table","displayName":"Stigmata of late congenital syphilis","title":"Stigmata of late congenital syphilis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stigmata of late congenital syphilis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Facial features</td> <td>Frontal bossing, saddle nose, short maxilla, protuberant mandible</td> </tr> <tr> <td>Ophthalmologic</td> <td>Interstitial keratitis, chorioretinitis, secondary glaucoma, corneal scarring, optic atrophy</td> </tr> <tr> <td>Ears</td> <td>Sensorineural hearing loss</td> </tr> <tr> <td>Oropharynx</td> <td>Hutchinson teeth, mulberry molars, perforation of hard palate</td> </tr> <tr> <td>Cutaneous</td> <td>Rhagades, gummas</td> </tr> <tr> <td>Central nervous system</td> <td>Intellectual disability, arrested hydrocephalus, seizures, optic atrophy, juvenile general paresis</td> </tr> <tr> <td>Skeletal</td> <td>Saber shins (anterior bowing of the tibia), Higoumenakis sign (enlargement of the sternoclavicular portion of the clavicle), Clutton joints (painless arthritis), scaphoid scapula</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=85194&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Ingall D, Sanchez PJ, Baker CH. Syphilis. In: Infectious Diseases of the Fetus and Newborn infant, 6th edition, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.545. </LI>&#xD;&#xA;<LI>Dobson SR, Sanchez PJ. Syphilis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al. (Eds), Elsevier Saunders, Philadelphia 2014. p.1761.</LI>&#xD;&#xA;<LI>Woods CR. Syphilis in children: congenital and acquired. Semin Pediatr Infect Dis 2005; 16:245. </LI>&#xD;&#xA;<LI>Chakraborty R, Luck S. Syphilis is on the increase: the implications for child health. Arch Dis Child 2008; 93:105. </LI></OL></div><div id=\"graphicVersion\">Graphic 81529 Version 3.0</div></div></div>"},"81531":{"type":"graphic_picture","displayName":"Male genital HSV","title":"Genital herpes simplex virus, male","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Genital herpes simplex virus, male</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/81531_Male_genital_HSV.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81531 Version 3.0</div></div></div>"},"81532":{"type":"graphic_table","displayName":"Diff dx mesenteric masses","title":"Differential diagnosis of mesenteric masses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of mesenteric masses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">CT appearance</td> <td class=\"subtitle1\">Pathologic conditions</td> <td class=\"subtitle1\">Associated findings</td> </tr> <tr> <td rowspan=\"6\">Round, well-defined mass(es)</td> <td>Non-Hodgkin lymphoma</td> <td>Retroperitoneal adenopathy</td> </tr> <tr> <td>Metastic deposits</td> <td>Small bowel nodules</td> </tr> <tr> <td>Mycobacterium avium complex infection</td> <td>Hepatic and splenic lesions</td> </tr> <tr> <td>Whipple's disease</td> <td>Thickened small bowel folds</td> </tr> <tr> <td>Mesenteric cysts</td> <td>Fat attenuation</td> </tr> <tr> <td>Castelman disease</td> <td>Hypervascular mass</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Ill-defined, irregular mass(es)</td> <td>Small bowel carcinoid</td> <td>Calcifications; small bowel mass</td> </tr> <tr> <td>Mesenteric fibromatosis (desmoid)</td> <td>Gardner's syndrome; abdominal wall infiltration</td> </tr> <tr> <td>Tumor infiltration (pancreas, gastric, colon)</td> <td>Primary tumor</td> </tr> <tr> <td>Lymphoma</td> <td>Retroperitoneal adenopathy</td> </tr> <tr> <td>Mesenteric panniculitis/sclerosing mesenteritis</td> <td>Calcifications</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Stellate mesentery</td> <td>Carcinomatosis</td> <td>Ascites</td> </tr> <tr> <td>Peritoneal lymphomatosis</td> <td>Adenopathy</td> </tr> <tr> <td>Peritoneal mesothelioma</td> <td>Ascites; pleuroperitoneal plaques</td> </tr> <tr> <td>Peritoneal tuberculosis</td> <td>Ileocolonic thickening; ascites; peritoneal enhancement</td> </tr> <tr> <td>Systemic amyloidosis</td> <td>Thrombosis; focal mesenteric thickening</td> </tr> <tr> <td>Vascular thrombosis</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Sheth S, Horton KM, Garland MR, Fishman EK. Mesenteric neoplasms: CT appearances of primary and secondary tumors and differential diagnosis. Radiographics 2003; 23:457. Copyright © 2003 Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 81532 Version 4.0</div></div></div>"},"81533":{"type":"graphic_picture","displayName":"Diffuse large B cell NHL","title":"Diffuse large B-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse large B-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:302px; height:286px;\" src=\"images/HEME/81533_Diffuse_large_B_cell_NHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node shows a diffuse pattern of involvement, with loss of normal structures such as sinuses and lymphoid follicles.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 81533 Version 1.0</div></div></div>"},"81535":{"type":"graphic_picture","displayName":"Foreign bodies B","title":"Examples of inorganic foreign bodies removed from children and adults","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examples of inorganic foreign bodies removed from children and adults</div><div class=\"cntnt\"><img style=\"width:362px; height:283px;\" src=\"images/PULM/81535_Foreign_bodies_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 81535 Version 2.0</div></div></div>"},"81536":{"type":"graphic_table","displayName":"Kindler syndrome 2","title":"Genotypic and phenotypic characteristics of Kindler syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genotypic and phenotypic characteristics of Kindler syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Site of cleavage</td> <td class=\"subtitle1\"> <p>Inheritance</p> <p>Mutated gene</p> <p>Targeted gene product</p> </td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td>Intraepidermal, junctional, or sublamina densa</td> <td> <p>Autosomal recessive</p> <p><em>FERMT1 </em>(<em>KIND1</em>)</p> <p>Fermitin family homologue 1 (kindlin-1)</p> </td> <td> <ul> <li>Generalized blistering at birth, atrophic scarring, skin fragility diminishes with advancing age; poikiloderma </li> <li>Photosensitivity </li> <li>Pseudosyndactyly </li> </ul> <ul> <li>Gingival hyperplasia, oral leukokeratosis, colitis, esophagitis </li> <li>Involvement of genitourinary tract (genital leukokeratosis) </li> <li>Conjunctivitis, ectropium </li> <li>Mental retardation </li> <li>Bone malformations (mandibular abnormalities) </li> <li>Increased risk of cutaneous squamous cell carcinoma after age 30 years&nbsp;</li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81536 Version 3.0</div></div></div>"},"81537":{"type":"graphic_diagnosticimage","displayName":"Normal upper GI series","title":"Normal upper GI series","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"81538":{"type":"graphic_figure","displayName":"Retinal vascularization","title":"Retinal vascularization - left eye","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal vascularization - left eye</div><div class=\"cntnt\"><img style=\"width:312px; height:280px;\" src=\"images/PEDS/81538_Retinal_vascularization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascularization of the retina begins at approximately 16 weeks' gestation at the optic nerve and proceeds peripherally. Retinal vessels reach the ora serrata (the periphery of the eye) on the nasal side at 32 weeks' gestation and on the temporal side at 36 to 40 weeks' gestation. The numbers in the figure are weeks of gestation.</div><div id=\"graphicVersion\">Graphic 81538 Version 2.0</div></div></div>"},"81539":{"type":"graphic_algorithm","displayName":"Occupation environment history","title":"Systematic approach to history taking and diagnosis of occupational or environmental illness","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Systematic approach to history taking and diagnosis of occupational or environmental illness</div><div class=\"cntnt\"><img style=\"width:543px; height:628px;\" src=\"images/PC/81539_Occupation_environment_hist.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Goldman RH, Peters JM. The occupational and environmental health history. JAMA 1981; 246:2831.</div><div id=\"graphicVersion\">Graphic 81539 Version 4.0</div></div></div>"},"81540":{"type":"graphic_table","displayName":"Causes diaper dermatitis","title":"Classification of diaper dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of diaper dermatitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\n<tr>\n\t<td class=\"container\">\n\t<table cellspacing=\"0\">\n\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Associated with diaper use</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Irritant diaper dermatitis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Candidal dermatitis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Jacquet's erosive dermatitis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Granuloma gluteale infantum</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Allergic contact dermatitis</td>\n\t\t\t\t</tr>\n\t\t\t\t\n\t\t\t\t</table>\n\t\t\t\t</td>\n\t\t\t\t\n\t\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Regardless of diaper use</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Seborrheic dermatitis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Atopic dermatitis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Psoriasis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Impetigo</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\t\n\t\t\t\t\t<td>Scabies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Langerhans histiocytosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nutritional deficiency</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Immunodeficiency</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Child abuse</td>\n\t\t\t\t</tr>\n\t\t\t\t</table>\n\t\t\t\t</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">1/15/2008--email to CM for original figure number. EDM</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=50573&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Causes_diaper_dermatitis.htm</title></head></div><div class=\"graphic_reference\">Data from: Singalavanija S, Frieden IJ. Diaper dermatitis. Pediatr Rev 1995; 16:142.</div><div id=\"graphicVersion\">Graphic 81540 Version 2.0</div></div></div>"},"81542":{"type":"graphic_table","displayName":"Negative symptoms in schizophrenia","title":"Negative symptoms in schizophrenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Negative symptoms in schizophrenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Negative symptom cluster</td> <td class=\"subtitle1\">Negative symptom</td> <td class=\"subtitle1\">As manifested by:</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">Diminished expression</td> <td class=\"divider_bottom\" rowspan=\"6\">Affective flattening</td> <td>Unchanging facial expression</td> </tr> <tr> <td>Little spontaneous movement</td> </tr> <tr> <td>Little use of expressive gestures</td> </tr> <tr> <td>Poor eye contact</td> </tr> <tr> <td>Affective non-responsivity</td> </tr> <tr class=\"divider_bottom\"> <td>Lack of vocal inflections</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Alogia</td> <td>Poverty of speech</td> </tr> <tr> <td>Thought blocking</td> </tr> <tr class=\"divider_bottom\"> <td>Increased latency of response</td> </tr> <tr> <td rowspan=\"7\">Avolition-apathy</td> <td class=\"divider_bottom\" rowspan=\"3\">Apathy</td> <td>Poor grooming and hygiene</td> </tr> <tr> <td>Failure of appropriate role responsibilities</td> </tr> <tr class=\"divider_bottom\"> <td>Anergy</td> </tr> <tr> <td rowspan=\"4\">Asociality/anhedonia</td> <td>Failure to engage with peers socially</td> </tr> <tr> <td>No interest in stimulating activities</td> </tr> <tr> <td>Little interest in sex</td> </tr> <tr> <td>Little to no intimacy with others</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Andreasen NC. Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry 1982; 39:784. Copyright &copy; 1982 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 81542 Version 13.0</div></div></div>"},"81543":{"type":"graphic_diagnosticimage","displayName":"Prenatal US ureterocele bil","title":"Prenatal ultrasound with ureteroceles","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound with ureteroceles</div><div class=\"cntnt\"><img style=\"width:504px; height:541px;\" src=\"images/PEDS/81543_Prenatal_US_ureterocele_bil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prenatal ultrasound at 22 weeks of gestation that demonstrates biliateral ureteroceles resulting in significant bilateral hydronephrosis. Panels A and B demonstrate left hydronephrosis, and panels C and D right hydronephrosis. Panels E, F, and G: Sonogram of the bladder with bilateral ureteroceles.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 81543 Version 4.0</div></div></div>"},"81548":{"type":"graphic_diagnosticimage","displayName":"HSG hydrosalpinx","title":"Hysterosalpingogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram</div><div class=\"cntnt\"><img style=\"width:396px; height:535px;\" src=\"images/OBGYN/81548_HSG_hydrosalpinx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hysterosalpingogram (HSG) showing a normal uterine cavity with filling,but no definite spillage from the tubes. (B) Hysterosalpingogram of the same patient shown in A after more dye was injected, now bilateral hydrosalpinx can be seen.</div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright © 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 81548 Version 3.0</div></div></div>"},"81549":{"type":"graphic_picture","displayName":"Colostomy irritant contact","title":"Irritant contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irritant contact dermatitis</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/GAST/81549_Colostomy_irritant_contact.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exposure to damaging effluent can produce severe skin breakdown in the area exposed to the drainage; this type of skin damage is characterized by severely denuded skin along the inferior aspect of the stoma and is most common among ileostomy patients and patients with problematic stomas (eg, stomas that are retracted and empty below skin level).</div><div class=\"graphic_reference\">Courtesy of Dorothy B Doughty, MN, RN, CWOCN, FAAN.</div><div id=\"graphicVersion\">Graphic 81549 Version 1.0</div></div></div>"},"81555":{"type":"graphic_table","displayName":"DSM-IV-TR criteria for specific phobia","title":"DSM-IV-TR criteria for specific phobia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV-TR criteria for specific phobia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Marked and persistent fear that is excessive or unreasonable, cued by the presence or anticipation of a specific object or situation (eg, flying, heights, animals, receiving an injection, seeing blood).</td> </tr> <tr> <td>Exposure to the phobic stimulus almost invariably provokes an immediate anxiety response, which may take the form of a situationally bound or situationally predisposed panic attack. (Note: In children, the anxiety may be expressed by crying, tantrums, freezing, or clinging.)</td> </tr> <tr> <td>The person recognizes that the fear is excessive or unreasonable. (Note: In children, this feature may be absent.)</td> </tr> <tr> <td>The phobic situation(s) is avoided or else endured with intense anxiety or distress.</td> </tr> <tr> <td>The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational (or academic) functioning, or social activities or relationships, or there is marked distress about having the phobia.</td> </tr> <tr> <td>In individuals under age 18 years, the duration is at least 6 months.</td> </tr> <tr> <td>The anxiety, panic attacks, or phobic avoidance associated with the specific object or situation are not better accounted for by another mental disorder, such as obsessive compulsive disorder (eg, fear of dirt in someone with an obsession about contamination), separation anxiety disorder (eg, avoidance of school), social phobia (eg, avoidance of social situations because of fear of embarrassment), panic disorder with agoraphobia, or agoraphobia without history of panic disorder.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">22</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=85619&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, (Copyright 2000). American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 81555 Version 6.0</div></div></div>"},"81557":{"type":"graphic_table","displayName":"Anticholinergics end of life","title":"Anticholinergic therapy for drying secretions* at the end of life","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticholinergic therapy for drying secretions* at the end of life</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agents</td> <td class=\"subtitle1\">Adult dose</td> </tr> <tr class=\"divider_bottom\"> <td>Glycopyrrolate (glycopyrronium)</td> <td> <p>0.2 mg SC every four to six hours<sup>[1]</sup></p> <p>OR</p> <p>0.2 mg SC once; followed after 30 minutes by SC or IV continuous infusion of 0.6 to 1.2 mg/day<sup>[1]</sup></p> <p>OR</p> 0.1 mg SL every six hours as needed (use commercially available or compounded oral liquid)<sup>[2]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Scopolamine (hyoscine<sup>&#182;</sup>) base transdermal</td> <td>Apply one patch every 72 hours (1.5 mg patch releases &#8776;1 mg scopolamine base over 72 hours)</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Scopolamine (hyoscine<sup>&#182;</sup>) BUTYLbromide</p> <p>(<strong>not</strong> available in United States)</p> SEE NOTE</td> <td> <p>20 mg SC every four to six hours</p> <p>OR</p> 20 mg SC once; followed after 30 minutes by SC or IV continuous infusion of 20 to 60 mg per day<sup>&#916;</sup><sup>[3]</sup></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Scopolamine (hyoscine<sup>&#182;</sup>) HYDRObromide<sup>&#9674;</sup></p> SEE NOTE</td> <td> <p>0.3 mg PO or SL every four to six hours (PO/SL <strong>not</strong> available in United States)</p> <p>OR</p> <p>0.4 to 0.6 mg SC every four to eight hours</p> <p>OR</p> 0.4 mg SC once; followed after 30 minutes by a SC or IV infusion of 1.2 to 2 mg per day<sup>[1,3]</sup></td> </tr> <tr> <td>Atropine<sup>&#167;</sup></td> <td> <p>0.4 to 0.6 mg SC every four to six hours</p> <p>OR</p> <p>One to two drops of 1% ophthalmic solution (0.5 mg/drop) administered SL every two to four hours<sup>&#9674;[4,5]</sup></p> <p>OR</p> 0.4 mg SC once; followed after 30 minutes by a SC infusion of 1.2 to 2 mg per day<sup>[2]</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IMPORTANT NOTE: Doses of scopolamine (hyoscine) BUTYLbromide are NOT equivalent to scopolamine (hyoscine) HYDRObromide on a mg basis and may not be interchanged. Preparations not available in the United States are widely available in other countries.</div><div class=\"graphic_footnotes\">SC: subcutaneous; IV: intravenous; SL: sublingual; PO: oral.<br />* Also known as \"death rattle.\"<br />¶ Hyoscine is an international generic name. Scopolamine is the United States generic name.<br />Δ Larger subcutaneous continuous infusion doses of scopolamine (hyoscine) BUTYLbromide up to 120 mg per day may be needed.<SUP>[2]</SUP> Adjust dose depending upon response. Repeat SC dose if needed.<SUP>[3]</SUP><br /><FONT class=lozenge>◊</FONT> Scopoloamine (hyoscine) HYDRObromide penetrates central nervous system; it is sedating and can cause or worsen delirium.<SUP>[2]</SUP><br />§ Atropine<SUP>[4,5]</SUP> is a&nbsp;second-line choice. Disadvantages include risk of central nervous system toxicity (eg, hallucinations) and/or cardiotoxicity. Sublingual administration of ipratropium nasal solution (two sprays) may be a useful alternative.<SUP>[4]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hugel H, Ellershaw J, Gambles M. Respiratory Tract Secretions in the Dying Patient: A Comparison between Glycopyrronium and Hyoscine Hydrobromide. J Palliat Med 2006; 9:279.</LI>&#xD;&#xA;<LI>Twycross R, Wilcock A (Eds). Hospice and palliative care formulary, 4th ed, Palliativedrugs.com Ltd. © 2012. p.637.</LI>&#xD;&#xA;<LI>Bennett M, Lucas V, Brennan M, et al. Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. Palliat Med 2002; 16:369.</LI>&#xD;&#xA;<LI>Kintzel PE, Chase SL, Thomas W, et al. Anticholinergic medications for managing noisy respirations in adult hospice patients. Am J Health Syst Pharm 2009; 66:458.</LI>&#xD;&#xA;<LI>Protus BM. Evaluation of atropine 1% ophthalmic solution adminstered sublingually for the management of terminal respiratory secretions. Am J Hosp Palliat Care 2013; 30:388.</LI></OL></div><div id=\"graphicVersion\">Graphic 81557 Version 12.0</div></div></div>"},"81558":{"type":"graphic_table","displayName":"Cerebrospinal fluid biochemical markers","title":"Cerebrospinal fluid biochemical markers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cerebrospinal fluid biochemical markers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Marker</td> <td class=\"subtitle1\">Associated malignancy</td> </tr> <tr> <td>Beta 2 microglobulin</td> <td>Lymphoma, infection, other tumors</td> </tr> <tr> <td>Beta glucuronidase</td> <td>Nonspecific</td> </tr> <tr> <td>CEA</td> <td>Colon, ovarian, breast, bladder, lung</td> </tr> <tr> <td>CA-125</td> <td>Ovarian</td> </tr> <tr> <td>CA-15-3</td> <td>Breast</td> </tr> <tr> <td>CA19-9</td> <td>Adenocarcinoma, biliary disease</td> </tr> <tr> <td>CK-BB</td> <td>Small cell lung cancer</td> </tr> <tr> <td>GFAP</td> <td>Glioma</td> </tr> <tr> <td>HCG subunit</td> <td>Choriocarcinoma, embryonal and germ cell tumors</td> </tr> <tr> <td>5-HIAA</td> <td>Carcinoid</td> </tr> <tr> <td>IgM</td> <td>Myeloma</td> </tr> <tr> <td>LDH isoenzyme D</td> <td>Carcinoma</td> </tr> <tr> <td>PSA</td> <td>Prostate</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Alexis Demopoulos, MD, and Jerome Posner, MD.</div><div id=\"graphicVersion\">Graphic 81558 Version 3.0</div></div></div>"},"81559":{"type":"graphic_table","displayName":"Gross motor milestones","title":"Average age of attainment of gross motor milestones","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Average age of attainment of gross motor milestones</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Age</td>\n\n      <td class=\"subtitle1\">Skill</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4 months</td>\n\n      <td>Rolls from front to back</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5 months</td>\n\n      <td>Rolls from back to front</td>\n\n    </tr>\n\n    <tr>\n\n      <td>6 months</td>\n\n      <td>Sits with support</td>\n\n    </tr>\n\n    <tr>\n\n      <td>9 months</td>\n\n      <td>Pulls to stand</td>\n\n    </tr>\n\n    <tr>\n\n      <td>12 months</td>\n\n      <td>Walks independently</td>\n\n    </tr>\n\n    <tr>\n\n      <td>18 months</td>\n\n      <td>Runs</td>\n\n    </tr>\n\n    <tr>\n\n      <td>27 months</td>\n\n      <td>Walks up stairs (both feet on each step)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">36 months</td>\n\n      <td>Walks up stairs alternating feet</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Rides tricycle</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">4 years</td>\n\n      <td>Hops</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Walks up and down stairs alternating feet</td>\n\n    </tr>\n\n    <tr>\n\n      <td >5 years</td>\n\n      <td>Skips</td>\n\n    </tr>\n\n<tr><td> 6 to 7 years</td>\n\n    \n      \n\n      <td>Rides bicycle without training wheels</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=52712&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Gross_motor_milestones.htm</title></head></div><div class=\"graphic_reference\">Adapted from Frankenburg, WE, Dodds, JB. The Denver Development Assessment (Denver II). University of Colorado Medical School, Denver, 1990 and Brown, FR III. Neurodevelopmental Evaluation: The Physician's Diagnostic Role in Learning Disabilities. In: Diagnosis and Management of Learning Disabilities: An Interdisciplinary/Lifestyle Approach, 2nd ed, Brown FR III, Aylward, EH, Keogh, BK (Eds), Singular Publishing Group, inc, San Diego, 1992.</div><div id=\"graphicVersion\">Graphic 81559 Version 1.0</div></div></div>"},"81561":{"type":"graphic_table","displayName":"Evaluation bronchiectasis 3","title":"Evaluation of bronchiectasis-3","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of bronchiectasis-3</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Category\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Specific examples\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Diagnostic tests\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Childhood infections</td>\r\n  \r\n   <td>Pertussis; measles</td>\r\n  \r\n   <td>History of infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bacterial infections</td>\r\n  \r\n   <td>Infections due to Staphylococcus aureus, Klebsiella, Pseudomonas aeruginosa</td>\r\n  \r\n   <td>History of infection; sputum culture</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Viral infections</td>\r\n  \r\n   <td>Infections due to adenovirus (particularly types 7 and 21), influenza, herpes simplex</td>\r\n  \r\n   <td>History/serologic evidence of infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Other infections</td>\r\n  \r\n   <td>Fungal (histoplasmosis); Mycobacterium tuberculosis, nontuberculous mycobacteria; possibly mycoplasma</td>\r\n  \r\n   <td>Fungal culture; AFB smear and mycobacterial culture</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">AFB: acid-fast bacilli.</div><div id=\"graphicVersion\">Graphic 81561 Version 2.0</div></div></div>"},"81562":{"type":"graphic_table","displayName":"Differential diagnosis Cogans","title":"Differential diagnosis of Cogan's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of Cogan's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Inflammatory eye disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chlamydial infection</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Lyme disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Herpes simplex and varicella zoster infection</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Leprosy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Mycobacterium tuberculosis infection</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Inner ear dysfunction</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Viral infection</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Meniere disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Autoimmune hearing loss</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cerebellopontine angle tumor</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Vascular insufficiency</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Perilymphatic fistulas</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Drug toxicity</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Demyelinating disease (eg, multiple sclerosis)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Both eye and inner ear disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sarcoidosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Congenital syphilis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Whipple's disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Vogt-Koyanagi-Harada syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>KID (keratitis, ichthyosis, and deafness) syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sj&#246;gren's syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Rheumatoid arthritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Systemic lupus erythematosus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Anti-phospholipid antibody syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Polyarteritis nodosa</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Granulomatosis with polyangiitis (Wegener's)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Relapsing polychondritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Beh&#231;et's syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Ulcerative colitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Crohn's disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Central nervous system lymphoma/leukemia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Retinocochleocerebral vasculopathy</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 81562 Version 3.0</div></div></div>"},"81563":{"type":"graphic_waveform","displayName":"Reverse typical atrial flutter","title":"Reverse typical atrial flutter","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Reverse typical atrial flutter</div><div class=\"cntnt\"><img style=\"width:591px; height:356px;\" src=\"images/CARD/81563_Rev_typical_atrial_flutter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in type I clockwise typical atrial flutter. The flutter waves are positive in the inferior leads (II, III, aVF), with a more sinusoidal appearance and a broad negative F wave in V1.</div><div id=\"graphicVersion\">Graphic 81563 Version 3.0</div></div></div>"},"81565":{"type":"graphic_figure","displayName":"Sensitivity of CTA for intracranial aneurysm","title":"Sensitivity of CTA for intracranial aneurysms","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Sensitivity of CTA for intracranial aneurysms</div><div class=\"cntnt\"><img style=\"width:479px; height:306px;\" src=\"images/NEURO/81565_CTA_sens_intracranial_aneur.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The graph shows the increasing sensitivity of CTA with increasing aneurysm size. Points represent the median, and error bars represent the 95 percent confidence limits. Aneurysms greater than 10 mm have been pooled.</div><div class=\"graphic_reference\">Data from: van Gelder, JM. Computed tomographic angiography for detecting cerebral aneurysms: implications of aneurysm size distribution for the sensitivity, specificity, and likelihood ratios. Neurosurgery 2003; 53:597.</div><div id=\"graphicVersion\">Graphic 81565 Version 2.0</div></div></div>"},"81566":{"type":"graphic_table","displayName":"CBTRUS incidence of primary CNS tumors","title":"Distribution of all primary brain and CNS tumors by site","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of all primary brain and CNS tumors by site</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Percent of total</td> <td class=\"subtitle1\">Annual incidence rate*</td> </tr> <tr> <td class=\"subtitle2_left\">Tumors of neuroepithelial tissue</td> <td class=\"subtitle2_left\">29.9</td> <td class=\"subtitle2_left\">6.62</td> </tr> <tr> <td class=\"indent1\">Pilocytic astrocytoma</td> <td>1.4</td> <td>0.34</td> </tr> <tr> <td class=\"indent1\">Diffuse astrocytoma</td> <td>2.3</td> <td>0.53</td> </tr> <tr> <td class=\"indent1\">Anaplastic astrocytoma</td> <td>1.7</td> <td>0.38</td> </tr> <tr> <td class=\"indent1\">Unique astrocytoma variants</td> <td>0.3</td> <td>0.07</td> </tr> <tr> <td class=\"indent1\">Glioblastoma</td> <td>15.1</td> <td>3.20</td> </tr> <tr> <td class=\"indent1\">Oligodendroglioma</td> <td>1.1</td> <td>0.25</td> </tr> <tr> <td class=\"indent1\">Anaplastic oligodendroglioma</td> <td>0.5</td> <td>0.10</td> </tr> <tr> <td class=\"indent1\">Oligoastrocytic tumors</td> <td>0.9</td> <td>0.20</td> </tr> <tr> <td class=\"indent1\">Ependymal tumors</td> <td>1.9</td> <td>0.43</td> </tr> <tr> <td class=\"indent1\">Glioma malignant, NOS</td> <td>2.0</td> <td>0.47</td> </tr> <tr> <td class=\"indent1\">Choroid plexus</td> <td>0.2</td> <td>0.05</td> </tr> <tr> <td class=\"indent1\">Other neuroepithelial tumors</td> <td>0.03</td> <td>0.01</td> </tr> <tr> <td class=\"indent1\">Neuronal and&nbsp;mixed neuronal-glial tumors</td> <td>1.2</td> <td>0.28</td> </tr> <tr> <td class=\"indent1\">Tumors of the pineal region</td> <td>0.2</td> <td>0.04</td> </tr> <tr> <td class=\"indent1\">Embryonal tumors</td> <td>1.1</td> <td>0.26</td> </tr> <tr> <td class=\"subtitle2_left\"><br /> Tumors of cranial and spinal nerves</td> <td class=\"subtitle2_left\"><br /> 8.1</td> <td class=\"subtitle2_left\"><br /> 1.76</td> </tr> <tr> <td class=\"indent1\">Nerve sheath tumors</td> <td>8.1</td> <td>1.76</td> </tr> <tr> <td class=\"subtitle2_left\"><br /> Tumors of meninges</td> <td class=\"subtitle2_left\"><br /> 37.6</td> <td class=\"subtitle2_left\"><br /> 8.13</td> </tr> <tr> <td class=\"indent1\">Meningioma</td> <td>36.4</td> <td>7.86</td> </tr> <tr> <td class=\"indent1\">Mesenchymal tumors</td> <td>0.4</td> <td>0.08</td> </tr> <tr> <td class=\"indent1\">Primary melanocytic lesions&nbsp;</td> <td>0.04</td> <td>0.01&nbsp;</td> </tr> <tr> <td class=\"indent1\">Other neoplasms related to the meninges</td> <td>0.8</td> <td>0.18</td> </tr> <tr> <td class=\"subtitle2_left\"><br /> Lymphomas and hematopoietic neoplasms</td> <td class=\"subtitle2_left\"><br /> 2.1</td> <td class=\"subtitle2_left\"><br /> 0.46</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> <td>2.0</td> <td>0.44</td> </tr> <tr> <td class=\"indent1\">Other hematopoietic neoplasms&nbsp;</td> <td>0.07&nbsp;</td> <td>0.01&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\"><br /> Germ cell tumors and cysts</td> <td class=\"subtitle2_left\"><br /> 0.4</td> <td class=\"subtitle2_left\"><br /> 0.10</td> </tr> <tr> <td class=\"indent1\">Germ cell tumors, cysts and heterotopias</td> <td>0.4</td> <td>0.10</td> </tr> <tr> <td class=\"subtitle2_left\"><br /> Tumors of sellar region</td> <td class=\"subtitle2_left\"><br /> 16.3</td> <td class=\"subtitle2_left\"><br /> 3.68</td> </tr> <tr> <td class=\"indent1\">Tumors of the pituitary</td> <td>15.5</td> <td>3.49</td> </tr> <tr> <td class=\"indent1\">Craniopharyngioma</td> <td>0.8</td> <td>0.18</td> </tr> <tr> <td class=\"subtitle2_left\"><br /> Unclassified tumors</td> <td class=\"subtitle2_left\"><br /> 5.6</td> <td class=\"subtitle2_left\"><br /> 1.23</td> </tr> <tr> <td class=\"indent1\">Hemangioma</td> <td>1.5</td> <td>0.34</td> </tr> <tr> <td class=\"indent1\">Neoplasm, unspecified</td> <td>4.0</td> <td>0.88</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">All other</td> <td>0.03</td> <td>0.01</td> </tr> <tr> <td><strong>TOTAL</strong></td> <td><strong>365,858</strong></td> <td><strong>100.0</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CBTRUS Statistical Report: NPCR and SEER Data from 2008 to 2012.<br />* Average annual age-adjusted incidence rate.</div><div class=\"graphic_footnotes\">CBTRUS: Central Brain Tumor Registry of the United States; CNS: central nervous system; NOS: not otherwise specified; NPCR: National Program of Cancer Registries; SEER: Surveillance, Epidemiology, and End Results Program.</div><div class=\"graphic_reference\">Data from: Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 Suppl 4:iv1.</div><div id=\"graphicVersion\">Graphic 81566 Version 9.0</div></div></div>"},"81567":{"type":"graphic_figure","displayName":"Patients with diabetes have worse outcomes non ST elevation ACS","title":"Diabetics with a non-ST elevation ACS have a worse outcome than nondiabetics","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diabetics with a non-ST elevation ACS have a worse outcome than nondiabetics</div><div class=\"cntnt\"><img style=\"width:391px; height:284px;\" src=\"images/CARD/81567_Outcome_diabetics_unstable.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the OASIS registry of 8013 patients with a non-ST elevation acute coronary syndrome (unstable angina or non Q-wave myocardial infarction), 21 percent had diabetes. After a two-year follow-up, diabetic patients had a significantly higher combined event rate (cardiovascular death, new myocardial infarction, stroke, new heart failure) than nondiabetics (relative risk 1.56).</div><div class=\"graphic_reference\">Data from Malmberg K, Yusuf S, Gerstein HC, et al. Circulation 2000; 102:1014.</div><div id=\"graphicVersion\">Graphic 81567 Version 3.0</div></div></div>"},"81569":{"type":"graphic_picture","displayName":"Severe mucosal HSV-2 ulceration in an HIV woman","title":"Chronic, severe mucosal HSV-2 ulceration in an HIV-infected woman","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Chronic, severe mucosal HSV-2 ulceration in an HIV-infected woman</div><div class=\"cntnt\"><img style=\"width:496px; height:372px;\" src=\"images/ID/81569_Sev_mucosal_HSV2_ulceration.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Christine Johnston, MD, MPH and Anna Wald, MD, MPH.</div><div id=\"graphicVersion\">Graphic 81569 Version 1.0</div></div></div>"},"81570":{"type":"graphic_figure","displayName":"Apical 4 chamber right atrial tumor","title":"Right atrial tumor seen on transthoracic echocardiography from the apical 4 chamber view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right atrial tumor seen on transthoracic echocardiography from the apical 4 chamber view</div><div class=\"cntnt\"><img style=\"width:306px; height:246px;\" src=\"images/CARD/81570_4chamberrightatrialtumo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber view shows a tumor mass (arrows) extending into the right ventricle (RV) from the right atrium (RA). This large mass occupies most of the RA and extends across the tricuspid valve into the inlet portion of the RV. Finding a mass of this sort should direct the examination at the inferior vena cava because an abdominal malignancy with intravascular extension is the usual origin. This particular tumor was a renal cell carcinoma.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 81570 Version 5.0</div></div></div>"},"81572":{"type":"graphic_table","displayName":"ASD CAM therapies","title":"Examples of complementary and alternative medicine therapies used for autism spectrum disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of complementary and alternative medicine therapies used for autism spectrum disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">No benefit</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Secretin </li> <li>Facilitated communication </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Possible benefit, potential risk</td> <td class=\"subtitle1_left\">Possible benefit, low risk</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Gluten-free casein-free diet* </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Music therapy </li> <li>Melatonin<sup>&#182;</sup> </li> <li>Oxytocin </li> <li>Therapeutic horseback riding<sup>&#916;</sup> </li> <li>Other types of animal/pet therapy </li> <li>Sulforaphane </li> <li>Transcranial magnetic stimulation </li> <li>Yoga </li> <li>Body work (eg, massage/qigong) </li> <li>Energy therapies (eg, healing touch, Reiki) </li> <li>Biofeedback/neurofeedback </li> <li>Hypnotherapy </li> <li>Vitamin C </li> <li>Vitamin B12 </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Unknown benefit, potential risk</td> <td class=\"subtitle1_left\">Unknown benefit, low risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Intravenous immunoglobulin </li> <li>Chelation<sup>&#9674;</sup> </li> <li>Hyperbaric oxygen therapy </li> <li>Antimicrobial agents </li> <li>Vitamin B6 and magnesium </li> <li>Vitamin A </li> <li>Vitamin D in excess of tolerable upper intake level<sup>&#167;</sup> </li> <li>Homeopathy </li> <li>Vagus nerve stimulation </li> <li>Stem cell therapy </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Auditory integration therapy </li> <li>Omega 3 fatty acids </li> <li>Probiotics </li> <li>Oxidative therapies other than vitamin C (eg, methylcobalamin, folate, N-acetylcysteine) </li> <li>Zinc </li> <li>Interactive metronome </li> <li>Herbal products </li> <li>Amino acids (eg, taurine, dimethylglycine) </li> <li>Digestive enzymes </li> <li>Mindfulness therapy </li> <li>Acupuncture </li> <li>Craniosacral manipulation &nbsp; </li> <li>Chiropractic<sup>&#165;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ASD: autism spectrum disorder.<br />* Children following a gluten-free casein-free diet should be monitored by a registered dietitian.<br />¶ Refer to the UpToDate topic on pharmacologic interventions for ASD for a discussion of the use of melatonin in the management of sleep disturbance in children with ASD.<br />Δ Therapeutic horseback riding is safe with proper precautions (eg, helmet, appropriate supervision).<br /><FONT class=lozenge>◊</FONT> Chelation is associated with potentially serious adverse effects including death.<br />§ Refer to UpToDate topic on vitamin D for details.<br />¥&nbsp;Chiropractic is generally safe for patients without spinal abnormalities.</div><div id=\"graphicVersion\">Graphic 81572 Version 10.0</div></div></div>"},"81573":{"type":"graphic_table","displayName":"Approach to diagnostic testing for adenovirus","title":"Approach to diagnostic testing for adenovirus based upon the clinical syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to diagnostic testing for adenovirus based upon the clinical syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical syndrome</td> <td class=\"subtitle1\">Suggested test(s) for adenovirus if diagnosis is necessary*</td> </tr> <tr> <td>Upper respiratory illness</td> <td>Viral culture if available and/or viral antigen assay on respiratory specimen(s) (eg, nasopharyngeal swab or aspirate; throat swab or wash)</td> </tr> <tr> <td>Epidemic keratoconjunctivitis</td> <td>Viral culture and/or adenovirus-specific antigen assay on conjunctival swab or scraping</td> </tr> <tr> <td>Pneumonia</td> <td>Viral culture or PCR of nasopharyngeal aspirate or swab, throat swab, sputum, tracheal aspirate or BAL material</td> </tr> <tr> <td>Prolonged diarrhea in young children</td> <td>Adenovirus-specific antigen assay on stool specimen</td> </tr> <tr> <td>Immunocompromised hosts</td> <td>Viral culture or PCR of affected sites; quantitative PCR of blood; biopsy if clinically indicated<sup>​&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; BAL: bronchoalveolar lavage.<br />* If there is a potential outbreak or an individual patient has a severe manifestation (to make decisions about antiviral therapy, exclude other treatable infections, determine prognosis, and/or initiate infection control measures).<br />¶ The appropriate diagnostic tests depend upon the severity and site(s) of infection, as well as the degree of immunocompromise.</div><div id=\"graphicVersion\">Graphic 81573 Version 4.0</div></div></div>"},"81577":{"type":"graphic_table","displayName":"Causes neuropsychiatric lupus","title":"Diagnostic possibilities to be considered in patients with lupus who have neuropsychiatric symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic possibilities to be considered in patients with lupus who have neuropsychiatric symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Active CNS lupus</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Sequelae of lupus that is now inactive</td>\n</tr>\n<tr>\n<td>Ischemia due to healed vascular lesions with luminal narrowing</td>\n</tr>\n<tr>\n<td>Persistent neurologic deficits</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Complications of chronic illness</td>\n</tr>\n<tr>\n<td>Functional disorders:</td>\n</tr>\n    <tr>\n      <td class=\"indent1\">Depression</td>\n    </tr>\n    <tr>\n      <td class=\"indent1\">Anxiety</td>\n    </tr>\n    <tr>\n      <td class=\"indent1\">Conversion reactions</td>\n    </tr>\n<tr>\n<td>Schizophrenia</td>\n</tr>\n<tr>\n<td>Manic-depression</td>\n</tr>\n<tr>\n<td>Dementia</td>\n</tr>\n<tr>\n<td>Obsessive compulsive disorder</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Complications of other organ system involvement</td>\n</tr>\n<tr>\n<td>Renal failure</td>\n</tr>\n<tr>\n<td>Liver failure</td>\n</tr>\n<tr>\n<td>Pulmonary failure</td>\n</tr>\n<tr>\n<td>Metabolic imbalance</td>\n</tr>\n<tr>\n<td>Thyroid disease</td>\n</tr>\n<tr>\n<td>Hypertension</td>\n</tr>\n<tr>\n<td>Vasculitis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Complications of treatment</td>\n</tr>\n<tr>\n<td>Steroid psychosis</td>\n</tr>\n<tr>\n<td>Drug induced meningitis - NSAIDs, azathioprine</td>\n</tr>\n<tr>\n<td>Infections</td>\n</tr>\n<tr>\n<td>Posterior leukoencephalopathy - cyclophosphamide</td>\n</tr>\n<tr>\n<td>Psychoactive medications - tranquilizers, antidepressants,\nnarcotics, analgesics, beta blockers, cimetidine,\ntrimethoprim-sulfamethoxazole, antimalarials, anticonvulsants, alcohol,\nstreet drugs, alpha-adrenergic agents, antiarrhythmics</td>\n</tr>\n<tr>\n<td>Hypertension</td>\n</tr>\n\n\n<tr>\n<td class=\"subtitle1_single\">Miscellaneous</td>\n</tr>\n<tr>\n<td>Hypoglycemia</td>\n</tr>\n<tr>\n<td>CNS tumors</td>\n</tr>\n<tr>\n<td>Head trauma</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81577 Version 1.0</div></div></div>"},"81578":{"type":"graphic_table","displayName":"Pharmacologic agents HTN","title":"Pharmacologic agents to treat hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic agents to treat hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Pharmacologic agent</td>\n\t\t\t\t\t<td class=\"subtitle1\">Class</td>\n\t\t\t\t\t<td class=\"subtitle1\">Standard dose</td>\n\t\t\t\t\t<td class=\"subtitle1\">Common side effects</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nifedipine</td>\n\t\t\t\t\t<td rowspan=\"4\">Calcium channel blocker</td>\n\t\t\t\t\t<td>10 to 20 mg three times daily, or extended release once daily</td>\n\t\t\t\t\t<td rowspan=\"4\">Hypotension, peripheral edema, headache, dizziness</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Amlodipine</td>\n\t\t\t\t\n\t\t\t\t\t<td>5 to 10 mg once daily</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Felodipine</td>\n\t\t\t\t\t\n\t\t\t\t\t<td>2.5 to 10 mg once daily</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nicardipine</td>\n\t\t\t\t\n\t\t\t\t\t<td>20 to 40 mg three times daily</td>\n\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Metoprolol</td>\n\t\t\t\t\t<td rowspan=\"2\">Beta blocker</td>\n\t\t\t\t\t<td>50 to 200 mg po twice daily, or extended release once daily </td>\n\t\t\t\t\t<td rowspan=\"2\">Hypotension, fatigue, dizziness, bradycardia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Atenolol</td>\n\t\t\t\t\n\t\t\t\t\t<td>50 to 100 mg once daily</td>\n\t\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Enalapril</td>\n\t\t\t\t\t<td rowspan=\"2\">ACE inhibitor</td>\n\t\t\t\t\t<td>5 to 40 mg once daily</td>\n\t\t\t\t\t<td rowspan=\"2\">Cough, dizziness, fatigue</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Lisinopril</td>\n\t\t\t\t\n\t\t\t\t\t<td>10 to 40 mg once daily </td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Losartan</td>\n\t\t\t\t\t<td>A2 receptor blocker</td>\n\t\t\t\t\t<td>25 to 100 mg once daily</td>\n\t\t\t\t\t<td rowspan=\"2\">Dizziness, headache, fatigue, URI symptoms</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Valsartan</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>80 to 320 mg once daily</td>\n\t\t\t\t\n\t\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81578 Version 1.0</div></div></div>"},"81579":{"type":"graphic_diagnosticimage","displayName":"Gradient echo MRI in CAA","title":"Old hemorrhages on gradient echo MRI","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Old hemorrhages on gradient echo MRI</div><div class=\"cntnt\"><img style=\"width:487px; height:208px;\" src=\"images/NEURO/81579_Gradient_echo_MRI_in_CAA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of CT scan (A), T2- weighted MRI (B), and gradient echo MRI (C) demonstrates the utility of the last for detecting old hemorrhages consistent with cerebral amyloid angiopathy. In addition to the the left frontoparietal hemorrhage seen on all studies (arrowheads), the gradient-echo sequence demonstrates multiple areas of decreased signal in gray-white regions (arrows) consistent with chronic hemorrhage.</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from Greenberg SM, Finklestein SP, Schaefer PW. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996; 46:1751.</div><div id=\"graphicVersion\">Graphic 81579 Version 12.0</div></div></div>"},"81580":{"type":"graphic_figure","displayName":"Appendicitis PI","title":"Appendicitis","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Appendicitis</div><div class=\"cntnt\"><img style=\"width:524px; height:559px;\" src=\"images/PI/81580_AppendicitisPIedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The appendix is a thin pouch that hangs down from a part of the large intestine. Appendicitis is the term doctors use when the appendix gets infected and inflamed.</div><div id=\"graphicVersion\">Graphic 81580 Version 2.0</div></div></div>"},"81582":{"type":"graphic_diagnosticimage","displayName":"Hip effusion plain film","title":"Plain film left hip effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain film left hip effusion</div><div class=\"cntnt\"><img style=\"width:396px; height:307px;\" src=\"images/PEDS/81582_Hip_effusion_plain_film.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The iliopsoas fat pad on the left is bowed and inferiorly displaced (arrows), suggesting effusion. The obturator (medial) and gluteal (superior) fat pads can also be displaced by effusion.</div><div class=\"graphic_reference\">Courtesy of Michael Rosenthal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 81582 Version 3.0</div></div></div>"},"81584":{"type":"graphic_figure","displayName":"Duodenal transection during total gastrectomy","title":"Duodenal transection during total gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Duodenal transection during total gastrectomy</div><div class=\"cntnt\"><img style=\"width:486px; height:702px;\" src=\"images/SURG/81584_Duodenum_transected.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The duodenum is transected just distal to the pylorus using a gastrointestinal anastomosis stapler (GIA) device. Care is taken to preserve the structures of the portal triad. The duodenal stump is oversewn using a 3-0 Prolene. The omentum is removed with the specimen when treating gastric adenocarcinoma.</div><div id=\"graphicVersion\">Graphic 81584 Version 3.0</div></div></div>"},"81585":{"type":"graphic_diagnosticimage","displayName":"Lateral view of minimally displaced transverse patella fracture","title":"Lateral view of minimally displaced transverse patella fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral view of minimally displaced transverse patella fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:383px;\" src=\"images/EM/81585_Patella_fx_close_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral plain radiograph shows a transverse patella fracture (arrow) with minimal displacement.</div><div class=\"graphic_reference\">Courtesy of Jim Blount, MD.</div><div id=\"graphicVersion\">Graphic 81585 Version 3.0</div></div></div>"},"81586":{"type":"graphic_picture","displayName":"Low cytokeratin stain","title":"Idiopathic adulthood ductopenia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic adulthood ductopenia</div><div class=\"cntnt\"><img style=\"width:432px; height:298px;\" src=\"images/GAST/81586_Low_cytokeratin_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a low power view of a liver biopsy using a CK7 cytokeratin immunostain specific for biliary epitheium from a patient with idiopathic adulthood ductopenia. The central vein is in the center of the slide with portal triads visible at the periphery. There is no well defined bile duct present. The brown staining in the area of the portal triads represents focal ductular proliferation.</div><div class=\"graphic_reference\">Courtesy of John Hart, MD.</div><div id=\"graphicVersion\">Graphic 81586 Version 2.0</div></div></div>"},"81587":{"type":"graphic_picture","displayName":"Mirena IUD","title":"Mirena IUD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mirena IUD</div><div class=\"cntnt\"><img style=\"width:396px; height:325px;\" src=\"images/OBGYN/81587_Mirena_IUD.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Berlex Laboratories. Copyright © Berlex Laboratories.</div><div id=\"graphicVersion\">Graphic 81587 Version 2.0</div></div></div>"},"81589":{"type":"graphic_picture","displayName":"Hypertrophic lichen planus2","title":"Hypertrophic lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic lichen planus</div><div class=\"cntnt\"><img style=\"width:295px; height:432px;\" src=\"images/DERM/81589_Hypertrophic_lichen_planus2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypertrophic lichen planus. Darkly pigmented hypertrophic lesions are present on the pretibial shaft.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81589 Version 2.0</div></div></div>"},"81594":{"type":"graphic_table","displayName":"Irinotecan and cisplatin SCLC","title":"Irinotecan and cisplatin chemotherapy for patients with extensive stage small cell lung cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Irinotecan and cisplatin chemotherapy for patients with extensive stage small cell lung cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 28 days for four cycles.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Irinotecan</strong>*</td> <td>60 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5 percent dextrose in water<sup>&#916;</sup> and administer over 90 minutes.</td> <td>Day 1, 8, and 15</td> </tr> <tr> <td><strong>Cisplatin</strong></td> <td>60 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline and administer over 120 minutes. Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hydration:</strong> IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> HIGH on day 1 (90 percent frequency of emesis). MODERATE on days 8 and 15 (30 to 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> There is no standard premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Cisplatin is an irritant but can cause significant tissue necrosis; avoid extravasation<sup>[2]</sup>. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not recommended (risk of febrile neutropenia approximately 3 percent<sup>[1]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial<sup>[1]</sup>. A lower starting dose of irinotecan may be needed for patients with hepatic or severe renal impairment<sup>[3]</sup>. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, give atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count weekly during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Electrolytes, liver and renal function prior to each cycle. Electrolytes may need to be assessed more frequently in patients with severe diarrhea.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for neurotoxicity prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Each cycle should not begin until the ANC is greater than 1500 cells/microL and platelets are &#62;100,000/microL<sup>[1]</sup>. During treatment, withhold irinotecan for nadir ANC &#60;500/microL, febrile neutropenia, or nadir platelet count &#8804;50,000/microL until recovery to &#8804;grade 1 toxicity. After recovery, omit the day 15 dose, administer reduce all subsequent irinotecan doses by 10 mg/m<sup>2</sup>, and administer further cycles with day 1 and 8 treatment every 21 days<sup>[1]</sup>. Cisplatin doses were reduced by 25 percent in subsequent cycles for grade 4 neutropenia, febrile neutropenia, or grade 4 thrombocytopenia<sup>[1]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neurologic toxicity:</strong> Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Refer to UpToDate topic on \"<span style=\"font-size: 11pt; font-family: calibri,sans-serif;\">Overview of neurologic complications of platinum-based chemotherapy</span>\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Nephrotoxicity:</strong> Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min<sup>[2]</sup>. In the original protocol, the cisplatin dose was reduced by 25 percent for grade 2 renal toxicity<sup>[1]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Diarrhea:</strong> Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop early diarrhea and/or cholinergic symptoms, premedication with atropine is an effective prophylaxis during later cycles. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</p> In the original protocol, patients with grade 3 or 4 diarrhea had irinotecan withheld until recovery to &#8804;grade 1<sup>[1]</sup>. After recovery, omit the day 15 dose, administer reduce all subsequent irinotecan doses by 10 mg/m<sup>2</sup>, and administer further cycles with day 1 and 8 treatment every 21 days.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count.<br />* A lower initial starting dose of <SPAN style=\"COLOR: black\">irinotecan may be considered for patients with poor performance status, prior pelvic or abdominal radiotherapy, or increased bilirubin levels<SUP>[3]</SUP>. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial.</SPAN> Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".<br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibilities.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Lara PN, et al. J Clin Oncol 2009; 27:2530. </LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 21, 2011). </LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011). </LI></OL></div><div id=\"graphicVersion\">Graphic 81594 Version 14.0</div></div></div>"},"81595":{"type":"graphic_figure","displayName":"Central line SC supra anat","title":"External landmarks for the supraclavicular approach to the subclavian vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External landmarks for the supraclavicular approach to the subclavian vein</div><div class=\"cntnt\"><img style=\"width:433px; height:578px;\" src=\"images/EM/81595_Central_line_SC_supra_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 81595 Version 5.0</div></div></div>"},"81596":{"type":"graphic_table","displayName":"Clinical features of common causes of vertigo","title":"Clinical features of common causes of vertigo*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of common causes of vertigo*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Time course</td> <td class=\"subtitle1\">Suggestive clinical setting</td> <td class=\"subtitle1\">Characteristics of nystagmus<sup>&#182;</sup></td> <td class=\"subtitle1\">Associated neurologic symptoms</td> <td class=\"subtitle1\">Auditory symptoms</td> <td class=\"subtitle1\">Other diagnostic features</td> </tr> <tr> <td><strong>Benign paroxysmal positional vertigo</strong></td> <td>Recurrent, brief (seconds)</td> <td>Predictable head movements or positions precipitate symptoms</td> <td>Peripheral characteristics</td> <td>None</td> <td>None</td> <td>Dix-Hallpike maneuver shows characteristic findings</td> </tr> <tr> <td><strong>Vestibular neuritis</strong></td> <td>Single episode, acute onset, lasts days</td> <td>Viral syndrome may accompany or precede vertigo</td> <td>Peripheral characteristics</td> <td>Falls toward side of lesion, no brainstem symptoms</td> <td>Usually none</td> <td>Head thrust test usually abnormal</td> </tr> <tr> <td><strong>Meniere disease</strong></td> <td>Recurrent episodes, last minutes to several hours</td> <td>Spontaneous onset</td> <td>Peripheral characteristics</td> <td>None</td> <td>Episodes may be preceded by ear fullness/pain, accompanied by vertigo, unilateral hearing loss, tinnitus</td> <td>Audiometry shows unilateral low frequency sensorineural hearing loss</td> </tr> <tr> <td><strong>Vestibular migraine</strong></td> <td>Recurrent episodes, last several minutes to hours</td> <td>History of migraine</td> <td>Central or peripheral characteristics may be present</td> <td>Migraine headache and/or other migrainous symptoms accompanying or following vertigo</td> <td>Usually none</td> <td>Between episodes, tests are usually normal</td> </tr> <tr> <td><strong>Vertebrobasilar TIA</strong></td> <td>Single or recurrent episodes lasting several minutes to hours</td> <td>Older patient, vascular risk factors, and or cervical trauma</td> <td>Central characteristics</td> <td>Usually other brainstem symptoms</td> <td>Usually none</td> <td>MRI w/DWI may demonstrate vascular lesion</td> </tr> <tr> <td><strong>Brainstem infarction</strong></td> <td>Sudden onset, persistent symptoms over days to weeks</td> <td>As above</td> <td>Central characteristics</td> <td><strong>Usually</strong> other brainstem symptoms, especially lateral medullary signs</td> <td>Usually none; an exception is anterior inferior cerebellar artery syndrome</td> <td>MRI will demonstrate lesion</td> </tr> <tr> <td><strong>Cerebellar infarction or hemorrhage</strong></td> <td>Sudden onset, persistent symptoms over days to weeks</td> <td>Older patient, vascular risk factors, especially hypertension</td> <td>Central characteristics</td> <td>Gait impairment is prominent. Headache, limb dysmetria, dysphagia <strong>may</strong> occur</td> <td>None</td> <td>Urgent MRI, CT will demonstrate lesion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Other diagnoses described in text \"Pathophysiology and differential diagnosis of vertigo\".<br />&para; Peripheral characteristics of nystagmus: horizontal or horizontal-torsional; suppresses with visual fixation, does not change direction with gaze. Central characteristics of nystagmus: may be horizontal, torsional, or vertical, does not suppress with visual fixation, may change direction with gaze.</div><div id=\"graphicVersion\">Graphic 81596 Version 10.0</div></div></div>"},"81597":{"type":"graphic_figure","displayName":"Non-disjunction","title":"Non-disjunction","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Non-disjunction</div><div class=\"cntnt\"><img style=\"width:474px; height:467px;\" src=\"images/PC/81597_Non-disjunction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Consequence of non-disjunction of chromosome 20, with two copies of chr20 in one gamete, and none in the other. Either monosomy (left) or trisomy (right) can result, depending on which of the two abnormal gametes contributes to embryo formation.</div><div id=\"graphicVersion\">Graphic 81597 Version 1.0</div></div></div>"},"81598":{"type":"graphic_diagnosticimage","displayName":"ERCP showing common bile duct stones","title":"ERCP showing common bile duct stones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ERCP showing common bile duct stones</div><div class=\"cntnt\"><img style=\"width:440px; height:445px;\" src=\"images/SURG/81598_ERCP_bileduct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiogram showing common bile duct stones.</div><div class=\"graphic_footnotes\">ERCP: Endoscopic retrograde cholangiopancreatography.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland, MW, Maier, RV, et al. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81598 Version 4.0</div></div></div>"},"81599":{"type":"graphic_picture","displayName":"Anesthesia machine charcoal filter","title":"Anesthesia machine charcoal filter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anesthesia machine charcoal filter</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/ANEST/81599_Anesthesia_charcoal_filter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anesthesia machines no longer need to be flushed through with oxygen prior to use by a MH-susceptible patient. A charcoal filter attached to the inspiratory and expiratory breathing circuit limbs effectively prevents residual concentrations of anesthestic gases from reaching the patient. It should also be used when an acute MH crisis is diagnosed to limit further exposure of anesthetic gas to the patient.</div><div class=\"graphic_footnotes\">MH: malignant hyperthermia.</div><div id=\"graphicVersion\">Graphic 81599 Version 6.0</div></div></div>"},"81600":{"type":"graphic_diagnosticimage","displayName":"Choledocholithiasis EBD ERCP","title":"Endoscopic removal of bile duct stones after endoscopic balloon dilation of the biliary sphincter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic removal of bile duct stones after endoscopic balloon dilation of the biliary sphincter</div><div class=\"cntnt\"><img style=\"width:360px; height:364px;\" src=\"images/GAST/81600_Choledocholithiasis_EBD_ERC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left: EN = endoscope positioned in descending duodenum; BD = bile duct filled with contrast, two bile duct stones visible; DB = dilation balloon placed in bile duct opening after passage over a guidewire (white arrow) and inflated with dilute contrast - biliary sphincter is seen as a &quot;waist&quot; in the balloon (black arrows). Middle: biliary sphincter adequately dilated if &quot;waist&quot; in balloon has completely disappeared. Right: after removal of bile duct stones.</div><div class=\"graphic_reference\">Reproduced with permission&nbsp;from: Bergman JJ, et al. Lancet 1997; 349:1124. Photo courtesy of Jacques Bergman and Kees Huibregtse.</div><div id=\"graphicVersion\">Graphic 81600 Version 4.0</div></div></div>"},"81601":{"type":"graphic_picture","displayName":"Light micrograph showing collapsing FSGS","title":"Light micrograph showing collapsing FSGS","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing collapsing FSGS</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/81601_Collapsing_FGS_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing collapsing glomerulosclerosis with few open loops in the sclerotic areas (long arrows); these findings are characteristic of HIV nephropathy but can also be seen in idiopathic disease. The degree of collapse can be appreciated by the openness of Bowman's space. Vacuolization and crowding of the glomerular epithelial cells (short arrows) is also frequently seen and reflects the primary epithelial cell injury in this disorder.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 81601 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"81602":{"type":"graphic_table","displayName":"Causes unintentional fatal injury child","title":"10 leading causes of unintentional injury deaths, United States, 2015, all races, both sexes (<1 to 24 years)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">10 leading causes of unintentional injury deaths, United States, 2015, all races, both sexes (&lt;1 to 24 years)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Rank</td> <td class=\"subtitle1\" colspan=\"5\">Age groups, years</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2\">&#60;1</td> <td class=\"subtitle2\">1 to 4</td> <td class=\"subtitle2\">5 to 9</td> <td class=\"subtitle2\">10 to 14</td> <td class=\"subtitle2\">15 to 19</td> <td class=\"subtitle2\">&nbsp;20 to 24</td> </tr> <tr> <td>1</td> <td> <p>Unintentional suffocation</p> <p>1125</p> </td> <td> <p>Unintentional drowning</p> <p>390</p> </td> <td> <p>Unintentional MV traffic</p> <p>351</p> </td> <td> <p>Unintentional MV traffic</p> <p>412</p> </td> <td> <p>Unintentional MV traffic</p> <p>2535</p> </td> <td> <p>Unintentional MV traffic</p> <p>4252</p> </td> </tr> <tr class=\"divider_top\"> <td>2</td> <td> <p>Unintentional MV traffic</p> <p>64</p> </td> <td> <p>Unintentional MV traffic</p> <p>332</p> </td> <td> <p>Unintentional drowning</p> <p>129</p> </td> <td> <p>Unintentional drowning</p> <p>87</p> </td> <td> <p>Unintentional poisoning</p> <p>676</p> </td> <td> <p>Unintentional poisoning</p> <p>3244&nbsp;</p> </td> </tr> <tr class=\"divider_top\"> <td>3</td> <td> <p>Unintentional drowning</p> <p>30</p> </td> <td> <p>Unintentional suffocation</p> <p>131</p> </td> <td> <p>Unintentional fire/burn</p> <p>72</p> </td> <td> <p>Unintentional other land transport </p> <p>51</p> </td> <td> <p>Unintentional drowning</p> <p>225</p> </td> <td> <p>Unintentional drowning</p> <p>279</p> </td> </tr> <tr class=\"divider_top\"> <td>4</td> <td> <p>Unintentional fire/burn</p> <p>22</p> </td> <td> <p>Unintentional fire/burn</p> <p>100</p> </td> <td> <p>Unintentional other land transport</p> <p>32</p> </td> <td> <p>Unintentional fire/burn</p> <p>41</p> </td> <td> <p>Unintentional other land transport</p> <p>85</p> </td> <td> <p>Unintentional fall</p> <p>153</p> </td> </tr> <tr class=\"divider_top\"> <td>5</td> <td> <p>Unintentional natural/ environment</p> <p>12</p> </td> <td> <p>Unintentional pedestrian, other</p> <p>75</p> </td> <td> <p>Unintentional suffocation</p> <p>31</p> </td> <td> <p>Unintentional poisoning</p> <p>36</p> </td> <td> <p>Unintentional fall</p> <p>64</p> </td> <td> <p>Unintentional other land transport</p> <p>116</p> </td> </tr> <tr class=\"divider_top\"> <td>6</td> <td> <p>Unintentional unspecified</p> <p>12</p> </td> <td> <p>Unintentional fall</p> <p>30</p> </td> <td> <p>Unintentional natural/environment</p> <p>24</p> </td> <td> <p>Unintentional suffocation</p> <p>26</p> </td> <td> <p>Unintentional unspecified</p> <p>60</p> </td> <td> <p>Unintentional unspecified</p> <p>75</p> </td> </tr> <tr class=\"divider_top\"> <td>7</td> <td> <p>Unintentional poisoning</p> <p>9</p> </td> <td> <p>Unintentional poisoning</p> <p>29</p> </td> <td> <p>Unintentional&nbsp;pedestrian, other&nbsp;</p> <p>20</p> </td> <td> <p>Unintentional unspecified</p> <p>16</p> </td> <td> <p>Unintentional firearm</p> <p>52</p> </td> <td> <p>Unintentional firearm</p> <p>69</p> </td> </tr> <tr class=\"divider_top\"> <td>8</td> <td> <p>Unintentional other land transport</p> <p>5</p> </td> <td> <p>Unintentional struck by or&nbsp; against</p> <p>27</p> </td> <td> <p>Unintentional poisoning</p> <p>17</p> </td> <td> <p>Unintentional firearm</p> <p>15</p> </td> <td> <p>Unintentional pedestrian, other</p> <p>51</p> </td> <td> <p>Unintentional pedestrian other</p> <p>67</p> </td> </tr> <tr class=\"divider_top\"> <td>9</td> <td> <p>Unintentional struck by or against</p> <p>5</p> </td> <td> <p>Unintentional unspecified</p> <p>26</p> </td> <td> <p>Unintentional struck by or against</p> <p>17</p> </td> <td> <p>Unintentional other transport</p> <p>14</p> </td> <td> <p>Unintentional suffocation</p> <p>32</p> </td> <td> <p>Unintentional suffocation</p> <p>65</p> </td> </tr> <tr class=\"divider_top\"> <td>10</td> <td> <p>Unintentional fall</p> <p>4</p> </td> <td> <p>Two tied*</p> <p>25</p> </td> <td> <p>Unintentional&nbsp;unspecified</p> <p>14</p> <br /> </td> <td> <p>Unintentional fall</p> <p>13</p> </td> <td> <p>Unintentional other specified, classifiable</p> <p>27</p> </td> <td> <p>Unintentional other transport</p> <p>55</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MV: motor vehicle.<br />* Unintentional firearm and unintentional natural/environment.</div><div class=\"graphic_reference\">Reproduced from:&nbsp;National Center for Injury Prevention and Control. Centers for Disease Control and Prevention.&nbsp;Available at: <A href=\"http://www.cdc.gov/injury/wisqars/LeadingCauses.html\">www.cdc.gov/injury/wisqars/LeadingCauses.html</A>. Accessed on June 26, 2017.</div><div id=\"graphicVersion\">Graphic 81602 Version 7.0</div></div></div>"},"81603":{"type":"graphic_figure","displayName":"Reservoir cannulas and SpO2","title":"Performance of the reservoir cannulas","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Performance of the reservoir cannulas</div><div class=\"cntnt\"><img style=\"width:458px; height:250px;\" src=\"images/PULM/81603_Reservoir_cannulas_and_SaO2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The reservoir cannulas (Oxymizer and Pendant) set at 0.5 L/min will achieve an oxygen saturation measured by oximetry (SpO<SUB>2</SUB>) equivalent to continuous flow at 2.0 L/min - an efficency of 4:1. Similarly, 2.0 L/min will achieve an SpO<SUB>2</SUB> equivalent to continuous flow at 4.0 L/min - an efficiency of 2:1.</div><div class=\"graphic_reference\">Data from: Tiep BL. Reservoir cannulas. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing, Mt Kisco, New York, 1991.</div><div id=\"graphicVersion\">Graphic 81603 Version 3.0</div></div></div>"},"81604":{"type":"graphic_picture","displayName":"Saber shins","title":"Congenital syphilis: Saber shins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Saber shins</div><div class=\"cntnt\"><img style=\"width:432px; height:308px;\" src=\"images/PEDS/81604_Saber_shins.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Sweet RL, Gibbs RS. Atlas of Infectious Diseases of the Female Genital Tract. Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &#169; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81604 Version 2.0</div></div></div>"},"81605":{"type":"graphic_picture","displayName":"PUPPP striae plaques","title":"Pruritic urticarial papules and plaques of pregnancy (PUPPP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pruritic urticarial papules and plaques of pregnancy (PUPPP)</div><div class=\"cntnt\"><img style=\"width:432px; height:321px;\" src=\"images/DERM/81605_PUPPP_striae_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques in the distribution of striae are present. Note the sparing of the periumbilical skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81605 Version 5.0</div></div></div>"},"81607":{"type":"graphic_table","displayName":"Diagn approach depres CA pt","title":"Approaches to the diagnosis of major depression in cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approaches to the diagnosis of major depression in cancer patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n\t<td class=\"subtitle1\">Approach</td>\n\t<td class=\"subtitle1\">Example</td>\n\t<td class=\"subtitle1\">Description</td>\n</tr>\n\n<tr>\n\t<td>Inclusive</td>\n\t<td>RDC (Research Diagnostic Criteria)</td>\n\t<td>Includes somatic symptoms in diagnostic criteria</td>\n</tr>\n\t\n<tr>\n\t<td>Exclusive</td>\n\t<td>HADS (Hospital Anxiety and Depression Scale)</td>\n\t<td>Completely excludes somatic symptoms</td>\n</tr>\n\n<tr>\n\t<td>Substitutive</td>\n\t<td>Endicott</td>\n\t<td>Substitutes cognitive for somatic symptomatology</td>\n</tr>\n\n<tr>\n\t<td>Etiologic</td>\n\t<td>-</td>\n\t<td>Determines whether particular symptom is due to medical causes before including or excluding in diagnostic criteria for depression</td>\n</tr>\n\n<tr>\n\t<td>Increased threshold</td>\n\t<td>-</td>\n\t<td>The increased threshold approach requires that 7, rather than 5, out of 9 DSM-IV criterion symptoms be present in order to qualify for a diagnosis of major depression</td>\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81607 Version 1.0</div></div></div>"},"81608":{"type":"graphic_figure","displayName":"Exercise and cardiac events","title":"Beneficial effects of any physical activity on coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Beneficial effects of any physical activity on coronary heart disease</div><div class=\"cntnt\"><img style=\"width:450px; height:321px;\" src=\"images/PC/81608_Exerciseandcardiacevents.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronary events are less frequent among those who exercise. In a study of 5159 men, aged 40 to 49 years, followed for an average of almost 19 years, the age-adjusted coronary heart disease event rate per 1000 person-years is lower in those who perform any physical activity compared with inactive subjects.</div><div class=\"graphic_reference\">Data from: Wannamethee SG, Shaper AG, Alberti KG. Arch Intern Med 2000; 160:2108.</div><div id=\"graphicVersion\">Graphic 81608 Version 4.0</div></div></div>"},"81609":{"type":"graphic_diagnosticimage","displayName":"Pathology electroanatomic map","title":"Correlation between electroanatomic map and pathological sections of infarcted heart","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Correlation between electroanatomic map and pathological sections of infarcted heart</div><div class=\"cntnt\"><img style=\"width:261px; height:486px;\" src=\"images/CARD/81609_Pathologyelectroanatomicm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows a section of the left ventricle in a patient with a subendocardial myocardial infarction (arrow). The superimposed colors in the reconstruction from an electroanatomic map (panel B) depict bipolar electrogram amplitude (BEA); purple indicates values &gt;6.1 mV; red indicates values &lt;2.1 mV. Beneath the reconstructed sections (panel C) are typical recordings of unipolar electrogram and derivatives, the unipolar electrogram amplitude (UEA) and slew rate (SR) and bipolar electrogram and amplitude from selected points at the core of the infarcted region (the distance between two white marks on the electrogram time scale denotes a 50-millisecond period).</div><div class=\"graphic_reference\">Reprinted with permission from the American College of Cardiology (Journal of the American College of Cardiology, 2001, 37:1590-7).</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 81609 Version 3.0</div></div></div>"},"81610":{"type":"graphic_picture","displayName":"Genesis of schistocyte","title":"Genesis of the schistocyte","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Genesis of the schistocyte</div><div class=\"cntnt\"><img style=\"width:316px; height:323px;\" src=\"images/HEME/81610_Genesis_of_schistocyte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This scanning electron microphotograph shows a red blood cell (white arrow) about to be &quot;guillotined&quot; by a fibrin strand (yellow arrow), produced as a result of intravascular coagulation. This results in the formation of a fragmented red blood cell, termed a schistocyte or &quot;helmet cell.&quot;</div><div class=\"graphic_reference\">From Bull BS, Kuhn IN: The production of schistocytes by fibrin strands (a scanning electron microscope study). Blood 1970; 35:104. Copyright American Society of Hematology, used by permission.</div><div id=\"graphicVersion\">Graphic 81610 Version 3.0</div></div></div>"},"81611":{"type":"graphic_table","displayName":"Asthma adherence I","title":"Identifying problems in taking medicines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Identifying problems in taking medicines</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Review your medicine record</td>\n\n\n    </tr>\n\n    <tr>\n      <td class=\"subtitle2_single\">Keep a record of when you take your medicines for about a week. In\naddition to the time of day, write down where you are and what you are\ndoing. After a week, you can review the record and answer the following\nquestions to help you see where you are having problems:</td>\n    </tr>\n    <tr>\n\n      <td class=\"indent1\">Are times of day\nrelated to problems in taking your medicine? What times are not\nconvenient? Did you miss a dose or take it late more than twice during\nthe week? Which doses were most often missed or late?</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Do\nsome locations interfere with your medicine schedule? How often are you\naway from home when you need to take your medicine? Does this cause a\nproblem? What locations cause the most problems?</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Do\nsome activities interfere with your medicine schedule? What activities\nhave been related to missing or being late taking your medicines? Which\nof these activities occur on a regular basis?</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Do\nother people interfere with your medicine schedule? Do you feel\nembarrassed to take your medicine in front of certain people? Who? Do\npeople tell you that you don't need to take so much medicine? How often\ndo you see these people?</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Do\nmoods or feelings interfere with your medicine schedule? What moods or\nfeelings cause problems? (For example, does feeling sad or discouraged\nmake you feel like taking your medicine?) How often and when do these\nfeelings occur?</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81611 Version 1.0</div></div></div>"},"81612":{"type":"graphic_figure","displayName":"Cervical vertebrae transverse view","title":"Cervical vertebrae transverse view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical vertebrae transverse view</div><div class=\"cntnt\"><img style=\"width:394px; height:672px;\" src=\"images/EM/81612_Cervvertebraetransview.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 3rd-6th cervical vertebrae have a &quot;typical&quot; structure; the 1st, 2nd, and 7th are &quot;atypical.&quot; Typical vertebrae demonstrate rectangular bodies with articular uncinate processes on their lateral aspects, triangular vertebral foramina, bifid spinous processes, and transverse foramina.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81612 Version 11.0</div></div></div>"},"81613":{"type":"graphic_figure","displayName":"Pseudoclawing metacarpal fracture","title":"Pseudoclawing metacarpal fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudoclawing metacarpal fracture</div><div class=\"cntnt\"><img style=\"width:428px; height:163px;\" src=\"images/EM/81613_Pseudoclawmetacarpalfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pseudoclawing stems from an imbalance of metacarpophalangeal joint hyperextension and proximal interphalangeal joint flexion that occurs when the patient attempts finger extension. It occurs in proportion to the degree of apex dorsal angulation at the metacarpal fracture site. This condition represents one indication for surgery.</div><div class=\"graphic_reference\">Reproduced with permission from: Henry MH. Upper extremity: Hand fractures and dislocations. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81613 Version 12.0</div></div></div>"},"81616":{"type":"graphic_figure","displayName":"Lumbar triangles","title":"Lumbar triangles","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Lumbar triangles</div><div class=\"cntnt\"><img style=\"width:508px; height:598px;\" src=\"images/SURG/81616_Lumbar_triangles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The superior lumbar triangle (Grynfeltt) is an inverted triangle. The&nbsp;base is the twelfth rib,&nbsp;the posterior border is the erector spinae, the anterior border is&nbsp;the posterior margin of the external oblique, and&nbsp;the apex is the iliac crest inferiorly.<br />The inferior triangle (Petit) is located between the external oblique, the latissimus dorsi, and the iliac crest</div><div id=\"graphicVersion\">Graphic 81616 Version 3.0</div></div></div>"},"81617":{"type":"graphic_waveform","displayName":"RNS variability due to artifact","title":"Repetitive nerve stimulation with variability due to artifact","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Repetitive nerve stimulation with variability due to artifact</div><div class=\"cntnt\"><img style=\"width:588px; height:202px;\" src=\"images/NEURO/81617_RNS_variability_artifact.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repetitive nerve stimulation at 2 Hz showing pseudo-decrement of 45 percent, most likely due to stimulator movement and submaximal stimulation.</div><div class=\"graphic_reference\">Courtesy of David Weinberg, MD.</div><div id=\"graphicVersion\">Graphic 81617 Version 2.0</div></div></div>"},"81618":{"type":"graphic_figure","displayName":"Celiac plexus intervention","title":"Celiac plexus intervention","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Celiac plexus intervention</div><div class=\"cntnt\"><img style=\"width:442px; height:302px;\" src=\"images/GAST/81618_Celiac_plexus_intervention.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An artist's rendition of endosonography-guided celiac plexus intervention. The position of the needle tip corresponds with the site of therapy when performing celiac plexus neurolysis.</div><div class=\"graphic_reference\">Courtesy of Mike King. Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.</div><div id=\"graphicVersion\">Graphic 81618 Version 9.0</div></div></div>"},"81619":{"type":"graphic_figure","displayName":"Conjunctiva anatomy PI","title":"Anatomy of the eye","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Anatomy of the eye</div><div class=\"cntnt\"><img style=\"width:539px; height:255px;\" src=\"images/PI/81619_Conjunctiva_anatomy_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81619 Version 4.0</div></div></div>"},"81621":{"type":"graphic_table","displayName":"Causes of an elevated CA 125","title":"Conditions associated with an elevated serum CA 125 concentration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with an elevated serum CA 125 concentration</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Gynecologic malignancies</td> </tr> <tr> <td class=\"indent1\">Epithelial ovarian, fallopian tube, and primary peritoneal cancers</td> </tr> <tr> <td class=\"indent1\">Endometrial cancer</td> </tr> <tr> <td class=\"subtitle1_single\">Benign gynecologic conditions</td> </tr> <tr> <td class=\"indent1\">Benign ovarian neoplasms</td> </tr> <tr> <td class=\"indent1\">Functional ovarian cysts</td> </tr> <tr> <td class=\"indent1\">Endometriosis</td> </tr> <tr> <td class=\"indent1\">Meig syndrome</td> </tr> <tr> <td class=\"indent1\">Adenomyosis</td> </tr> <tr> <td class=\"indent1\">Uterine leiomyomas</td> </tr> <tr> <td class=\"indent1\">Pelvic inflammatory disease</td> </tr> <tr> <td class=\"indent1\">Ovarian hyperstimulation</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Menstruation</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Nongynecologic conditions</td> </tr> <tr> <td class=\"indent1\">Cirrhosis and other liver disease</td> </tr> <tr> <td class=\"indent1\">Ascites</td> </tr> <tr> <td class=\"indent1\">Colitis</td> </tr> <tr> <td class=\"indent1\">Diverticulitis</td> </tr> <tr> <td class=\"indent1\">Appendicular abscess</td> </tr> <tr> <td class=\"indent1\">Tuberculosis peritonitis</td> </tr> <tr> <td class=\"indent1\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">Pleural effusion</td> </tr> <tr> <td class=\"indent1\">Pulmonary embolism</td> </tr> <tr> <td class=\"indent1\">Pneumonia</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> </tr> <tr> <td class=\"indent1\">Myocardiopathy</td> </tr> <tr> <td class=\"indent1\">Myocardial infarction</td> </tr> <tr> <td class=\"indent1\">Pericardial disease</td> </tr> <tr> <td class=\"indent1\">Renal insufficiency</td> </tr> <tr> <td class=\"indent1\">Urinary tract infection</td> </tr> <tr> <td class=\"indent1\">Recent surgery</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Nongynecologic cancers</td> </tr> <tr> <td class=\"indent1\">Breast</td> </tr> <tr> <td class=\"indent1\">Colon</td> </tr> <tr> <td class=\"indent1\">Liver</td> </tr> <tr> <td class=\"indent1\">Gallbladder</td> </tr> <tr> <td class=\"indent1\">Pancreas</td> </tr> <tr> <td class=\"indent1\">Lung</td> </tr> <tr> <td class=\"indent1\">Hematologic malignancies</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CA: cancer antigen.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 2000; 75:264. </LI>&#xD;&#xA;<LI>Miralles C, Orea M, Espana P, et. al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003; 10:150. </LI>&#xD;&#xA;<LI>Moss EL, Hollingworth J, Reynolds TM.&nbsp;The role of CA125 in clinical practice. J Clin Pathol 2005; 58:308. </LI></OL></div><div id=\"graphicVersion\">Graphic 81621 Version 7.0</div></div></div>"},"81624":{"type":"graphic_picture","displayName":"Angiokeratomas","title":"Angiokeratomas are distributed in a typical symmetrical fashion on the torso","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiokeratomas are distributed in a typical symmetrical fashion on the torso</div><div class=\"cntnt\"><img style=\"width:396px; height:331px;\" src=\"images/NEPH/81624_Angiokeratomas.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cho ME, Kopp JB. Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol 2004; 19:583. Copyright © 2004 Springer Science and Business Media.</div><div id=\"graphicVersion\">Graphic 81624 Version 2.0</div></div></div>"},"81625":{"type":"graphic_figure","displayName":"Eisenmenger heart specimen","title":"Eisenmenger syndrome heart specimen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eisenmenger syndrome heart specimen</div><div class=\"cntnt\"><img style=\"width:354px; height:250px;\" src=\"images/CARD/81625_Eisenmenger_heart_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathology specimen from a patient with Eisenmenger syndrome shows a large ventricular septal defect (VSD) and marked right ventricular hypertrophy.</div><div class=\"graphic_reference\">Courtesy of Heidi Connolly, MD.</div><div id=\"graphicVersion\">Graphic 81625 Version 2.0</div></div></div>"},"81626":{"type":"graphic_table","displayName":"Testicular tumors","title":"Classification of testicular tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of testicular tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Germ cell tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Seminoma</td> </tr> <tr> <td class=\"subtitle2_single\">Nonseminomatous germ cell tumors</td> </tr> <tr> <td class=\"indent2\">Embryonal carcinoma</td> </tr> <tr> <td class=\"indent2\">Choriocarcinoma</td> </tr> <tr> <td class=\"indent2\">Yolk sac tumor (endodermal sinus tumor)</td> </tr> <tr> <td class=\"indent2\">Teratoma</td> </tr> <tr> <td class=\"indent2\">Teratoma with malignant/somatic transformation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Mixed germ cell tumor</td> </tr> <tr> <td class=\"subtitle2_single\">Spermatocytic Tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Sex cord-stromal tumors</td> </tr> <tr> <td class=\"indent1\">Sertoli cell tumor</td> </tr> <tr> <td class=\"indent1\">Leydig cell tumor</td> </tr> <tr> <td class=\"indent1\">Granulosa cell tumor</td> </tr> <tr> <td class=\"indent1\">Mixed types (eg, Sertoli-Leydig cell tumor)</td> </tr> <tr> <td class=\"indent1\">Unclassified</td> </tr> <tr> <td class=\"subtitle1_single\">Mixed germ cell and stromal tumors</td> </tr> <tr> <td class=\"indent1\">Gonadoblastoma</td> </tr> <tr> <td class=\"subtitle1_single\">Adnexal and paratesticular tumors</td> </tr> <tr> <td class=\"indent1\">Adenocarcinoma of rete testis</td> </tr> <tr> <td class=\"indent1\">Adenocarcinoma of the epididymis</td> </tr> <tr> <td class=\"indent1\">Mesothelioma</td> </tr> <tr> <td class=\"indent2\">Malignant mesothelioma</td> </tr> <tr> <td class=\"indent2\">Adenomatoid tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous tumors</td> </tr> <tr> <td class=\"indent1\">Carcinoid</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"indent1\">Metastatic tumors</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Tumours of the Urinary System and Male Genital Organs.&nbsp;Moch H, Humphrey PA, Ulbright TM, et al&nbsp;(Eds), In: World Health Organization Classification of Tumours. Lyon 2016.</div><div id=\"graphicVersion\">Graphic 81626 Version 6.0</div></div></div>"},"81627":{"type":"graphic_diagnosticimage","displayName":"Fibrous dysplasia","title":"Radiographic appearance of fibrous dysplasia in McCune-Albright syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Radiographic appearance of fibrous dysplasia in McCune-Albright syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:300px;\" src=\"images/PEDS/81627_Fibrous_dysplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) A proximal femur with typical ground glass appearance and shepherd's crook deformity characteristic of fibrous dysplasia (FD) in a 10-year-old child. B) The appearance of FD in the femur of an untreated 40-year-old man demonstrates the tendency for FD to appear more sclerotic with time. C) The typical ground glass appearance of FD in the craniofacial region on a CT image of a 10-year-old child is shown. The white arrows indicate the optic nerves, which are typically encased with FD. D) A CT image in a 40-year-old woman demonstrates the typical appearance of craniofacial FD in an older person, with mixed solid and &quot;cystic&quot; lesions. The Hounsfield Unit measurements of &quot;cystic&quot; lesions are quite useful in distinguishing soft tissue &quot;cystic&quot; lesions from true fluid-filled cysts, which are much more uncommon and tend to behave aggressively with rapid expansion and compression of vital structures. E-G) Bone Scintigraphy in FD. Representative 99Tc-MDP bone scans which show tracer uptake at affected skeletal sites, and the associated skeletal disease burden score are shown. E) A 50-year-old woman with monostotic FD confined to a single focus involving contiguous bones in the craniofacial region. F) A 42-year-old man with polyostotic FD shows the tendency for FD to be predominantly (but not exclusively) unilateral, and to involve the skull base and proximal femur. G) A 16-year-old boy with McCune-Albright syndrome and involvement of virtually all skeletal sites (panostotic) is shown.</div><div class=\"graphic_reference\">Reproduced from: Dumitrescu, CE, Collins, MT. McCune-Albright syndrome. Orphanet J Rare Dis 2008; 3:12. Copyright ©2008 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 81627 Version 2.0</div></div></div>"},"81629":{"type":"graphic_picture","displayName":"Keratoacanthoma on ear","title":"Keratoacanthoma","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Keratoacanthoma</div><div class=\"cntnt\"><img style=\"width:506px; height:352px;\" src=\"images/DERM/81629_keratoacanthoma_ear_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A crateriform nodule with central hyperkeratosis on the helix of the ear.</div><div id=\"graphicVersion\">Graphic 81629 Version 2.0</div></div></div>"},"81630":{"type":"graphic_figure","displayName":"Positive predict value ETT","title":"Estimated positive predictive value of exercise test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Estimated positive predictive value of exercise test</div><div class=\"cntnt\"><img style=\"width:357px; height:168px;\" src=\"images/CARD/81630_Positive_predict_value_ETT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The positive predictive value of an ECG exercise test is related to the pretest probability of coronary heart disease (CHD), ie, the prevalence of CHD in the population studied.</div><div id=\"graphicVersion\">Graphic 81630 Version 1.0</div></div></div>"},"81631":{"type":"graphic_table","displayName":"Fibromyalgia diagnostic criteria","title":"American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Criteria</td> </tr> <tr> <td colspan=\"4\">A patient satisfies diagnostic criteria for fibromyalgia if the following&nbsp;three conditions are met:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">1) Widespread pain index (WPI) &#8805;7 and symptom severity (SS) scale score &#8805;5 or WPI 3 to 6 and SS scale score &#8805;9.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">2) Symptoms have been present at a similar level for at least&nbsp;three months.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">3) The patient does not have a disorder that would otherwise explain the pain.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Ascertainment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">1) WPI</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Note the number areas in which the patient has had pain over the last week. In how many areas has the patient had pain? Score will be between 0 and 19.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Neck</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Jaw, left</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Jaw, right</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Shoulder girdle, left</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Shoulder girdle, right</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Upper arm, left</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Upper arm, right</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Lower arm, left</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Lower arm, right</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Chest</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Abdomen</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Upper back</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Lower back</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Hip (buttock, trochanter), left</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Hip (buttock, trochanter), right</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Upper leg, left</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Upper leg, right</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Lower leg, left</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Lower leg, right</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">2) SS scale score</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">For the each of the&nbsp;three symptoms below, indicate the level of severity over the past week using the following scale:</td> </tr> <tr> <td class=\"indent1\">0 = no problem</td> <td>1 = slight or mild problems, generally mild or intermittent</td> <td>2 = moderate, considerable problems, often present and/or at a moderate level</td> <td>3 = severe, pervasive, continuous, life-disturbing problems</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">- Fatigue (0 to 3)</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">- Waking unrefreshed (0 to 3)</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">- Cognitive symptoms (0 to 3)</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Considering somatic symptoms in general,<sup>*&#182;</sup> indicate whether the patient has:</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">- No symptoms (0)</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">- Few symptoms (1)</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">- A moderate number of symptoms (2)</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">- A great deal of symptoms (3)</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">The SS scale score is the sum of the severity of the&nbsp;three symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the extent (severity) of somatic symptoms in general. The final score is between 0 and 12.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*&nbsp;Somatic symptoms that might be considered: muscle pain, irritable bowel syndrome, fatigue/tiredness, thinking or remembering problem, muscle weakness, headache, pain/cramps in the abdomen, numbness/tingling, dizziness, insomnia, depression, constipation, pain in the upper abdomen, nausea, nervousness, chest pain, blurred vision, fever, diarrhea, dry mouth, itching, wheezing, Raynaud phenomenon, hives/welts, ringing in ears, vomiting, heartburn, oral ulcers, loss of/change in taste, seizures, dry eyes, shortness of breath, loss of appetite, rash, sun sensitivity, hearing difficulties, easy bruising, hair loss, frequent urination, painful urination, and bladder spasms.<br />¶&nbsp;As an alternative to somatic symptoms in general, one point each may be added to the SS scale score if the following symptoms occurred during the previous six months: headaches, pain or cramps in lower abdomen, and depression (0-3).<SUP>[1]</SUP></div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Wolfe F, Clauw DJ, Fitzcharles M, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: A modification of the ACR preliminary diagnostic criteria for fibromyalgia.&nbsp;J Rheumatol 2011; 38:1113.</LI></OL>Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010; 62:600. Copyright © 2010 American College of Rheumatology. Reproduced with permission of John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 81631 Version 5.0</div></div></div>"},"81632":{"type":"graphic_picture","displayName":"Large basal cell carcinoma on ear","title":"Destructive basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Destructive basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/81632_Large_basal_cell_carcin_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large basal cell carcinoma causing destruction of the ear.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81632 Version 4.0</div></div></div>"},"81633":{"type":"graphic_picture","displayName":"Bipolar stain of Yersinia pestis","title":"Wayson stain of Yersinia pestis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wayson stain of Yersinia pestis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/81633_Bipolar_stain_Yersinia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the characteristic &quot;safety pin&quot; appearance of the bacteria.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/ncidod/dvbid/plague/wayson.htm.</div><div id=\"graphicVersion\">Graphic 81633 Version 2.0</div></div></div>"},"81634":{"type":"graphic_figure","displayName":"Blood pressure change and salt intake","title":"Blood pressure change and sodium reduction","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Blood pressure change and sodium reduction</div><div class=\"cntnt\"><img style=\"width:598px; height:278px;\" src=\"images/NEPH/81634_BP_change_and_salt_intake.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pooled results from all sodium-reduction trials concerning the mean net change in blood pressure due to restrictions in sodium intake among various subsets of patients.</div><div class=\"graphic_footnotes\">SBP: systolic blood pressure; DBP: diastolic blood pressure.<br />* The mean change is compared with control values.</div><div class=\"graphic_reference\">Data from: Cutler JA, Follmann D, Allender PS. Am J Clin Nutr 1997; 65:643S.</div><div id=\"graphicVersion\">Graphic 81634 Version 4.0</div></div></div>"},"81638":{"type":"graphic_figure","displayName":"Mobilization of the splenic flexure","title":"Mobilization of the splenic flexure","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Mobilization of the splenic flexure</div><div class=\"cntnt\"><img style=\"width:525px; height:454px;\" src=\"images/SURG/81638_Mobilization-splenic-flexure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts mobilizing the splenic flexure, one of the challenging components of a left colectomy. The dissection progresses from the midtransverse colon medially to distally, a technique particularly helpful in obese patients or in settings when the splenic flexure cannot be safely approached and mobilized laterally.</div><div id=\"graphicVersion\">Graphic 81638 Version 2.0</div></div></div>"},"81639":{"type":"graphic_waveform","displayName":"12 lead ECG uncommon AVNRT","title":"12 lead ECG of an uncommon form of an atrioventricular nodal reentrant tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">12 lead ECG of an uncommon form of an atrioventricular nodal reentrant tachycardia</div><div class=\"cntnt\"><img style=\"width:543px; height:351px;\" src=\"images/CARD/81639_12_lead_ECG_uncommon_AVNRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12 lead ECG shows a regular, narrow complex tachycardia at a rate of 130 beats per minute. The QRS complexes are normal. There is an abnormal &quot;notching&quot; within the ST segment, representing a retrograde P wave (*). The interval from the proceeding R wave (RP interval) is longer than the PR interval; this is a &quot;long RP tachycardia&quot;, due to an atypical atrioventricular nodal reentrant tachycardia.</div><div class=\"graphic_reference\">Courtesy of Martin Burke, DO.</div><div id=\"graphicVersion\">Graphic 81639 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"81640":{"type":"graphic_picture","displayName":"Fish tank granuloma","title":"Fish tank granuloma","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Fish tank granuloma</div><div class=\"cntnt\"><img style=\"width:517px; height:198px;\" src=\"images/ID/81640_Fish_tank_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81640 Version 4.0</div></div></div>"},"81642":{"type":"graphic_figure","displayName":"Plasma concentrations C","title":"GLP-1 concentrations (top) and GIP concentrations (bottom) using NH2-terminal assays","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">GLP-1 concentrations (top) and GIP concentrations (bottom) using NH2-terminal assays</div><div class=\"cntnt\"><img style=\"width:297px; height:410px;\" src=\"images/PC/81642_Plasma_concentrations_C.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data are means ±SE.</div><div class=\"graphic_footnotes\">GLP-1: glucagon-like peptide-1;&nbsp;GIP: glucose-dependent insulinotropic polypeptide;&nbsp;SE: standard error.<br />* p &lt;0.05 for differences between type 2 diabetic patients and healthy subjects.</div><div class=\"graphic_reference\">Modified with permission from: Vilsboll T, Krarup T, Deacon C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609. Copyright © 2001 The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 81642 Version 2.0</div></div></div>"},"81643":{"type":"graphic_picture","displayName":"Ablative fractional resurfacing - before and after","title":"Improvement in facial wrinkles following ablative fractional laser resurfacing","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Improvement in facial wrinkles following ablative fractional laser resurfacing</div><div class=\"cntnt\"><img style=\"width:511px; height:211px;\" src=\"images/DERM/81643_Ablative_frac_resurfacing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient was treated with a fractional CO<sub>2</sub> laser for facial wrinkles. She is shown before (A) and after treatment (B).</div><div id=\"graphicVersion\">Graphic 81643 Version 1.0</div></div></div>"},"81644":{"type":"graphic_figure","displayName":"Insulin benefit in NOD mouse","title":"Insulin prevents diabetes in NOD mouse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insulin prevents diabetes in NOD mouse</div><div class=\"cntnt\"><img style=\"width:447px; height:245px;\" src=\"images/ENDO/81644_Insulin_benefit_in_NOD_mous.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of immunization with intact insulin, the A or B chain of insulin, or diluent on the development of diabetes in the NOD mouse. Both intact insulin and the B chain were protective.</div><div class=\"graphic_reference\">Data from: Muir A, Peck A, Clare-Salzler M, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription.&nbsp;J Clin Invest 1995; 95:628.</div><div id=\"graphicVersion\">Graphic 81644 Version 2.0</div></div></div>"},"81646":{"type":"graphic_table","displayName":"Issues anticoag for malignancy","title":"Issues to be considered when making decisions concerning the use or non-use of anticoagulation in patients with malignancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Issues to be considered when making decisions concerning the use or non-use of anticoagulation in patients with malignancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Overall treatment plan and prognosis</td> </tr> <tr> <td class=\"indent1\">Therapeutic goal (eg, palliation of symptoms related to VTE, planned oncologic intervention, immediate prognosis, Hospice care)</td> </tr> <tr> <td class=\"indent1\">Planned chemotherapy</td> </tr> <tr> <td class=\"indent1\">Stage of the malignancy, overall prognosis</td> </tr> <tr> <td class=\"indent1\">Other causes for hypercoagulability (eg, bed ridden, pathologic fracture, recent surgery or invasive procedures, use of hormonal agents or other medications with a high incidence of thrombotic side-effects, presence of a central venous access line)</td> </tr> <tr> <td class=\"subtitle1_single\">Patient preferences, logistic, and financial issues</td> </tr> <tr> <td class=\"indent1\">Inpatient or outpatient care planned</td> </tr> <tr> <td class=\"indent1\">Who will supervise medication's use and required monitoring, if any?</td> </tr> <tr> <td class=\"indent1\">Patient preferences (eg, oral versus injectable agent, need for frequent monitoring of coagulation status)</td> </tr> <tr> <td class=\"indent1\">Food and Drug Administration approval of agent chosen</td> </tr> <tr> <td class=\"indent1\">Treatment costs. Will the patient's insurance pay for the medication?</td> </tr> <tr> <td class=\"subtitle1_single\">Relative contraindications to anticoagulation</td> </tr> <tr> <td class=\"sublist2_start\">Presence of central nervous system involvement</td> </tr> <tr> <td class=\"sublist2\">- Central nervous system primary or metastases</td> </tr> <tr> <td class=\"sublist2\">- Prior intracerebral hemorrhage</td> </tr> <tr> <td class=\"indent1\">Thrombocytopenia or bleeding diathesis present?</td> </tr> <tr> <td class=\"indent1\">Are risk factors for bleeding after use of warfarin present? (eg, impaired liver function, hepatic metastases, concomitant medication, poor nutrition)</td> </tr> <tr> <td class=\"subtitle1_single\">Technical issues</td> </tr> <tr> <td class=\"indent1\">Selection of appropriate dosing (eg, impaired renal function, obesity, advanced age)</td> </tr> <tr> <td class=\"indent1\">Need for monitoring of treatment (eg, INR for treatment with warfarin)</td> </tr> <tr> <td class=\"indent1\">Ability or inability to reverse anticoagulation if bleeding occurs</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81646 Version 5.0</div></div></div>"},"81647":{"type":"graphic_picture","displayName":"COP lung biopsy low power","title":"Cryptogenic organizing pneumonia: Low power","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptogenic organizing pneumonia: Low power</div><div class=\"cntnt\"><img style=\"width:351px; height:243px;\" src=\"images/PULM/81647_BOOP_Light_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of specimen from open lung biopsy in a patient with cryptogenic organizing pneumonia. Polypoid masses of granulation tissue fill the lumens of a respiratory bronchiole and alveolar ducts (right side). Adjacent alveolar interstices are broadened by a lymphoplasmacytic inflammatory infiltrate. Hematoxylin and eosin stain.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 81647 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/54820_Normal_lung_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 54820 Version 1.0</div></div></div>"},"81648":{"type":"graphic_table","displayName":"Psychodynamic defense mechanisms","title":"Psychodynamic defense mechanisms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Psychodynamic defense mechanisms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Defense mechanisms</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Primitive defenses</td> </tr> <tr> <td class=\"indent1\">Splitting</td> <td>Compartmentalizing internal representations of self and others so that conflict is avoided and integration of these representations is not possible</td> </tr> <tr> <td class=\"indent1\">Projective identification</td> <td>A defense involving subtle interpersonal pressure so that the target of a projection takes on characteristics of either an aspect of the self or the internal object that is being projected</td> </tr> <tr> <td class=\"indent1\">Projection</td> <td>Externalizing unacceptable inner impulses and their derivatives by attributing them to someone else</td> </tr> <tr> <td class=\"indent1\">Denial</td> <td>Avoiding awareness of aspects of external realities that are difficult to face by dismissing perceptions that are obvious to everyone else in the environment. What is not perceived is not real, and thus cannot cause pain. The unpleasant aspects that are denied may be replaced by a more pleasant internal fantasy.</td> </tr> <tr> <td class=\"indent1\">Disavowal</td> <td>Dismissing or failing to acknowledge thoughts or feelings that are uncomfortable</td> </tr> <tr> <td class=\"indent1\">Schizoid fantasy</td> <td>Retreating into one's private, internal world to avoid anxiety about interpersonal situations</td> </tr> <tr> <td class=\"indent1\">Regression</td> <td>A partial or total return to earlier patterns of adaptation or behavior</td> </tr> <tr> <td class=\"indent1\">Conversion</td> <td>Development of symbolic physical symptoms and distortions involving the voluntary muscles or special sense organs; symptoms are not under voluntary control and cannot be explained by any physical disorder</td> </tr> <tr> <td class=\"indent1\">Undoing</td> <td>Symbolically acting out in reverse something unacceptable that has already been done or against an impulse which the ego must defend itself</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Higher-level defenses</td> </tr> <tr> <td class=\"indent1\">Rationalization</td> <td>Justifying irrational or unacceptable behavior, motives, or feelings by making them appear rational and reasonable through belief in plausible explanations that are false</td> </tr> <tr> <td class=\"indent1\">Displacement</td> <td>Shifting unacceptable feelings associated with one idea or object to another that resembles the original in some way</td> </tr> <tr> <td class=\"indent1\">Intellectualization</td> <td>Using excessive and abstract rational and logical reasoning to avoid difficult feelings</td> </tr> <tr> <td class=\"indent1\">Isolation of affect</td> <td>Separating an idea or impulse from its associated feeling or affect to avoid emotional turmoil</td> </tr> <tr> <td class=\"indent1\">Sexualization</td> <td>Endowing an object or behavior with sexual significance to turn a negative experience into an exciting and stimulating one</td> </tr> <tr> <td class=\"indent1\">Reaction formation</td> <td>Transforming an unacceptable wish or impulse into its opposite</td> </tr> <tr> <td class=\"indent1\">Sublimation</td> <td>Energy associated with unacceptable impulses or wishes is diverted into personally and socially acceptable channels</td> </tr> <tr> <td class=\"indent1\">Humor</td> <td>Finding comic and/or ironic elements in difficult situations to reduce unpleasant affect and personal discomfort</td> </tr> <tr> <td class=\"indent1\">Anticipation</td> <td>Committing oneself to the needs of others over and above one's own needs</td> </tr> <tr> <td class=\"indent1\">Suppression</td> <td>Consciously deciding not to attend to a particular feeling, state, or impulse</td> </tr> <tr> <td class=\"indent1\">Repression</td> <td>Expelling unacceptable ideas or impulses, thus blocking them from entering consciousness (repression is more closely linked with inner states, whereas denial involves external sensory data)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Gabbard, GO. Long-Term Psychodynamic Psychotherapy: a Basic Text, 2nd ed, American Psychiatric Publishing Arlington, VA 2007.</div><div id=\"graphicVersion\">Graphic 81648 Version 2.0</div></div></div>"},"81649":{"type":"graphic_table","displayName":"Causes of acute muscle weakness in children","title":"Causes of acute muscle weakness in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute muscle weakness in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anatomic region</td> <td class=\"subtitle1\">Condition</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Cerebral cortex</td> <td>Intracranial hemorrhage (SAH)*</td> </tr> <tr> <td>Head trauma (EDH, SDH)*</td> </tr> <tr> <td>Stroke (thrombotic or embolic)*</td> </tr> <tr> <td>Brain tumor*</td> </tr> <tr> <td>Postictal Todd paralysis</td> </tr> <tr> <td>Hemisyndrome migraine</td> </tr> <tr class=\"divider_bottom\"> <td>Alternating hemiplegia of childhood</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Spinal cord</td> <td>Spinal cord trauma (eg, EDH)*</td> </tr> <tr> <td>Spinal cord tumor*</td> </tr> <tr> <td>Discitis (vertebral osteomyelitis)</td> </tr> <tr> <td>Epidural abscess*</td> </tr> <tr> <td>Transverse myelitis</td> </tr> <tr class=\"divider_bottom\"> <td>Vascular abnormality (ie, stroke)</td> </tr> <tr class=\"divider_bottom\"> <td>Anterior horn cell</td> <td>Poliomyelitis*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Peripheral nerve</td> <td>Guillain-Barr&#233; syndrome*</td> </tr> <tr> <td>Ciguatera poisoning*</td> </tr> <tr> <td>Heavy metal poisoning (eg, arsenic, mercury)*</td> </tr> <tr> <td>Paralytic shellfish poisoning*</td> </tr> <tr> <td>Acute intermittent porphyria*</td> </tr> <tr class=\"divider_bottom\"> <td>Other acquired peripheral neuropathy<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Neuromuscular junction</td> <td>Botulism*</td> </tr> <tr> <td>Myasthenia gravis*</td> </tr> <tr> <td>Organophosphate poisoning*</td> </tr> <tr> <td>Neurotoxic snake envenomation*</td> </tr> <tr class=\"divider_bottom\"> <td>Tick paralysis*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Muscle</td> <td>Rhabdomyolysis*</td> </tr> <tr> <td>Viral myositis</td> </tr> <tr> <td>Pyomyositis</td> </tr> <tr> <td>Periodic paralysis (may be associated with high, low, or normal potassium)</td> </tr> <tr class=\"divider_bottom\"> <td>Trichinellosis</td> </tr> <tr> <td rowspan=\"3\">Other</td> <td>Electrolyte disturbance (eg, hypokalemia, hypophosphatemia, hypocalcemia, hyponatremia)*</td> </tr> <tr> <td>Drug-related<sup>&#916;</sup></td> </tr> <tr> <td>Conversion disorder</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SAH: subarachnoid hemorrhage; EDH: epidural hematoma; SDH: subdural hematoma.<br />* Life-threatening condition.<br />¶ See UpToDate review: \"Overview of acquired peripheral neuropathies in children\".<br />Δ Refer to \"Polyneuropathy drugs toxins\" table.</div><div id=\"graphicVersion\">Graphic 81649 Version 3.0</div></div></div>"},"81650":{"type":"graphic_table","displayName":"Eval infants mother with WNV","title":"Recommended clinical evaluation of infants born to mothers infected with West Nile virus (WNV) during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended clinical evaluation of infants born to mothers infected with West Nile virus (WNV) during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>A thorough physical examination of the newborn should\nbe conducted, including careful measurement of the infant's head\ncircumference, length, weight, and assessment of gestational age.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>The newborn should be evaluated carefully for\nneurologic abnormalities, dysmorphic features, splenomegaly,\nhepatomegaly, and rash or other skin lesions. Any rash, skin lesions,\nor dysmorphic features should be photographed. If an abnormality is\nnoted, consultation with an appropriate specialist is recommended.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infant serum should be obtained within 2 days of birth\nand at about age 8 weeks to test for IgM and IgG antibody to WNV. Free\ntesting of samples by CDC can be arranged by contacting state public\nhealth laboratories.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>A newborn hearing screen should be completed by evoked\notoacoustic emissions testing or auditory brainstem response testing,\neither before discharge from the hospital or within 1 month after\nbirth. Infants who fail the initial hearing screen should be referred\nto an audiologist for further evaluation.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Initial examination of the placenta by a pathologist is\nencouraged. Regardless of whether this is done, the entire placenta, a\nsample of umbilical cord tissue, and a sample of serum from the\numbilical cord should be retained for further evaluation if congenital\nWNV infection is identified or strongly suspected. A section of the\nplacenta and umbilical cord should be frozen, and the remainder of the\nplacenta should be preserved in formalin; a sample of umbilical cord\nblood should be centrifuged, and the serum should be refrigerated or\nfrozen.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">www.cdc.gov.</div><div id=\"graphicVersion\">Graphic 81650 Version 1.0</div></div></div>"},"81651":{"type":"graphic_picture","displayName":"Chalazion","title":"Chalazion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chalazion</div><div class=\"cntnt\"><img style=\"width:389px; height:260px;\" src=\"images/PC/81651_Chalazion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">With permission from Slomovits TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 81651 Version 3.0</div></div></div>"},"81654":{"type":"graphic_table","displayName":"Causes of thrombocytopenia HIV","title":"Common causes of secondary thrombocytopenia in HIV-infected patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of secondary thrombocytopenia in HIV-infected patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\">Bacteremia/sepsis</td> </tr> <tr> <td class=\"indent1\">Bartonellosis</td> </tr> <tr> <td class=\"indent1\">Ehrlichiosis</td> </tr> <tr> <td class=\"subtitle2_single\">Parasitic</td> </tr> <tr> <td class=\"indent1\">Toxoplasma</td> </tr> <tr> <td class=\"indent1\">Babesia</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis</td> </tr> <tr> <td class=\"subtitle2_single\">Mycobacterial</td> </tr> <tr> <td class=\"indent1\">Disseminated tuberculosis</td> </tr> <tr> <td class=\"indent1\">Disseminated mycobacterium avium-complex</td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> </tr> <tr> <td class=\"indent1\">HIV</td> </tr> <tr> <td class=\"indent1\">Rubella</td> </tr> <tr> <td class=\"indent1\">HHV-8, with associated multicentric Castleman's disease</td> </tr> <tr> <td class=\"subtitle2_single\">Fungal</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis</td> </tr> <tr> <td class=\"indent1\">Coccidioidomycosis</td> </tr> <tr> <td class=\"indent1\">Other disseminated fungal infections</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td>Kaposi's sarcoma</td> </tr> <tr> <td>Metastatic adenocarcinomas</td> </tr> <tr> <td>Non-Hodgkin's lymphoma</td> </tr> <tr> <td>Chemotherapy-associated thrombocytopenia</td> </tr> <tr> <td>Hodgkin's lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td>Ketoconazole</td> </tr> <tr> <td>Trimetrexate</td> </tr> <tr> <td>Ganciclovir<span class=\"sublist1_start\"></span></td> </tr> <tr> <td>Pyrimethamine</td> </tr> <tr> <td>Foscarnet</td> </tr> <tr> <td>Flucytosine</td> </tr> <tr> <td>Cidofovir</td> </tr> <tr> <td>Pentamidine</td> </tr> <tr> <td>Acyclovir</td> </tr> <tr> <td>Pyrazinamide</td> </tr> <tr> <td>Interferon</td> </tr> <tr> <td>Rifampin</td> </tr> <tr> <td>Chemotherapeutic agents, heparin</td> </tr> <tr> <td>Rifabutin</td> </tr> <tr> <td>Valganciclovir</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary hypersplenism</td> </tr> <tr> <td>Chronic viral hepatitis/cirrhosis</td> </tr> <tr> <td>Other causes of hepatitis/cirrhosis</td> </tr> <tr> <td class=\"subtitle1_single\">Thrombotic microangiopathy (TMA)</td> </tr> <tr> <td>Thrombotic thrombocytopenic purpura (TTP)</td> </tr> <tr> <td>Hemolytic uremic syndrome (HUS)</td> </tr> <tr> <td>Drug-induced thrombotic microangiopathy (DITMA)</td> </tr> <tr> <td class=\"subtitle1_single\">Disseminated intravascular coagulation (DIC)</td> </tr> <tr> <td class=\"subtitle1_single\">Hemophagocytic lymphohistiocytosis (HLH)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on hematologic manifestations of HIV for details.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; HHV-8: human herpesvirus 8.</div><div id=\"graphicVersion\">Graphic 81654 Version 4.0</div></div></div>"},"81655":{"type":"graphic_table","displayName":"Air embolism lab findings","title":"Laboratory findings associated with air emboli","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings associated with air emboli</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Electrocardiographic changes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sinus tachycardia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Right heart strain (peaked P-wave)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Non-specific ST-segment and T-wave changes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute myocardial ischemia or infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Radiographic findings</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Normal (most common finding)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary edema</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Other findings rarely reported include:</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Air in the main pulmonary artery*</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Focal oligemia (especially upper lobes)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Pulmonary artery enlargement</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Atelectasis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Intracardiac air</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Air in the hepatic circulation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Arterial blood gas abnormalities</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypoxemia (may be severe)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypercarbia (increased dead space)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Hemodynamic changes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Increase in central venous pressure</td>\n\n    </tr>\n\n    <tr>\n      <td>Increase in pulmonary artery pressures </td>\n    </tr>\n    <tr>\n      <td>Increase in right ventricular pressure</td>\n    </tr>\n    <tr>\n      <td>Fall in cardiac output</td>\n    </tr>\n    <tr>\n      <td>Fall in mean arterial pressure</td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_single\">Serological findings</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fall in platelet count</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Although this finding is only rarely reported, it is pathognomonic for air embolism.</div><div id=\"graphicVersion\">Graphic 81655 Version 1.0</div></div></div>"},"81656":{"type":"graphic_picture","displayName":"Female LGV","title":"Female lymphogranuloma venereum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female lymphogranuloma venereum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/81656_Female_LGV.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81656 Version 3.0</div></div></div>"},"81657":{"type":"graphic_diagnosticimage","displayName":"Type 2 odontoid fracture","title":"Odontoid fracture type II","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Odontoid fracture type II</div><div class=\"cntnt\"><img style=\"width:508px; height:353px;\" src=\"images/EM/81657_Odontoid_fx_type2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type II odontoid fractures are the most common type and occur at the base of the odontoid process where it attaches to C2. They are considered unstable.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 81657 Version 3.0</div></div></div>"},"81658":{"type":"graphic_picture","displayName":"Shoulder axillary view","title":"Axillary view of shoulder","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Axillary view of shoulder</div><div class=\"cntnt\"><img style=\"width:531px; height:394px;\" src=\"images/EM/81658_Shoulder_axillary_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axillary view is taken with the radiograph plate placed on the patients shoulder and the x-ray beam projected through the axilla to the plate. The patient's arm need not be abducted 90°, as this position causes pain. About 10 to 15° of abduction, or just enough to get the x-ray tube between the patient's arm and hip, is usually sufficient.</div><div id=\"graphicVersion\">Graphic 81658 Version 5.0</div></div></div>"},"81659":{"type":"graphic_algorithm","displayName":"Hemodynamics in cirrhosis","title":"Pathogenic mechanisms responsible for the activation of vasoactive systems and hyperdynamic circulation in cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Pathogenic mechanisms responsible for the activation of vasoactive systems and hyperdynamic circulation in cirrhosis</div><div class=\"cntnt\"><img style=\"width:503px; height:644px;\" src=\"images/GAST/81659_Hemodynamics_cirrhosis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RES: reticuloendothelial system; DNA: deoxyribonucleic acid; NSAIDs: non-steroidal anti-inflammatory drugs;&nbsp;PGs:&nbsp;prostaglandins; NO: nitric oxide.</div><div id=\"graphicVersion\">Graphic 81659 Version 4.0</div></div></div>"},"81661":{"type":"graphic_diagnosticimage","displayName":"Penetrating duodenal ulcer on fluoroscopy","title":"Penetrating duodenal ulcer on fluoroscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penetrating duodenal ulcer on fluoroscopy</div><div class=\"cntnt\"><img style=\"width:366px; height:396px;\" src=\"images/SURG/81661_Duodenal_ulcer_UGI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Air contrast upper gastrointestinal series demonstrating an ulcer involving the duodenal bulb. The ulcer was found to penetrate into the pancreas (black arrow).</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 81661 Version 8.0</div></div></div>"},"81662":{"type":"graphic_table","displayName":"Medical history in children with chronic diarrhea","title":"Implications of some aspects of the medical history in children with chronic diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Implications of some aspects of the medical history in children with chronic diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Line of questioning</td> <td class=\"subtitle1\">Clinical implication</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Onset</td> </tr> <tr> <td class=\"sublist1\">Congenital</td> <td class=\"sublist_other\"><span class=\"sublist_other\" style=\"color: #000000;\">Congenital persistent diarrheas (eg, congenital chloride diarrhea, congenital sodium diarrhea, tufting enteropathy)</span></td> </tr> <tr> <td class=\"sublist1\">Abrupt</td> <td class=\"sublist_other\">Infections</td> </tr> <tr> <td class=\"sublist1\">Gradual</td> <td class=\"sublist_other\">Everything else</td> </tr> <tr> <td class=\"sublist1\">Coincides with introduction of wheat cereals</td> <td class=\"sublist_other\">Celiac disease</td> </tr> <tr> <td class=\"sublist1\">Coincides with introduction of a specific sugar or food&nbsp;</td> <td class=\"sublist_other\">Lactose intolerance, sucrase deficiency, or food protein-induced enteropathy/enteritis/proctocolitis* (eg, due to cow's milk)&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Stool characteristics</td> </tr> <tr> <td class=\"sublist1\">Daytime only</td> <td class=\"sublist_other\">Functional diarrhea (chronic nonspecific diarrhea of childhood)</td> </tr> <tr> <td class=\"sublist1\">Nocturnal</td> <td class=\"sublist_other\">Organic etiology</td> </tr> <tr> <td class=\"sublist1\">Blood&nbsp;</td> <td class=\"sublist_other\">Food protein-induced proctocolitis* (eg, due to cow's milk),&nbsp;or inflammatory bowel disease</td> </tr> <tr> <td class=\"sublist1\">White/light tan color</td> <td class=\"sublist_other\">Absence of bile; celiac disease</td> </tr> <tr> <td>Family history</td> <td class=\"sublist_other\">Congenital absorptive defects, inflammatory bowel disease, celiac disease, multiple endocrine neoplasia</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Dietary history</td> </tr> <tr> <td class=\"sublist1\">\"Sugar-free\" foods</td> <td class=\"sublist_other\">Fructose, sorbitol, or mannitol ingestion</td> </tr> <tr> <td class=\"sublist1\">Excessive juice</td> <td class=\"sublist_other\">Osmotic diarrhea/chronic nonspecific diarrhea</td> </tr> <tr> <td class=\"sublist1\"><span class=\"sublist1\" style=\"color: #000000;\">Milk or other&nbsp;sources of lactose&nbsp;</span></td> <td class=\"sublist_other\"><span class=\"sublist_other\" style=\"color: #000000;\">Possibility of&nbsp;lactose intolerance</span></td> </tr> <tr> <td class=\"sublist1\">Sucrose or starch in&nbsp;diet&nbsp;</td> <td class=\"sublist_other\">Possibility of sucrose deficiency</td> </tr> <tr> <td class=\"sublist1\">Any specific food trigger (especially milk, soy or eggs)&nbsp;</td> <td class=\"sublist_other\">Food allergy, including food protein-induced enteropathy, enteritis, or proctocolitis*&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Raw milk</td> <td class=\"sublist_other\">Brainerd diarrhea</td> </tr> <tr> <td class=\"sublist1\">Exposure to potentially impure water source</td> <td class=\"sublist_other\">Chronic bacterial infections (eg, aeromonas), giardiasis, cryptosporidiosis, Brainerd diarrhea</td> </tr> <tr> <td>Travel history</td> <td>Infectious diarrhea, chronic idiopathic secretory diarrhea</td> </tr> <tr> <td>Failure to thrive/weight loss</td> <td>Malabsorption, pancreatic exocrine insufficiency, anorexia nervosa</td> </tr> <tr> <td>Previous therapeutic interventions (drugs, radiation, surgery, antibiotics)</td> <td>Drug side effects, radiation enteritis, postsurgical status, pseudomembranous colitis (C. difficile), post-cholecystectomy diarrhea</td> </tr> <tr> <td>Secondary gain from illness</td> <td>Laxative abuse</td> </tr> <tr> <td>Systemic illness symptoms</td> <td>Hyperthyroidism, diabetes, inflammatory bowel disease, tuberculosis, mastocytosis</td> </tr> <tr> <td>Intravenous drug abuse, sexual promiscuity (in adolescent or in child's parent)</td> <td>HIV disease</td> </tr> <tr> <td>Immune problems</td> <td>HIV disease, immunoglobulin deficiencies</td> </tr> <tr> <td>Abdominal pain</td> <td>Obstruction, irritable bowel syndrome</td> </tr> <tr> <td>Excessive flatus</td> <td>Carbohydrate malabsorption</td> </tr> <tr> <td>Leakage of stool</td> <td>Fecal incontinence (consider occult constipation)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>C. difficile: Clostridium difficile; IgE: Immunoglobulin E.<br />* The term, \"food protein-induced proctocolitis/enteritis\"&nbsp;is now preferred. Previously used terms (eg, milk protein intolerance, cow's milk sensitivity, and soy intolerance) are no longer recommended. The new terminology helps to distinguish the non-IgE-mediated disorders from classical food allergies/hypersensitivities that are mediated by IgE. It also distinguishes them from food intolerances that do not involve immunologic mechanisms (eg, lactose intolerance).&nbsp;&nbsp;</FONT> </div><div class=\"graphic_reference\">Adapted with permission from: Fine, KD, Schiller, LR, AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.</div><div id=\"graphicVersion\">Graphic 81662 Version 8.0</div></div></div>"},"81663":{"type":"graphic_figure","displayName":"Quantitative real time PCR","title":"Quantitative real-time polymerase chain reaction (PCR)","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Quantitative real-time polymerase chain reaction (PCR)</div><div class=\"cntnt\"><img style=\"width:457px; height:462px;\" src=\"images/PC/81663_Quantitative_real_time_PCR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mechanism of quantitative real-time PCR, which is based upon a probe that contains a fluorogenic reporter dye at its 5' end and a quencher at the 3' end (shown as a black line with a white box and a Q at its 5' and 3' end, respectively). With this technique, the tagged probe, which is designed to hybridize to one strand of the target DNA sequence (blue line), is added to a normal PCR. The quencher blocks fluorescence emission as long as it is in close proximity to the reporter. As the primer extends downstream during amplification (extended green arrow), the exonuclease activity of the DNA polymerase cleaves away the hybridized probe and removes the connection between the&nbsp;fluorescent dye (black box) and the quencher (Q). An increase in fluorescence signal ensues as more amplicons are generated.</div><div class=\"graphic_footnotes\">Q: quencher.</div><div id=\"graphicVersion\">Graphic 81663 Version 3.0</div></div></div>"},"81664":{"type":"graphic_figure","displayName":"Anatomy of the visceral pleura","title":"Anatomy of the visceral pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the visceral pleura</div><div class=\"cntnt\"><img style=\"width:237px; height:360px;\" src=\"images/PULM/81664_Anatomy_of_the_visceral_ple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The visceral pleura (VP) of the sheep, an animal with similar pleural anatomy to humans. The visceral pleura lies between the pleural space (PS) and the alveoli (Alv). It is approximately 20 to 80 &#181;m thick and consists of a single mesothelial layer (M) and a subpleural connective tissue layer. The subpleural connective tissue layer contains both collagen and elastin as well as the bronchial arteries (A, which drain into pulmonary veins) and subpleural lymphatics (which do not connect to the pleural space). The bronchial microvessels and lymphatics are relatively far from the pleural space (20 to 50 &#181;m versus 10 to 12 &#181;m in the parietal pleura).</div><div class=\"graphic_reference\">Staub, NC, Wiener-Kronish, JP, Albertine, KH, in: The Pleural in Health and Disease, Chretien, J, Bignon, J, Hirsch, A (Eds), Marcel Dekker, New York, 1985, by courtesy of Marcel Dekker, Inc.</div><div id=\"graphicVersion\">Graphic 81664 Version 1.0</div></div></div>"},"81665":{"type":"graphic_table","displayName":"TNM stage mesothelioma","title":"TNM staging system for diffuse malignant pleural mesothelioma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging system for diffuse malignant pleural mesothelioma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr> <td>TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"sublist1_start\">T1</td> <td class=\"sublist_other_start\" colspan=\"3\">Tumor limited to the ipsilateral parietal pleura with or without mediastinal pleura and with or without diaphragmatic pleural involvement</td> </tr> <tr> <td class=\"sublist1\">T1a</td> <td class=\"sublist_other\" colspan=\"3\">No involvement of the visceral pleura</td> </tr> <tr> <td class=\"sublist1\">T1b</td> <td class=\"sublist_other\" colspan=\"3\">Tumor also involving the visceral pleura</td> </tr> <tr> <td rowspan=\"3\">T2</td> <td class=\"sublist1_start\" colspan=\"3\">Tumor involving each of the ipsilateral pleural surface (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Involvement of diaphragmatic muscle</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Extension of tumor from visceral pleura into the underlying pulmonary parenchyma</td> </tr> <tr> <td rowspan=\"6\">T3</td> <td colspan=\"3\">Locally advanced but potentially resectable tumor</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Involvement of the endothoracic fascia</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Extension into the mediastinal fat</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Nontransmural involvement of the pericardium</td> </tr> <tr> <td rowspan=\"8\">T4</td> <td colspan=\"3\">Locally advanced technically unresectable tumor</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Direct transdiaphragmatic extension of tumor to the peritoneum</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Direct extension of tumor to the contralateral pleura</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Direct extension of tumor to mediastinal organs</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Direct extension of tumor into the spine</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Tumor extending through to the internal surface of the pericardium with or without a pericardial effusion or tumor involving the myocardium</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr> <td>NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td>N0</td> <td colspan=\"3\">No regional lymph node metastases</td> </tr> <tr> <td>N1</td> <td colspan=\"3\">Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes</td> </tr> <tr> <td>N2</td> <td colspan=\"3\">Metastases in the subcarinal or the ipsilateral mediastinal lymph nodes including the ipsilateral internal mammary and peridiaphragmatic nodes</td> </tr> <tr> <td>N3</td> <td colspan=\"3\">Metastases in the contralateral mediastinal, contralateral internal mammary, ipsilateral or contralateral supraclavicular lymph nodes</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr> <td>M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td>MI</td> <td colspan=\"3\">Distant metastasis present</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Anatomic stage/prognostic groups</td> </tr> <tr> <td>Stage I</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IA</td> <td>T1a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IB</td> <td>T1b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage II</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage III</td> <td>T1, T2</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T1, T2</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N0, N1, N2</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage IV</td> <td>T4</td> <td>Any N</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>N3</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">4/1/2010--These are in the AJCC folder and should be renewed annually for the life of the 7th Edition; this has been paid for 2010 (JD). The total fee of $&amp;quot;160.00&amp;quot;was originally charged to TNM_staging_adrenal_CA TNM_staging_ampullary_CA anal_cancer_TNM_stage anal_cancer_stage_group Anal_outcome_hist_AJCC TNM_stage_append_CA TNM_stage_append_carcinoid Surv_rates_appendix_CA TNM_staging_bone_tumors TNM_stage_breast_cancer Breast_reg_lymph_nodes 2002_TNM_breast_cancer Staging_cervical_cancer TNM_staging_colorec_CA CRC_tumor_regression_grade SEER_surv_adeno_colon SEER_surv_adeno_rectum Reg_nodes_colorec_CA CRC_resection_margin Staging_uterine_carcinoma Staging_uterine_sarcoma TNM_distal_cholangio TNM_staging_esoph_SCC TNM_staging_esoph_EGJ_adenoCA Esoph_CA_site T_stage_esophageal_cancer Staging_fallopian_cancer TNM_staging_gallbladder_CA OS_gallbladder_CA TNM_staging_GIST Dis_prog_gastric_GIST Dis_prog_small_int_GIST Staging_gest_trop_neoplas TNM_stage_hypopharynx TNM_small_bowel_cancer TNM_intrahep_cholangio SEER_surv_intrahep_cholang TNM_staging_RCC TNM_stage_larynx TNM_stage_oral_cavity TNM_staging_HCC 7th_TNM_lung_stage system Lung_CA staging_6th_TNM 7th_TNM_lung_CA_changes TNM_path_staging_mel_conj TNM_clin_staging_mel_conj Melanoma_7thTNM_stage_group Melanoma_7th_TNM_staging TNM_staging_muc_melanoma_HN Muc_melanoma_HN_stage_group Ciliary_choroid_thickness TNM_stage_uveal_melanoma TNM_stage_Merkel_cell_CA TNM_stage_sinonasal_sites TNM_stage_nasopharynx TNM_stage_gastric_carcinoid TNM_gastrointest_carcinoid TNM_amp_sm_bowel_carcinoid TNM_staging_CRC_carcinoid Surv_rates_GI_neuroendo Staging_ovar_prim_perit_ca TNM_panc_endo_exo_CA NCDB_no_surg_surv_panc NCDB_surg_surv_panc Prog_panc_neuroendo_tum TNM_staging_penile_cancer TNM_perihilar_cholangio TNM_stage_oropharynx TNM_stage_mesothelioma TNM_staging_prostate_CA TNM_group_prostate_CA TNM_staging_renal_pelvis TNM_stage_salivary_glands TNM_stage_sarcoma_orbit TNM_staging_soft_tis_sarc 2010_TNM_staging_STS TNM_stage_cutan_SCC 2010_TNM_staging_stomach_CA SEER_survival_gast_CA TMN_staging_testicular_CA Stage_group_testicular_CA TNM_staging_thyroid_cancer Urethral_CA_TNM_women TNM_stage_group_urethra Urethral_CA_TNM_men TNM_staging_bladder_CA Staging_vaginal_cancer Staging_vulvar_cancer</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=69427&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 81665 Version 13.0</div></div></div>"},"81666":{"type":"graphic_table","displayName":"LOS and inhalation injury","title":"Mean length of hospital stay based on age and associated inhalation injury with burn","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mean length of hospital stay based on age and associated inhalation injury with burn</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Age group\n   </td>\n   <td  class=\"subtitle1\">\n   Mean LOS* burn only\n   </td>\n   <td  class=\"subtitle1\">\n   Mean LOS burn with inhalation injury\n   </td>\n   </tr>\n   <tr>\n   <td>0 - 0.9</td>\n   <td>5.8</td>\n   <td>28.1</td>\n   </tr>\n   <tr>\n   <td>1.0 - 1.9</td>\n   <td>5.1</td>\n   <td>33.7</td>\n   </tr>\n   <tr>\n   <td>2.0 - 4.9</td>\n   <td>6.9</td>\n   <td>31.4</td>\n   </tr>\n   <tr>\n   <td>5.0 - 15.9</td>\n   <td>7.7</td>\n   <td>32.8</td>\n   </tr>\n   <tr>\n   <td>16.0 - 19.9</td>\n   <td>6.8</td>\n   <td>25.1</td>\n   </tr>\n   <tr>\n   <td>20.0 - 29.9</td>\n   <td>7.6</td>\n   <td>26.1</td>\n   </tr>\n   <tr>\n   <td>30.0 - 39.9</td>\n   <td>7.9</td>\n   <td>25.6</td>\n   </tr>\n   <tr>\n   <td>40.0 - 49.9</td>\n   <td>9.0</td>\n   <td>25.8</td>\n   </tr>\n   <tr>\n   <td>50.0 - 59.9</td>\n   <td>10.4</td>\n   <td>25.4</td>\n   </tr>\n   <tr>\n   <td>60.0 - 69.9</td>\n   <td>12.2</td>\n   <td>22.9</td>\n   </tr>\n   <tr>\n   <td>70.0 - 79.9</td>\n   <td>14.4</td>\n   <td>19.6</td>\n   </tr>\n   <tr>\n   <td>80+</td>\n   <td>14.2</td>\n   <td>18.6</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">* LOS: length of hospital stay in days.</div><div class=\"graphic_reference\">Data from: American Burn Association. National Burn Repository, Version 5.0 2009. Available online at: www.ameriburn.org/2009NBRAnnualReport.pdf</div><div id=\"graphicVersion\">Graphic 81666 Version 1.0</div></div></div>"},"81667":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa wound healed","title":"Hidradenitis suppurativa wound healed","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa wound healed</div><div class=\"cntnt\"><img style=\"width:504px; height:264px;\" src=\"images/SURG/81667_Fourweekslater.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the healed wound following unroofing of an inflamed nodule and multiple sinus tracts in a patient with extensive hidradenitis suppurativa of the groin. The wound healed in four weeks, dressed with petrolatum only. In order to avoid damage to the reepithelialization process, no gauze or other dressings were used.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 81667 Version 6.0</div></div></div>"},"81669":{"type":"graphic_diagnosticimage","displayName":"Anterior temporal lobe CADASIL","title":"Anterior temporal lobe involvement in CADASIL","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anterior temporal lobe involvement in CADASIL</div><div class=\"cntnt\"><img style=\"width:542px; height:432px;\" src=\"images/NEURO/81669_Anterior_temporal_lobe_CADA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI of a 46-year-old male with CADASIL and skin biopsy positive for granular osmiophilic material. There is hyperintensity in the periventricular and subcortical white matter on T2-weighted (A) and FLAIR (B) sequences, a nonspecific pattern that may be seen with other small vessel ischemic disease processes. In addition, there is increased signal intensity in the anterior temporal lobe white matter on T2-weighted (D) and FLAIR (E) sequences, a finding that may be more specific for CADASIL. Additional findings include a right periventricular lacunar infarction of CSF signal intensity (A, B, C) and involvement of the pons (D, E).</div><div class=\"graphic_footnotes\"><FONT id=footnote data-bind=\"template: 'footnoteTemplate'\"><FONT jQuery1479418628734=\"3402\">CADASIL: cerebral&nbsp;autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery.</FONT></FONT><IMG id=edit-footnote class=edit-rich-text style=\"DISPLAY: none\" alt=\"Edit Footnote\" src=\"http://editorial00p/images/pencil.png\" jQuery1479418628734=\"2624\"></div><div class=\"graphic_reference\">Images courtesy of Eric Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 81669 Version 3.0</div></div></div>"},"81670":{"type":"graphic_figure","displayName":"LLETZ procedure","title":"Large loop excision of the transformation zone of the uterine cervix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large loop excision of the transformation zone of the uterine cervix</div><div class=\"cntnt\"><img style=\"width:398px; height:316px;\" src=\"images/OBGYN/81670_LLETZ_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 81670 Version 2.0</div></div></div>"},"81673":{"type":"graphic_table","displayName":"Pretreat risk stratify prost CA","title":"Pretreatment risk stratification for prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pretreatment risk stratification for prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk group</td> <td class=\"subtitle1\">Clinical stage</td> <td class=\"subtitle1\">Gleason score</td> <td class=\"subtitle1\">Serum PSA</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Standard risk groups</td> </tr> <tr> <td class=\"indent1\">Low-risk</td> <td>T1c-T2a</td> <td>&#8804;6</td> <td>&#60;10 ng/mL</td> </tr> <tr> <td class=\"indent1\">Intermediate-risk</td> <td>T2b</td> <td>7</td> <td>10 to 20 ng/mL</td> </tr> <tr> <td class=\"indent1\">High-risk</td> <td>T2c</td> <td>8 to 10</td> <td>&#62;20 ng/mL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Risk groupings used by Memorial Sloan-Kettering and Seattle groups<sup>[1,2]</sup></td> </tr> <tr> <td class=\"indent1\">Low-risk</td> <td>&#8804;T2a</td> <td>&#8804;6</td> <td>&#60;10 ng/mL</td> </tr> <tr> <td class=\"indent1\">Intermediate-risk</td> <td colspan=\"3\">One elevated risk factor:<br /> Clinical stage &#8805;T2a disease, Gleason score &#8805;7, PSA &#8805;10 ng/mL</td> </tr> <tr> <td class=\"indent1\">High-risk</td> <td colspan=\"3\">Two elevated risk factors</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PSA: prostate-specific antigen; T1c: tumor identified by needle biopsy (eg, because of elevated PSA); T2a: tumor involves one-half of one lobe or less; T2b: tumor involves more than one-half of one lobe but not both lobes; T2c: tumor involving both lobes.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Zelefsky M, et al. Int J Radiat Oncol Biol Phys 2000; 47:1261.</li>&#xD;&#xA;    <li>Blasko J, et al. Int J Radiat Oncol Biol Phys 2000; 48:111.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 81673 Version 4.0</div></div></div>"},"81674":{"type":"graphic_algorithm","displayName":"Blunt chest trauma in adults algorithm","title":"Blunt chest trauma in adults ED management algorithm","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Blunt chest trauma in adults ED management algorithm</div><div class=\"cntnt\"><img style=\"width:594px; height:606px;\" src=\"images/EM/81674_Blunt_chest_trauma_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AP: anterior-posterior; CT: computed tomography; CXR: chest x-ray; ECG: electrocardiogram; ED: emergency department; FAST: Focused Assessment with Sonography in Trauma; OR: operating room; PA: posterior-anterior; PTX: pneumothorax; TEE: transesophageal echocardiography; US: ultrasound.<br />* This algorithm is a general guide; sophisticated imaging may not be necessary in all circumstances.</div><div id=\"graphicVersion\">Graphic 81674 Version 3.0</div></div></div>"},"81675":{"type":"graphic_table","displayName":"Ratings scales in the assessment and monitoring of ADHD","title":"Ratings scales in the assessment and monitoring of ADHD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ratings scales in the assessment and monitoring of ADHD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Scales</td> <td class=\"subtitle1\">Behaviors assessed</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Broadband assessment</td> </tr> <tr> <td class=\"indent1\">Conners 3<sup>rd</sup> Edition<sup>[1]</sup></td> <td>Inattention, hyperactivity/impulsivity, learning problems, executive functioning, aggression, peer relations, DSM-IV symptoms scales for inattentive, hyperactive-impulsive and combined type of ADHD (DSM-5 scoring is also available as a supplement), ODD, conduct disorder</td> </tr> <tr> <td class=\"indent1\">Behavior Assessment System for Children (BASC)<sup>[2]</sup></td> <td>Hyperactivity, aggression, conduct problems, anxiety, depression, somatization, atypicality, withdrawal, attention problems, learning problems, lack of adaptability/social/leadership/study skills</td> </tr> <tr> <td class=\"indent1\">Child Behavior Checklist/Teacher Report Form<sup>[3,4]</sup></td> <td>Somatic complaints, social/thought/attention problems, anxiety/depression, aggressive/delinquent behavior, withdrawal</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Narrow-band assessment</td> </tr> <tr> <td class=\"indent1\">ADHD Comprehensive Teacher's Rating Scale (ACTeRS): Boys' and girls' form<sup>[5]</sup></td> <td>Attention problems, hyperactivity, lack of social skills, oppositional</td> </tr> <tr> <td class=\"indent1\">ADHD Rating Scale<sup>[6]</sup></td> <td>Symptoms of ADHD according to DSM-IV criteria</td> </tr> <tr> <td class=\"indent1\">Childhood Attention Problems Scale<sup>[7]</sup></td> <td>Combined measure of attention problems, impulsivity, hyperactivity</td> </tr> <tr> <td class=\"indent1\">Conners 3<sup>rd</sup> Edition: Short version<sup>[1]</sup></td> <td>Selected items from the long version to measure inattention, hyperactivity/impulsivity, learning problems, executive function, aggression, and peer relations </td> </tr> <tr> <td class=\"indent1\">BASC Monitor Rating Scale<sup>[8]</sup></td> <td>Attention/adaptive problems, hyperactivity, problems with internalizing</td> </tr> <tr> <td class=\"indent1\">Disruptive Behavior Rating Scale<sup>[9]</sup></td> <td>DSM-IV symptoms of ODD, ADHD, and CD (parent form only)</td> </tr> <tr> <td class=\"indent1\">Vanderbilt Assessment Scales<sup>[10,11]</sup></td> <td>Symptoms of ADHD according to DSM-IV criteria; screen for comorbid conditions (ODD, CD, anxiety, depression)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Assessment of medication side effects</td> </tr> <tr> <td class=\"indent1\">Side Effects Rating Scale<sup>[9]</sup></td> <td>Sleeping/appetite problems, staring/daydreaming, withdrawal, anxiety, irritability, somatic complaints, emotional lability, dizziness, tics</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADHD: attention-deficit hyperactivity disorder; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, fifth edition; ODD: oppositional-defiant disorder; CD: conduct disorder.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Conners CK. Conners 3<SUP>rd</SUP> Edition. Toronto, Multi-Health Systems, Inc., 2008. </LI>&#xD;&#xA;<LI>Reynolds CF, Kamphaus RW. Behavior Assessment System for Children-Second Edition. Minneapolis, MN, NC Pearson, Inc., 2004. </LI>&#xD;&#xA;<LI>Achenbach TM. Manual for the Child Behavior Checklist. University of Vermont, Department of Psychiatry, Burlington, 1991. </LI>&#xD;&#xA;<LI>Achenbach TM. Manual for the Teachers Report Form. University of Vermont, Department of Psychiatry, Burlington, 1991. </LI>&#xD;&#xA;<LI>Ullmann RK, Sleator EK, Sprague RL. A new rating scale for diagnosis and monitoring of ADD children. Psychopharmacol Bull 1984; 20:160. </LI>&#xD;&#xA;<LI>DuPaul GJ. Parent and teacher ratings of ADHD symptoms: Psychometric properties in a community based sample. J Clin Child Psychol 1991; 20:242. </LI>&#xD;&#xA;<LI>Edelbrock C. Child Attention Problems Scale (unpublished manuscript). Penn State University, University Park, 1978. </LI>&#xD;&#xA;<LI>Kamphaus RW, Reynolds CR. BASC Monitor for ADHD: Manual and Software Guide. American Guidance Service, Circle Pine, MN 1998. </LI>&#xD;&#xA;<LI>Barkley RA, Murphy KR. Attention Deficit Hyperactivity Disorder: A Clinical Workbook. Guilford Press, New York 1998. </LI>&#xD;&#xA;<LI>Wolraich ML, Feurer ID, Hannah JN, et al. Obtaining systematic teacher reports of disruptive behaviors utilizing DSM-IV. J Abnorm Child Psychol 1998; 26:141. </LI>&#xD;&#xA;<LI>Wolraich ML, Lambert W, Doffing MA, et al. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol 2003; 28:559. </LI></OL></div><div id=\"graphicVersion\">Graphic 81675 Version 7.0</div></div></div>"},"81676":{"type":"graphic_diagnosticimage","displayName":"MRI of Grade II medial collateral ligament injury","title":"MRI of Grade II medial collateral ligament injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of Grade&nbsp;II medial collateral ligament injury</div><div class=\"cntnt\"><img style=\"width:380px; height:372px;\" src=\"images/EM/81676_MCL_grade2_injury_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This MRI image reveals a partial tear, with high signal edema (arrowheads) seen both superficial and deep to the medial collateral ligament fibers.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 81676 Version 4.0</div></div></div>"},"81677":{"type":"graphic_figure","displayName":"Mutations in TSH cascade","title":"TSH receptor and G<sub>s</sub>-alpha are oncogenes in toxic thyroid nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TSH receptor and G<sub>s</sub>-alpha are oncogenes in toxic thyroid nodules</div><div class=\"cntnt\"><img style=\"width:433px; height:279px;\" src=\"images/ENDO/81677_Mutations_in_TSH_cascade.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; Gs-alpha: the alpha subunit of the guanyl nucleotide stimulatory protein; TSHR: TSH&nbsp;receptor; GTP: guanosine triphosphate; AC: adenyl cyclase; ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate; GDP: guanosine diphosphate; P: phosphate;&nbsp;T4: thyroxine; T3: triiodothyronine.</div><div id=\"graphicVersion\">Graphic 81677 Version 3.0</div></div></div>"},"81678":{"type":"graphic_picture","displayName":"Giant urticaria","title":"Giant urticaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant urticaria</div><div class=\"cntnt\"><img style=\"width:248px; height:360px;\" src=\"images/ID/81678_Giant_urticaria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Very large erythematous annular lesion of the shoulder with central clearing. This patient had several large lesions of this type, which could be confused with erythema migrans.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 81678 Version 4.0</div></div></div>"},"81680":{"type":"graphic_diagnosticimage","displayName":"NSCLC malig pl eff","title":"Malignant pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant pleural effusion</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/PULM/81680_NSCLC_malig_pl_eff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large pleural effusion in a 60-year-old man cytologically positive for adenocarcinoma consistent with lung primary.</div><div id=\"graphicVersion\">Graphic 81680 Version 2.0</div></div></div>"},"81682":{"type":"graphic_picture","displayName":"Stye PI","title":"Stye","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stye</div><div class=\"cntnt\"><img style=\"width:432px; height:310px;\" src=\"images/PI/81682_Stye_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This person has a stye in the middle of the lower eyelid.</div><div id=\"graphicVersion\">Graphic 81682 Version 1.0</div></div></div>"},"81683":{"type":"graphic_figure","displayName":"Flow cytometric analysis for WAS","title":"Flow cytometric analysis for Wiskott-Aldrich syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow cytometric analysis for Wiskott-Aldrich syndrome</div><div class=\"cntnt\"><img style=\"width:442px; height:464px;\" src=\"images/ALLRG/81683_Flow_cytometr_analy_WAS_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood mononuclear cells were stained with antibodies to Wiskott-Aldrich syndrome protein (WASP).</div><div id=\"graphicVersion\">Graphic 81683 Version 1.0</div></div></div>"},"81684":{"type":"graphic_table","displayName":"Incidence of maternal thrombocytopenia","title":"Incidence of maternal thrombocytopenia in 15,471 consecutive women admitted for labor and delivery, 1986-1992","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of maternal thrombocytopenia in 15,471 consecutive women admitted for labor and delivery, 1986-1992</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mother's health status<br /> (percent of all 15,471 women)</td> <td class=\"subtitle1\">Maternal platelet count &#60;150,000/microL<br /> (percent)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Normal - 13,925 (90%)</strong></td> <td><strong>756 (5%)</strong>*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"small highlight_gray_text\" style=\"line-height: 1em;\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td>Preeclampsia - 1414 (9%)</td> <td>216 (15%)</td> </tr> <tr> <td>ITP - 46 (0.3%)</td> <td>31 (67%)</td> </tr> <tr> <td>Systemic lupus erythematosus - 55 (0.4%)</td> <td>8 (15%)</td> </tr> <tr> <td>At risk for neonatal alloimmune thrombocytopenia<sup>&#182;</sup> - 18 (0.1%)</td> <td>3 (17%)</td> </tr> <tr> <td>Other hematologic and medical disorders<sup>&#916;</sup> - 13 (0.1%)<sup>&#916;</sup></td> <td>13 (100%)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topic on thrombocytopenia in pregnancy for further discussion.</div><div class=\"graphic_footnotes\">* These women most likely had gestational thrombocytopenia (GT). Two-thirds of them had platelet counts of 130,000 to 150,000/microL.<br />¶ These women had maternal-paternal platelet alloantigen mismatch diagnosed because of a previous thrombocytopenic fetus (15 women) or were sisters of women who had infants with alloimmune thrombocytopenia.<br />Δ The other hematologic or medical disorders were not further specified.</div><div class=\"graphic_reference\">Data from: Burrows RF, Kelton JG, N Engl J Med 1993; 329:1463.</div><div id=\"graphicVersion\">Graphic 81684 Version 5.0</div></div></div>"},"81685":{"type":"graphic_diagnosticimage","displayName":"Adenoid cystic carcinoma CXR","title":"Adenoid cystic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adenoid cystic carcinoma</div><div class=\"cntnt\"><img style=\"width:320px; height:322px;\" src=\"images/PULM/81685_Adenoid_cystic_carcinoma_CX.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of the neck shows a posterior cervical tracheal wall lesion. The patient had been treated for atypical asthma.</div><div id=\"graphicVersion\">Graphic 81685 Version 2.0</div></div></div>"},"81686":{"type":"graphic_table","displayName":"Mediators of HPS","title":"Proposed mediators of the hepatopulmonary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed mediators of the hepatopulmonary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Vasodilators</td> </tr> <tr> <td>Vasodilator prostaglandins</td> </tr> <tr> <td>Prostacyclin</td> </tr> <tr> <td>PGE1</td> </tr> <tr> <td>PGI2</td> </tr> <tr> <td>Vasoactive intestinal peptide (VIP)</td> </tr> <tr> <td>Calcitonin</td> </tr> <tr> <td>Glucagon</td> </tr> <tr> <td>Substance P</td> </tr> <tr> <td>Nitric oxide</td> </tr> <tr> <td>Atrial naturetic factor</td> </tr> <tr> <td>Platelet activating factor</td> </tr> <tr> <td>Ferritin</td> </tr> <tr> <td>Estrogens</td> </tr> <tr> <td>Carbon monoxide</td> </tr> <tr> <td class=\"subtitle1_single\">Vasoconstrictors</td> </tr> <tr> <td>Tyrosine</td> </tr> <tr> <td>Serotonin</td> </tr> <tr> <td>Endothelin</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:&nbsp;Krowka MJ, Cortese DA. Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. Hepatology 1990; 11:138.</div><div id=\"graphicVersion\">Graphic 81686 Version 2.0</div></div></div>"},"81687":{"type":"graphic_table","displayName":"Aeroallergen SCIT – One-day schedule","title":"Aeroallergen subcutaneous immunotherapy (SCIT) – One-day schedule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aeroallergen subcutaneous immunotherapy (SCIT) – One-day schedule</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time (minutes)</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Dilution</td> <td class=\"subtitle1\">Color vial</td> </tr> <tr> <td>0</td> <td>0.30</td> <td>1:1000</td> <td>Green</td> </tr> <tr> <td>30</td> <td>0.10</td> <td>1:100</td> <td>Blue</td> </tr> <tr> <td>60</td> <td>0.30</td> <td>1:100</td> <td>Blue</td> </tr> <tr> <td>90</td> <td>0.05</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>120</td> <td>0.15</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>180</td> <td>0.30</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>240</td> <td>0.05</td> <td>1:1</td> <td>Red</td> </tr> <tr> <td>300</td> <td>0.10</td> <td>1:1</td> <td>Red</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Sharkey P, Portnoy J. Rush immunotherapy: Experience with a one-day schedule. Ann Allergy Asthma Immunol 1996; 76:175.</div><div id=\"graphicVersion\">Graphic 81687 Version 4.0</div></div></div>"},"81690":{"type":"graphic_waveform","displayName":"ECG RMVT from LVOT","title":"12-lead electrocardiogram (ECG) recorded in a patient with repetitive monomorphic ventricular tachycardia (RMVT) arising from the left ventricular outflow tract (LVOT)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) recorded in a patient with repetitive monomorphic ventricular tachycardia (RMVT) arising from the left ventricular outflow tract (LVOT)</div><div class=\"cntnt\"><img style=\"width:504px; height:310px;\" src=\"images/CARD/81690_RMVT_from_LVOT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This electrocardiogram (ECG) illustrates repetitive monomorphic ventricular tachycardia (RMVT) with a right bundle, inferior axis morphology signifying its left ventricular site of origin. This VT was localized to the area of the aorto-mitral continuity in the left ventricular outflow tract (LVOT).</div><div id=\"graphicVersion\">Graphic 81690 Version 3.0</div></div></div>"},"81691":{"type":"graphic_figure","displayName":"FTT growth trajectory","title":"Typical growth trajectory in children with undernutrition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical growth trajectory in children with undernutrition</div><div class=\"cntnt\"><img style=\"width:405px; height:537px;\" src=\"images/PEDS/81691_FTTgrowthtrajectory.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The typical growth trajectory for children with undernutrition demonstrates normal growth parameters at birth, followed by deceleration in weight (as depicted above) and finally deceleration in length.</div><div class=\"graphic_reference\">Data from: The National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000). Available at www.cdc.gov/growthcharts.</div><div id=\"graphicVersion\">Graphic 81691 Version 2.0</div></div></div>"},"81692":{"type":"graphic_picture","displayName":"Tophus of the knee","title":"Tophus of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tophus of the knee</div><div class=\"cntnt\"><img style=\"width:340px; height:274px;\" src=\"images/RHEUM/81692_Tophusoftheknee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large tophus and multiple superficial tophi of the knee in patient with uncontrolled gout.</div><div class=\"graphic_reference\">Courtesy of Peter H Schur, MD.</div><div id=\"graphicVersion\">Graphic 81692 Version 3.0</div></div></div>"},"81693":{"type":"graphic_picture","displayName":"Acanthosis nigricans - close view","title":"Acanthosis nigricans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acanthosis nigricans</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81693_Acanthosis_nigricans_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Close view of acanthosis nigricans on the posterior neck. Hyperpigmented velvety plaques are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81693 Version 3.0</div></div></div>"},"81694":{"type":"graphic_diagnosticimage","displayName":"CT Grade V renal injury","title":"CT of Grade V renal injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of Grade V renal injury</div><div class=\"cntnt\"><img style=\"width:432px; height:334px;\" src=\"images/EM/81694_Renal_injury_V_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This CT image demonstrates severe injury to the right kidney, which is surrounded by a large amount of blood (arrow). In contrast, the left kidney fills uniformly with IV dye and shows no obvious sign of injury (arrow-head).</div><div class=\"graphic_reference\">Courtesy of Michael S Runyon, MD, FAAEM.</div><div id=\"graphicVersion\">Graphic 81694 Version 2.0</div></div></div>"},"81695":{"type":"graphic_diagnosticimage","displayName":"Endo MFP","title":"Ultrasonography of the uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasonography of the uterus</div><div class=\"cntnt\"><img style=\"width:389px; height:260px;\" src=\"images/ENDO/81695_Endo_MFP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Triple line appearance of the endometrium in the mid-follicular phase.</div><div class=\"graphic_reference\">Courtesy of Judith Adams, DMU.</div><div id=\"graphicVersion\">Graphic 81695 Version 2.0</div></div></div>"},"81696":{"type":"graphic_table","displayName":"Serum albumin ascites gradient","title":"Classification of ascites by the serum-to-ascites albumin gradient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of ascites by the serum-to-ascites albumin gradient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High albumin gradient (SAAG &#8805;1.1 g/dL)</td> </tr> <tr> <td class=\"indent1\">Cirrhosis</td> </tr> <tr> <td class=\"indent1\">Alcoholic hepatitis</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> </tr> <tr> <td class=\"indent1\">Massive hepatic metastases</td> </tr> <tr> <td class=\"indent1\">Heart failure/constrictive pericarditis</td> </tr> <tr> <td class=\"indent1\">Budd-Chiari syndrome</td> </tr> <tr> <td class=\"indent1\">Portal vein thrombosis</td> </tr> <tr> <td class=\"indent1\">Idiopathic portal fibrosis</td> </tr> <tr> <td class=\"subtitle1_single\">Low albumin gradient (SAAG &#60;1.1 g/dL)</td> </tr> <tr> <td class=\"indent1\">Peritoneal carcinomatosis</td> </tr> <tr> <td class=\"indent1\">Peritoneal tuberculosis</td> </tr> <tr> <td class=\"indent1\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">Serositis</td> </tr> <tr> <td class=\"indent1\">Nephrotic syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81696 Version 5.0</div></div></div>"},"81698":{"type":"graphic_figure","displayName":"Pulmon stenosis CW Doppler II","title":"Pulmonary valve stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary valve stenosis</div><div class=\"cntnt\"><img style=\"width:241px; height:217px;\" src=\"images/CARD/81698_Pulmon_stenosis_CW_Dopple1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The continuous wave Doppler shows a peak systolic velocity across the pulmonary valve of 4.5 m/sec or a gradient of 81 mmHg.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 81698 Version 2.0</div></div></div>"},"81700":{"type":"graphic_figure","displayName":"MRCP endo choledochocele","title":"Choledochocele","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Choledochocele</div><div class=\"cntnt\"><img style=\"width:512px; height:520px;\" src=\"images/GAST/81700_MRCP_endo_choledochocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper panels show magnetic resonance cholangiopancreatography (MRCP) images of the distal common&nbsp;bile duct with a choledochocele bulging into the duodenum. The lower images show the corresponding endoscopic views obtained with forward- (left lower panel) and side-viewing (right lower panel) endoscopes. The patient is an 85-year-old woman who presented with abdominal pain and mild, chronic elevation of serum alkaline phosphatase.</div><div class=\"graphic_reference\">Courtesy of Eric D. Libby, MD.</div><div id=\"graphicVersion\">Graphic 81700 Version 2.0</div></div></div>"},"81702":{"type":"graphic_table","displayName":"Distribution of pathogens in acute bacterial rhinosinusitis","title":"Distribution of pathogens in acute bacterial rhinosinusitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of pathogens in acute bacterial rhinosinusitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Pathogen </td> <td class=\"subtitle1\">Incidence (%) </td> </tr> <tr> <td><em>Streptococcus pneumoniae</em></td> <td>41</td> </tr> <tr> <td><em>Haemophilus influenzae</em></td> <td>35</td> </tr> <tr> <td><em>Moraxella catarrhalis</em></td> <td>4</td> </tr> <tr> <td><em>Staphylococcus aureus</em></td> <td>3</td> </tr> <tr> <td>Anaerobes</td> <td>7</td> </tr> <tr> <td><em>Streptococcus</em> species</td> <td>7</td> </tr> <tr> <td>Other</td> <td>4</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81702 Version 2.0</div></div></div>"},"81703":{"type":"graphic_picture","displayName":"Atypical carcinoid lung","title":"Atypical carcinoid tumor of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical carcinoid tumor of the lung</div><div class=\"cntnt\"><img style=\"width:400px; height:260px;\" src=\"images/PULM/81703_Atypical_carcinoid_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph showing an atypical carcinoid tumor of the lung. The tumor shows a growth pattern reminiscent of that seen in carcinoid tumors of the more usual type, but differs in that there is associated tumor necrosis as seen in the upper portion of the photomicrograph (arrow).</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 81703 Version 1.0</div></div></div>"},"81704":{"type":"graphic_figure","displayName":"Electronic pressure gauge","title":"Electronic pressure gauge for measuring maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electronic pressure gauge for measuring maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)</div><div class=\"cntnt\"><img style=\"width:396px; height:430px;\" src=\"images/PULM/81704_Electronicpressuregauge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electronic pressure gauge for measuring maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and maximal sniff nasal inspiratory pressure (SNIP).&nbsp;</div><div class=\"graphic_reference\">Courtesy of www.micromedical.co.uk.</div><div id=\"graphicVersion\">Graphic 81704 Version 2.0</div></div></div>"},"81706":{"type":"graphic_figure","displayName":"A1C with intensive therapy","title":"Glycemic control in type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Glycemic control in type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:464px; height:372px;\" src=\"images/ENDO/81706_HbA1cwithintensivetherap.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glycemic control, estimated from the median hemoglobin A1C value, in patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study (UKPDS) who were randomly assigned to receive intensive therapy with a sulfonylurea or insulin or to conventional treatment with diet; drugs were added if there were hyperglycemic symptoms or if the fasting blood glucose concentration was greater than 270 mg/dL (15 mmol/L). The A1C values were lower in the intensive therapy group but rose in both groups over time. The circles represent data for all patients, while the lines represent data for patients followed for 10 years.</div><div class=\"graphic_footnotes\">A1C: HbA1c, glycated hemoglobin.</div><div class=\"graphic_reference\">Data from: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.</div><div id=\"graphicVersion\">Graphic 81706 Version 4.0</div></div></div>"},"81708":{"type":"graphic_figure","displayName":"Radiation survey documentation B","title":"Radiation survey documentation B","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Radiation survey documentation B</div><div class=\"cntnt\"><img style=\"width:530px; height:648px;\" src=\"images/PEDS/81708_Radiation_survey_B.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81708 Version 2.0</div></div></div>"},"81709":{"type":"graphic_figure","displayName":"Trunk dermatomes","title":"Dermatomes of the trunk","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Dermatomes of the trunk</div><div class=\"cntnt\"><img style=\"width:536px; height:327px;\" src=\"images/SURG/81709_Trunk_cutaneous_innervation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">• The thoracic intercostal nerves supply the parietal pleura; lateral and anterior branches are sensory to the skin of the lateral and anterior thorax.<br />• The thoracoabdominal intercostal and subcostal nerves supply the peritoneum; lateral and anterior sensory cutaneous branches supply the skin.<br />• The subcostal nerve provides cutaneous branches to the superior gluteal region.<br />• Other cutaneous nerves of the lower abdomen include the lateral femoral cutaneous, genitofemoral, ilioinguinal, and iliohypogastric nerves. The ilioinguinal and iliohypogastric nerves arise from the the lumbar plexus (L1) and provide cutaneous sensory innervation in the groin and upper hip and thigh regions.</div><div id=\"graphicVersion\">Graphic 81709 Version 4.0</div></div></div>"},"81710":{"type":"graphic_table","displayName":"Etiologies of thunderclap headache","title":"Etiologies of thunderclap headache","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of thunderclap headache</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Most common causes of thunderclap headache:</td> </tr> <tr> <td class=\"indent1\">Subarachnoid hemorrhage</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Reversible cerebral vasoconstriction syndromes (RCVS)</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions that less commonly cause thunderclap headache:</td> </tr> <tr> <td class=\"indent1\">Cerebral infection (eg, meningitis, acute complicated sinusitis)</td> </tr> <tr> <td class=\"indent1\">Cerebral venous thrombosis</td> </tr> <tr> <td class=\"indent1\">Cervical artery dissection</td> </tr> <tr> <td class=\"indent1\">Spontaneous intracranial hypotension</td> </tr> <tr> <td class=\"indent1\">Acute hypertensive crisis</td> </tr> <tr> <td class=\"indent1\">Posterior reversible leukoencephalopathy syndrome (PRES)</td> </tr> <tr> <td class=\"indent1\">Intracerebral hemorrhage</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ischemic stroke</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions that uncommonly or rarely cause thunderclap headache:</td> </tr> <tr> <td class=\"indent1\">Pituitary apoplexy</td> </tr> <tr> <td class=\"indent1\">Colloid cyst of the third ventricle</td> </tr> <tr> <td class=\"indent1\">Acute myocardial infarction</td> </tr> <tr> <td class=\"indent1\">Aortic arch dissection</td> </tr> <tr> <td class=\"indent1\">Aqueductal stenosis</td> </tr> <tr> <td class=\"indent1\">Brain tumor</td> </tr> <tr> <td class=\"indent1\">Giant cell arteritis</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"indent1\">Pneumocephalus</td> </tr> <tr> <td class=\"indent1\">Retroclival hematoma</td> </tr> <tr> <td class=\"indent1\">Spinal epidural hematoma</td> </tr> <tr> <td class=\"indent1\">Varicella zoster virus vasculopathy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vogt-Koyanagi-Harada syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Uncertain relationship with thunderclap headache:</td> </tr> <tr> <td class=\"indent1\">Sentinel headache (unruptured intracranial aneurysm)</td> </tr> <tr> <td class=\"indent1\">Primary thunderclap headache</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81710 Version 6.0</div></div></div>"},"81711":{"type":"graphic_figure","displayName":"Cephalocaudad neurulation","title":"Drawing of the closing neural tube, with the anterior and posterior neuropores still open","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drawing of the closing neural tube, with the anterior and posterior neuropores still open</div><div class=\"cntnt\"><img style=\"width:364px; height:256px;\" src=\"images/PEDS/81711_Cephalocaudad_neurul_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fusion of the neural tube begins in the cervical region and proceeds in both the cephalad and caudal directions, forming anterior and posterior neuropores. The anterior neuropore closes on the 25th day after conception; closure of the posterior neuropore normally occurs approximately two days later.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Martin Ronan, Medical Sciences, Indiana University. Copyright &#169; 2009 Martin Ronan. Accessed (Jan. 27, 2009) at: http://www.indiana.edu/~phys215/lecture/lecnotes/ chap8N.html.</div><div id=\"graphicVersion\">Graphic 81711 Version 3.0</div></div></div>"},"81715":{"type":"graphic_figure","displayName":"Variable incidence of Ewing sarcoma","title":"Geographic and ethnic variation in incidence of Ewing sarcoma family of tumors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Geographic and ethnic variation in incidence of Ewing sarcoma family of tumors</div><div class=\"cntnt\"><img style=\"width:386px; height:547px;\" src=\"images/ONC/81715_Ethnicity_and_Ewings_sarcom.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Striking differences in the incidence of Ewing sarcoma are well documented and are graphically evident in this illustration. The well-known near-total lack of incidence in native Africans (Zimbabwe and Nigeria with no reported incidence) as opposed to striking incidence in whites (Los Angeles, white, 3.4) fails to convey the entire story. Surveillance, Epidemiology and End Results (SEER) network data clearly document an even greater incidence in Spain and Israel (approximately 3.5) as well as in at least two Polynesian populations, the New Zealand Maori and the Hawaiian Polynesian, with a similar incidence. At the same time, considerable variation among Asian populations is evident: China has the lowest reported incidence (0.1), Korea is intermediate (0.5), and Japan is the highest (1.0). These striking ethnic differences are not paralleled by any childhood malignancy.</div><div class=\"graphic_reference\">Data adapted from: Triche TJ, Sorensen PHB. Molecular pathology of pediatric malignancies. In: Principles and Practice of Pediatric Oncology, 4th ed. Pizzo PA, Poplack DG (Eds), Lippincott Williams and Wilkins, Philadelphia 2002. p. 163.</div><div id=\"graphicVersion\">Graphic 81715 Version 5.0</div></div></div>"},"81718":{"type":"graphic_figure","displayName":"Pilonidal cyst PI","title":"Pilonidal cyst","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Pilonidal cyst</div><div class=\"cntnt\"><img style=\"width:485px; height:523px;\" src=\"images/PI/81718_Pilonidal-cyst-PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81718 Version 1.0</div></div></div>"},"81720":{"type":"graphic_table","displayName":"Antidotes pediatric poisoning B","title":"Recommended antidotes in pediatric poisonings (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended antidotes in pediatric poisonings (continued)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antidote</td> <td class=\"subtitle1\">Poisoning indication</td> <td class=\"subtitle1\">Pediatric dose</td> </tr> <tr> <td rowspan=\"2\">Ethanol (10 percent)</td> <td>Methanol</td> <td rowspan=\"2\">Loading dose 10 mg/kg IV or PO, followed by maintenance dose 1 to 2 mL/kg per hour IV or PO</td> </tr> <tr> <td>Ethylene glycol</td> </tr> <tr> <td rowspan=\"2\">Fomepizole (4-methylpyrazole)</td> <td>Methanol</td> <td rowspan=\"2\">15 mg IV bolus, then 10 mg/kg IV every 12 hours for four doses; after these, increase dose back to 15 mg/kg</td> </tr> <tr> <td>Ethylene glycol</td> </tr> <tr> <td rowspan=\"2\">Glucagon</td> <td>Beta-adrenergic antagonist</td> <td rowspan=\"2\">0.15 mg/kg IV bolus followed by 0.1 mg/kg per hour IV infusion titrated to effect</td> </tr> <tr> <td>Calcium channel blocker</td> </tr> <tr> <td>Methylene blue</td> <td>Methemoglobinemia</td> <td>1 to 2 mg/kg slow IV infusion, repeat doses are common</td> </tr> <tr> <td>Naloxone</td> <td>Acute opioid poisoning</td> <td>0.4 to 2 mg IV, titrated to effect</td> </tr> <tr> <td>Pralidoxime chloride (PAM)</td> <td>Organophosphate insecticide</td> <td>20 to 40 mg/kg slow IV infusion, followed by 5 to 10 mg/kg per hour continuous infusion or 20 mg/kg every four hours</td> </tr> <tr> <td>Pyridoxine</td> <td>Isoniazid (INH)</td> <td>1 gm per gram ingested or empiric dosing 75 mg/kg IV bolus up to 5 g</td> </tr> <tr> <td rowspan=\"3\">Sodium bicarbonate</td> <td>Tricyclic antidepressant</td> <td rowspan=\"2\">1 to 2 mEq/kg IV bolus, titrate repeat boluses to QRS duration do not exceed arterial pH 7.55)</td> </tr> <tr> <td>Cocaine</td> </tr> <tr> <td>Salicylates</td> <td>150 mEq + 40 mEq KCl in 1L of D5W infused to maintain urine output at 1 to 2 mL/kg per hour and a urine pH approximately 7.5</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Dart, RC, Goldfrank, LR, Chyka, PA, Lotzer, D. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 2000; 36:126 and Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1999; 33:735.</div><div id=\"graphicVersion\">Graphic 81720 Version 2.0</div></div></div>"},"81721":{"type":"graphic_table","displayName":"Common long-term and late effects of breast cancer treatment","title":"Common long-term and late effects of breast cancer treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common long-term and late effects of breast cancer treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Effect</td> <td class=\"subtitle1\">Management options</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Surgical</td> </tr> <tr> <td class=\"indent1\">Cosmetic effects</td> <td>Plastic surgery</td> </tr> <tr> <td class=\"indent1\">Functional disability of arm or chest wall, pain</td> <td>Physical therapy</td> </tr> <tr> <td class=\"indent1\">Scarring/adhesions</td> <td>Plastic surgery</td> </tr> <tr> <td class=\"indent1\">Lymphedema</td> <td>Physical therapy, avoid trauma to involved arm</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Radiation</td> </tr> <tr> <td class=\"indent1\">Second malignancies</td> <td>Image masses arising near radiation field</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> <td>Check TSH if symptoms of hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Pneumonitis, pulmonary fibrosis</td> <td>Symptomatic management</td> </tr> <tr> <td class=\"indent1\">Cardiac damage</td> <td>Lifestyle risk-reduction (diet, exercise, tobacco avoidance)</td> </tr> <tr> <td class=\"indent1\">Lymphedema</td> <td>As above</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Systemic therapy</td> </tr> <tr> <td class=\"indent1\">Second malignancies (myelodysplasia and leukemia)</td> <td>Check CBC if symptoms of leukemia arise</td> </tr> <tr> <td class=\"indent1\">Ototoxicity (eg, cisplatin)</td> <td>Symptomatic management</td> </tr> <tr> <td class=\"indent1\">Cardiomyopathy (eg, anthracyclines)</td> <td>Symptomatic management</td> </tr> <tr> <td class=\"indent1\">Renal toxicity (eg, cisplatin)</td> <td>Symptomatic management</td> </tr> <tr> <td class=\"indent1\">Premature menopause and infertility (eg, alkylating agents)</td> <td>Referral to infertility specialist</td> </tr> <tr> <td class=\"indent1\">Menopausal symptoms</td> <td>Gabapentin, SNRI (eg, venlafaxine), SSRI</td> </tr> <tr> <td class=\"indent1\">Sexual dysfunction</td> <td>Counseling, lubricants</td> </tr> <tr> <td class=\"indent1\">Osteoporosis (eg, hormonal therapy, chemotherapy)</td> <td>Calcium, vitamin D, exercise, bisphosphonate</td> </tr> <tr> <td class=\"indent1\">Neuropathy (eg, taxanes and platinums)</td> <td>Symptomatic management (eg, antidepressants, antiepileptics for painful neuropathy)</td> </tr> <tr> <td class=\"indent1\">Cognitive dysfunction</td> <td>Cognitive therapy</td> </tr> <tr> <td class=\"indent1\">Weight gain</td> <td>Exercise and diet</td> </tr> <tr> <td class=\"indent1\">Fatigue</td> <td>Exercise, rule out other causes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; SNRI: serotonin-norepinephrine reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TSH: thyroid stimulating hormone.</div><div class=\"graphic_reference\">Source: Hayes DF. Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med 2007; 356:2505.</div><div id=\"graphicVersion\">Graphic 81721 Version 2.0</div></div></div>"},"81722":{"type":"graphic_picture","displayName":"Megakaryocyte responsiveness","title":"Megakaryocyte response to changes in platelet count","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Megakaryocyte response to changes in platelet count</div><div class=\"cntnt\"><img style=\"width:236px; height:367px;\" src=\"images/HEME/81722_Megakaryocyte_respons_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The physiologic response of bone marrow megakaryocytes in mice made acutely thrombocytopenic by the injection of antiplatelet antibody (Panel A) or made thrombocytotic by the transfusion of platelets (Panel C) and compared with untreated mice (Panel B) (x16). The number, size, and nuclear lobulation of bone marrow megakaryocytes increased during thrombocytopenia and decreased during thrombocytosis when compared with normal animals.</div><div class=\"graphic_reference\">Reprinted by permission from: Penington, DG, Olsen, TE, Br J Haematol 1970; 18:447.</div><div id=\"graphicVersion\">Graphic 81722 Version 6.0</div></div></div>"},"81723":{"type":"graphic_waveform","displayName":"M-mode echocardiogram in cardiac tamponade","title":"M-mode echocardiogram in cardiac tamponade","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram in cardiac tamponade</div><div class=\"cntnt\"><img style=\"width:445px; height:211px;\" src=\"images/CARD/81723_Cardiac_tamponade_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram showing respiratory motion of the interventricular septum in cardiac tamponade such that during inspiration, the right ventricle enlarges, and the left ventricle becomes smaller.</div><div class=\"graphic_footnotes\">RV-I: right ventricle in inspiration; RV-E: right ventricle in expiration; LV-I: left ventricle in inspiration; LV-E: left ventricle in expiration.</div><div class=\"graphic_reference\">Reproduced by permission of the American Heart Association from Settle, et al. Circulation 1977; 56:951.</div><div id=\"graphicVersion\">Graphic 81723 Version 3.0</div></div></div>"},"81727":{"type":"graphic_figure","displayName":"Sites central venous access","title":"Sites for central venous access","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sites for central venous access</div><div class=\"cntnt\"><img style=\"width:450px; height:621px;\" src=\"images/PEDS/81727_Sites_central_venous_access.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The three primary sites for central venous access in infants and children are the femoral vein, subclavian vein, and the internal jugular vein.</div><div id=\"graphicVersion\">Graphic 81727 Version 1.0</div></div></div>"},"81729":{"type":"graphic_picture","displayName":"Macular stain - face","title":"Macular stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Macular stain</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/81729_Macular_stain_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous patches are present on the forehead and eyelids of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81729 Version 3.0</div></div></div>"},"81730":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of umbilical cord angiomyxoma","title":"Prenatal ultrasound image of umbilical cord angiomyxoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of umbilical cord angiomyxoma</div><div class=\"cntnt\"><img style=\"width:327px; height:570px;\" src=\"images/OBGYN/81730_US_umb_cord_angiomyx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Umbilical cord angiomyxoma. Upper panel, angiomyxoma presenting as&nbsp;an echogenic mass in close relation with a pseudocyst (C). Lower panel, color flow imaging depicts the umbilical vessels and shows blood flow within the echogenic mass.</div><div class=\"graphic_reference\">Reproduced with permission from: Luis Izquierdo, MD.</div><div id=\"graphicVersion\">Graphic 81730 Version 4.0</div></div></div>"},"81731":{"type":"graphic_picture","displayName":"Tuberculosis verrucosa cutis on knee","title":"Tuberculosis verrucosa cutis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculosis verrucosa cutis</div><div class=\"cntnt\"><img style=\"width:277px; height:287px;\" src=\"images/DERM/81731_Tuber_verruc_cut_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A violaceous plaque with a verrucous surface is present on the knee. Scars are evident at the periphery of the plaque.</div><div class=\"graphic_reference\">Courtesy of the Research Institute for Tropical Medicine, Philippines.</div><div id=\"graphicVersion\">Graphic 81731 Version 2.0</div></div></div>"},"81735":{"type":"graphic_table","displayName":"GUD clinical manifestations","title":"Clinical characteristics of infectious causes of genital ulcer disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical characteristics of infectious causes of genital ulcer disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">GUD syndrome </td> <td class=\"subtitle1\">Etiologic agent </td> <td class=\"subtitle1\">Classic ulcer characteristics </td> <td class=\"subtitle1\">Incubation </td> <td class=\"subtitle1\">Pain </td> <td class=\"subtitle1\">Adenopathy </td> </tr> <tr> <td rowspan=\"2\">HSV </td> <td>HSV-1 and HSV-2</td> <td>Multiple small grouped ulcers; erythematous base. Occasionally, single lesions/fissures can be seen</td> <td>2 to 7 days</td> <td>Usually painful; can be painless or pruritic</td> <td>Reactive painful nodes common</td> </tr> <tr> <td>&nbsp;</td> <td>Vesicles can open, forming shallow ulcers/erosions that may coalesce</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"4\">Syphilis </td> <td><em>Treponema pallidum</em></td> <td>Indurated, smooth firm borders</td> <td>7 to 90 days</td> <td>Usually painless; rarely can be painful</td> <td>Firm, rubbery nodes</td> </tr> <tr> <td>&nbsp;</td> <td>Clean base</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Not tender</td> </tr> <tr> <td>&nbsp;</td> <td>Heals spontaneously</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Regional</td> </tr> <tr> <td>&nbsp;</td> <td>Usually singular, although multiple chancres can occur</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Discrete</td> </tr> <tr> <td rowspan=\"4\">Chancroid </td> <td><em>Haemophilus ducreyi</em></td> <td>Sharply circumscribed or irregular, ragged undermined edges</td> <td>3 to 10 days</td> <td>Marked</td> <td>50 percent with inguinal adenopathy</td> </tr> <tr> <td>&nbsp;</td> <td>Not indurated</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Usually unilateral</td> </tr> <tr> <td>&nbsp;</td> <td>Base may have gray or yellow exudate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Often painful</td> </tr> <tr> <td>&nbsp;</td> <td>Multiple ulcers</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>May suppurate/rupture</td> </tr> <tr> <td rowspan=\"6\">LGV </td> <td><em>Chlamydia trachomatis </em>L1-L3</td> <td>Usually not observed</td> <td>5 to 21 days</td> <td>Usually painless</td> <td>More common in males</td> </tr> <tr> <td>&nbsp;</td> <td>Small and shallow</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Matted clusters</td> </tr> <tr> <td>&nbsp;</td> <td>Rapid spontaneous healing</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Unilateral or often bilateral</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Large painful fluctuant \"buboe\"</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Painful groove sign</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Sinus tracts common</td> </tr> <tr> <td rowspan=\"3\">Granuloma inguinale </td> <td><em>Klebsiella&nbsp;granulomatis</em></td> <td>Extensive, progressive</td> <td>7 to 90 days</td> <td>Usually painless</td> <td>Pseudobuboes</td> </tr> <tr> <td>&nbsp;</td> <td>Granulation-like tissue</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>Rolled edges</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GUD: genital ulcer disease; HSV: herpes simplex virus; LGV: lymphogranuloma venereum.</div><div id=\"graphicVersion\">Graphic 81735 Version 3.0</div></div></div>"},"81737":{"type":"graphic_picture","displayName":"CMV focal cytopathic changes","title":"CMV focal cytopathic changes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CMV focal cytopathic changes</div><div class=\"cntnt\"><img style=\"width:378px; height:251px;\" src=\"images/PEDS/81737_CMV_focal_cytopathic_change.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cell culture monolayer of human foreskin fibroblast cells, showing typical focal cytopathic effect of cytomegalovirus (CMV).</div><div id=\"graphicVersion\">Graphic 81737 Version 2.0</div></div></div>"},"81739":{"type":"graphic_picture","displayName":"Bronchocentric granuloma Low","title":"Bronchocentric granulomatosis in a patient with ABPA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchocentric granulomatosis in a patient with ABPA</div><div class=\"cntnt\"><img style=\"width:392px; height:294px;\" src=\"images/PULM/81739_Bronchocentric_granuloma_Lo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low magnification photomicrograph (original magnification 100x) showing a necrotizing granuloma centered on an airway. A centrally necrotic lumen (upper right) is surrounded by epithelioid and palisaded histiocytes to form a necrotizing granuloma adjacent to a pulmonary artery (lower left), the only clue that the lesion is centered on a bronchiole.</div><div id=\"graphicVersion\">Graphic 81739 Version 1.0</div></div></div>"},"81740":{"type":"graphic_diagnosticimage","displayName":"Erosive hand osteoarthritis","title":"Erosive osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erosive osteoarthritis</div><div class=\"cntnt\"><img style=\"width:296px; height:360px;\" src=\"images/RHEUM/81740_Erosive_hand_osteoarthritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of the hand shows erosive osteoarthritis. There is normal bone mineralization with extensive erosive changes involving the distal interphalangeal joint spaces (arrows). These changes are associated with soft tissue swelling and with osteophyte formation. The proximal interphalangeal and metacarpophalangeal joints and the intercarpal joint spaces are relatively spared.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 81740 Version 3.0</div></div></div>"},"81741":{"type":"graphic_picture","displayName":"Arcuate skin lesion","title":"Arcuate skin lesion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Arcuate skin lesion</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/81741_Arcuate_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lesion identified by the arrow represents an arcuate lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81741 Version 4.0</div></div></div>"},"81742":{"type":"graphic_diagnosticimage","displayName":"CXR - pulmonary involvement of CLM","title":"Chest radiograph - pulmonary involvement of cutaneous larva migrans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph&nbsp;- pulmonary involvement of cutaneous larva migrans</div><div class=\"cntnt\"><img style=\"width:407px; height:432px;\" src=\"images/ID/81742_CXR_pulm_involvement_CLM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior chest radiograph showing bilaterial reticulonodular infiltrates.</div><div class=\"graphic_reference\">Reproduced from: Mackowiak PA. A rash and cough in a traveler. Clin Infect Dis 2011; 53:167, by permission of Oxford University Press. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 81742 Version 8.0</div></div></div>"},"81743":{"type":"graphic_algorithm","displayName":"Blood culture followup in children 3 to 36 months of age","title":"Blood culture follow-up in children 3 to 36 months of age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blood culture follow-up in children 3 to 36 months of age</div><div class=\"cntnt\"><img style=\"width:348px; height:381px;\" src=\"images/EM/81743_Blood_culture_followup.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BC: blood culture; LP: lumbar puncture; IV: intravenous.<br>* Well patients with blood culture positive for E. coli or S. aureus do not need a lumbar puncture; for other pathogens, which are encountered rarely, the decision should be individualized.<br>• Outpatient care is only appropriate in patients without evidence of meningitis on CSF examination.</div><div id=\"graphicVersion\">Graphic 81743 Version 2.0</div></div></div>"},"81744":{"type":"graphic_picture","displayName":"Typical granuloma of Crohn disease","title":"Typical granuloma of Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical granuloma of Crohn disease</div><div class=\"cntnt\"><img style=\"width:333px; height:119px;\" src=\"images/GAST/81744_Granuloma_Crohns_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrographs showing a granulomatous lesion that is diagnostic of Crohn disease. Low and high power views show a central giant cell surrounded by epitheliod cells and rimmed by lymphocytes.</div><div class=\"graphic_reference\">Courtesy of the American Gastroenterological Association©. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 81744 Version 3.0</div></div></div>"},"81745":{"type":"graphic_figure","displayName":"Ovulation aromatase inhibitors","title":"Aromatase inhibitor treatment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aromatase inhibitor treatment</div><div class=\"cntnt\"><img style=\"width:443px; height:446px;\" src=\"images/OBGYN/81745_Ovulation_aromatase_inhibit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Clomiphene citrate:</strong> (Day 5) Administration of CC from days 3 to 7 results in ER depletion at the level of the pituitary and mediobasal hypothalamus. As a result, estrogen negative feedback centrally is interrupted and FSH secretion increases from the anterior pituitary leading to multiple follicular growth. (Day 10) By the late follicular phase, because of the long tissue retention of CC, there continues to be ER depletion centrally and increased E2 secretion from the ovary is not capable of normal negative feedback on FSH. The result is multiple dominant follicle growth and multiple ovulation.<br /><strong>Aromatase inhibitor:</strong> (Day 5) Administration of an AI from 3 to 7 days results in suppression of ovarian E2 secretion and reduction in estrogen negative feedback at the pituitary and mediobasal hypothalamus. Increased FSH secretion from the anterior pituitary results in stimulation of multiple ovarian growth. (Day 10) Later in the follicular phase, the effect of the AI is reduced and E2 levels increase as a result of follicular growth. Because AIs do not affect ERs centrally, the increased E2 levels result in normal negative feedback on FSH secretion and follicles less than dominant follicle size undergo atresia, with resultant monofollicular ovulation in most cases.</div><div class=\"graphic_footnotes\">CC: clomiphene citrate; ER: estrogen receptor; FSH: follicle-stimulating hormone; E2: estradiol; AI: aromatase inhibitor.</div><div id=\"graphicVersion\">Graphic 81745 Version 5.0</div></div></div>"},"81746":{"type":"graphic_figure","displayName":"Robertsonian translocation","title":"Robertsonian translocation","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Robertsonian translocation</div><div class=\"cntnt\"><img style=\"width:480px; height:413px;\" src=\"images/HEME/81746_Robertsonian_translocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of a Robertsonian translocation in which the long arms of one chromosome 14 and one chromosome 21 are fused in the carrier parent (upper panel) is a cause of Down syndrome in the offspring. One of the three viable gametes will be normal, one will have a balanced rearrangement, and one will contain the fused chromosome [der(14;21)] as well as the unaffected chromosome 21. Normal fertilization of this gamete results in a fetus with trisomy 21. Other possible segregation products are gametes lacking a chromosome 21, gametes lacking a chromosome 14, and gametes with one chromosome 14 and a derivative chromosome der(14;21), all of which are not viable.</div><div class=\"graphic_reference\">Courtesy of Iris Schrijver, MD.</div><div id=\"graphicVersion\">Graphic 81746 Version 1.0</div></div></div>"},"81747":{"type":"graphic_table","displayName":"PSI Step 2 ","title":"Pneumonia Severity Index Step 2: Risk factors and assigned points","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pneumonia Severity Index Step 2: Risk factors and assigned points</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk factors</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Demographic factors</td> </tr> <tr> <td class=\"indent1\">Age for a man</td> <td>Age (in years)</td> </tr> <tr> <td class=\"indent1\">Age for a woman</td> <td>Age (in years) - 10</td> </tr> <tr> <td class=\"indent1\">Nursing home resident</td> <td>+10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Coexisting illnesses</td> </tr> <tr> <td class=\"indent1\">Neoplastic disease (active)</td> <td>+30</td> </tr> <tr> <td class=\"indent1\">Chronic liver disease</td> <td>+20</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> <td>+10</td> </tr> <tr> <td class=\"indent1\">Cerebrovascular disease</td> <td>+10</td> </tr> <tr> <td class=\"indent1\">Chronic renal disease</td> <td>+10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Physical examination findings</td> </tr> <tr> <td class=\"indent1\">Altered mental status</td> <td>+20</td> </tr> <tr> <td class=\"indent1\">Respiratory rate &#8805;30/minute</td> <td>+20</td> </tr> <tr> <td class=\"indent1\">Systolic blood pressure &#60;90 mmHg</td> <td>+20</td> </tr> <tr> <td class=\"indent1\">Temperature &#60;35&#176;C or &#8805;40&#176;C</td> <td>+15</td> </tr> <tr> <td class=\"indent1\">Pulse &#8805;125 beats/minute</td> <td>+10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Laboratory and radiographic findings</td> </tr> <tr> <td class=\"indent1\">Arterial pH &#60;7.35</td> <td>+30</td> </tr> <tr> <td class=\"indent1\">Blood urea nitrogen &#8805;30 mg/dL (11 mmol/L)</td> <td>+20</td> </tr> <tr> <td class=\"indent1\">Sodium &#60;130 mmol/L</td> <td>+20</td> </tr> <tr> <td class=\"indent1\">Glucose &#8805;250 mg/dL (14 mmol/L)</td> <td>+10</td> </tr> <tr> <td class=\"indent1\">Hematocrit &#60;30 percent</td> <td>+10</td> </tr> <tr> <td class=\"indent1\">Partial pressure of arterial oxygen &#60;60 mmHg*</td> <td>+10</td> </tr> <tr> <td class=\"indent1\">Pleural effusion on chest radiograph</td> <td>+10</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Or an oxygen saturation of &lt;90 percent on pulse oximetry.</div><div class=\"graphic_reference\">Adapted from: Fine MJ, Auble TE, Yealy DM, et al. N Engl J Med 1997; 336:243.</div><div id=\"graphicVersion\">Graphic 81747 Version 4.0</div></div></div>"},"81749":{"type":"graphic_table","displayName":"Differential diagnosis of excess intestinal gas","title":"Differential diagnosis of excess intestinal gas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of excess intestinal gas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Intestinal obstruction</td> </tr> <tr> <td class=\"sublist1\">Adhesions</td> </tr> <tr> <td class=\"sublist1\">Malignancy</td> </tr> <tr> <td class=\"sublist1_start\">Motility disorder</td> </tr> <tr> <td class=\"sublist1\">Diabetes</td> </tr> <tr> <td class=\"sublist1\">Scleroderma</td> </tr> <tr> <td class=\"sublist1\">Pseudo-obstruction</td> </tr> <tr> <td class=\"sublist1\">Medications</td> </tr> <tr> <td>Irritable bowel syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Malabsorption</td> </tr> <tr> <td class=\"sublist1\">Lactose intolerance</td> </tr> <tr> <td class=\"sublist1\">Fructose intolerance</td> </tr> <tr> <td class=\"sublist1\">Celiac disease</td> </tr> <tr> <td class=\"sublist1\">Pancreatic insufficiency</td> </tr> <tr> <td class=\"sublist1_start\">Infectious</td> </tr> <tr> <td class=\"sublist1\">Small intestinal bacterial overgrowth</td> </tr> <tr> <td class=\"sublist1\">Giardiasis</td> </tr> <tr> <td class=\"sublist1_start\">Psychological<span class=\"sublist1_start\"></span></td> </tr> <tr> <td class=\"sublist1\">Anxiety (aerophagia)</td> </tr> <tr> <td class=\"sublist1_start\">Dietary</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81749 Version 4.0</div></div></div>"},"81750":{"type":"graphic_picture","displayName":"Carcinoid lung low power","title":"Carcinoid tumor of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carcinoid tumor of the lung</div><div class=\"cntnt\"><img style=\"width:400px; height:273px;\" src=\"images/PULM/81750_Carcinoid_lung_low_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph showing a carcinoid tumor of the lung with a characteristic neuroendocrine growth pattern.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 81750 Version 1.0</div></div></div>"},"81752":{"type":"graphic_figure","displayName":"IgG-mediated anaphylaxis in mice","title":"IgG-mediated anaphylaxis in mice","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">IgG-mediated anaphylaxis in mice</div><div class=\"cntnt\"><img style=\"width:355px; height:475px;\" src=\"images/ALLRG/81752_IgG_anaphylaxis_mice.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a mouse model of anaphylaxis, allergen interacts with allergen-specific IgG on the surface of macrophages, through the IgG receptor Fc-gamma-RIII. Cross-linking of multiple IgG molecules by allergen initiates intracellular signaling and macrophage activation. In mice, macrophage-derived platelet-activating factor and other inflammatory mediators trigger signs and symptoms similar to those of IgE-mediated anaphylaxis in humans.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 81752 Version 4.0</div></div></div>"},"81753":{"type":"graphic_figure","displayName":"Treatment of macular edema","title":"Photocoagulation for macular edema slows progression to severe visual loss","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photocoagulation for macular edema slows progression to severe visual loss</div><div class=\"cntnt\"><img style=\"width:444px; height:263px;\" src=\"images/ENDO/81753_Treatment_of_macula_edema.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative rate of developing severe visual loss in untreated eyes with macular edema and eyes treated with focal laser therapy. Photocoagulation slowed the rate of severe visual loss.</div><div class=\"graphic_reference\">Data from: Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.&nbsp;Ophthalmology 1991; 98:766.</div><div id=\"graphicVersion\">Graphic 81753 Version 2.0</div></div></div>"},"81755":{"type":"graphic_picture","displayName":"Ulcerative colitis endosc","title":"Ulcerative colitis","html":"<div class=\"graphic normal\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:538px; height:181px;\" src=\"images/GAST/81755_Ulcerative_colitis_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of ulcerative colitis. Extensive ulceration of the mucosa is the most common endoscopic finding (panel A). The surface is irregular, friable, and erythematous, with loss of the normal vascular markings. Pseudopolyps may form as a reaction to inflammation (panel B); these can become quite extensive (panel C).</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 81755 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal sigmoid colon</div><div class=\"cntnt\"><img style=\"width:216px; height:216px;\" src=\"images/GAST/55563_Normal_sigmoid_colon_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 55563 Version 1.0</div></div></div>"},"81756":{"type":"graphic_figure","displayName":"Prevalence of HTN in men","title":"Prevalence of hypertension in men in the United States","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prevalence of hypertension in men in the United States</div><div class=\"cntnt\"><img style=\"width:378px; height:298px;\" src=\"images/NEPH/81756_Prevalence_of_HTN_in_men.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of hypertension in men according to age and race/ethnicity in the United States from the NHANES-III survey. Hypertension occurs earlier and more frequently in African-American men.</div><div class=\"graphic_reference\">Data from: Burt VL, Whelton P, Roccella EJ, et al. Hypertension 1995; 25:305.</div><div id=\"graphicVersion\">Graphic 81756 Version 3.0</div></div></div>"},"81757":{"type":"graphic_table","displayName":"Causes of ST segment elevation","title":"Causes of ST segment elevation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of ST segment elevation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Myocardial ischemia or infarction </td> </tr> <tr> <td class=\"sublist1\">Noninfarction, transmural ischemia (Prinzmetal's angina pattern or acute takotsubo syndrome) </td> </tr> <tr> <td class=\"sublist1\">Acute myocardial infarction (MI) usually due to coronary atherosclerosis or occasionally to other causes (eg, acute takotsubo syndrome) </td> </tr> <tr> <td class=\"sublist1\">Post-MI (ventricular aneurysm pattern) </td> </tr> <tr> <td>Acute pericarditis</td> </tr> <tr> <td>Abnormal early repolarization syndromes</td> </tr> <tr> <td>Normal variants (including benign early repolarization)</td> </tr> <tr> <td class=\"sublist1_start_left\">Left ventricular hypertrophy or left bundle branch block (V1-V2 or V3) </td> </tr> <tr> <td class=\"sublist1_start\">Other </td> </tr> <tr> <td class=\"sublist1\">Myocarditis (may look like MI or pericarditis) </td> </tr> <tr> <td class=\"sublist1\">Massive pulmonary embolism (leads V1-V2 in occasional cases) </td> </tr> <tr> <td class=\"sublist1\">Brugada-type patterns (V1-V3 with right bundle branch block-appearing morphology) </td> </tr> <tr> <td class=\"sublist1\">Myocardial tumor </td> </tr> <tr> <td class=\"sublist1\">Myocardial trauma </td> </tr> <tr> <td class=\"sublist1\">Hyperkalemia (only leads V1 and V2) </td> </tr> <tr> <td class=\"sublist1\">Hypothermia (J wave/Osborn wave)</td> </tr> <tr> <td class=\"sublist1\">Hypercalcemia (rarely)</td> </tr> <tr> <td class=\"sublist1\">Post-DC cardioversion (rarely)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81757 Version 2.0</div></div></div>"},"81759":{"type":"graphic_figure","displayName":"Intraosseous cannulation technique","title":"Intraosseous cannulation technique","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Intraosseous cannulation technique</div><div class=\"cntnt\"><img style=\"width:554px; height:631px;\" src=\"images/PEDS/81759_IO_cannulation_techniq_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Insert the needle in the proximal tibia on the flat surface located distal and medial to the tibial tuberosity. Direct the needle caudad (away from growth plate) at a 10 to 15 degree angle. Use downward pressure from the heel of the hand, and a twisting motion until resistance decreases. See text for details.<br> (B) Marrow can sometimes be aspirated.<br> (C) The needle will flush easily when it is in the marrow cavity and should stand without support.<br> Once successful placement is established, immobilize the leg and secure the needle.</div><div id=\"graphicVersion\">Graphic 81759 Version 5.0</div></div></div>"},"81760":{"type":"graphic_figure","displayName":"RE digestion of PCR product","title":"Restriction enzyme digestion products","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Restriction enzyme digestion products</div><div class=\"cntnt\"><img style=\"width:421px; height:333px;\" src=\"images/PC/81760_RE_digestion_of_PCR_product.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This representation of an agarose gel shows how restriction enzyme digestion can be used to distinguish between an individual who is homozygous for a normal version of a gene versus individuals homozygous or heterozygous for a mutation in that gene. In this case the mutation creates a new restriction enzyme site. The normal piece of DNA is 200 base pairs long and lacks the restriction enzyme site, so it is not cut by the enzyme. The DNA with the mutation has the restriction enzyme sit, so it is cut into two pieces of 180 and 20 base pairs. <BR>Lane 2: Individual with the normal gene; only the 200 base pair DNA is seen.<BR>Lane 3: Individual heterozygous for the mutation; the normal 200 base pair DNA and the 180 and 20 base pair pieces are seen.<BR>Lane 4: Individual heterozygous for the mutation; only the 180 and 20 base pair pieces are seen.</div><div id=\"graphicVersion\">Graphic 81760 Version 2.0</div></div></div>"},"81761":{"type":"graphic_figure","displayName":"Retracted TBNA needle position","title":"Position of the needle prior to TBNA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Position of the needle prior to TBNA</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/PULM/81761_Retracted_TBNA_needle_posit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Correct position of the metal needle prior to TBNA: the entire beveled end is placed inside the metal hub. (B) Incorrect position of the metal needle: the sharp end of the needle is extending beyond the metal hub, and can potentially lacerate the working channel of the bronchoscope. (C and D) Incorrect position of the metal needle: the needle is placed too proximal to the metal hub and can perforate its own plastic catheter during forward thrust and potentially damage the working channel of the bronchoscope.</div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 81761 Version 1.0</div></div></div>"},"81762":{"type":"graphic_table","displayName":"CHOP-21","title":"Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-21) for peripheral T-cell non-Hodgkin lymphoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-21) for peripheral T-cell non-Hodgkin lymphoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cyclophosphamide</td> <td>750 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS) or 5% dextrose in water (D5W) and administer over 30 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Doxorubicin</td> <td>50 mg/m<sup>2</sup> IV</td> <td>Dilute in 50 mL NS or D5W and administer over three to five minutes.</td> <td>Day 1</td> </tr> <tr> <td>Vincristine</td> <td>1.4 mg/m<sup>2</sup> IV (max dose 2 mg)</td> <td>Dilute in 50 mL NS or D5W and administer over 15 to 20 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Prednisone*</td> <td>100 mg orally</td> <td>Administer 30 minutes prior to chemotherapy on day 1, then every 24 hours on days 2 to 5.</td> <td>Days 1 to 5</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>No premedication to prevent infusion reactions. </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin and vincristine are vesicants; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The risk of febrile neutropenia with this regimen is 10 to 20%;<sup>[1]</sup> primary prophylaxis with hematopoietic growth factors should be considered on an individual basis, particularly for high-risk patients such as those with preexisting neutropenia, advanced disease, poor performance status, or patients over age 65 years. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Adjustment of initial cyclophosphamide, doxorubicin, and vincristine doses may be needed for preexisting liver dysfunction.<sup>[2-4]</sup> In addition, dose adjustment of cyclophosphamide may be required for renal dysfunction. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiac screening</strong></td> <td colspan=\"3\"> <ul> <li>LVEF should be evaluated prior to initiation of therapy. Dose alterations should be considered for LVEF &#60;50%, and doxorubicin therapy is contraindicated in patients with LVEF &#60;30% at initiation. Infusion times and schedule may be adjusted to decrease the risk of cardiotoxicity in individuals at high risk for its development. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Vincristine may cause constipation, and in severe cases, paralytic ileus. A routine prophylactic regimen against constipation is recommended in all patients receiving vincristine. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (creatinine and electrolytes) and liver function prior to each subsequent treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>LVEF should be evaluated periodically based on LVEF at initiation of therapy and cumulative dose of doxorubicin. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelosuppression</strong></td> <td colspan=\"3\"> <ul> <li>Treatment should be delayed until ANC is &#62;1000/microL and platelet count is &#62;100,000/microL. If a patient develops grade 4 (ANC &#60;500) neutropenia or febrile neutropenia with any cycle, HGF support is added to the regimen for subsequent cycles. If grade 4 neutropenia or febrile neutropenia occurs despite HGF support, or if the patient develops grade 3 (25,000 to 50,000 platelets) or 4 (&#60;25,000 platelets) thrombocytopenia with any cycle, the doses of cyclophosphamide and doxorubicin should be decreased by 50% for subsequent cycles. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment of vincristine may be necessary if the severity of neuropathy persists or worsens. No specific guidelines are available for dose adjustments. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; ANC: absolute neutrophil count; HGF: hematopoietic growth factor.<br />* Many prospective studies have dosed prednisone by body surface area with doses ranging from 40 mg/m<SUP>2</SUP>/day to 100 mg/m<SUP>2</SUP>/day; however, many institutions use the 100 mg/day dosing listed for convenience without apparent loss in efficacy.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Simon A, et al. Br J Haematol 2010; 151:159.</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 10, 2012).</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 10, 2012).</LI>&#xD;&#xA;<LI>Vincristine sulfate injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 10, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 81762 Version 11.0</div></div></div>"},"81763":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of velamentous umbilical cord","title":"Ultrasound image of velamentous umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of velamentous umbilical cord</div><div class=\"cntnt\"><img style=\"width:504px; height:394px;\" src=\"images/OBGYN/81763_Ultra_velam_umbilical_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grey scale image of umbilical cord (arrow) inserting into the fetal membranes, away from the placenta (P).</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 81763 Version 1.0</div></div></div>"},"81764":{"type":"graphic_figure","displayName":"Shoulder anatomy anterior","title":"Anterior view of shoulder anatomy","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Anterior view of shoulder anatomy</div><div class=\"cntnt\"><img style=\"width:593px; height:462px;\" src=\"images/EM/81764_Shoulder_anatomy_anterior.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81764 Version 2.0</div></div></div>"},"81767":{"type":"graphic_picture","displayName":"MRI of hyperacute ICH","title":"Hyperacute intracerebral hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Hyperacute intracerebral hemorrhage</div><div class=\"cntnt\"><img style=\"width:510px; height:593px;\" src=\"images/NEURO/81767_MRI_of_hyperacute_ICH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT and MRI studies were obtained less than six hours from symptom onset in a patient with spontaneous acute intracerebral hemorrhage. The CT scan shows a hyperdense hemorrhage predominantly in the left frontal lobe. On MRI, the central portion of the hematoma is isointense to brain parenchyma on the T1-weighted image and hyperintense on the T2-weighted and T2* gradient echo images, consistent with hemorrhage containing oxyhemoglobin. On the T2-weighted and T2* gradient echo images, the periphery of the hemorrhage is hypointense, consistent with deoxygenation that occurs more rapidly at the borders. On the T2 weighted image, tissue adjacent to and surrounding the hematoma is hyperintense, consistent with vasogenic edema.</div><div id=\"graphicVersion\">Graphic 81767 Version 1.0</div></div></div>"},"81768":{"type":"graphic_waveform","displayName":"EEG Positive occipital sharp transients of sleep POSTS","title":"Positive occipital sharp transients of sleep (POSTS)","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Positive occipital sharp transients of sleep (POSTS)</div><div class=\"cntnt\"><img style=\"width:537px; height:610px;\" src=\"images/NEURO/81768_POSTS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) POSTS (Positive occipital sharp transients of sleep), in runs, in a bipolar montage (red arrows). B) A referential recording confirms the positivity in the occipital regions (downgoing waves; green arrows). These are normal discharges.</div><div class=\"graphic_reference\">Courtesy of Drs. Lawrence Hirsch and Hiba Arif.</div><div id=\"graphicVersion\">Graphic 81768 Version 3.0</div></div></div>"},"81769":{"type":"graphic_table","displayName":"Conflict resolution","title":"Six steps to conflict resolution for adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Six steps to conflict resolution for adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">1. Keep your temper; stay calm. </td> </tr> <tr> <td>Anger increases the heart rate and initiates a \"fight-or-flight\" response. </td> </tr> <tr> <td class=\"subtitle1_single\">2. Understand what triggers fighting. </td> </tr> <tr> <td class=\"subtitle1_single\">3. Understand that sometimes people use fighting to make themselves feel better. </td> </tr> <tr> <td>Remember that the other person is upset and wants to use fighting to solve the problem. </td> </tr> <tr> <td>The provocation is a response to their need, not to an irrevocable circumstance. </td> </tr> <tr> <td>Do not get manipulated into fighting because they want you to fight to solve their problem. </td> </tr> <tr> <td class=\"subtitle1_single\">4. Understand that the other person is a decent human being. </td> </tr> <tr> <td class=\"subtitle1_single\">5. Talk to the decent side of the other person instead of matching insults. </td> </tr> <tr> <td>\"This isn't worth fighting about.\"</td> </tr> <tr> <td>\"I have nothing against you. I don't want to fight you about this.\"</td> </tr> <tr> <td>\"If I have done something wrong, you can talk with me and I will apologize and try to fix it. </td> </tr> <tr> <td>\"If I haven't done anything wrong, I'll tell you that, but I don't want to settle this by fighting.\" </td> </tr> <tr> <td class=\"subtitle1_single\">6. If these steps do not work, walk away from the situation. Try to use humor as you leave. </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Stringham P. Pediatr Clin North Am 1998; 45:439.</div><div id=\"graphicVersion\">Graphic 81769 Version 3.0</div></div></div>"},"81770":{"type":"graphic_picture","displayName":"Scabies infant abdomen","title":"Scabies, infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies, infant</div><div class=\"cntnt\"><img style=\"width:396px; height:303px;\" src=\"images/PC/81770_Scabies_infant_abdomen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scabies. This infant has papular and vesicular lesions on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81770 Version 3.0</div></div></div>"},"81771":{"type":"graphic_table","displayName":"Fibromyalgia v myofascial pain","title":"Clinical features of fibromyalgia versus myofascial pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of fibromyalgia versus myofascial pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Fibromyalgia</td> <td class=\"subtitle1\">Myofascial pain</td> </tr> <tr> <td>Pain</td> <td>Generalized</td> <td>Localized</td> </tr> <tr> <td>Examination</td> <td>Tender points</td> <td>Trigger points</td> </tr> <tr> <td>Fatigue</td> <td>Prominent</td> <td>Data unknown</td> </tr> <tr> <td>Gender</td> <td>90 percent female</td> <td>Data unknown</td> </tr> <tr> <td>Course</td> <td>Chronic</td> <td>May be self-limited</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81771 Version 4.0</div></div></div>"},"81776":{"type":"graphic_picture","displayName":"Laryngeal mask airway","title":"Laryngeal mask airway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laryngeal mask airway</div><div class=\"cntnt\"><img style=\"width:374px; height:274px;\" src=\"images/PULM/81776_Laryngeal_mask_airway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The laryngeal mask airway (LMA) allows flexible bronchoscopy and ventilation to be performed under general anesthesia. The device can also serve as an excellent rescue airway.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 81776 Version 1.0</div></div></div>"},"81778":{"type":"graphic_table","displayName":"Carboplatin plus pemetrexed for non-small cell lung cancer","title":"Carboplatin plus pemetrexed for non-small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carboplatin plus pemetrexed for non-small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Every 21 days for a maximum of four cycles. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Carboplatin</td> <td>AUC* = 5 mg/mL &times; min IV</td> <td>Dilute in 250 mL normal saline (NS)<sup>&#182;</sup> and administer over 30 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Pemetrexed</td> <td>500 mg/m<sup>2</sup> IV</td> <td>Dilute with 100 mL NS and administer over 10 minutes. Do not administer with calcium-containing IV fluids such as Lactated Ringer's solution.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for skin rashes</strong></td> <td colspan=\"3\"> <ul> <li>Premedication with dexamethasone (4 mg orally twice daily for three days starting the day before drug administration) is recommended to reduce cutaneous toxicity.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Carboplatin is an irritant.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The incidence of neutropenic infections was 8% but may be higher in patients 75 years of age and older.<sup>[1]</sup> The decision to use primary prophylaxis with a hematopoietic growth factor should be individualized according to current guidelines.</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Avoid use of pemetrexed if creatinine clearance is &#60;45 mL/min. Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.* There are recommendations for avoidance of NSAIDs in the days prior to and immediately following each dose of pemetrexed in patients with mild to moderate renal dysfunction (CrCl 45 to 79 mL/min) because of the potential for decreased clearance of pemetrexed.</li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", \"Dosing of anticancer agents in adults\", and \"Pemetrexed: Drug information\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Vitamin supplementation</strong></td> <td colspan=\"3\"> <ul> <li>Vitamin supplementation with folic acid and B12 is recommended prior to administration of pemetrexed and during treatment to reduce both hematologic and nonhematologic side effects.<sup>[2]</sup></li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count before each treatment and once midcycle between days 10 to 14.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Electrolytes, renal, and liver function before each cycle.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Chemotherapy should be delayed for one week if the ANC is &#60;1000/microL and/or the platelet count is &#60;75,000/microL prior to the start of each cycle. Doses for subsequent cycles are reduced by 25% if the ANC is 1000 to 1499 cells/microL or platelets are 75,000 to 99,000/microL on day 22 after the preceding cycle, or if the nadir ANC was &#60;500/microL. A 50% dose reduction should be considered if the platelet nadir is &#60;50,000/microL. Consider discontinuing therapy if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days. Dose reductions should be maintained for subsequent cycles.<sup>[1]</sup></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Nonhematologic toxicity</strong><sup>&#9674;</sup></td> <td colspan=\"3\"> <ul> <li>Creatinine clearance should be &#8805;45 mL/min, and grade 3 and 4 toxicities should be resolved prior to beginning therapy. A delay in therapy by one week should be considered if toxicities are not resolved or the creatinine clearance &#8804;45 mL/min. It is recommended that subsequent cycles be dose reduced by 25% if the patient has grade 3 or 4 toxicity (excluding grade 3 or 4 mucositis, for which a 50% dose reduction is warranted) and discontinued if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days. Dose reductions should be maintained for subsequent cycles.<sup>[1]</sup></li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; NSAIDs: nonsteroidal anti-inflammatory drugs; CrCl: creatinine clearance; CBC: complete blood count; ANC: absolute neutrophil count; GFR: glomerular filtration rate.<br />* AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Δ Dose adjustments in the study may differ slightly from that recommended by the manufacturer. The manufacturer's recommendations can be found in the United States Prescribing Information.<SUP>[2,3]</SUP><br /><FONT class=lozenge>◊</FONT> Toxicity was graded using the Common Terminology Criteria of Adverse Events version 3.0.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gronberg BH, et al. J Clin Oncol. 2009; 27:3217.</LI>&#xD;&#xA;<LI>Pemetrexed disodium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 81778 Version 22.0</div></div></div>"},"81779":{"type":"graphic_picture","displayName":"Poikiloderma of Civatte","title":"Poikiloderma of Civatte","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Poikiloderma of Civatte</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81779_Poikiloderma_Civatte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic sun&nbsp;damage is associated with the development of poikiloderma of Civatte, which typically presents as redness, telangiectasias, and mottled hyperpigmentation on the lateral neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81779 Version 4.0</div></div></div>"},"81781":{"type":"graphic_table","displayName":"Antiarrhythmics and energy","title":"The effect of antiarrhythmic agents on cardioversion energy requirements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The effect of antiarrhythmic agents on cardioversion energy requirements</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antiarrhythmic agent</td> <td class=\"subtitle1\">Energy requirement</td> </tr> <tr> <td>Lidocane</td> <td>Increased or no change</td> </tr> <tr> <td>Quinidine</td> <td>Increased</td> </tr> <tr> <td>Phenytoin</td> <td>Increased</td> </tr> <tr> <td>Amiodarone</td> <td>Increased</td> </tr> <tr> <td>Flecainide</td> <td>Increased</td> </tr> <tr> <td>Ibutilide</td> <td>Decreased</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 81781 Version 3.0</div></div></div>"},"81782":{"type":"graphic_picture","displayName":"Actinomyces sulfur granules","title":"Sulfur granules of actinomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sulfur granules of actinomycosis</div><div class=\"cntnt\"><img style=\"width:364px; height:240px;\" src=\"images/ID/81782_Actinomyces_sulfur_granules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of aspirate from oral abscess (x1000). <EM>Actinomyces</EM> frequently grows in aggregates, termed \"sulfur granules.\" Note the branching, gram-positive filaments on the edge of this granule. <EM>Actinomyces</EM> is a fastidious obligate anaerobe requiring anaerobic culture.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 81782 Version 4.0</div></div></div>"},"81783":{"type":"graphic_diagnosticimage","displayName":"K pneum liver abscess","title":"Liver abscess with K. pneumoniae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liver abscess with K. pneumoniae</div><div class=\"cntnt\"><img style=\"width:325px; height:509px;\" src=\"images/ID/81783_K_pneum_liver_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiographic film shows abnormal gas accumulation in the right upper abdomen (A). CT of the abdomen shows a huge gas-forming liver abscess (B). Blood and drained liver pus yielded K. pneumoniae.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Wen-Liang Yu, MD and Yin-Ching Chuang, MD.</div><div id=\"graphicVersion\">Graphic 81783 Version 3.0</div></div></div>"},"81784":{"type":"graphic_picture","displayName":"Inflammatory gingival overgrowth","title":"Chronic inflammatory gingival enlargement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic inflammatory gingival enlargement</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/PEDS/81784_Inflammatory_gingival_overg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gingival enlargement that occurred in response to longstanding plaque accumulation secondary to orthodontic appliances.</div><div class=\"graphic_reference\">Courtesy of Ann Griffen, DDS, MS.</div><div id=\"graphicVersion\">Graphic 81784 Version 3.0</div></div></div>"},"81785":{"type":"graphic_diagnosticimage","displayName":"Cryptogenic organizing pneumonia CT I","title":"Cryptogenic organizing pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptogenic organizing pneumonia</div><div class=\"cntnt\"><img style=\"width:354px; height:310px;\" src=\"images/PULM/81785_BOOP_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution CT scan in cryptogenic organizing pneumonia. Asymmetric ground glass opacities are seen, with a predominantly peripheral distribution (arrows).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 81785 Version 4.0</div></div></div>"},"81788":{"type":"graphic_diagnosticimage","displayName":"Isoechoic nodule","title":"Isoechoic nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Isoechoic nodule</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ENDO/81788_Isoechoic_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A longitudinal image of the left thyroid lobe that shows a 2.76 X 1.65 cm isoechoic nodule (+ --- + &amp; X --- X). A thin halo (arrows) is evident. A 10.0 MHz transducer was used.</div><div id=\"graphicVersion\">Graphic 81788 Version 2.0</div></div></div>"},"81789":{"type":"graphic_algorithm","displayName":"Treatment of fever and neutropenia","title":"Management of febrile neutropenic patients with unknown etiology of neutropenia","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Management of febrile neutropenic patients with unknown etiology of neutropenia</div><div class=\"cntnt\"><img style=\"width:464px; height:561px;\" src=\"images/HEME/81789_Treatment_fever_neutro_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TPR: temperature, pulse, respiration; BP: blood pressure; Wt: weight; CBC: complete blood count; ANC: absolute neutrophil count; VS: vital signs.<br> * See topic for antibiotic regimens.</div><div id=\"graphicVersion\">Graphic 81789 Version 2.0</div></div></div>"},"81790":{"type":"graphic_diagnosticimage","displayName":"Spiral fracture of middle toe","title":"Spiral fracture of the proximal phalanx of the middle toe","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Spiral fracture of the proximal phalanx of the middle toe</div><div class=\"cntnt\"><img style=\"width:485px; height:482px;\" src=\"images/EM/81790_Spiral_fx_proximal_phalanx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On first glance, the position appears normal. However, comparing the orientation of the fractured toe with the adjacent toes helps one appreciate the slightly abnormal position. The tip of the third toe lies closer to the fourth toe than to the second due to 5 to 10 degrees of angulation. The middle and distal phalanx of the third toe have a slight &quot;curve&quot; laterally while the second and fourth appear to curve straight down or medially. This suggests 10 to 20 degrees of rotation at the fracture site. Although the angulation and rotation seen in this radiograph are well within the acceptable range, they could be improved by a gentle reduction maneuver before buddy taping to the second toe. Because the tip of the third toe angulates away from the second toe, buddy taping to the second toe would be preferable to taping to the fourth toe.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 81790 Version 3.0</div></div></div>"},"81791":{"type":"graphic_diagnosticimage","displayName":"Esophageal perforation CT","title":"Esophageal perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal perforation</div><div class=\"cntnt\"><img style=\"width:312px; height:288px;\" src=\"images/GAST/81791_Esophageal_perforation_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of the chest in a patient with spontaneous esophageal perforation. There is widening of the mediastinum, air in the mediastinum (appearing as black dots, arrows), and bilateral pleural effusions.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Robert E Mindelzun, MD, Department of Radiology, Stanford University.</div><div id=\"graphicVersion\">Graphic 81791 Version 3.0</div></div></div>"},"81792":{"type":"graphic_figure","displayName":"TPMT testing II","title":"A suggested approach for the initiation of therapy with azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A suggested approach for the initiation of therapy with azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease</div><div class=\"cntnt\"><img style=\"width:425px; height:462px;\" src=\"images/GAST/81792_TPMT_testing_II_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TPMT: thiopurine methyltransferase; AZA: azathioprine; 6-MP: 6-mercaptopurine.</div><div class=\"graphic_reference\">Adapted with permission from: Lichtenstein, GR. Use of laboratory testing to guide 6-mercaptopurine azathioprine therapy. Gastroenterology 2004; 127:1558. Copyright &#169; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 81792 Version 3.0</div></div></div>"},"81794":{"type":"graphic_picture","displayName":"Lymphoma bone CT","title":"Primary lymphoma of bone","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Primary lymphoma of bone</div><div class=\"cntnt\"><img style=\"width:452px; height:297px;\" src=\"images/HEME/81794_Lymphoma_bone_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This axial CT scan through the level of the distal femoral bones reveals a pattern of osteosclerosis in the involved right femur (arrow).</div><div class=\"graphic_reference\">Courtesy of Heather Pacholke, MD.</div><div id=\"graphicVersion\">Graphic 81794 Version 2.0</div></div></div>"},"81795":{"type":"graphic_picture","displayName":"Reactive vs diffuse node","title":"Reactive lymph node versus diffuse involvement with lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reactive lymph node versus diffuse involvement with lymphoma</div><div class=\"cntnt\"><img style=\"width:441px; height:288px;\" src=\"images/HEME/81795_Reactive_vs_diffuse_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: lymph node with reactive follicular hyperplasia. Right panel: lymph node from a patient with small lymphocytic lymphoma, in which the normal architecture is effaced by infiltration of small lymphocytes.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 81795 Version 1.0</div></div></div>"},"81796":{"type":"graphic_picture","displayName":"Ocular causes of anisocoria","title":"Pupillary abnormalities related to ocular causes","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Pupillary abnormalities related to ocular causes</div><div class=\"cntnt\"><img style=\"width:515px; height:382px;\" src=\"images/NEURO/81796_Ocular_causes_of_anisocoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Sphincter atrophy- Angle closure glaucoma. B) Traumatic iris sphincter tear. c) Mydriasis due to surgical trauma. D) Pupillary distortion from congenital Reiger's syndrome.</div><div id=\"graphicVersion\">Graphic 81796 Version 1.0</div></div></div>"},"81801":{"type":"graphic_table","displayName":"Topical antimicrobial agents used for burns","title":"Topical antimicrobial agents used for burns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical antimicrobial agents used for burns</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial agents</td> <td class=\"subtitle1\">Clinical indications</td> <td class=\"subtitle1\">Effectiveness</td> <td class=\"subtitle1\">Contraindications</td> <td class=\"subtitle1\">Adverse effects</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Silver sulfadiazine* (SSD)</p> 1%</td> <td>Small, medium, and large surface area burns</td> <td> <p>No evidence to support improved wound healing or reduction in bacterial wound infections</p> <p>Decreased colonization of wounds</p> <p>Alleviates pain</p> Broad spectrum</td> <td> <p>Burns near eyes</p> <p>Pregnant</p> <p>Breastfeeding</p> <p>Newborns &#60;2 months</p> <p>Allergic to sulfonamides</p> Signs of reepithelialization</td> <td> <p>Skin hypersensitivity</p> <p>Neutropenia (usually transient)</p> <p>Leukopenia (usually transient)</p> Methemoglobinemia</td> </tr> <tr class=\"divider_bottom\"> <td>Silver sulfadiazine (SSD) plus cerium</td> <td>Small, medium, and large surface area burns</td> <td>Improved reepithelialization over SSD alone</td> <td> <p>Burns near eyes</p> <p>Pregnancy</p> <p>Breastfeeding</p> <p>Newborns &#60;2 months</p> <p>Allergic to sulfonamides</p> Signs of reepithelialization</td> <td> <p>Skin hypersensitivity</p> <p>Neutropenia (usually transient)</p> <p>Leukopenia (usually transient)</p> Methemoglobinemia</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Bacitracin ointment</p> 500 units/gram</td> <td> <p>Small burns</p> <p>Face</p> <p>Ears</p> <p>Perineum</p> <p>Graft sites</p> Alternative if allergic to sulfonamides</td> <td> <p>Ease of application and of removal</p> <p>Painless</p> Frequent dressing changes</td> <td> <p>Bacterial resistance</p> Signs of reepithelialization</td> <td> <p>Yeast colonization</p> Skin hypersensitivity</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Combination antibiotic ointment</p> (eg, bacitracin, neomycin, and polymyxin B)</td> <td> <p>Small burns</p> <p>Face</p> <p>Ears</p> <p>Perineum</p> <p>Graft sites</p> Alternative if allergic to sulfonamides</td> <td> <p>Ease of application and of removal</p> <p>Painless</p> Frequent dressing changes</td> <td> <p>Bacterial resistance</p> <p>Allergic reaction</p> Signs of reepithelialization</td> <td> <p>Yeast colonization</p> <p>Skin hypersensitivity</p> Ototoxicity and nephrotoxicity with neomycin-containing ointments (eg, Neosporin)</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Mupirocin ointment</p> 2%</td> <td> <p>Small burns</p> <p>Face</p> <p>Ears</p> <p>Nose</p> <p>Perineum</p> Alternative if allergic to sulfonamides</td> <td> <p>Gram-positive coverage includes methicillin-resistant <em>Staphylococcus aureus </em>(MRSA)</p> <p>Ease of application and of removal</p> <p>Painless</p> Frequent dressing changes</td> <td> <p>Bacterial resistance</p> <p>Allergic reaction</p> Signs of reepithelialization</td> <td> <p>Yeast colonization</p> Skin hypersensitivity</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Mafenide</p> <p>8.5% cream</p> 5% solution</td> <td> <p>Ears</p> <p>Nose</p> Dense bacterial proliferation</td> <td> <p>Excellent eschar penetration</p> <p>Penetrates cartilage</p> Gram-negative coverage includes <em>Pseudomonas</em></td> <td> <p>Burns &#62;40 percent total body surface area</p> Allergic to sulfonamides</td> <td> <p>Metabolic acidosis (inhibits carbonic anhydrase)</p> <p>Painful</p> Inhibits epithelial regeneration</td> </tr> <tr class=\"divider_bottom\"> <td>Chlorhexidine</td> <td>Only superficial burns</td> <td> <p>Does not interfere with reepithelialization</p> Can be used with SSD</td> <td>Deep burns</td> <td>Skin hypersensitivity</td> </tr> <tr> <td>Povidone-iodine</td> <td> <p>Controversial&nbsp;&ndash; toxic to fibroblasts</p> Reduces cell proliferation</td> <td>Only when no other agent is available</td> <td> <p>Children under 2 years</p> <p>Pregnant</p> <p>Breastfeeding</p> <p>Thyroid disorders</p> Signs of reepithelialization</td> <td> <p>Cytotoxicity</p> <p>Painful</p> <p>Skin hypersensitivities</p> <p>Chemical burn</p> <p>Iodine toxicity</p> <p>Renal failure</p> <p>Acidosis</p> Anaphylaxis</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Topical antimicrobial agents may increase risk of host fungal infections. Nystatin ointment or powder may be useful in combination with topical antimicrobials to decrease fungal colonization.</div><div class=\"graphic_footnotes\">* Nanocrystalline silver dressings that gradually release silver into the wound are discussed in the topic.</div><div class=\"graphic_reference\">Prepared with data from: Gauglitz GG. Treatment of infection in burns. In: Handbook of Burns, Jeschke MG (Ed), Springer-Verlag,&nbsp;New York 2012. Vol 1: Acute Burn Care. </div><div id=\"graphicVersion\">Graphic 81801 Version 12.0</div></div></div>"},"81802":{"type":"graphic_table","displayName":"Risk of thromboembolism in AF","title":"Risk of systemic thromboembolism in nonvalvular atrial fibrillation from the SPAF-III trial in patients treated with aspirin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of systemic thromboembolism in nonvalvular atrial fibrillation from the SPAF-III trial in patients treated with aspirin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk category</td> <td class=\"subtitle1\">Thromboembolic risk, percent per year</td> <td class=\"subtitle1\">NNT*</td> <td class=\"subtitle1\">General recommendations</td> </tr> <tr> <td>Prior stroke or TIA</td> <td>10</td> <td>14</td> <td>Warfarin</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Primary prevention</td> </tr> <tr> <td class=\"sublist1\">High</td> <td class=\"sublist_other\">6</td> <td class=\"sublist_other\">33</td> <td class=\"sublist_other\">Warfarin</td> </tr> <tr> <td class=\"sublist1\">Moderate</td> <td class=\"sublist_other\">3</td> <td class=\"sublist_other\">66</td> <td class=\"sublist_other\">Warfarin or aspirn</td> </tr> <tr> <td class=\"sublist1\">Low</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">200</td> <td class=\"sublist_other\">Aspirin</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Definitions</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\"><strong>High</strong> - one or more of the following</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">Previous thromboembolism</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">Woman older than 75 years of age</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">Systolic pressure &#62;160 mm Hg</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">Heart failure or severe left ventricular dysfunction</td> </tr> <tr> <td colspan=\"4\"><strong>Moderate</strong> - none of the above but a history of hypertension</td> </tr> <tr> <td colspan=\"4\"><strong>Low</strong> - none of the above</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* NNT: number needed to treat with warfarin rather than aspirin for one year to prevent one event.</div><div class=\"graphic_reference\">Adapated from Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633; and The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 1998; 279:1273.</div><div id=\"graphicVersion\">Graphic 81802 Version 2.0</div></div></div>"},"81803":{"type":"graphic_diagnosticimage","displayName":"TEE right pulmonary vessels","title":"Left atrium, right pulmonary vein and artery on tranesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrium, right pulmonary vein and artery on tranesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:287px; height:191px;\" src=\"images/CARD/81803_TEE_right_pulmonary_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vertical (90º) imaging plane with very anterior rotation shows the left atrium (LA) and right upper pulmonary vein (RUPV). The right pulmonary artery (RPA)&nbsp;may also be seen.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 81803 Version 3.0</div></div></div>"},"81807":{"type":"graphic_picture","displayName":"Pelagia noctiluca specimen","title":"Pelagia noctiluca specimen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelagia noctiluca specimen</div><div class=\"cntnt\"><img style=\"width:288px; height:258px;\" src=\"images/PC/81807_Pelagia_noctiluca_specimen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pelagia noctiluca specimen.</div><div class=\"graphic_reference\">Reproduced with permission from Junghanss, T, Bodio, M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright &#169; 2006 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 81807 Version 1.0</div></div></div>"},"81810":{"type":"graphic_picture","displayName":"Squamous cell carcinoma - tongue","title":"Squamous cell carcinoma of the tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma of the tongue</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81810_Squa_cell_carc_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This nodule on the ventral surface of the tongue is a squamous cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81810 Version 3.0</div></div></div>"},"81811":{"type":"graphic_table","displayName":"Initial functional assessment hosp older adults","title":"Initial functional assessment for hospitalized older adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial functional assessment for hospitalized older adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Self-care (physical or cognitive function)</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>IADLs<sup>&#182;</sup><br /> - Are you able to pay your own bills, or do you need help with your checkbook?<br /> - Do you do your own cooking?<br /> - How do you get to your doctor appointments? </li> <li>Do you sometimes find yourself confused? (Mini-Cog<sup>&#916;[1]</sup>) </li> <li>Can you climb a flight of stairs? If not, what limits you? (eg, pain, dyspnea, strength, balance) </li> <li>Do you require assistance with bathing? (ADLs<sup>&#167;</sup>) </li> <li>When was the last time you fell? What happened? </li> <li>Do you have difficulty with balance or walking? </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"2\">Advance directives</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>Do you have an advance directive? </li> <li>Who would you like to help you make medical decisions, or make them in your place in the event you are unable to participate in the discussion? </li> <li>Rank the following (in order of preference) of how you would like us to focus your care<sup>[2]</sup>:<br /> 1) Life prolongation<br /> 2) Maintaining function<br /> 3) Comfort </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"2\">Living situation and social support</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>Who do you turn to when you need help? </li> <li>Who do you live with? </li> <li>What kind of help do you have at home? </li> <li>Where you live, do you have:<br /> - Meals prepared for you<br /> - Help taking your pills, checking your blood sugar, etc<br /> - Do you need to climb stairs to get to your apartment/home/bedroom? </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"2\">General screening</td> </tr> <tr> <td class=\"indent1\">Nutrition</td> <td>Have you lost any weight in the last year?<sup>[3]</sup></td> </tr> <tr> <td class=\"indent1\">Visual impairment</td> <td>Do you have difficulty driving, watching TV, or reading because of your eyesight?</td> </tr> <tr> <td class=\"indent1\">Hearing</td> <td>Do you have difficulty hearing or understanding what a person says talking in a normal voice?</td> </tr> <tr> <td class=\"indent1\">Urinary incontinence</td> <td>Do you sometimes lose control of your urine and, if so, is that bothersome to you?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IADLs: instrumental activities of daily living; ADL: activities of daily living.<br />* See the US Department of State's \"Caring for Elderly Parents\" website at: <A href=\"http://www.state.gov/m/dghr/flo/c23141.htm\" target=_blank>http://www.state.gov/m/dghr/flo/c23141.htm</A>.<br />Δ IADLs: Using the telephone, shopping, preparing meals, housekeeping, doing laundry, using public transportation or driving, taking medication, handling finances.<br />◊ Mini-Cog: Three-item recall and clock-drawing test.<br />§&nbsp;ADLs: Bathing, dressing, toileting, transferring, maintaining continence, feeding.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Borson S, Scanlan J, Brush M, et al. The Mini-Cog: A cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry 2000; 15:1021. </li> <li>Gillick MR. Choosing appropriate medical care for the elderly. J Am Med Dir Assoc 2001; 2:305. </li> <li>Wallace JI, Schwartz RS, LaCroix AZ, et al. “Involuntary weight loss in older outpatients. J Am Geriatr Soc 1995; 43:329. </li> </ol></div><div id=\"graphicVersion\">Graphic 81811 Version 2.0</div></div></div>"},"81812":{"type":"graphic_figure","displayName":"High and standard dose HEMO","title":"Survival curves for high and standard dialysis doses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival curves for high and standard dialysis doses</div><div class=\"cntnt\"><img style=\"width:395px; height:269px;\" src=\"images/NEPH/81812_High_and_standard_dose_HEMO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graph showing that mortality in the high and standard dialysis dose groups were the same in the HEMO study. There was a nonsignificant 4 percent lower mortality in the high dose group compared with the standard dose group.</div><div class=\"graphic_footnotes\">HEMO: Hemodialysis study.</div><div class=\"graphic_reference\">Redrawn from Eknoyan G, Beck, GJ Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.</div><div id=\"graphicVersion\">Graphic 81812 Version 2.0</div></div></div>"},"81813":{"type":"graphic_figure","displayName":"Middle cerebral artery territory","title":"Middle cerebral artery distribution and signs and symptoms of occlusion","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Middle cerebral artery distribution and signs and symptoms of occlusion</div><div class=\"cntnt\"><img style=\"width:581px; height:588px;\" src=\"images/NEURO/81813_Mid_cerebral_artery_territo.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kistler JP, et al, Cerebrovascular Diseases, Harrison's Principles of Internal Medicine, 13th ed. McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 81813 Version 2.0</div></div></div>"},"81815":{"type":"graphic_table","displayName":"Immediate release preparations","title":"Selected immediate-release stimulant preparations for children with attention deficit hyperactivity disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected immediate-release stimulant preparations for children with attention deficit hyperactivity disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication<br /> (how supplied)</td> <td class=\"subtitle1\">United States trade name<br /> (generic availability)</td> <td class=\"subtitle1\">Duration of action</td> <td class=\"subtitle1\">Initial dose*</td> <td class=\"subtitle1\">Dose advancement*</td> <td class=\"subtitle1\">Maximum dose<br /> (per day)</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Methylphenidate</p> (5, 10, 20 mg tablets; 2.5, 5, 10 mg chewable tablets; 5 mg/5 mL flavored oral solution, 10 mg/5 mL flavored oral solution)</td> <td> <p>Ritalin (generic available)</p> <p>Methylin chewable tablets (generic available)</p> Methylin oral suspension (generic available)</td> <td>3 to 5 hours</td> <td> <p>5 mg/day x 1 day; then</p> <p>5 mg 2 times per day</p> Children &#8804;25 kg may be started with 2.5 mg per day</td> <td> <p>Increments of 5 mg per day every 3 to 7 days</p> Children &#8804;25 kg may be increased by 2.5 mg per day every 3 to 7 days</td> <td> <p>&#8804;25 kg: 35 mg</p> 25 kg: 60 mg</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Dexmethylphenidate<sup>&#182;</sup></p> (2.5, 5, 10 mg tablets, non-scored)</td> <td>Focalin (generic available)</td> <td>5 to 6 hours</td> <td>2.5 mg 2 times per day (patients not taking methylphenidate). For patients taking methylphenidate, dose is half current daily dose up to 10 mg twice per day.</td> <td>Increments of 2.5 to 5 mg per day every 3 to 7 days</td> <td>20 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Dextroamphetamine</p> (2.5, 5 [scored], 7.5, 10 [scored], 15, 20, 30&nbsp;mg tablets; 5 mg/5 mL flavored oral solution)</td> <td class=\"divider_bottom\" rowspan=\"4\">Dexedrine, Zenzedi (generic available for 5 and 10 mg strengths), ProCentra oral solution (generic available)</td> <td class=\"divider_bottom\" rowspan=\"4\">4 to 6 hours</td> <td class=\"sublist1_start\" colspan=\"3\">3 to 5 years</td> </tr> <tr> <td class=\"sublist1\"> <p>2.5 mg/day x 1 day</p> 2.5 mg 2 times/day</td> <td class=\"sublist_other\">Increments of 2.5 mg per day every 3 to 7 days</td> <td class=\"sublist_other\">20 mg</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">&#8805;6 years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\"> <p>5 mg x 1 day</p> 5 mg 2 times/day</td> <td class=\"sublist_other\">Increments of 5 mg per day every 3 to 7 days</td> <td class=\"sublist_other\"> <p>&#8804;50 kg: 40 mg</p> &#62;50 kg: 60 mg<sup>&#916;</sup></td> </tr> <tr> <td rowspan=\"4\"> <p>Amphetamine-dextroamphetamine</p> (5, 7.5, 10, 12.5, 15, 20, 30 mg scored tablets)</td> <td rowspan=\"4\">Adderall (generic available)</td> <td rowspan=\"4\">4 to 6 hours</td> <td class=\"sublist1_start\" colspan=\"2\">3 to 5 years</td> <td rowspan=\"4\"> <p>&#8804;50 kg: 40 mg</p> &#62;50 kg: 60 mg<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist1\"> <p>2.5 mg/day x 1 day</p> 2.5 mg 2 times/day</td> <td class=\"sublist_other\">Increments of 2.5 mg per day every 3 to 7 days</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">&#8805;6 years</td> </tr> <tr> <td class=\"sublist1\"> <p>&#8805;5 mg x 1 day</p> 5 mg 2 times/day</td> <td class=\"sublist_other\">Increments of 5 mg per day every 3 to 7 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Doses of immediate-release preparations are given in morning on rising and at lunch time 4 to 6 hours later. Three times per day dosing is an option for children needing control of symptoms in late afternoon or early evening.<br />&#182; Dexmethylphenidate may not be an appropriate choice for children aged &lt;6 years due to its relatively higher potency and lack of commercially available chewable tablets or flavored oral solution.<br />&Delta; Doses above 40 mg per day total are rarely needed and warrant close monitoring for adverse effects.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.</LI>&#xD;&#xA;<LI>Subcommittee on attention-deficit/hyperactivity disorder, Steering committee on quality improvement and management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Supplemental information. Pediatrics 2011. </LI>&#xD;&#xA;<LI>Drugs for treatment of ADHD. Treat Guidel Med Lett 2011; 9:24.</LI>&#xD;&#xA;<LI>Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev 2001; 22:183.</LI>&#xD;&#xA;<LI>Drugs for ADHD. Med Lett Drugs Ther 2015; 57:37.</LI></OL></div><div id=\"graphicVersion\">Graphic 81815 Version 10.0</div></div></div>"},"81817":{"type":"graphic_diagnosticimage","displayName":"Ground glass pulmonary edema CT","title":"Pulmonary edema after cocaine freebasing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary edema after cocaine freebasing</div><div class=\"cntnt\"><img style=\"width:371px; height:281px;\" src=\"images/PULM/81817_Ground_glass_pulmonary_edem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral patchy areas of ground glass opacity are seen.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 81817 Version 2.0</div></div></div>"},"81818":{"type":"graphic_picture","displayName":"Pedicle advancement ab flap","title":"Abdominal pedicle flap and burned hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdominal pedicle flap and burned hand</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/81818_Pedicle_advancement_ab_flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A burned hand is placed in a pedicle abdominal flap for coverage of exposed joints and tendons of the digits. The hand will remain in place until the wound is revascularized, approximately two to three weeks. The pedicle will then be severed and the wounds closed.</div><div id=\"graphicVersion\">Graphic 81818 Version 3.0</div></div></div>"},"81819":{"type":"graphic_table","displayName":"Revised FLACC pain score","title":"Revised FLACC pain score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised FLACC pain score</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Categories</td> <td class=\"subtitle1\" colspan=\"3\">Scoring</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> </tr> <tr> <td class=\"centered\"> <p><strong>F</strong></p> <p>Face</p> </td> <td>No particular expression or smile</td> <td>Occasional grimace or frown, withdrawn, disinterested; <em>appears sad or worried</em></td> <td>Frequent to constant frown, clenched jaw, quivering chin; <em>distressed-looking face: expression of fright or panic</em></td> </tr> <tr> <td class=\"centered\"> <p><strong>L</strong></p> <p>Legs</p> </td> <td>Normal position or relaxed</td> <td>Uneasy, restless, tense; <em>occasional tremors</em></td> <td>Kicking, or legs drawn up; <em>marked increase in spasticity, constant tremors or jerking</em></td> </tr> <tr> <td class=\"centered\"> <p><strong>A</strong></p> <p>Activity</p> </td> <td>Lying quietly, normal position, moves easily</td> <td>Squirming, shifting back and forth, tense; <em>mildly agitated (eg, head back and forth, aggression); shallow and splinting respirations, intermittent sighs</em></td> <td>Arched, rigid, or jerking; <em>severe agitation, head banging; shivering (not rigors); breath-holding, gasping or sharp intake of breath; severe splinting</em></td> </tr> <tr> <td class=\"centered\"> <p><strong>C</strong></p> <p>Cry</p> </td> <td>No cry (awake or asleep)</td> <td>Moans or whimpers, occasional complaint; <em>occasional verbal outburst or grunt</em></td> <td>Crying steadily, screams or sobs, frequent complaints; <em>repeated outbursts, constant grunting</em></td> </tr> <tr> <td class=\"centered\"> <p><strong>C</strong></p> <p>Consolability</p> </td> <td>Content, relaxed</td> <td>Reassured by occasional touching, hugging, or being talked to, distractable</td> <td>Difficult to console or comfort; <em>pushing away caregiver, resisting care or comfort measures</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This pain score can be used to assess pain from burns and other etiologies for preverbal children.<br> <ul> <li>Each of the five categories (F) Face; (L) Legs; (A) Activity; (C) Cry; (C) Consolability is scored from 0-2, which results in a total score between zero and ten. </li> <li><strong>Patients who are awake:</strong> Observe for at least 1-2 minutes. Observe legs and body uncovered. Reposition patient or observe activity, assess body for tenseness and tone. Initiate consoling interventions if needed. </li> <li><strong>Patients who are asleep:</strong> Observe for at least 2 minutes or longer. Observe body and legs uncovered. If possible reposition the patient. Touch the body and assess for tenseness and tone. </li> <li>The revised FLACC can be used for children with cognitive disability. The additional descriptors (in italics) are included with the original FLACC. The nurse can review the descriptors within each category with parents. Ask them if there are additional behaviors that are better indicators of pain in their child. Add these behaviors to the tool in the appropriate category. </li> </ul></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &#169; 2002 The Regents of the University of Michigan.</div><div id=\"graphicVersion\">Graphic 81819 Version 2.0</div></div></div>"},"81820":{"type":"graphic_table","displayName":"Syncope causes dangerous","title":"Major life threatening causes of syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major life threatening causes of syncope</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Cardiovascular syncope</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Arrhythmia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Ventricular tachycardia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Long QT syndrome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Brugada syndrome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Bradycardia: Mobitz type II or 3rd degree heart block</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Significant sinus pause  &gt;3 seconds</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Ischemia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Acute coronary syndrome, myocardial infarction</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Structural Abnormalities</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Valvular heart disease: aortic stenosis, mitral stenosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Cardiomyopathy (ischemic, dilated, hypertrophic)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Atrial myxoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Cardiac tamponade</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Aortic dissection</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Significant hemorrhage</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Trauma with significant blood loss</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gastrointestinal bleeding</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tissue rupture: aortic aneurysm, spleen, ovarian cyst, ectopic pregnancy, retroperitoneal hemorrhage</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Pulmonary embolism</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Saddle embolus resulting in outflow tract obstruction or severe hypoxia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Subarachnoid hemorrhage</td>\n\t\t\t\t</tr>\n\t\t\t\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81820 Version 1.0</div></div></div>"},"81821":{"type":"graphic_picture","displayName":"Secondary lesions","title":"Child","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Child</div><div class=\"cntnt\"><img style=\"width:468px; height:300px;\" src=\"images/ID/81821_Secondary_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Secondary lesions, 5/27/03, adjacent to primary inoculation site on left hand.</div><div class=\"graphic_reference\">Reproduced with permission from: Marshfield Clinic. Copyright &#169; 2005 Marshfield Clinic.</div><div id=\"graphicVersion\">Graphic 81821 Version 2.0</div></div></div>"},"81823":{"type":"graphic_figure","displayName":"Miscarriage rates by age","title":"Percentages of ART cycles using fresh nondonor eggs or embryos that resulted in miscarriage, by age of woman, 2006","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Percentages of ART cycles using fresh nondonor eggs or embryos that resulted in miscarriage, by age of woman, 2006</div><div class=\"cntnt\"><img style=\"width:519px; height:401px;\" src=\"images/OBGYN/81823_Miscarriage_rates_by_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A woman's age not only affects the chance for pregnancy when her own eggs are used, but also affects her risk for miscarriage. The above figure shows the percentages of ART cycles started in 2006 that resulted in miscarriage for women of different ages. The percentages of ART cycles that resulted in miscarriage were below 14 percent among women younger than 35. The percentages of ART cycles that resulted in miscarriages began to increase among women in their mid- to late 30s and continued to increase with age, reaching 28 percent at age 40 and 56 percent among women older than 43.<br> The risk for miscarriage observed among women undergoing ART procedures using fresh nondonor eggs or embryos appear to be similar to those reported in various studies of other pregnant women in the United States.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.</div><div id=\"graphicVersion\">Graphic 81823 Version 1.0</div></div></div>"},"81824":{"type":"graphic_picture","displayName":"Sorafenib hand-foot skin reaction","title":"Hand-foot skin reaction in patients given sorafenib","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand-foot skin reaction in patients given sorafenib</div><div class=\"cntnt\"><img style=\"width:444px; height:286px;\" src=\"images/ONC/81824_Sorafenib_HFSR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note patchy hyperkeratosis on plantar pressure areas.</div><div class=\"graphic_reference\">Reproduced with permission from: Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60:299. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 81824 Version 4.0</div></div></div>"},"81825":{"type":"graphic_table","displayName":"Representative costs to treat venous disease","title":"Representative costs to treat venous disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Representative costs to treat venous disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"46%\"></colgroup><colgroup span=\"3\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Supply</td> <td class=\"subtitle1\">Expense/unit</td> <td class=\"subtitle1\">Unit</td> <td class=\"subtitle1\">Life-span of item</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Compression stockings</td> </tr> <tr> <td class=\"indent1\">Over the counter knee high (&#60;15 mmHg compression)</td> <td>$$</td> <td>per pair</td> <td>6 months</td> </tr> <tr> <td class=\"indent1\">30-40 mmHg knee high, fitted</td> <td>$$</td> <td>per pair</td> <td>6 months</td> </tr> <tr> <td class=\"indent1\">30-40 mmHg thigh high, fitted</td> <td>$$</td> <td>per pair</td> <td>6 months</td> </tr> <tr> <td class=\"indent1\">Higher grade, custom</td> <td>$$$</td> <td>per pair</td> <td>6 months</td> </tr> <tr> <td>Jobst Ulcer Care</td> <td>$$</td> <td>per pair</td> <td>6 months*</td> </tr> <tr> <td>CircAid legging</td> <td>$$$$</td> <td>each extremity</td> <td>6 months</td> </tr> <tr> <td>Unna Boot Kit</td> <td>$</td> <td>per kit</td> <td>1 to 2 weeks</td> </tr> <tr> <td>Four layer compression wrap</td> <td>$$</td> <td>per kit</td> <td>1 to 2 weeks</td> </tr> <tr> <td>DuoDerm occlusive dressing (4 cm x 4 cm)</td> <td>$</td> <td>per dressing</td> <td>3 to 5 days</td> </tr> <tr> <td>Nonadherent dressing (2 cm x 3 cm)</td> <td>&#162;</td> <td>per dressing</td> <td>1 per day</td> </tr> <tr> <td>Intermittent pneumatic compression</td> <td>$$$$$</td> <td>rental per month</td> <td>Not applicable</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">&cent;: &le;$1 USD.<br />$: &le;$19 USD.<br />$$: $20 to $199 USD.<br />$$$: $200 to $499 USD.<br />$$$$: $500 to $1999 USD.<br />$$$$$: &gt;$2000 USD.</div><div class=\"graphic_footnotes\">USD: United States dollar.<br />* Decreased lifespan when used with to treat active ulcer.</div><div id=\"graphicVersion\">Graphic 81825 Version 7.0</div></div></div>"},"81828":{"type":"graphic_waveform","displayName":"APB with aberration tutorial","title":"Atrial premature beat with aberration","html":"<div class=\"graphic normal\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Atrial premature beat with aberration</div><div class=\"cntnt\"><img style=\"width:482px; height:159px;\" src=\"images/CARD/81828_APB_with_aberration_tutoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The atrial premature beat in this tracing is superimposed upon the T wave of the preceding sinus beat. Since the atrial premature beat occurs early, before the right bundle has fully recovered, •the QRS complex has a complete right bundle branch block morphology (RSR'), reflecting the inability of the right bundle branch to conduct the impulse since it is still refractory.</div><div id=\"graphicVersion\">Graphic 81828 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"81831":{"type":"graphic_picture","displayName":"Laparoscopic electocautery insulation failure","title":"Laparoscopic electocautery insulation failure","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Laparoscopic electocautery insulation failure</div><div class=\"cntnt\"><img style=\"width:469px; height:294px;\" src=\"images/OBGYN/81831_Insulation_failure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insulation failure results from breakdown of the insulation covering the shaft of the active electrode.</div><div class=\"graphic_reference\">Reprinted from: www.encision.com/tech.html Copyright &#169; 2006 Encision Inc.</div><div id=\"graphicVersion\">Graphic 81831 Version 3.0</div></div></div>"},"81832":{"type":"graphic_diagnosticimage","displayName":"Large field RT portal seminoma","title":"Large field radiation therapy for seminoma","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Large field radiation therapy for seminoma</div><div class=\"cntnt\"><img style=\"width:479px; height:399px;\" src=\"images/ONC/81832_Large_field_RT_portal_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large-field (&quot;hockey stick&quot; or &quot;dog leg&quot;) radiation therapy portal for a left-sided stage I seminoma.</div><div class=\"graphic_reference\">Courtesy of Clair Beard, MD.</div><div id=\"graphicVersion\">Graphic 81832 Version 4.0</div></div></div>"},"81833":{"type":"graphic_table","displayName":"Causes of FUO in pediatric HIV","title":"Important causes of FUO in HIV-infected children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important causes of FUO in HIV-infected children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bacterial infection </td> </tr> <tr> <td>Occult focal bacterial infection (eg, sinusitis, pneumonia, internal abscess)</td> </tr> <tr> <td>Salmonellosis</td> </tr> <tr> <td>Mycobacterial infection (eg, <em>M. tuberculosis</em>, <em>M. avium</em> complex, <em>M. kansasii</em>)</td> </tr> <tr> <td class=\"subtitle1_single\">Fungal infection </td> </tr> <tr> <td>Disseminated cryptococcosis</td> </tr> <tr> <td>Disseminated histoplasmosis</td> </tr> <tr> <td>Pneumocystis jirovecii infection</td> </tr> <tr> <td>Occult focal fungal infection (eg, sinusitis, pneumonia, internal abscess)</td> </tr> <tr> <td class=\"subtitle1_single\">Viral infection </td> </tr> <tr> <td>Cytomegalovirus infection</td> </tr> <tr> <td>Epstein-Barr virus infection</td> </tr> <tr> <td>Herpes simplex virus infection</td> </tr> <tr> <td>Hepatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Parasitic infection </td> </tr> <tr> <td>Toxoplasmosis</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy </td> </tr> <tr> <td>Lymphoma and other types of malignancy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FUO: fever of unknown origin; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 81833 Version 2.0</div></div></div>"},"81835":{"type":"graphic_table","displayName":"Diagnostic criteria for JHS","title":"1998 diagnostic criteria for the joint hypermobility syndrome (Brighton criteria)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">1998 diagnostic criteria for the joint hypermobility syndrome (Brighton criteria)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major criteria</td> </tr> <tr> <td class=\"indent1\">1. Beighton score of 4/9 or greater (currently or historically)</td> </tr> <tr> <td class=\"indent1\">2. Arthralgia for longer than three months in four or more joints</td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria</td> </tr> <tr> <td class=\"indent1\">1. A Beighton score of 1, 2, or 3/9 if age greater than 50 years</td> </tr> <tr> <td class=\"indent1\">2. Arthralgia for longer than three months in one to three joints; back pain for three months or more; or spondylosis, spondylolysis, or spondylolisthesis</td> </tr> <tr> <td class=\"indent1\">3. Dislocation or subluxation in more than one joint, or in one joint on more than one occasion</td> </tr> <tr> <td class=\"indent1\">4. Soft tissue rheumatism (eg, epicondylitis, tenosynovitis, bursitis) in three or more locations</td> </tr> <tr> <td class=\"indent1\">5. Marfanoid habitus</td> </tr> <tr> <td class=\"indent1\">6. Abnormal skin (eg, striae, hyperextensibility, thin skin, or papyraceous scarring)</td> </tr> <tr> <td class=\"indent1\">7. Eye abnormalities (eg, drooping eyelids, myopia, or \"anti-mongoloid\"<sup>&#182;</sup> slant)</td> </tr> <tr> <td class=\"indent1\">8. Varicose veins, hernia, or uterine/rectal prolapse</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Joint hypermobility syndrome (JHS) is diagnosed in the presence of two major criteria, one major and two minor criteria, or four minor criteria. Two minor criteria suffice where there is an unequivocally affected first-degree relative. JHS is excluded by the presence of Marfan or Ehlers-Danlos syndromes (EDS) other than the EDS-hypermobility type (formerly termed EDS III). The first major and minor criteria (based upon the Beighton score) are mutually exclusive, as are the second major and minor criteria (based upon the presence of arthralgia or spinal involvement).<br />&#182; A downward slant of the palpebral fissure by which the lateral canthus is lower than the medial canthus.</div><div class=\"graphic_reference\">Grahame R, Bird HA, Child A, et al. J Rheumatol 2000; 27:1777.</div><div id=\"graphicVersion\">Graphic 81835 Version 3.0</div></div></div>"},"81845":{"type":"graphic_picture","displayName":"Casting tape short arm","title":"Casting tape for a short arm cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Casting tape for a short arm cast</div><div class=\"cntnt\"><img style=\"width:355px; height:468px;\" src=\"images/EM/81845_Casting_tape_short_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Casting tape is applied over the cast padding in a distal to caudal direction. When applying fiberglass tape, stretch and then relax the tape during application to reduce the skin surface pressure.</div><div class=\"graphic_reference\">Courtesy of Stephen Titus, MD.</div><div id=\"graphicVersion\">Graphic 81845 Version 1.0</div></div></div>"},"81846":{"type":"graphic_table","displayName":"Antibio skin test conc","title":"Nonirritating concentrations for skin testing with common antibiotics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonirritating concentrations for skin testing with common antibiotics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial drug</td> <td class=\"subtitle1\">Full-strength concentration</td> <td class=\"subtitle1\">Nonirritating concentration</td> </tr> <tr> <td>Cefotaxime</td> <td>100 mg/mL</td> <td>10<sup>&ndash;1</sup></td> </tr> <tr> <td>Cefuroxime</td> <td>100 mg/mL</td> <td>10<sup>&ndash;1</sup></td> </tr> <tr> <td>Cefazolin</td> <td>330 mg/mL</td> <td>10<sup>&ndash;1</sup></td> </tr> <tr> <td>Ceftazidime</td> <td>100 mg/mL</td> <td>10<sup>&ndash;1</sup></td> </tr> <tr> <td>Ceftriaxone</td> <td>100 mg/mL</td> <td>10<sup>&ndash;1</sup></td> </tr> <tr> <td>Tobramycin</td> <td>80 mg/2 mL</td> <td>10<sup>&ndash;1</sup></td> </tr> <tr> <td>Ticarcillin</td> <td>200 mg/mL</td> <td>10<sup>&ndash;1</sup></td> </tr> <tr> <td>Clindamycin</td> <td>150 mg/mL</td> <td>10<sup>&ndash;1</sup></td> </tr> <tr> <td>Gentamicin</td> <td>40 mg/mL</td> <td>10<sup>&ndash;1</sup></td> </tr> <tr> <td>Cotrimoxazole</td> <td>80 mg/mL</td> <td>10<sup>&ndash;2</sup></td> </tr> <tr> <td>Levofloxacin</td> <td>25 mg/mL</td> <td>10<sup>&ndash;3</sup></td> </tr> <tr> <td>Erythromycin</td> <td>50 mg/mL</td> <td>10<sup>&ndash;3</sup></td> </tr> <tr> <td>Azithromycin</td> <td>100 mg/mL</td> <td>10<sup>&ndash;4</sup></td> </tr> <tr> <td>Nafcillin</td> <td>250 mg/mL</td> <td>10<sup>&ndash;4</sup></td> </tr> <tr> <td>Vancomycin</td> <td>50 mg/mL</td> <td>10<sup>&ndash;4</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Nonirritating concentrations are expressed as dilutions from the full-strength intravenous preparation.</div><div class=\"graphic_reference\">Reproduced from: Empedrad R, Darter A, Earl H, Gruchalla R. Letters to the Editor. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2009; 112:629. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 81846 Version 3.0</div></div></div>"},"81847":{"type":"graphic_picture","displayName":"Gastric MZL endoscopy","title":"Gastric marginal zone lymphoma of mucosa associated lymphoid tissues (MALT) on endoscopy","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Gastric marginal zone&nbsp;lymphoma of mucosa associated lymphoid tissues (MALT) on endoscopy</div><div class=\"cntnt\"><img style=\"width:543px; height:236px;\" src=\"images/GAST/81847_Gastric_MALT_lymphoma_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing a superficial ulceration with mucosal thickening in the incisura with surrounding erythema.</div><div class=\"graphic_reference\">Courtesy of John K. Kwon, MD and Harry Anastopoulus, MD.</div><div id=\"graphicVersion\">Graphic 81847 Version 4.0</div></div></div>"},"81849":{"type":"graphic_figure","displayName":"Sphincter repair end-to-end","title":"Anal sphincter repair: Incision and end-to-end approach","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Anal sphincter repair: Incision and end-to-end approach</div><div class=\"cntnt\"><img style=\"width:507px; height:552px;\" src=\"images/OBGYN/81849_Sphincter_repair_end-to-end.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81849 Version 1.0</div></div></div>"},"81850":{"type":"graphic_picture","displayName":"Myocardial siderosis","title":"Myocardial siderosis in sideroblastic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myocardial siderosis in sideroblastic anemia</div><div class=\"cntnt\"><img style=\"width:386px; height:529px;\" src=\"images/HEME/81850_Myocardial_siderosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sections of the heart from a 45-year-old man with pyridoxine-responsive sideroblastic anemia, showing marked myocardial siderosis. Top panel: hematoxylin and eosin stain. Bottom panel: Prussian blue (iron) stain.</div><div class=\"graphic_reference\">Courtesy of Sylvia Bottomley, MD.</div><div id=\"graphicVersion\">Graphic 81850 Version 1.0</div></div></div>"},"81852":{"type":"graphic_figure","displayName":"Risk cardiac arrest among hemodialysis patients","title":"Figure showing risk of cardiac arrest among hemodialysis patients","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Figure showing risk of cardiac arrest among hemodialysis patients</div><div class=\"cntnt\"><img style=\"width:726px; height:364px;\" src=\"images/NEPH/81852_Event_rates_in_dialysis_pt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incident Medicare dialysis patients age 20 years and older, 2000 to 2002 combined. Monthly event rates during the first six months and mean monthly event rates during each following six-month interval. Adjusted for age, gender, race, and diabetic status.</div><div class=\"graphic_reference\">Data from US Renal Data System. USRDS 2006 Annual Data Report. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.</div><div id=\"graphicVersion\">Graphic 81852 Version 3.0</div></div></div>"},"81854":{"type":"graphic_table","displayName":"Glasgow Coma Scale (GCS)","title":"Glasgow Coma Scale (GCS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glasgow Coma Scale (GCS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eye opening</td> </tr> <tr> <td class=\"indent1\">Spontaneous</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Response to verbal command</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Response to pain</td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">No eye opening</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Best verbal response</td> </tr> <tr> <td class=\"indent1\">Oriented</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Confused</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Inappropriate words</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Incomprehensible sounds</td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">No verbal response</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Best motor response</td> </tr> <tr> <td class=\"indent1\">Obeys commands</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">Localizing response to pain</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Withdrawal response to pain</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Flexion to pain</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Extension to pain</td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">No motor response</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_top\"> <td><strong>Total</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The GCS is scored between 3 and 15, 3 being the worst and 15 the best. It is composed of three parameters: best eye response (E), best verbal response (V), and best motor response (M). The components of the GCS should be recorded individually; for example, E2V3M4 results in a GCS score of 9. A score of 13 or higher correlates with mild brain injury, a score of 9 to 12 correlates with moderate injury, and a score of 8 or less represents severe brain injury.</div><div id=\"graphicVersion\">Graphic 81854 Version 7.0</div></div></div>"},"81856":{"type":"graphic_table","displayName":"Drugs chemicals affecting smell","title":"Drugs and chemicals that impair the sense of smell","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs and chemicals that impair the sense of smell</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Mechanism</td> </tr> <tr> <td>Amlodipine</td> <td>&nbsp;</td> </tr> <tr> <td>Beta blockers</td> <td>&nbsp;</td> </tr> <tr> <td>Cadmium</td> <td>Cell toxicity, zinc displacement</td> </tr> <tr> <td>Ciprofloxacin</td> <td>&nbsp;</td> </tr> <tr> <td>Cocaine</td> <td>Microinfarction</td> </tr> <tr> <td>Cytosine arabinoside</td> <td>Mucosal tissue death</td> </tr> <tr> <td>Diltiazem</td> <td>Impairs sensory transmission by nerves</td> </tr> <tr> <td>Doxycycline</td> <td>Unknown</td> </tr> <tr> <td>Enalapril</td> <td>&nbsp;</td> </tr> <tr> <td>Felodipine</td> <td>&nbsp;</td> </tr> <tr> <td>Flusinolide*</td> <td>&nbsp;</td> </tr> <tr> <td>Interferon-alpha</td> <td>Single case report, mechanism unknown</td> </tr> <tr> <td>Lovastatin</td> <td>Unknown</td> </tr> <tr> <td>Methotrexate</td> <td>Impairs mucosal cell growth and replacement</td> </tr> <tr> <td>Nifedipine</td> <td>Impairs sensory transmission by nerves</td> </tr> <tr> <td>Silver nitrate (argyrosis)</td> <td>Deposition of silver in tissue</td> </tr> <tr> <td>Terbinafine</td> <td>Mucosal tissue death</td> </tr> <tr> <td>Tobacco products and smoke</td> <td>Altered second messenger systems?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Incidence greater than 3 percent.</div><div class=\"graphic_reference\">Reprinted with permission from Ackerman, BH, Kasbekar, N, Pharmacotherapy 1997; 17:1.</div><div id=\"graphicVersion\">Graphic 81856 Version 2.0</div></div></div>"},"81857":{"type":"graphic_picture","displayName":"Elbow joint external landmarks","title":"Elbow joint external landmarks","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elbow joint external landmarks</div><div class=\"cntnt\"><img style=\"width:432px; height:316px;\" src=\"images/EM/81857_Elbow_joint_photo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The elbow joint is best palpated as the soft spot in the middle of a triangle formed by the lateral epicondyle, olecranon, and radial head.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD</div><div id=\"graphicVersion\">Graphic 81857 Version 3.0</div></div></div>"},"81858":{"type":"graphic_table","displayName":"Incubation period for rash II","title":"Incubation period for infectious diseases associated with fever and rash","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incubation period for infectious diseases associated with fever and rash</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent/disease</td> <td class=\"subtitle1\">Incubation period</td> </tr> <tr> <td><em>Mycoplasma pneumoniae</em></td> <td>7 to 28 days</td> </tr> <tr> <td><em>Neisseria meningitidis</em></td> <td>1 to 10 days</td> </tr> <tr> <td>Onchocerciasis</td> <td>6&nbsp;to 12 months</td> </tr> <tr> <td>Parvovirus B19</td> <td>7&nbsp;to 21 days</td> </tr> <tr> <td>Reiter's syndrome</td> <td>7&nbsp;to 14 days</td> </tr> <tr> <td>Relapsing fever</td> <td>4&nbsp;to 18 days</td> </tr> <tr> <td>Rheumatic fever</td> <td>7&nbsp;to 35 days</td> </tr> <tr> <td>Rickettsialpox, <em>Rickettsia akari</em> </td> <td>10&nbsp;to 14 days</td> </tr> <tr> <td>Rocky Mountain spotted fever, <em>Rickettsia rickettsii</em> </td> <td>2&nbsp;to 14 days</td> </tr> <tr> <td>Roseola infantum</td> <td>5&nbsp;to 15 days</td> </tr> <tr> <td>Rubella</td> <td>5&nbsp;to 21 days</td> </tr> <tr> <td>Rubeola</td> <td>10&nbsp;to 14 days</td> </tr> <tr> <td><em>Salmonella</em> <em>typhi</em> (enteric fever)</td> <td>3&nbsp;to 60 days</td> </tr> <tr> <td><em>Spirillum minus</em></td> <td>7&nbsp;to 24 days</td> </tr> <tr> <td><em>Sporothrix schenckii</em></td> <td>7&nbsp;to 30 days</td> </tr> <tr> <td>Staphylococcal toxic shock syndrome </td> <td>2 days</td> </tr> <tr> <td><em>Streptobacillus moniliformis</em></td> <td>3&nbsp;to 22 days</td> </tr> <tr> <td>Syphilis</td> <td>9&nbsp;to 90 days</td> </tr> <tr> <td><em>Toxoplasma gondii</em></td> <td>4&nbsp;to 21 days</td> </tr> <tr> <td><em>Trypanosoma cruzi</em></td> <td>5&nbsp;to 14 days</td> </tr> <tr> <td>Tularemia</td> <td>1&nbsp;to 21 days</td> </tr> <tr> <td>Typhus: endemic flea-borne, <em>Rickettsia</em> <em>typhi </em></td> <td>7&nbsp;to 14 days</td> </tr> <tr> <td>Typhus: epidemic louse-borne, <em>Rickettsia prowazekii</em> </td> <td>7&nbsp;to 14 days</td> </tr> <tr> <td>Typhus: scrub, <em>Rickettsia orientalis</em>/<em>Rickettsia tsutsugamushi</em> </td> <td>6&nbsp;to 21 days</td> </tr> <tr> <td><em>Vibrio vulnificus</em></td> <td>1&nbsp;to 4 days</td> </tr> <tr> <td>West Nile virus&nbsp;</td> <td>2 to 14 days</td> </tr> <tr> <td><em>Yersinia pestis</em></td> <td>2&nbsp;to 8 days</td> </tr> <tr> <td>Zika virus</td> <td>2 to 14 days</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from Sanders CV. Diagnosis of the patient with&nbsp;fever and rash. In: The Skin and Infection: A Color Atlas and Text,&nbsp;Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div id=\"graphicVersion\">Graphic 81858 Version 3.0</div></div></div>"},"81859":{"type":"graphic_table","displayName":"Outcome of placebo group NINDS trial","title":"Stroke outcome at three months in the placebo group of the NINDS trial","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stroke outcome at three months in the placebo group of the NINDS trial</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Baseline NIHSS score</td> <td class=\"subtitle1\">Percent with favorable outcome<br /> (three-month NIHSS score = 0 or 1)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age &#60;60 y</td> </tr> <tr> <td class=\"indent1\">0-9</td> <td>42</td> </tr> <tr> <td class=\"indent1\">10-14</td> <td>18</td> </tr> <tr> <td class=\"indent1\">15-20</td> <td>27</td> </tr> <tr> <td class=\"indent1\">&#62;20</td> <td>12</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age 61-68 y</td> </tr> <tr> <td class=\"indent1\">0-9</td> <td>37</td> </tr> <tr> <td class=\"indent1\">10-14</td> <td>25</td> </tr> <tr> <td class=\"indent1\">15-20</td> <td>25</td> </tr> <tr> <td class=\"indent1\">&#62;20</td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age 69-75 y</td> </tr> <tr> <td class=\"indent1\">0-9</td> <td>54</td> </tr> <tr> <td class=\"indent1\">10-14</td> <td>27</td> </tr> <tr> <td class=\"indent1\">15-20</td> <td>0</td> </tr> <tr> <td class=\"indent1\">&#62;20</td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age &#62;75 y</td> </tr> <tr> <td class=\"indent1\">0-9</td> <td>36</td> </tr> <tr> <td class=\"indent1\">10-14</td> <td>15</td> </tr> <tr> <td class=\"indent1\">15-20</td> <td>6</td> </tr> <tr> <td class=\"indent1\">&#62;20</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NIHSS: National Institutes of Health Stroke Scale.</div><div class=\"graphic_reference\">Adapted from: NINDS t-PA Stroke Study Group, Stroke 1997; 28:2119.</div><div id=\"graphicVersion\">Graphic 81859 Version 4.0</div></div></div>"},"81861":{"type":"graphic_figure","displayName":"Lactate threshold with training","title":"Lactate threshold: Effect of training","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lactate threshold: Effect of training</div><div class=\"cntnt\"><img style=\"width:404px; height:365px;\" src=\"images/PEDS/81861_Lactate_threshold_with_trai.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">It is possible to increase the lactate threshold by performing vigorous aerobic training. In this example, the training program increased the lactate threshold from stage 3 (b) to stage 4 (a).</div><div class=\"graphic_footnotes\">(b): lactate threshold before a training program; (a): lactate threshold after a training program.</div><div id=\"graphicVersion\">Graphic 81861 Version 1.0</div></div></div>"},"81862":{"type":"graphic_figure","displayName":"Chromosomal banding GTG","title":"Chromosomal banding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chromosomal banding</div><div class=\"cntnt\"><img style=\"width:406px; height:308px;\" src=\"images/PC/81862_Chromosomal_banding_GTG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">GTG (G-banding with trypsin and Giemsa)-banding technique, of a male with a normal karotype, 46, XY.</div><div id=\"graphicVersion\">Graphic 81862 Version 1.0</div></div></div>"},"81863":{"type":"graphic_figure","displayName":"Left atrial thrombus AF Echo","title":"Left atrial thrombus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial thrombus</div><div class=\"cntnt\"><img style=\"width:360px; height:249px;\" src=\"images/CARD/81863_Left_atrial_thrombus_AF_Ech.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiogram showing a thrombus (T) in the left atrial appendage (LAA) in a patient with atrial fibrillation.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 81863 Version 1.0</div></div></div>"},"81865":{"type":"graphic_picture","displayName":"Darier disease - nails","title":"Darier disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Darier disease</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/81865_Darier_disease_nails.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal notching and linear, red and white bands are present on the nails.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81865 Version 6.0</div></div></div>"},"81867":{"type":"graphic_table","displayName":"Extraintestinal manifestations of inflammatory bowel disease","title":"Extraintestinal manifestations of inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extraintestinal manifestations of inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Common extraintestinal manifestations</td> </tr> <tr> <td class=\"subtitle2_single\">Musculoskeletal</td> </tr> <tr> <td class=\"indent1\">Arthritis - Colitic type, ankylosing spondylitis, isolated joint involvement such as sacroiliitis</td> </tr> <tr> <td class=\"indent1\">Hypertrophic osteoarthropathy - Clubbing, periostitis, metastatic Crohn disease</td> </tr> <tr> <td class=\"indent1\">Miscellaneous - Osteoporosis, aseptic necrosis, polymyositis, osteomalacia</td> </tr> <tr> <td class=\"subtitle2_single\">Skin and mouth</td> </tr> <tr> <td class=\"indent1\">Reactive lesions - Erythema nodosum, pyoderma gangrenosum, aphthous ulcers, vesiculopustular eruption, cutaneous vasculitis, neutrophilic dermatosis, metastatic Crohn disease, epidermolysis bullosa acquisita</td> </tr> <tr> <td class=\"indent1\">Specific lesions - Fissures and fistulas, oral Crohn disease, drug rashes</td> </tr> <tr> <td class=\"indent1\">Nutritional deficiency - Acrodermatitis enteropathica (zinc), purpura (vitamins C&nbsp;and K), glossitis (vitamin B), hair loss and brittle nail (protein)</td> </tr> <tr> <td class=\"indent1\">Associated diseases - Vitiligo, psoriasis, amyloidosis, epidermolysis bullosa acquisita</td> </tr> <tr> <td class=\"subtitle2_single\">Hepatobiliary</td> </tr> <tr> <td class=\"indent1\">Specific complications - Primary sclerosing cholangitis (PSC) and bile duct carcinoma, small duct PSC, cholelithiasis</td> </tr> <tr> <td class=\"indent1\">Associated inflammation - Autoimmune chronic active hepatitis, pericholangitis, portal fibrosis and cirrhosis, granuloma in Crohn disease</td> </tr> <tr> <td class=\"indent1\">Metabolic - Fatty liver, gallstones associated with ileal Crohn disease</td> </tr> <tr> <td class=\"subtitle2_single\">Ocular</td> </tr> <tr> <td class=\"indent1\">Uveitis iritis, episcleritis, scleromalacia, corneal ulcers, retinal vascular disease, retrobulbar neuritis, Crohn keratopathy</td> </tr> <tr> <td class=\"subtitle2_single\">Metabolic</td> </tr> <tr> <td class=\"indent1\">Growth retardation in children and adolescents, delayed sexual maturation</td> </tr> <tr> <td class=\"subtitle1_single\">Less common extraintestinal manifestations</td> </tr> <tr> <td class=\"subtitle2_single\">Blood and vascular</td> </tr> <tr> <td class=\"indent1\">Anemia due to iron, folate, or B12 deficiency or autoimmune hemolytic anemia, anemia of chronic disease, thrombocytopenic purpura; leukocytosis and thrombocytosis; thrombophlebitis and thromboembolism, arteritis and arterial occlusion, polyarteritis nodosa, Takayasu arteritis, cutaneous vasculitis, anticardiolipin antibody, hyposplenism.</td> </tr> <tr> <td class=\"subtitle2_single\">Renal and genitourinary tract</td> </tr> <tr> <td class=\"indent1\">Urinary calculi (oxalate stones in ileal disease), local extension of Crohn disease involving ureter or bladder, amyloidosis, drug-related nephrotoxicity.</td> </tr> <tr> <td class=\"indent1\">Renal tubular damage with increased urinary excretion of various enzymes (eg, beta N-acetyl-D-glucosaminidase).</td> </tr> <tr> <td class=\"subtitle2_single\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Up to 3 percent of patients may have non-iatrogenic neurologic involvement, including peripheral neuropathy, myelopathy, vestibular dysfunction, pseudotumor cerebri, myasthenia gravis, and cerebrovascular disorders. Incidence equal in ulcerative colitis and Crohn disease. These disorders usually appear five to six years after the onset of inflammatory bowel disease and are frequently associated with other extraintestinal manifestations.</td> </tr> <tr> <td class=\"subtitle2_single\">Airway and parenchymal lung disease</td> </tr> <tr> <td class=\"indent1\">Pulmonary fibrosis, vasculitis, bronchitis, necrobiotic nodules, acute laryngotracheitis, interstitial lung disease, sarcoidosis. Abnormal pulmonary function tests without clinical symptoms are common (up to 50 percent&nbsp;of cases).</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Pericarditis, myocarditis, endocarditis, and heart block: more common in ulcerative colitis than in Crohn disease; cardiomyopathy, cardiac failure due to anti-TNF therapy.</td> </tr> <tr> <td class=\"indent1\">Pericarditis may also occur from sulfasalazine/5-aminosalicylates.</td> </tr> <tr> <td class=\"subtitle2_single\">Pancreas</td> </tr> <tr> <td class=\"indent1\">Acute pancreatitis: more common in Crohn disease than in ulcerative colitis. Risk factors include 6-mercaptopurine and 5-aminosalicylate therapy, duodenal Crohn disease.</td> </tr> <tr> <td class=\"subtitle2_single\">Autoimmune</td> </tr> <tr> <td class=\"indent1\">Drug-induced lupus and autoimmune diseases secondary to anti-TNF-alpha therapy.</td> </tr> <tr> <td class=\"indent1\">Positive ANA, anti-double-stranded DNA, cutaneous and systemic manifestations of lupus.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANA: antinuclear antibody; TNF: tumor necrosis factor.</div><div class=\"graphic_reference\">Modified from: Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: New insights into autoimmune pathogenesis. Dig Dis Sci 1999; 44:1.</div><div id=\"graphicVersion\">Graphic 81867 Version 9.0</div></div></div>"},"81871":{"type":"graphic_picture","displayName":"Urothelial dysplasia C","title":"Urothelial dysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial dysplasia</div><div class=\"cntnt\"><img style=\"width:432px; height:267px;\" src=\"images/ONC/81871_Urothelial_dysplasia_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 81871 Version 1.0</div></div></div>"},"81872":{"type":"graphic_figure","displayName":"Childhood Asthma Control Test for children aged 4 to 11 years","title":"Childhood Asthma Control Test for children aged 4 to 11 years","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Childhood Asthma Control Test for children aged 4 to 11 years</div><div class=\"cntnt\"><img style=\"width:616px; height:786px;\" src=\"images/PEDS/81872_Child_asthma_cont_test_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007; 119:817. Copyright &copy; 2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 81872 Version 6.0</div></div></div>"},"81874":{"type":"graphic_picture","displayName":"Disseminated superficial actinic porokeratosis","title":"Disseminated superficial actinic porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Disseminated superficial actinic porokeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/81874_Dis_superficial_actinic_por.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple well-defined, erythematous macules with a peripheral rim of scale are present on the leg of this patient with disseminated superficial actinic porokeratosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 81874 Version 3.0</div></div></div>"},"81875":{"type":"graphic_movie","displayName":"VSD malalignment of long axis 2D","title":"VSD malalignment of long axis 2D","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">VSD malalignment of long axis 2D</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/81875_VSDmalalignlongaxmovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:550px; height:415px;\" src=\"images/CARD/81875_VSDmalalignlongaxposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aortic override and the relationship between the moving aortic valve apparatus and the trabecular and displaced conal portions of the septum are demonstrated in this parasternal long axis view.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; AO: aorta; LA: left atrium; CS: conal septum; IVS: trabecular portion of interventricular septum; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 81875 Version 4.0</div></div></div>"},"81876":{"type":"graphic_diagnosticimage","displayName":"Ultrasound depth selectionrecxxc","title":"Importance of proper ultrasound depth selection for vascular access","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Importance of proper ultrasound depth selection for vascular access</div><div class=\"cntnt\"><img style=\"width:438px; height:564px;\" src=\"images/EM/81876_US_depth_selection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse ultrasound images of the right arm demonstrate the importance of proper image parameter selection.<br />(A) Poor image quality due to excessive depth (green arrow) and improperly positioned focal zone (asterisk). Note signal dropout in the lower half of the image, as the high frequency transducer cannot penetrate to 8 cm depth.<br />(B) Improved image quality with properly selected depth (green arrow) and focal zone (asterisk). There is now detailed resolution of the brachial artery (red arrow), paired brachial veins (blue arrows) and the biceps muscle. The humerus is also seen as a bright curved line deep to the vessels.</div><div class=\"graphic_reference\">Courtesy of Lauren W Averill, MD.</div><div id=\"graphicVersion\">Graphic 81876 Version 4.0</div></div></div>"},"81881":{"type":"graphic_diagnosticimage","displayName":"MRI lateral disc L5","title":"Lumbar spine MRI showing a lateral disc extrusion impinging the L5 nerve root","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lumbar spine MRI showing a lateral disc extrusion impinging the L5 nerve root</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/NEURO/81881_Lateral_disc_L5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal T1-weighted MRI shows a disc extrusion (arrow) at the L4-5 disc level.<br />(B) Axial T2-weighted image at the L4-5 disc level shows the disc extrusion to be left paracentral in location (arrow), obliterating the left lateral recess where the descending L5 nerve root would be expected. Note the normal appearing right descending L5 nerve root within the contralateral lateral recess just prior to its exit from the thecal sac (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 81881 Version 4.0</div></div></div>"},"81882":{"type":"graphic_figure","displayName":"Perineal vessels","title":"Arteries of the female perineum","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Arteries of the female perineum</div><div class=\"cntnt\"><img style=\"width:538px; height:452px;\" src=\"images/OBGYN/81882_Perineal_vessels.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81882 Version 1.0</div></div></div>"},"81883":{"type":"graphic_diagnosticimage","displayName":"CPAM prenatal ultrasound_axial","title":"Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*</div><div class=\"cntnt\"><img style=\"width:432px; height:364px;\" src=\"images/PEDS/81883_CCAM_USG_axial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On this axial view of the thorax, the cardiac silhouette is displaced to the right by the left sided chest mass. The CPAM is echobright and appears \"solid\" due to many microcysts.</div><div class=\"graphic_footnotes\">* CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).</div><div class=\"graphic_reference\">Courtesy of Courtney Stephenson, DO, and Andrew Shuller, RDMS.</div><div id=\"graphicVersion\">Graphic 81883 Version 6.0</div></div></div>"},"81884":{"type":"graphic_table","displayName":"Low-fat low-sugar guide B","title":"Tips for maintaining a healthy weight: Low-fat, low-sugar eating guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for maintaining a healthy weight: Low-fat, low-sugar eating guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food group</td> <td class=\"subtitle1\">Food to choose more often</td> <td class=\"subtitle1\">Food to limit</td> </tr> <tr> <td>Fats</td> <td>Almonds, avocado, canola oil; fat-free or reduced-fat margarine, mayonnaise and salad dressings; olives, olive oil, peanut butter, peanuts, sunflower seeds, walnuts</td> <td>Bacon, butter, chitterlings, coconut; cream (half and half, whipped cream), cream cheese, saturated fats such as coconut, palm and palm kernel oils; shortening or lard, sour cream</td> </tr> <tr> <td>Sweets</td> <td>Sugar substitutes such as Equal, Sweet 'n Low, or Splenda; light or sugar-free syrups, light or low-sugar jams and jellies; sugar-free gelatin; sugar-free Popsicles</td> <td>Candy, sugar, syrup, honey, jam, jelly, gelatin, Popsicles and fruit juice bars, fruit snacks and fruit leather</td> </tr> <tr> <td>Beverages</td> <td>Water, diet sodas, sugar-free drink mixes, sugar-free flavored water, unsweetened iced tea, coffee</td> <td>Regular sodas, fruit juices, sports drinks, drink mixes, sweet tea, and flavored coffee beverages</td> </tr> <tr> <td>Miscellaneous</td> <td>Catsup, mustard, pickles, salsa, spices, lemon juice</td> <td>&nbsp;</td> </tr> <tr> <td>Snacks (in very limited amounts)</td> <td>Low-fat popcorn, pretzels, baked or low-fat chips, rice cakes, graham crackers, granola bars, fat-free and low-fat frozen yogurt, fat-free fudge bars, homemade fruit smoothies</td> <td>Chips, buttered popcorn; store bought cakes, cookies and pies; chocolate, sherbet, ice cream, pudding</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 81884 Version 3.0</div></div></div>"},"81885":{"type":"graphic_waveform","displayName":"Intermediate case 9","title":"Intermediate case 9","html":"<div class=\"graphic normal\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Intermediate case 9</div><div class=\"cntnt\"><img style=\"width:533px; height:99px;\" src=\"images/CARD/81885_Intermediate_case_9.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81885 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"81886":{"type":"graphic_picture","displayName":"Postadolescent acne","title":"Postadolescent acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postadolescent acne</div><div class=\"cntnt\"><img style=\"width:432px; height:280px;\" src=\"images/PC/81886_Postadolescent_acne.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic location of acne along the jaw line in a woman. Multiple papules have been excoriated.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81886 Version 3.0</div></div></div>"},"81887":{"type":"graphic_figure","displayName":"Pressure volume relationships in chest","title":"Pressure-volume characteristics of the respiratory system","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Pressure-volume characteristics of the respiratory system</div><div class=\"cntnt\"><img style=\"width:452px; height:418px;\" src=\"images/PULM/81887_Chestwallvolvspressure.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure-volume characteristics of the respiratory system. This diagram shows the passive pressure-volume characteristics of the lung and chest wall in isolation, as well as the two integrated together as the respiratory system. Note that the resting position of the lungs is at a volume below the residual volume (RV), and the resting position of the chest wall is close to the total lung capacity (TLC). The schematics of the lung and chest wall show the forces exerted by the lungs and chest wall at the different volumes. At functional residual capacity (FRC), the forces exerted by the chest wall and the lungs are equal in intensity and opposite in direction. Thus, this is the resting position of the respiratory system. At volumes above FRC, the balance of forces is such that the respiratory system wants to get smaller; at volumes below FRC, the balance of forces pushes the system toward a higher volume, that is, back to FRC.</div><div class=\"graphic_footnotes\">VC: vital capacity.</div><div class=\"graphic_reference\">Reproduced with permission from: Schwartzstein RM, Parker MJ. Respiratory Physiology: A clinical approach, Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81887 Version 6.0</div></div></div>"},"81889":{"type":"graphic_picture","displayName":"PJS duodenal polyp Light","title":"Duodenal Peutz-Jeghers polyp","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duodenal Peutz-Jeghers polyp</div><div class=\"cntnt\"><img style=\"width:284px; height:394px;\" src=\"images/GAST/81889_PJS_duodenal_polyp_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a duodenal Peutz-Jeghers polyp shows a tree-like proliferation of smooth muscle lined by normal small intestinal epithelium; the overlying epithelium is normal.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 81889 Version 1.0</div></div><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Normal small intestine</div><div class=\"cntnt\"><img style=\"width:517px; height:168px;\" src=\"images/GAST/63225_Normal_small_bowel_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of the normal villous architecture of the small intestine. The high power view shows the enterocytes and interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 63225 Version 1.0</div></div></div>"},"81891":{"type":"graphic_table","displayName":"Hormone therapy for desmoids","title":"Hormone therapy in the treatment of desmoid tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hormone therapy in the treatment of desmoid tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agents used</td> <td class=\"subtitle1\">No of patients</td> <td class=\"subtitle1\">Duration of therapy (in months)</td> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Duration of response</td> <td class=\"subtitle1\">Author, year</td> </tr> <tr class=\"divider_bottom\"> <td>Toremifene or tamoxifen followed by toremifene*</td> <td>20</td> <td>1-29 (median 5.5)</td> <td>65 percent CBRR</td> <td>NR</td> <td>Brooks M; 1992</td> </tr> <tr class=\"divider_bottom\"> <td>Testolactone</td> <td>10</td> <td>2-60 (median 6.5)</td> <td> <p>2 CR<sup>&#182;</sup></p> <p>2 PR</p> 6 PD</td> <td>NR</td> <td>Waddell W; 1991</td> </tr> <tr class=\"divider_bottom\"> <td>Progesterone</td> <td>11</td> <td>NR</td> <td> <p>6 CR</p> <p>2 PR</p> 3 SD/PD<sup>&#916;</sup></td> <td>NR</td> <td>Lanari A; 1983</td> </tr> <tr class=\"divider_bottom\"> <td>Raloxifene</td> <td>13</td> <td>12-29</td> <td> <p>8 CR</p> 5 PR</td> <td>NR</td> <td>Tonelli F; 2003</td> </tr> <tr> <td>Toremifene</td> <td>27</td> <td>NR</td> <td> <p>7 PR</p> <p>19 SD</p> 2 PD</td> <td>NR</td> <td>Fiore M; 2011</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBRR: chemical benefit response rate; CR: complete response; PR: partial response; PD: progressive disease; NR: not reported; SD: stable disease.<br />* One patient was treated with toremifene for a month and discontinued due to blurry vision and was started on tamoxifen.<br />¶ In some cases response evaluation was accomplished by palpation.<br />Δ Author describes outcome as \"did not improve with progesterone\" and does not specify patients who had stable disease and progressive disease.</div><div id=\"graphicVersion\">Graphic 81891 Version 6.0</div></div></div>"},"81895":{"type":"graphic_picture","displayName":"Dilated gastrojejunostomy","title":"Dilated gastrojejunostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilated gastrojejunostomy</div><div class=\"cntnt\"><img style=\"width:432px; height:388px;\" src=\"images/SURG/81895_Dialated_gastrojejunostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dilation of the gastrojejunostomy is considered a technical failure of a gastric bypass. A limited UGI series may demonstrate the stomal diameter of the gastrojejunostomy. Endoscopy will show a dilated gastrojejunostomy as pictured here.</div><div class=\"graphic_reference\">Courtesy of Christopher S Huang, MD.</div><div id=\"graphicVersion\">Graphic 81895 Version 3.0</div></div></div>"},"81896":{"type":"graphic_diagnosticimage","displayName":"Normal bowel gas pattern on plain abdominal radiograph","title":"Normal bowel gas pattern on plain abdominal radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal bowel gas pattern on plain abdominal radiograph</div><div class=\"cntnt\"><img style=\"width:396px; height:482px;\" src=\"images/OBGYN/81896_KUB_normal_bowel_gas_patter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain abdominal radiograph shows a normal pattern with gas throughout nondilated loops of small and large bowel.</div><div class=\"graphic_reference\">Reproduced with permission from: Deborah Levine, MD. Copyright &copy; Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 81896 Version 4.0</div></div></div>"},"81897":{"type":"graphic_figure","displayName":"Segmental anatomy of liver","title":"Segmental anatomy of liver","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Segmental anatomy of liver</div><div class=\"cntnt\"><img style=\"width:566px; height:467px;\" src=\"images/SURG/81897_Segmental_anatomy_of_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Drawing depicting the functional segments of the liver (Couinaud's segments). Segments II to IV make up the left lobe and segments V to VIII constitute the right lobe.</div><div id=\"graphicVersion\">Graphic 81897 Version 3.0</div></div></div>"},"81899":{"type":"graphic_waveform","displayName":"Basic case 7","title":"Basic case 7","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basic case 7</div><div class=\"cntnt\"><img style=\"width:436px; height:100px;\" src=\"images/CARD/81899_Basic_case_7.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81899 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"81902":{"type":"graphic_table","displayName":"Hemorrhagic cystitis treatment","title":"Treatment of hemorrhagic cystitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of hemorrhagic cystitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Mild hematuria</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. Suprahydration</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. Saline continuous bladder irrigation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Moderate and severe hematuria</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. Alum irrigation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. Formalin instillation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. Silver nitrate instillation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4. Estrogen</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5. Pentosan polysufate</td>\n\n    </tr>\n\n    <tr>\n\n      <td>6. Phenol instillation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>7. Prostaglandin instillation or irrigation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>8. Hyperbaric oxygen</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">9. Embolization</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">a. Autologous clot</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">b. Gelfoam</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">c. Occlusive coils</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">d. Ethanol</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">e. Isobutyl-2-cyanoacrylate</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">10. Surgery</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">a. Percutaneous nephrostomy tube placement &plusmn; ureteral occlusion balloons</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">b. Hypogastric artery ligation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">c. Ileal loop diversion</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">d. Cutaneous ureterostomy</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">e. Ureterosigmoidostomy</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81902 Version 1.0</div></div></div>"},"81903":{"type":"graphic_picture","displayName":"Hurler kyphoscoliosis","title":"Kyphoscoliosis in mucopolysaccharidosis type I (MPS I, Hurler syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kyphoscoliosis in mucopolysaccharidosis type I (MPS I, Hurler syndrome)</div><div class=\"cntnt\"><img style=\"width:150px; height:366px;\" src=\"images/PEDS/81903_Hurler_kyphoscoliosis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kyphoscoliosis in four-year-old male following bone marrow transplantation.</div><div class=\"graphic_reference\">Courtesy of Ed Wraith, MD.</div><div id=\"graphicVersion\">Graphic 81903 Version 5.0</div></div></div>"},"81905":{"type":"graphic_waveform","displayName":"Hemodynamics during septal ablation for HCM","title":"Hemodynamics during septal ablation for HCM","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Hemodynamics during septal ablation for HCM</div><div class=\"cntnt\"><img style=\"width:548px; height:448px;\" src=\"images/CARD/81905_HemodynseptaablationHCM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Outflow gradient in hypertrophic cardiomyopathy (HCM) decreased by alcohol septal ablation. Resting gradient of &gt;100 mmHg is present with pigtail catheter in left ventricular apex and coronary guide assessing aortic pressure.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Baim, DS. Grossman's Cardiac Catheterization, Angiography, and Intervention, Seventh Ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81905 Version 3.0</div></div></div>"},"81907":{"type":"graphic_figure","displayName":"21 hydroxylase deficiency","title":"Synthetic defect in CYP21A2 (21-hydroxylase) deficiency","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Synthetic defect in CYP21A2 (21-hydroxylase) deficiency</div><div class=\"cntnt\"><img style=\"width:565px; height:253px;\" src=\"images/ENDO/81907_21_hydroxylase_deficiency.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathways of adrenal steroid synthesis. A synthetic defect in 21-hydroxylase leads to diminished cortisol synthesis, increased release of corticotropin (ACTH), accumulation of 17-hydroxyprogesterone (particularly after the administration of ACTH), possible virilization due to increased androgen production, and possible salt-wasting due to diminished production of aldosterone and deoxycorticosterone.</div><div class=\"graphic_footnotes\">The numbers at the arrows refer to specific enzymes: 17α: 17α-hydroxylase (P450c17); 17,20: 17,20 lyase which is part of the P450c17 enzyme; 3β: 3β-hydroxysteroid dehydrogenase; 21: 21-hydroxylase (P450c21); 11β: 11β-hydroxylase; (P450c11); 18 refers to the two-step process of aldosterone synthase (P450c11as), resulting in the addition of an hydroxyl group that is then oxidized to an aldehyde group at the 18-carbon position; ?: unclear if pathway functions in vivo; DHEA: dehydroepiandrostenedione; 17KSR: 17-ketosteroid reductase; and A: aromatase.</div><div id=\"graphicVersion\">Graphic 81907 Version 4.0</div></div></div>"},"81908":{"type":"graphic_figure","displayName":"Platelet interactions","title":"The platelet and its interactions","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">The platelet and its interactions</div><div class=\"cntnt\"><img style=\"width:526px; height:542px;\" src=\"images/HEME/81908_Platelet_interactions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing of the platelet (top figure), showing its alpha and dense granules and canalicular system. The bottom figure illustrates the platelet's major functions, including secretion of stored products, as well as its attachment, via specific surface glycoproteins (GP), to denuded epithelium (bottom) and other platelets (left).</div><div class=\"graphic_footnotes\">VWF: von Willebrand factor; TSP: thrombospondin; PF4: platelet factor 4; PDGF: platelet derived growth factor; &#946;-TG: beta thromboglobulin; ADP: adenosine diphosphate; ATP: adenosine triphosphate.</div><div class=\"graphic_reference\">Courtesy of Steven Coutre, MD.</div><div id=\"graphicVersion\">Graphic 81908 Version 2.0</div></div></div>"},"81909":{"type":"graphic_figure","displayName":"Supination flexion technique","title":"Supination-flexion technique","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Supination-flexion technique</div><div class=\"cntnt\"><img style=\"width:527px; height:350px;\" src=\"images/PEDS/81909_Supination_flexion_techniqu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the supination/flexion technique, the examiner supports the child's arm at the elbow and exerts moderate pressure on the radial head with the thumb or one finger. With the other hand, the examiner holds the child's distal forearm, and then pulls with gentle traction. While maintaining traction, the examiner fully supinates the child's forearm and then fully flexes the elbow in one smooth motion. A click may be felt by the finger over the radial head or a pop may be heard by the examiner, when the subluxation is reduced.</div><div id=\"graphicVersion\">Graphic 81909 Version 2.0</div></div></div>"},"81911":{"type":"graphic_table","displayName":"Campisi staging system for lymphedema","title":"Campisi staging system for lymphedema","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Campisi staging system for lymphedema</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Stage I</td> </tr> <tr> <td>A.\"Latent\" lymphedema, without clinical evidence of edema, but with impaired lymph transport capacity (provable by lymphoscintigraphy) and with initial immuno-histochemical alterations of lymph nodes, lymph vessels and extracellular matrix.</td> </tr> <tr> <td>B.\"Initial\" lymphedema, totally or partially decreasing by rest and draining position, with worsening impairment of lymph transport capacity and of immuno-histochemical alterations of lymph collectors, nodes and extracellular matrix.</td> </tr> <tr> <td class=\"subtitle1_single\">Stage II</td> </tr> <tr> <td>A. \"Increasing\" lymphedema, with vanishing lymph transport capacity, relapsing lymphangitic attacks, fibroindurative skin changes, and developing disability.</td> </tr> <tr> <td>B. \"Column shaped\" limb fibrolymphedema, with lymphostatic skin changes, suppressed lymph transport capacity and worsening disability.</td> </tr> <tr> <td class=\"subtitle1_single\">Stage III</td> </tr> <tr> <td>A. Properly called \"elephantiasis\", with scleroindurative pachydermitis, papillomatous lymphostatic verrucosis, no lymph transport capacity and life-threatening disability.</td> </tr> <tr> <td>B. \"Extreme elephantiasis\" with total disability.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Campisi C, Campisis C, Accogli S, et al. Lymphedema staging and surgical indications in geriatric age. BMC Geriatrics 2010; 10(Suppl 1):A50. Copyright © 2010.</div><div id=\"graphicVersion\">Graphic 81911 Version 2.0</div></div></div>"},"81912":{"type":"graphic_table","displayName":"Irradiation blood indications","title":"Indication for irradiation of cellular blood components for the prevention of transfusion-associated graft-versus-host disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indication for irradiation of cellular blood components for the prevention of transfusion-associated graft-versus-host disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Currently accepted indications</td> </tr> <tr> <td class=\"indent1\">Immunocompromised hematopoietic stem cell recipients or organ transplant recipients</td> </tr> <tr> <td class=\"indent1\">Patients with hematologic disorders who will be undergoing marrow transplantation imminently</td> </tr> <tr> <td class=\"indent1\">Intrauterine transfusion</td> </tr> <tr> <td class=\"indent1\">Neonatal exchange transfusions</td> </tr> <tr> <td class=\"indent1\">Premature, low birthweight neonates</td> </tr> <tr> <td class=\"indent1\">Hodgkin lymphoma</td> </tr> <tr> <td class=\"sublist2_start\">Congenital cell-mediated immunodeficiencies</td> </tr> <tr> <td class=\"sublist2\">Thymic hypoplasia (DiGeorge syndrome), Wiskott-Aldrich syndrome, Leiner's disease, 5' nucleotidase deficiency</td> </tr> <tr> <td class=\"indent1\">Chronic lymphocytic leukemia (CLL) patients or other patients receiving fludarabine</td> </tr> <tr> <td class=\"indent1\">Recipients of directed donations from biologic relatives</td> </tr> <tr> <td class=\"indent1\">Recipients of donation from HLA-matched donors</td> </tr> <tr> <td class=\"indent1\">Recipients who are heterozygous at an HLA locus for which the donor is homozygous and shares an allele; most common in genetically homogeneous populations</td> </tr> <tr> <td class=\"subtitle1_single\">Probably indicated</td> </tr> <tr> <td class=\"indent1\">Hematologic malignancies other than Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Solid tumors treated with cytotoxic agents</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Przepiorka D, et al. Am J Clin Pathol 1996; 106:6 and Webb IJ, et al. Transfusion-associated graft-vs-host disease. In: Transfusion reactions, 3rd ed, Popovsky MA (Ed), American Association of Blood Banks Press, Bethesda 2007. p.237.</li>&#xD;&#xA;    <li>AABB Technical Manual, 17th ed, Roback JD, Grossman BJ, Harris T, et al, (Eds). American Association of Blood Banks Press, Bethesda 2011. p.755.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 81912 Version 6.0</div></div></div>"},"81914":{"type":"graphic_waveform","displayName":"ECG in evolving anterior MI","title":"Electrocardiogram (ECG) in an evolving anterior myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) in an evolving anterior myocardial infarction</div><div class=\"cntnt\"><img style=\"width:518px; height:267px;\" src=\"images/CARD/81914_Evolving_anterior_MI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram shows findings typical of an evolving Q-wave anterior MI: loss of R waves in leads V1 to V3, ST segment elevations in V2 to V4, and T wave inversions in leads I, aVL, and V2 to V5. Sinus bradycardia (55 beats/min) is present due to concurrent therapy with a beta blocker.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 81914 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"81915":{"type":"graphic_table","displayName":"Retinal hemorrhage etiology","title":"Causes of retinal hemorrhage in infants and young children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of retinal hemorrhage in infants and young children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition*</td> <td class=\"subtitle1\">Frequency of retinal hemorrhages</td> <td class=\"subtitle1\">Hemorrhage description</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td><strong>Abusive head trauma</strong></td> <td>50 to 100 percent of cases</td> <td>Numerous, extend to retinal periphery, involve multiple layers of the retina</td> <td>History inconsistent with injuries; commonly associated with subdural hemorrhage, fractures, bruising, and intraabdominal injury</td> </tr> <tr> <td><strong>Perinatal retinal hemorrhages</strong></td> <td> <p>20 to 30 percent of newborns examined during first 24 hours</p> <p>10 to 15 percent of newborns examined during first 72 hours</p> </td> <td>May be numerous and extend to retinal periphery; usually intraretinal, but may be preretinal or vitreal</td> <td> <p>More common in vacuum-assisted deliveries</p> <p>Resolves by 4 to 6 weeks</p> </td> </tr> <tr> <td><strong>Unintentional head injury</strong></td> <td>0-10 percent of patients</td> <td>Typically few in number and confined to posterior pole</td> <td>Associated with severe mechanism of injury (eg, motor vehicle crash, fall from great height)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Hematologic conditions</td> </tr> <tr> <td class=\"indent1\">Bleeding disorder (eg, hemophilia, von Willebrand disease, vitamin K deficiency)</td> <td>Unknown</td> <td>All layers of retina, vitreous</td> <td>Characteristic history of bleeding disorder and abnormal coagulation studies</td> </tr> <tr> <td class=\"indent1\">Leukemia</td> <td>Unknown; most patients have fundoscopic changes at some point in disease</td> <td>Usually at the posterior pole in the deep layers of the retina, but may occur in all layers and in the vitreous</td> <td>Characteristic laboratory features (eg, lymphoblasts on peripheral blood smear)</td> </tr> <tr> <td class=\"indent1\">Anemia (juvenile pernicious, iron deficiency, sickle cell)</td> <td>Unknown, more common in adults than children</td> <td>Intraretinal dot, blot, flame, or splinter</td> <td>Anemia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Metabolic conditions</td> </tr> <tr> <td class=\"indent1\">Glutaric aciduria type 1</td> <td>Rare</td> <td>Few in number and confined to the posterior pole</td> <td>Macrocephaly, characteristic basal ganglia findings, may present with subdural hematomas; absence of bony abnormalities</td> </tr> <tr> <td class=\"indent1\">Galactosemia</td> <td>Rare</td> <td>Vitreous hemorrhage</td> <td>Failure to thrive, cataracts</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Infection</td> </tr> <tr> <td class=\"indent1\">Cerebral malaria</td> <td>20 to 60 percent of children with severe cerebral malaria</td> <td>Multiple white lesions</td> <td>Travel history; fever, anemia, characteristic blood smear findings</td> </tr> <tr> <td class=\"indent1\">Meningitis</td> <td>Rare</td> <td>Various</td> <td>Fever, characteristic cerebrospinal fluid findings</td> </tr> <tr> <td class=\"indent1\">Retinal infection (eg, CMV, HSV, toxoplasmosis, rickettsiae)</td> <td>Rare</td> <td>Small, intraretinal at areas of retinal necrosis; may span all layers of necrotic retina</td> <td>Systemic signs of infection may be present; immunodeficiency</td> </tr> <tr> <td class=\"indent1\">Endocarditis</td> <td>Rare</td> <td>White-centered oval hemorrhages</td> <td>Other characteristic features (eg, cardiac murmur, fever, splinter hemorrhages in the nail beds, Janeway lesions)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Primary retinal disease</td> </tr> <tr> <td class=\"indent1\">Retinopathy of prematurity</td> <td>Rare</td> <td>Small, usually intraretinal on the surface of the neovascular ridge; may extend to the vitreous</td> <td>History of prematurity; retinal neovascularization</td> </tr> <tr> <td class=\"indent1\">Coats disease</td> <td>Rare</td> <td>Usually intraretinal but may extend to vitreous</td> <td>Usually unilateral; subretinal exudate; telangiectatic vessels</td> </tr> <tr> <td class=\"indent1\">Persistent fetal vasculature</td> <td>Rare</td> <td>May present with vitreous hemorrhage</td> <td>Usually unilateral; may be associated with mild microphthalmos; intralenticular hemorrhage; retrolental membrane</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Other</td> </tr> <tr> <td class=\"indent1\">Intracranial hemorrhage</td> <td>Rare in absence of abusive head injury</td> <td>May be extensive</td> <td>Characteristic neuroradiographic features (eg, aneurysm, arterio-venous malformation)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Chest compression</td> </tr> <tr> <td class=\"indent1\">Cardiopulmonary resuscitation</td> <td>Rare if ever</td> <td>Few in number, small in size</td> <td>History of cardiopulmonary resuscitation</td> </tr> <tr> <td class=\"indent1\">Thoracic crush injury (Purtscher syndrome)</td> <td>Rare</td> <td>Superficial; white retinal patches</td> <td>History of thoracic injury</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; HSV: herpes simplex virus.<br> * The presence of an underlying condition does not exclude the possibility of abusive head trauma.</div><div class=\"graphic_reference\">This appendix is modified from an article entitled, &quot;A 12-Year Ophthalmologic Experience with the Shaken Baby Syndrome at a Regional Children's Hospital&quot; in the Trans Am Ophthalmol Soc 1999; 97:545-581 and republished with permission of the American Ophthalmological Society.<br> Additional data from: Aryan HE, Ghosheh FR, Jandial R, Levy ML. Retinal hemorrhage and pediatric brain injury: etiology and review of the literature. J Clin Neurosci 2005; 12:624 and Kaur B, Taylor D. Fundus hemorrhages in infancy. Surv Ophthalmol 1992; 37:1.</div><div id=\"graphicVersion\">Graphic 81915 Version 3.0</div></div></div>"},"81916":{"type":"graphic_table","displayName":"Histologic features of diffuse alveolar damage","title":"Histologic features of diffuse alveolar damage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic features of diffuse alveolar damage</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Key histologic features</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Diffuse distribution</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Uniform temporal appearance</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Alveolar septal thickening due to organizing fibrosis, usually diffuse</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Airspace organization (may be patchy or diffuse)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hyaline membranes (may be focal or diffuse)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Pertinent negative findings</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Lack of granulomas, necrosis, or abscesses</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Lack of infectious agents (no viral inclusions and negative results with special stains for organisms)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Lack of prominent eosinophils and neutrophils</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Negative cultures</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 81916 Version 2.0</div></div></div>"},"81918":{"type":"graphic_figure","displayName":"Normal response to metyrapone","title":"Normal response to metyrapone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal response to metyrapone</div><div class=\"cntnt\"><img style=\"width:364px; height:444px;\" src=\"images/ENDO/81918_Normal_response_to_metyrapo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum concentrations of 11-DOC and cortisol before and after the administration of metyrapone (750 mg every four hours for six doses) in normal subjects. The fall in serum cortisol concentrations stimulates the secretion of ACTH, leading to a marked increase in serum 11-DOC concentrations. To convert serum deoxycortisol values to nmol/L, multiply by 28.9.</div><div class=\"graphic_footnotes\">11-DOC: 11-deoxycortisol; ACTH: corticotropin.</div><div class=\"graphic_reference\">Data from: Spark RF. Simplified assessment of pituitary-adrenal reserve. Measurement of serum 11-deoxycortisol and cortisol after metyrapone. Ann Intern Med 1971; 75:717.</div><div id=\"graphicVersion\">Graphic 81918 Version 8.0</div></div></div>"},"81919":{"type":"graphic_diagnosticimage","displayName":"Thoracic aortic dissection on computed tomography","title":"Thoracic aortic dissection on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic aortic dissection on computed tomography</div><div class=\"cntnt\"><img style=\"width:360px; height:252px;\" src=\"images/CARD/81919_Aortic_dissection_Spiral_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse plane through ascending (AA) and descending (DA) thoracic aorta showing the intimal flap (arrows) and both lumens of a type A aortic dissection. One cannot distinguish between the true and false lumens based on this view alone.</div><div class=\"graphic_reference\">Courtesy of Vassilios Raptopoulos, MD.</div><div id=\"graphicVersion\">Graphic 81919 Version 3.0</div></div></div>"},"81921":{"type":"graphic_table","displayName":"TMP SMX adverse effects","title":"Major adverse effects of trimethoprim-sulfamethoxazole","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major adverse effects of trimethoprim-sulfamethoxazole</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Systemic allergic reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anaphylaxis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serum sickness</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Cutaneous reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rash</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stevens-Johnson syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Erythema muliforme</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Urticaria</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Toxic epidermal necrolysis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Photodermatis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Gastrointestinal and hepatic reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nausea and vomiting</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diarrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hepatotoxicity</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Hematologic reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pancytopenia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Agranulocytosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thrombocytopenia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Renal disorders</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Transient rise in creatinine due to impaired secretion by trimethoprim</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute interstitial nephritis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Crystalluria due to precipitation of sulfamethoxazole</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperkalemia due to trimethoprim-induced blockade of collecting tubule sodium channel</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Other reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Central nervous system - headache, confusion, aseptic meningitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fever</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Phlebitis</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 81921 Version 1.0</div></div></div>"},"81922":{"type":"graphic_figure","displayName":"Putting on compression stockings PI","title":"Putting on compression stockings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Putting on compression stockings</div><div class=\"cntnt\"><img style=\"width:421px; height:437px;\" src=\"images/PI/81922_Applying_stockings_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81922 Version 3.0</div></div></div>"},"81924":{"type":"graphic_figure","displayName":"Hypoxic ventilatory response","title":"Hypoxic ventilatory response","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypoxic ventilatory response</div><div class=\"cntnt\"><img style=\"width:393px; height:314px;\" src=\"images/PULM/81924_Hypoxic_vent_response_edit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ventilatory response to decreasing inspired oxygen concentration in two subjects. End-tidal PCO<sub>2</sub> is held constant. The left panel shows the linear response of ventilation plotted against oxygen saturation. On the right is the more traditional hyperbolic response, obtained from plotting ventilation against alveolar PO<sub>2</sub>.</div><div class=\"graphic_footnotes\">VE: minute ventilation; SO<sub>2</sub>: oxygen saturation; PO<sub>2</sub>: partial pressure of oxygen; PCO<sub>2</sub>: partial pressure of carbon dioxide.</div><div class=\"graphic_reference\">Redrawn from: Rebuck AS, Campbell EJM, Am Rev Respir Dis 1974; 109:345.</div><div id=\"graphicVersion\">Graphic 81924 Version 2.0</div></div></div>"},"81925":{"type":"graphic_table","displayName":"Autoimmune disorders in common variable immunodeficiency","title":"Autoimmune disorders in common variable immunodeficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Autoimmune disorders in common variable immunodeficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Dermatologic</td> </tr> <tr> <td class=\"indent1\">Alopecia totalis</td> </tr> <tr> <td class=\"indent1\">Vitiligo</td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic</td> </tr> <tr> <td class=\"indent1\">Immune thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Autoimmune hemolytic anemia</td> </tr> <tr> <td class=\"indent1\">Autoimmune neutropenia</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrinologic</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"subtitle1_single\">Rheumatologic</td> </tr> <tr> <td class=\"indent1\">Vasculitis</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"indent1\">Juvenile rheumatoid arthritis</td> </tr> <tr> <td class=\"indent1\">Sicca syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Primary biliary cholangitis</td> </tr> <tr> <td class=\"indent1\">Autoimmune hepatitis</td> </tr> <tr> <td class=\"indent1\">Pernicious anemia</td> </tr> <tr> <td class=\"indent1\">Atrophic gastritis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 2009; 9:347, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 81925 Version 6.0</div></div></div>"},"81926":{"type":"graphic_figure","displayName":"Sorbitol pathway in diabetes","title":"Role of sorbitol in diabetic microvascular disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Role of sorbitol in diabetic microvascular disease</div><div class=\"cntnt\"><img style=\"width:409px; height:194px;\" src=\"images/ENDO/81926_Sorbitol_pathway_in_diabete.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the pathways of sorbitol synthesis and metabolism. Hyperglycemia is associated with increased cell glucose in certain tissues, such as the peripheral nerves and the retina, leading to the accumulation of sorbitol. The increase in cell osmolality, decreased cell myoinositol, and perhaps other factors may contribute to tissue injury.</div><div class=\"graphic_reference\">Adapted from: Frank RN. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology 1991; 98:586.</div><div id=\"graphicVersion\">Graphic 81926 Version 2.0</div></div></div>"},"81927":{"type":"graphic_table","displayName":"Swallowing therapy","title":"Swallowing therapy techniques, indications, and rationale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Swallowing therapy techniques, indications, and rationale</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Technique\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Execution, rationale\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Indication\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">\r\n  \r\n   Dietary modification\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Thickened liquids\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   \t<p>Reduced tendency to spill over tongue base</p>\n\t<p>Preswallow spill/aspiration</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   \t<p>Disordered tongue function</p>\n\t<p>Impaired laryngeal closure</p>\n\t<p>Weak pharyngeal contraction</p>\n\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Thin liquids\r\n  \r\n   </td>\r\n  \r\n   <td>Offers less resistance to flow</td>\r\n  \r\n   <td>Reduced cricopharyngeal opening</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">\r\n  \r\n   Maneuvers\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Supraglottic swallow\r\n  \r\n   </td>\r\n  \r\n   <td>Breath hold, double swallow, forceful expiration (closes vocal folds before and during swallowing)</td>\r\n  \r\n   <td>Aspiration: reduced/late vocal fold closure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Super-supraglottic swallow\r\n  \r\n   </td>\r\n  \r\n   <td>\t<p>Effortful breath hold (closes vocal folds before and during swallow)</p>\n\t<p>Increased anterior tilting of arytenoids</p>\n</td>\r\n  \r\n   <td>Aspiration (poor closure of laryngeal introitus)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Effortful swallow\r\n  \r\n   </td>\r\n  \r\n   <td>Effortful tongue action (increases posterior motion tongue base)</td>\r\n  \r\n   <td>Poor posterior tongue base motion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Mendelsohn maneuver\r\n  \r\n   </td>\r\n  \r\n   <td>Prolong hyoid excursion guided by manual palpation (prolongs UES opening)</td>\r\n  \r\n   <td>Poor pharyngeal clearance and laryngeal movement</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">\r\n  \r\n   Postural adjustments\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\" colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Head tilt\r\n  \r\n   </td>\r\n  \r\n   <td>Tilt posteriorly at swallow initiation (gravity clears oral cavity)</td>\r\n  \r\n   <td>Poor tongue control</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tilt laterally to unaffected side (directs bolus down stronger side)</td>\r\n  \r\n   <td>Unilateral pharyngeal weakness</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Chin tuck\r\n  \r\n   </td>\r\n  \r\n   <td>Chin down (widens valleculae, displaces tongue base and epiglottis posteriorly)</td>\r\n  \r\n   <td>Aspiration, delayed pharyngeal response, reduced posterior tongue base motion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Head rotation\r\n  \r\n   </td>\r\n  \r\n   <td>Rotate head to affected side (isolates damaged side from bolus path, reduces LES pressure)</td>\r\n  \r\n   <td>Unilateral pharyngeal weakness</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\" colspan=\"1\" rowspan=\"1\">\r\n  \r\n   Head rotation\r\n  \r\n   </td>\r\n  \r\n   <td>Rotate head to affected side with extrinsic pressure on thyroid cartilage (increases adduction)</td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   \t<p>Unilateral laryngeal dysfunction</p>\n\t<p>Unilateral pharyngeal dysfunction</p>\n\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Lying on side, elevation\r\n  \r\n   </td>\r\n  \r\n   <td>R or L lateral (bypass laryngeal introitus)</td>\r\n  \r\n   <td>Aspiration, bilateral pharyngeal impairment or reduced laryngeal elevation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">\r\n  \r\n   Facilitatory techniques\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Strengthening exercises\r\n  \r\n   </td>\r\n  \r\n   <td>Various</td>\r\n  \r\n   <td>Nonprogressive disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Biofeedback\r\n  \r\n   </td>\r\n  \r\n   <td>Augment volitional component</td>\r\n  \r\n   <td>Poor pharyngeal clearance</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Thermal stimulation\r\n  \r\n   </td>\r\n  \r\n   <td>Cold, tactile stimulation to anterior faucial pillar</td>\r\n  \r\n   <td>Delayed/absent swallow response</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Gustatory stimulation\r\n  \r\n   </td>\r\n  \r\n   <td>Sour bolus (facilitates swallow response)</td>\r\n  \r\n   <td>Huntington's chorea, stroke</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from Cook, IJ, Kahrilas, PJ. AGA: Technical review: Management of oropharyngeal dysphagia. Gastroenterology 1999; 116:455.</div><div id=\"graphicVersion\">Graphic 81927 Version 1.0</div></div></div>"},"81929":{"type":"graphic_diagnosticimage","displayName":"Lemon sign","title":"The \"lemon\" sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The \"lemon\" sign</div><div class=\"cntnt\"><img style=\"width:410px; height:266px;\" src=\"images/OBGYN/81929_Lemon_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The frontal bossing (arrows) typically termed the lemon sign is present in cases of open spina bifida.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 81929 Version 3.0</div></div></div>"},"81931":{"type":"graphic_picture","displayName":"Compound nevus","title":"Compound nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Compound nevus</div><div class=\"cntnt\"><img style=\"width:370px; height:366px;\" src=\"images/PEDS/81931_Compoundnevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compound nevus with central elevation. This lesion is symmetric with a regular outline and uniform pigmentation.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 81931 Version 2.0</div></div></div>"},"81933":{"type":"graphic_diagnosticimage","displayName":"Loculated pleural hematoma CT","title":"Loculated pleural hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Loculated pleural hematoma</div><div class=\"cntnt\"><img style=\"width:342px; height:326px;\" src=\"images/PULM/81933_Loculated_pleural_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loculated pleural hematoma in left hemithorax after CABG. The loculated collection of blood has higher attenuation than the chest wall musculature.</div><div class=\"graphic_footnotes\">CABG: coronary artery bypass graft.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 81933 Version 3.0</div></div></div>"},"81936":{"type":"graphic_picture","displayName":"Marginal cord insertion","title":"Marginal cord insertion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Marginal cord insertion</div><div class=\"cntnt\"><img style=\"width:344px; height:504px;\" src=\"images/OBGYN/81936_Marginal_cord_insertion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 81936 Version 1.0</div></div></div>"},"81938":{"type":"graphic_waveform","displayName":"EPS tracing AVRT initiation termination","title":"Initiation and termination of an atrioventricular reentrant tachycardia captured during invasive electrophysiology studies (EPS)","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Initiation and termination of an atrioventricular reentrant tachycardia captured during invasive electrophysiology studies (EPS)</div><div class=\"cntnt\"><img style=\"width:514px; height:708px;\" src=\"images/CARD/81938_Initiation_termination_AVRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During atrial pacing (S1), a premature atrial beat (S2) is blocked antegradely in the accessory pathway and conducts through the atrioventricular node with a long delay (A2H2 interval), which allows for the recovery of the accessory pathway before retrograde conduction (panel A). The mechanism is an orthodromic atrioventricular reentrant tachycardia (AVRT) using a left-sided pathway, suggested by the atrial activation sequence; earliest retrograde atrial activation during the first echo beat of AVRT (Ae) is in the mid coronary sinus (CSm). A single venticular premature beat (VPB) terminates the AVRT (panel B). The VPB conducts to the left atrium but encounters the refractory period of the AV node and is blocked, interrupting conduction in the antegrade limb and terminating the arrhythmia.</div><div class=\"graphic_footnotes\">V: ventricular electrogram; A: atrial electrogram; NSR: normal sinus rhythm; d: distal; p: proximal.</div><div id=\"graphicVersion\">Graphic 81938 Version 6.0</div></div></div>"},"81939":{"type":"graphic_diagnosticimage","displayName":"Common bile duct stone on cholangiography","title":"Common bile duct stone on cholangiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common bile duct stone on cholangiography</div><div class=\"cntnt\"><img style=\"width:432px; height:573px;\" src=\"images/SURG/81939_Common_bile_duct_stone_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common bile duct stone (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg, RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 81939 Version 4.0</div></div></div>"},"81940":{"type":"graphic_figure","displayName":"W sitting position","title":"\"W sitting position","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">&quot;W sitting position</div><div class=\"cntnt\"><img style=\"width:520px; height:510px;\" src=\"images/PEDS/81940_W-sitting-position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Children with increased femoral anteversion may prefer to sit in the &quot;W&quot; position, as depicted above.</div><div id=\"graphicVersion\">Graphic 81940 Version 1.0</div></div></div>"},"81945":{"type":"graphic_table","displayName":"Enteric pathogens","title":"Enteric pathogens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Enteric pathogens</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pathogen</td> <td class=\"subtitle1\">Small bowel</td> <td class=\"subtitle1\">Colon</td> </tr> <tr class=\"divider_bottom\"> <td>Bacteria</td> <td> <p>Salmonella*</p> <p>Escherichia coli<sup>&#182;</sup></p> <p>Clostridium perfringens</p> <p>Staphylococcus aureus</p> <p>Aeromonas hydrophila</p> <p>Bacillus cereus</p> Vibrio cholerae</td> <td> <p>Campylobacter*</p> <p>Shigella</p> <p>Clostridium difficile</p> <p>Yersinia</p> <p>Vibrio parahaemolyticus</p> <p>Enteroinvasive E. coli</p> <p>Plesiomonas shigelloides</p> Klebsiella oxytoca(rare)</td> </tr> <tr class=\"divider_bottom\"> <td>Virus</td> <td> <p>Rotavirus</p> <p>Norovirus</p> Astrovirus</td> <td> <p>Cytomegalovirus*</p> <p>Adenovirus</p> Herpes simplex virus</td> </tr> <tr> <td>Protozoa</td> <td> <p>Cryptosporidium*</p> <p>Microsporidium*</p> <p>Cystoisospora</p> <p>Cyclospora</p> Giardia lamblia</td> <td>Entamoeba histolytica</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Can involve both the small and large bowel, but are most likely to occur as listed.<br />¶ EPEC, EAggEC, EHEC, ETEC may all contribute; routine laboratories and cultures will not differentiate these from E. coli which are normal flora.</div><div id=\"graphicVersion\">Graphic 81945 Version 6.0</div></div></div>"},"81946":{"type":"graphic_figure","displayName":"Submandibular space anatomy","title":"Submandibular space","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Submandibular space</div><div class=\"cntnt\"><img style=\"width:504px; height:398px;\" src=\"images/ID/81946_Submandibular_space_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81946 Version 3.0</div></div></div>"},"81947":{"type":"graphic_table","displayName":"Treatment pediatric MS","title":"Treatment of pediatric multiple sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of pediatric multiple sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t\t<tr>\n\t\t\t<td>Glatiramer acetate</td>\n\t\t\t<td>Copaxone</td>\n\t\t\t<td>20 mg subcutaneous injection daily</td>\n\t\t</tr>\n\t<tr>\n\t\t\t\t\t<td>Interferon beta-1a</td>\n\t\t\t\t\t<td>Avonex</td>\n\t\t\t\t\t<td>30 mcg intramuscular injection weekly</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Interferon beta-1a</td>\n\t\t\t\t\t<td>Rebif</td>\n\t\t\t\t\t<td>22 mcg or 44 mcg subcutaneous injection three times weekly</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Interferon beta-1b</td>\n\t\t\t\t\t<td>Betaseron</td>\n\t\t\t\t\t<td>8 million IU subcutaneous injection every other day</td>\n\t\t\t\t</tr>\n\t\t\t\n</tbody>\n</table></div><div class=\"graphic_footnotes\">IU: international units; mcg: micrograms; mg: milligrams.</div><div id=\"graphicVersion\">Graphic 81947 Version 2.0</div></div></div>"},"81948":{"type":"graphic_table","displayName":"Emesis pt risk factors","title":"Individual risk factors for radiotherapy emetogenicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Individual risk factors for radiotherapy emetogenicity</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\" colspan=\"2\">\n   Risk factor\n   </td>\n   <td  class=\"subtitle1\">\n   Risk score\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Age\n   </td>\n   <td>&#62;55 years</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>&#60;55 years</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Sex\n   </td>\n   <td>Male</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td>Female</td>\n   <td>2</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Alcohol consumption\n   </td>\n   <td>Yes (&#62;100 g/day)</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>No</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Previous N&V\n   </td>\n   <td>Yes</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td>No</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Anxiety\n   </td>\n   <td>Yes</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td>No</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td><strong>Risk profile; 4 = normal risk, 5-6 = high risk</strong></td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Data from: Feyer, P. Acta Oncol 2004; 43 Suppl 15:5, and Feyer P, et al. Support Cancer Care 2005; 13:122.</div><div id=\"graphicVersion\">Graphic 81948 Version 2.0</div></div></div>"},"81949":{"type":"graphic_picture","displayName":"Epicond eccentric rehab PI","title":"Epicondylitis eccentric rehabilitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epicondylitis eccentric rehabilitation</div><div class=\"cntnt\"><img style=\"width:396px; height:321px;\" src=\"images/PI/81949_Epicond_eccentric_rehab_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph demonstrates an eccentric exercise for the wrist extensor muscles. Eccentric exercise involves the application of a load during the lengthening of a muscle and may assist with healing of a tendinopathy. Here the wrist extensors are contracting eccentrically against the resistance of an exercise band.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD.</div><div id=\"graphicVersion\">Graphic 81949 Version 2.0</div></div></div>"},"81950":{"type":"graphic_diagnosticimage","displayName":"Lead flecks","title":"Lead flecks","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lead flecks</div><div class=\"cntnt\"><img style=\"width:318px; height:433px;\" src=\"images/PEDS/81950_Lead_flecks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal radiograph demonstrates flecks of lead in the pelvis of a child who ingested lead paint chips.</div><div class=\"graphic_reference\">Courtesy of Richard Hurwitz, MD and Dean A Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 81950 Version 2.0</div></div></div>"},"81951":{"type":"graphic_diagnosticimage","displayName":"Anterior shoulder dislocation radiograph","title":"Anterior shoulder dislocation on the AP radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior shoulder dislocation on the AP radiograph</div><div class=\"cntnt\"><img style=\"width:426px; height:342px;\" src=\"images/EM/81951_Anterir_shldr_dslctn_rdgrph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this AP radiograph, the humeral head clearly lies outside the glenoid and below the coracoid process.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div id=\"graphicVersion\">Graphic 81951 Version 5.0</div></div></div>"},"81952":{"type":"graphic_diagnosticimage","displayName":"Thyroid calcification echo","title":"Thyroid calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyroid calcification</div><div class=\"cntnt\"><img style=\"width:325px; height:275px;\" src=\"images/ENDO/81952_Thyroid_calcification_Echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of the right lobe of the thyroid gland in the longitudinal plane that shows a dense bright arc (arrow), which is a coarse calcification. Blockade of the ultrasound signal distally produces shadowing.</div><div class=\"graphic_footnotes\">L: thyroid lobe.</div><div class=\"graphic_reference\">Courtesy of Manfred Blum, MD.</div><div id=\"graphicVersion\">Graphic 81952 Version 4.0</div></div></div>"},"81953":{"type":"graphic_diagnosticimage","displayName":"Serous cystadenoma EUS","title":"Pancreatic serous cystadenoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pancreatic serous cystadenoma</div><div class=\"cntnt\"><img style=\"width:504px; height:417px;\" src=\"images/GAST/81953_Serous_cystadenoma_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Appearance of a pancreatic serous cystadenoma on endoscopic ultrasound.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 81953 Version 2.0</div></div></div>"},"81956":{"type":"graphic_picture","displayName":"Fibrinoid nec flood vessel","title":"Fibrinoid necrosis within blood vessel wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrinoid necrosis within blood vessel wall</div><div class=\"cntnt\"><img style=\"width:396px; height:268px;\" src=\"images/RHEUM/81956_Fibrinoid_nec_flood_vessel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibrinoid necrosis within the blood vessel wall of an artery/arteriole supplying a peripheral nerve.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 81956 Version 1.0</div></div></div>"},"81959":{"type":"graphic_figure","displayName":"Heartport bypass system","title":"Heartport bypass system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heartport bypass system</div><div class=\"cntnt\"><img style=\"width:416px; height:471px;\" src=\"images/CARD/81959_Heartport_bypass_syst_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The endoaortic balloon occlusion catheter is inflated in the ascending aorta and antegrade cardioplegia is delivered through the central lumen. The endopulmonary vent assists in ventricular decompression.</div><div class=\"graphic_reference\">Adapted from: Standbridge RD, Hadjinikolaou LK, Cohen AS, et al. Ann Thorac Surg 1997; 65(6 Suppl):S53.</div><div id=\"graphicVersion\">Graphic 81959 Version 7.0</div></div></div>"},"81960":{"type":"graphic_figure","displayName":"Venous drainage of the colon and rectum","title":"Venous drainage of the colon and rectum","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Venous drainage of the colon and rectum</div><div class=\"cntnt\"><img style=\"width:534px; height:562px;\" src=\"images/SURG/81960_Veins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mesenteric veins parallel their corresponding arteries. The SMV drains the small intestine, cecum, and ascending and transverse colon via the jejunal, ileal, ileocolic, right colic, and middle colic veins. The IMV drains the descending colon through the left colic, the sigmoid through the sigmoid vein, and the rectum through the superior rectal vein. The IMV fuses with the splenic vein, which then joins the SMV to form the portal vein.</div><div class=\"graphic_footnotes\">SMV: superior mesenteric vein; IMV: inferior mesenteric vein.</div><div id=\"graphicVersion\">Graphic 81960 Version 4.0</div></div></div>"},"81961":{"type":"graphic_diagnosticimage","displayName":"Normal HSG","title":"Normal hysterosalpingogram with a Jarcho cannula","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Normal hysterosalpingogram with a Jarcho cannula</div><div class=\"cntnt\"><img style=\"width:468px; height:321px;\" src=\"images/OBGYN/81961_Normal_HSG_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright © 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 81961 Version 7.0</div></div></div>"},"81965":{"type":"graphic_picture","displayName":"Pagets dis with carcinoma2","title":"Extramammary Paget disease of the vulva with adenocarcinoma-2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extramammary Paget disease of the vulva with adenocarcinoma-2</div><div class=\"cntnt\"><img style=\"width:400px; height:300px;\" src=\"images/OBGYN/81965_Paget_dis_with_carcinoma2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 81965 Version 1.0</div></div></div>"},"81966":{"type":"graphic_algorithm","displayName":"Crohns vs UC","title":"Algorithm to guide the diagnosis of Crohn disease versus ulcerative colitis in children","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Algorithm to guide the diagnosis of Crohn disease versus ulcerative colitis in children</div><div class=\"cntnt\"><img style=\"width:482px; height:738px;\" src=\"images/PEDS/81966_Crohns_vs_UC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm to assist clinicians in differentiating ulcerative colitis from Crohn disease.</div><div class=\"graphic_footnotes\">UGI/SBFT: upper gastrointestinal series with small bowel follow-through; MRE: magnetic resonance enterography; CT: computerized tomography.<br />* Either UGI/SBFT, MRE, or CT may provide evidence of small bowel disease, supporting the diagnosis of Crohn disease. Where expertise in MRE is available, this technique is favored over UGI/SBFT, to reduce radiation exposure. CT is an option used particularly in emergencies, but generally is not recommended as first-line option for small bowel imaging because of the higher radiation dose.</div><div class=\"graphic_reference\">Adapted from: North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Colitis Foundation of America, Bousvaros A, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44:653. Copyright &copy; 2007 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 81966 Version 7.0</div></div></div>"},"81967":{"type":"graphic_picture","displayName":"Roseola rash","title":"Characteristic roseola rash","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Characteristic roseola rash</div><div class=\"cntnt\"><img style=\"width:515px; height:276px;\" src=\"images/PEDS/81967_Roseola_rash_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rash of roseola appears as the fever abates. It starts on the neck and trunk and spreads to the extremities. As depicted above, it is erythematous, blanching, and macular or maculopapular.</div><div class=\"graphic_reference\">Courtesy of Michael Brady, MD.</div><div id=\"graphicVersion\">Graphic 81967 Version 2.0</div></div></div>"},"81968":{"type":"graphic_diagnosticimage","displayName":"Pneumothorax ex vacuo PA","title":"Chest radiograph of a pneumothorax ex vacuo","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a pneumothorax ex vacuo</div><div class=\"cntnt\"><img style=\"width:324px; height:311px;\" src=\"images/PULM/81968_Pneumothorax_ex_vacuo_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows right upper lobe atelectasis and a pneumothorax surrounding strictly the atelectatic lobe. After bronchoscopy and removal of the obstructing mucous plug, the pneumothorax disappeared.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 81968 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"81969":{"type":"graphic_table","displayName":"Comparison of esophageal motility findings","title":"Comparison of esophageal motility findings using conventional manometry and high resolution manometry","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of esophageal motility findings using conventional manometry and high resolution manometry</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Conventional manometry</td> <td class=\"subtitle1\">High resolution manometry</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Normal</td> </tr> <tr> <td class=\"indent1\">Velocity</td> <td>&#60;8 cm/sec (8 to 3 cm above LES)</td> <td>&#60;8 cm/sec CFV</td> </tr> <tr> <td class=\"indent1\">Amplitude</td> <td>DEA &#60;220 mmHg</td> <td>DCI &#60;8000 mmHg&#8226;cm&#8226;sec</td> </tr> <tr> <td class=\"indent1\">LESP</td> <td>10 to 45 mmHg</td> <td>10 to 35 mmHg</td> </tr> <tr> <td class=\"indent1\">LESR</td> <td>&#60;8 mmHg</td> <td>&#60;15 mmHg (4-second IRP)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Distal esophageal spasm</td> </tr> <tr> <td class=\"indent1\">Velocity</td> <td>&#62;8 cm/sec</td> <td>CFV &#62;8 cm/sec; distal latency &#60;4.5 sec</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nutcracker esophagus</td> </tr> <tr> <td class=\"indent1\">Amplitude</td> <td>DEA &#62;220 mmHg</td> <td> <p>DCI &#62;8000 mmHg&#8226;cm&#8226;sec</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Hypertensive lower esophageal sphincter</td> </tr> <tr> <td class=\"indent1\">LESP</td> <td>&#62;45 mmHg</td> <td>&#62;35 mmHg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LES: lower esophageal sphincter; LESP: lower esophageal sphincter pressure; CFV: contractile front velocity; DEA: distal esophageal amplitude; DCI: distal contractile integral; IRP: integrated relaxation pressure; LESR: lower esophageal sphincter relaxation.</div><div id=\"graphicVersion\">Graphic 81969 Version 5.0</div></div></div>"},"81970":{"type":"graphic_table","displayName":"Chest tube size in children","title":"Chest tube sizes for pediatric trauma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chest tube sizes for pediatric trauma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Weight (kg)</td> <td class=\"subtitle1\">Chest tube (French)*</td> </tr> <tr> <td>Infant (up to 1 year)</td> <td class=\"centered\">3 to 9</td> <td class=\"centered\">10 to 12</td> </tr> <tr> <td>Toddler (1 to 3 years)</td> <td class=\"centered\">10 to 11</td> <td class=\"centered\">16 to 20</td> </tr> <tr> <td>Preschool child (3 to 5 years)</td> <td class=\"centered\">12 to 18</td> <td class=\"centered\">20 to 24</td> </tr> <tr> <td>School-aged child (5 to 12 years)</td> <td class=\"centered\">19 to 29</td> <td class=\"centered\">24 to 32</td> </tr> <tr> <td>Over 12 years</td> <td class=\"centered\">&#8805;30</td> <td class=\"centered\">32 to 38</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In addition to considering age and weight, the clinician should evaluate the distance between the ribs to arrive at the correctly sized chest tube for placement.</div><div class=\"graphic_reference\">Data from: Hazinski MF, Samson R, Schexnayder S (Eds). 2010 Handbook of Emergency Cardiovascular Care for Healthcare Providers. American Heart Association 2010.</div><div id=\"graphicVersion\">Graphic 81970 Version 4.0</div></div></div>"},"81971":{"type":"graphic_diagnosticimage","displayName":"EUS fiducial pancreatic tumor","title":"EUS-guided fiducial placement for pancreatic tumor localization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">EUS-guided fiducial placement for pancreatic tumor localization</div><div class=\"cntnt\"><img style=\"width:432px; height:345px;\" src=\"images/GAST/81971_EUS_fiducial_pancreat_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EUS&nbsp;image of fiducial within the pancreatic tumor.</div><div class=\"graphic_footnotes\">EUS: endoscopic ultrasound.</div><div class=\"graphic_reference\">Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.</div><div id=\"graphicVersion\">Graphic 81971 Version 4.0</div></div></div>"},"81973":{"type":"graphic_diagnosticimage","displayName":"FAST perisplenic normal","title":"FAST: Perisplenic (left flank) view","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Perisplenic (left flank) view</div><div class=\"cntnt\"><img style=\"width:504px; height:404px;\" src=\"images/EM/81973_FAST_splenorenal_normal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image, obtained as part of the FAST examination, shows normal juxtaposition of the spleen (S) and left kidney (K) without free fluid.</div><div class=\"graphic_footnotes\">FAST: Focused Assessment with Sonography for Trauma.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 81973 Version 3.0</div></div></div>"},"81974":{"type":"graphic_table","displayName":"WHO GCTs","title":"Classification of GCTs according to tumor markers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of GCTs according to tumor markers</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\" rowspan=\"2\">Tumor type </td>\n<td class=\"subtitle1\" colspan=\"4\">Marker </td>\n\n</tr>\n\n<tr>\n<td class=\"subtitle2\"> \t<sub>&#946;</sub>-HCG</td>\n<td class=\"subtitle2\"> AFP</td>\n<td class=\"subtitle2\"> PLAP</td>\n<td class=\"subtitle2\"> c-Kit</td>\n\n</tr>\n\n<tr>\n<td>Pure germinoma </td>\n<td>- </td>\n<td>- </td>\n<td> +/-</td>\n<td>+ </td>\n</tr>\n\n<tr>\n<td> Germinoma (syncytiotrophoblastic)</td>\n<td> +</td>\n<td> -</td>\n<td> +/-</td>\n<td>+ </td>\n</tr>\n\n<tr>\n<td>Endodermal sinus tumor </td>\n<td>- </td>\n<td> +</td>\n<td>+/- </td>\n<td> -</td>\n</tr>\n\n<tr>\n<td> Choriocarcinoma</td>\n<td> +</td>\n<td> -</td>\n<td>+/- </td>\n<td> -</td>\n</tr>\n\n<tr>\n<td>Embryonal carcinoma </td>\n<td> -</td>\n<td> -</td>\n<td> +</td>\n<td> -</td>\n</tr>\n\n<tr>\n<td>Mixed GCT </td>\n<td> +/-</td>\n<td> +/-</td>\n<td> +/-</td>\n<td> +/-</td>\n</tr>\n\n<tr>\n<td>Mature teratoma </td>\n<td>- </td>\n<td> -</td>\n<td>- </td>\n<td> -</td>\n</tr>\n\n<tr>\n<td>Immature teratoma </td>\n<td> +/-</td>\n<td>+/- </td>\n<td>- </td>\n<td> +/-</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">3/9/2009--Requested permission (JD). 6/8/2009--Permission granted; figures to Terrence (JD). 5/15/2010--Renewal requested (JD). 6/16/2010--Renewal granted (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48703&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>WHO_GCTs.htm</title></head></div><div class=\"graphic_footnotes\">AFP: alpha-fetoprotein; <sub>β</sub>-HCG: <sub>β</sub>-human chorionic gonadotropin; GCT: germ cell tumor; PLAP: placental alkaline phosphatase.</div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Louis DN, Ohgaki H, Wiesterl O, et al. World Health Organization Classification of Tumours of the Central Nervous System, 3rd Edition, IARC Press, Lyon, 2007. Copyright © 2007 IARC Press.</div><div id=\"graphicVersion\">Graphic 81974 Version 9.0</div></div></div>"},"81977":{"type":"graphic_picture","displayName":"Quadriceps strength testing","title":"Quadriceps strength testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Quadriceps strength testing</div><div class=\"cntnt\"><img style=\"width:430px; height:574px;\" src=\"images/EM/81977_Quadricepsstrength.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This maneuver is used to evaluate the integrity of the quadriceps mechanism and estimate quadriceps muscle strength. The patient is asked to extend the leg against resistance placed at the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: Quadriceps femoris. In: Muscles: Testing and Function with Posture and Pain, 5th ed, Kendall FP, MCreary EK, Provance PG, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81977 Version 7.0</div></div></div>"},"81978":{"type":"graphic_picture","displayName":"European hornets","title":"European hornets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">European hornets</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/81978_European_hornets.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 81978 Version 1.0</div></div></div>"},"81979":{"type":"graphic_diagnosticimage","displayName":"RLL atelectasis II","title":"Right lower lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:325px; height:371px;\" src=\"images/PULM/81979_RLL_atelectasis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overpenetrated frontal chest&nbsp;radiograph showing complete right lower lobe atelectasis due to bronchogenic carcinoma. The collapsed right lower lobe forms a right paraspinal mass (large arrow). The residual hyperaerated right lung is smaller than the left lung. The right hilum is not visible since it is engulfed by the atelectasis. The major fissure shows a convex bulge which represents a variant of Golden's S sign and is formed by the tumor mass. Note the superior triangle sign formed by shift of the mediastinal fat and vessels to the right of the trachea.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 81979 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"81981":{"type":"graphic_picture","displayName":"Adult female Ixodes tick","title":"Adult female Ixodes scapularis tick","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Adult female Ixodes scapularis tick</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/ID/81981_Adult_female_Ixodes_tick.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Female Ixodes ticks are orange-reddish, with a dark brown oval-shaped structure called a scutum covering the superior portion of the dorsal surface. Unengorged adults are approximately 3 mm in length.</div><div class=\"graphic_reference\">Courtesy of Dr. Michael E Ross.</div><div id=\"graphicVersion\">Graphic 81981 Version 2.0</div></div></div>"},"81982":{"type":"graphic_diagnosticimage","displayName":"Distal phalanx fracture of great toe","title":"Nondisplaced distal phalanx fracture of great toe","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Nondisplaced distal phalanx fracture of great toe</div><div class=\"cntnt\"><img style=\"width:496px; height:486px;\" src=\"images/EM/81982_Distal_phalanx_fx_great_toe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the middle view, note the apparent lucency running obliquely across the medial sesamoid of the great toe (black arrow). This is an illusion created by the overlying cortex of the first metatarsal, and does not represent a fracture. This is supported by the normal appearance of the sesamoid on the other views.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 81982 Version 3.0</div></div></div>"},"81983":{"type":"graphic_figure","displayName":"Upper cervical vertebrae","title":"Anatomy of upper cervical vertebrae","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Anatomy of upper cervical vertebrae</div><div class=\"cntnt\"><img style=\"width:500px; height:401px;\" src=\"images/NEURO/81983_Upper_cervical_vertebrae.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81983 Version 2.0</div></div></div>"},"81985":{"type":"graphic_table","displayName":"Common street names cocaine","title":"Common street names for cocaine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common street names for cocaine</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine base (smokable)</td>\n\t\t\t\t\t\t<td>Base, black rock, crack, electric kool-aid, rock, gravel, purple caps, Scotty, scramble, supercoke, twinkie, window pane, yam</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine HCl</td>\n\t\t\t\t\t<td>Aspirin, Big C, blow, coconut, coke, devil's dandruff, flake, Florida snow, foo-foo dust, happy dust, lady, nose candy, white dragon, white lady, yao</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine paste</td>\n\t\t\t\t\t\t<td>Basuco, bazooka, pasta</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine in vagina</td>\n\t\t\t\t\t\t<td>Balling</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + heroin</td>\n\t\t\t\t\t\t<td>Belushi, bipping, blanco, boy-girl, dynamite, goof ball, he-she, murder one, sandwich, snowball, speedball</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + marijuana</td>\n\t\t\t\t\t\t<td>51, banano, bazooka, blunt, C &#38; M, candy sticks, caviar, champagne, cocktail, cocoa puff, crack bash, dirties, geek-joint, Greek, lace, P-dogs, premos, primo, Sherman stick, woo blunts, woolie</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + MDMA (ecstasy)</td>\n\t\t\t\t\t\t<td>Bumping up</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + MDMA + LSD</td>\n\t\t\t\t\t\t<td>Candy flipping on a string</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + methamphetamine</td>\n\t\t\t\t\t\t<td>Croak, shabu</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + methcathinone</td>\n\t\t\t\t\t\t<td>Wild cat</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + morphine</td>\n\t\t\t\t\t\t<td>C &#38; M</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + PCP</td>\n\t\t\t\t\t\t<td>Beam me up Scottie, space ball, space base, space dust</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + tobacco</td>\n\t\t\t\t\t\t<td>Cigamos, coolie, geek-joint</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + marijuana + PCP</td>\n\t\t\t\t\t\t<td>Jim Jones, speed boat, squirrel, wickie</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + heroin + tobacco</td>\n\t\t\t\t\t\t<td>Flamethrowers, primos</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cocaine + heroin + methamphetamine +flunitrazepam + alcohol</td>\n\t\t\t\t\t\t<td>Five-way</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t</table></div><div class=\"graphic_lgnd\">Note that street names change over time and may differ by location. The same name may refer to more than one drug.</div><div id=\"graphicVersion\">Graphic 81985 Version 1.0</div></div></div>"},"81986":{"type":"graphic_figure","displayName":"Staying centered on values","title":"The struggle to stay centered on values in the profession of medicine","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">The struggle to stay centered on values in the profession of medicine</div><div class=\"cntnt\"><img style=\"width:535px; height:240px;\" src=\"images/PC/81986_Staying_centered_on_values.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Inui TS. A Flag in the Wind: Educating for Professionalism in Medicine. Association of American Medical Colleges, Washington, DC 2003. Copyright © 2003 Association of American Medical Colleges.</div><div id=\"graphicVersion\">Graphic 81986 Version 4.0</div></div></div>"},"81987":{"type":"graphic_picture","displayName":"Thumb spica splint","title":"Thumb spica splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb spica splint</div><div class=\"cntnt\"><img style=\"width:383px; height:322px;\" src=\"images/EM/81987_Thumb_spica_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thumb spica splint provides&nbsp;excellent immobilization for the thumb. It is often used for carpometacarpal osteoarthritis, de Quervain's tenosynovitis, ulnar collateral ligament injury (gamekeeper's or skier's&nbsp;thumb), and fractures of the scaphoid, trapezium, and first metacarpal.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 81987 Version 3.0</div></div></div>"},"81988":{"type":"graphic_picture","displayName":"Absence of pus in LAD","title":"Absence of pus in leukocyte-adhesion deficiency","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Absence of pus in leukocyte-adhesion deficiency</div><div class=\"cntnt\"><img style=\"width:502px; height:196px;\" src=\"images/ALLRG/81988_Absence_pus_LAD_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The absence of pus formation at the sites of infection is a hallmark of leukocyte-adhesion deficiency syndromes. This elbow lesion shows the effect of a profound impairment of leukocyte mobilization into extravascular sites of inflammation.</div><div id=\"graphicVersion\">Graphic 81988 Version 6.0</div></div></div>"},"81989":{"type":"graphic_figure","displayName":"Audiograms in Cogans II","title":"Audiograms in Cogan's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Audiograms in Cogan's syndrome</div><div class=\"cntnt\"><img style=\"width:443px; height:197px;\" src=\"images/RHEUM/81989_Audiograms_in_Cogans_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial audiograms demonstating improving hearing with corticosteroid therapy: A) Hearing thresholds prior to therapy; B) Hearing thresholds after corticosteroid therapy. O-----O, right ear; X-----X, left ear.</div><div class=\"graphic_reference\">Reproduced with permission from: McCallum, RM, St. Clair, EW, Haynes, BF. Cogan's syndrome. In: Inflammatory Diseases of Blood Vessels, Hoffman, GS, Weyand, CM (Eds). Marcel Dekker, Inc., New York City 2002. Copyright &#169;2002 Marcel Dekker, Inc.</div><div id=\"graphicVersion\">Graphic 81989 Version 1.0</div></div></div>"},"81990":{"type":"graphic_diagnosticimage","displayName":"Arteriovenous malformation III","title":"Pulmonary arteriovenous malformation in the right upper lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary arteriovenous malformation in the right upper lobe</div><div class=\"cntnt\"><img style=\"width:432px; height:330px;\" src=\"images/PULM/81990_Arteriovenous_malform_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal CT image with mediastinal window settings show a right upper lobe solitary pulmonary nodule with several tentacle-like extensions suspicious for an arteriovenous malformation. The enhancement of the nodule is identical to that of the central pulmonary arterial branches.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 81990 Version 3.0</div></div></div>"},"81992":{"type":"graphic_picture","displayName":"Retracted end colostomy","title":"Retracted end sigmoid colostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retracted end sigmoid colostomy</div><div class=\"cntnt\"><img style=\"width:399px; height:251px;\" src=\"images/GAST/81992_Retracted_end_colostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A flush or retracted stoma is undesirable because it may require more specialized equipment or additional accessories to aid in the appliance fit and therefore facilitate drainage.</div><div class=\"graphic_reference\">Courtesy of Jeffrey B Matthews, MD.</div><div id=\"graphicVersion\">Graphic 81992 Version 1.0</div></div></div>"},"81993":{"type":"graphic_table","displayName":"Components cardiovascular risk","title":"Components of cardiovascular risk factors in patients with hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of cardiovascular risk factors in patients with hypertension</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Major risk factors</td></tr>\n\t\t\t\t\t\t<tr><td>Hypertension</td></tr>\n\t\t\t\t\t\t<tr><td>Cigarette smoking</td></tr>\n\t\t\t\t\t\t<tr><td>Obesity (BMI &#8805;30 kg/m2)</td></tr>\n\t\t\t\t\t\t<tr><td>Physical inactivity</td></tr>\n\t\t\t\t\t\t<tr><td>Dyslipidemia</td></tr>\n\t\t\t\t\t\t<tr><td>Diabetes mellitus</td></tr>\n\t\t\t\t\t\t<tr><td>Microalbuminuria or estimated GFR &#60;60 mL/min</td></tr>\n\t\t\t\t\t\t<tr><td>Age &#62;55 years for men, &#62;65 years in women</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Family history of premature coronary disease</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Men - &#60;55 years </td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Women - &#60;65 years</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Target organ damage</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Heart disease</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Left ventricular hypertrophy</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Angina or prior myocardial infarction</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Prior coronary revascularization</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Heart failure</td></tr>\n\t\t\t\t\t\t<tr><td>Stroke or transient ischemic attack</td></tr>\n\t\t\t\t\t\t<tr><td>Chronic kidney disease</td></tr>\n\t\t\t\t\t\t<tr><td>Peripheral arterial disease</td></tr>\n\t\t\t\t\t\t<tr><td>Retinopathy</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t</tr>\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. The JNC 7 report. JAMA 2003; 289:2560.</div><div id=\"graphicVersion\">Graphic 81993 Version 1.0</div></div></div>"},"81994":{"type":"graphic_picture","displayName":"Antibody-mediated rejection in RT biopsy","title":"Light microscopy showing antibody-mediated rejection in renal transplant biopsy, ATN, and polymorphonuclear leukocytes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy showing antibody-mediated rejection in renal transplant biopsy, ATN, and polymorphonuclear leukocytes</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/NEPH/81994_Low_mag_Ab_Mediated_Rej_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous interstitial polymorphonuclear leukocytes (PMNs) and extensive acute tubular necrosis are evident in this renal transplant biopsy. Histologic findings in antibody-mediated rejection may include PMN infiltration. This specimen also demonstrated positive C4d staining on immunofluorescence.</div><div class=\"graphic_footnotes\">ATN: acute tubular necrosis.</div><div class=\"graphic_reference\">Courtesy of Dr. Helen Liapis, Washington University School of Medicine.</div><div id=\"graphicVersion\">Graphic 81994 Version 4.0</div></div></div>"},"81996":{"type":"graphic_diagnosticimage","displayName":"Ultrasound normal fetal brain transcerebellar view","title":"Transcerebellar plane","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Transcerebellar plane</div><div class=\"cntnt\"><img style=\"width:480px; height:423px;\" src=\"images/OBGYN/81996_Transcerebellar_plane.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 81996 Version 2.0</div></div></div>"},"81997":{"type":"graphic_picture","displayName":"CO2 detector for endotracheal tube confirmation","title":"CO2 detector for endotracheal tube confirmation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CO2 detector for endotracheal tube confirmation</div><div class=\"cntnt\"><img style=\"width:256px; height:588px;\" src=\"images/EM/81997_ETTCO2confirmation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Capnography in the operating room. <br />(B) CO<SUB>2</SUB> color-change indicator: purple color before connection to circuit. <br />(C) The indicator turns yellow when connected to the circuit, indicating correct ETT placement.</div><div class=\"graphic_footnotes\">CO<SUB>2</SUB>: carbon dioxide; ETT: endotracheal tube.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Confirmation of endotracheal tube placement. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 81997 Version 12.0</div></div></div>"},"81999":{"type":"graphic_picture","displayName":"Hyphal form of Sporothrix","title":"<EM>Sporothrix schenckii</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Sporothrix schenckii</EM></div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/81999_Hyphal_form_of_Sporothrix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic view of growth of <EM>S. schenckii</EM> at 25°C. Thin septate hyphae with numerous attached conidia in bouquet-like arrangements.</div><div class=\"graphic_reference\">Reproduced with permission from: Kauffman C. Diagnosis and Treatment of Human Mycoses. Duane Hospenthal, ed. Humana Press. Copyright © 2008 Springer Science and Business Media.</div><div id=\"graphicVersion\">Graphic 81999 Version 3.0</div></div></div>"}};